,drugName,drugid,description,drugtype,maxPhase,withdrawn,blackBox,approvalYear,list_targets,list_diseases,has_any_sc_evidence,has_any_genetic_evidence,num_indications,mechanism,action_type,target_type
0,DESLORATADINE,CHEMBL1172,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 10 investigational indications.,,4.0,,False,2001,['ENSG00000196639'],"['EFO_0007214', 'EFO_0005531', 'EFO_0005854', 'MONDO_0002406', 'HP_0000964', 'EFO_0007141', 'HP_0000989', 'EFO_1001417', 'EFO_0003060', 'MONDO_0005271', 'EFO_0008520', 'Orphanet_79292', 'EFO_0003956', 'EFO_0000274']",True,False,14,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
1,CETRORELIX,CHEMBL1200490,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 7 investigational indications.,,4.0,,False,2000,['ENSG00000109163'],"['EFO_0000545', 'MONDO_0011972', 'EFO_0000685', 'EFO_0001065', 'EFO_0000284', 'EFO_0000545', 'EFO_0000660']",False,False,7,Gonadotropin-releasing hormone receptor antagonist ,ANTAGONIST ,single protein 
2,ZIDOVUDINE,CHEMBL129,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,[],"['EFO_0000558', 'MONDO_0018076', 'EFO_0007448', 'EFO_0002950', 'MONDO_0019471', 'MONDO_0015564', 'EFO_0007527', 'HP_0002014', 'EFO_0002608', 'EFO_1001365', 'EFO_1001486', 'EFO_0000764', 'EFO_0000180', 'EFO_0007137', 'EFO_0000763', 'EFO_0000765', 'MONDO_0100096', 'EFO_0000544', 'MONDO_0015974', 'MONDO_0021094', 'EFO_0000574']",False,False,21,Human immunodeficiency virus type 1 reverse transcriptase inhibitor ,INHIBITOR ,single protein 
3,BUPARLISIB,CHEMBL2017974,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,3.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_1000581', 'MONDO_0044903', 'EFO_0000519', 'EFO_0000403', 'EFO_0000565', 'EFO_0000702', 'EFO_0003060', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0008903', 'MONDO_0011719', 'MONDO_0007576', 'MONDO_0007254', 'EFO_0006859', 'MONDO_0002108', 'EFO_0001421', 'EFO_1001469', 'EFO_0003086', 'EFO_0000616', 'EFO_0000756', 'EFO_1001951', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0002974', 'EFO_0000181', 'MONDO_0008315']",True,False,26,PI3-kinase class I inhibitor ,INHIBITOR ,protein complex group 
4,SASANLIMAB,CHEMBL4298191,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0003060', 'EFO_0008528', 'MONDO_0001187', 'EFO_0000673', 'EFO_0009708']",False,False,5,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
5,URACIL,CHEMBL566,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004992', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0007254', 'EFO_0000182', 'EFO_0003060', 'EFO_0006859', 'EFO_1001951', 'EFO_1000657', 'EFO_0003869', 'EFO_0000199', 'MONDO_0021355', 'MONDO_0001187']",False,False,13,,,
6,NIRAPARIB,CHEMBL1094636,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 39 investigational indications.,,4.0,,False,2017,"['ENSG00000129484', 'ENSG00000143799']","['EFO_1000251', 'EFO_0004230', 'EFO_0003869', 'MONDO_0008315', 'EFO_0001075', 'EFO_0000519', 'EFO_0001075', 'Orphanet_145', 'EFO_0001663', 'EFO_0000174', 'MONDO_0004992', 'EFO_1001512', 'MONDO_0011962', 'EFO_0002517', 'EFO_0006859', 'MONDO_0002158', 'EFO_1000657', 'EFO_0000707', 'EFO_0000616', 'MONDO_0008903', 'MONDO_0002974', 'EFO_0000181', 'EFO_0003060', 'EFO_0003893', 'EFO_0000305', 'EFO_0000564', 'EFO_0000196', 'MONDO_0007254', 'EFO_0002617', 'EFO_0000574', 'MONDO_0002087', 'EFO_0000095', 'EFO_0002618', 'EFO_0003863', 'MONDO_0001056', 'EFO_0000702', 'EFO_0000588', 'EFO_0000673', 'EFO_1001100', 'EFO_0008528', 'EFO_0001061', 'EFO_0000365', 'MONDO_0001187', 'MONDO_0008170']",True,False,44,Poly [ADP-ribose] polymerase-1 inhibitor Poly [ADP-ribose] polymerase 2 inhibitor ,INHIBITOR ,single protein 
7,DARATUMUMAB,CHEMBL1743007,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 34 investigational indications.,,4.0,,False,2015,['ENSG00000004468'],"['MONDO_0019438', 'EFO_0001378', 'EFO_0000222', 'EFO_0005952', 'MONDO_0007915', 'EFO_0007160', 'EFO_0003060', 'EFO_0006475', 'EFO_0000403', 'EFO_0005761', 'MONDO_0018906', 'EFO_0004256', 'EFO_0000198', 'EFO_1001875', 'EFO_0000220', 'EFO_1001469', 'EFO_0000349', 'EFO_0000616', 'EFO_0003073', 'MONDO_0018904', 'EFO_1001115', 'EFO_0000574', 'EFO_0000519', 'EFO_0009441', 'EFO_0000203', 'EFO_0000209', 'EFO_0000183', 'EFO_1001051', 'EFO_0000673', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000095', 'EFO_0004599', 'MONDO_0004975', 'EFO_0006738', 'EFO_0005558', 'MONDO_0008315']",True,False,37,Lymphocyte differentiation antigen CD38 inhibitor ,INHIBITOR ,single protein 
8,INSULIN DETEMIR,CHEMBL2104391,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 5 investigational indications.,,4.0,,False,2005,['ENSG00000171105'],"['EFO_0003914', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0005147', 'MONDO_0009061', 'EFO_0000537', 'EFO_0001645', 'HP_0003124']",False,False,8,Insulin receptor agonist ,AGONIST ,single protein 
9,LIPROTAMASE,CHEMBL2108703,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0001684', 'MONDO_0009061']",False,False,2,,,
10,TCN-032,CHEMBL2109619,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,Matrix protein 2 inhibitor ,INHIBITOR ,single protein 
11,SOLCITINIB,CHEMBL3301606,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000162434'],"['MONDO_0007915', 'EFO_0000676', 'EFO_0000729']",False,False,3,Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
12,DENINTUZUMAB MAFODOTIN,CHEMBL3545371,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000177455'],"['EFO_1001469', 'EFO_0000220', 'EFO_0000403', 'EFO_0000309', 'MONDO_0018906']",False,False,5,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
13,PAMIDRONATE DISODIUM,CHEMBL3989401,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications.,,4.0,,False,1991,['ENSG00000160752'],"['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'MONDO_0019019']",True,False,4,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
14,ELUFORSEN,CHEMBL4594587,Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
15,IDREVLORIDE,CHEMBL5095031,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']",['MONDO_0009061'],False,False,1,"Amiloride-sensitive sodium channel, ENaC blocker ",BLOCKER ,protein complex 
16,DIVARASIB,CHEMBL5095236,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
17,PEGLOPRASTIDE,CHEMBL5095310,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0006318']",False,False,2,,,
18,MOTESANIB,CHEMBL572881,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.,,3.0,,False,no approval year,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853']","['MONDO_0007254', 'MONDO_0021063', 'MONDO_0008903', 'MONDO_0007254', 'EFO_1000657', 'MONDO_0007576', 'EFO_0003060', 'MONDO_0002087', 'MONDO_0008170', 'MONDO_0011719', 'EFO_0002618', 'EFO_0000616', 'EFO_0007331', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0002108', 'EFO_0004243', 'EFO_0000574', 'MONDO_0016537']",True,True,19,Tyrosine-protein kinase receptor RET inhibitor Platelet-derived growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein complex protein family 
19,IROFULVEN,CHEMBL118218,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008315', 'MONDO_0007254', 'MONDO_0011962', 'MONDO_0002691', 'EFO_0000616', 'MONDO_0002158', 'EFO_0000565', 'EFO_0000198', 'MONDO_0002367', 'EFO_0002618', 'MONDO_0008903', 'EFO_1000158', 'MONDO_0001056', 'EFO_0000389', 'MONDO_0002974', 'MONDO_0002087', 'MONDO_0002108', 'MONDO_0008170', 'EFO_1001951']",False,False,19,,,
20,PARICALCITOL,CHEMBL1200622,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 16 investigational indications.,,4.0,,False,1998,['ENSG00000111424'],"['EFO_0000616', 'EFO_0003086', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0001378', 'EFO_0002517', 'EFO_0000401', 'MONDO_0005148', 'HP_0002901', 'EFO_0004194', 'EFO_0002618', 'EFO_0003896', 'EFO_1000657', 'HP_0000093', 'EFO_1001173', 'EFO_0005754', 'EFO_0008506', 'EFO_0003884', 'EFO_0004285']",True,False,19,Vitamin D receptor agonist ,AGONIST ,single protein 
21,HUHMFG1,CHEMBL2109637,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000185499'],"['EFO_0000305', 'MONDO_0007254']",False,False,2,Mucin-1 other ,OTHER ,single protein 
22,DAROTROPIUM,CHEMBL2365940,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000133019', 'ENSG00000180720', 'ENSG00000168539', 'ENSG00000181072', 'ENSG00000184984']",['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor antagonist ,ANTAGONIST ,protein family 
23,GENTAMICIN,CHEMBL3039597,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 8 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1970,[],"['EFO_1000657', 'EFO_0003843', 'MONDO_0007254', 'EFO_1001272', 'MP_0001845', 'EFO_0000544', 'EFO_0009449', 'EFO_0003106', 'EFO_1001888', 'EFO_1001753', 'EFO_1000702', 'EFO_0005044', 'EFO_0009536', 'MONDO_0009179', 'MONDO_0009179', 'HP_0000964', 'HP_0100806', 'MONDO_0004992', 'MONDO_0009061', 'MONDO_0017612', 'EFO_0003102', 'MONDO_0018914', 'EFO_0006862', 'EFO_1000690', 'EFO_0009450', 'EFO_0009425', 'EFO_1001865', 'EFO_0000544', 'DOID_7551', 'MONDO_0010311', 'EFO_0000771', 'MONDO_0010679', 'EFO_1001459', 'EFO_0000771', 'EFO_0000274', 'MONDO_0021063', 'EFO_0009948', 'MONDO_0002406', 'EFO_0007195', 'EFO_0005046']",False,False,40,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
24,METHOTREXATE,CHEMBL34259,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 22 approved and 139 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1953,['ENSG00000228716'],"['EFO_1001209', 'MONDO_0019460', 'EFO_0000221', 'EFO_1000785', 'EFO_0000717', 'EFO_0000339', 'MONDO_0019338', 'EFO_0004192', 'EFO_0000224', 'MONDO_0019469', 'EFO_0003027', 'EFO_0003811', 'EFO_0006859', 'EFO_1001469', 'MONDO_0018944', 'MONDO_0021054', 'EFO_1001012', 'EFO_0002609', 'EFO_0000232', 'EFO_0000616', 'MONDO_0004979', 'EFO_0002939', 'EFO_0000574', 'MONDO_0015540', 'EFO_0000384', 'EFO_0004208', 'EFO_0000389', 'EFO_0003778', 'MONDO_0004192', 'EFO_0000096', 'EFO_0000255', 'EFO_0000612', 'MONDO_0005178', 'EFO_1001486', 'EFO_0000565', 'EFO_1000131', 'EFO_0006475', 'MONDO_0044917', 'MONDO_0011382', 'EFO_1001471', 'EFO_1001365', 'EFO_0005952', 'EFO_0009784', 'MONDO_0004986', 'HP_0012410', 'EFO_0000274', 'EFO_1000309', 'MONDO_0010518', 'EFO_0000094', 'EFO_0002893', 'EFO_0000095', 'EFO_0003025', 'MONDO_0005090', 'EFO_0007187', 'MONDO_0100096', 'EFO_0000209', 'EFO_0000198', 'MONDO_0015253', 'EFO_0001642', 'EFO_0000729', 'MONDO_0009833', 'EFO_0009441', 'EFO_0005531', 'EFO_0004284', 'EFO_0000305', 'MONDO_0002041', 'MONDO_0000873', 'EFO_0001068', 'EFO_0000540', 'MONDO_0018848', 'MP_0001845', 'MONDO_0008903', 'EFO_0000181', 'MONDO_0008170', 'EFO_0003032', 'MONDO_0024280', 'MONDO_0005575', 'EFO_1001779', 'EFO_0005297', 'EFO_0008528', 'MONDO_0017198', 'MONDO_0003005', 'EFO_0003898', 'MONDO_0019200', 'EFO_0000770', 'EFO_0003802', 'EFO_1000318', 'MONDO_0019471', 'MONDO_0001187', 'EFO_0002428', 'EFO_0000191', 'EFO_0000707', 'EFO_1001494', 'EFO_0000223', 'MONDO_0016717', 'EFO_0004289', 'MONDO_0044881', 'EFO_1000298', 'MONDO_0005301', 'EFO_0002430', 'EFO_0000557', 'EFO_0000691', 'EFO_0003869', 'EFO_0000403', 'MONDO_0002367', 'EFO_0000588', 'EFO_1001951', 'EFO_0005856', 'EFO_0004599', 'MONDO_0007254', 'EFO_0009708', 'EFO_0000637', 'MONDO_0002038', 'MONDO_0013730', 'EFO_0006803', 'EFO_0002429', 'EFO_0000764', 'MONDO_0002974', 'EFO_0000309', 'EFO_0001075', 'MONDO_0001657', 'MONDO_0000159', 'MONDO_0015974', 'MONDO_0018975', 'EFO_1000956', 'MONDO_0004992', 'EFO_0003833', 'MONDO_0020077', 'EFO_0000183', 'EFO_1001231', 'MONDO_0019391', 'EFO_0000211', 'EFO_0004991', 'EFO_0006818', 'MONDO_0000870', 'EFO_0000220', 'EFO_1000158', 'EFO_1001176', 'EFO_1000986', 'EFO_1001051', 'EFO_0005235', 'EFO_0001645', 'EFO_0000676', 'EFO_0000319', 'EFO_1001129', 'EFO_0000220', 'EFO_0004251', 'EFO_1001830', 'EFO_0000218', 'HP_0001915', 'EFO_0000222', 'MONDO_0007915', 'EFO_0000685', 'MONDO_0003478', 'EFO_0009907', 'MONDO_0044903', 'MONDO_0019472', 'EFO_0000621', 'EFO_0001378', 'MONDO_0018906', 'EFO_0000398']",True,False,161,Dihydrofolate reductase inhibitor ,INHIBITOR ,single protein 
25,VOXTALISIB,CHEMBL3545366,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,2.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']","['EFO_0003060', 'MONDO_0007254', 'MONDO_0003268', 'EFO_0000756', 'EFO_0000574', 'EFO_0000616', 'EFO_0000095', 'EFO_1001469', 'EFO_1001951', 'EFO_0000519', 'MONDO_0004992', 'MONDO_0008170']",True,False,12,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
26,GSK2256294,CHEMBL3818875,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000120915'],['EFO_0000341'],False,True,1,Epoxide hydratase inhibitor ,INHIBITOR ,single protein 
27,ANDECALIXIMAB,CHEMBL3833374,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000100985'],"['EFO_0000341', 'EFO_0000685', 'EFO_0000384', 'EFO_0000729', 'MONDO_0009061', 'EFO_0000503']",False,True,6,Matrix metalloproteinase 9 inhibitor ,INHIBITOR ,single protein 
28,CHLOROQUINE HYDROCHLORIDE,CHEMBL4297165,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and has 2 investigational indications.,,4.0,,False,1949,[],"['MONDO_0007915', 'EFO_0000685']",False,False,2,,,
29,AVASOPASEM MANGANESE,CHEMBL4297957,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0003086', 'EFO_0002618', 'HP_0100633', 'MONDO_0044926', 'EFO_0000199', 'EFO_1001904']",False,False,7,,,
30,EMD-1201081,CHEMBL4297993,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000239732'],"['EFO_0000681', 'EFO_0003060', 'EFO_1001951']",False,False,3,Toll-like receptor 9 agonist ,AGONIST ,single protein 
31,BOTENSILIMAB,CHEMBL4650435,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000756', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0008170', 'MONDO_0011962', 'EFO_0003968', 'EFO_0003060']",False,False,7,,,
32,INDOXIMOD,CHEMBL571209,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000141564', 'ENSG00000167965']","['EFO_0000756', 'EFO_1000028', 'MONDO_0007254', 'EFO_0002617', 'EFO_0002939', 'EFO_0003060', 'EFO_0000222', 'EFO_0000616', 'EFO_1001465', 'EFO_0000196']",False,False,10,mTORC1 activator ,ACTIVATOR ,protein complex 
33,MEMANTINE,CHEMBL807,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and has 50 investigational indications.,,4.0,,False,2003,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']","['HP_0012167', 'EFO_0000326', 'MONDO_0010383', 'MONDO_0005180', 'MONDO_0004985', 'EFO_0009386', 'EFO_0005611', 'EFO_0003890', 'EFO_0003758', 'MONDO_0007079', 'MONDO_0004976', 'HP_0100543', 'EFO_0007328', 'MONDO_0005090', 'MONDO_0002050', 'MONDO_0017276', 'MONDO_0002009', 'EFO_0003757', 'HP_0002140', 'MONDO_0005277', 'EFO_0003833', 'MONDO_0011382', 'MONDO_0004975', 'HP_0001268', 'EFO_0005411', 'MONDO_0002046', 'EFO_0001073', 'EFO_0004699', 'EFO_0004329', 'MONDO_0002491', 'EFO_1001801', 'EFO_0004240', 'MONDO_0007739', 'MONDO_0004681', 'EFO_0000519', 'MONDO_0007915', 'EFO_0005407', 'EFO_0005230', 'EFO_0003768', 'EFO_0003758', 'EFO_0003843', 'MONDO_0004976', 'MONDO_0004975', 'EFO_0004242', 'HP_0012228', 'MONDO_0005301', 'EFO_0004190', 'EFO_1001465', 'EFO_0005762', 'EFO_0003756', 'EFO_0005687', 'EFO_0002610']",False,False,52,Glutamate [NMDA] receptor negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,protein complex group 
34,ENZALUTAMIDE,CHEMBL1082407,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 15 investigational indications.,,4.0,,False,2012,['ENSG00000169083'],"['EFO_1001469', 'EFO_0000196', 'EFO_0001663', 'EFO_0001421', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000349', 'EFO_0003086', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0000305', 'EFO_0000673', 'EFO_0003859', 'MONDO_0100096', 'EFO_0002618', 'EFO_0000182', 'EFO_0000616', 'MONDO_0100096', 'MONDO_0001187', 'EFO_0000313', 'MONDO_0007254']",True,False,21,Androgen Receptor antagonist ,ANTAGONIST ,single protein 
35,ZINC ACETATE,CHEMBL1200928,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for exanthem and movement disorder and has 5 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'HP_0012735', 'EFO_1000697', 'MONDO_0010200', 'EFO_0003106', 'EFO_0004280', 'EFO_1001904']",False,False,7,,,
36,NORGESTIMATE,CHEMBL1200934,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for acne and has 7 investigational indications.,,4.0,,False,1989,['ENSG00000082175'],"['MONDO_0018075', 'EFO_0003894', 'MONDO_0009061', 'HP_0100608', 'EFO_0003882', 'EFO_0003047', 'EFO_0000764', 'MONDO_0005277']",False,False,8,Progesterone receptor agonist ,AGONIST ,single protein 
37,CUDC-305,CHEMBL2419346,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['EFO_1001494', 'EFO_0000574', 'MONDO_0004992', 'EFO_0003060']",False,False,4,,,
38,SOTAGLIFLOZIN,CHEMBL3039507,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 5 investigational indications.,,4.0,,False,no approval year,"['ENSG00000100170', 'ENSG00000140675']","['EFO_0000400', 'EFO_0003144', 'MONDO_0005148', 'EFO_0003086', 'EFO_0001421', 'MONDO_0005147']",False,False,6,Sodium/glucose cotransporter 1 inhibitor Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
39,DEXTROTHYROXINE SODIUM,CHEMBL3545058,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 2 investigational indications.,,4.0,,False,1967,"['ENSG00000126351', 'ENSG00000151090']","['EFO_1001375', 'EFO_0000612']",False,False,2,Thyroid hormone receptor agonist ,AGONIST ,protein complex 
40,PF-06651600,CHEMBL4085457,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113263', 'ENSG00000102010', 'ENSG00000135605', 'ENSG00000074966', 'ENSG00000010671', 'ENSG00000105639']","['EFO_0000384', 'EFO_0004208', 'EFO_0004192', 'EFO_0001421', 'EFO_0003086', 'EFO_0000729', 'EFO_0000685']",True,False,7,TEC family kinase inhibitor Tyrosine-protein kinase JAK3 inhibitor ,INHIBITOR ,protein family single protein 
41,PENPULIMAB,CHEMBL4297571,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000702', 'EFO_0003060', 'EFO_0003108', 'MONDO_0002108', 'EFO_0000183', 'EFO_0003860', 'MONDO_0004992', 'EFO_0002618', 'EFO_0003869', 'EFO_0000708', 'EFO_0000574', 'EFO_0000178', 'EFO_0000519', 'EFO_0004252', 'MONDO_0008903', 'EFO_0000182', 'MONDO_0002974', 'EFO_0000403', 'EFO_0005922', 'EFO_1001951']",True,False,20,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
42,LANIQUIDAR,CHEMBL539378,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
43,CYSTEAMINE,CHEMBL602,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for eye disease and cystinosis and has 10 investigational indications.,,4.0,,False,1994,[],"['MONDO_0016239', 'EFO_0000764', 'MONDO_0044970', 'EFO_0007328', 'EFO_0003966', 'EFO_0003095', 'MONDO_0009061', 'MONDO_0004979', 'MONDO_0016239', 'HP_0001397', 'MONDO_0100096', 'EFO_0003106', 'MONDO_0016239']",False,False,13,,,
44,CELECOXIB,CHEMBL118,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 17 approved and 93 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000073756'],"['HP_0012532', 'MONDO_0005090', 'EFO_1001893', 'MP_0001914', 'MONDO_0001657', 'EFO_0005279', 'EFO_0009606', 'EFO_0000546', 'EFO_0002496', 'EFO_0004239', 'EFO_0004251', 'EFO_0005252', 'EFO_0003868', 'MONDO_0018975', 'EFO_0005406', 'EFO_0003843', 'EFO_0000284', 'HP_0100607', 'MONDO_0042487', 'EFO_0001075', 'MONDO_0018076', 'MONDO_0004976', 'MONDO_0011705', 'MONDO_0002087', 'HP_0004398', 'MONDO_0004247', 'EFO_0000668', 'EFO_0004142', 'EFO_0000616', 'MP_0001845', 'EFO_0000681', 'MONDO_0002363', 'EFO_0007328', 'MONDO_0002974', 'EFO_0000621', 'EFO_0001073', 'MONDO_0004985', 'EFO_0004242', 'EFO_0000685', 'EFO_1001904', 'EFO_0002939', 'EFO_0005543', 'EFO_0004288', 'HP_0003418', 'EFO_0001416', 'MONDO_0008170', 'MONDO_0044937', 'EFO_0007453', 'MONDO_0021063', 'MONDO_0007254', 'EFO_0004252', 'EFO_0008525', 'EFO_1001950', 'EFO_0000673', 'EFO_0010072', 'MONDO_0002258', 'EFO_0003893', 'EFO_0000691', 'MONDO_0010200', 'MONDO_0001187', 'EFO_0000305', 'EFO_0005669', 'EFO_0002609', 'MONDO_0002715', 'MONDO_0004975', 'EFO_0005755', 'EFO_0000203', 'HP_0011110', 'EFO_0002618', 'MONDO_0007576', 'EFO_1001250', 'MONDO_0004992', 'EFO_0003898', 'MONDO_0002050', 'MONDO_0003937', 'EFO_0004274', 'EFO_0009625', 'EFO_0004142', 'EFO_0001072', 'EFO_0000537', 'EFO_0000756', 'EFO_0000199', 'MONDO_0002009', 'EFO_0003869', 'EFO_0000365', 'EFO_0004616', 'EFO_0005762', 'MONDO_0005178', 'EFO_1001951', 'EFO_1000786', 'MONDO_0008903', 'Orphanet_733', 'EFO_0003060', 'MONDO_0005277', 'EFO_0000712', 'MONDO_0002691', 'MONDO_0100096', 'EFO_1000158', 'EFO_1001466', 'EFO_0006859', 'MONDO_0024475', 'MONDO_0008315', 'EFO_0000519', 'EFO_0001668', 'EFO_0003768', 'HP_0003419', 'EFO_1000657', 'MONDO_0004658', 'EFO_0001378', 'EFO_0000182']",True,False,110,Cyclooxygenase-2 inhibitor ,INHIBITOR ,single protein 
45,INTERFERON BETA-1B,CHEMBL1201563,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for neoplasm and multiple sclerosis and has 5 investigational indications.,,4.0,,False,1993,"['ENSG00000142166', 'ENSG00000159110']","['EFO_0000616', 'MONDO_0100096', 'EFO_0000764', 'MONDO_0005301', 'MONDO_0100116', 'EFO_0000318', 'EFO_0003929']",True,True,7,Interferon alpha/beta receptor agonist ,AGONIST ,protein complex 
46,CANAKINUMAB,CHEMBL1201834,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 33 investigational indications.,,4.0,,False,2009,['ENSG00000125538'],"['MONDO_0011776', 'EFO_0001365', 'EFO_1000906', 'MONDO_0018088', 'EFO_0008518', 'EFO_0000756', 'MONDO_0017708', 'EFO_0000275', 'EFO_0004265', 'EFO_0000341', 'EFO_0002609', 'EFO_0002517', 'EFO_0004274', 'MONDO_0005148', 'EFO_0004246', 'EFO_1001345', 'MONDO_0005147', 'EFO_0003914', 'MONDO_0007254', 'MONDO_0016168', 'EFO_0000540', 'EFO_0000681', 'EFO_0004214', 'MONDO_0008633', 'EFO_1001165', 'HP_0000999', 'HP_0001945', 'EFO_1001478', 'MONDO_0005178', 'EFO_0003106', 'EFO_0003780', 'EFO_0001071', 'DOID_13406', 'EFO_0000685', 'EFO_0003060', 'HP_0001943', 'MONDO_0011382', 'MONDO_0100096', 'EFO_0007135', 'EFO_0000198']",True,False,40,Interleukin-1 beta inhibitor ,INHIBITOR ,single protein 
47,CEFUROXIME,CHEMBL1436,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 4 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000771', 'EFO_0007149', 'MONDO_0016047', 'EFO_1001888', 'EFO_0003106', 'EFO_0000544', 'EFO_0003102']",False,False,7,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
48,LTX-109,CHEMBL1817968,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000714', 'EFO_1000710', 'MONDO_0100096', 'EFO_0005681']",False,False,4,,,
49,TACROLIMUS,CHEMBL269732,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for eczema and immune system disease and has 128 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000088832'],"['EFO_1000794', 'EFO_0003086', 'EFO_0000274', 'EFO_1000309', 'MONDO_0018906', 'MONDO_0019469', 'MONDO_0013730', 'MONDO_0002334', 'EFO_0004254', 'EFO_0002687', 'EFO_0000183', 'EFO_0004251', 'HP_0001399', 'EFO_0003777', 'MONDO_0004979', 'EFO_1000690', 'EFO_0000198', 'EFO_0001423', 'EFO_0000400', 'MONDO_0100096', 'EFO_0008517', 'EFO_1002048', 'EFO_0003834', 'EFO_0000255', 'EFO_0000403', 'EFO_0000211', 'MONDO_0004992', 'EFO_1001993', 'MONDO_0021193', 'EFO_0004194', 'EFO_0003032', 'HP_0012410', 'EFO_0004228', 'MONDO_0005147', 'EFO_0000574', 'EFO_0001378', 'EFO_0003884', 'EFO_0006475', 'EFO_0000729', 'MONDO_0010518', 'EFO_0003047', 'EFO_0004208', 'MONDO_0000873', 'MONDO_0015253', 'MONDO_0009833', 'EFO_0009441', 'EFO_0000222', 'HP_0003124', 'EFO_0006803', 'EFO_0000676', 'HP_0001915', 'EFO_0002428', 'EFO_0005676', 'MONDO_0004768', 'EFO_0004991', 'EFO_0004236', 'EFO_0000544', 'EFO_0000339', 'EFO_0000685', 'EFO_0009510', 'EFO_0006927', 'HP_0000964', 'EFO_1001020', 'EFO_1001051', 'EFO_0007183', 'EFO_1000131', 'MONDO_0004976', 'EFO_0004599', 'Orphanet_848', 'EFO_0000621', 'MONDO_0019471', 'EFO_0000191', 'EFO_0000309', 'MONDO_0005301', 'EFO_0003818', 'EFO_0001361', 'EFO_0000540', 'EFO_1000764', 'MONDO_0044881', 'EFO_1001469', 'MONDO_0008315', 'EFO_1000785', 'EFO_1001413', 'EFO_0007141', 'EFO_0003872', 'MONDO_0044903', 'EFO_0009373', 'MONDO_0000870', 'EFO_0004255', 'EFO_0000545', 'EFO_0000096', 'MONDO_0015760', 'EFO_0000691', 'EFO_1001996', 'EFO_0000095', 'MONDO_0002898', 'EFO_0002430', 'EFO_0005803', 'EFO_0000512', 'EFO_0007157', 'MONDO_0004907', 'EFO_0002429', 'EFO_0004220', 'EFO_0001365', 'EFO_0000717', 'EFO_0005761', 'MONDO_0015974', 'MONDO_0000159', 'EFO_1000956', 'MONDO_0020077', 'EFO_0007160', 'EFO_0000616', 'MONDO_0019297', 'EFO_0000565', 'EFO_1000318', 'EFO_0000546', 'EFO_1000652', 'MONDO_0019472', 'EFO_0000220', 'MONDO_0018923', 'EFO_0005952', 'EFO_0000384', 'EFO_0001642', 'MONDO_0011382', 'EFO_0000182', 'EFO_0001421', 'EFO_0004286', 'EFO_1001779', 'EFO_1000623', 'MONDO_0002367']",True,False,130,FK506-binding protein 1A inhibitor ,INHIBITOR ,single protein 
50,TRANIMILAST,CHEMBL3113974,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['MONDO_0004979', 'EFO_0000341']",True,False,2,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
51,TUCATINIB,CHEMBL3989868,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 approved and 8 investigational indications.,,4.0,,False,2020,['ENSG00000141736'],"['MONDO_0007254', 'EFO_0000339', 'EFO_1000294', 'EFO_0001421', 'EFO_0003060', 'EFO_0003833', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0004142', 'EFO_0000182', 'EFO_0003968', 'EFO_0000305', 'EFO_0005537']",False,True,14,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
52,XENTUZUMAB,CHEMBL4297850,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000167244', 'ENSG00000017427']","['EFO_0000616', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008315', 'EFO_0003060']",False,False,5,Insulin-like growth factor II inhibitor Insulin-like growth factor I inhibitor ,INHIBITOR ,single protein 
53,CC-90001,CHEMBL4847106,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0001421', 'EFO_0009448', 'EFO_0000768']",False,False,3,,,
54,VINCRISTINE,CHEMBL90555,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for neoplasm and has 89 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1963,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000174', 'MONDO_0000870', 'EFO_0000248', 'EFO_0000220', 'MONDO_0008380', 'EFO_1000292', 'MONDO_0015760', 'EFO_0000094', 'EFO_0000183', 'MONDO_0016717', 'EFO_1001469', 'EFO_1001830', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289', 'EFO_0000255', 'EFO_0002918', 'EFO_0003833', 'EFO_0000574', 'EFO_0000403', 'EFO_0000621', 'EFO_0005952', 'EFO_0000096', 'MONDO_0008903', 'EFO_1000131', 'EFO_0000180', 'EFO_0000565', 'EFO_0005235', 'EFO_0000502', 'EFO_1000292', 'EFO_0000220', 'EFO_1000635', 'EFO_0002499', 'MONDO_0008380', 'EFO_1001951', 'EFO_0000209', 'EFO_0000211', 'EFO_0000095', 'MONDO_0015540', 'MONDO_0044881', 'MONDO_0002974', 'EFO_0007160', 'MONDO_0003478', 'HP_0001871', 'EFO_0000211', 'EFO_0000403', 'MONDO_0000873', 'MONDO_0009348', 'MONDO_0018271', 'EFO_0003833', 'EFO_0000309', 'EFO_0000222', 'EFO_0000437', 'EFO_0000272', 'EFO_1001469', 'EFO_0000309', 'EFO_0000094', 'MONDO_0000873', 'EFO_0009254', 'MONDO_0006058', 'EFO_0000313', 'EFO_0004289', 'MONDO_0018975', 'MONDO_0000432', 'EFO_0006859', 'EFO_0000095', 'EFO_1001365', 'EFO_0000198', 'MONDO_0018906', 'EFO_0000558', 'EFO_0000248', 'EFO_0000437', 'EFO_0001378', 'EFO_0003032', 'EFO_0000519', 'MONDO_0004095', 'EFO_1000158', 'EFO_1001042', 'EFO_0000756', 'EFO_0009708', 'EFO_0000621', 'MONDO_0002367', 'EFO_0003032', 'EFO_0000616', 'MONDO_0016700', 'EFO_0001378', 'MONDO_0019004', 'MONDO_0001657', 'MONDO_0000430', 'EFO_0000616', 'EFO_0000574', 'EFO_0000702', 'EFO_0000637', 'MONDO_0000870', 'EFO_1000318', 'EFO_0000209', 'MONDO_0018944', 'EFO_0002939', 'MONDO_0015564', 'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'EFO_1000158', 'EFO_0000565', 'EFO_0000588', 'MONDO_0009348', 'MONDO_0006058', 'EFO_0000222', 'EFO_1001365', 'EFO_0009441', 'MONDO_0018906', 'EFO_0000691', 'EFO_0000096', 'MONDO_0019471', 'EFO_0000765', 'EFO_0002918', 'EFO_0000174', 'MONDO_0044917']",True,False,118,Tubulin inhibitor ,INHIBITOR ,protein complex group 
55,DICLOFENAC EPOLAMINE,CHEMBL1201180,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for pain and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000073756', 'ENSG00000095303']","['MONDO_0007254', 'EFO_0009582', 'EFO_0003843', 'EFO_1000652']",True,False,4,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
56,VITAMIN K,CHEMBL1201519,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 11 investigational indications.,,4.0,,False,2000,[],"['EFO_0000729', 'HP_0004936', 'EFO_0000685', 'EFO_0000384', 'EFO_0003929', 'MONDO_0000831', 'EFO_0000616', 'EFO_0000275', 'MONDO_0004975', 'EFO_0003144', 'EFO_0003907']",False,False,11,,,
57,ERTAPENEM SODIUM,CHEMBL1232,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for osteomyelitis and infection and has 4 investigational indications.,,4.0,,False,2001,[],"['EFO_0003102', 'EFO_0003106', 'EFO_0003103', 'EFO_1001459', 'EFO_0000544', 'HP_0100806']",False,False,6,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
58,ERTAPENEM,CHEMBL1359,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 12 investigational indications.,,4.0,,False,2001,[],"['EFO_0003884', 'EFO_0000544', 'EFO_0003106', 'DOID_7551', 'EFO_0000771', 'EFO_0003106', 'EFO_1001312', 'EFO_0003103', 'EFO_1001459', 'EFO_0000544', 'EFO_1001141', 'HP_0100806', 'EFO_0007149', 'EFO_0003103', 'EFO_0003102', 'EFO_1001459', 'EFO_0003102', 'MONDO_0018076']",False,False,18,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
59,OLOKIZUMAB,CHEMBL1743050,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000136244'],"['MONDO_0100096', 'EFO_0000384', 'EFO_0000685', 'MONDO_0005178']",True,True,4,Interleukin-6 inhibitor ,INHIBITOR ,single protein 
60,TALAPORFIN,CHEMBL2111186,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002499', 'EFO_0000519', 'EFO_0004683', 'EFO_0000284', 'EFO_0000182']",False,False,5,,,
61,GRAPIPRANT,CHEMBL3039498,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000171522'],"['EFO_0003060', 'MONDO_0005178', 'EFO_0000305', 'EFO_1001951']",False,False,4,Prostanoid EP4 receptor antagonist ,ANTAGONIST ,single protein 
62,DEFACTINIB,CHEMBL3137331,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,"['ENSG00000120899', 'ENSG00000169398']","['EFO_0000466', 'EFO_0002618', 'EFO_0001378', 'EFO_0002517', 'MONDO_0008170', 'EFO_0000770', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000770', 'MONDO_0008170']",False,False,10,Focal adhesion kinase 1 inhibitor Protein tyrosine kinase 2 beta inhibitor ,INHIBITOR ,single protein 
63,M4344,CHEMBL4650286,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,['ENSG00000175054'],"['MONDO_0007254', 'MONDO_0008170', 'EFO_0000616']",False,False,3,Serine-protein kinase ATR inhibitor ,INHIBITOR ,single protein 
64,HPPH,CHEMBL500853,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008903', 'EFO_0000199', 'EFO_0007535', 'MONDO_0007576', 'EFO_0000280', 'EFO_0000181', 'MONDO_0044926', 'EFO_0006859', 'EFO_0000571', 'EFO_0000708']",False,False,10,,,
65,PROPOFOL,CHEMBL526,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 52 investigational indications.,,4.0,,False,1989,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']","['EFO_0004698', 'EFO_0000713', 'EFO_0003918', 'EFO_0003870', 'EFO_0004259', 'HP_0000989', 'EFO_0001074', 'EFO_0003855', 'EFO_0005251', 'EFO_0007355', 'MONDO_0002009', 'HP_0011110', 'HP_0003418', 'EFO_0002618', 'EFO_0003884', 'MONDO_0002050', 'EFO_0003917', 'EFO_0002687', 'HP_0000713', 'EFO_0006834', 'EFO_0004273', 'MONDO_0007576', 'EFO_0000662', 'MONDO_0043510', 'EFO_0001422', 'EFO_0001073', 'EFO_0009854', 'EFO_0003869', 'EFO_0000616', 'HP_0100806', 'EFO_0000537', 'EFO_0000712', 'HP_0031273', 'HP_0002093', 'EFO_0007490', 'HP_0000486', 'MONDO_0005277', 'EFO_0003843', 'EFO_0000546', 'EFO_0000565', 'MONDO_0004992', 'EFO_0000694', 'EFO_0008526', 'EFO_1002048', 'MP_0001845', 'EFO_1000644', 'EFO_1000637', 'EFO_1001951', 'EFO_0003777', 'EFO_1001454', 'EFO_0001645', 'MONDO_0021117']",True,False,52,GABA-A receptor; anion channel positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,protein complex group 
66,ISOTRETINOIN,CHEMBL547,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for acne and has 47 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1982,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']","['MONDO_0100096', 'EFO_0000632', 'EFO_0000180', 'EFO_0000502', 'EFO_0000616', 'EFO_0000565', 'EFO_1001051', 'EFO_0000544', 'EFO_0002501', 'MONDO_0008315', 'EFO_0000464', 'EFO_0000339', 'EFO_0001378', 'MONDO_0002974', 'EFO_1000309', 'EFO_0000621', 'MONDO_0003268', 'EFO_0004236', 'EFO_1000760', 'MONDO_0008903', 'EFO_0000519', 'EFO_1001465', 'EFO_0000403', 'EFO_0007512', 'EFO_0000198', 'MONDO_0002367', 'EFO_0002499', 'EFO_0000309', 'EFO_0003833', 'EFO_0000183', 'EFO_1000690', 'EFO_0002496', 'EFO_1001006', 'EFO_1000158', 'MONDO_0000870', 'MONDO_0000873', 'MONDO_0007254', 'EFO_0000681', 'EFO_0002939', 'EFO_0000222', 'EFO_0006859', 'EFO_1000910', 'EFO_0003894', 'EFO_0000224', 'EFO_0000279', 'MONDO_0004975', 'MONDO_0006058', 'MONDO_0019269']",True,False,48,Retinoic acid receptor agonist ,AGONIST ,protein family 
67,AFATINIB,CHEMBL1173655,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 25 investigational indications.,,4.0,,False,2013,"['ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']","['EFO_0003869', 'MONDO_0021117', 'EFO_0000673', 'MONDO_0001657', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378', 'EFO_0004142', 'MONDO_0008978', 'HP_0000083', 'EFO_0000707', 'EFO_0003859', 'EFO_0000702', 'MONDO_0007254', 'EFO_0002618', 'EFO_0003863', 'EFO_0009709', 'EFO_0000616', 'EFO_0004284', 'EFO_0005543', 'EFO_1001956', 'EFO_0000519', 'EFO_0000181', 'EFO_0005922', 'MONDO_0004992', 'EFO_0001421', 'EFO_0001065', 'EFO_0003060']",False,True,28,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
68,BERAPROST,CHEMBL1207745,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0001361', 'MONDO_0001134', 'HP_0004419', 'EFO_0003884', 'EFO_0003086']",False,False,5,,,
69,PIXANTRONE DIMALEATE,CHEMBL2103844,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000565', 'EFO_0000574', 'MONDO_0007254']",False,False,3,,,
70,TECEMOTIDE,CHEMBL3039544,Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000185499'],"['EFO_0003060', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0008903', 'MONDO_0044937', 'EFO_1000657', 'MONDO_0007254', 'EFO_1001950']",True,False,8,Mucin-1 vaccine antigen ,VACCINE ANTIGEN ,single protein 
71,PICOPLATIN,CHEMBL3544907,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000616', 'EFO_0006859', 'MONDO_0008170', 'MONDO_0001187', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0008903', 'EFO_0000702']",False,False,10,,,
72,JNJ-49095397,CHEMBL3695568,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003956', 'EFO_0000341', 'EFO_1001413']",False,False,3,,,
73,TOMIVOSERTIB,CHEMBL4073443,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000099875', 'ENSG00000079277']","['EFO_0000574', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000616']",True,False,7,MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor ,INHIBITOR ,protein family 
74,GENISTEIN,CHEMBL44,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000673', 'EFO_0001645', 'EFO_0000195', 'EFO_0003060', 'MONDO_0001187', 'EFO_1001951', 'MONDO_0007254', 'EFO_0009448', 'MONDO_0009061', 'EFO_0003882', 'MONDO_0004986', 'EFO_0000694', 'MONDO_0008315', 'EFO_1000657', 'MONDO_0021063', 'MONDO_0004992', 'EFO_0002618']",False,False,17,,,
75,MECAPEGFILGRASTIM,CHEMBL5095279,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
76,OPRELVEKIN,CHEMBL1201573,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for thrombocytopenia and neoplasm and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000137070'],"['Orphanet_903', 'EFO_0000095', 'EFO_0000191', 'EFO_0000339', 'MONDO_0018906', 'HP_0001873', 'MONDO_0010602', 'EFO_0009441', 'EFO_0000616']",False,False,9,Interleukin 11 receptor alpha agonist ,AGONIST ,single protein 
77,METHYLTESTOSTERONE,CHEMBL1395,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 1 investigational indication.,,4.0,,False,1973,['ENSG00000169083'],"['EFO_0003922', 'MONDO_0007254', 'MONDO_0002146', 'EFO_1001078']",True,False,4,Androgen Receptor agonist ,AGONIST ,single protein 
78,VIDOFLUDIMUS,CHEMBL197194,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000102967'],"['EFO_0000685', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0004268', 'EFO_0003767', 'EFO_0003929', 'EFO_0000729']",False,False,7,Dihydroorotate dehydrogenase inhibitor ,INHIBITOR ,single protein 
79,DELAFLOXACIN,CHEMBL2105637,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for bacterial disease and skin disease and has 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2017,[],"['EFO_0001421', 'EFO_1001272', 'EFO_0000771', 'EFO_0000701', 'EFO_0000544', 'DOID_7551', 'EFO_0003106']",False,False,7,Bacterial DNA gyrase inhibitor Topoisomerase IV inhibitor ,INHIBITOR ,protein complex 
80,CROFELEMER,CHEMBL2108184,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for diarrhea and aids and has 2 investigational indications.,,4.0,,False,2012,"['ENSG00000001626', 'ENSG00000131620']","['HP_0002014', 'EFO_0000555', 'MONDO_0007254', 'EFO_0000765']",False,False,4,Anoctamin-1 blocker Cystic fibrosis transmembrane conductance regulator inhibitor ,BLOCKER INHIBITOR ,single protein 
81,CORN OIL,CHEMBL2108243,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002009', 'EFO_0003884', 'EFO_0000612', 'MONDO_0004979', 'EFO_0004211', 'EFO_0000474', 'EFO_0003914', 'EFO_0001073', 'MONDO_0002050']",False,False,9,,,
82,AFURESERTIB,CHEMBL2219422,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']","['MONDO_0008170', 'MONDO_0008315', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0004992', 'EFO_1000318']",True,False,7,Serine/threonine-protein kinase AKT inhibitor ,INHIBITOR ,protein family 
83,CUSTIRSEN SODIUM,CHEMBL2219773,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000120885'],"['MONDO_0008315', 'MONDO_0007254', 'EFO_0003060']",True,False,3,Clusterin mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
84,LCL-161,CHEMBL2431768,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0002429', 'MONDO_0007254', 'EFO_0000616', 'EFO_0002618', 'EFO_0002430', 'MONDO_0044903', 'EFO_0001378']",False,False,7,,,
85,TALAZOPARIB TOSYLATE,CHEMBL3137318,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 4 investigational indications.,,4.0,,False,2018,"['ENSG00000143799', 'ENSG00000129484']","['EFO_0000616', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000222', 'EFO_0000305', 'EFO_0003869', 'EFO_0005537']",True,False,7,Poly [ADP-ribose] polymerase-1 inhibitor Poly [ADP-ribose] polymerase 2 inhibitor ,INHIBITOR ,single protein 
86,FENOTEROL,CHEMBL32800,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 3 investigational indications. It was withdrawn in at least one region.,,4.0,,False,no approval year,['ENSG00000169252'],"['EFO_0000373', 'HP_0006536', 'MONDO_0004979', 'EFO_0000341']",False,False,4,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
87,ASAPIPRANT,CHEMBL3545043,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000168229'],"['EFO_0003956', 'MONDO_0100096']",True,False,2,Prostanoid DP receptor antagonist ,ANTAGONIST ,single protein 
88,IBANDRONATE SODIUM,CHEMBL3989569,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for postmenopausal osteoporosis and osteoporosis and has 3 investigational indications.,,4.0,,False,2003,['ENSG00000160752'],"['EFO_0003854', 'MONDO_0007254', 'EFO_0003843', 'EFO_0003882', 'HP_0000938']",True,False,5,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
89,ZIMBERELIMAB,CHEMBL4297856,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000756', 'EFO_0000616', 'EFO_0000673', 'EFO_1000657', 'EFO_0002618', 'MONDO_0002974', 'MONDO_0009348', 'EFO_0000181', 'EFO_0003060', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0000519']",False,False,12,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
90,PLX-8394,CHEMBL4303729,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications.,,1.0,,False,no approval year,['ENSG00000157764'],"['EFO_0003060', 'EFO_0000616', 'EFO_0000756', 'HP_0100727', 'EFO_0005221', 'EFO_1000956', 'MONDO_0002108', 'EFO_1001951']",False,True,8,Serine/threonine-protein kinase B-raf inhibitor ,INHIBITOR ,single protein 
91,MOLNUPIRAVIR,CHEMBL4650320,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003086', 'EFO_0001421', 'MONDO_0100096', 'EFO_0000694']",False,False,4,,,
92,OCIPERLIMAB,CHEMBL4650411,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000181847'],"['EFO_0003060', 'EFO_0000182', 'EFO_0000403', 'EFO_0000702', 'EFO_0005922', 'MONDO_0002974', 'EFO_0000616']",True,False,7,T-cell immunoreceptor with Ig and ITIM domains inhibitor ,INHIBITOR ,single protein 
93,MONTELUKAST SODIUM,CHEMBL1200681,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000173198'],"['HP_0040187', 'MONDO_0004979', 'EFO_0003956', 'HP_0011950', 'EFO_0007183', 'EFO_1001417', 'EFO_0000341', 'EFO_0008521', 'EFO_0005854', 'EFO_0004232', 'HP_0100806']",False,False,11,Cysteinyl leukotriene receptor 1 antagonist ,ANTAGONIST ,single protein 
94,GADOLINIUM,CHEMBL1232993,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_1000026', 'MONDO_0002959', 'EFO_0003060', 'EFO_0003833', 'EFO_0000676', 'EFO_0000519', 'MONDO_0043510', 'EFO_0000341', 'MONDO_0003778', 'MONDO_0005277', 'EFO_0000326']",False,False,12,,,
95,SPIRONOLACTONE,CHEMBL1393,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 8 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1960,['ENSG00000151623'],"['EFO_0000401', 'HP_0001397', 'EFO_0000537', 'MONDO_0010679', 'EFO_0003894', 'EFO_0000400', 'EFO_1000899', 'EFO_0000275', 'EFO_0008586', 'EFO_0000319', 'EFO_0001422', 'EFO_0000373', 'EFO_0000574', 'EFO_0001361', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000266', 'HP_0001919', 'EFO_0003144', 'EFO_0000668', 'EFO_0001365', 'EFO_1001249', 'EFO_0000612', 'EFO_0000222', 'EFO_0004255', 'EFO_0000685', 'EFO_0008585', 'Orphanet_247', 'MONDO_0001134', 'EFO_0003884', 'MONDO_0000088', 'EFO_0000694', 'MONDO_0100096', 'EFO_0003963', 'HP_0012424', 'EFO_0005669', 'EFO_0000660', 'EFO_1001496']",True,False,38,Mineralocorticoid receptor antagonist ,ANTAGONIST ,single protein 
96,DENUFOSOL TETRASODIUM,CHEMBL1767407,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000175591'],"['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417']",False,False,4,Purinergic receptor P2Y2 agonist ,AGONIST ,single protein 
97,AMIKACIN,CHEMBL177,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,[],"['EFO_0003103', 'EFO_1001865', 'EFO_1001272', 'EFO_0003106', 'EFO_0009429', 'HP_0100806', 'EFO_1001888', 'EFO_1001272', 'EFO_0000341', 'EFO_0000771', 'MONDO_0009061', 'EFO_0000341', 'EFO_0000544', 'EFO_0000584', 'EFO_0008588', 'MONDO_0018076', 'EFO_0005681', 'EFO_0003818', 'EFO_0003102']",False,False,19,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
98,PALBOCICLIB,CHEMBL189963,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 40 investigational indications.,,4.0,,False,2015,"['ENSG00000110092', 'ENSG00000105810', 'ENSG00000135446']","['EFO_0008528', 'MONDO_0008170', 'EFO_0003060', 'EFO_1001950', 'EFO_0006318', 'EFO_0001378', 'EFO_0003869', 'EFO_0000305', 'EFO_0000349', 'EFO_0000569', 'EFO_0000616', 'EFO_0000182', 'EFO_0005952', 'MONDO_0007254', 'MONDO_0008978', 'EFO_0000574', 'MONDO_0008315', 'EFO_0000228', 'EFO_0000632', 'EFO_0002626', 'EFO_0002618', 'EFO_0004252', 'EFO_1001469', 'EFO_0000707', 'EFO_0000220', 'EFO_0000174', 'MONDO_0004992', 'EFO_1000045', 'EFO_0000630', 'EFO_0000637', 'Orphanet_145', 'EFO_0000181', 'MONDO_0011962', 'EFO_0002517', 'EFO_0000616', 'MONDO_0100096', 'EFO_0000708', 'EFO_0003086', 'EFO_0000519', 'EFO_0006859', 'EFO_0000681', 'EFO_1001968', 'MONDO_0008903', 'EFO_0000756', 'EFO_0000222']",True,True,45,CDK6/cyclin D1 inhibitor Cyclin-dependent kinase 4/cyclin D1 inhibitor ,INHIBITOR ,protein complex 
99,RADIUM DICHLORIDE,CHEMBL2111187,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 6 investigational indications.,,4.0,,False,2013,[],"['MONDO_0008315', 'EFO_0000691', 'EFO_0009708', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0001663', 'EFO_0003060', 'EFO_0009870', 'EFO_0000673', 'EFO_0000196', 'EFO_0001378', 'EFO_0003869']",False,False,12,,,
100,TESMILIFENE,CHEMBL26424,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
101,PICLIDENOSON,CHEMBL3989873,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000282608'],"['EFO_0004616', 'EFO_1000906', 'EFO_0000685', 'EFO_1000986', 'EFO_0000676', 'MONDO_0005041', 'MONDO_0100096', 'EFO_1001069', 'EFO_1001119']",False,False,9,Adenosine A3 receptor agonist ,AGONIST ,single protein 
102,ALX-009,CHEMBL4297691,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0009061', 'HP_0002110']",False,False,2,,,
103,PIMURUTAMAB,CHEMBL4594549,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_1001951', 'EFO_0005922', 'EFO_0003060', 'EFO_0000182', 'EFO_0000616', 'EFO_0000702', 'EFO_0000181']",False,True,7,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
104,APREMILAST,CHEMBL514800,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 23 investigational indications.,,4.0,,False,2014,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['MONDO_0015597', 'EFO_0003894', 'EFO_1000710', 'MONDO_0002406', 'MONDO_0007079', 'MONDO_0019558', 'EFO_0000729', 'EFO_0000685', 'EFO_0003106', 'MONDO_0100096', 'EFO_0003898', 'EFO_1000760', 'EFO_0000676', 'EFO_1000726', 'EFO_0007328', 'EFO_0003830', 'EFO_1000668', 'HP_0000155', 'EFO_0003778', 'EFO_0003780', 'EFO_1001231', 'EFO_0008517', 'EFO_0004208', 'HP_0000964', 'EFO_0000540', 'EFO_0000274', 'EFO_0000398', 'EFO_0004274']",True,False,28,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
105,MANNITOL,CHEMBL689,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 approved and 29 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000339', 'MONDO_0005178', 'MONDO_0004979', 'MONDO_0009061', 'EFO_1001139', 'EFO_0004238', 'MONDO_0100096', 'MONDO_0043510', 'HP_0002110', 'EFO_1001793', 'MONDO_0002492', 'MONDO_0041052', 'EFO_1001291', 'EFO_0000546', 'EFO_0006834', 'EFO_0005611', 'HP_0002019', 'EFO_0000712', 'EFO_0000341', 'EFO_0005207', 'EFO_0005251', 'EFO_0003843', 'EFO_1000845', 'EFO_1000158', 'MONDO_0001657', 'EFO_1000992', 'EFO_0003918', 'MONDO_0002367', 'EFO_0000519', 'EFO_0001645', 'EFO_0001068', 'EFO_0002501', 'EFO_1000783', 'EFO_0009715']",False,False,34,,,
106,LITHIUM CARBONATE,CHEMBL1200826,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 5 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1970,"['ENSG00000133731', 'ENSG00000105723', 'ENSG00000082701']","['MONDO_0005090', 'EFO_0004216', 'MONDO_0002050', 'MONDO_0007079', 'EFO_0000712', 'EFO_0005407', 'EFO_0009963', 'MONDO_0008315', 'EFO_1002017', 'MONDO_0015277', 'EFO_0011023', 'EFO_1000158', 'MONDO_0001475', 'EFO_1001901', 'MONDO_0005301', 'MONDO_0018982', 'MONDO_0017276', 'MONDO_0004976', 'MONDO_0019037', 'MONDO_0007739', 'MONDO_0001657', 'Orphanet_733', 'EFO_0000702', 'EFO_0003761', 'EFO_0003931', 'MONDO_0005180', 'EFO_0002615', 'EFO_1001919', 'MONDO_0008458', 'EFO_1001050', 'EFO_0009854', 'MONDO_0004975', 'MONDO_0004985', 'EFO_0003756', 'MONDO_0008119', 'EFO_0003015', 'Orphanet_98757', 'MONDO_0002009', 'EFO_0005230']",False,False,39,Glycogen synthase kinase-3 inhibitor Inositol-1(or 4)-monophosphatase 1 inhibitor ,INHIBITOR ,protein family single protein 
107,DICLOFENAC,CHEMBL139,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 15 approved and 32 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1988,"['ENSG00000073756', 'ENSG00000095303']","['EFO_0009582', 'MP_0001845', 'EFO_1000786', 'MONDO_0005277', 'EFO_0009582', 'EFO_0003898', 'MONDO_0005178', 'EFO_1001412', 'MONDO_0005178', 'EFO_0004616', 'EFO_0003843', 'EFO_0000685', 'EFO_0003843', 'HP_0003326', 'EFO_0010072', 'MONDO_0001187', 'EFO_1000652', 'EFO_1001139', 'EFO_0000649', 'MONDO_0005178', 'MP_0001845', 'EFO_0003843', 'EFO_0004274', 'EFO_1000720', 'MONDO_0007254', 'EFO_0000685', 'EFO_0003843', 'GO_0007568', 'EFO_0010072', 'MONDO_0005277', 'MONDO_0005129', 'EFO_1001366', 'EFO_0000545', 'HP_0100607', 'EFO_0000685', 'HP_0003419', 'EFO_0004272', 'EFO_0010072', 'EFO_0000546', 'EFO_0002496', 'EFO_0002496', 'MONDO_0002050', 'EFO_0009560', 'EFO_0000616', 'EFO_0004616', 'EFO_0002970', 'EFO_0009454', 'MP_0001914', 'HP_0002829', 'MONDO_0002959', 'EFO_0004193', 'EFO_0009582', 'HP_0100607', 'EFO_0005755', 'EFO_0003958', 'HP_0012532', 'EFO_0005752', 'EFO_0000313', 'EFO_0003827']",True,False,59,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
108,SONIDEGIB,CHEMBL2105737,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for basal cell carcinoma and neoplasm and has 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,['ENSG00000128602'],"['EFO_0004193', 'EFO_0002618', 'EFO_0004193', 'MONDO_0008315', 'EFO_0000616', 'EFO_0001378', 'MONDO_0007254', 'EFO_0003869', 'MONDO_0007576', 'MONDO_0008170', 'EFO_0001421', 'MONDO_0005341', 'EFO_0002939', 'MONDO_0013730', 'EFO_0000565']",False,False,15,Smoothened homolog inhibitor ,INHIBITOR ,single protein 
109,NAQUOTINIB,CHEMBL3663929,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0003060', 'EFO_0000616', 'EFO_0003060']",False,True,3,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
110,AVELUMAB,CHEMBL3833373,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 60 investigational indications.,,4.0,,False,2017,['ENSG00000120217'],"['MONDO_0100342', 'EFO_0000574', 'EFO_0004142', 'MONDO_0008170', 'MONDO_0011962', 'EFO_1000158', 'EFO_1001951', 'EFO_0000349', 'EFO_0006859', 'EFO_0000181', 'MONDO_0008315', 'MONDO_0016642', 'EFO_0000707', 'EFO_0008528', 'EFO_1001471', 'EFO_0002517', 'EFO_0000339', 'EFO_0000637', 'MONDO_0004992', 'MONDO_0002087', 'EFO_0000222', 'MONDO_0021063', 'EFO_0000182', 'EFO_0002618', 'EFO_0000403', 'EFO_1001901', 'EFO_0000365', 'EFO_0000231', 'EFO_0000096', 'MONDO_0007254', 'EFO_0000305', 'MONDO_0018906', 'EFO_0003968', 'MONDO_0002898', 'EFO_0003869', 'MONDO_0004986', 'MONDO_0002120', 'EFO_0000588', 'EFO_0000228', 'MONDO_0044903', 'EFO_0004252', 'EFO_0000519', 'EFO_0001378', 'EFO_1000581', 'MONDO_0002158', 'EFO_0000503', 'EFO_1000576', 'MONDO_0001187', 'EFO_0002890', 'EFO_0003863', 'EFO_0000564', 'EFO_0000681', 'MONDO_0018944', 'EFO_0000756', 'EFO_0005922', 'EFO_1000657', 'MONDO_0008978', 'EFO_0000616', 'EFO_0005952', 'EFO_0008528', 'EFO_0000196', 'EFO_0000183', 'EFO_0003060', 'EFO_0000702']",False,False,64,Programmed cell death 1 ligand 1 other ,OTHER ,single protein 
111,FILGRASTIM,CHEMBL1201567,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 165 investigational indications.,,4.0,,False,1991,['ENSG00000119535'],"['MONDO_0008867', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0001422', 'EFO_0000565', 'EFO_0009708', 'EFO_0000223', 'EFO_0001421', 'EFO_1001469', 'MONDO_0004643', 'EFO_0003833', 'EFO_0004272', 'MONDO_0015760', 'EFO_0003811', 'MONDO_0007576', 'EFO_0000198', 'EFO_0002918', 'MONDO_0002334', 'EFO_0000574', 'EFO_0003060', 'EFO_0000612', 'EFO_0003929', 'EFO_0000239', 'EFO_0000183', 'MONDO_0001475', 'EFO_0000637', 'EFO_0000545', 'MONDO_0008315', 'EFO_0005537', 'EFO_0003869', 'EFO_0008583', 'EFO_1001779', 'MONDO_0011382', 'EFO_0000221', 'EFO_0003802', 'MONDO_0002087', 'EFO_0000095', 'EFO_0001642', 'MONDO_0004986', 'HP_0001871', 'EFO_0003032', 'EFO_0000616', 'EFO_0004142', 'MONDO_0002974', 'Orphanet_848', 'Orphanet_303', 'EFO_0005529', 'EFO_1001345', 'MONDO_0003783', 'EFO_1001968', 'EFO_0000313', 'EFO_1001365', 'EFO_0003922', 'MONDO_0002691', 'EFO_0000220', 'MONDO_0009348', 'EFO_0004991', 'EFO_0004251', 'EFO_0000209', 'EFO_0000096', 'EFO_0000182', 'HP_0031217', 'MONDO_0008903', 'MONDO_0019460', 'EFO_0000196', 'EFO_1001465', 'EFO_0001378', 'HP_0008209', 'MONDO_0019391', 'EFO_1000749', 'EFO_0006803', 'EFO_0000760', 'EFO_0007416', 'EFO_0006927', 'EFO_0000717', 'EFO_0000702', 'EFO_0005952', 'EFO_0003928', 'EFO_0003029', 'MONDO_0003751', 'EFO_0007362', 'HP_0001399', 'HP_0001945', 'EFO_0000544', 'MONDO_0004192', 'MONDO_0005180', 'MONDO_0013730', 'EFO_1000131', 'EFO_0000339', 'EFO_0001376', 'MONDO_0018906', 'EFO_0003859', 'MONDO_0002158', 'EFO_0006475', 'EFO_0009441', 'EFO_0000384', 'EFO_0000218', 'EFO_0000466', 'EFO_0002428', 'EFO_1001951', 'EFO_0003875', 'MONDO_0007915', 'MONDO_0005301', 'EFO_0000691', 'EFO_0002939', 'EFO_1000796', 'EFO_0003025', 'HP_0002721', 'MONDO_0001056', 'MONDO_0000870', 'MONDO_0008170', 'MONDO_0001657', 'EFO_0004145', 'EFO_1000984', 'EFO_0004256', 'EFO_0000211', 'MONDO_0019438', 'EFO_0004281', 'EFO_0007498', 'MONDO_0005147', 'EFO_1001042', 'EFO_0002618', 'MONDO_0008380', 'EFO_0004252', 'MONDO_0004975', 'EFO_0000309', 'EFO_0000712', 'EFO_0006859', 'MONDO_0020077', 'HP_0002140', 'EFO_0000764', 'EFO_0000174', 'EFO_0000191', 'EFO_0001645', 'EFO_0000094', 'MONDO_0044903', 'HP_0012410', 'EFO_0000514', 'EFO_0002430', 'EFO_1000318', 'EFO_0003893', 'MONDO_0011962', 'MONDO_0015974', 'EFO_0000389', 'EFO_0005235', 'EFO_0000403', 'EFO_0000222', 'EFO_1000158', 'EFO_0000756', 'EFO_0000181', 'MONDO_0008978', 'MONDO_0006058', 'EFO_0004265', 'EFO_0000621', 'MONDO_0002367', 'MONDO_0044881', 'EFO_0006861', 'EFO_0007359', 'EFO_0003027', 'MONDO_0000873', 'MONDO_0019471', 'EFO_0000681', 'EFO_0000224', 'MONDO_0004976', 'HP_0001915', 'EFO_1000043', 'MONDO_0001187', 'EFO_0000407', 'EFO_1000632']",True,False,169,Granulocyte colony stimulating factor receptor agonist ,AGONIST ,single protein 
112,OTELIXIZUMAB,CHEMBL1743053,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000198851'],"['MONDO_0005147', 'EFO_1001466', 'EFO_0000685']",False,False,3,T-cell surface glycoprotein CD3 epsilon chain binding agent ,BINDING AGENT ,single protein 
113,GS-441524,CHEMBL2016757,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
114,OLODATEROL HYDROCHLORIDE,CHEMBL2105743,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications.,,4.0,,False,2014,['ENSG00000169252'],"['EFO_0006505', 'EFO_0000341', 'EFO_0000464']",False,False,3,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
115,TESETAXEL,CHEMBL2107787,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000178', 'EFO_0000756', 'EFO_0003869', 'MONDO_0008315', 'EFO_0000616', 'MONDO_0007254']",False,False,6,,,
116,INSULIN PEGLISPRO,CHEMBL2108569,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000171105'],"['MONDO_0005147', 'MONDO_0005148']",False,False,2,Insulin receptor agonist ,AGONIST ,single protein 
117,X-82,CHEMBL3545401,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_0001365', 'EFO_0000228', 'EFO_0003860', 'EFO_0000616']",False,False,4,Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor ,INHIBITOR ,protein family protein complex 
118,2'-FUCOSYLLACTOSE,CHEMBL4297252,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000729', 'EFO_0000384']",False,False,2,,,
119,RASDEGAFUSP ALFA,CHEMBL4297923,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000054219', 'ENSG00000184033', 'ENSG00000268651']","['MONDO_0004992', 'EFO_0000389', 'EFO_0003060']",False,False,3,Lymphocyte antigen 75 binding agent Cancer/testis antigen 1 vaccine antigen ,BINDING AGENT VACCINE ANTIGEN ,single protein 
120,ZANDELISIB,CHEMBL4650214,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000171608'],"['EFO_0000096', 'MONDO_0018906', 'EFO_0000403', 'MONDO_0004992', 'EFO_1001469', 'EFO_0000095']",True,False,6,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
121,PROFLAVINE,CHEMBL55400,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000280', 'MONDO_0021400', 'EFO_0000707', 'EFO_1001331', 'MONDO_0002715', 'EFO_0000280']",False,False,6,,,
122,ABEQUOLIXRON,CHEMBL573677,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,"['ENSG00000025434', 'ENSG00000131408']","['EFO_0003060', 'MONDO_0011962']",False,False,2,Liver X receptor agonist ,AGONIST ,protein family 
123,PROCAINAMIDE,CHEMBL640,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1950,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0004278', 'HP_0004308', 'EFO_0000612', 'EFO_0004269', 'EFO_0003144', 'EFO_0004287', 'EFO_0000275', 'EFO_0000275', 'EFO_0004269']",False,False,9,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
124,ETHANE DIMETHANE SULFONATE,CHEMBL170630,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0008903', 'EFO_0000681', 'MONDO_0007254', 'MONDO_0021063', 'EFO_0005952']",False,False,5,,,
125,AMISULPRIDE,CHEMBL243712,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 9 investigational indications.,,4.0,,False,2020,"['ENSG00000179097', 'ENSG00000135914', 'ENSG00000164270', 'ENSG00000135312', 'ENSG00000166736', 'ENSG00000178394', 'ENSG00000179546', 'ENSG00000102468', 'ENSG00000147246', 'ENSG00000168830', 'ENSG00000148680', 'ENSG00000158748', 'ENSG00000157219', 'ENSG00000186038', 'ENSG00000149305', 'ENSG00000186090', 'ENSG00000178084', 'ENSG00000149295', 'ENSG00000151577']","['MONDO_0005351', 'MONDO_0004985', 'EFO_0006911', 'EFO_0003884', 'EFO_0005230', 'MONDO_0002009', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0005407', 'EFO_0004888', 'HP_0002017', 'EFO_0004242']",True,False,12,Serotonin (5-HT) receptor antagonist Dopamine receptors; D2 & D3 antagonist ,ANTAGONIST ,protein family selectivity group 
126,TEPOTINIB,CHEMBL3402762,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for neoplasm and non-small cell lung carcinoma and has 6 investigational indications.,,4.0,,False,2021,['ENSG00000105976'],"['EFO_0003833', 'EFO_0003060', 'EFO_0001421', 'EFO_0000182', 'EFO_0000616', 'EFO_0004142', 'EFO_0000616', 'EFO_0003060']",False,False,8,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
127,MEFLOQUINE,CHEMBL416956,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1989,[],"['MONDO_0100096', 'EFO_0007444', 'EFO_0007455', 'EFO_0009686', 'EFO_0007444', 'EFO_0001068', 'EFO_1001465', 'EFO_0007445', 'EFO_0007530', 'EFO_0001068', 'EFO_0007541']",False,False,11,,,
128,MK-4280,CHEMBL4297784,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000089692'],"['EFO_0000616', 'EFO_0000183', 'EFO_0005952', 'EFO_0000681', 'EFO_0005922', 'EFO_0000756', 'EFO_0000702', 'EFO_0003060', 'EFO_1001951']",True,False,9,Lymphocyte activation gene 3 protein inhibitor ,INHIBITOR ,single protein 
129,BENEGRASTIM,CHEMBL4297950,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0001475']",False,False,2,,,
130,APILIMOD MESYLATE,CHEMBL4298111,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000115020'],"['EFO_0000685', 'EFO_0000384']",False,False,2,1-phosphatidylinositol 3-phosphate 5-kinase inhibitor ,INHIBITOR ,single protein 
131,TT-00420,CHEMBL4594509,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0005221']",False,False,2,,,
132,GLYCINE,CHEMBL773,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 12 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0005411', 'EFO_0008572', 'MONDO_0004979', 'EFO_0004242', 'MONDO_0005090', 'EFO_0000537', 'MONDO_0009061', 'MONDO_0004985', 'HP_0100543', 'MONDO_0100096', 'MONDO_0001673', 'MONDO_0004975']",False,False,12,,,
133,CLAVULANIC ACID,CHEMBL777,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 6 approved and 35 investigational indications.,,4.0,,False,1984,[],"['EFO_0006505', 'EFO_0004992', 'EFO_0007486', 'EFO_0003103', 'EFO_0003833', 'EFO_0000544', 'EFO_1001272', 'EFO_0000544', 'EFO_0004992', 'EFO_0007503', 'HP_0100806', 'EFO_1001141', 'EFO_0003768', 'EFO_1000961', 'EFO_1000049', 'EFO_0003030', 'MONDO_0004979', 'EFO_0003103', 'EFO_0002610', 'MONDO_0018076', 'MONDO_0002009', 'HP_0100806', 'EFO_0007328', 'MONDO_0100096', 'EFO_1001034', 'EFO_0003102', 'EFO_1001313', 'MONDO_0018076', 'EFO_0003106', 'HP_0001082', 'EFO_1001391', 'EFO_0003106', 'EFO_0004234', 'HP_0002014', 'EFO_0007486', 'EFO_0002499', 'EFO_0001073', 'MONDO_0024355', 'EFO_0000519', 'MONDO_0024355', 'MONDO_0000327', 'EFO_0006859', 'MONDO_0001187']",False,False,43,Bacterial beta-lactamase TEM inhibitor ,INHIBITOR ,single protein 
134,EMTRICITABINE,CHEMBL885,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2003,[],"['EFO_1001486', 'MONDO_0018076', 'EFO_0000180', 'EFO_0003047', 'EFO_0000764', 'EFO_0000544', 'EFO_0000765', 'EFO_0004197', 'MONDO_0100096', 'EFO_0002614', 'EFO_0004239', 'EFO_0000763']",False,False,12,Human immunodeficiency virus type 1 reverse transcriptase inhibitor ,INHIBITOR ,single protein 
135,IBANDRONIC ACID,CHEMBL997,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 11 investigational indications.,,4.0,,False,2003,['ENSG00000160752'],"['HP_0002027', 'EFO_0003854', 'EFO_0003820', 'EFO_0003854', 'MONDO_0007254', 'EFO_0003882', 'EFO_0004260', 'EFO_0001642', 'EFO_0001378', 'MONDO_0007254', 'EFO_0009708', 'EFO_0003843', 'EFO_0003843', 'EFO_0004259', 'EFO_0003882', 'HP_0000938']",True,False,16,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
136,GONADORELIN,CHEMBL1007,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 12 investigational indications.,,4.0,,False,1982,['ENSG00000109163'],"['MONDO_0018555', 'EFO_0000673', 'EFO_0003882', 'EFO_0000196', 'EFO_0001663', 'MONDO_0007254', 'EFO_0002610', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000545', 'MONDO_0018800', 'MONDO_0007254', 'MONDO_0002146']",False,False,13,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
137,PYRIDOSTIGMINE,CHEMBL1115,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1955,['ENSG00000087085'],"['EFO_0003144', 'EFO_0000764', 'MONDO_0100096', 'EFO_0005251', 'MONDO_0004567', 'MONDO_0005180', 'Orphanet_365', 'EFO_0004991', 'EFO_0005252', 'EFO_0005252', 'EFO_0000400', 'MONDO_0009672', 'EFO_0005687', 'Orphanet_83419']",False,False,14,Acetylcholinesterase inhibitor ,INHIBITOR ,single protein 
138,GLUTATHIONE,CHEMBL1543,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003843', 'MONDO_0005180', 'EFO_0002687', 'EFO_0007430', 'EFO_0004149', 'EFO_0003100', 'MONDO_0007254', 'MONDO_0009061', 'EFO_0002618']",False,False,9,,,
139,FOLITIXORIN CALCIUM,CHEMBL2103811,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0021063', 'EFO_1000657']",False,False,3,,,
140,"STARCH, CORN",CHEMBL2108052,Oligosaccharide drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
141,SEVITERONEL,CHEMBL3264610,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000169083', 'ENSG00000148795']","['EFO_0000616', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0008315']",True,False,4,Cytochrome P450 17A1 inhibitor Androgen Receptor antagonist ,INHIBITOR ANTAGONIST ,single protein 
142,SR16234,CHEMBL3545211,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000091831'],['MONDO_0007254'],False,True,1,Estrogen receptor alpha antagonist ,ANTAGONIST ,single protein 
143,DEXAMETHASONE,CHEMBL384467,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 74 approved and 211 investigational indications.,,4.0,,False,1958,['ENSG00000113580'],"['EFO_0001663', 'EFO_0000546', 'EFO_0009449', 'EFO_0000224', 'EFO_0003811', 'EFO_0000182', 'MONDO_0002331', 'EFO_1000657', 'EFO_1001267', 'EFO_1000941', 'EFO_1000694', 'EFO_0009456', 'EFO_1000764', 'MONDO_0013730', 'EFO_0004237', 'MONDO_0004992', 'EFO_0000095', 'HP_0000265', 'EFO_0007160', 'EFO_0003932', 'EFO_0009491', 'MONDO_0004565', 'EFO_0002913', 'MONDO_0019460', 'HP_0009926', 'MONDO_0019438', 'EFO_0000588', 'EFO_1001469', 'EFO_0003025', 'HP_0011950', 'EFO_0009441', 'EFO_0000729', 'EFO_0000673', 'EFO_0007405', 'EFO_1001012', 'EFO_0000565', 'EFO_0001642', 'MONDO_0003005', 'EFO_0003917', 'EFO_0000685', 'EFO_0003843', 'EFO_1000879', 'MONDO_0004658', 'EFO_0005952', 'EFO_1001205', 'MONDO_0009348', 'EFO_0000681', 'MONDO_0018479', 'EFO_0001068', 'EFO_0003956', 'HP_0002013', 'EFO_0000309', 'EFO_0000220', 'EFO_0003769', 'EFO_0000684', 'EFO_0004276', 'EFO_0007520', 'EFO_0006912', 'MONDO_0015564', 'EFO_0004238', 'EFO_0003802', 'MONDO_0015540', 'EFO_0009536', 'EFO_0006862', 'EFO_0004255', 'EFO_0006859', 'EFO_0007297', 'EFO_0000183', 'EFO_0000094', 'MONDO_0011962', 'HP_0000486', 'EFO_0000616', 'MONDO_0002406', 'EFO_0003770', 'EFO_0000223', 'HP_0030833', 'HP_0001094', 'EFO_0000708', 'EFO_0000384', 'HP_0003072', 'EFO_0003106', 'EFO_0000676', 'EFO_0008997', 'MONDO_0001280', 'EFO_0003103', 'MONDO_0002471', 'MONDO_0015128', 'EFO_1001115', 'EFO_0009609', 'EFO_1001250', 'HP_0002094', 'EFO_1000049', 'EFO_0009560', 'EFO_0004236', 'MONDO_0001056', 'EFO_1000965', 'EFO_0007541', 'EFO_0009552', 'EFO_0005752', 'EFO_0003893', 'EFO_0003778', 'MONDO_0019472', 'EFO_1001129', 'EFO_1001417', 'HP_0012378', 'MONDO_0007254', 'EFO_0008517', 'MONDO_0019338', 'EFO_0005221', 'MONDO_0017816', 'EFO_1001896', 'MONDO_0002959', 'MONDO_0005301', 'EFO_0005319', 'MONDO_0005041', 'EFO_0009430', 'EFO_0000274', 'MONDO_0008170', 'MONDO_0007935', 'EFO_1000726', 'HP_0001873', 'EFO_0004274', 'MONDO_0018076', 'EFO_0003032', 'EFO_1001494', 'EFO_0000218', 'MONDO_0044917', 'EFO_0003894', 'MONDO_0100096', 'EFO_1001194', 'MONDO_0006412', 'EFO_0005755', 'MONDO_0001572', 'EFO_0000222', 'EFO_0008520', 'EFO_0003073', 'EFO_0000221', 'EFO_0000613', 'EFO_1001968', 'EFO_0009869', 'MONDO_0007576', 'EFO_1001435', 'EFO_0007200', 'HP_0003418', 'EFO_0003027', 'MONDO_0000873', 'MONDO_0008903', 'MONDO_0002691', 'EFO_1000997', 'EFO_0001422', 'EFO_1001801', 'EFO_0009507', 'EFO_0000544', 'EFO_1001961', 'EFO_0000694', 'HP_0011868', 'EFO_0001063', 'EFO_0007228', 'EFO_0003884', 'EFO_0000209', 'EFO_0004888', 'EFO_0003966', 'MONDO_0001657', 'EFO_1001222', 'EFO_0003086', 'MONDO_0004979', 'EFO_0007231', 'EFO_0009104', 'MONDO_0005271', 'EFO_0006475', 'EFO_1000131', 'EFO_0001378', 'EFO_0007257', 'MONDO_0001718', 'EFO_1001119', 'EFO_1000845', 'EFO_0004616', 'EFO_0003869', 'EFO_0003957', 'MONDO_0007079', 'EFO_0005207', 'HP_0012532', 'Orphanet_1930', 'MONDO_0018896', 'MONDO_0018906', 'EFO_0000618', 'EFO_1001909', 'EFO_1000684', 'HP_0001915', 'EFO_1001830', 'EFO_1001051', 'EFO_0000198', 'EFO_0007403', 'MONDO_0008728', 'EFO_0009448', 'EFO_0004208', 'EFO_0004992', 'MONDO_0011382', 'EFO_0000365', 'EFO_0005570', 'EFO_0009708', 'EFO_0006738', 'EFO_1001951', 'MONDO_0000465', 'MONDO_0008315', 'MONDO_0000870', 'MONDO_0019091', 'EFO_0007486', 'HP_0002015', 'EFO_0002618', 'EFO_1000811', 'EFO_0002950', 'MONDO_0005178', 'EFO_0005592', 'EFO_0002609', 'HP_0011110', 'EFO_0005854', 'EFO_0005558', 'MONDO_0044881', 'MONDO_0100130', 'EFO_1000986', 'EFO_0000713', 'EFO_0007149', 'EFO_0004272', 'EFO_0004274', 'MONDO_0002462', 'HP_0002017', 'EFO_1000039', 'EFO_0000211', 'EFO_1001176', 'MONDO_0100053', 'EFO_0000373', 'EFO_0000181', 'EFO_0000756', 'MONDO_0021148', 'HP_0012424', 'EFO_1001157', 'EFO_0000691', 'EFO_0004252', 'EFO_0003898', 'EFO_0004719', 'EFO_0001365', 'EFO_0004710', 'MONDO_0001705', 'HP_0100806', 'EFO_0003060', 'MP_0001914', 'EFO_0007344', 'EFO_1000637', 'EFO_1001779', 'EFO_0007141', 'EFO_1000797', 'EFO_0000305', 'EFO_0004289', 'MONDO_0016226', 'EFO_0007355', 'MONDO_0011972', 'EFO_1001216', 'EFO_0008528', 'EFO_1000749', 'EFO_0006911', 'MONDO_0005277', 'EFO_0000537', 'HP_0004398', 'MONDO_0021108', 'EFO_0000403', 'EFO_0008571', 'EFO_0001075', 'MONDO_0007915', 'MONDO_0019471', 'EFO_1000906', 'HP_0002018', 'EFO_0004683', 'EFO_1000992', 'MONDO_0005129', 'EFO_0000096', 'EFO_1001875', 'MONDO_0001187', 'MP_0001845', 'EFO_1000318', 'EFO_0000574', 'EFO_0000702', 'HP_0001742', 'HP_0002315', 'EFO_1001158']",True,False,285,Glucocorticoid receptor agonist ,AGONIST ,single protein 
144,QUETMOLIMAB,CHEMBL4297942,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000006210'],"['EFO_0000685', 'EFO_1001486', 'EFO_0000384']",True,False,3,Fractalkine inhibitor ,INHIBITOR ,single protein 
145,OMEGA-3 FATTY ACIDS,CHEMBL4298065,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002950', 'MONDO_0002009', 'EFO_0003884', 'MONDO_0007254', 'MONDO_0005301', 'EFO_0000474', 'EFO_0000649', 'EFO_0003917', 'EFO_0000765']",False,False,9,,,
146,GLUTAMATE DECARBOXYLASE 2,CHEMBL4594599,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005147', 'EFO_0009706']",False,False,2,,,
147,EXISULIND,CHEMBL488025,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0009708', 'EFO_0003869', 'MONDO_0008315', 'MONDO_0008903', 'EFO_0003060', 'EFO_1001951', 'EFO_0000673']",False,False,7,,,
148,PENTAMIDINE,CHEMBL55,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 4 approved and 15 investigational indications.,,4.0,,False,1984,[],"['EFO_1001365', 'EFO_1001951', 'EFO_0000544', 'EFO_0000389', 'EFO_0003086', 'EFO_0000183', 'MONDO_0005147', 'EFO_0006346', 'EFO_0005044', 'EFO_0003060', 'DOID_10113', 'EFO_0003106', 'EFO_0007448', 'DOID_10113', 'EFO_0005044', 'EFO_0000764', 'EFO_0007448', 'EFO_0002618', 'EFO_0000182']",False,False,19,,,
149,VILANTEROL TRIFENATATE,CHEMBL1084172,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications.,,4.0,,False,2013,['ENSG00000169252'],"['EFO_0000341', 'EFO_0000464', 'MONDO_0004979', 'EFO_0006505']",False,False,4,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
150,IMIPRAMINE,CHEMBL11,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1959,"['ENSG00000103546', 'ENSG00000108576']","['MONDO_0002050', 'HP_0100749', 'EFO_0000519', 'EFO_0003761', 'EFO_0005230', 'EFO_0009687', 'EFO_0004278', 'EFO_0003948', 'MONDO_0024290', 'EFO_0004287', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0008623', 'MONDO_0007254', 'EFO_0000612', 'HP_0003419', 'EFO_0010282']",True,False,17,Norepinephrine transporter inhibitor Serotonin transporter inhibitor ,INHIBITOR ,single protein 
151,CINACALCET HYDROCHLORIDE,CHEMBL1200776,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 1 investigational indication.,,4.0,,False,2004,['ENSG00000036828'],"['EFO_1001173', 'EFO_1000456', 'EFO_0000673', 'EFO_0000313', 'EFO_0003884']",True,False,5,Calcium sensing receptor positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,single protein 
152,CEFACLOR,CHEMBL1201018,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 9 approved and 1 investigational indication.,,4.0,,False,1979,[],"['EFO_0004992', 'EFO_0003103', 'EFO_0009582', 'MONDO_0002258', 'EFO_0003106', 'EFO_0000544', 'HP_0011110', 'EFO_0006505', 'EFO_0003102', 'EFO_0000771']",False,False,10,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
153,ECULIZUMAB,CHEMBL1201828,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for atypical hemolytic-uremic syndrome and immune system disease and has 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,['ENSG00000106804'],"['EFO_0000400', 'EFO_0001365', 'EFO_0004826', 'EFO_0007292', 'MONDO_0100096', 'MONDO_0001549', 'EFO_0009473', 'EFO_1001311', 'EFO_0004256', 'EFO_0004599', 'MONDO_0016244', 'MONDO_0019736', 'EFO_0004991', 'HP_0001873', 'EFO_0003884', 'MONDO_0018904', 'EFO_0000565', 'EFO_0000540', 'EFO_0000398']",False,False,19,Complement C5 inhibitor ,INHIBITOR ,single protein 
154,OBINUTUZUMAB,CHEMBL1743048,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,['ENSG00000156738'],"['MONDO_0001023', 'EFO_0005761', 'EFO_0000183', 'MONDO_0018906', 'EFO_0000309', 'EFO_0000403', 'EFO_0005952', 'EFO_1001951', 'EFO_1001469', 'MONDO_0004992', 'EFO_0000574', 'EFO_0000565', 'EFO_0009441', 'MONDO_0007915', 'EFO_0003060', 'MONDO_0013730', 'EFO_0000096', 'EFO_0004236', 'EFO_1001051', 'EFO_0003086', 'EFO_0003884', 'EFO_0000095', 'EFO_1000956', 'EFO_0000220', 'EFO_0000616']",True,False,25,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
155,DULAGLUTIDE,CHEMBL2108027,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000112164'],"['EFO_0004319', 'MONDO_0005147', 'EFO_0000400', 'EFO_0003884', 'MONDO_0005148', 'HP_0001959']",False,False,6,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
156,BIW-8962,CHEMBL2109426,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000702', 'EFO_0003060', 'EFO_0000588', 'EFO_0001378']",False,False,4,,,
157,ELDELUMAB,CHEMBL2109664,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000169245'],"['EFO_0000729', 'EFO_0000384', 'EFO_0000685']",True,False,3,C-X-C motif chemokine 10 inhibitor ,INHIBITOR ,single protein 
158,ZAVEGEPANT,CHEMBL2397415,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000132329', 'ENSG00000064989']","['MONDO_0005277', 'MONDO_0004979', 'MONDO_0100096']",True,False,3,"Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist ",ANTAGONIST ,protein complex 
159,R-333,CHEMBL3545159,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000165025', 'ENSG00000105639']",['MONDO_0007915'],False,False,1,Tyrosine-protein kinase SYK inhibitor Tyrosine-protein kinase JAK3 inhibitor ,INHIBITOR ,single protein 
160,EPACADOSTAT,CHEMBL3545369,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 31 investigational indications.,,3.0,,False,no approval year,['ENSG00000131203'],"['EFO_0000691', 'EFO_0000702', 'MONDO_0002158', 'EFO_0000196', 'Orphanet_145', 'EFO_0002517', 'MONDO_0008903', 'MONDO_0044881', 'EFO_0000222', 'EFO_1000251', 'EFO_0003863', 'MONDO_0001187', 'MONDO_0002087', 'EFO_0000616', 'EFO_0000181', 'EFO_1001512', 'EFO_0008528', 'EFO_1000657', 'EFO_0006859', 'EFO_0000756', 'EFO_0000574', 'EFO_0003060', 'MONDO_0011719', 'EFO_0000519', 'EFO_0000681', 'EFO_1000576', 'MONDO_0008170', 'EFO_0001075', 'EFO_0000389', 'EFO_0000198', 'MONDO_0011962']",True,False,31,"Indoleamine 2,3-dioxygenase inhibitor ",INHIBITOR ,single protein 
161,RIFAMPIN,CHEMBL374478,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for tuberculosis and pulmonary tuberculosis and has 47 investigational indications.,,4.0,,False,1971,[],"['EFO_0000685', 'EFO_0000095', 'EFO_0000544', 'EFO_0007386', 'MONDO_0000565', 'HP_0100806', 'EFO_1001249', 'EFO_1001050', 'MONDO_0001134', 'MONDO_0018076', 'EFO_0001645', 'MONDO_0019338', 'HP_0000083', 'MONDO_0004992', 'EFO_0000764', 'HP_0002019', 'EFO_1001314', 'EFO_0000756', 'MONDO_0005180', 'EFO_0000574', 'EFO_0000400', 'EFO_0006911', 'EFO_0001065', 'MONDO_0021108', 'MONDO_0009061', 'EFO_0005952', 'EFO_0003102', 'EFO_1000049', 'MONDO_0000831', 'MONDO_0005148', 'EFO_0001054', 'EFO_0007402', 'EFO_1001413', 'EFO_0002617', 'EFO_0003884', 'EFO_0007460', 'EFO_0001361', 'MONDO_0005301', 'EFO_0000765', 'EFO_0007470', 'EFO_0000183', 'EFO_0004239', 'MONDO_0002041', 'MONDO_0000327', 'HP_0002014', 'EFO_0000180', 'EFO_0003060', 'EFO_0000616', 'MONDO_0004975']",False,False,49,Bacterial DNA-directed RNA polymerase inhibitor ,INHIBITOR ,protein complex 
162,CIFORADENANT,CHEMBL4297184,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000128271'],"['EFO_0003060', 'EFO_0000681', 'EFO_0001378', 'EFO_0003888', 'MONDO_0005180']",True,False,5,Adenosine A2a receptor antagonist ,ANTAGONIST ,single protein 
163,TOZORAKIMAB,CHEMBL4650490,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000341', 'EFO_0000274', 'MONDO_0004979', 'EFO_0006505', 'EFO_0000401']",False,False,5,,,
164,CP-724714,CHEMBL483321,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000141736'],"['EFO_0003869', 'MONDO_0007254', 'EFO_0009708']",False,False,3,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
165,VOCIPROTAFIB,CHEMBL5095375,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000616', 'EFO_0009709']",False,False,3,,,
166,LEFLUNOMIDE,CHEMBL960,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000102967'],"['EFO_0000756', 'MONDO_0007915', 'EFO_0000764', 'EFO_0005761', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000616', 'EFO_0000540', 'EFO_0003073', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0004991', 'EFO_1000965', 'MONDO_0016537', 'EFO_0008518', 'EFO_1000158', 'EFO_1001231', 'EFO_0003778', 'MONDO_0007254', 'EFO_0007187', 'EFO_0000699', 'EFO_0000685']",True,False,22,Dihydroorotate dehydrogenase inhibitor ,INHIBITOR ,single protein 
167,SEVELAMER HYDROCHLORIDE,CHEMBL1201492,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for chronic kidney disease and kidney disease and has 4 investigational indications.,,4.0,,False,1998,[],"['EFO_0003884', 'EFO_1001152', 'HP_0003124', 'EFO_0003086', 'HP_0002905', 'EFO_0002614']",False,False,6,,,
168,PHENYLBUTANOIC ACID,CHEMBL1469,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 18 investigational indications.,,4.0,,False,1996,[],"['MONDO_0008815', 'EFO_0000574', 'EFO_0003833', 'EFO_1000049', 'MONDO_0004739', 'MONDO_0009563', 'EFO_0008525', 'MONDO_0004976', 'EFO_0000565', 'Orphanet_98757', 'MONDO_0019169', 'MONDO_0009061', 'EFO_0007323', 'EFO_0000621', 'MONDO_0007739', 'Orphanet_79167', 'MONDO_0020077', 'EFO_0000764', 'MONDO_0016486', 'EFO_0000198', 'HP_0001987', 'EFO_1000049']",False,False,22,,,
169,ATACICEPT,CHEMBL1742986,Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000102524', 'ENSG00000161955']","['MONDO_0007915', 'EFO_0005761', 'EFO_0007405', 'EFO_0000685', 'MONDO_0005301', 'EFO_0004194']",True,False,6,Tumor necrosis factor ligand superfamily member 13B inhibitor Tumor necrosis factor ligand superfamily member 13 inhibitor ,INHIBITOR ,single protein 
170,ZABOFLOXACIN,CHEMBL2107811,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003106', 'EFO_0000341']",False,False,2,Bacterial DNA gyrase inhibitor Topoisomerase IV inhibitor ,INHIBITOR ,protein complex 
171,LMB-9,CHEMBL2109503,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0008903', 'MONDO_0007576', 'EFO_1001951', 'EFO_0002618', 'MONDO_0001056', 'MONDO_0007254', 'MONDO_0008170', 'MONDO_0001187']",False,False,8,,,
172,SAR-566658,CHEMBL2109635,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000185499'],"['MONDO_0007254', 'EFO_0000616']",False,False,2,Mucin-1 binding agent ,BINDING AGENT ,single protein 
173,ISEGANAN,CHEMBL2110753,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003106', 'EFO_1001904']",False,False,2,,,
174,ULOCUPLUMAB,CHEMBL3039543,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.,,1.0,,False,no approval year,['ENSG00000121966'],"['MONDO_0018906', 'EFO_0000222', 'EFO_0000565', 'EFO_0000616', 'EFO_0009441', 'EFO_0001378', 'EFO_0000095']",False,False,7,C-X-C chemokine receptor type 4 inhibitor ,INHIBITOR ,single protein 
175,TESEVATINIB,CHEMBL3544983,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000196411', 'ENSG00000146648']","['MONDO_0009889', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000519', 'EFO_1001496', 'EFO_0003833', 'MONDO_0004992']",False,True,7,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor Ephrin type-B receptor 4 inhibitor ,INHIBITOR ,single protein 
176,UPADACITINIB,CHEMBL3622821,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for immune system disease and rheumatoid arthritis and has 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2019,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['EFO_0000274', 'EFO_0003778', 'EFO_0002609', 'EFO_0000384', 'EFO_1001209', 'EFO_0000729', 'EFO_1000710', 'EFO_0004208', 'EFO_0000540', 'EFO_0003898', 'EFO_0000685', 'MONDO_0007915']",True,True,12,Janus Kinase (JAK) inhibitor ,INHIBITOR ,protein family 
177,ARUNDINE,CHEMBL446452,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000673', 'MONDO_0002974', 'MONDO_0007254']",False,False,3,,,
178,UCN-01,CHEMBL574737,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 43 investigational indications.,,2.0,,False,no approval year,"['ENSG00000135446', 'ENSG00000115825', 'ENSG00000163558', 'ENSG00000154229', 'ENSG00000126583', 'ENSG00000163932', 'ENSG00000166501', 'ENSG00000067606', 'ENSG00000171132', 'ENSG00000027075', 'ENSG00000184304', 'ENSG00000065675', 'ENSG00000105810', 'ENSG00000140992', 'ENSG00000149554', 'ENSG00000123374']","['MONDO_0002158', 'EFO_1001013', 'EFO_0000756', 'EFO_1001512', 'EFO_0003025', 'EFO_0000209', 'MONDO_0007254', 'MONDO_0004669', 'EFO_0003027', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0002367', 'EFO_0007535', 'EFO_0000224', 'MONDO_0011719', 'EFO_1000407', 'MONDO_0008315', 'MONDO_0003196', 'MONDO_0044926', 'EFO_0003060', 'EFO_0002938', 'EFO_0000339', 'MONDO_0002537', 'MONDO_0018364', 'EFO_0005537', 'MONDO_0002974', 'EFO_0004193', 'MONDO_0001879', 'EFO_0000616', 'EFO_0006352', 'EFO_0000221', 'MONDO_0001056', 'MONDO_0007576', 'EFO_0003028', 'EFO_0000702', 'MONDO_0005411', 'EFO_0000218', 'EFO_0000574', 'MONDO_0008170', 'EFO_0002618', 'EFO_0000223', 'EFO_0000673', 'EFO_0000565']",True,False,43,Cyclin-dependent kinase 4 inhibitor 3-phosphoinositide dependent protein kinase-1 inhibitor Protein kinase C (PKC) inhibitor Cyclin-dependent kinase 6 inhibitor Serine/threonine-protein kinase Chk1 inhibitor Cyclin-dependent kinase 2 inhibitor ,INHIBITOR ,single protein protein family 
179,FLUVOXAMINE,CHEMBL814,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000108576'],"['EFO_1001916', 'EFO_1001917', 'EFO_0000694', 'EFO_0003758', 'EFO_0004262', 'EFO_0005230', 'MONDO_0005090', 'EFO_0004242', 'EFO_0000616', 'EFO_0003761', 'EFO_0004242', 'MONDO_0002050', 'MONDO_0100096', 'MONDO_0100096', 'EFO_1001892', 'EFO_0000694', 'EFO_1002014']",False,False,17,Serotonin transporter inhibitor ,INHIBITOR ,single protein 
180,ALBUMIN HUMAN,CHEMBL1201451,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for nephrosis and lung disease and has 31 investigational indications.,,4.0,,False,1997,[],"['Orphanet_60', 'EFO_0006834', 'EFO_1000158', 'EFO_0009606', 'MONDO_0002679', 'MONDO_0001056', 'EFO_0003086', 'MONDO_0002331', 'EFO_0000713', 'EFO_0003106', 'EFO_0005669', 'MONDO_0004976', 'MP_0001845', 'EFO_0002618', 'EFO_1000868', 'HP_0002140', 'HP_0031273', 'EFO_1000954', 'EFO_0000341', 'EFO_1001207', 'EFO_0005252', 'EFO_0009505', 'EFO_0000717', 'HP_0100806', 'EFO_0001422', 'EFO_0009373', 'MONDO_0013730', 'EFO_0000616', 'EFO_0003818', 'EFO_0003929', 'MONDO_0015339', 'HP_0001541', 'MONDO_0004975']",False,False,33,,,
181,ENOXAPARIN SODIUM,CHEMBL1201476,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1993,['ENSG00000117601'],"['EFO_0000275', 'EFO_0000616', 'EFO_0003964', 'MONDO_0008170', 'EFO_0000495', 'EFO_0005681', 'MONDO_0000831', 'EFO_0004286', 'EFO_0005672', 'EFO_0000702', 'HP_0004936', 'HP_0004419', 'MP_0001914', 'EFO_0009314', 'EFO_1001375', 'EFO_0004255', 'EFO_0003827', 'EFO_0000712', 'EFO_0000612', 'MONDO_0100096', 'EFO_1000954', 'HP_0001907', 'MONDO_0021148', 'EFO_0003086', 'EFO_0003907', 'EFO_0003060', 'EFO_0002916', 'EFO_0002618', 'EFO_0001073', 'EFO_0008583', 'MONDO_0004992', 'EFO_0008585', 'EFO_0000574', 'EFO_0000544', 'EFO_0001422']",False,False,35,Antithrombin-III activator ,ACTIVATOR ,single protein 
182,AURANOFIN,CHEMBL1366,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for rheumatic disease and rheumatoid arthritis and has 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,[],"['EFO_0005755', 'EFO_0003060', 'EFO_0007144', 'MONDO_0018076', 'EFO_0003843', 'EFO_0000571', 'EFO_0001075', 'EFO_0000764', 'EFO_0000702', 'EFO_0000095', 'EFO_0000685', 'EFO_0000708', 'EFO_0000519']",False,False,13,,,
183,DOXYCYCLINE ANHYDROUS,CHEMBL1433,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 70 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1967,"['ENSG00000137745', 'ENSG00000118113', 'ENSG00000137673', 'ENSG00000196611']","['EFO_0008510', 'EFO_0002618', 'EFO_1001466', 'EFO_1000906', 'EFO_0009536', 'EFO_1001896', 'EFO_0000341', 'EFO_0004214', 'EFO_0003955', 'EFO_0009659', 'EFO_0003102', 'MONDO_0018076', 'EFO_0007470', 'EFO_0009425', 'EFO_0000662', 'EFO_0001068', 'MONDO_0007947', 'EFO_0000778', 'EFO_0000574', 'EFO_1002047', 'EFO_0007460', 'HP_0001250', 'EFO_1001466', 'MONDO_0004992', 'EFO_0000729', 'EFO_1001898', 'EFO_0007205', 'EFO_1001788', 'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438', 'MP_0001914', 'EFO_1001051', 'EFO_0007430', 'EFO_0000612', 'MONDO_0004975', 'EFO_0002913', 'MONDO_0019180', 'MONDO_0005178', 'EFO_0003770', 'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_1001388', 'EFO_0000199', 'EFO_0000464', 'EFO_0003894', 'EFO_0000756', 'EFO_0007205', 'EFO_1001951', 'EFO_1001388', 'EFO_0000649', 'EFO_0000274', 'EFO_1000760', 'EFO_0000544', 'HP_0000964', 'EFO_0000365', 'EFO_0000771', 'MONDO_0005180', 'MONDO_0017816', 'EFO_0003878', 'EFO_0005952', 'EFO_1000760', 'EFO_0008517', 'EFO_0009117', 'EFO_0007272', 'EFO_0007480', 'EFO_0000096', 'EFO_0000544', 'EFO_0003106', 'EFO_0000649', 'EFO_1001459', 'EFO_0000694', 'EFO_0001365', 'EFO_1001875', 'EFO_0007410', 'EFO_0003843', 'DOID_7551', 'EFO_0003060', 'EFO_0007504', 'EFO_1000785', 'EFO_0003894', 'MONDO_0100096', 'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444', 'EFO_0002687']",True,True,88,Matrix metalloproteinase 13 inhibitor Matrix metalloproteinase 7 inhibitor Matrix metalloproteinase 8 inhibitor Matrix metalloproteinase-1 inhibitor Bacterial 70S ribosome inhibitor ,INHIBITOR ,single protein protein nucleic-acid complex 
184,MYCOPHENOLATE MOFETIL,CHEMBL1456,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 123 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,"['ENSG00000106348', 'ENSG00000178035']","['EFO_0000404', 'EFO_0000519', 'EFO_1000784', 'EFO_0004719', 'EFO_1000309', 'EFO_0000222', 'MONDO_0019469', 'EFO_1000965', 'EFO_0004826', 'MONDO_0002334', 'EFO_0000681', 'EFO_0000616', 'EFO_0002618', 'EFO_0003777', 'MONDO_0002367', 'EFO_0000565', 'MONDO_0044881', 'EFO_1001779', 'EFO_0000255', 'MONDO_0013730', 'EFO_0000211', 'MONDO_0021193', 'EFO_0003032', 'EFO_0004228', 'EFO_0004236', 'EFO_1000560', 'MONDO_0000870', 'MONDO_0010518', 'Orphanet_79292', 'EFO_0000676', 'EFO_0006803', 'EFO_0000319', 'EFO_0005761', 'MONDO_0015253', 'EFO_0000389', 'EFO_1002048', 'EFO_0000339', 'EFO_1001857', 'EFO_0006927', 'EFO_0004251', 'MONDO_0007915', 'MONDO_0001705', 'EFO_0004256', 'HP_0001915', 'MONDO_0018906', 'HP_0001871', 'MONDO_0019391', 'EFO_0004991', 'EFO_0000574', 'EFO_0000699', 'EFO_0007196', 'EFO_0000764', 'EFO_0002428', 'EFO_1001469', 'EFO_1001051', 'MONDO_0004976', 'DOID_13406', 'Orphanet_848', 'EFO_0000621', 'MONDO_0019471', 'EFO_0003047', 'EFO_0000191', 'EFO_0004244', 'EFO_0005952', 'EFO_0001365', 'EFO_0000401', 'EFO_0000220', 'EFO_0003086', 'EFO_1000785', 'MONDO_0005147', 'EFO_0004274', 'EFO_0000685', 'MONDO_0044903', 'EFO_1001231', 'EFO_1001017', 'EFO_0000096', 'EFO_1000680', 'MONDO_0015760', 'EFO_0000309', 'EFO_0000384', 'EFO_0000198', 'EFO_0000537', 'EFO_0000182', 'MONDO_0005301', 'EFO_0005297', 'EFO_0001062', 'EFO_0002430', 'MONDO_0009387', 'EFO_0000095', 'EFO_0002429', 'MONDO_0000873', 'EFO_0004194', 'EFO_0001378', 'MONDO_0015974', 'EFO_1000956', 'MONDO_0009833', 'EFO_0003884', 'EFO_0004255', 'EFO_1000690', 'EFO_0001642', 'EFO_1000318', 'MONDO_0011382', 'MONDO_0019472', 'EFO_0005140', 'EFO_0000717', 'EFO_1001345', 'MONDO_0018923', 'EFO_0000702', 'EFO_0000403', 'EFO_0004599', 'EFO_0009441', 'EFO_0007187', 'EFO_0004254', 'EFO_0007160', 'HP_0002721', 'EFO_0000183', 'EFO_0007359', 'EFO_0001421', 'EFO_1000102', 'EFO_0008507', 'MONDO_0019262', 'EFO_1001465', 'MONDO_0004992']",True,False,123,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor ,INHIBITOR ,protein family 
185,ABEXINOSTAT,CHEMBL2103863,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']","['MONDO_0018906', 'EFO_0005952', 'EFO_0000616', 'EFO_0000691', 'EFO_0000681', 'EFO_0000183', 'EFO_0000403']",False,False,7,Histone deacetylase inhibitor ,INHIBITOR ,protein family 
186,GLUFOSFAMIDE,CHEMBL2107143,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001968', 'MONDO_0008903', 'EFO_0003860', 'EFO_0000702', 'EFO_1000158', 'EFO_0002618', 'MONDO_0008170']",False,False,7,,,
187,BIMAGRUMAB,CHEMBL3137353,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000114739'],"['EFO_1000653', 'HP_0004326', 'EFO_0009851', 'EFO_0007323', 'EFO_0000341', 'MONDO_0005148']",False,True,6,Activin receptor type-2B antagonist ,ANTAGONIST ,single protein 
188,SIMOTINIB,CHEMBL3545235,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
189,NEBIVOLOL,CHEMBL434394,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications.,,4.0,,False,2007,"['ENSG00000043591', 'ENSG00000169252']","['MONDO_0100096', 'EFO_0000537', 'EFO_0003882', 'MONDO_0001134', 'EFO_0000537', 'MONDO_0007947', 'EFO_0000712', 'EFO_0000712', 'EFO_0000768', 'EFO_0000319']",True,False,10,Beta-1 adrenergic receptor antagonist Beta-2 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
190,CANDESARTAN,CHEMBL1016,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,3.0,,False,no approval year,['ENSG00000144891'],"['EFO_0000373', 'MONDO_0005277', 'EFO_0003896', 'EFO_0002610', 'MONDO_0100096', 'EFO_0003100', 'MONDO_0100431', 'MONDO_0004985', 'MONDO_0005147', 'EFO_0003047', 'MONDO_0005148', 'EFO_0003144', 'MONDO_0005475', 'EFO_0000407', 'EFO_0000319', 'EFO_0000275', 'EFO_0000280', 'EFO_0003777', 'MONDO_0001134', 'EFO_0004701', 'MONDO_0002491', 'EFO_0008573', 'EFO_0000538', 'HP_0100543', 'EFO_0000537', 'EFO_0000266']",False,False,26,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
191,VILANTEROL .ALPHA.-PHENYL CINNAMATE,CHEMBL1084173,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000169252'],['EFO_0000341'],False,False,1,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
192,DEFEROXAMINE MESYLATE,CHEMBL1234,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 2 investigational indications.,,4.0,,False,1968,[],"['EFO_0005669', 'MONDO_0005147']",False,False,2,,,
193,BETA CAROTENE,CHEMBL1293,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001375', 'EFO_0000384', 'EFO_0000612', 'EFO_0009606', 'MONDO_0005129']",False,False,5,,,
194,PHYTONADIONE,CHEMBL1550,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,no approval year,[],"['MONDO_0009061', 'EFO_0000519', 'EFO_0003854', 'EFO_0003884', 'MONDO_0008315', 'EFO_0003882', 'EFO_0005669', 'MP_0001914', 'EFO_0000319', 'EFO_0006890', 'EFO_0001060', 'EFO_0000685', 'EFO_0000729', 'MONDO_0024298', 'EFO_0004239']",False,False,15,,,
195,ZIBOTENTAN,CHEMBL1628688,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,['ENSG00000151617'],"['MONDO_0008315', 'EFO_1001951', 'EFO_0003876', 'EFO_0004265', 'EFO_0003884', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0001421', 'EFO_0009708']",False,False,12,Endothelin receptor ET-A antagonist ,ANTAGONIST ,single protein 
196,HYDROXYCHLOROQUINE SULFATE,CHEMBL1690,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for rheumatoid arthritis and malaria and has 12 investigational indications.,,4.0,,False,1955,"['ENSG00000239732', 'ENSG00000196664']","['EFO_0000685', 'EFO_0007224', 'EFO_0002618', 'EFO_0001068', 'EFO_0004244', 'EFO_0005221', 'EFO_0003834', 'MONDO_0007915', 'EFO_0005755', 'MONDO_0100096', 'MONDO_0010520', 'EFO_0002689', 'EFO_0000389', 'EFO_0003818']",True,True,14,Toll-like receptor 7 antagonist Toll-like receptor 9 antagonist ,ANTAGONIST ,single protein 
197,POLIGLUSAM,CHEMBL2108133,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_1001459', 'EFO_0003843', 'EFO_1001139', 'MONDO_0008315']",False,False,5,,,
198,ISPINESIB,CHEMBL228814,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,['ENSG00000138160'],"['MONDO_0004992', 'EFO_0003869', 'EFO_0000681', 'EFO_1000657', 'MONDO_0008170', 'MONDO_0002691', 'EFO_0000673', 'EFO_0003060', 'MONDO_0021063', 'EFO_0000389']",False,False,10,Kinesin-like protein 1 inhibitor ,INHIBITOR ,single protein 
199,ARTENIMOL,CHEMBL252518,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for malaria and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0007445', 'EFO_0007444', 'EFO_0001068', 'EFO_0003060', 'HP_0001945', 'MONDO_0007915']",False,False,6,,,
200,TARIQUIDAR,CHEMBL348475,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000085563'],"['EFO_1000796', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0005762', 'EFO_0003060']",True,False,6,P-glycoprotein 1 inhibitor ,INHIBITOR ,single protein 
201,AZD8683,CHEMBL3545222,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000133019'],['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
202,AUTOGENE CEVUMERAN,CHEMBL4650376,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0001187', 'MONDO_0002367', 'MONDO_0007254', 'EFO_0002618', 'EFO_0000365', 'EFO_0000756', 'EFO_0003060', 'EFO_0006859', 'EFO_1001951']",False,False,9,,,
203,PONATINIB,CHEMBL1171837,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000097007', 'ENSG00000186716']","['EFO_0000222', 'EFO_0000571', 'EFO_0000198', 'EFO_0003841', 'MONDO_0015277', 'EFO_0000339', 'EFO_0000519', 'EFO_0000222', 'EFO_0000339', 'EFO_0000702', 'EFO_0000616', 'EFO_0000565', 'EFO_1000131', 'EFO_0000220', 'EFO_0003060', 'MONDO_0004992', 'EFO_1000131', 'MONDO_0011719', 'EFO_0000220']",False,False,19,Bcr/Abl fusion protein inhibitor ,INHIBITOR ,chimeric protein 
204,OZARELIX,CHEMBL2108312,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000109163'],"['MONDO_0008315', 'EFO_0000284']",False,False,2,Gonadotropin-releasing hormone receptor antagonist ,ANTAGONIST ,single protein 
205,DUPILUMAB,CHEMBL2108675,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 22 investigational indications.,,4.0,,False,2017,['ENSG00000077238'],"['EFO_0007425', 'EFO_0007141', 'EFO_0004232', 'MONDO_0009735', 'EFO_0007140', 'EFO_0007187', 'EFO_0003060', 'EFO_0000684', 'EFO_0000274', 'EFO_0004192', 'EFO_1001361', 'EFO_0005854', 'EFO_0000341', 'EFO_1000391', 'EFO_0004212', 'MONDO_0004979', 'MONDO_0008315', 'EFO_1000740', 'HP_0000964', 'MONDO_0100096', 'MONDO_0002406', 'EFO_0007486', 'EFO_0005531', 'HP_0000989', 'HP_0100582', 'EFO_0005532']",True,False,26,Interleukin-4 receptor subunit alpha antagonist ,ANTAGONIST ,single protein 
206,BEMIPARIN SODIUM,CHEMBL2108806,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,4.0,,False,no approval year,['ENSG00000117601'],"['EFO_0003907', 'MONDO_0100096']",False,False,2,Antithrombin-III activator ,ACTIVATOR ,single protein 
207,LACTOBACILLUS ACIDOPHILUS,CHEMBL2109070,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 21 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0003095', 'HP_0002014', 'HP_0001397', 'EFO_1001904', 'EFO_0000384', 'EFO_0003882', 'EFO_0000555', 'MONDO_0007915', 'EFO_1001494', 'EFO_0000729', 'Orphanet_733', 'EFO_0003956', 'HP_0001298', 'MONDO_0004979', 'HP_0002015', 'EFO_1000657', 'EFO_1001353', 'EFO_1001034', 'MONDO_0018309', 'EFO_0000474', 'HP_0002019']",False,False,21,,,
208,METOPROLOL SUCCINATE,CHEMBL2356097,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,['ENSG00000043591'],"['MONDO_0010679', 'EFO_0000341', 'EFO_0000538', 'HP_0001653', 'EFO_0000537', 'EFO_0000275', 'EFO_0000266', 'EFO_0000373', 'EFO_0003913', 'Orphanet_79292', 'EFO_0003144']",False,False,11,Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
209,ISUZINAXIB HYDROCHLORIDE,CHEMBL4650358,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
210,INCOMPLETE FREUND'S ADJUVANT,CHEMBL4650400,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007445', 'EFO_0002618', 'EFO_0000339', 'EFO_0006475', 'MONDO_0008315', 'EFO_0000681', 'EFO_0000519', 'MONDO_0002158', 'EFO_0000389', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0008170', 'EFO_0000616', 'EFO_1001465', 'MONDO_0002898', 'EFO_0000222', 'MONDO_0007576', 'EFO_0000756', 'EFO_0003811', 'EFO_0003893', 'EFO_1001951', 'EFO_0000673', 'MONDO_0005411', 'MONDO_0008903', 'EFO_0001378', 'MONDO_0001056', 'MONDO_0007254', 'MONDO_0005301']",False,False,28,,,
211,GOSOGLIPTIN,CHEMBL515387,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000197635'],"['EFO_0003884', 'MONDO_0005148']",True,False,2,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
212,LEVAMISOLE,CHEMBL1454,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for helminthiasis and has 6 investigational indications. It was withdrawn in at least one region.,,4.0,,False,1990,[],"['EFO_1001951', 'EFO_0004255', 'MONDO_0100096', 'EFO_1001342', 'HP_0001915', 'EFO_0000182', 'EFO_0003894']",False,False,7,Nicotinic acetylcholine receptor alpha subunit agonist ,AGONIST ,single protein 
213,DROZITUMAB,CHEMBL1743008,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000120889'],"['EFO_0000333', 'EFO_0005952', 'EFO_0003060', 'EFO_1001951']",False,False,4,Tumor necrosis factor receptor superfamily member 10B agonist ,AGONIST ,single protein 
214,ROSUVASTATIN CALCIUM,CHEMBL1744447,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 11 investigational indications.,,4.0,,False,2003,['ENSG00000113161'],"['MONDO_0005147', 'EFO_0003144', 'Orphanet_79211', 'EFO_0003914', 'EFO_0004911', 'EFO_0005672', 'EFO_0001645', 'EFO_0000400', 'MONDO_0018473', 'Orphanet_309005', 'HP_0002140', 'MONDO_0005148', 'EFO_0004211', 'EFO_0000537', 'MONDO_0021187', 'HP_0003124', 'EFO_0004239']",False,False,17,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
215,ICOSAPENT ETHYL,CHEMBL2095209,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for pancreatitis and hypertriglyceridemia and has 8 investigational indications.,,4.0,,False,2012,[],"['EFO_0000305', 'EFO_1001249', 'MONDO_0100096', 'Orphanet_309005', 'EFO_0000319', 'EFO_0000278', 'MONDO_0004975', 'EFO_0005406', 'MONDO_0021063', 'EFO_0004211']",False,False,10,,,
216,RG-4733,CHEMBL4297422,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 19 investigational indications.,,2.0,,False,no approval year,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']","['EFO_0000365', 'EFO_1000251', 'MONDO_0021063', 'EFO_0000616', 'EFO_0005537', 'EFO_0000756', 'EFO_0001378', 'EFO_0000673', 'EFO_0001075', 'EFO_0002501', 'EFO_0000349', 'EFO_1001465', 'EFO_0000389', 'EFO_1000657', 'EFO_0006861', 'EFO_0002499', 'MONDO_0007254', 'EFO_0000305', 'EFO_0003060']",True,False,19,Gamma-secretase inhibitor ,INHIBITOR ,protein complex 
217,CERTOLIZUMAB,CHEMBL4297565,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008903', 'EFO_0000571', 'EFO_0000685']",False,False,3,,,
218,SULOPENEM ETZADROXIL,CHEMBL4594246,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003106', 'EFO_0000544', 'EFO_0003103']",False,False,3,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
219,TRANSCROCETIN,CHEMBL464792,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004244', 'EFO_0000519', 'MONDO_0100096', 'EFO_0003876', 'MONDO_0100342', 'EFO_0000519', 'EFO_0009444']",False,False,7,,,
220,ACETAMINOPHEN,CHEMBL112,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 12 approved and 92 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1968,"['ENSG00000073756', 'ENSG00000095303', 'ENSG00000196689', 'ENSG00000117480']","['MONDO_0100096', 'HP_0002013', 'HP_0002315', 'EFO_0000546', 'EFO_0000685', 'MONDO_0007915', 'EFO_0000220', 'EFO_0000384', 'EFO_0005592', 'EFO_1001139', 'MONDO_0005147', 'HP_0011110', 'EFO_0002460', 'HP_0012076', 'EFO_0009615', 'Orphanet_365', 'EFO_0000540', 'EFO_0000389', 'HP_0001945', 'EFO_1000783', 'EFO_0010282', 'EFO_0003086', 'EFO_0006859', 'MONDO_0005148', 'MONDO_0043510', 'HP_0002018', 'HP_0000175', 'EFO_0000574', 'HP_0000989', 'HP_0002027', 'MONDO_0005180', 'EFO_0000544', 'EFO_0000095', 'EFO_0000339', 'EFO_0000537', 'EFO_0000403', 'EFO_0001378', 'EFO_0000222', 'EFO_0003843', 'MONDO_0007254', 'HP_0003419', 'EFO_0004599', 'EFO_0001068', 'EFO_0004209', 'EFO_0004253', 'EFO_1000831', 'EFO_0000618', 'MONDO_0005041', 'EFO_0001073', 'EFO_0005230', 'HP_0100806', 'MONDO_0005178', 'MONDO_0002258', 'HP_0000545', 'EFO_0003060', 'EFO_0000198', 'EFO_1000249', 'EFO_0004197', 'EFO_0003931', 'EFO_0004888', 'EFO_1001216', 'EFO_0009846', 'HP_0001643', 'EFO_0010072', 'EFO_1000749', 'EFO_0007160', 'EFO_1001250', 'EFO_0000616', 'HP_0008419', 'EFO_1001476', 'EFO_1001412', 'MONDO_0005301', 'EFO_0004616', 'EFO_0007214', 'MONDO_0005277', 'EFO_0000668', 'EFO_0001074', 'EFO_0000096', 'HP_0012228', 'EFO_0005856', 'EFO_0004269', 'MONDO_0004992', 'HP_0012532', 'EFO_0007486', 'HP_0030833', 'EFO_0004273', 'HP_0100607', 'EFO_0000764', 'EFO_0005762', 'EFO_0007359', 'EFO_0005761', 'MP_0001914', 'MONDO_0100342', 'EFO_0011023', 'MONDO_0044917', 'EFO_0005952', 'MONDO_0017287', 'EFO_0009267', 'EFO_1000786', 'MONDO_0024355', 'EFO_0007328', 'HP_0003418', 'EFO_0007444', 'EFO_1001898']",True,False,104,Cyclooxygenase inhibitor Anandamide amidohydrolase inhibitor Vanilloid receptor opener ,INHIBITOR OPENER ,protein family single protein 
221,PSEUDOEPHEDRINE HYDROCHLORIDE,CHEMBL1200724,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 10 approved and 1 investigational indication.,,4.0,,False,1975,['ENSG00000103546'],"['EFO_0003843', 'EFO_0005854', 'HP_0001742', 'MONDO_0005271', 'EFO_0007328', 'MONDO_0005277', 'EFO_0007486', 'EFO_0007214', 'MONDO_0024290', 'HP_0012735', 'EFO_0003956']",False,False,11,Norepinephrine transporter releasing agent ,RELEASING AGENT ,single protein 
222,FERUMOXYTOL,CHEMBL1201867,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for anemia (phenotype) and anemia and has 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,[],"['EFO_0000519', 'EFO_0004272', 'MONDO_0002280', 'EFO_0003060', 'EFO_0000616', 'EFO_0002608', 'HP_0001891']",False,False,7,,,
223,FIGITUMUMAB,CHEMBL1743019,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,['ENSG00000140443'],"['EFO_0006859', 'EFO_0000673', 'EFO_0000691', 'EFO_0003869', 'EFO_0003050', 'EFO_0001378', 'EFO_0004142', 'EFO_0000702', 'MONDO_0004992', 'MONDO_0021117', 'EFO_0000174', 'MONDO_0007254', 'EFO_0000707', 'EFO_0003060']",False,False,14,Insulin-like growth factor I receptor antagonist ,ANTAGONIST ,single protein 
224,FIBOFLAPON SODIUM,CHEMBL1922673,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000132965'],"['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061']",False,False,3,5-lipoxygenase activating protein inhibitor ,INHIBITOR ,single protein 
225,CONESTAT ALFA,CHEMBL2108350,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hereditary angioedema and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000508', 'MONDO_0100096', 'HP_0001919', 'EFO_0007224', 'EFO_0004599', 'MONDO_0019623', 'EFO_0008586']",False,False,7,,,
226,MILK THISTLE,CHEMBL2108623,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['HP_0012167', 'EFO_0000401', 'EFO_0003884', 'EFO_0004699', 'EFO_0000764', 'MONDO_0021063', 'EFO_0004220']",False,False,7,,,
227,CIMETIDINE,CHEMBL30,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved and 11 investigational indications.,,4.0,,False,1977,['ENSG00000113749'],"['MP_0001914', 'MONDO_0004976', 'EFO_0000341', 'MONDO_0011962', 'EFO_0000544', 'HP_0002239', 'EFO_0000274', 'EFO_0004607', 'EFO_1001892', 'HP_0004398', 'EFO_0003948', 'MONDO_0004658', 'MONDO_0043839', 'MONDO_0001676']",False,False,14,Histamine H2 receptor antagonist ,ANTAGONIST ,single protein 
228,VACTOSERTIB,CHEMBL3260567,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,['ENSG00000106799'],"['EFO_0003060', 'EFO_0002618', 'EFO_0009907', 'EFO_0004251', 'EFO_0008528', 'EFO_0000198', 'EFO_0000616', 'EFO_0003897', 'EFO_0001378', 'MONDO_0001056']",False,False,10,TGF-beta receptor type I inhibitor ,INHIBITOR ,single protein 
229,TRILACICLIB,CHEMBL3894860,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for small cell lung carcinoma and has 5 investigational indications.,,4.0,,False,2021,"['ENSG00000105810', 'ENSG00000135446']","['EFO_0003060', 'EFO_0000702', 'MONDO_0007254', 'EFO_0000702', 'EFO_0003968', 'EFO_0005537']",True,False,6,Cyclin-dependent kinase 6 inhibitor Cyclin-dependent kinase 4 inhibitor ,INHIBITOR ,single protein 
230,BMS-986207,CHEMBL4297707,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000616']",False,False,2,,,
231,INTERLEUKIN-7,CHEMBL4297772,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000574', 'EFO_0000389', 'EFO_0000198', 'EFO_0007322', 'EFO_0000196', 'EFO_0000339', 'EFO_0003047', 'EFO_0000222', 'EFO_0000616', 'HP_0100806', 'EFO_0009429', 'EFO_0000764', 'MONDO_0007254']",False,False,13,,,
232,RETIFANLIMAB,CHEMBL4298037,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000181', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000519', 'EFO_0008528', 'EFO_0005537', 'EFO_0000756', 'EFO_0002618', 'MONDO_0008315', 'EFO_0000707', 'MONDO_0007576', 'EFO_1000852', 'MONDO_0007254', 'EFO_0000691', 'EFO_1001901', 'EFO_0006859', 'EFO_1001471', 'EFO_1001968', 'EFO_0002517', 'MONDO_0011962']",False,False,21,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
233,TRPH-222,CHEMBL4594508,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0018906', 'EFO_1001469', 'EFO_0000403']",False,False,3,,,
234,TPX-0131,CHEMBL4802183,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
235,MIRDAMETINIB,CHEMBL507361,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000169032', 'ENSG00000126934']","['MONDO_0004992', 'EFO_0000616', 'MONDO_0018975', 'EFO_1001951', 'EFO_0003060']",False,False,5,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Dual specificity mitogen-activated protein kinase kinase 2 inhibitor ,INHIBITOR ,single protein 
236,RIMANTADINE HYDROCHLORIDE,CHEMBL535396,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for infection and influenza.,,4.0,,False,1993,[],"['EFO_0000544', 'EFO_0007328']",False,False,2,Influenza virus A matrix protein M2 inhibitor ,INHIBITOR ,single protein 
237,COPPER,CHEMBL55643,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 10 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0000691', 'MONDO_0004976', 'EFO_0003932', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000519', 'EFO_0002618', 'MONDO_0004975', 'EFO_0001378']",False,False,10,,,
238,PLINABULIN,CHEMBL1096380,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0001378', 'EFO_0003060', 'MONDO_0001475', 'EFO_0000702', 'MONDO_0004992']",True,False,5,Tubulin inhibitor ,INHIBITOR ,protein complex group 
239,VILANTEROL,CHEMBL1198857,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 2 investigational indications.,,4.0,,False,2013,['ENSG00000169252'],"['EFO_0000341', 'MONDO_0004979', 'EFO_0000464', 'MONDO_0004979', 'EFO_0000341', 'EFO_0006505']",False,False,6,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
240,CEFEPIME HYDROCHLORIDE,CHEMBL1200962,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 4 investigational indications.,,4.0,,False,1996,[],"['EFO_0009582', 'EFO_0000544', 'HP_0031217', 'HP_0001945', 'MONDO_0001475', 'EFO_0003106', 'EFO_0003033', 'EFO_0003102', 'EFO_0003103']",False,False,9,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
241,AZACITIDINE,CHEMBL1489,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 55 investigational indications.,,4.0,,False,2004,"['ENSG00000130816', 'ENSG00000119772']","['MONDO_0007576', 'EFO_1001951', 'MONDO_0018906', 'EFO_0006861', 'MONDO_0008170', 'EFO_0000389', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000339', 'EFO_0000569', 'EFO_1001779', 'MONDO_0044903', 'EFO_0005952', 'MONDO_0018076', 'EFO_0006859', 'MONDO_0003478', 'EFO_0000403', 'EFO_1001257', 'EFO_0000220', 'EFO_0003869', 'EFO_0003833', 'EFO_0000681', 'MONDO_0009348', 'EFO_0000707', 'EFO_0000222', 'Orphanet_848', 'EFO_0003811', 'EFO_0001642', 'MONDO_0020077', 'EFO_0000209', 'EFO_0001378', 'MONDO_0044881', 'EFO_1000028', 'MONDO_0021063', 'EFO_0000326', 'EFO_0000574', 'EFO_0002517', 'EFO_0002617', 'EFO_0002618', 'MONDO_0007254', 'EFO_0000198', 'EFO_0000673', 'EFO_0004251', 'EFO_1000657', 'EFO_0000637', 'EFO_0004252', 'EFO_0000181', 'EFO_0000183', 'MONDO_0019469', 'MONDO_0013730', 'HP_0001873', 'EFO_0004289', 'EFO_0000255', 'MONDO_0008315', 'MONDO_0002492', 'EFO_0000211', 'MONDO_0002280', 'MONDO_0000430', 'EFO_0000565', 'EFO_0000095', 'EFO_0000616', 'MONDO_0016486']",True,False,62,DNA (cytosine-5)-methyltransferase 3A inhibitor DNA (cytosine-5)-methyltransferase 1 inhibitor ,INHIBITOR ,single protein 
242,SILDENAFIL CITRATE,CHEMBL1737,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 28 investigational indications.,,4.0,,False,1998,['ENSG00000138735'],"['MONDO_0006058', 'EFO_0000341', 'MONDO_0008315', 'EFO_1001893', 'EFO_1001103', 'MONDO_0043510', 'EFO_1001145', 'EFO_0009441', 'EFO_0003144', 'EFO_1001017', 'EFO_1001827', 'EFO_0003833', 'EFO_0000404', 'EFO_0000668', 'EFO_0000519', 'MONDO_0100096', 'MONDO_0008347', 'EFO_0000464', 'EFO_1001986', 'EFO_0003047', 'EFO_1000824', 'HP_0100607', 'EFO_0000537', 'EFO_0001365', 'EFO_0011023', 'EFO_0000616', 'MONDO_0005149', 'EFO_0004234', 'EFO_0000495', 'EFO_0000712', 'EFO_0000545', 'EFO_0001361', 'EFO_1001134']",True,False,33,Phosphodiesterase 5A inhibitor ,INHIBITOR ,single protein 
243,MATUZUMAB,CHEMBL2108038,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_0003060', 'MONDO_0008170']",False,True,2,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
244,LEFAMULIN,CHEMBL3291398,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for bacterial pneumonia and bacterial disease and has 2 investigational indications.,,4.0,,False,2019,[],"['MONDO_0009061', 'EFO_1001272', 'EFO_0000771', 'EFO_0003106']",False,False,4,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
245,RESIQUIMOD,CHEMBL383322,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,2.0,,False,no approval year,"['ENSG00000196664', 'ENSG00000101916']","['EFO_0002913', 'EFO_0000756', 'EFO_0000632', 'EFO_0000519', 'EFO_0002496', 'EFO_0002499', 'EFO_0007328', 'EFO_0004193', 'EFO_0002617', 'MONDO_0004992', 'EFO_0000389', 'EFO_0004197']",True,False,12,Toll-like receptor 8 agonist Toll-like receptor 7 agonist ,AGONIST ,single protein 
246,PEGILODECAKIN,CHEMBL3989992,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000243646', 'ENSG00000110324']","['EFO_0003060', 'EFO_0002618']",False,False,2,IL-10 receptor agonist ,AGONIST ,protein complex 
247,CERALASERTIB,CHEMBL4285417,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,['ENSG00000175054'],"['MONDO_0003059', 'MONDO_0007254', 'EFO_0000707', 'EFO_0000181', 'MONDO_0008170', 'EFO_0000637', 'EFO_0000756', 'MONDO_0001023', 'EFO_0000616', 'EFO_0000228', 'MONDO_0008315', 'EFO_0000313', 'EFO_0000305', 'EFO_0000403', 'EFO_0000702', 'EFO_0003869', 'MONDO_0004992', 'EFO_0000095', 'EFO_0003060']",False,False,19,Serine-protein kinase ATR inhibitor ,INHIBITOR ,single protein 
248,TU-100,CHEMBL4297331,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['HP_0002019', 'EFO_0000384', 'MONDO_0004567', 'EFO_0000555']",False,False,4,,,
249,BIIB-068,CHEMBL4650450,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007915'],False,False,1,,,
250,TRIMIX,CHEMBL4802184,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0004234', 'MONDO_0007254', 'EFO_0000764', 'EFO_0000756']",False,False,4,,,
251,INDACATEROL,CHEMBL1095777,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 4 investigational indications.,,4.0,,False,2011,['ENSG00000169252'],"['MONDO_0004979', 'EFO_0000341', 'HP_0006536', 'EFO_0000341', 'EFO_0006505', 'MONDO_0004979', 'EFO_0000464', 'EFO_0003144', 'MONDO_0004979']",False,False,9,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
252,NITRIC OXIDE,CHEMBL1200689,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 49 investigational indications.,,4.0,,False,1999,"['ENSG00000061918', 'ENSG00000123201', 'ENSG00000152402', 'ENSG00000164116']","['MONDO_0011382', 'EFO_0000341', 'EFO_0000373', 'EFO_1001375', 'EFO_0004272', 'EFO_1001923', 'MONDO_0005299', 'EFO_0000544', 'EFO_0004278', 'EFO_0009444', 'EFO_0000694', 'EFO_0007512', 'MONDO_0100096', 'EFO_0009447', 'EFO_0005762', 'EFO_0007486', 'MONDO_0019091', 'EFO_0005611', 'HP_0100806', 'EFO_0008585', 'EFO_0005046', 'EFO_1001399', 'EFO_1000644', 'EFO_1001951', 'MONDO_0043510', 'MONDO_0009061', 'EFO_1000637', 'EFO_1001459', 'EFO_0003827', 'EFO_0003917', 'HP_0011950', 'EFO_0007067', 'MONDO_0004992', 'EFO_0000684', 'EFO_0009686', 'EFO_0008583', 'EFO_0005207', 'EFO_0003106', 'MONDO_0005149', 'HP_0001919', 'EFO_0001068', 'EFO_0003818', 'EFO_0007541', 'EFO_0002687', 'MP_0001845', 'EFO_0009492', 'EFO_1001103', 'EFO_0000712', 'HP_0002094', 'HP_0200042', 'EFO_0000768', 'EFO_0001361', 'HP_0002093', 'EFO_0007224']",True,False,54,Soluble guanylate cyclase activator ,ACTIVATOR ,protein complex group 
253,DIPHENHYDRAMINE HYDROCHLORIDE,CHEMBL1620,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 14 investigational indications.,,4.0,,False,1946,['ENSG00000196639'],"['MONDO_0005271', 'EFO_0000095', 'EFO_1000657', 'MONDO_0007915', 'EFO_0005252', 'EFO_1000783', 'EFO_0000701', 'EFO_0005761', 'HP_0002315', 'MONDO_0007254', 'EFO_0000403', 'EFO_0003843', 'MONDO_0002367', 'EFO_0005854']",False,False,14,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
254,SOVATELITIDE,CHEMBL3188091,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0003891', 'EFO_0000313', 'EFO_1001919']",False,False,4,,,
255,TIROFIBAN HYDROCHLORIDE,CHEMBL3189072,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for myocardial infarction.,,4.0,,False,1998,"['ENSG00000259207', 'ENSG00000005961']",['EFO_0000612'],True,True,1,Integrin alpha-IIb/beta-3 inhibitor ,INHIBITOR ,protein complex 
256,ZOPTARELIN DOXORUBICIN,CHEMBL3544954,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000109163'],"['MONDO_0007254', 'MONDO_0011962', 'EFO_0008528']",False,False,3,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
257,TXA127,CHEMBL3545347,Protein drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,2.0,,False,no approval year,['ENSG00000130368'],"['EFO_0000198', 'EFO_0000616', 'EFO_0003144', 'GO_0007568', 'EFO_0000537', 'MONDO_0004992', 'EFO_0001073', 'MONDO_0100096', 'EFO_0000764', 'EFO_0004265', 'EFO_0009686']",True,False,11,Proto-oncogene Mas agonist ,AGONIST ,single protein 
258,1018 ISS,CHEMBL4297680,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000239732'],"['EFO_0004197', 'EFO_0005952', 'MONDO_0100096', 'EFO_0004142', 'EFO_0000764']",False,False,5,Toll-like receptor 9 agonist ,AGONIST ,single protein 
259,PEGZILARGINASE,CHEMBL4297803,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004992', 'EFO_0000222', 'EFO_0000198', 'Orphanet_90', 'EFO_0000702']",False,False,5,,,
260,GOSSYPOL ACETIC ACID,CHEMBL447686,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000158', 'EFO_0001378', 'EFO_0000095', 'EFO_1001465', 'EFO_1000796', 'EFO_0000702']",False,False,6,,,
261,ITEPEKIMAB,CHEMBL4594594,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000137033'],"['EFO_0000274', 'MONDO_0004979', 'EFO_0000341']",False,False,3,Interleukin-33 inhibitor ,INHIBITOR ,single protein 
262,KETAMINE,CHEMBL742,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 81 investigational indications.,,4.0,,False,1970,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']","['EFO_1001998', 'HP_0012532', 'MONDO_0002050', 'EFO_0007224', 'EFO_0003756', 'EFO_0000713', 'EFO_0005762', 'EFO_0001074', 'EFO_0002460', 'MONDO_0002009', 'EFO_0009854', 'EFO_1001412', 'EFO_0000512', 'EFO_0000546', 'EFO_0004320', 'EFO_0003768', 'EFO_0004320', 'EFO_1001898', 'EFO_0003890', 'MONDO_0005129', 'MONDO_0002009', 'HP_0002315', 'EFO_0005279', 'EFO_0009963', 'EFO_0000712', 'EFO_0007191', 'MONDO_0010726', 'EFO_0009513', 'HP_0012378', 'EFO_0003957', 'EFO_0007430', 'MONDO_0011382', 'MONDO_0007079', 'EFO_0000713', 'MONDO_0007079', 'HP_0000486', 'EFO_0003843', 'EFO_0009552', 'EFO_0004242', 'EFO_0009267', 'EFO_0000474', 'EFO_1001917', 'EFO_0005323', 'EFO_1000637', 'MONDO_0008903', 'MONDO_0005351', 'EFO_0007453', 'MONDO_0004985', 'HP_0012076', 'EFO_0000677', 'MONDO_0002050', 'MONDO_0002038', 'MONDO_0002070', 'HP_0100806', 'EFO_0009854', 'EFO_0003761', 'EFO_0005611', 'EFO_0002610', 'HP_0000360', 'HP_0100543', 'HP_0000989', 'EFO_0007149', 'EFO_0008590', 'MONDO_0043510', 'EFO_0009686', 'EFO_0009492', 'MONDO_0004992', 'MONDO_0100096', 'EFO_0001358', 'EFO_0006834', 'EFO_0002610', 'EFO_0000546', 'EFO_0005611', 'EFO_0003931', 'MONDO_0002258', 'EFO_0008526', 'EFO_0009620', 'EFO_0003931', 'HP_0002140', 'MONDO_0004992', 'HP_0025428', 'EFO_0000474', 'MONDO_0005090', 'HP_0000713', 'MONDO_0007254', 'HP_0100543', 'MONDO_0004985', 'EFO_0003015', 'MONDO_0024417', 'EFO_0000694']",False,False,90,Glutamate [NMDA] receptor negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,protein complex group 
263,CAMOSTAT MESILATE,CHEMBL85164,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000694', 'HP_0002243', 'MONDO_0100096']",False,False,3,,,
264,EFAPROXIRAL,CHEMBL18901,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000206172', 'ENSG00000188536', 'ENSG00000244734']","['MONDO_0008903', 'EFO_0000616', 'EFO_1000158', 'MONDO_0007254']",True,False,4,Hemoglobin HbA negative modulator ,NEGATIVE MODULATOR ,protein complex 
265,SILDENAFIL,CHEMBL192,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 6 approved and 77 investigational indications.,,4.0,,False,1998,['ENSG00000138735'],"['EFO_0000198', 'HP_0000802', 'EFO_0002950', 'MONDO_0004933', 'EFO_1001893', 'EFO_0004225', 'MONDO_0043510', 'EFO_0001422', 'EFO_0009441', 'EFO_1001017', 'EFO_0004265', 'EFO_1001145', 'HP_0001919', 'EFO_0009085', 'MONDO_0100096', 'EFO_0003917', 'EFO_0003144', 'MONDO_0008347', 'EFO_0008560', 'MONDO_0019091', 'EFO_0000545', 'HP_0200023', 'EFO_0000537', 'EFO_1001134', 'EFO_0004714', 'MONDO_0100096', 'MONDO_0005149', 'EFO_0000712', 'HP_0001655', 'EFO_0001361', 'EFO_0000495', 'EFO_0000284', 'HP_0200042', 'EFO_0000701', 'EFO_0003777', 'MONDO_0005475', 'EFO_1001134', 'MONDO_0006058', 'EFO_0009429', 'MONDO_0010679', 'EFO_0000341', 'EFO_1000824', 'MONDO_0008315', 'EFO_0004234', 'EFO_0000668', 'EFO_1001103', 'MONDO_0005041', 'EFO_0000400', 'MONDO_0005180', 'EFO_1001145', 'EFO_0003144', 'EFO_1001827', 'EFO_0003833', 'EFO_0000404', 'EFO_0003060', 'HP_0001298', 'EFO_0000668', 'MONDO_0043510', 'EFO_0000519', 'EFO_0000373', 'EFO_0000717', 'MONDO_0005149', 'EFO_0000768', 'EFO_0000464', 'EFO_1001986', 'EFO_0003047', 'HP_0002140', 'EFO_1000824', 'HP_0100607', 'EFO_0001365', 'EFO_0000537', 'EFO_0011023', 'EFO_0009200', 'EFO_0008493', 'MONDO_0011382', 'HP_0000020', 'EFO_0000616', 'EFO_0004234', 'EFO_0000495', 'MONDO_0010311', 'EFO_1001993', 'MONDO_0009061', 'EFO_0000545', 'EFO_0003818', 'MONDO_0002013', 'EFO_0001361', 'EFO_1001103', 'EFO_0001645', 'EFO_0003827']",True,False,89,Phosphodiesterase 5A inhibitor ,INHIBITOR ,single protein 
266,SEPANTRONIUM BROMIDE,CHEMBL2105734,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000403', 'EFO_0000756', 'MONDO_0004992', 'EFO_0001663', 'EFO_0005952']",False,False,8,,,
267,TETANUS TOXOID,CHEMBL2108875,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000389', 'EFO_0000685', 'MONDO_0008170', 'EFO_0000095', 'EFO_1001951', 'EFO_0003106', 'EFO_0000764', 'EFO_0004227', 'MONDO_0002087', 'EFO_0006859', 'EFO_1001040', 'MONDO_0002158', 'EFO_0000632', 'MONDO_0005301', 'MONDO_0004975', 'EFO_0000272', 'EFO_0001378', 'EFO_0000616', 'EFO_0000544', 'EFO_0004249', 'EFO_0006789']",False,False,21,,,
268,OBLIMERSEN SODIUM,CHEMBL2109229,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.,,3.0,,False,no approval year,['ENSG00000171791'],"['EFO_0000403', 'MONDO_0008170', 'EFO_0000095', 'EFO_1001471', 'MONDO_0008903', 'EFO_0003086', 'EFO_0000756', 'EFO_0000681', 'MONDO_0002691', 'EFO_0001378', 'MONDO_0002367', 'EFO_0006861', 'EFO_0000339', 'EFO_1001951', 'EFO_1001469', 'EFO_0000574', 'EFO_0009441', 'MONDO_0008315', 'MONDO_0018906', 'MONDO_0011719', 'EFO_0000389', 'MONDO_0007576', 'MONDO_0007254', 'EFO_0000702', 'EFO_0006859', 'EFO_0000616', 'MONDO_0001187', 'EFO_0000565']",True,False,28,Bcl-2 mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
269,CANFOSFAMIDE,CHEMBL2111086,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002158', 'MONDO_0008903', 'MONDO_0002087', 'EFO_0003869', 'MONDO_0008170', 'EFO_0003893', 'EFO_0003060']",False,False,7,,,
270,VANTICTUMAB,CHEMBL2364652,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,"['ENSG00000180340', 'ENSG00000163251', 'ENSG00000155760', 'ENSG00000177283', 'ENSG00000157240']","['EFO_0000616', 'MONDO_0007254', 'EFO_0002618']",False,False,3,Frizzled-8 antagonist Frizzled-1 antagonist Frizzled-2 antagonist Frizzled-7 antagonist Frizzled-5 antagonist ,ANTAGONIST ,single protein 
271,SR16234,CHEMBL3545210,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000091831'],['MONDO_0007254'],False,True,1,Estrogen receptor alpha antagonist ,ANTAGONIST ,single protein 
272,AZD-5423,CHEMBL4072756,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000113580'],"['MONDO_0004979', 'EFO_0000341']",False,True,2,Glucocorticoid receptor modulator ,MODULATOR ,single protein 
273,SBR-759,CHEMBL5095380,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003884'],False,False,1,,,
274,BENDAMUSTINE HYDROCHLORIDE,CHEMBL1201734,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 16 investigational indications.,,4.0,,False,2008,[],"['MONDO_0004992', 'MONDO_0008903', 'MONDO_0018906', 'EFO_0000702', 'MONDO_0044881', 'EFO_0000565', 'EFO_0000403', 'EFO_0005952', 'EFO_0000095', 'EFO_0002499', 'MONDO_0009348', 'EFO_0002501', 'EFO_0000096', 'EFO_0000183', 'MONDO_0019438', 'EFO_1001469', 'EFO_0000574', 'EFO_1001465', 'EFO_0001378']",False,False,19,,,
275,PHENYLEPHRINE,CHEMBL1215,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 11 approved and 32 investigational indications.,,4.0,,False,1952,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0009688', 'EFO_0007328', 'HP_0000989', 'EFO_0005751', 'EFO_0000712', 'HP_0001742', 'EFO_0006834', 'HP_0001742', 'EFO_0006834', 'EFO_0007533', 'EFO_0008521', 'EFO_0000319', 'EFO_0003956', 'EFO_0001073', 'EFO_0000178', 'EFO_0005251', 'HP_0011499', 'EFO_0005252', 'EFO_0005251', 'EFO_0000537', 'EFO_0009552', 'MONDO_0005129', 'HP_0100543', 'MONDO_0005271', 'EFO_0009523', 'EFO_0004269', 'EFO_0003843', 'EFO_0003966', 'HP_0002140', 'EFO_0003956', 'EFO_0004610', 'HP_0011950', 'HP_0000138', 'EFO_0000616', 'EFO_0007486', 'EFO_1000645', 'EFO_0007214', 'MONDO_0024355', 'EFO_1001898', 'EFO_0007214', 'EFO_0000544', 'EFO_0000319', 'EFO_0004264', 'MONDO_0024355', 'EFO_0001358']",False,False,45,Adrenergic receptor alpha-1 agonist ,AGONIST ,protein family 
276,LENVATINIB,CHEMBL1289601,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 58 investigational indications.,,4.0,,False,2015,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_1001961', 'MONDO_0004992', 'EFO_1000158', 'EFO_0004252', 'EFO_0000181', 'EFO_0005221', 'EFO_0000501', 'MONDO_0007576', 'MONDO_0002367', 'EFO_0002517', 'EFO_0000333', 'EFO_0001421', 'MONDO_0009348', 'EFO_0005922', 'EFO_0002892', 'EFO_0000349', 'EFO_0004142', 'EFO_1001961', 'MONDO_0002120', 'EFO_0002892', 'EFO_0000228', 'MONDO_0002108', 'EFO_0000616', 'EFO_0000574', 'MONDO_0002974', 'MONDO_0003060', 'MONDO_0008903', 'EFO_1000796', 'MONDO_0008315', 'EFO_0003891', 'EFO_0000756', 'EFO_0000178', 'EFO_0002617', 'EFO_0001378', 'MONDO_0008170', 'EFO_0003086', 'EFO_0004239', 'EFO_0000681', 'MONDO_0002108', 'EFO_1001471', 'EFO_0004230', 'MONDO_0001056', 'EFO_0000637', 'EFO_0003060', 'EFO_0000183', 'EFO_0000681', 'EFO_0000691', 'MONDO_0004992', 'EFO_0000616', 'EFO_0002517', 'EFO_0000313', 'EFO_1001901', 'EFO_0000641', 'EFO_0008528', 'EFO_0005543', 'EFO_0000702', 'EFO_0000182', 'EFO_0000231', 'EFO_0000571', 'MONDO_0011962', 'EFO_0000588', 'EFO_1001012', 'EFO_0003060', 'EFO_1000657', 'MONDO_0007254', 'EFO_1000613']",True,False,66,Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,protein family 
277,RUNCACIGUAT,CHEMBL4650322,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000061918', 'ENSG00000123201', 'ENSG00000152402', 'ENSG00000164116']","['EFO_0003884', 'EFO_0003770']",True,False,2,Soluble guanylate cyclase activator ,ACTIVATOR ,protein complex group 
278,ACLIDINIUM BROMIDE,CHEMBL551466,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 1 investigational indication.,,4.0,,False,2012,['ENSG00000133019'],"['EFO_0000341', 'EFO_0000464', 'EFO_0006505', 'MONDO_0004979', 'HP_0006536', 'EFO_0003768']",True,True,6,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
279,GLUCAGON HYDROCHLORIDE,CHEMBL1201618,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications.,,4.0,,False,1960,['ENSG00000215644'],"['EFO_0000400', 'MONDO_0005147', 'HP_0001943', 'MONDO_0005148']",False,False,4,Glucagon receptor agonist ,AGONIST ,single protein 
280,ROSE BENGAL FREE ACID,CHEMBL1208422,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 7 investigational indications.,,4.0,,False,1971,[],"['EFO_0003768', 'EFO_0000676', 'EFO_0000389', 'EFO_0007126', 'EFO_1001901', 'EFO_0000756', 'MONDO_0007254']",False,False,7,,,
281,TENOFOVIR DISOPROXIL,CHEMBL1538,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 7 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,[],"['EFO_1001486', 'EFO_0008496', 'EFO_0000763', 'EFO_0000764', 'EFO_0005741', 'MONDO_0100096', 'EFO_0007304', 'MONDO_0100096', 'EFO_1000727', 'EFO_0000765', 'EFO_0004220', 'EFO_0004197', 'EFO_0000544', 'EFO_0004197', 'EFO_0000180', 'EFO_0003047', 'HP_0012115', 'MONDO_0018076', 'EFO_0004239', 'EFO_0002614', 'EFO_0001421', 'EFO_0004239', 'EFO_0000574', 'EFO_0007304', 'EFO_0000764', 'EFO_0004239']",False,False,26,Human immunodeficiency virus type 1 reverse transcriptase inhibitor ,INHIBITOR ,single protein 
282,TALACTOFERRIN ALFA,CHEMBL2108651,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['HP_0100806', 'EFO_0000544', 'EFO_0003060']",False,False,3,,,
283,ELUBRIXIN,CHEMBL2178579,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000180871'],"['EFO_0000341', 'EFO_0000729', 'EFO_0000341', 'MONDO_0009061']",False,True,4,Interleukin-8 receptor B antagonist ,ANTAGONIST ,single protein 
284,ANTROQUINONOL,CHEMBL3235620,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0004197', 'EFO_0003060', 'EFO_0004239', 'MONDO_0021187', 'EFO_0000222', 'EFO_0003860', 'EFO_0000274', 'MONDO_0100096']",False,False,8,,,
285,APOCYNIN,CHEMBL346919,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0004979', 'EFO_0000341', 'EFO_0000319']",False,False,3,,,
286,REMDESIVIR,CHEMBL4065616,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2020,[],"['EFO_1000637', 'MONDO_0100096', 'EFO_0000763', 'EFO_0007243', 'EFO_0000694', 'EFO_0007541']",False,False,6,Replicase polyprotein 1ab inhibitor RNA-directed RNA polymerase L inhibitor ,INHIBITOR ,single protein 
287,CP-461,CHEMBL4243974,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000384', 'EFO_0000756', 'MONDO_0008315', 'EFO_0000095', 'EFO_0000681']",False,False,5,,,
288,NNC0114-0006,CHEMBL4297797,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000138684'],['MONDO_0005147'],False,True,1,Interleukin-21 binding agent ,BINDING AGENT ,single protein 
289,MEZAGITAMAB,CHEMBL4297833,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000004468'],"['EFO_0001378', 'EFO_0004991', 'EFO_0007160', 'EFO_0003086', 'EFO_0005140', 'MONDO_0007915']",True,False,6,Lymphocyte differentiation antigen CD38 binding agent ,BINDING AGENT ,single protein 
290,IMIPENEM,CHEMBL43708,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 8 investigational indications.,,4.0,,False,1985,[],"['EFO_0001642', 'EFO_0000771', 'EFO_0000544', 'MONDO_0044881', 'EFO_1001865', 'HP_0100806', 'EFO_0000465', 'EFO_1001272', 'EFO_0003102', 'EFO_0003106', 'EFO_0003103', 'EFO_1001313', 'EFO_1001141']",False,False,13,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
291,PREDNISONE,CHEMBL635,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 62 approved and 146 investigational indications.,,4.0,,False,1955,['ENSG00000113580'],"['DOID_13406', 'EFO_0000318', 'Orphanet_77260', 'MONDO_0019391', 'EFO_0005319', 'EFO_1001194', 'EFO_0005531', 'EFO_0003898', 'MONDO_0019338', 'MONDO_0015760', 'EFO_1001968', 'EFO_0003956', 'EFO_0004826', 'EFO_0008997', 'EFO_1001896', 'EFO_0007403', 'MP_0001845', 'EFO_0003777', 'EFO_1000318', 'MONDO_0009061', 'EFO_0000764', 'EFO_1001264', 'EFO_0000729', 'EFO_0000211', 'EFO_0000196', 'EFO_0004274', 'MONDO_0005301', 'EFO_0001378', 'EFO_1000997', 'EFO_0004255', 'EFO_1000965', 'EFO_1000131', 'EFO_0000768', 'MONDO_0008903', 'EFO_0004991', 'HP_0001094', 'EFO_0002428', 'EFO_0003086', 'EFO_0000222', 'HP_0012424', 'EFO_1001205', 'MONDO_0016537', 'EFO_0005856', 'MONDO_0018906', 'EFO_0008518', 'MONDO_0044903', 'HP_0001952', 'EFO_0004256', 'EFO_0009456', 'EFO_0000691', 'EFO_0009448', 'MONDO_0005178', 'MONDO_0009348', 'EFO_0004599', 'EFO_0000182', 'MONDO_0015540', 'MONDO_0018896', 'MONDO_0008315', 'EFO_0007405', 'EFO_1000784', 'MONDO_0017719', 'EFO_0005952', 'EFO_0000616', 'HP_0001871', 'EFO_0000198', 'EFO_0005801', 'EFO_0000209', 'EFO_0004236', 'EFO_0007313', 'EFO_0000673', 'EFO_0007537', 'EFO_0000574', 'EFO_0000183', 'MONDO_0018998', 'EFO_0002430', 'MONDO_0013730', 'EFO_0007187', 'EFO_0000565', 'EFO_0007486', 'EFO_0002609', 'MONDO_0015564', 'EFO_1001383', 'MONDO_0000873', 'EFO_1001051', 'MONDO_0007915', 'EFO_0004254', 'EFO_0000557', 'MONDO_0004976', 'HP_0012410', 'EFO_0000220', 'EFO_1001467', 'EFO_0003032', 'EFO_0007160', 'EFO_0009491', 'EFO_0000096', 'EFO_0000398', 'EFO_0007167', 'MONDO_0001085', 'EFO_0003818', 'EFO_0007541', 'EFO_0009609', 'HP_0003072', 'EFO_1001417', 'EFO_1000684', 'EFO_0004719', 'EFO_0000403', 'MONDO_0000870', 'EFO_1001413', 'EFO_0001663', 'MONDO_0000432', 'EFO_0002626', 'MONDO_0004979', 'EFO_1001345', 'EFO_0000094', 'EFO_0007498', 'EFO_1001469', 'EFO_1001466', 'EFO_0004238', 'EFO_0007168', 'EFO_0007520', 'EFO_0000095', 'MONDO_0017287', 'MONDO_0004095', 'EFO_1000635', 'EFO_0000479', 'EFO_1001176', 'MONDO_0018150', 'EFO_0005558', 'EFO_1000049', 'MONDO_0005271', 'EFO_0000274', 'EFO_0000255', 'MONDO_0004992', 'EFO_0006803', 'MONDO_0001280', 'MONDO_0008728', 'EFO_1000694', 'EFO_1000391', 'EFO_1001435', 'EFO_0003884', 'EFO_1000986', 'EFO_1000158', 'EFO_0003047', 'HP_0002043', 'EFO_0009538', 'EFO_0003144', 'EFO_0003063', 'EFO_1001857', 'MONDO_0010602', 'EFO_1000749', 'EFO_0002429', 'MONDO_0004975', 'EFO_0000756', 'EFO_0001063', 'MONDO_0044881', 'EFO_0003106', 'HP_0001915', 'MONDO_0002367', 'EFO_0004289', 'MONDO_0000430', 'HP_0001873', 'MONDO_0005180', 'EFO_0004194', 'MONDO_0010079', 'EFO_1001209', 'EFO_0003929', 'MONDO_0015128', 'MONDO_0017276', 'EFO_0003778', 'EFO_1000764', 'HP_0011868', 'EFO_0005297', 'EFO_0005140', 'EFO_0005854', 'MONDO_0010679', 'MONDO_0007254', 'EFO_0000676', 'EFO_1000941', 'EFO_0000373', 'EFO_0004276', 'MONDO_0018076', 'EFO_0000384', 'EFO_0003843', 'EFO_0000685', 'MONDO_0005148', 'EFO_1001365', 'EFO_0007141', 'MONDO_0100096', 'EFO_0005761', 'EFO_0008517', 'EFO_1001231', 'MONDO_0018848', 'EFO_0000309', 'EFO_0004251', 'EFO_1001119', 'EFO_0007208', 'EFO_1001222', 'EFO_0000621', 'EFO_0009449', 'MONDO_0019471', 'EFO_0003060', 'EFO_0000341', 'MONDO_0011719', 'EFO_1000039', 'EFO_0000765', 'EFO_0007257', 'EFO_0005676', 'MONDO_0044917']",True,True,208,Glucocorticoid receptor agonist ,AGONIST ,single protein 
292,TELITHROMYCIN,CHEMBL1136,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,[],"['EFO_0000771', 'MONDO_0004979', 'EFO_0007503', 'MONDO_0002258', 'EFO_0007480', 'EFO_0000544', 'HP_0011110', 'EFO_0007361', 'EFO_0003106', 'EFO_0004992']",False,False,10,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
293,TETRAHYDROURIDINE,CHEMBL1236475,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005952', 'EFO_0000096', 'EFO_0000616', 'MONDO_0011382', 'EFO_0000198', 'EFO_0006859', 'EFO_0003060', 'EFO_1000158']",False,False,8,,,
294,TRAMADOL,CHEMBL1237044,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,['ENSG00000112038'],"['HP_0012532', 'HP_0003419', 'EFO_1001250', 'HP_0002027', 'EFO_0000181', 'EFO_0003964', 'EFO_0005762', 'EFO_0005800', 'EFO_0000546', 'HP_0012532', 'MONDO_0002009', 'MONDO_0005178', 'EFO_1000783', 'MONDO_0007254', 'EFO_0010072', 'EFO_0005611', 'EFO_0003843', 'HP_0003419', 'EFO_0003843', 'EFO_0006859', 'EFO_0005687', 'EFO_0004616', 'EFO_0003890', 'MONDO_0004992']",False,False,24,Mu opioid receptor agonist ,AGONIST ,single protein 
295,PIXANTRONE,CHEMBL167731,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 9 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000403', 'EFO_0000222', 'EFO_0000565', 'EFO_0000574', 'MONDO_0018906', 'MONDO_0007254', 'EFO_0005952', 'EFO_0000616', 'EFO_0000095', 'EFO_0000574']",False,False,10,,,
296,PLERIXAFOR,CHEMBL18442,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 31 investigational indications.,,4.0,,False,2008,['ENSG00000121966'],"['MONDO_0003783', 'EFO_0000095', 'EFO_0000222', 'MONDO_0000870', 'EFO_0000198', 'MONDO_0015760', 'EFO_1001311', 'EFO_0001378', 'EFO_1001996', 'EFO_0000717', 'EFO_0000565', 'MONDO_0018305', 'MONDO_0001475', 'EFO_0002618', 'MONDO_0011382', 'EFO_0000220', 'EFO_0000403', 'EFO_0000691', 'EFO_1001465', 'EFO_0003086', 'MONDO_0018906', 'MONDO_0019391', 'EFO_1001469', 'MONDO_0044881', 'EFO_0000574', 'MONDO_0019460', 'EFO_0000220', 'EFO_0000616', 'EFO_0006859', 'EFO_0005952', 'EFO_0000183', 'EFO_1001459', 'Orphanet_848', 'MONDO_0005147', 'EFO_1000654', 'EFO_0004599']",False,False,36,C-X-C chemokine receptor type 4 partial agonist ,PARTIAL AGONIST ,single protein 
297,MOTESANIB DIPHOSPHATE,CHEMBL2107357,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0021063', 'MONDO_0008903', 'EFO_1000657', 'MONDO_0007576', 'MONDO_0002087', 'EFO_0003060', 'MONDO_0008170', 'MONDO_0011719', 'EFO_0002618', 'EFO_0000616', 'EFO_0007331', 'MONDO_0002158', 'MONDO_0002108', 'EFO_0004243', 'EFO_0000574', 'MONDO_0016537']",False,False,17,,,
298,MAPATUMUMAB,CHEMBL2108621,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000104689'],"['EFO_0003060', 'MONDO_0002974', 'EFO_0005952', 'EFO_0001378', 'EFO_0000182']",False,False,5,TRAIL receptor-1 agonist ,AGONIST ,single protein 
299,GALICAFTOR,CHEMBL4101487,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
300,VISMODEGIB,CHEMBL473417,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,['ENSG00000128602'],"['MONDO_0007254', 'MONDO_0008170', 'EFO_0000702', 'EFO_0002618', 'EFO_0002939', 'MONDO_0008315', 'MONDO_0003684', 'EFO_0000222', 'EFO_1001465', 'MONDO_0004992', 'EFO_0000768', 'EFO_0000616', 'EFO_0000673', 'EFO_0004193', 'EFO_0002517', 'EFO_0003897', 'MONDO_0044903', 'MONDO_0005341', 'EFO_0000326', 'MONDO_0007187', 'EFO_0001378', 'EFO_0000519', 'EFO_1001041', 'MONDO_0016642', 'EFO_0000305']",False,False,25,Smoothened homolog inhibitor ,INHIBITOR ,single protein 
301,EPALRESTAT,CHEMBL56337,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000085662'],"['MONDO_0007254', 'EFO_1000783']",True,False,2,Aldose reductase inhibitor ,INHIBITOR ,single protein 
302,LAQUINIMOD,CHEMBL66092,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007915', 'MONDO_0007739', 'EFO_0003929', 'EFO_0008520', 'EFO_0003966', 'MONDO_0005301', 'EFO_0000384', 'EFO_0005761']",False,False,8,,,
303,PYRIDOSTIGMINE BROMIDE,CHEMBL812,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1955,['ENSG00000087085'],"['EFO_0003144', 'MONDO_0100096', 'MONDO_0009672', 'EFO_0005251', 'MONDO_0004567', 'MONDO_0005180', 'Orphanet_365', 'EFO_0004991', 'EFO_0005252']",False,False,9,Acetylcholinesterase inhibitor ,INHIBITOR ,single protein 
304,OCTREOTIDE,CHEMBL1680,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 39 investigational indications.,,4.0,,False,1988,"['ENSG00000162009', 'ENSG00000180616', 'ENSG00000132671', 'ENSG00000139874', 'ENSG00000278195']","['EFO_0000544', 'EFO_0000182', 'EFO_1000852', 'MONDO_0005277', 'EFO_1001496', 'MONDO_0004565', 'EFO_0000768', 'EFO_1000852', 'MONDO_0024503', 'EFO_0005252', 'MONDO_0017611', 'EFO_1000045', 'MONDO_0019180', 'EFO_0002626', 'HP_0002014', 'EFO_0000616', 'EFO_0007331', 'EFO_1001485', 'MONDO_0016642', 'EFO_0001073', 'MONDO_0007254', 'EFO_1001485', 'EFO_1001901', 'EFO_0000555', 'MONDO_0017182', 'HP_0002239', 'EFO_1001485', 'EFO_0000574', 'HP_0002014', 'MONDO_0002120', 'EFO_1002048', 'MONDO_0008300', 'EFO_1001901', 'MONDO_0043579', 'EFO_1000581', 'EFO_0009708', 'EFO_0000616', 'EFO_0004243', 'HP_0002019', 'MONDO_0007254', 'EFO_0003770', 'EFO_0002618', 'EFO_0004243', 'MONDO_0004992', 'MONDO_0024503', 'EFO_0001073', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0008315', 'MONDO_0004565']",False,False,50,Somatostatin receptor agonist ,AGONIST ,protein family 
305,SILVER NITRATE,CHEMBL177367,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0009637', 'EFO_0009516', 'EFO_0007205', 'EFO_0003819', 'EFO_0003884']",False,False,5,,,
306,CO-TRIMOXAZOLE,CHEMBL195591,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0008588', 'HP_0100806', 'EFO_0000771', 'MONDO_0018076']",False,False,5,Bacterial dihydropteroate synthase inhibitor Bacterial dihydrofolate reductase inhibitor ,INHIBITOR ,single protein 
307,PECTIN,CHEMBL2108751,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001069', 'MONDO_0011382', 'MONDO_0004992', 'EFO_0000384', 'EFO_0000555', 'HP_0002019', 'EFO_0003843']",False,False,7,,,
308,MEDI-6469,CHEMBL2109531,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000186827'],"['EFO_0002617', 'EFO_0006859', 'EFO_0004142', 'EFO_0000574', 'EFO_0000196', 'MONDO_0007254']",True,False,6,Tumor necrosis factor receptor superfamily member 4 agonist ,AGONIST ,single protein 
309,ISOQUERCETIN,CHEMBL250450,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003884', 'EFO_0000681', 'MONDO_0100096', 'MONDO_0011382']",False,False,4,,,
310,AZD-8186,CHEMBL3408248,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications.,,1.0,,False,no approval year,"['ENSG00000051382', 'ENSG00000171608']","['EFO_0000196', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0003060', 'EFO_0000305']",False,False,6,PI3-kinase p110-delta subunit inhibitor PI3-kinase p110-beta subunit inhibitor ,INHIBITOR ,single protein 
311,IRINOTECAN HYDROCHLORIDE,CHEMBL3989514,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for carcinoma and adenocarcinoma and has 98 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000198900'],"['EFO_1001013', 'EFO_0001075', 'EFO_1000657', 'MONDO_0002367', 'MONDO_0002158', 'EFO_1001512', 'MONDO_0004669', 'EFO_0000313', 'EFO_1000292', 'EFO_0002617', 'EFO_0000681', 'EFO_0000228', 'EFO_0000707', 'EFO_0000574', 'EFO_0000403', 'EFO_0000365', 'EFO_1000407', 'MONDO_0008315', 'MONDO_0002120', 'MONDO_0044926', 'EFO_0000309', 'EFO_0000305', 'MONDO_0000873', 'EFO_1001951', 'EFO_0002938', 'MONDO_0001056', 'MONDO_0002537', 'MONDO_0018364', 'EFO_1001051', 'EFO_0002501', 'MONDO_0008170', 'MONDO_0021063', 'EFO_0005537', 'MONDO_0007576', 'MONDO_0002974', 'HP_0002014', 'EFO_0004193', 'EFO_0000621', 'EFO_0002517', 'MONDO_0008903', 'EFO_0006352', 'EFO_0002918', 'EFO_0000437', 'EFO_1000475', 'MONDO_0003060', 'EFO_0000191', 'EFO_1001465', 'EFO_0004243', 'MONDO_0020634', 'MONDO_0001475', 'EFO_1000251', 'EFO_0000702', 'EFO_0000519', 'EFO_0002618', 'MONDO_0044937', 'MONDO_0100342', 'MONDO_0005411', 'EFO_0000632', 'MONDO_0002087', 'MONDO_0001325', 'EFO_0000095', 'MONDO_0019471', 'MONDO_0016717', 'EFO_0007535', 'EFO_1000785', 'MONDO_0011719', 'EFO_1001469', 'MONDO_0001187', 'MONDO_0003196', 'MONDO_0001879', 'EFO_0000183', 'EFO_0000389', 'EFO_1001365', 'EFO_0000502', 'EFO_0000637', 'EFO_1001471', 'EFO_0006859', 'MONDO_0002691', 'EFO_0002939', 'EFO_1000158', 'EFO_1001042', 'EFO_0004142', 'EFO_0000691', 'EFO_0001071', 'EFO_0000248', 'EFO_0000616', 'EFO_0000503', 'EFO_0000174', 'EFO_0003032', 'EFO_0002499', 'EFO_0000178', 'MONDO_0021633', 'MONDO_0004192', 'MONDO_0018906', 'MONDO_0004992', 'MONDO_0018271', 'MONDO_0007254', 'EFO_0000565', 'EFO_0003060', 'EFO_0000255']",False,False,100,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
312,PAROXETINE,CHEMBL490,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 9 approved and 24 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,['ENSG00000108576'],"['MONDO_0005180', 'EFO_0003922', 'EFO_0006788', 'MONDO_0002009', 'EFO_0000612', 'EFO_1001917', 'EFO_0004242', 'EFO_1001892', 'MONDO_0002050', 'EFO_0005762', 'EFO_0005230', 'HP_0031217', 'EFO_0004262', 'EFO_0005687', 'EFO_0001358', 'EFO_0005230', 'MONDO_0004985', 'HP_0000360', 'EFO_0001358', 'MONDO_0005090', 'EFO_0004220', 'EFO_1001917', 'MONDO_0007079', 'MONDO_0002050', 'EFO_0004242', 'EFO_0003761', 'EFO_0004262', 'EFO_0003761', 'EFO_1001872', 'EFO_0003922', 'MONDO_0002775', 'EFO_0000685', 'EFO_0000768', 'MONDO_0002009']",False,False,34,Serotonin transporter inhibitor ,INHIBITOR ,single protein 
313,ERYTHROMYCIN,CHEMBL532,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 3 approved and 18 investigational indications.,,4.0,,False,1964,[],"['EFO_0000764', 'EFO_0003894', 'EFO_0000095', 'EFO_0005204', 'EFO_0003047', 'EFO_0000771', 'EFO_0004234', 'EFO_0007205', 'MONDO_0005147', 'EFO_0003060', 'HP_0002239', 'EFO_1000948', 'EFO_1001888', 'MONDO_0001056', 'EFO_0003106', 'EFO_1000690', 'EFO_0000365', 'EFO_0003102', 'EFO_0000341', 'HP_0002248', 'HP_0000083']",False,False,21,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
314,TAMOXIFEN CITRATE,CHEMBL786,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved and 45 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1977,['ENSG00000091831'],"['MONDO_0001187', 'MONDO_0010679', 'EFO_0009907', 'MONDO_0002158', 'EFO_0003843', 'EFO_0000536', 'EFO_0000294', 'MONDO_0011962', 'EFO_0000545', 'MONDO_0007254', 'EFO_0004248', 'EFO_0000519', 'MONDO_0018364', 'HP_0000771', 'EFO_0000305', 'MONDO_0008170', 'EFO_0003833', 'EFO_0009708', 'EFO_1000158', 'EFO_1001512', 'MONDO_0002087', 'EFO_0003922', 'EFO_0000389', 'MONDO_0002691', 'EFO_0004220', 'MONDO_0004985', 'EFO_1001901', 'EFO_0000232', 'EFO_0001075', 'EFO_0000616', 'MONDO_0018848', 'EFO_0000764', 'EFO_0005543', 'EFO_0000637', 'EFO_1000251', 'MONDO_0008315', 'MONDO_0019180', 'EFO_0006861', 'EFO_1001375', 'MONDO_0004992', 'MONDO_0100096', 'EFO_0000432', 'Orphanet_145', 'EFO_0000537', 'MONDO_0004976', 'EFO_0001416', 'EFO_1000984', 'EFO_0003869']",True,True,48,Estrogen receptor alpha modulator ,MODULATOR ,single protein 
315,NALOXONE,CHEMBL80,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 30 investigational indications.,,4.0,,False,1971,"['ENSG00000082556', 'ENSG00000116329', 'ENSG00000112038']","['MONDO_0018555', 'MONDO_0001583', 'EFO_0003047', 'MONDO_0005147', 'EFO_0003843', 'HP_0000989', 'EFO_0005611', 'EFO_0010702', 'EFO_0005203', 'EFO_0004270', 'EFO_1001051', 'HP_0012532', 'EFO_0006834', 'EFO_1000785', 'MONDO_0004565', 'EFO_0001073', 'EFO_0004699', 'HP_0003419', 'EFO_0005762', 'EFO_0005611', 'MONDO_0004992', 'EFO_0004240', 'EFO_0000474', 'MONDO_0005178', 'HP_0002019', 'EFO_0000555', 'EFO_0003761', 'HP_0002019', 'EFO_0005800', 'MONDO_0004565', 'EFO_0003843', 'EFO_0003890', 'MONDO_0005180', 'EFO_0005612']",False,False,34,Opioid receptors; mu/kappa/delta antagonist ,ANTAGONIST ,protein family 
316,ALDESLEUKIN,CHEMBL1201438,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 5 approved and 104 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']","['EFO_0002617', 'EFO_0000564', 'EFO_0000673', 'EFO_1000954', 'EFO_0005672', 'EFO_0003780', 'EFO_0000565', 'EFO_0000389', 'EFO_0009709', 'EFO_0000223', 'EFO_0009708', 'EFO_0004251', 'EFO_0000222', 'MONDO_0100096', 'EFO_0001062', 'EFO_0003811', 'EFO_0004719', 'EFO_0004599', 'EFO_0000783', 'EFO_0000691', 'EFO_1000251', 'EFO_0003865', 'EFO_0000403', 'EFO_0000313', 'MONDO_0001187', 'EFO_0000681', 'EFO_0003025', 'EFO_0001378', 'MONDO_0002367', 'EFO_0000220', 'EFO_0000616', 'EFO_0000729', 'MONDO_0007915', 'EFO_1001051', 'EFO_0005531', 'EFO_0008518', 'EFO_0000588', 'EFO_0000339', 'MONDO_0002108', 'MONDO_0007576', 'EFO_0000574', 'MONDO_0024475', 'MONDO_0004975', 'EFO_0000182', 'MONDO_0002087', 'MONDO_0019956', 'EFO_0000765', 'EFO_1001148', 'EFO_0000180', 'EFO_0001061', 'EFO_1001806', 'EFO_1000984', 'MONDO_0013730', 'EFO_0001075', 'EFO_0000183', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0018906', 'MONDO_0008170', 'EFO_1000158', 'EFO_0000398', 'MONDO_0004992', 'EFO_0008528', 'EFO_0004255', 'EFO_0000198', 'EFO_1000131', 'MONDO_0008903', 'MONDO_0020077', 'MONDO_0007254', 'EFO_0000095', 'EFO_1001471', 'EFO_0001645', 'MONDO_0008315', 'MONDO_0044881', 'EFO_0003869', 'EFO_0006861', 'EFO_0005846', 'EFO_0005952', 'EFO_1000785', 'EFO_0000756', 'EFO_0003029', 'EFO_0007141', 'EFO_0000309', 'EFO_0000349', 'EFO_0001668', 'MONDO_0004976', 'MONDO_0002691', 'EFO_0003027', 'EFO_0000764', 'MONDO_0002898', 'HP_0001871', 'EFO_0004192', 'EFO_0000384', 'EFO_0001376', 'EFO_0002428', 'EFO_0000218', 'EFO_0003893', 'EFO_0006859', 'EFO_0003047', 'EFO_1001951', 'EFO_1001264', 'EFO_1001779', 'MONDO_0005147', 'EFO_0000621', 'EFO_0000096', 'EFO_1001465', 'EFO_0003802', 'MONDO_0010518', 'EFO_0000221']",True,True,109,Interleukin-2 receptor agonist ,AGONIST ,protein complex 
317,PILARALISIB,CHEMBL3360203,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_0000574', 'EFO_0000519', 'EFO_0004230', 'EFO_0003060', 'MONDO_0011962', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254']",True,False,8,PI3-kinase class I inhibitor ,INHIBITOR ,protein complex group 
318,SENEXIN B,CHEMBL4076837,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
319,RSLV-132,CHEMBL4297821,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000699', 'MONDO_0007915']",False,False,3,,,
320,HYALURONATE SODIUM,CHEMBL4594244,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for skin ulcer and nasal congestion and has 10 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1000906', 'HP_0200042', 'EFO_1001178', 'EFO_0004143', 'HP_0001742', 'EFO_1000786', 'EFO_0000341', 'EFO_0005802', 'EFO_0004616', 'EFO_1001345', 'MONDO_0005178', 'HP_0008419']",False,False,12,,,
321,DORIPENEM,CHEMBL491571,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 7 investigational indications.,,4.0,,False,2007,[],"['EFO_0000278', 'EFO_0003106', 'MONDO_0021108', 'EFO_0007149', 'EFO_1001141', 'EFO_0000771', 'EFO_1001865', 'HP_0001082', 'EFO_0003103', 'EFO_0008588', 'EFO_0000544']",False,False,11,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
322,DNK333,CHEMBL105060,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000115353'],"['EFO_0000341', 'EFO_0000274', 'EFO_0000555']",False,False,3,Neurokinin 1 receptor antagonist ,ANTAGONIST ,single protein 
323,VALSARTAN,CHEMBL1069,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000144891'],"['EFO_0000275', 'EFO_0004265', 'EFO_0008583', 'HP_0003124', 'EFO_0008586', 'EFO_0000712', 'EFO_0000195', 'EFO_0007148', 'EFO_0005672', 'MONDO_0005149', 'EFO_0003086', 'EFO_0000538', 'MONDO_0100096', 'EFO_0000373', 'EFO_0005529', 'Orphanet_309005', 'EFO_0000612', 'EFO_0008585', 'EFO_0000537', 'EFO_0003144', 'EFO_0000400', 'EFO_0001645', 'EFO_0000319', 'EFO_0003914', 'EFO_0003884', 'MONDO_0005148', 'MONDO_0001134', 'MONDO_0018965']",False,False,28,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
324,VANCOMYCIN HYDROCHLORIDE,CHEMBL1200628,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for endocarditis and infection and has 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1964,[],"['EFO_1001849', 'EFO_0003030', 'EFO_0000771', 'EFO_0009130', 'EFO_0000701', 'EFO_0000465', 'MONDO_0009061', 'EFO_0000544', 'EFO_0003035', 'MONDO_0043544']",False,False,10,,,
325,DARBEPOETIN ALFA,CHEMBL1201566,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,['ENSG00000187266'],"['HP_0001298', 'EFO_0004272', 'EFO_0000095', 'EFO_0003884', 'EFO_0000198', 'EFO_0000574', 'EFO_0001642', 'MONDO_0002280', 'EFO_0000565', 'MONDO_0007254', 'EFO_0000222', 'MONDO_0043510', 'EFO_0000702', 'EFO_0003086', 'EFO_0000612', 'HP_0001919', 'MONDO_0005299', 'MONDO_0003002', 'MONDO_0004992', 'EFO_0008583', 'EFO_0000403']",True,False,21,Erythropoietin receptor agonist ,AGONIST ,single protein 
326,RAD-140,CHEMBL1672635,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
327,AVIBACTAM,CHEMBL1689063,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 8 investigational indications.,,4.0,,False,2015,[],"['HP_0000083', 'EFO_0000544', 'EFO_0003103', 'EFO_0000544', 'EFO_0003103', 'EFO_0000771', 'EFO_0003106', 'EFO_0000544', 'EFO_1001478', 'EFO_1001141', 'EFO_1001141']",False,False,11,Bacterial beta-lactamase TEM inhibitor ,INHIBITOR ,single protein 
328,SIRUKUMAB,CHEMBL1743071,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,['ENSG00000136244'],"['MONDO_0007915', 'EFO_0000540', 'MONDO_0004979', 'MONDO_0100096', 'EFO_0003834', 'EFO_1001209', 'EFO_0005761', 'EFO_0008518', 'EFO_0000685', 'MONDO_0002009']",True,False,10,Interleukin-6 inhibitor ,INHIBITOR ,single protein 
329,COBICISTAT,CHEMBL2095208,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 8 investigational indications.,,4.0,,False,2012,"['ENSG00000160868', 'ENSG00000106258', 'ENSG00000021461', 'ENSG00000160870']","['EFO_0000765', 'EFO_0007448', 'EFO_0001068', 'EFO_0000220', 'EFO_0002517', 'EFO_0000544', 'MONDO_0100096', 'EFO_0000764', 'EFO_0002614', 'EFO_0003060', 'EFO_0000180']",True,False,11,Cytochrome P450 3A inhibitor ,INHIBITOR ,protein family 
330,"GINSENG, ASIAN",CHEMBL2108467,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0004992', 'MONDO_0100096', 'EFO_1001951', 'EFO_0000400', 'HP_0012378', 'MONDO_0005090', 'EFO_0000544', 'EFO_0000537']",False,False,8,,,
331,(+)-SECOISOLARICIRESINOL,CHEMBL368347,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
332,TICAGRELOR,CHEMBL398435,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,['ENSG00000169313'],"['EFO_0008585', 'EFO_0001645', 'EFO_0003884', 'MONDO_0005148', 'EFO_0003913', 'EFO_0000275', 'EFO_0005672', 'EFO_0003870', 'EFO_0002615', 'EFO_0004265', 'EFO_0008586', 'EFO_0000341', 'EFO_0000712', 'EFO_0000319', 'EFO_0000266', 'EFO_0000612', 'EFO_0008583', 'EFO_0003086', 'EFO_0007328', 'MONDO_0011382', 'MONDO_0000831', 'HP_0004419', 'EFO_0003106', 'EFO_0004214', 'MONDO_0100096', 'EFO_0000556']",True,False,26,Purinergic receptor P2Y12 negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,single protein 
333,TALC,CHEMBL3990276,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for pleural effusion and has 4 investigational indications.,,4.0,,False,1997,[],"['EFO_1000786', 'EFO_0003957', 'EFO_0003060', 'EFO_0009637', 'EFO_0004616']",False,False,5,,,
334,ANFIBATIDE,CHEMBL4297694,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000185245'],"['EFO_0000612', 'MONDO_0019740']",False,False,2,Platelet glycoprotein Ib alpha chain antagonist ,ANTAGONIST ,single protein 
335,TISLELIZUMAB,CHEMBL4297840,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 50 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['MONDO_0019472', 'MONDO_0015760', 'EFO_0005952', 'EFO_0000294', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0000756', 'EFO_0004142', 'EFO_0000313', 'MONDO_0004992', 'EFO_0004252', 'EFO_0005537', 'EFO_0006859', 'EFO_0005922', 'MONDO_0021063', 'EFO_0003891', 'HP_0001541', 'EFO_0000181', 'EFO_0002618', 'EFO_1001951', 'MONDO_0002367', 'EFO_0000702', 'MONDO_0008315', 'EFO_0000574', 'EFO_0000707', 'EFO_1000350', 'EFO_1000657', 'MONDO_0008903', 'EFO_0002517', 'EFO_0002609', 'EFO_0000183', 'EFO_0000616', 'MONDO_0008170', 'EFO_0003060', 'MONDO_0007254', 'MONDO_0011962', 'MONDO_0001056', 'EFO_0000403', 'MONDO_0002974', 'MONDO_0002691', 'MONDO_0005575', 'EFO_0008528', 'EFO_1001961', 'EFO_0000519', 'MONDO_0003060', 'MONDO_0009348', 'MONDO_0001187', 'EFO_0000708', 'EFO_0000182', 'EFO_0000565']",True,False,50,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
336,TELITACICEPT,CHEMBL5095293,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002689', 'MONDO_0007915']",False,False,2,,,
337,CARMOTEROL,CHEMBL1094785,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000169252'],['EFO_0000341'],False,False,1,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
338,PHENIRAMINE MALEATE,CHEMBL1653,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications.,,4.0,,False,1994,['ENSG00000196639'],"['EFO_0007214', 'MONDO_0024355', 'EFO_0007328']",False,False,3,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
339,AMELUBANT,CHEMBL1742420,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000213903'],"['MONDO_0009061', 'EFO_0000685', 'EFO_0000341', 'MONDO_0004979']",False,False,4,Leukotriene B4 receptor 1 antagonist ,ANTAGONIST ,single protein 
340,ACETAZOLAMIDE,CHEMBL20,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 8 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1953,"['ENSG00000167434', 'ENSG00000074410', 'ENSG00000133742', 'ENSG00000104267']","['MONDO_0005301', 'EFO_0002617', 'MONDO_0005147', 'EFO_0003086', 'Orphanet_37553', 'EFO_0003918', 'EFO_1000961', 'MONDO_0005041', 'EFO_1001065', 'HP_0012532', 'HP_0002104', 'EFO_0009373', 'MONDO_0005090', 'EFO_0005252', 'EFO_0008526', 'MONDO_0003005', 'EFO_1001132', 'EFO_0000182', 'EFO_0001361', 'EFO_1000782', 'MONDO_0005041', 'EFO_0007231', 'EFO_0003144', 'EFO_0000702', 'MONDO_0001744', 'EFO_0000712', 'HP_0001250', 'EFO_0000373', 'MONDO_0001744', 'HP_0001250', 'EFO_0000474', 'EFO_0009373', 'EFO_1001010']",False,False,33,Carbonic anhydrase I inhibitor Carbonic anhydrase XII inhibitor Carbonic anhydrase II inhibitor Carbonic anhydrase IV inhibitor ,INHIBITOR ,single protein 
341,ALDOXORUBICIN HYDROCHLORIDE,CHEMBL2107827,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000182', 'MONDO_0008978', 'MONDO_0007254', 'EFO_0002618', 'EFO_0000707']",False,False,5,,,
342,CALDARET MONOHYDRATE,CHEMBL4297401,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000373', 'EFO_0000612']",False,False,2,,,
343,TRU-015,CHEMBL4297845,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000156738'],"['MONDO_0007915', 'EFO_0000574', 'EFO_0000685']",True,False,3,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
344,DOXORUBICIN,CHEMBL53463,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 23 approved and 168 investigational indications.,,4.0,,False,no approval year,['ENSG00000131747'],"['EFO_0003869', 'EFO_0005537', 'MONDO_0002928', 'MONDO_0002974', 'EFO_0004289', 'EFO_0002618', 'EFO_0000309', 'MONDO_0003175', 'EFO_0002918', 'MONDO_0018906', 'EFO_1001951', 'EFO_0005561', 'MONDO_0000873', 'EFO_0002617', 'EFO_1000292', 'MONDO_0015760', 'MONDO_0018531', 'EFO_0003060', 'MONDO_0004192', 'MONDO_0004986', 'EFO_0007143', 'MONDO_0018364', 'MONDO_0021117', 'MONDO_0000870', 'EFO_0000096', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000691', 'EFO_0000239', 'EFO_0000702', 'EFO_0000183', 'EFO_0000094', 'EFO_0000637', 'MONDO_0017387', 'MONDO_0017816', 'MONDO_0000870', 'MONDO_0002691', 'MONDO_0004986', 'EFO_0002913', 'EFO_0000621', 'EFO_0000220', 'EFO_0000565', 'EFO_0000432', 'EFO_0009708', 'EFO_0000621', 'EFO_0003032', 'EFO_0000760', 'EFO_1000131', 'MONDO_0002367', 'Orphanet_145', 'EFO_0000569', 'EFO_0000574', 'EFO_0000702', 'MONDO_0001056', 'EFO_0000220', 'MONDO_0008170', 'EFO_1001968', 'EFO_0003869', 'EFO_0000502', 'MONDO_0000873', 'EFO_0000305', 'MONDO_0019460', 'EFO_0000095', 'EFO_0000565', 'EFO_0000403', 'EFO_0000313', 'EFO_0000222', 'EFO_1000984', 'EFO_0000182', 'EFO_1000158', 'EFO_0001378', 'EFO_0003859', 'EFO_0000389', 'EFO_0005537', 'MONDO_0009348', 'MONDO_0001187', 'EFO_0000632', 'EFO_0000255', 'EFO_0004252', 'MONDO_0004992', 'MONDO_0020077', 'EFO_0000248', 'MONDO_0100342', 'HP_0001871', 'EFO_0003968', 'EFO_0000209', 'EFO_0000630', 'EFO_0000182', 'EFO_0009708', 'EFO_0001378', 'MONDO_0008380', 'EFO_0006861', 'EFO_0005952', 'EFO_1001100', 'MONDO_0007576', 'MONDO_0015540', 'EFO_0000503', 'MONDO_0018906', 'MONDO_0008315', 'MONDO_0002691', 'EFO_0000305', 'EFO_1001365', 'EFO_0008528', 'MONDO_0018364', 'EFO_0000313', 'EFO_0006475', 'MONDO_0016691', 'EFO_0003868', 'EFO_1000796', 'EFO_0000564', 'EFO_0003893', 'EFO_1001042', 'MONDO_0011934', 'MONDO_0011962', 'EFO_0003060', 'EFO_1000292', 'MONDO_0007254', 'EFO_0000223', 'MONDO_0006058', 'EFO_0000681', 'MONDO_0016717', 'EFO_0000403', 'EFO_0001376', 'MONDO_0021054', 'MONDO_0002974', 'EFO_1000350', 'MONDO_0000432', 'EFO_0006861', 'MONDO_0007254', 'EFO_0000198', 'EFO_0003085', 'EFO_0000437', 'EFO_0000198', 'EFO_0003144', 'EFO_0000558', 'EFO_1000984', 'MONDO_0005094', 'EFO_1000251', 'HP_0002017', 'EFO_0000309', 'MONDO_0002730', 'MONDO_0002367', 'MONDO_0015540', 'MONDO_0008315', 'EFO_0002517', 'MONDO_0004095', 'EFO_0003893', 'MONDO_0002158', 'EFO_0000588', 'EFO_0000588', 'EFO_1000576', 'MONDO_0002108', 'EFO_1001469', 'EFO_0000211', 'MONDO_0001475', 'EFO_0000211', 'EFO_1001365', 'MONDO_0008903', 'EFO_0005952', 'MONDO_0008380', 'EFO_0000637', 'EFO_0000174', 'EFO_0000519', 'EFO_0003032', 'EFO_0000616', 'EFO_0007160', 'EFO_0004230', 'MONDO_0019472', 'MONDO_0004992', 'MONDO_0019004', 'MONDO_0002087', 'MONDO_0001187', 'EFO_0000673', 'EFO_0006475', 'MONDO_0044881', 'MONDO_0001657', 'MONDO_0008170', 'EFO_0000502', 'MONDO_0000430', 'EFO_0009254', 'MONDO_0002158', 'EFO_0000691', 'EFO_0003968', 'MONDO_0004192', 'MONDO_0001056', 'MONDO_0004986', 'EFO_0000183', 'EFO_1001469', 'MONDO_0015564', 'EFO_0000574', 'EFO_0005221', 'EFO_0000096', 'MONDO_0002678', 'EFO_0000222', 'MONDO_0004669', 'EFO_0000770', 'EFO_0001075', 'EFO_0000231', 'EFO_0006859', 'EFO_0000174', 'EFO_1000581', 'EFO_0000681', 'EFO_1001968', 'MONDO_0009348', 'EFO_1000251', 'EFO_0002918', 'EFO_0001075', 'EFO_0000616', 'EFO_0002499', 'MONDO_0011962', 'EFO_0000209', 'EFO_0000564', 'EFO_1001901', 'EFO_1000595', 'MONDO_0019471', 'EFO_0000558', 'EFO_1001100', 'EFO_0000094', 'EFO_0000765', 'MONDO_0004658', 'MONDO_0044917']",True,False,221,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
345,MEXILETINE,CHEMBL558,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['MONDO_0003441', 'MONDO_0016107', 'EFO_0004278', 'EFO_0000612', 'MONDO_0015626', 'HP_0004308', 'EFO_0004287', 'EFO_0004269', 'Orphanet_273', 'Orphanet_93955', 'HP_0012532', 'EFO_0009387', 'EFO_0000555']",False,False,13,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
346,TEMPOL,CHEMBL607023,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000319', 'MONDO_0004907', 'MONDO_0008315', 'EFO_0000519', 'MONDO_0100096', 'MONDO_0001879']",False,False,6,,,
347,ADALIMUMAB,CHEMBL1201580,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 7 approved and 25 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,['ENSG00000232810'],"['MP_0001845', 'EFO_0003780', 'EFO_0003898', 'EFO_1001209', 'EFO_0000685', 'MONDO_0009735', 'MONDO_0002108', 'EFO_0008507', 'MONDO_0100096', 'EFO_0000384', 'EFO_0003872', 'MONDO_0019338', 'MONDO_0009661', 'HP_0011868', 'EFO_0004616', 'EFO_1001231', 'HP_0000999', 'MONDO_0010674', 'MONDO_0004979', 'EFO_0004236', 'EFO_0000540', 'MONDO_0005178', 'EFO_0000676', 'EFO_0002609', 'EFO_0004229', 'EFO_0000729', 'EFO_1000710', 'EFO_0003767', 'EFO_0004683', 'EFO_1000941', 'EFO_0005856', 'EFO_0003778']",True,True,32,TNF-alpha inhibitor ,INHIBITOR ,single protein 
348,WARFARIN,CHEMBL1464,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 9 approved and 58 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1954,['ENSG00000167397'],"['EFO_0000275', 'HP_0004419', 'EFO_0003764', 'EFO_0006911', 'EFO_0003875', 'EFO_0002950', 'HP_0004936', 'EFO_0000685', 'MONDO_0005178', 'EFO_0003929', 'EFO_0004286', 'EFO_0002689', 'EFO_0003827', 'EFO_0000275', 'MONDO_0002009', 'EFO_0000319', 'EFO_1001161', 'HP_0001907', 'EFO_0003911', 'EFO_0000712', 'EFO_0000574', 'EFO_0003907', 'EFO_0004277', 'EFO_0000612', 'EFO_1001249', 'HP_0002140', 'EFO_0000612', 'EFO_0001073', 'HP_0001907', 'HP_0004936', 'EFO_0004239', 'EFO_0000384', 'EFO_0003914', 'HP_0004936', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000712', 'EFO_0001645', 'HP_0004418', 'EFO_0000685', 'EFO_0001422', 'EFO_0004211', 'MONDO_0001134', 'MONDO_0004992', 'EFO_0001361', 'EFO_0003907', 'EFO_0003777', 'EFO_0000274', 'EFO_0000275', 'EFO_0000676', 'MP_0001914', 'MONDO_0005149', 'EFO_0000266', 'MONDO_0005180', 'EFO_0003144', 'HP_0001907', 'EFO_0000768', 'EFO_0000474', 'EFO_0000400', 'MONDO_0000831', 'MONDO_0004975', 'EFO_1000781', 'HP_0001873', 'EFO_0000729', 'MONDO_0002679', 'EFO_0001642', 'EFO_0002618', 'MONDO_0005148', 'EFO_0003827', 'EFO_1001375']",True,True,70,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor ,INHIBITOR ,single protein 
349,RIBAVIRIN,CHEMBL1643,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,['ENSG00000106348'],"['EFO_0001422', 'EFO_0000764', 'EFO_0006890', 'EFO_0003047', 'EFO_0000616', 'HP_0012115', 'MONDO_0100096', 'HP_0001873', 'EFO_0000222', 'EFO_0007299', 'EFO_0000694', 'EFO_0007328', 'EFO_0007338', 'EFO_1001413', 'MONDO_0002050', 'EFO_0004197', 'EFO_0007332', 'MONDO_0005147', 'EFO_0004220', 'MONDO_0007254', 'EFO_0000544', 'EFO_0007304', 'EFO_0004239', 'EFO_0000763']",True,False,24,Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor Inosine-5'-monophosphate dehydrogenase 1 inhibitor ,INHIBITOR ,single protein 
350,2'-DEOXYTHIOGUANOSINE,CHEMBL3250476,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
351,TENAPANOR HYDROCHLORIDE,CHEMBL3301627,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for constipation disorder and irritable bowel syndrome and has 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2019,['ENSG00000066230'],"['EFO_0003884', 'MONDO_0002203', 'EFO_0000555', 'HP_0002905']",False,False,4,Sodium/hydrogen exchanger 3 inhibitor ,INHIBITOR ,single protein 
352,LUMRETUZUMAB,CHEMBL3707404,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,['ENSG00000065361'],"['MONDO_0007254', 'EFO_0003060', 'EFO_0000616']",False,False,3,Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
353,PIPERINE,CHEMBL43185,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['HP_0002015', 'EFO_0003843', 'MONDO_0007915']",False,False,3,,,
354,FIRTECAN PEGOL,CHEMBL4594234,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000574', 'MONDO_0007254', 'EFO_0000616']",False,False,3,,,
355,EFTILAGIMOD ALFA,CHEMBL4594557,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000089692'],"['EFO_0000681', 'MONDO_0007254', 'EFO_0000389', 'EFO_0000756']",False,False,4,Lymphocyte activation gene 3 protein vaccine antigen ,VACCINE ANTIGEN ,single protein 
356,TENOFOVIR,CHEMBL483,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007304', 'EFO_0000765', 'EFO_0000182', 'EFO_0002614', 'EFO_0000180', 'EFO_0004239', 'EFO_0000764', 'EFO_0000544', 'EFO_0004197', 'MONDO_0100096', 'EFO_0004220']",False,False,11,Human immunodeficiency virus type 1 reverse transcriptase inhibitor DNA polymerase/reverse transcriptase inhibitor ,INHIBITOR ,single protein 
357,RO-0622,CHEMBL519846,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Human immunodeficiency virus type 1 reverse transcriptase inhibitor Reverse transcriptase inhibitor Replicase polyprotein 1ab inhibitor ,INHIBITOR ,single protein 
358,ALMITRINE,CHEMBL1183717,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for respiratory system disease and has 2 investigational indications. It was withdrawn in at least one region.,,4.0,,False,no approval year,[],"['EFO_0000684', 'EFO_0009686', 'MONDO_0100096']",False,False,3,,,
359,FLUTICASONE PROPIONATE,CHEMBL1473,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 12 approved and 15 investigational indications.,,4.0,,False,1990,['ENSG00000113580'],"['EFO_0000662', 'EFO_1001942', 'EFO_0000341', 'EFO_0006505', 'EFO_0007486', 'HP_0001742', 'EFO_1000024', 'EFO_0003956', 'EFO_0000464', 'EFO_0005854', 'EFO_0007227', 'MONDO_0100096', 'EFO_0000274', 'EFO_0000400', 'HP_0011950', 'EFO_0000701', 'EFO_1001417', 'EFO_0008521', 'HP_0100582', 'EFO_1000391', 'MONDO_0004979', 'EFO_0003918', 'EFO_0009536', 'HP_0010307', 'EFO_0004232', 'EFO_0007183', 'HP_0006536']",True,True,27,Glucocorticoid receptor agonist ,AGONIST ,single protein 
360,ENISAMIUM,CHEMBL1740071,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007328', 'MONDO_0100096', 'EFO_0000763']",False,False,3,,,
361,CLARITHROMYCIN,CHEMBL1741,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 41 investigational indications.,,4.0,,False,1991,[],"['MONDO_0021107', 'EFO_1000961', 'MONDO_0001056', 'EFO_0000191', 'EFO_0007200', 'EFO_0007386', 'EFO_0003777', 'EFO_1001272', 'EFO_0000095', 'EFO_0000649', 'EFO_0000384', 'MONDO_0005180', 'EFO_0004607', 'EFO_0005952', 'HP_0011110', 'EFO_0006505', 'EFO_0001378', 'EFO_0006834', 'EFO_0004286', 'HP_0100806', 'MONDO_0000327', 'EFO_0003102', 'MONDO_0002258', 'EFO_0000217', 'EFO_0000544', 'MONDO_0008315', 'MONDO_0100096', 'EFO_0007361', 'MP_0001914', 'EFO_0007486', 'EFO_0000616', 'EFO_0000708', 'EFO_0003106', 'MONDO_0004979', 'EFO_0007183', 'EFO_0004992', 'MONDO_0019091', 'EFO_0009454', 'EFO_0007456', 'EFO_0009708', 'MONDO_0002009', 'MONDO_0002775', 'EFO_0000574', 'EFO_0003060', 'MONDO_0018044', 'EFO_0000180', 'MONDO_0018076', 'MONDO_0009061', 'MONDO_0004992', 'EFO_0000764', 'EFO_0000771']",False,False,51,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
362,BELIMUMAB,CHEMBL1789843,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 15 investigational indications.,,4.0,,False,2011,['ENSG00000102524'],"['MONDO_0013730', 'EFO_0000685', 'EFO_0006803', 'MONDO_0007915', 'MONDO_0003783', 'EFO_0002689', 'EFO_0000464', 'MONDO_0005301', 'EFO_0000783', 'EFO_0005761', 'EFO_0000699', 'EFO_0004254', 'EFO_0007160', 'EFO_0004256', 'EFO_0000095', 'EFO_0000540', 'EFO_0000717', 'EFO_0004255']",True,False,18,Tumor necrosis factor ligand superfamily member 13B inhibitor ,INHIBITOR ,single protein 
363,CENPLACEL-L,CHEMBL2107867,Cell drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000384', 'DOID_13406', 'EFO_0000685']",False,False,3,,,
364,TALADEGIB,CHEMBL2142592,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000128602'],"['EFO_0000768', 'EFO_0009708', 'EFO_0000702', 'MONDO_0004992', 'EFO_0000616']",False,False,5,Smoothened homolog antagonist ,ANTAGONIST ,single protein 
365,LEDIPASVIR,CHEMBL2374220,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for chronic hepatitis c virus infection and hepatitis c virus infection and has 4 investigational indications.,,4.0,,False,2014,[],"['EFO_0004220', 'MONDO_0100096', 'EFO_0004197', 'EFO_0003047', 'EFO_0000574', 'EFO_0000544']",False,False,6,Nonstructural protein 5A inhibitor ,INHIBITOR ,single protein 
366,ABEMACICLIB,CHEMBL3301610,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 46 investigational indications.,,4.0,,False,2017,"['ENSG00000135446', 'ENSG00000105810']","['EFO_0002517', 'EFO_0000616', 'EFO_0000182', 'EFO_0003060', 'EFO_0004284', 'EFO_0000588', 'MONDO_0008903', 'EFO_0002618', 'MONDO_0008170', 'EFO_0009708', 'EFO_0000702', 'MONDO_0008315', 'EFO_0000349', 'MONDO_0001187', 'EFO_0000632', 'EFO_0000181', 'EFO_0005701', 'EFO_0005543', 'MONDO_0100342', 'EFO_0003869', 'EFO_0003825', 'EFO_0001378', 'EFO_1001951', 'MONDO_0011962', 'EFO_0005537', 'EFO_0000574', 'MONDO_0002108', 'EFO_0003085', 'EFO_0006861', 'EFO_1001469', 'EFO_0000637', 'EFO_0002918', 'EFO_0005952', 'EFO_0000174', 'EFO_0001075', 'EFO_0000673', 'MONDO_0004992', 'EFO_0000389', 'EFO_0000313', 'EFO_0003833', 'EFO_0000756', 'EFO_1000026', 'MONDO_0007254', 'EFO_0000558', 'EFO_0000621', 'EFO_0000305', 'EFO_0000519', 'EFO_0003968', 'EFO_1001331', 'MONDO_0016642', 'MONDO_0018975']",True,False,51,Cyclin-dependent kinase 6 inhibitor Cyclin-dependent kinase 4 inhibitor ,INHIBITOR ,single protein 
367,TRADIPITANT,CHEMBL3544984,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000115353'],"['EFO_0000274', 'EFO_1000948', 'EFO_0006928', 'HP_0000989', 'MONDO_0007079', 'EFO_1001917', 'MONDO_0100096']",False,False,7,Neurokinin 1 receptor antagonist ,ANTAGONIST ,single protein 
368,INOSINE PRANOBEX,CHEMBL3833327,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for viral disease and has 1 investigational indication.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000763']",False,False,2,,,
369,SAXAGLIPTIN,CHEMBL385517,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 5 investigational indications.,,4.0,,False,2009,['ENSG00000197635'],"['MONDO_0005148', 'EFO_0008583', 'EFO_0000660', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0002546', 'EFO_0000400']",False,False,7,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
370,PRALUZATAMAB RAVTANSINE,CHEMBL4297736,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000170017']",['MONDO_0007254'],True,False,1,Tubulin inhibitor CD166 antigen binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
371,MATRIX-M1 ADJUVANT,CHEMBL4650407,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0001068', 'EFO_1001413', 'EFO_0007328', 'EFO_0000694', 'EFO_0007243', 'EFO_0007444']",False,False,7,,,
372,EVEXOMOSTAT,CHEMBL4802217,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
373,VIMNERIXIN,CHEMBL5095217,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0000341'],False,False,1,,,
374,ACAZICOLCEPT,CHEMBL5095304,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007915', 'MONDO_0013730']",False,False,2,,,
375,DAPSONE,CHEMBL1043,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 3 approved and 14 investigational indications.,,4.0,,False,1979,[],"['EFO_0000764', 'EFO_1000760', 'EFO_1000680', 'EFO_1000684', 'EFO_0003060', 'EFO_0000712', 'EFO_0007448', 'EFO_0004719', 'EFO_0009448', 'HP_0001945', 'EFO_0007444', 'EFO_0003894', 'MONDO_0019338', 'EFO_0007445', 'EFO_0001068', 'EFO_0001054', 'MONDO_0100096']",False,False,17,Dihydropteroate synthase 1 inhibitor ,INHIBITOR ,single protein 
376,OSELTAMIVIR PHOSPHATE,CHEMBL1200340,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for chronic kidney disease and influenza and has 1 investigational indication.,,4.0,,False,1999,[],"['EFO_0000763', 'EFO_0003884', 'EFO_0007328']",False,False,3,Neuraminidase inhibitor ,INHIBITOR ,single protein 
377,ISOSULFAN BLUE,CHEMBL1201275,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and has 1 investigational indication.,,4.0,,False,1981,[],['MONDO_0007254'],False,False,1,,,
378,VORAPAXAR SULFATE,CHEMBL2107386,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000181104'],"['EFO_0000712', 'EFO_0000612', 'EFO_0005672', 'EFO_0004265']",False,False,4,Proteinase-activated receptor 1 antagonist ,ANTAGONIST ,single protein 
379,ALPELISIB,CHEMBL2396661,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 16 investigational indications.,,4.0,,False,2019,['ENSG00000121879'],"['MONDO_0011962', 'EFO_0001421', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000181', 'EFO_0001378', 'EFO_0005922', 'EFO_1001931', 'EFO_0004284', 'EFO_0002618', 'EFO_1000657', 'EFO_0000707', 'EFO_0003869', 'MONDO_0011719', 'MONDO_0044704', 'EFO_0000305', 'MONDO_0001056', 'MONDO_0016642', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0007254']",False,False,21,PI3-kinase p110-alpha subunit inhibitor ,INHIBITOR ,single protein 
380,GILTERITINIB,CHEMBL3301622,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2018,"['ENSG00000122025', 'ENSG00000167601']","['EFO_1000131', 'EFO_0000198', 'EFO_0001421', 'EFO_0000222', 'EFO_0003060', 'EFO_0003086', 'MONDO_0004643', 'EFO_0000222', 'EFO_0000616']",False,False,9,Tyrosine-protein kinase receptor UFO inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,single protein 
381,ABT 737,CHEMBL376408,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
382,CHLORINE DIOXIDE,CHEMBL4297725,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0002038', 'MONDO_0100096', 'EFO_0000546']",False,False,3,,,
383,FENTANYL CITRATE,CHEMBL688,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for cancer and pain and has 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1968,['ENSG00000112038'],"['HP_0003419', 'EFO_0005762', 'MONDO_0004992', 'EFO_0003843', 'EFO_0004244', 'HP_0002094', 'HP_0012532', 'EFO_1001139', 'EFO_0009727', 'EFO_0000546']",False,False,10,Mu opioid receptor agonist ,AGONIST ,single protein 
384,MOXIFLOXACIN HYDROCHLORIDE,CHEMBL1200735,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,[],"['EFO_0000544', 'EFO_1001388', 'EFO_0007486', 'EFO_0003106', 'MONDO_0016899', 'MONDO_0007254', 'EFO_0005741', 'MONDO_0005129', 'MONDO_0009061', 'EFO_1000829', 'EFO_0006505', 'EFO_0003102', 'MONDO_0013730']",False,False,13,Topoisomerase IV inhibitor Bacterial DNA gyrase inhibitor ,INHIBITOR ,protein complex 
385,METRONIDAZOLE,CHEMBL137,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 9 approved and 44 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1963,[],"['MONDO_0002041', 'MONDO_0002026', 'EFO_0003030', 'EFO_0000095', 'EFO_1000760', 'EFO_1000961', 'EFO_0003921', 'EFO_0009536', 'EFO_0009365', 'EFO_0005952', 'EFO_1001314', 'EFO_0008572', 'EFO_0000574', 'EFO_0000764', 'HP_0001298', 'EFO_0000544', 'EFO_1000657', 'EFO_0007521', 'EFO_1000874', 'EFO_0000649', 'EFO_0000384', 'EFO_0003060', 'HP_0100806', 'EFO_0003102', 'EFO_0000365', 'EFO_0002618', 'HP_0010769', 'EFO_0007149', 'EFO_0009784', 'MONDO_0002234', 'EFO_1001388', 'EFO_0004253', 'EFO_0008517', 'EFO_0004268', 'EFO_1001391', 'EFO_0000701', 'EFO_0001061', 'EFO_0009130', 'EFO_0000771', 'EFO_0009552', 'MONDO_0002508', 'DOID_10718', 'MONDO_0003632', 'EFO_0000729', 'DOID_1947', 'EFO_0009523', 'EFO_0004142', 'EFO_0000544', 'EFO_0007381', 'EFO_0003932', 'EFO_0003106', 'HP_0002014', 'EFO_0004607']",False,False,53,,,
386,MERCAPTOPURINE,CHEMBL1425,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 4 approved and 19 investigational indications.,,4.0,,False,1953,['ENSG00000128059'],"['EFO_0000574', 'MONDO_0019460', 'EFO_0000565', 'EFO_0000224', 'EFO_0003833', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729', 'EFO_0004289', 'MONDO_0000870', 'EFO_0000209', 'EFO_0000616', 'MONDO_0044917', 'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872', 'MONDO_0000873', 'EFO_0002499', 'EFO_1000318', 'EFO_0000220', 'EFO_0000222', 'EFO_0000309']",False,False,23,Amidophosphoribosyltransferase inhibitor ,INHIBITOR ,single protein 
387,ERTUMAXOMAB,CHEMBL2108029,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000198851']","['MONDO_0007254', 'EFO_0000616']",True,False,2,T-cell surface glycoprotein CD3 epsilon chain cross-linking agent Receptor protein-tyrosine kinase erbB-2 cross-linking agent ,CROSS-LINKING AGENT ,single protein 
388,GUSELKUMAB,CHEMBL2364648,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 12 investigational indications.,,4.0,,False,2017,"['ENSG00000113302', 'ENSG00000110944']","['EFO_0008573', 'EFO_0003778', 'EFO_0000676', 'MONDO_0015597', 'EFO_0000540', 'EFO_0000685', 'MONDO_0100017', 'EFO_0005761', 'EFO_1001494', 'EFO_1001209', 'EFO_0000384', 'Orphanet_733', 'EFO_1000710', 'EFO_0000717', 'EFO_0000729', 'EFO_0001060', 'EFO_0002609']",False,True,17,Interleukin-23 inhibitor ,INHIBITOR ,protein complex 
389,FISETIN,CHEMBL31574,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000654', 'MONDO_0005178', 'EFO_0000694', 'EFO_0004143', 'EFO_0004616', 'MONDO_0100096']",False,False,6,,,
390,OLMUTINIB,CHEMBL3786343,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_0000616', 'EFO_0003060']",False,True,2,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
391,MAVEROPEPIMUT-S,CHEMBL4594319,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0002158', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0002087', 'EFO_0000403']",False,False,5,,,
392,VEMURAFENIB,CHEMBL1229517,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 16 investigational indications.,,4.0,,False,2011,['ENSG00000157764'],"['EFO_0000389', 'EFO_0000616', 'EFO_0000326', 'EFO_0000756', 'MONDO_0002108', 'EFO_0003060', 'EFO_1000956', 'EFO_1000209', 'MONDO_0002898', 'EFO_0000222', 'EFO_0002892', 'HP_0100727', 'EFO_0000365', 'MONDO_0004992', 'EFO_0002618', 'EFO_0002617', 'EFO_0001378', 'EFO_0000574', 'EFO_1000318', 'EFO_0009259', 'EFO_1001951']",False,True,21,Serine/threonine-protein kinase B-raf inhibitor ,INHIBITOR ,single protein 
393,TEZACITABINE,CHEMBL2105467,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']","['MONDO_0004992', 'EFO_0004142', 'EFO_0000228', 'EFO_0003897', 'EFO_0002916']",False,False,5,Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,protein complex group 
394,BB-10901,CHEMBL2109484,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000149294'],"['EFO_0001378', 'EFO_0000702']",True,False,2,Neural cell adhesion molecule 1 binding agent ,BINDING AGENT ,single protein 
395,LANADELUMAB,CHEMBL3545189,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hereditary angioedema and has 4 investigational indications.,,4.0,,False,2018,['ENSG00000164344'],"['EFO_0000546', 'EFO_0005532', 'MONDO_0019623', 'EFO_0005251', 'MONDO_0100096']",False,False,5,Plasma kallikrein inhibitor ,INHIBITOR ,single protein 
396,TOCOTRIENOL,CHEMBL4297330,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['HP_0002140', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001951']",False,False,4,,,
397,UPANOVIMAB,CHEMBL4802216,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
398,P-TOLUENESULFONAMIDE,CHEMBL574,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000182', 'EFO_0003060', 'EFO_0000616']",False,False,3,,,
399,CHLOROQUINE,CHEMBL76,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for malaria and has 24 investigational indications.,,4.0,,False,1949,[],"['EFO_0001068', 'MONDO_0007254', 'EFO_0005774', 'EFO_0004227', 'EFO_0000432', 'EFO_0000702', 'EFO_0001068', 'EFO_0007445', 'EFO_0002618', 'EFO_0007444', 'MONDO_0100096', 'EFO_0001378', 'MONDO_0007915', 'EFO_0002950', 'EFO_0000764', 'EFO_0000275', 'EFO_0007328', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000685', 'MONDO_0004992', 'MONDO_0011382', 'EFO_0000694', 'EFO_0000764', 'EFO_0000765', 'EFO_0007541', 'EFO_1001465', 'EFO_0000519', 'MONDO_0100096']",False,False,29,,,
400,LOPERAMIDE,CHEMBL841,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for diarrhea and has 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1976,['ENSG00000112038'],"['EFO_0000305', 'MONDO_0004565', 'EFO_0000616', 'EFO_0009130', 'MONDO_0007254', 'EFO_0009523', 'EFO_0000512', 'MONDO_0004992', 'EFO_0003060', 'HP_0000964', 'HP_0002014', 'EFO_0003869', 'HP_0002014', 'EFO_0003843']",False,False,14,Mu opioid receptor agonist ,AGONIST ,single protein 
401,ISOFLURANE,CHEMBL1256,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 6 investigational indications.,,4.0,,False,1979,"['ENSG00000100433', 'ENSG00000169427', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000171303', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000082482', 'ENSG00000186795']","['EFO_0005611', 'HP_0000023', 'EFO_0009686', 'MONDO_0100096', 'EFO_0000713', 'EFO_0003777']",True,False,6,Glycine receptor (alpha-1/beta) positive modulator Potassium channel subfamily K member 9 opener Potassium channel subfamily K member 18 opener Potassium channel subfamily K member 2 opener GABA-A receptor; anion channel positive allosteric modulator Potassium channel subfamily K member 3 opener Potassium channel subfamily K member 10 opener ,POSITIVE MODULATOR OPENER POSITIVE ALLOSTERIC MODULATOR ,protein complex single protein protein complex group 
402,DARUNAVIR,CHEMBL1323,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 5 approved and 9 investigational indications.,,4.0,,False,2006,[],"['EFO_0003047', 'EFO_0000763', 'MONDO_0100096', 'EFO_0000544', 'EFO_0000764', 'EFO_0000180', 'EFO_0007448', 'EFO_0000180', 'EFO_0000764', 'EFO_0002614', 'MONDO_0004976', 'EFO_0000544', 'MONDO_0021094', 'EFO_0000765']",False,False,14,Human immunodeficiency virus type 1 protease inhibitor ,INHIBITOR ,single protein 
403,ALISPORIVIR,CHEMBL1651956,Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000196262'],"['EFO_0001421', 'EFO_0004220', 'MONDO_0100096', 'EFO_0003884', 'EFO_0003047']",True,False,5,Cyclophilin A inhibitor ,INHIBITOR ,single protein 
404,ERIBULIN,CHEMBL1683590,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 5 approved and 31 investigational indications.,,4.0,,False,2010,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0001187', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000305', 'MONDO_0004669', 'EFO_0006859', 'Orphanet_145', 'EFO_1001968', 'EFO_0000681', 'EFO_0002617', 'MONDO_0004192', 'EFO_0000691', 'EFO_0000305', 'EFO_1000251', 'MONDO_0015523', 'MONDO_0002974', 'EFO_0000389', 'MONDO_0007254', 'EFO_0005537', 'MONDO_0007254', 'EFO_0001075', 'MONDO_0004992', 'EFO_0003968', 'EFO_0003060', 'EFO_0000616', 'EFO_0000574', 'EFO_0000637', 'EFO_1000984', 'EFO_0000616', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'MONDO_0016238', 'EFO_0003060', 'EFO_0005537', 'EFO_0003869', 'MONDO_0008315']",True,False,37,Tubulin inhibitor ,INHIBITOR ,protein complex group 
405,PF-03715455,CHEMBL1938400,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000112062'],"['EFO_0000341', 'MONDO_0004979']",False,False,2,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
406,ETHASELEN,CHEMBL2035460,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
407,VENETOCLAX,CHEMBL3137309,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 35 investigational indications.,,4.0,,False,2016,['ENSG00000171791'],"['MONDO_0001023', 'EFO_0000616', 'EFO_0000574', 'EFO_1000560', 'MONDO_0007254', 'EFO_0003032', 'EFO_0002913', 'EFO_0005952', 'EFO_0004251', 'EFO_0000096', 'EFO_0000339', 'EFO_0000702', 'EFO_0000209', 'MONDO_0004992', 'EFO_0000196', 'MONDO_0044881', 'EFO_0000403', 'EFO_0009441', 'EFO_0004289', 'EFO_0000309', 'EFO_0000220', 'MONDO_0019438', 'MONDO_0044917', 'EFO_0000565', 'EFO_0003086', 'EFO_0000094', 'EFO_0003869', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000095', 'EFO_0000222', 'MONDO_0018906', 'EFO_0003060', 'EFO_1001469', 'MONDO_0019460', 'EFO_0001378', 'EFO_1000131', 'EFO_0000198']",True,False,38,Apoptosis regulator Bcl-2 inhibitor ,INHIBITOR ,single protein 
408,PEMBROLIZUMAB,CHEMBL3137343,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 162 investigational indications.,,4.0,,False,2014,['ENSG00000188389'],"['EFO_0000588', 'EFO_0000519', 'EFO_0009708', 'EFO_0000673', 'MONDO_0003660', 'MONDO_0018531', 'MONDO_0005411', 'EFO_0000094', 'EFO_0003851', 'MONDO_0002363', 'EFO_0000691', 'EFO_1000576', 'MONDO_0003659', 'MONDO_0021148', 'EFO_0000571', 'EFO_1001469', 'EFO_0000294', 'MONDO_0004992', 'MONDO_0002367', 'EFO_0003893', 'EFO_0005543', 'EFO_0001416', 'MONDO_0008903', 'EFO_0004230', 'EFO_1000465', 'MONDO_0002108', 'MONDO_0021117', 'EFO_1000581', 'MONDO_0015277', 'EFO_0007541', 'EFO_0003968', 'EFO_0000403', 'EFO_0000616', 'EFO_0003073', 'EFO_0000222', 'EFO_0000231', 'EFO_0002617', 'EFO_0002618', 'EFO_0000760', 'MONDO_0009348', 'EFO_0002913', 'MONDO_0002715', 'EFO_0000621', 'EFO_0000702', 'MONDO_0003199', 'EFO_1000785', 'EFO_0000764', 'MONDO_0003060', 'EFO_0003869', 'EFO_1000984', 'MONDO_0020634', 'EFO_0009259', 'MONDO_0016642', 'MONDO_0001879', 'MONDO_0002158', 'EFO_0009441', 'Orphanet_145', 'EFO_0005952', 'EFO_0000503', 'MONDO_0002038', 'EFO_0001061', 'MONDO_0001056', 'EFO_1001512', 'MONDO_0002898', 'EFO_0000717', 'MONDO_0002120', 'MONDO_0100342', 'MONDO_0100096', 'EFO_1001931', 'EFO_0003891', 'MONDO_0024474', 'EFO_0004284', 'EFO_0000096', 'MONDO_0021063', 'EFO_0000574', 'EFO_0006352', 'EFO_0005922', 'EFO_1000613', 'EFO_0000349', 'EFO_0002921', 'EFO_0000756', 'EFO_0000707', 'EFO_0000432', 'EFO_1000251', 'MONDO_0017387', 'HP_0002745', 'MONDO_0000521', 'MONDO_0018906', 'MONDO_0004658', 'EFO_0000640', 'MONDO_0044881', 'EFO_0000681', 'MONDO_0001187', 'EFO_0000637', 'EFO_0005950', 'EFO_0002499', 'EFO_0000272', 'MONDO_0007576', 'EFO_1001465', 'MONDO_0004986', 'MONDO_0004700', 'EFO_0003833', 'EFO_0000365', 'EFO_0000181', 'EFO_0000565', 'MONDO_0001657', 'EFO_0000183', 'EFO_0000770', 'MONDO_0008170', 'EFO_0008528', 'MONDO_0000430', 'MONDO_0008315', 'EFO_0000558', 'EFO_1001951', 'MONDO_0011719', 'MONDO_0002974', 'EFO_0006861', 'EFO_1001901', 'EFO_0006859', 'EFO_0000196', 'EFO_0001642', 'MONDO_0005575', 'EFO_0002517', 'EFO_1000657', 'EFO_0004142', 'EFO_0000228', 'EFO_0000220', 'EFO_0004252', 'MONDO_0019472', 'EFO_0004198', 'EFO_0000313', 'EFO_0001378', 'EFO_0002916', 'EFO_0004289', 'EFO_0003897', 'MONDO_0005341', 'EFO_0005221', 'MONDO_0007254', 'EFO_0000389', 'EFO_0009709', 'MONDO_0043243', 'EFO_1001471', 'EFO_1001100', 'MONDO_0018944', 'EFO_0002892', 'EFO_0000182', 'EFO_1001051', 'EFO_0003868', 'EFO_0000305', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0021054', 'EFO_1000796', 'EFO_0007143', 'EFO_0004243', 'EFO_0000095', 'EFO_1001968', 'MONDO_0002928', 'EFO_0005537', 'EFO_1000595', 'EFO_0003860', 'EFO_0001075', 'EFO_0003863', 'EFO_1001012', 'MONDO_0011962', 'EFO_0003060', 'MONDO_0024503']",True,False,167,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
409,ENTOSPLETINIB,CHEMBL3265032,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000165025'],"['MONDO_0018906', 'EFO_0000222', 'EFO_1001469', 'EFO_0005952', 'EFO_0000220', 'EFO_0000403', 'EFO_0000095', 'MONDO_0004992']",False,False,8,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
410,PBF-509,CHEMBL3694769,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,['ENSG00000128271'],"['MONDO_0005180', 'EFO_0003060']",True,False,2,Adenosine A2a receptor antagonist ,ANTAGONIST ,single protein 
411,LEROCICLIB,CHEMBL3904602,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0006318', 'EFO_0003060']",False,False,3,,,
412,ALVOCIDIB,CHEMBL428690,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,3.0,,False,no approval year,"['ENSG00000170312', 'ENSG00000134058', 'ENSG00000136807', 'ENSG00000105810', 'ENSG00000135446', 'ENSG00000123374']","['EFO_0001378', 'MONDO_0007254', 'EFO_1001469', 'EFO_0009441', 'EFO_0000095', 'EFO_0000616', 'MONDO_0018906', 'EFO_0000222', 'EFO_0000222', 'EFO_0000691', 'EFO_0000191', 'EFO_0000565', 'EFO_0006861', 'MONDO_0008315', 'MONDO_0001023', 'EFO_0001642', 'MONDO_0007576', 'MONDO_0002691', 'EFO_0000403', 'EFO_0000389', 'EFO_0001378', 'EFO_0000095', 'EFO_0000574', 'MONDO_0001023', 'MONDO_0002367', 'MONDO_0011962']",True,False,26,Cyclin-dependent kinase 7 inhibitor Cyclin-dependent kinase 6 inhibitor Cyclin-dependent kinase 1 inhibitor Cyclin-dependent kinase 4 inhibitor Cyclin-dependent kinase 9 inhibitor Cyclin-dependent kinase 2 inhibitor ,INHIBITOR ,single protein 
413,BMS-275183,CHEMBL4297268,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000616', 'EFO_0003060']",True,False,2,Tubulin stabiliser ,STABILISER ,protein complex group 
414,CX-024414,CHEMBL4650491,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001413', 'EFO_0006510', 'EFO_0000772', 'MONDO_0100096']",False,False,4,Spike glycoprotein vaccine antigen ,VACCINE ANTIGEN ,single protein 
415,GLYCOPYRROLATE,CHEMBL1201027,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for gastrointestinal disease and airway obstruction and has 7 investigational indications.,,4.0,,False,1961,"['ENSG00000133019', 'ENSG00000168539']","['MONDO_0004979', 'EFO_0010282', 'HP_0000975', 'MONDO_0002050', 'HP_0002307', 'EFO_0009516', 'EFO_0000341', 'EFO_0003086', 'HP_0006536']",True,True,9,Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M1 antagonist ,ANTAGONIST ,single protein 
416,ALEMTUZUMAB,CHEMBL1201587,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 62 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,['ENSG00000169442'],"['MONDO_0019469', 'EFO_1001996', 'EFO_0000183', 'EFO_0000211', 'EFO_0000621', 'EFO_0003086', 'EFO_0000095', 'EFO_0000403', 'EFO_0002428', 'EFO_0005952', 'EFO_1000785', 'EFO_0003884', 'MONDO_0011382', 'MONDO_0005301', 'EFO_0000685', 'MONDO_0015974', 'EFO_1002048', 'EFO_0000384', 'EFO_1001264', 'MONDO_0008170', 'EFO_0001378', 'EFO_0004272', 'EFO_1001257', 'EFO_0000220', 'MONDO_0000870', 'MONDO_0044348', 'EFO_0000540', 'EFO_0000094', 'EFO_0000222', 'MONDO_0001023', 'MONDO_0021193', 'EFO_0007160', 'MONDO_0019472', 'EFO_1000560', 'MONDO_0002087', 'EFO_1000690', 'MONDO_0013730', 'MONDO_0015540', 'MONDO_0004992', 'MONDO_0017198', 'EFO_0000209', 'HP_0001915', 'EFO_0000616', 'MONDO_0005147', 'MONDO_0002158', 'EFO_0001642', 'MONDO_0019391', 'HP_0100727', 'EFO_0000565', 'EFO_0006803', 'Orphanet_848', 'EFO_0000574', 'EFO_0004289', 'MONDO_0044881', 'EFO_0003929', 'EFO_1001051', 'EFO_0009441', 'EFO_0006927', 'MONDO_0018305', 'EFO_0001421', 'EFO_0000198', 'EFO_0007323', 'EFO_0004599', 'EFO_0000255', 'MONDO_0002367']",True,False,65,CAMPATH-1 antigen inhibitor ,INHIBITOR ,single protein 
417,"PETROLATUM, WHITE",CHEMBL1201719,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 investigational indications.,,4.0,,False,2006,[],"['EFO_1001494', 'EFO_0000701', 'MONDO_0100096']",False,False,3,,,
418,CEFOTAXIME,CHEMBL1730,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 4 investigational indications.,,4.0,,False,1981,[],"['EFO_0007149', 'EFO_0000544', 'DOID_7551', 'EFO_0003106', 'EFO_0000771', 'HP_0100806', 'EFO_0003102', 'EFO_0008588']",False,False,8,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
419,FOSTAMATINIB,CHEMBL2103830,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications.,,4.0,,False,2018,['ENSG00000165025'],"['EFO_0000574', 'MONDO_0007915', 'EFO_0004194', 'EFO_0000685', 'MP_0001914', 'HP_0001873', 'MONDO_0008170', 'EFO_0007160', 'EFO_0000403', 'EFO_0003106', 'EFO_0001642', 'EFO_0007160', 'MONDO_0044903', 'EFO_1000710', 'MONDO_0100096', 'EFO_0000574', 'EFO_0000685', 'EFO_0004194', 'EFO_1001264', 'EFO_1001264']",True,False,20,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
420,LUMACAFTOR,CHEMBL2103870,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for cystic fibrosis and has 1 investigational indication.,,4.0,,False,2015,['ENSG00000001626'],"['MONDO_0009061', 'EFO_0001421']",False,True,2,Cystic fibrosis transmembrane conductance regulator stabiliser ,STABILISER ,single protein 
421,FIBRIN,CHEMBL2108390,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 23 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0011962', 'HP_0003040', 'EFO_0009660', 'EFO_0010282', 'EFO_1001250', 'EFO_0010680', 'EFO_1001896', 'EFO_0000546', 'EFO_1001459', 'MONDO_0002635', 'EFO_1001866', 'EFO_0009516', 'EFO_0000678', 'EFO_0009472', 'EFO_0000649', 'EFO_0005323', 'MP_0001914', 'MONDO_0019297', 'EFO_0002892', 'EFO_0003875', 'MONDO_0002974', 'MONDO_0007254', 'GO_0007568']",False,False,23,,,
422,EMIPLACEL,CHEMBL4297243,Cell drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0003876', 'EFO_0003964', 'EFO_0000556', 'EFO_0000694', 'EFO_0000546', 'EFO_0001361', 'EFO_0004265']",False,False,8,,,
423,AZD-1236,CHEMBL4297352,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000262406', 'ENSG00000100985']","['EFO_0000341', 'MONDO_0009061']",False,True,2,Matrix metalloproteinase 12 inhibitor Matrix metalloproteinase 9 inhibitor ,INHIBITOR ,single protein 
424,BIFIDOBACTERIUM SPP.,CHEMBL4297912,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001121', 'EFO_1001904', 'EFO_0000384', 'EFO_0001060', 'MONDO_0004985', 'EFO_0000555', 'EFO_0000319', 'HP_0002014', 'EFO_0003956', 'EFO_0000729', 'EFO_0008572', 'MONDO_0005148', 'EFO_0008517']",False,False,13,,,
425,DAPAGLIFLOZIN,CHEMBL429910,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 30 investigational indications.,,4.0,,False,2014,['ENSG00000140675'],"['MONDO_0005148', 'EFO_0001645', 'EFO_0000660', 'EFO_0003144', 'EFO_1000783', 'EFO_0000195', 'GO_0007568', 'EFO_0003884', 'EFO_0001073', 'EFO_0000275', 'EFO_0000612', 'EFO_1002048', 'HP_0001919', 'MONDO_0007254', 'EFO_0002687', 'EFO_1000899', 'EFO_0009104', 'EFO_1001249', 'EFO_0001663', 'MONDO_0005148', 'MONDO_0100096', 'MONDO_0005147', 'MONDO_0009067', 'HP_0001397', 'MONDO_0005147', 'EFO_0001361', 'EFO_0003144', 'EFO_0000401', 'EFO_0000400', 'EFO_0002618', 'EFO_0003770', 'EFO_0004285', 'MONDO_0004975', 'HP_0001824']",False,False,34,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
426,ADG-106,CHEMBL4594519,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0003060', 'EFO_0005952', 'MONDO_0007254']",False,False,4,,,
427,AFIMETORAN,CHEMBL4650329,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003834', 'MONDO_0007915']",False,False,2,,,
428,AMUBARVIMAB,CHEMBL4650382,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
429,ZANSECIMAB,CHEMBL4650486,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000091879'],"['MONDO_0100096', 'EFO_0003106', 'EFO_0000616']",True,False,3,Angiopoietin-2 inhibitor ,INHIBITOR ,single protein 
430,ISUZINAXIB,CHEMBL4650894,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
431,CEFTAROLINE FOSAMIL,CHEMBL501122,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 10 investigational indications.,,4.0,,False,2010,[],"['EFO_0000544', 'EFO_1001272', 'EFO_0003103', 'EFO_0007328', 'EFO_0003086', 'EFO_0000771', 'MONDO_0021108', 'HP_0100806', 'EFO_0003884', 'EFO_1001478', 'EFO_0003106', 'MONDO_0100096', 'EFO_1001272']",False,False,13,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
432,NAPABUCASIN,CHEMBL64130,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0002618', 'EFO_0000519', 'MONDO_0004992', 'MONDO_0044881', 'EFO_0002517', 'EFO_0000182', 'EFO_1001951']",False,False,8,,,
433,DALTEPARIN SODIUM,CHEMBL1201460,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000117601'],"['EFO_0002618', 'EFO_0000712', 'EFO_0001378', 'HP_0001907', 'EFO_1000954', 'MONDO_0043510', 'MONDO_0011382', 'HP_0004419', 'MONDO_0008903', 'EFO_0000681', 'MONDO_0007254', 'EFO_1001951', 'EFO_0004286', 'MONDO_0008315', 'HP_0004936', 'MONDO_0008170', 'EFO_0009315', 'EFO_0002950', 'EFO_1000158', 'MONDO_0019514', 'EFO_0003884', 'MONDO_0100096', 'EFO_1001459', 'EFO_0006834', 'EFO_0003907']",False,False,25,Antithrombin-III activator ,ACTIVATOR ,single protein 
434,POLYETHYLENE GLYCOL 3350,CHEMBL1201479,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for constipation disorder and constipation and has 8 investigational indications.,,4.0,,False,1984,[],"['EFO_0004220', 'MONDO_0021063', 'EFO_0000384', 'EFO_0003047', 'EFO_1001951', 'MONDO_0002203', 'HP_0002019', 'EFO_0000400', 'EFO_0009510', 'EFO_1000874']",False,False,10,,,
435,TRIAMCINOLONE ACETONIDE,CHEMBL1504,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 21 approved and 44 investigational indications.,,4.0,,False,1960,['ENSG00000113580'],"['EFO_0004719', 'EFO_0003943', 'EFO_0003956', 'EFO_1000809', 'EFO_0007363', 'EFO_0000497', 'MONDO_0004037', 'EFO_1001898', 'EFO_1001494', 'EFO_0004229', 'MONDO_0002406', 'EFO_1000706', 'MONDO_0002041', 'EFO_0003843', 'EFO_0009606', 'EFO_1001896', 'EFO_0004208', 'EFO_1000680', 'MONDO_0005129', 'EFO_0010822', 'EFO_1000941', 'EFO_1001250', 'EFO_0000693', 'EFO_1001222', 'MONDO_0005178', 'MONDO_0007935', 'EFO_0000685', 'EFO_0004683', 'EFO_1001157', 'MONDO_0004979', 'HP_0001742', 'EFO_0000701', 'EFO_0008521', 'HP_0030834', 'EFO_1001231', 'EFO_0004212', 'EFO_1000726', 'EFO_1001129', 'MONDO_0003005', 'EFO_1001887', 'EFO_0008507', 'EFO_0003770', 'MONDO_0018092', 'MONDO_0005041', 'HP_0012735', 'EFO_1000786', 'MONDO_0002471', 'MONDO_0005301', 'MONDO_0002959', 'EFO_1001435', 'EFO_0004238', 'EFO_0001365', 'EFO_0009485', 'EFO_0004616', 'EFO_0007415', 'EFO_0008517', 'MONDO_0007254', 'MONDO_0002280', 'MONDO_0004857', 'EFO_0004274', 'EFO_0004192', 'EFO_1000049', 'EFO_0000274', 'EFO_0000546', 'EFO_0005854']",False,False,65,Glucocorticoid receptor agonist ,AGONIST ,single protein 
436,ADAVOSERTIB,CHEMBL1976040,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 29 investigational indications.,,2.0,,False,no approval year,['ENSG00000166483'],"['EFO_0000181', 'EFO_0003060', 'EFO_0001075', 'MONDO_0007254', 'EFO_0000702', 'MONDO_0001187', 'EFO_1000131', 'MONDO_0044704', 'EFO_1000043', 'EFO_0000349', 'EFO_0002939', 'MONDO_0002715', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0006352', 'EFO_0000503', 'EFO_0005537', 'EFO_1001960', 'EFO_0000519', 'MONDO_0008903', 'EFO_0001378', 'EFO_1000251', 'EFO_0002618', 'EFO_0000466', 'MONDO_0008315', 'EFO_0000707', 'MONDO_0002087', 'MONDO_0008170']",False,False,29,Serine/threonine-protein kinase WEE1 inhibitor ,INHIBITOR ,single protein 
437,ICATIBANT ACETATE,CHEMBL2028852,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hereditary angioedema and angioedema and has 2 investigational indications.,,4.0,,False,2011,['ENSG00000168398'],"['MONDO_0100096', 'MONDO_0019623', 'MP_0001845', 'EFO_0005532']",False,False,4,Bradykinin B2 receptor antagonist ,ANTAGONIST ,single protein 
438,ATAMESTANE,CHEMBL2105987,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0003869']",False,False,2,,,
439,TRIDECACTIDE,CHEMBL2108340,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003929', 'MONDO_0100096']",False,False,2,,,
440,NELIPEPIMUT-S,CHEMBL2108684,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000432']",False,False,2,,,
441,LORLATINIB,CHEMBL3286830,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 4 investigational indications.,,4.0,,False,2018,"['ENSG00000171094', 'ENSG00000143924']","['EFO_0000621', 'EFO_0003032', 'EFO_0003060', 'EFO_0003086', 'EFO_0001421', 'EFO_0000574', 'EFO_0000616', 'MONDO_0004992']",False,False,8,ALK tyrosine kinase receptor inhibitor EML4-ALK  inhibitor ,INHIBITOR ,single protein chimeric protein 
442,DURVALUMAB,CHEMBL3301587,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 10 approved and 80 investigational indications.,,4.0,,False,2017,['ENSG00000120217'],"['EFO_0000514', 'MONDO_0008315', 'MONDO_0021117', 'EFO_0000313', 'EFO_0000198', 'EFO_0000501', 'EFO_0000181', 'EFO_0000588', 'EFO_0003897', 'EFO_0003060', 'MONDO_0004986', 'EFO_0000228', 'EFO_0000640', 'EFO_0000503', 'MONDO_0018906', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0000707', 'EFO_0001378', 'EFO_0000681', 'EFO_0001075', 'EFO_0000708', 'EFO_0001642', 'EFO_0002430', 'EFO_0000691', 'EFO_0003868', 'EFO_0005922', 'EFO_0009709', 'EFO_1001931', 'EFO_0000294', 'EFO_0003968', 'MONDO_0002974', 'EFO_0000365', 'EFO_0002618', 'MONDO_0003001', 'EFO_0000770', 'MONDO_0001056', 'EFO_0002913', 'EFO_0000222', 'EFO_0003863', 'EFO_0005537', 'MONDO_0004992', 'EFO_0000673', 'EFO_0000199', 'MONDO_0003199', 'MONDO_0002898', 'EFO_0004230', 'EFO_0003869', 'MONDO_0008170', 'EFO_0000519', 'EFO_1000251', 'EFO_0000616', 'MONDO_0044903', 'EFO_0005221', 'EFO_0003891', 'EFO_0006859', 'MONDO_0003060', 'MONDO_0021148', 'EFO_1001951', 'EFO_0000182', 'EFO_0000571', 'MONDO_0021063', 'EFO_0000641', 'MONDO_0003059', 'MONDO_0044704', 'EFO_0000095', 'EFO_0004284', 'MONDO_0005575', 'EFO_0000348', 'MONDO_0011962', 'EFO_1001961', 'EFO_0002429', 'EFO_0008528', 'EFO_1000657', 'MONDO_0007576', 'EFO_0003050', 'EFO_0005952', 'EFO_0000756', 'EFO_0000305', 'EFO_0000702', 'EFO_0000349', 'EFO_0002517', 'EFO_1001968', 'EFO_0000403', 'EFO_0005220', 'MONDO_0003002', 'EFO_0000574', 'EFO_0006738', 'MONDO_0002108', 'MONDO_0001187']",False,False,90,Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
443,POSENACAFTOR,CHEMBL4594274,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
444,KN-026,CHEMBL4594568,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000141736'],"['MONDO_0007254', 'MONDO_0001056', 'EFO_0000616']",False,False,3,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
445,QUISOVALIMAB,CHEMBL4802198,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000125735'],"['MONDO_0004979', 'EFO_0000384', 'EFO_0000729']",False,False,3,Tumor necrosis factor ligand superfamily member 14 inhibitor ,INHIBITOR ,single protein 
446,MK-0873,CHEMBL485629,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['EFO_0000676', 'EFO_0000685', 'EFO_0000341']",True,False,3,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
447,MORPHINE,CHEMBL70,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 4 approved and 51 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1984,['ENSG00000112038'],"['EFO_0000228', 'EFO_0000768', 'EFO_0009688', 'HP_0011110', 'HP_0003418', 'EFO_0003843', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000768', 'EFO_0004240', 'EFO_0006859', 'EFO_0005611', 'EFO_0003890', 'EFO_0003931', 'MONDO_0004992', 'EFO_0000341', 'EFO_0005323', 'EFO_0004270', 'EFO_0003918', 'EFO_0010702', 'EFO_0000222', 'EFO_0009513', 'HP_0000989', 'EFO_0005611', 'HP_0002019', 'EFO_0010702', 'HP_0000989', 'EFO_1001412', 'EFO_0009842', 'EFO_0003843', 'EFO_0000546', 'EFO_0003917', 'EFO_0003918', 'EFO_0009727', 'MONDO_0011382', 'EFO_0008583', 'EFO_1001250', 'HP_0012532', 'EFO_0005799', 'EFO_0003843', 'EFO_0004273', 'EFO_0002950', 'EFO_0000612', 'EFO_0009492', 'EFO_0009314', 'HP_0012532', 'EFO_0004253', 'EFO_0004616', 'HP_0001822', 'HP_0003419', 'EFO_0005799', 'EFO_0000341', 'MP_0001914', 'EFO_0009620', 'EFO_0005762', 'MONDO_0008315', 'EFO_0001073', 'EFO_0005755', 'EFO_0001361', 'MONDO_0011382', 'EFO_1001898', 'EFO_0005611']",True,False,62,Mu opioid receptor agonist ,AGONIST ,single protein 
448,PHENELZINE SULFATE,CHEMBL1200895,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1961,"['ENSG00000189221', 'ENSG00000069535']","['EFO_0000673', 'MONDO_0007254']",True,False,2,Monoamine oxidase inhibitor ,INHIBITOR ,protein family 
449,AMINO ACIDS,CHEMBL1201498,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001901', 'EFO_1000653', 'EFO_0002614', 'MONDO_0100342', 'EFO_0008572', 'EFO_0009851', 'MONDO_0100096', 'EFO_0000546', 'EFO_1002048']",False,False,9,,,
450,IRBESARTAN,CHEMBL1513,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000144891'],"['EFO_0003884', 'MONDO_0007947', 'EFO_0004220', 'EFO_0004194', 'EFO_0000373', 'MONDO_0005148', 'EFO_0000537', 'EFO_0000275', 'EFO_0000401', 'HP_0001919', 'EFO_0000319', 'EFO_0003884', 'EFO_0004236', 'EFO_1001375', 'MONDO_0017314', 'HP_0100806', 'EFO_0007243', 'HP_0003124', 'MONDO_0001134']",False,False,19,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
451,ERGOCALCIFEROL,CHEMBL1536,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1941 and has 3 approved and 78 investigational indications.,,4.0,,False,1941,['ENSG00000111424'],"['EFO_0007319', 'EFO_0000574', 'EFO_0003854', 'HP_0002901', 'EFO_0007176', 'EFO_0004278', 'EFO_0008519', 'EFO_0004593', 'EFO_0004288', 'EFO_0003917', 'MONDO_0002171', 'EFO_0003834', 'EFO_0003882', 'HP_0002148', 'MONDO_0005148', 'MONDO_0100096', 'Orphanet_309005', 'EFO_0004261', 'EFO_0003762', 'HP_0000938', 'EFO_0000389', 'EFO_0009706', 'EFO_1001375', 'MONDO_0011962', 'MONDO_0024300', 'HP_0003549', 'EFO_0004270', 'EFO_0009451', 'MONDO_0019019', 'EFO_0009314', 'EFO_0003869', 'EFO_0003095', 'MONDO_0008315', 'EFO_1001494', 'MONDO_0008903', 'EFO_0003843', 'EFO_0000673', 'MONDO_0007254', 'EFO_0003767', 'EFO_0003144', 'EFO_0008572', 'EFO_0004247', 'EFO_0005952', 'MONDO_0021063', 'MONDO_0004975', 'MONDO_0005277', 'HP_0005521', 'EFO_1000049', 'EFO_0000764', 'EFO_1000783', 'EFO_0004616', 'MONDO_0018076', 'EFO_0009516', 'EFO_1001951', 'EFO_0005762', 'MONDO_0002974', 'EFO_0002614', 'EFO_0003922', 'EFO_0000660', 'EFO_0003964', 'MONDO_0005147', 'EFO_1000653', 'MONDO_0004992', 'EFO_0003931', 'EFO_0003047', 'EFO_1001792', 'EFO_0007405', 'EFO_0003884', 'EFO_1001919', 'Orphanet_89936', 'EFO_0001073', 'EFO_0000729', 'MONDO_0005301', 'MONDO_0004979', 'MONDO_0011382', 'EFO_0000565', 'EFO_0004220', 'EFO_0002950', 'EFO_0000384', 'EFO_0004192', 'EFO_0000400']",True,False,81,Vitamin D receptor agonist ,AGONIST ,single protein 
452,PRAMLINTIDE,CHEMBL2103758,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for diabetes mellitus and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,"['ENSG00000004948', 'ENSG00000132329', 'ENSG00000131477', 'ENSG00000122679']","['EFO_0001073', 'EFO_0001073', 'MONDO_0005148', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0005147', 'MONDO_0005147']",False,False,7,"Amylin receptor AMY3; CALCR/RAMP3 agonist Amylin receptor AMY2; CALCR/RAMP2 agonist Amylin receptor AMY1, CALCR/RAMP1 agonist ",AGONIST ,protein complex 
453,"CHARCOAL, ACTIVATED",CHEMBL2106049,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000341', 'MONDO_0001056', 'EFO_0004698', 'MONDO_0002009', 'EFO_0003921', 'MONDO_0008903', 'MONDO_0004979', 'EFO_0003948', 'MONDO_0005301', 'MONDO_0005271', 'EFO_0003767', 'EFO_0003884', 'HP_0001298', 'EFO_0000555', 'MONDO_0005148']",False,False,15,,,
454,SEMAPIMOD,CHEMBL2107779,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000112062'],['EFO_0000384'],False,False,1,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
455,APOLIZUMAB,CHEMBL2108252,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000231679', 'ENSG00000198502', 'ENSG00000196126', 'ENSG00000231021']","['EFO_0000403', 'EFO_0000095', 'EFO_0000574', 'MONDO_0018906', 'EFO_1001469']",True,False,5,Human leukocyte antigen DR beta chain inhibitor ,INHIBITOR ,protein family 
456,FINERENONE,CHEMBL2181927,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cardiovascular disease and chronic kidney disease and has 2 investigational indications.,,4.0,,False,2021,['ENSG00000151623'],"['EFO_0000319', 'EFO_0000401', 'EFO_0003144', 'EFO_0003884']",False,False,4,Mineralocorticoid receptor antagonist ,ANTAGONIST ,single protein 
457,RIVOCERANIB MESYLATE,CHEMBL3545414,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 61 investigational indications.,,3.0,,False,no approval year,['ENSG00000128052'],"['EFO_0000182', 'EFO_0000231', 'MONDO_0008170', 'EFO_0000616', 'EFO_0001061', 'EFO_0000702', 'EFO_0004252', 'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221', 'MONDO_0002120', 'EFO_0004142', 'MONDO_0007254', 'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'MONDO_0001056', 'MONDO_0003060', 'EFO_0001071', 'EFO_0000756', 'EFO_0005537', 'MONDO_0100342', 'EFO_0000199', 'MONDO_0002108', 'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869', 'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637', 'EFO_0000313', 'EFO_0002916', 'EFO_0005543', 'EFO_0003897', 'EFO_0002618', 'EFO_0000181', 'EFO_0000571', 'EFO_0005922', 'EFO_0003893', 'EFO_0000691', 'EFO_0000621', 'MONDO_0018944', 'EFO_0000707', 'MONDO_0007576', 'EFO_1002017', 'EFO_0009708', 'EFO_0000365', 'EFO_0000574', 'MONDO_0002691', 'EFO_0000503', 'EFO_0003860', 'EFO_0000681', 'MONDO_0008315']",False,False,61,Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
458,BREQUINAR,CHEMBL38434,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000102967'],"['MONDO_0100096', 'MONDO_0100096', 'EFO_0000222']",False,False,3,Dihydroorotate dehydrogenase inhibitor ,INHIBITOR ,single protein 
459,IMARADENANT,CHEMBL4594442,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000128271'],"['MONDO_0008315', 'EFO_0003060', 'MONDO_0004992']",True,False,3,Adenosine A2a receptor antagonist ,ANTAGONIST ,single protein 
460,DENUFOSOL,CHEMBL507282,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000175591'],"['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417']",False,False,4,Purinergic receptor P2Y2 agonist ,AGONIST ,single protein 
461,CYCLOSERINE,CHEMBL771,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for extrapulmonary tuberculosis and tuberculosis and has 28 investigational indications.,,4.0,,False,1964,[],"['MONDO_0000368', 'EFO_0004329', 'EFO_0003757', 'MONDO_0005090', 'MONDO_0004985', 'MONDO_0043510', 'EFO_1001917', 'EFO_1001872', 'EFO_0005411', 'EFO_0001358', 'EFO_0003877', 'EFO_0004895', 'EFO_0000712', 'EFO_0004319', 'EFO_0003102', 'EFO_0003890', 'MONDO_0018076', 'EFO_0005230', 'HP_0003419', 'MONDO_0002009', 'EFO_0000341', 'EFO_0003768', 'EFO_0003758', 'EFO_1001908', 'EFO_0002610', 'EFO_0004242', 'EFO_0003843', 'EFO_0005687', 'EFO_0004262', 'EFO_0005611']",False,False,30,Alanine racemase inhibitor D-alanylalanine synthetase inhibitor ,INHIBITOR ,single protein 
462,BOSENTAN,CHEMBL957,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,"['ENSG00000136160', 'ENSG00000151617']","['EFO_0000768', 'EFO_1001103', 'EFO_0000373', 'EFO_0000537', 'MONDO_0005149', 'EFO_0003877', 'HP_0001945', 'EFO_0000616', 'EFO_1000809', 'EFO_0009200', 'EFO_0001361', 'EFO_1001346', 'EFO_0001422', 'MONDO_0004979', 'EFO_0002618', 'MONDO_0004933', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0008347', 'EFO_0000717', 'EFO_0005207', 'EFO_0005207', 'MONDO_0043839', 'EFO_0000341', 'EFO_0000756', 'MONDO_0005041', 'EFO_0007372']",False,True,27,"Endothelin receptor, ET-A/ET-B antagonist ",ANTAGONIST ,protein family 
463,SAXAGLIPTIN,CHEMBL2103745,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0008583', 'EFO_0000660', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0002546', 'EFO_0000400']",False,False,6,,,
464,DELCASERTIB,CHEMBL2107872,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000163932'],['EFO_0000612'],True,False,1,Protein kinase C delta inhibitor ,INHIBITOR ,single protein 
465,HU3S193,CHEMBL2109506,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008170', 'MONDO_0002087', 'MONDO_0007254', 'MONDO_0002158', 'EFO_1001951', 'MONDO_0008903']",False,False,6,,,
466,PROCALCITONIN,CHEMBL2207138,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0000341'],False,False,1,,,
467,FENEBRUTINIB,CHEMBL4065122,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000010671'],"['MONDO_0005301', 'EFO_0003840', 'EFO_0005531', 'MONDO_0007915', 'EFO_0000685']",False,False,5,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
468,CIBISATAMAB,CHEMBL4298091,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_1001951', 'EFO_0000616']",False,False,3,,,
469,LEVILIMAB,CHEMBL4650406,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000160712'],"['EFO_0000685', 'MONDO_0100096']",True,False,2,Interleukin-6 receptor alpha subunit inhibitor ,INHIBITOR ,single protein 
470,JMT-101,CHEMBL4650481,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000707', 'EFO_0000616']",False,False,3,,,
471,CEDIRANIB,CHEMBL491473,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 39 investigational indications.,,3.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_1000657', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004992', 'EFO_0000616', 'EFO_1001951', 'EFO_0000702', 'EFO_0006861', 'EFO_0000681', 'EFO_1001465', 'EFO_0000222', 'EFO_0003893', 'EFO_0003060', 'MONDO_0002974', 'EFO_0000770', 'MONDO_0002974', 'MONDO_0008903', 'EFO_0000681', 'EFO_0000305', 'EFO_0000673', 'MONDO_0008903', 'EFO_1001951', 'EFO_0003891', 'EFO_0000196', 'EFO_0000588', 'EFO_0000673', 'EFO_0007143', 'MONDO_0002158', 'EFO_0003833', 'EFO_0000389', 'MONDO_0011962', 'EFO_0000519', 'EFO_0000349', 'MONDO_0001056', 'EFO_0003060', 'EFO_0002892', 'EFO_0000182', 'EFO_0002617', 'MONDO_0007254', 'EFO_0000095', 'MONDO_0008315', 'EFO_0000565', 'EFO_0000519', 'EFO_0009709', 'MONDO_0002087']",True,False,45,Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein complex protein family 
472,DABIGATRAN ETEXILATE,CHEMBL539697,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 5 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2010,['ENSG00000180210'],"['EFO_0001645', 'HP_0000083', 'EFO_0000275', 'HP_0001907', 'EFO_0003095', 'EFO_0000712', 'EFO_0003884', 'EFO_0000275', 'EFO_0000712', 'EFO_1000652', 'EFO_0003907', 'EFO_0004286', 'HP_0004936', 'HP_0004419', 'HP_0001871', 'MONDO_0000831', 'EFO_0000673']",False,False,17,Thrombin inhibitor ,INHIBITOR ,single protein 
473,ZILEUTON,CHEMBL93,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for asthma and has 8 investigational indications.,,4.0,,False,1996,['ENSG00000012779'],"['EFO_0003768', 'MONDO_0008903', 'EFO_0000341', 'EFO_0000768', 'EFO_0000339', 'MONDO_0011382', 'MONDO_0004979', 'EFO_0003894', 'MP_0001845']",False,False,9,Arachidonate 5-lipoxygenase inhibitor ,INHIBITOR ,single protein 
474,CI-1040,CHEMBL105442,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000169032', 'ENSG00000126934']","['EFO_0002618', 'EFO_0003860', 'EFO_1001951', 'EFO_0004142', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0003060', 'EFO_0003869']",True,False,8,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Dual specificity mitogen-activated protein kinase kinase 2 inhibitor ,INHIBITOR ,single protein 
475,REBAMIPIDE,CHEMBL1697771,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000906', 'MONDO_0005178', 'EFO_0000685', 'EFO_0000217', 'EFO_0003898', 'EFO_0000729', 'EFO_0006859', 'EFO_0000337', 'EFO_0009454', 'HP_0004398', 'EFO_0003948']",False,False,11,,,
476,DIMESNA,CHEMBL2104318,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000571']",False,False,2,,,
477,QAX-576,CHEMBL2109465,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000169194'],"['EFO_0005854', 'EFO_0004212', 'EFO_0009448', 'EFO_0004232', 'MONDO_0004979', 'EFO_0000768', 'EFO_0000384', 'EFO_0000717']",False,False,8,Interleukin-13 inhibitor ,INHIBITOR ,single protein 
478,IADADEMSTAT,CHEMBL3781751,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000702'],False,False,1,,,
479,APILIMOD,CHEMBL4297643,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000115020'],"['MONDO_0100096', 'EFO_0000384', 'MONDO_0015517']",False,False,3,1-phosphatidylinositol 3-phosphate 5-kinase inhibitor ,INHIBITOR ,single protein 
480,ACETYLCYSTEINE,CHEMBL600,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 5 approved and 108 investigational indications.,,4.0,,False,1963,[],"['EFO_0000555', 'EFO_0002610', 'EFO_0005204', 'EFO_1001459', 'MONDO_0044903', 'MONDO_0018975', 'EFO_0002687', 'EFO_0008560', 'EFO_1000905', 'EFO_0000768', 'HP_0012167', 'EFO_0007430', 'MONDO_0018896', 'MONDO_0009061', 'EFO_0001358', 'EFO_0004895', 'MONDO_0005180', 'EFO_0003768', 'EFO_0000389', 'GO_0007568', 'MONDO_0002492', 'EFO_0003917', 'Orphanet_77259', 'HP_0001871', 'EFO_0007456', 'MONDO_0019514', 'EFO_0004238', 'EFO_0003033', 'EFO_0007191', 'EFO_0000474', 'EFO_0003840', 'EFO_0000479', 'MONDO_0005301', 'MONDO_0002050', 'EFO_0008585', 'EFO_1000906', 'EFO_1001141', 'HP_0002140', 'EFO_0005687', 'EFO_0006505', 'MONDO_0005148', 'MONDO_0015339', 'EFO_0004269', 'EFO_0000404', 'EFO_0000545', 'MONDO_0043510', 'EFO_0003756', 'HP_0001873', 'MONDO_0044970', 'MONDO_0013730', 'MONDO_0000153', 'EFO_0000756', 'EFO_0004242', 'MONDO_0007254', 'EFO_0003867', 'EFO_0004610', 'EFO_0003843', 'EFO_0000538', 'EFO_1001902', 'MONDO_0002009', 'EFO_0000574', 'EFO_0004699', 'EFO_1001898', 'EFO_0003086', 'MONDO_0004737', 'EFO_0007160', 'EFO_0003884', 'EFO_0000275', 'EFO_0003966', 'MONDO_0100096', 'EFO_1000637', 'EFO_0000684', 'MONDO_0002491', 'MONDO_0018076', 'EFO_0004329', 'MONDO_0016033', 'MONDO_0018982', 'EFO_0000546', 'MONDO_0019200', 'EFO_0008583', 'EFO_0007486', 'EFO_0004701', 'EFO_0009963', 'EFO_0000660', 'EFO_0009448', 'MONDO_0005090', 'EFO_0002429', 'MONDO_0004985', 'EFO_0003758', 'MONDO_0007079', 'EFO_0004228', 'EFO_1001254', 'EFO_1001345', 'EFO_0000341', 'MONDO_0011382', 'MONDO_0007915', 'Orphanet_98974', 'MONDO_0016486', 'EFO_0005762', 'EFO_1000782', 'EFO_1002048', 'EFO_0000612', 'EFO_0003757', 'EFO_0000677', 'EFO_0001645', 'HP_0006554', 'MONDO_0024355', 'EFO_0007214', 'EFO_0004145', 'MONDO_0008867', 'EFO_0000712', 'HP_0100543', 'MONDO_0004975']",False,False,113,,,
481,GOSERELIN,CHEMBL1201247,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 22 investigational indications.,,4.0,,False,1989,['ENSG00000109163'],"['EFO_0006861', 'MONDO_0002087', 'MONDO_0008315', 'EFO_0001663', 'EFO_0001663', 'MONDO_0008170', 'EFO_0000313', 'EFO_0000195', 'EFO_0003922', 'MONDO_0002158', 'EFO_0000545', 'MONDO_0000521', 'EFO_0000305', 'EFO_0000196', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0001065', 'EFO_0000616', 'EFO_1001757', 'EFO_0000305', 'EFO_0000731', 'EFO_0000673', 'EFO_0000545', 'HP_0008209', 'EFO_0000673', 'EFO_0003869', 'EFO_0000183', 'EFO_0000195', 'EFO_0000553']",False,False,31,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
482,VARDENAFIL,CHEMBL1520,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for erectile dysfunction and has 7 investigational indications.,,4.0,,False,2003,['ENSG00000138735'],"['HP_0000360', 'EFO_0002687', 'EFO_0004234', 'MONDO_0009061', 'EFO_0000284', 'EFO_0004234', 'EFO_1001145', 'EFO_1000781', 'MONDO_0005149']",False,False,9,Phosphodiesterase 5A inhibitor ,INHIBITOR ,single protein 
483,EPIGALOCATECHIN GALLATE,CHEMBL297453,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 39 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003929', 'EFO_0001422', 'MONDO_0005180', 'EFO_0000763', 'MONDO_0007915', 'EFO_0000731', 'EFO_0000673', 'EFO_0000280', 'EFO_0004252', 'EFO_0001378', 'MONDO_0008903', 'MONDO_0021063', 'EFO_0003882', 'Orphanet_303', 'EFO_1001050', 'EFO_0000768', 'MONDO_0005148', 'MONDO_0043510', 'MONDO_0007739', 'MONDO_0010383', 'EFO_0007147', 'MONDO_0018906', 'EFO_0003060', 'MP_0001845', 'MONDO_0007254', 'EFO_0008517', 'MONDO_0004975', 'EFO_0000565', 'MONDO_0019438', 'EFO_0000764', 'MONDO_0008315', 'EFO_0000432', 'MONDO_0010679', 'EFO_0000284', 'EFO_0000616', 'EFO_0001065', 'EFO_0001064', 'MONDO_0005301', 'MONDO_0001187']",False,False,39,,,
484,TETULOMAB TETRAXETAN LU-177,CHEMBL4297907,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0005952', 'MONDO_0018906', 'EFO_0000403']",False,False,3,,,
485,GUSACITINIB,CHEMBL4594275,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000165025', 'ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['MONDO_0002406', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000403', 'EFO_0000274']",False,False,5,Tyrosine-protein kinase SYK inhibitor Janus Kinase (JAK) inhibitor ,INHIBITOR ,single protein protein family 
486,INSULIN SUSP ISOPHANE RECOMBINANT HUMAN,CHEMBL1201540,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 8 investigational indications.,,4.0,,False,1982,['ENSG00000171105'],"['EFO_0003914', 'MONDO_0005147', 'HP_0003074', 'MONDO_0005148', 'EFO_0000537', 'EFO_0001645', 'HP_0003124', 'EFO_0000400']",False,False,8,Insulin receptor agonist ,AGONIST ,single protein 
487,BARDOXOLONE METHYL,CHEMBL1762621,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,"['ENSG00000116044', 'ENSG00000079999', 'ENSG00000132170', 'ENSG00000104365']","['EFO_0001361', 'EFO_0000756', 'MONDO_0100096', 'EFO_0000401', 'EFO_0003884', 'EFO_0002618', 'MONDO_0018965', 'EFO_0001642', 'EFO_0001421', 'MONDO_0005149', 'EFO_1001496']",True,False,11,Keap1/Nrf2 inhibitor Peroxisome proliferator-activated receptor gamma antagonist Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor ,INHIBITOR ANTAGONIST ,protein-protein interaction single protein 
488,RANPIRNASE,CHEMBL2108479,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000588', 'EFO_0007147']",False,False,3,,,
489,CINNAMON,CHEMBL2108924,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003819', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0000660', 'EFO_0001073']",False,False,6,,,
490,IPRATROPIUM BROMIDE,CHEMBL2134724,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 10 approved and 4 investigational indications.,,4.0,,False,1986,['ENSG00000133019'],"['HP_0025428', 'MONDO_0005180', 'HP_0002307', 'EFO_0006505', 'HP_0001742', 'EFO_0000464', 'Orphanet_1764', 'EFO_0000341', 'EFO_0003956', 'EFO_0001361', 'EFO_0007214', 'HP_0006536', 'MONDO_0004979', 'EFO_0000274']",True,True,14,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
491,SHR3680,CHEMBL4650276,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000169083'],"['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001421', 'EFO_0005537']",True,False,5,Androgen Receptor antagonist ,ANTAGONIST ,single protein 
492,TALETRECTINIB,CHEMBL4650989,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000047936', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538']","['EFO_0003060', 'EFO_0000616', 'MONDO_0004992']",False,False,3,Proto-oncogene tyrosine-protein kinase ROS inhibitor Neurotrophic tyrosine kinase receptor inhibitor ,INHIBITOR ,single protein protein family 
493,FLURANDRENOLIDE,CHEMBL1201012,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for skin disease and has 1 investigational indication.,,4.0,,False,1965,['ENSG00000113580'],"['EFO_0000701', 'EFO_0003884']",True,False,2,Glucocorticoid receptor agonist ,AGONIST ,single protein 
494,MANGAFODIPIR,CHEMBL1201301,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 investigational indications.,,4.0,,False,1997,[],"['MONDO_0021063', 'MONDO_0004992', 'EFO_0000612']",False,False,3,,,
495,PRASUGREL HYDROCHLORIDE,CHEMBL1201773,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000169313'],"['EFO_0000612', 'EFO_0005672', 'MP_0001914']",True,False,3,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
496,TESAMORELIN,CHEMBL1237026,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome and has 5 investigational indications.,,4.0,,False,2010,['ENSG00000106128'],"['EFO_0000341', 'EFO_1001348', 'EFO_1001348', 'EFO_0000764', 'MONDO_0005148', 'HP_0100543']",False,False,6,Growth hormone-releasing hormone receptor agonist ,AGONIST ,single protein 
497,DORGENMELTUCEL-L,CHEMBL3301573,Cell drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000222']",False,False,2,,,
498,DVX-201,CHEMBL5095332,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
499,SIMVASTATIN,CHEMBL1064,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 93 investigational indications.,,4.0,,False,1991,['ENSG00000113161'],"['EFO_0000713', 'EFO_0009441', 'MONDO_0011382', 'EFO_0003060', 'EFO_0004264', 'EFO_0007405', 'MONDO_0008315', 'EFO_0004319', 'HP_0012532', 'HP_0002140', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0008522', 'EFO_0006834', 'EFO_0000474', 'EFO_0007328', 'EFO_0000685', 'EFO_0004268', 'MONDO_0100096', 'EFO_0005669', 'EFO_0000764', 'EFO_0003770', 'EFO_0001645', 'MONDO_0008903', 'HP_0003124', 'EFO_0004208', 'EFO_0008583', 'EFO_0003884', 'EFO_1001898', 'EFO_0001422', 'EFO_0009783', 'MONDO_0010035', 'EFO_1001343', 'EFO_0000731', 'EFO_1001466', 'EFO_0000195', 'EFO_1001951', 'MONDO_0018997', 'EFO_0005672', 'MONDO_0004985', 'EFO_0000712', 'EFO_0000666', 'EFO_0008568', 'EFO_0001663', 'EFO_0002618', 'MONDO_0007915', 'EFO_0004192', 'MONDO_0004992', 'EFO_0000649', 'HP_0003119', 'MONDO_0010557', 'MONDO_0001187', 'MONDO_0005180', 'EFO_0600064', 'EFO_0000341', 'EFO_0001378', 'EFO_0000660', 'EFO_0003106', 'MONDO_0005277', 'EFO_1001231', 'EFO_0000266', 'EFO_0001361', 'MONDO_0021118', 'EFO_0000702', 'MP_0001845', 'EFO_1001375', 'EFO_0000407', 'EFO_0000612', 'MONDO_0002009', 'EFO_0007486', 'EFO_0000574', 'EFO_0004211', 'MONDO_0005301', 'MONDO_0005149', 'MONDO_0008170', 'EFO_0003144', 'EFO_0000401', 'MONDO_0004979', 'MONDO_0001056', 'EFO_0000095', 'MONDO_0007254', 'MONDO_0009061', 'EFO_0000275', 'EFO_0000319', 'EFO_0003914', 'HP_0100806', 'EFO_1000652', 'MONDO_0001134', 'Orphanet_309005', 'EFO_0004911', 'EFO_0000305', 'EFO_0004265', 'Orphanet_79211', 'EFO_0000537', 'MONDO_0004975', 'EFO_1000657', 'EFO_0003876', 'EFO_0004197', 'EFO_1001121', 'MONDO_0021187', 'EFO_0009854', 'EFO_0003929', 'EFO_0000400']",True,True,103,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
500,DOXERCALCIFEROL,CHEMBL1200810,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 3 investigational indications.,,4.0,,False,1999,['ENSG00000111424'],"['EFO_1001173', 'EFO_0003884', 'EFO_0000676', 'MONDO_0008315', 'EFO_0000616', 'EFO_0005754']",True,False,6,Vitamin D receptor agonist ,AGONIST ,single protein 
501,VELTUZUMAB,CHEMBL1743088,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000156738'],"['EFO_0000220', 'EFO_0005952', 'EFO_0000095', 'EFO_0007160', 'EFO_0000685', 'EFO_0000403', 'EFO_0000574', 'MONDO_0018906', 'MONDO_0000432']",False,False,9,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
502,SODIUM PHENYLBUTYRATE,CHEMBL1746,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 13 investigational indications.,,4.0,,False,1996,[],"['EFO_0000574', 'MONDO_0004739', 'EFO_0008525', 'MONDO_0004976', 'EFO_0000565', 'Orphanet_98757', 'MONDO_0019169', 'MONDO_0009061', 'MONDO_0007739', 'Orphanet_79167', 'MONDO_0020077', 'EFO_0000764', 'MONDO_0008815', 'EFO_0000198', 'HP_0001987', 'EFO_1000049']",False,False,16,,,
503,SESAME OIL,CHEMBL2108113,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0003843', 'EFO_0008517', 'MONDO_0044881', 'EFO_0008568']",False,False,5,,,
504,HUMAX-IL8,CHEMBL2109617,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000169429'],"['MONDO_0100096', 'MONDO_0004992', 'EFO_0000181', 'EFO_0002618', 'EFO_0000756', 'EFO_0000198', 'EFO_0000673', 'EFO_0000616', 'EFO_0000182']",True,False,9,Interleukin-8 inhibitor ,INHIBITOR ,single protein 
505,ITACITINIB,CHEMBL3622820,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 27 investigational indications.,,3.0,,False,no approval year,['ENSG00000162434'],"['MONDO_0009348', 'EFO_0000540', 'MONDO_0044881', 'MONDO_0015540', 'MONDO_0008903', 'EFO_0000183', 'EFO_0000717', 'MONDO_0011962', 'EFO_0002618', 'EFO_0000182', 'EFO_0004251', 'EFO_0000616', 'EFO_0000756', 'MONDO_0044903', 'EFO_0003060', 'EFO_0007183', 'EFO_0004599', 'EFO_0000676', 'HP_0000989', 'EFO_0005803', 'EFO_0000729', 'MONDO_0007254', 'MONDO_0013730', 'EFO_0000574', 'MONDO_0004992', 'EFO_1000560', 'EFO_0007183', 'EFO_0000685']",True,False,28,Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
506,ATORVASTATIN CALCIUM,CHEMBL393220,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 13 approved and 94 investigational indications.,,4.0,,False,1996,['ENSG00000113161'],"['EFO_0000537', 'MONDO_0018473', 'EFO_0001422', 'EFO_0009426', 'EFO_0000198', 'EFO_0007328', 'MONDO_0021187', 'EFO_0007129', 'EFO_0008568', 'MONDO_0019338', 'EFO_0003086', 'EFO_0005672', 'EFO_0008586', 'MONDO_0002679', 'EFO_1001771', 'MONDO_0005301', 'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'MONDO_0021661', 'EFO_0003095', 'EFO_0000764', 'EFO_0000676', 'MONDO_0018076', 'MONDO_0013730', 'MONDO_0018373', 'EFO_0004911', 'EFO_0003144', 'EFO_0001645', 'EFO_0003869', 'EFO_0006818', 'EFO_0004616', 'HP_0003119', 'EFO_0000616', 'EFO_0000685', 'EFO_0000373', 'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444', 'EFO_0000319', 'MONDO_0005147', 'EFO_0000180', 'EFO_0000222', 'EFO_0008583', 'EFO_0003884', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000519', 'EFO_0004208', 'EFO_0004264', 'MONDO_0004782', 'EFO_1000984', 'EFO_0003913', 'EFO_1001993', 'EFO_0000660', 'Orphanet_79211', 'EFO_0000538', 'Orphanet_413', 'EFO_0005952', 'MONDO_0001134', 'EFO_0004211', 'MONDO_0011962', 'HP_0003124', 'EFO_0000673', 'EFO_0008585', 'EFO_1001249', 'EFO_0000384', 'HP_0002140', 'MONDO_0004992', 'EFO_0003870', 'EFO_1001466', 'MONDO_0005835', 'EFO_0004246', 'EFO_0000649', 'EFO_0000574', 'EFO_0000400', 'EFO_0004252', 'EFO_0000365', 'MONDO_0005148', 'EFO_0000681', 'EFO_0001378', 'Orphanet_309005', 'EFO_0003929', 'EFO_0004236', 'EFO_0004286', 'EFO_0003914', 'EFO_0003047', 'EFO_0000612', 'HP_0100806', 'EFO_0001365', 'EFO_0000668', 'EFO_1001801', 'EFO_0000474', 'EFO_0004194', 'EFO_0003918', 'EFO_0000195', 'HP_0000083', 'EFO_0000712', 'EFO_0007160', 'MONDO_0004979', 'MONDO_0004975', 'MONDO_0100096', 'EFO_0000565', 'MONDO_0007915', 'HP_0001647', 'MONDO_0011382']",True,True,107,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
507,ZIMLOVISERTIB,CHEMBL4081711,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000198001'],"['EFO_1000710', 'MONDO_0100096', 'EFO_0000685']",False,False,3,Interleukin-1 receptor-associated kinase 4 inhibitor ,INHIBITOR ,single protein 
508,EPIRUBICIN,CHEMBL417,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,[],"['MONDO_0001056', 'EFO_0000220', 'EFO_0000616', 'EFO_0003060', 'EFO_0002618', 'EFO_1001968', 'MONDO_0001187', 'EFO_0005537', 'EFO_0000389', 'EFO_1001968', 'EFO_0000096', 'EFO_0000503', 'MONDO_0002158', 'MONDO_0001187', 'EFO_0000305', 'EFO_0000182', 'EFO_0004252', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0008903', 'MONDO_0011962', 'MONDO_0009348', 'MONDO_0007576', 'EFO_0003869', 'EFO_0005952', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0002691', 'EFO_1000984', 'EFO_0004281', 'MONDO_0007576', 'MONDO_0000831', 'EFO_0002916', 'EFO_0006861', 'EFO_0000565', 'MONDO_0008170', 'EFO_0000691', 'EFO_0005537', 'EFO_0002618', 'EFO_0000702', 'MONDO_0002087', 'EFO_0000313', 'EFO_0000182', 'EFO_0000574', 'EFO_0000514', 'HP_0100806', 'EFO_0000588', 'MONDO_0001056', 'EFO_0000211', 'EFO_0003897', 'EFO_1000984', 'EFO_0000702', 'EFO_0003869', 'EFO_0000403', 'EFO_0000228', 'MONDO_0007254', 'MONDO_0008315']",False,False,57,,,
509,CRIZANLIZUMAB,CHEMBL4297734,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for sickle cell anemia and has 3 investigational indications.,,4.0,,False,2019,['ENSG00000174175'],"['MONDO_0100096', 'MONDO_0044903', 'HP_0200023', 'MONDO_0011382']",False,False,4,P-selectin blocker ,BLOCKER ,single protein 
510,AZD-4785,CHEMBL4297900,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
511,QUAVONLIMAB,CHEMBL4650419,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000163599'],"['EFO_0000182', 'EFO_0000756', 'EFO_1001951', 'EFO_0000681', 'EFO_0000702', 'EFO_0003060', 'EFO_0000616']",True,False,7,Cytotoxic T-lymphocyte protein 4 inhibitor ,INHIBITOR ,single protein 
512,CARMUSTINE,CHEMBL513,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 11 approved and 35 investigational indications.,,4.0,,False,1977,['ENSG00000104687'],"['EFO_0003833', 'EFO_0005543', 'EFO_1001469', 'EFO_0000565', 'EFO_0000756', 'EFO_0004256', 'EFO_1001051', 'EFO_0003929', 'EFO_0000621', 'EFO_0000096', 'EFO_1001465', 'EFO_0000519', 'EFO_1000785', 'EFO_0000305', 'EFO_0000183', 'EFO_0000095', 'EFO_0007498', 'MONDO_0008170', 'EFO_0002939', 'EFO_1000028', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000211', 'MONDO_0100342', 'EFO_1000158', 'EFO_0005952', 'EFO_0000616', 'MONDO_0018906', 'HP_0001871', 'MONDO_0007254', 'EFO_0004991', 'EFO_0000574', 'EFO_0006475', 'EFO_0000389', 'EFO_0000691', 'EFO_0002499', 'MONDO_0001657', 'EFO_1001383', 'EFO_0002501', 'EFO_0009538', 'EFO_0004599', 'MONDO_0003268', 'EFO_0000272', 'EFO_0000403', 'EFO_1001951', 'EFO_0002913']",False,False,46,Glutathione reductase inhibitor ,INHIBITOR ,single protein 
513,PENTOXIFYLLINE,CHEMBL628,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and has 47 investigational indications.,,4.0,,False,1984,"['ENSG00000170425', 'ENSG00000128271', 'ENSG00000138735', 'ENSG00000065989', 'ENSG00000172572', 'ENSG00000139053', 'ENSG00000185527', 'ENSG00000186642', 'ENSG00000205268', 'ENSG00000115252', 'ENSG00000160191', 'ENSG00000133256', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000156973', 'ENSG00000132915', 'ENSG00000152270', 'ENSG00000095464', 'ENSG00000113231', 'ENSG00000112541', 'ENSG00000123360', 'ENSG00000105650', 'ENSG00000154678', 'ENSG00000073417', 'ENSG00000171408']","['EFO_0000764', 'EFO_1001249', 'EFO_0000278', 'MONDO_0004985', 'MONDO_0100096', 'MONDO_0002050', 'MONDO_0010679', 'EFO_0001065', 'EFO_0000401', 'EFO_0000545', 'EFO_0004272', 'EFO_1001346', 'EFO_0003780', 'MONDO_0008867', 'EFO_1001345', 'HP_0001919', 'EFO_0006890', 'EFO_0003928', 'EFO_1001486', 'EFO_0000319', 'EFO_0005046', 'EFO_1000158', 'EFO_0003869', 'EFO_0005774', 'MONDO_0018373', 'MONDO_0002462', 'EFO_0003060', 'EFO_0004255', 'EFO_0000384', 'EFO_0003884', 'EFO_0005044', 'EFO_0004284', 'MONDO_0005090', 'HP_0001643', 'HP_0001397', 'EFO_1000844', 'MONDO_0002009', 'EFO_0007444', 'HP_0040187', 'EFO_0001645', 'EFO_0005672', 'HP_0001399', 'MONDO_0004992', 'EFO_0000546', 'EFO_0001422', 'EFO_1000652', 'EFO_0000220', 'DOID_13406']",True,True,48,"Adenosine A2 receptor antagonist 3',5'-cyclic phosphodiesterase inhibitor ",ANTAGONIST INHIBITOR ,protein family 
514,INTERFERON ALFA-2B,CHEMBL1201558,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 11 approved and 24 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1986,"['ENSG00000142166', 'ENSG00000159110']","['EFO_0001378', 'MONDO_0008170', 'EFO_0000182', 'MONDO_0024503', 'EFO_0001668', 'EFO_0000756', 'EFO_0000616', 'EFO_0004197', 'MONDO_0100096', 'EFO_0000673', 'MONDO_0018906', 'EFO_0000764', 'EFO_0000681', 'EFO_0009708', 'EFO_0000349', 'MONDO_0044881', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0002618', 'EFO_0004239', 'MONDO_0019471', 'EFO_0007147', 'MONDO_0002367', 'EFO_0004220', 'EFO_1000956', 'EFO_0001422', 'EFO_0003047', 'EFO_0000339', 'EFO_0000389', 'EFO_0000565', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0002691', 'MONDO_0004658', 'EFO_0000558']",True,True,35,Interferon alpha/beta receptor agonist ,AGONIST ,protein complex 
515,DASATINIB,CHEMBL1421,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 7 approved and 71 investigational indications.,,4.0,,False,2006,"['ENSG00000113721', 'ENSG00000157404', 'ENSG00000097007', 'ENSG00000186716', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000142627']","['EFO_0000768', 'EFO_1000956', 'EFO_0000255', 'EFO_0000339', 'EFO_0003884', 'MONDO_0019469', 'MONDO_0011719', 'EFO_0000191', 'EFO_0000588', 'MONDO_0019472', 'EFO_1001469', 'EFO_0002429', 'EFO_1000475', 'MONDO_0004975', 'MONDO_0018906', 'EFO_0000770', 'EFO_1001951', 'EFO_0000702', 'MONDO_0000870', 'EFO_0000095', 'MONDO_0002087', 'EFO_0006859', 'MONDO_0004992', 'EFO_0005774', 'EFO_0000708', 'MONDO_0000873', 'MONDO_0100096', 'MONDO_0008903', 'EFO_0000220', 'EFO_0000309', 'EFO_1001465', 'EFO_0002617', 'MONDO_0016586', 'MONDO_0004643', 'EFO_0000183', 'EFO_0003869', 'EFO_0000621', 'MONDO_0021063', 'EFO_1000026', 'EFO_0000565', 'EFO_0002618', 'MONDO_0011962', 'GO_0007568', 'EFO_0000181', 'EFO_0000673', 'EFO_0002918', 'EFO_0000196', 'EFO_0003032', 'EFO_1001993', 'EFO_0000389', 'EFO_0001378', 'EFO_0000182', 'EFO_0000403', 'EFO_1000158', 'MONDO_0008315', 'EFO_0009441', 'EFO_0000756', 'EFO_0000574', 'MONDO_0100342', 'EFO_1001051', 'EFO_0000198', 'EFO_0003833', 'EFO_0005952', 'EFO_1000657', 'EFO_0003060', 'EFO_1000654', 'EFO_0000222', 'EFO_1000785', 'MONDO_0008170', 'EFO_0000305', 'MONDO_0019471', 'EFO_0004289', 'EFO_0000519', 'MONDO_0003175', 'EFO_0005221', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0002158']",True,False,78,Platelet-derived growth factor receptor beta inhibitor Tyrosine-protein kinase ABL inhibitor Ephrin type-A receptor 2 inhibitor Bcr/Abl fusion protein Stem cell growth factor receptor inhibitor SRC inhibitor ,INHIBITOR ,single protein chimeric protein protein family 
516,OMEPRAZOLE,CHEMBL1503,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 7 approved and 63 investigational indications.,,4.0,,False,1989,"['ENSG00000105675', 'ENSG00000186009']","['MONDO_0001056', 'EFO_0000191', 'MONDO_0015277', 'EFO_1001095', 'EFO_0003948', 'HP_0001601', 'MONDO_0004247', 'EFO_0005741', 'MONDO_0009061', 'EFO_0003929', 'MONDO_0007254', 'EFO_0000280', 'MONDO_0043839', 'EFO_0009130', 'EFO_1001951', 'EFO_0003756', 'EFO_0004272', 'EFO_0002617', 'EFO_0008533', 'EFO_0009784', 'EFO_0000768', 'EFO_0000181', 'EFO_0004607', 'EFO_0000616', 'EFO_0007231', 'MONDO_0024475', 'MP_0001914', 'HP_0002239', 'MONDO_0004975', 'EFO_0000199', 'EFO_0000546', 'EFO_0004239', 'EFO_0008525', 'EFO_0000685', 'EFO_0007549', 'HP_0012735', 'EFO_0003948', 'MONDO_0005041', 'EFO_0000729', 'HP_0002239', 'MONDO_0001684', 'EFO_0000764', 'HP_0004398', 'EFO_0003898', 'EFO_0000341', 'EFO_0006859', 'HP_0100633', 'MONDO_0008315', 'EFO_0000384', 'EFO_0003843', 'EFO_0000180', 'EFO_0000574', 'EFO_0009454', 'EFO_0000274', 'EFO_0000676', 'EFO_1000961', 'MONDO_0044970', 'EFO_0004234', 'MONDO_0003523', 'EFO_0000305', 'EFO_0000400', 'EFO_0004220', 'EFO_0002618', 'MONDO_0005148', 'HP_0032252', 'MONDO_0005178', 'EFO_0000544', 'HP_0012532', 'EFO_0003047', 'MONDO_0005147', 'MONDO_0004992']",False,False,71,Potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex 
517,MEMANTINE HYDROCHLORIDE,CHEMBL1699,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and has 12 investigational indications.,,4.0,,False,2003,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']","['MONDO_0004976', 'EFO_0004699', 'EFO_0000326', 'EFO_0007328', 'MONDO_0017276', 'EFO_1001801', 'EFO_0003757', 'MONDO_0004681', 'EFO_1001465', 'EFO_0003833', 'MONDO_0011382', 'MONDO_0004975', 'EFO_0003758']",False,False,13,Glutamate [NMDA] receptor negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,protein complex group 
518,PEMETREXED,CHEMBL225072,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 79 investigational indications.,,4.0,,False,2004,"['ENSG00000228716', 'ENSG00000176890', 'ENSG00000159131']","['MONDO_0001187', 'EFO_0001075', 'MONDO_0007254', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0006859', 'MONDO_0011962', 'EFO_0000574', 'EFO_1001951', 'EFO_0003863', 'EFO_1001951', 'EFO_0000365', 'EFO_1001901', 'EFO_0002617', 'EFO_0006859', 'EFO_0002618', 'EFO_0000708', 'MONDO_0021117', 'MONDO_0004192', 'MONDO_0001056', 'EFO_0003060', 'EFO_0000616', 'EFO_0000708', 'EFO_0000305', 'EFO_0003897', 'MONDO_0002586', 'MONDO_0007576', 'MONDO_0000521', 'EFO_0003060', 'MONDO_0002087', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0000707', 'MONDO_0008170', 'EFO_0005952', 'EFO_0002618', 'MONDO_0021117', 'MONDO_0008170', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0009708', 'EFO_1000576', 'MONDO_0002974', 'EFO_0000702', 'EFO_0000588', 'EFO_1000251', 'EFO_0003863', 'EFO_0002916', 'EFO_0000228', 'MONDO_0011962', 'EFO_0000637', 'EFO_0003050', 'MONDO_0002691', 'MONDO_0008903', 'MONDO_0100342', 'EFO_0000308', 'EFO_0000681', 'MONDO_0008978', 'EFO_0000228', 'EFO_1000657', 'EFO_0000691', 'EFO_0000571', 'EFO_0003050', 'EFO_0008528', 'EFO_0000313', 'EFO_1001012', 'MONDO_0008903', 'EFO_0005567', 'EFO_0004252', 'EFO_0000403', 'EFO_1000581', 'EFO_0000574', 'EFO_0000389', 'MONDO_0044903', 'MONDO_0002158', 'MONDO_0004992', 'MONDO_0018944', 'EFO_0003860', 'EFO_0004142', 'MONDO_0007254', 'EFO_0000178', 'MONDO_0002108', 'EFO_0008528', 'EFO_0003869', 'MONDO_0002087', 'EFO_0006861', 'EFO_0000691', 'EFO_0002939', 'MONDO_0002974', 'EFO_0000181', 'EFO_0009708', 'EFO_0000588', 'EFO_0003050', 'EFO_0000770', 'EFO_0004284', 'MONDO_0003060', 'EFO_0000571', 'EFO_1000581', 'EFO_0000770', 'EFO_0000616']",True,False,100,Thymidylate synthase inhibitor Dihydrofolate reductase inhibitor GAR transformylase inhibitor ,INHIBITOR ,single protein 
519,TOPSALYSIN,CHEMBL2364656,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000284', 'MONDO_0008315']",False,False,2,,,
520,SAPITINIB,CHEMBL2408045,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000146648', 'ENSG00000141736', 'ENSG00000065361']","['EFO_0003060', 'EFO_0000365', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003869']",False,True,5,Receptor protein-tyrosine kinase erbB-2 inhibitor Epidermal growth factor receptor erbB1 inhibitor Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
521,VERINURAD,CHEMBL3707347,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000197891'],"['EFO_0003884', 'EFO_0003144', 'EFO_0004274', 'EFO_0009104']",False,False,4,Solute carrier family 22 member 12 inhibitor ,INHIBITOR ,single protein 
522,UBIDECARENONE,CHEMBL454801,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 36 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000899', 'MONDO_0000437', 'EFO_0000668', 'EFO_1000653', 'MONDO_0004985', 'EFO_0001645', 'EFO_1000690', 'EFO_0000546', 'MONDO_0044970', 'MONDO_0008300', 'EFO_0004540', 'EFO_0000707', 'EFO_0000319', 'MONDO_0005147', 'EFO_0004278', 'EFO_0004193', 'EFO_0003144', 'MONDO_0007254', 'MONDO_0100096', 'MONDO_0005180', 'EFO_1001373', 'EFO_1001465', 'EFO_0000182', 'EFO_0000660', 'EFO_0009492', 'EFO_0000519', 'MONDO_0007739', 'MONDO_0015626', 'MONDO_0002050', 'EFO_0003884', 'EFO_0008517', 'MONDO_0019037', 'MONDO_0004976', 'HP_0100806', 'EFO_0002618', 'MONDO_0010679']",False,False,36,,,
523,CADONILIMAB,CHEMBL4594456,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,"['ENSG00000163599', 'ENSG00000188389']","['EFO_0003060', 'EFO_0000349', 'MONDO_0008170', 'EFO_0001061', 'EFO_0004252', 'EFO_1001951', 'EFO_0000616', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0008903', 'MONDO_0002974']",False,False,12,Programmed cell death protein 1 inhibitor Cytotoxic T-lymphocyte protein 4 inhibitor ,INHIBITOR ,single protein 
524,DAVAMOTECAN PEGADEXAMER,CHEMBL4802201,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0002158', 'EFO_1000657', 'MONDO_0008170', 'EFO_0001663', 'EFO_0000681', 'EFO_0000616', 'EFO_0003060']",False,False,7,,,
525,CERITINIB,CHEMBL2403108,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 10 investigational indications.,,4.0,,False,2014,"['ENSG00000171094', 'ENSG00000143924', 'ENSG00000181163']","['EFO_0000756', 'EFO_0003060', 'EFO_0003032', 'MONDO_0004992', 'EFO_0000519', 'EFO_0001421', 'EFO_1001968', 'EFO_0000389', 'MONDO_0015798', 'EFO_0000621', 'EFO_0005221', 'MONDO_0002108', 'EFO_0000616']",False,False,13,EML4-ALK ALK tyrosine kinase receptor inhibitor NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) ,INHIBITOR ,chimeric protein single protein 
526,DIFLOMOTECAN,CHEMBL306280,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000198900'],['EFO_0000702'],False,False,1,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
527,LY-2606368,CHEMBL3545377,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000149554'],"['MONDO_0004992', 'MONDO_0008170', 'MONDO_0007254']",False,False,3,Serine/threonine-protein kinase Chk1 inhibitor ,INHIBITOR ,single protein 
528,UTOMILUMAB,CHEMBL3707324,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,['ENSG00000049249'],"['EFO_0000403', 'MONDO_0018906', 'EFO_0000616', 'MONDO_0004992', 'EFO_0001075', 'EFO_0000096', 'EFO_0000365', 'EFO_0000196', 'EFO_0000305', 'MONDO_0007254']",True,False,10,Tumor necrosis factor receptor superfamily member 9 agonist ,AGONIST ,single protein 
529,RELATLIMAB,CHEMBL3990044,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 25 investigational indications.,,4.0,,False,2022,['ENSG00000089692'],"['EFO_1001968', 'MONDO_0008978', 'MONDO_0044881', 'MONDO_0007576', 'EFO_0003060', 'EFO_0000519', 'EFO_0004142', 'EFO_0000616', 'EFO_0000403', 'EFO_0000681', 'EFO_0000365', 'EFO_0002617', 'EFO_1001465', 'EFO_0000756', 'EFO_0000181', 'EFO_0003016', 'MONDO_0001056', 'EFO_0000574', 'EFO_0000182', 'EFO_0001378', 'MONDO_0018906', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000222', 'EFO_0004193']",True,False,25,Lymphocyte activation gene 3 protein inhibitor ,INHIBITOR ,single protein 
530,TRO-40303,CHEMBL4297500,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000612'],False,False,1,,,
531,LYSINE,CHEMBL8085,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 24 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000479', 'EFO_0003060', 'EFO_0000305', 'MONDO_0001187', 'EFO_0000389', 'EFO_1001121', 'EFO_1000158', 'EFO_0008583', 'EFO_0000616', 'MONDO_0005148', 'MONDO_0044903', 'EFO_0003833', 'EFO_0002618', 'EFO_0000588', 'EFO_1000984', 'EFO_0000519', 'EFO_0000182', 'EFO_0002913', 'EFO_0005543', 'EFO_0001075', 'EFO_0000756', 'MONDO_0018906', 'EFO_0005537', 'EFO_0000222']",False,False,24,,,
532,DAPAGLIFLOZIN PROPYLENE GLYCOL,CHEMBL2103802,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and heart failure and has 1 investigational indication.,,4.0,,False,2014,['ENSG00000140675'],"['MONDO_0005148', 'MONDO_0005147', 'EFO_0003144']",False,False,3,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
533,SULODEXIDE,CHEMBL2108086,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['HP_0004419', 'MONDO_0100096', 'EFO_0004265', 'EFO_0003770', 'EFO_0000401', 'HP_0000360', 'EFO_0004286', 'EFO_0003884', 'MONDO_0019736']",False,False,9,,,
534,AMG-557,CHEMBL2109249,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000160223'],"['MONDO_0007915', 'EFO_0000699', 'EFO_0003834', 'EFO_0000676']",True,False,4,ICOS ligand inhibitor ,INHIBITOR ,single protein 
535,KB-001,CHEMBL2109536,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0009061', 'EFO_0003106']",False,False,2,Low calcium response locus protein V inhibitor ,INHIBITOR ,single protein 
536,ABITUZUMAB,CHEMBL2109621,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000138448', 'ENSG00000115221', 'ENSG00000082781', 'ENSG00000259207', 'ENSG00000150093', 'ENSG00000105855']","['MONDO_0008170', 'EFO_0004244', 'EFO_0000717', 'EFO_1001951', 'MONDO_0008315']",False,False,5,Integrin alpha-V/beta-6 inhibitor Integrin alpha-V/beta-5 inhibitor Integrin alpha-V/beta-3 inhibitor Integrin alpha-V/beta-1 inhibitor Integrin alpha-V/beta-8 inhibitor ,INHIBITOR ,protein complex 
537,ANAMORELIN,CHEMBL2110579,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000121853'],"['HP_0004326', 'HP_0012378', 'EFO_0002618', 'HP_0004326', 'EFO_0003060']",False,False,5,Ghrelin receptor agonist ,AGONIST ,single protein 
538,OZANIMOD,CHEMBL3707247,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for multiple sclerosis and immune system disease and has 5 investigational indications.,,4.0,,False,2020,['ENSG00000170989'],"['EFO_0000729', 'MONDO_0100096', 'EFO_0001421', 'EFO_0000384', 'MONDO_0005301', 'MONDO_0005301', 'EFO_0000540']",True,False,7,Sphingosine 1-phosphate receptor Edg-1 modulator ,MODULATOR ,single protein 
539,PROPOLIS WAX,CHEMBL4298075,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005148', 'EFO_0003843', 'MP_0001845', 'MONDO_0100096', 'EFO_0009540', 'EFO_0003884', 'MONDO_0005271', 'EFO_0001065']",False,False,8,,,
540,EDOTECARIN,CHEMBL435191,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['MONDO_0007254', 'EFO_0000519', 'EFO_0003897']",False,False,3,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
541,DEUCRAVACITINIB,CHEMBL4435170,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 8 investigational indications.,,4.0,,False,2022,['ENSG00000105397'],"['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540', 'EFO_0003086', 'EFO_0000676', 'EFO_0005761', 'HP_0001410', 'MONDO_0007915']",False,True,9,Tyrosine-protein kinase TYK2 negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,single protein 
542,TEMELIMAB,CHEMBL4594547,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000242950'],"['MONDO_0005147', 'EFO_0003929', 'MONDO_0005301']",False,False,3,Syncytin-1 inhibitor ,INHIBITOR ,single protein 
543,ORELABRUTINIB,CHEMBL4650321,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000010671'],"['MONDO_0018906', 'EFO_0000095', 'EFO_1001469', 'EFO_0007160', 'MONDO_0007915', 'EFO_0000403', 'EFO_0003929', 'EFO_0009441', 'EFO_0000183', 'MONDO_0004992', 'EFO_0000096']",True,False,11,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
544,CAMIZESTRANT,CHEMBL4650365,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000091831'],['MONDO_0007254'],False,True,1,Estrogen receptor alpha degrader ,DEGRADER ,single protein 
545,ZAPNOMETINIB,CHEMBL4802192,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
546,MOBOCERTINIB SUCCINATE,CHEMBL4802239,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for non-small cell lung carcinoma. This drug has a black box warning from the FDA.,,4.0,,True,2021,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
547,PAPAVERINE HYDROCHLORIDE,CHEMBL98123,Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication.,,4.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
548,NIACINAMIDE,CHEMBL1140,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 27 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000707', 'MONDO_0100339', 'HP_0001891', 'EFO_0008572', 'EFO_0005952', 'EFO_0003884', 'Orphanet_100', 'MONDO_0005301', 'EFO_0008620', 'MONDO_0002050', 'EFO_1001068', 'EFO_0000676', 'MONDO_0007915', 'HP_0002905', 'EFO_0000183', 'EFO_0003963', 'EFO_0003834', 'EFO_0004272', 'MONDO_0011382', 'EFO_0002496', 'EFO_0000095', 'EFO_1000783', 'EFO_0003894', 'MONDO_0004975', 'MONDO_0001187', 'EFO_0005772', 'EFO_0001070', 'EFO_0000668', 'EFO_0004193', 'HP_0001919']",False,False,31,,,
549,NORETHINDRONE ACETATE,CHEMBL1201146,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 7 investigational indications.,,4.0,,False,1973,['ENSG00000082175'],"['MONDO_0007254', 'EFO_0000574', 'EFO_0002950', 'EFO_0001065', 'HP_0008209', 'MP_0001914', 'EFO_0003894', 'EFO_0000731', 'MONDO_0002146', 'MONDO_0009061', 'EFO_0003843']",False,False,11,Progesterone receptor agonist ,AGONIST ,single protein 
550,OTERACIL,CHEMBL181932,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 33 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000503', 'EFO_0003897', 'EFO_1001951', 'EFO_0003060', 'EFO_0000182', 'MONDO_0007254', 'EFO_0006859', 'EFO_0000228', 'MONDO_0002974', 'EFO_0003860', 'MONDO_0002120', 'EFO_0003086', 'EFO_0001421', 'EFO_0000178', 'EFO_0000702', 'EFO_0000365', 'EFO_0004142', 'MONDO_0001056', 'MONDO_0044937', 'MONDO_0007576', 'EFO_0005922', 'EFO_0002618', 'EFO_0002517', 'EFO_0004252', 'EFO_0000181', 'EFO_0000616', 'MONDO_0005575', 'EFO_0005221', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000657', 'MONDO_0003060', 'EFO_0002916']",False,False,33,,,
551,BELOTECAN,CHEMBL2111084,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['MONDO_0008903', 'EFO_0000616', 'EFO_0000702', 'EFO_0003060', 'MONDO_0008170', 'MONDO_0002974']",False,False,6,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
552,IFENPRODIL,CHEMBL305187,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 3 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000768', 'EFO_0001358', 'EFO_0000319']",False,False,4,,,
553,RELUSCOVTOGENE RALAPLASMID,CHEMBL5095348,Gene drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
554,GSK-256066,CHEMBL570015,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['EFO_0003956', 'EFO_0000341', 'MONDO_0004979']",True,False,3,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
555,TOZASERTIB,CHEMBL572878,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000178999', 'ENSG00000105146', 'ENSG00000087586']","['EFO_1001951', 'EFO_0003060', 'MONDO_0004992', 'EFO_0004289', 'EFO_0000339', 'EFO_0000220', 'EFO_0000198', 'EFO_0000565']",False,False,8,Serine/threonine-protein kinase Aurora inhibitor ,INHIBITOR ,protein family 
556,DEXRAZOXANE HYDROCHLORIDE,CHEMBL1200778,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 9 investigational indications.,,4.0,,False,1995,[],"['EFO_0000318', 'EFO_0000691', 'MONDO_0000870', 'EFO_1000984', 'EFO_0000574', 'EFO_0000565', 'MONDO_0007254', 'EFO_0000222', 'EFO_0000616', 'EFO_0000209', 'EFO_1000158']",False,False,11,,,
557,OXYGEN,CHEMBL1234886,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 79 investigational indications.,,4.0,,False,2015,[],"['EFO_0007512', 'HP_0002140', 'MONDO_0005148', 'EFO_0007167', 'MONDO_0004992', 'HP_0011110', 'EFO_0001358', 'EFO_0000400', 'EFO_0009448', 'EFO_0000465', 'EFO_0000768', 'EFO_1001919', 'MONDO_0100096', 'MONDO_0043839', 'EFO_1000637', 'EFO_0003917', 'MONDO_0005090', 'EFO_0003103', 'EFO_0003106', 'EFO_0009516', 'EFO_0003931', 'EFO_0000729', 'MONDO_0019297', 'EFO_0005774', 'MONDO_0011382', 'MONDO_0004567', 'MONDO_0043510', 'EFO_0004278', 'EFO_0011023', 'EFO_0000712', 'EFO_0005762', 'EFO_0000544', 'EFO_1000809', 'EFO_1000158', 'EFO_0003827', 'EFO_0001361', 'HP_0001919', 'MONDO_0007254', 'EFO_0001645', 'EFO_0000556', 'EFO_0004264', 'EFO_1001158', 'EFO_0003913', 'EFO_0000181', 'EFO_1001465', 'HP_0000999', 'EFO_1001998', 'EFO_0000694', 'EFO_0000546', 'HP_0031273', 'EFO_0001378', 'EFO_0009444', 'EFO_0003843', 'GO_0007568', 'EFO_1001821', 'EFO_0005611', 'EFO_0004234', 'EFO_0003818', 'EFO_0009869', 'EFO_0008590', 'EFO_0003060', 'EFO_0009842', 'HP_0011106', 'EFO_0003758', 'EFO_0003918', 'MONDO_0005277', 'EFO_0003756', 'MONDO_0002358', 'EFO_0003144', 'EFO_0005230', 'EFO_0008583', 'HP_0100806', 'HP_0011950', 'MONDO_0019200', 'EFO_0002687', 'EFO_0004259', 'EFO_0002950', 'EFO_0000341', 'EFO_0004888']",False,False,79,,,
558,ZANAMIVIR,CHEMBL222813,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for influenza and viral disease and has 3 investigational indications.,,4.0,,False,1999,[],"['MONDO_0005148', 'EFO_0007328', 'EFO_0000763', 'EFO_0005547', 'EFO_0000544']",False,False,5,Neuraminidase inhibitor ,INHIBITOR ,single protein 
559,VARLILUMAB,CHEMBL3137347,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,['ENSG00000139193'],"['EFO_0000574', 'EFO_0000756', 'EFO_0003060', 'EFO_1001956', 'EFO_0000632', 'EFO_0000519', 'EFO_0003863', 'EFO_0000272', 'EFO_0000681', 'EFO_0000630']",False,False,10,CD27 antigen agonist ,AGONIST ,single protein 
560,"LIPOIC ACID, ALPHA",CHEMBL33864,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 24 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005148', 'EFO_0003918', 'EFO_0000765', 'EFO_1001898', 'EFO_0001365', 'MONDO_0009067', 'MONDO_0004975', 'HP_0003124', 'MONDO_0019037', 'EFO_0003884', 'EFO_0003100', 'EFO_0007405', 'EFO_0009538', 'MONDO_0004985', 'EFO_0008522', 'MONDO_0015339', 'HP_0000951', 'MONDO_0001583', 'EFO_0004143', 'EFO_0008520', 'EFO_0003840', 'EFO_0000537', 'MONDO_0005301', 'EFO_0000712']",False,False,24,,,
561,FERRIC HYDROXIDE,CHEMBL3707285,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0004272']",False,False,2,,,
562,NAQUOTINIB MESYLATE,CHEMBL3707350,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
563,LXH254,CHEMBL4583691,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000132155', 'ENSG00000157764']","['EFO_0003060', 'EFO_0000756']",False,True,2,B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor ,INHIBITOR ,protein family 
564,APL-501,CHEMBL4594355,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000188389'],"['MONDO_0004992', 'MONDO_0002974', 'EFO_0000211', 'EFO_0007143', 'EFO_0003060', 'EFO_0000096']",False,False,6,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
565,SOCAZOLIMAB,CHEMBL4802221,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000120217'],"['EFO_0000702', 'EFO_0000637', 'MONDO_0002974', 'EFO_0002617', 'EFO_0008528', 'MONDO_0003060']",False,False,6,Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
566,AMOXICILLIN,CHEMBL1082,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 11 approved and 52 investigational indications.,,4.0,,False,1974,[],"['EFO_0000191', 'EFO_1001272', 'EFO_0000544', 'EFO_1000961', 'MP_0001845', 'EFO_1000049', 'EFO_0003030', 'EFO_0005952', 'EFO_0008572', 'HP_0003419', 'EFO_0003103', 'EFO_0007328', 'MONDO_0100096', 'EFO_1001034', 'MONDO_0000565', 'EFO_0003102', 'EFO_0009784', 'EFO_0000729', 'HP_0001082', 'MP_0001914', 'EFO_0003033', 'EFO_0001074', 'EFO_0009454', 'HP_0002014', 'EFO_0007456', 'EFO_1001345', 'EFO_0001073', 'EFO_0000519', 'EFO_0008533', 'EFO_0006859', 'MONDO_0001187', 'EFO_0003833', 'EFO_0007503', 'EFO_1001141', 'EFO_0005323', 'EFO_0007219', 'MONDO_0001475', 'MONDO_0024355', 'EFO_0000649', 'EFO_1001216', 'HP_0011110', 'EFO_0000574', 'MONDO_0002258', 'MONDO_0004979', 'MONDO_0018076', 'EFO_0003106', 'EFO_0004607', 'DOID_7551', 'EFO_1001313', 'MONDO_0005271', 'EFO_0000217', 'EFO_0003932', 'EFO_0004992', 'EFO_0007205', 'EFO_1001391', 'EFO_0007486', 'EFO_0000771', 'HP_0001945', 'EFO_0003106', 'EFO_0005741', 'EFO_0002499', 'MONDO_0000327', 'EFO_0006505', 'EFO_0000544', 'EFO_0007444']",False,False,65,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
567,CEFUROXIME AXETIL,CHEMBL1095930,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 9 approved and 1 investigational indication.,,4.0,,False,1987,[],"['EFO_0007486', 'MONDO_0002258', 'HP_0011110', 'EFO_0004992', 'EFO_0003103', 'EFO_0006505', 'EFO_0007361', 'EFO_0003106', 'EFO_0003102', 'EFO_0000544']",False,False,10,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
568,LONIDAMINE,CHEMBL1257030,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000284', 'EFO_0000616']",False,False,2,,,
569,CLOFAZIMINE,CHEMBL1292,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for leprosy and has 7 investigational indications.,,4.0,,False,1986,[],"['MONDO_0041806', 'EFO_0001054', 'EFO_0007386', 'EFO_1000049', 'EFO_0000384', 'MONDO_0018076', 'MONDO_0015474', 'EFO_0007381']",False,False,8,,,
570,ARGININE,CHEMBL1485,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 39 investigational indications.,,4.0,,False,no approval year,[],"['HP_0100806', 'MONDO_0100096', 'EFO_0000668', 'EFO_0001645', 'EFO_0000649', 'EFO_1000049', 'MONDO_0010679', 'EFO_0003843', 'EFO_0004265', 'MONDO_0005090', 'EFO_0000702', 'EFO_0004278', 'MONDO_0009258', 'MONDO_0009061', 'EFO_1001345', 'EFO_0000685', 'EFO_0000319', 'MONDO_0008815', 'MONDO_0005271', 'EFO_0000182', 'Orphanet_550', 'MONDO_0011382', 'EFO_0007444', 'EFO_0001422', 'EFO_0000574', 'EFO_0003086', 'EFO_0000537', 'HP_0001952', 'EFO_0000519', 'MONDO_0005148', 'MONDO_0008315', 'Orphanet_848', 'MONDO_0004975', 'EFO_0005207', 'EFO_0003819', 'EFO_0000373', 'MONDO_0004979', 'MONDO_0001134', 'EFO_0000616']",False,False,39,,,
571,ALISKIREN,CHEMBL1639,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,['ENSG00000143839'],"['EFO_0000537', 'EFO_0000275', 'EFO_0000537', 'EFO_0000400', 'EFO_0003884', 'MONDO_0001134', 'MONDO_0005148', 'EFO_0000319', 'EFO_0000712', 'MONDO_0007947', 'EFO_0000401', 'EFO_0004194', 'EFO_0003144', 'EFO_0000373', 'EFO_0003086', 'EFO_0005672', 'MONDO_0021661', 'EFO_0003914', 'EFO_0003896', 'EFO_0000612']",False,False,20,Renin inhibitor ,INHIBITOR ,single protein 
572,CONATUMUMAB,CHEMBL1743003,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000120889'],"['EFO_0000183', 'EFO_0003060', 'EFO_1001469', 'EFO_0002618', 'EFO_0000403', 'EFO_1001968', 'MONDO_0008170', 'MONDO_0002158']",False,False,8,Tumor necrosis factor receptor superfamily member 10B agonist ,AGONIST ,single protein 
573,MILVETEROL,CHEMBL1940832,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000169252'],['EFO_0000341'],False,False,1,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
574,FIBOFLAPON,CHEMBL1922660,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000132965'],"['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061', 'MONDO_0004979']",False,False,4,5-lipoxygenase activating protein inhibitor ,INHIBITOR ,single protein 
575,TIVOZANIB HYDROCHLORIDE,CHEMBL2105756,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for renal cell carcinoma and has 2 investigational indications.,,4.0,,False,2021,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721']","['MONDO_0007254', 'EFO_0001421', 'EFO_0000681']",True,False,3,Vascular endothelial growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor beta inhibitor ,INHIBITOR ,protein family single protein 
576,CALCIUM DOBESILATE,CHEMBL2106191,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for varicose veins and has 5 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005148', 'EFO_0000545', 'HP_0000132', 'HP_0002619', 'MONDO_0100096', 'EFO_1000760']",False,False,6,,,
577,LACTOSE MONOHYDRATE,CHEMBL2106323,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002050', 'EFO_0004197', 'EFO_0003047', 'MONDO_0100096', 'EFO_0007328', 'EFO_0007303', 'EFO_0007305']",False,False,7,,,
578,OLIVE OIL,CHEMBL2107910,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 13 investigational indications.,,4.0,,False,2013,[],"['EFO_0000676', 'MONDO_0005148', 'EFO_0003777', 'EFO_1000906', 'EFO_0001073', 'MONDO_0002406', 'MONDO_0002635', 'EFO_0004211', 'EFO_0004616', 'HP_0040187', 'EFO_1000653', 'MONDO_0007915', 'HP_0003419']",False,False,13,,,
579,CHONDROITIN SULFATE SODIUM,CHEMBL2108922,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0008507', 'EFO_0005755', 'EFO_0004616', 'MONDO_0005178', 'EFO_0000384']",False,False,5,,,
580,GANCOTAMAB,CHEMBL3833344,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000131747', 'ENSG00000141736']",['MONDO_0007254'],False,False,1,Receptor protein-tyrosine kinase erbB-2 binding agent DNA topoisomerase II alpha inhibitor ,BINDING AGENT INHIBITOR ,single protein 
581,CABIRALIZUMAB,CHEMBL4297713,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000182578'],"['EFO_0000685', 'EFO_0000211', 'EFO_0000181', 'MONDO_0004992', 'EFO_0002618', 'MONDO_0007254', 'EFO_0000182']",False,False,7,Macrophage colony stimulating factor receptor antagonist ,ANTAGONIST ,single protein 
582,CHO-H01,CHEMBL4297726,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0018906'],False,False,1,,,
583,ZILTIVEKIMAB,CHEMBL4297732,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000136244'],"['EFO_0003884', 'EFO_0004272']",False,False,2,Interleukin-6 binding agent ,BINDING AGENT ,single protein 
584,CARRIMYCIN,CHEMBL4650385,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000199', 'MONDO_0100096']",False,False,2,,,
585,ENMD-981693,CHEMBL52885,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000128052', 'ENSG00000087586', 'ENSG00000010810', 'ENSG00000197122', 'ENSG00000182866', 'ENSG00000176105', 'ENSG00000136573', 'ENSG00000101336', 'ENSG00000254087', 'ENSG00000111816', 'ENSG00000000938', 'ENSG00000125508', 'ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000122025']","['EFO_1001951', 'EFO_0003060', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000616']",True,True,6,SRC inhibitor Platelet-derived growth factor receptor inhibitor Serine/threonine-protein kinase Aurora-A inhibitor Vascular endothelial growth factor receptor 2 inhibitor Fibroblast growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,protein family protein complex single protein 
586,TIROFIBAN,CHEMBL916,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 11 investigational indications.,,4.0,,False,1998,"['ENSG00000259207', 'ENSG00000005961']","['MONDO_0100096', 'EFO_0004286', 'EFO_0000612', 'EFO_0007541', 'HP_0004419', 'EFO_0001645', 'EFO_0005672', 'EFO_0009686', 'HP_0002140', 'EFO_0008583', 'EFO_0000612', 'EFO_0000712', 'HP_0000083']",True,True,13,Integrin alpha-IIb/beta-3 inhibitor ,INHIBITOR ,protein complex 
587,TAMSULOSIN HYDROCHLORIDE,CHEMBL1200914,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 5 investigational indications.,,4.0,,False,1997,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['HP_0000016', 'EFO_0005323', 'EFO_0000537', 'HP_0000011', 'EFO_0003830', 'EFO_0000284', 'EFO_0001663']",False,False,7,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
588,ESTRAMUSTINE PHOSPHATE,CHEMBL1756,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for neoplasm and carcinoma and has 6 investigational indications.,,4.0,,False,1981,['ENSG00000140009'],"['MONDO_0007254', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000574', 'EFO_0000616', 'MONDO_0002367', 'MONDO_0008315', 'EFO_0000313']",False,False,8,Estrogen receptor beta modulator ,MODULATOR ,single protein 
589,SULOPENEM,CHEMBL1908305,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001272', 'EFO_0003106', 'EFO_0000544', 'EFO_0003103']",False,False,4,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
590,OCTANOIC ACID,CHEMBL324846,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005221', 'EFO_0003060', 'EFO_0003108', 'EFO_0000702', 'EFO_1000286', 'EFO_0000198', 'EFO_0004606', 'EFO_0000222']",False,False,8,,,
591,VB-201,CHEMBL4297333,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000170458', 'ENSG00000137462']","['EFO_0000676', 'EFO_0000729', 'MONDO_0100096']",True,False,3,Toll-like receptor 2 inhibitor Monocyte differentiation antigen CD14 inhibitor ,INHIBITOR ,single protein 
592,TIOMOLIBDATE CHOLINE,CHEMBL4594259,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0010200', 'MONDO_0007254', 'EFO_0000756', 'MONDO_0008315']",False,False,4,,,
593,BI-2536,CHEMBL513909,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000166851'],"['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0003860', 'EFO_0003060', 'EFO_0000673', 'EFO_0000702']",False,False,7,Serine/threonine-protein kinase PLK1 inhibitor ,INHIBITOR ,single protein 
594,FICLATUZUMAB,CHEMBL1743018,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000019991'],"['EFO_0000181', 'EFO_0000707', 'EFO_0001378', 'EFO_0000519', 'EFO_0002618', 'EFO_0003060', 'EFO_0000222']",False,False,7,Hepatocyte growth factor inhibitor ,INHIBITOR ,single protein 
595,DINUTUXIMAB,CHEMBL3137342,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and neuroblastoma and has 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,[],"['EFO_0000564', 'EFO_0000702', 'EFO_0000502', 'EFO_0000616', 'EFO_0000621', 'EFO_0000637']",False,False,6,,,
596,INCB-047986,CHEMBL3545225,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000162434'],"['EFO_0000685', 'EFO_0000198', 'EFO_0000183', 'MONDO_0007254']",True,False,4,Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
597,SAR-407899,CHEMBL3545341,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000134318', 'ENSG00000067900']","['EFO_0003884', 'EFO_0004234', 'EFO_0001645']",False,False,3,Rho-associated protein kinase inhibitor ,INHIBITOR ,protein family 
598,LENIOLISIB,CHEMBL3643413,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000171608'],"['MONDO_0015517', 'EFO_0000699']",False,False,2,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
599,CFI-400945,CHEMBL4297462,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000142731'],"['MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254']",False,False,3,Serine/threonine-protein kinase PLK4 inhibitor ,INHIBITOR ,single protein 
600,THROMBOPOIETIN,CHEMBL5095296,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
601,TIOTROPIUM,CHEMBL1900528,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 5 investigational indications.,,4.0,,False,2004,['ENSG00000133019'],"['EFO_1001919', 'HP_0006536', 'HP_0000083', 'HP_0025428', 'MONDO_0009061', 'EFO_0000616', 'EFO_0000341', 'MONDO_0004979', 'EFO_0000341', 'EFO_0006505', 'EFO_0000464']",True,True,11,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
602,AMOXICILLIN SODIUM,CHEMBL2105950,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pneumonia and infection.,,4.0,,False,no approval year,[],"['EFO_0003106', 'EFO_0000544']",False,False,2,,,
603,BLISIBIMOD,CHEMBL2107877,Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000102524'],"['EFO_0007160', 'EFO_0005297', 'EFO_0004194', 'MONDO_0007915', 'EFO_1000784']",True,False,5,Tumor necrosis factor ligand superfamily member 13B inhibitor ,INHIBITOR ,single protein 
604,SILODOSIN,CHEMBL24778,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for benign prostatic hyperplasia and has 3 investigational indications.,,4.0,,False,2008,['ENSG00000120907'],"['MONDO_0008315', 'EFO_0000284', 'EFO_0004253', 'EFO_0003830']",False,False,4,Alpha-1a adrenergic receptor antagonist ,ANTAGONIST ,single protein 
605,BORTEZOMIB,CHEMBL325041,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 96 investigational indications.,,4.0,,False,2003,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']","['EFO_1001961', 'EFO_1000158', 'MONDO_0004192', 'MONDO_0002367', 'MONDO_0003175', 'EFO_0000574', 'EFO_0000519', 'EFO_1001226', 'MONDO_0008170', 'MONDO_0017816', 'EFO_0000588', 'EFO_0000096', 'EFO_0000095', 'EFO_0007160', 'MONDO_0016537', 'MONDO_0019438', 'MONDO_0008627', 'EFO_0000183', 'EFO_0003060', 'EFO_0000094', 'EFO_0006859', 'EFO_0005952', 'EFO_0009441', 'EFO_0000339', 'EFO_0000220', 'EFO_0002517', 'EFO_0000182', 'EFO_0003811', 'EFO_0000681', 'EFO_0000616', 'EFO_0000571', 'MONDO_0019460', 'EFO_0005543', 'EFO_0004599', 'EFO_0001642', 'EFO_0003884', 'MONDO_0019471', 'EFO_0001378', 'MONDO_0001705', 'EFO_1001365', 'EFO_0007183', 'EFO_1001469', 'EFO_1001968', 'EFO_0000209', 'EFO_0000198', 'MONDO_0002974', 'MONDO_0007254', 'EFO_1001052', 'EFO_0000224', 'MONDO_0015277', 'EFO_0000309', 'MONDO_0007576', 'EFO_1001875', 'MONDO_0001056', 'EFO_0000641', 'EFO_0000501', 'EFO_0000621', 'MONDO_0004986', 'EFO_0002618', 'EFO_0003032', 'MONDO_0004992', 'MONDO_0044881', 'MONDO_0009348', 'EFO_0000191', 'EFO_0004252', 'EFO_1001051', 'EFO_0000222', 'MONDO_0001187', 'EFO_1000785', 'EFO_0000255', 'EFO_0000305', 'EFO_0007332', 'EFO_0000403', 'EFO_0003073', 'EFO_0000231', 'MONDO_0013730', 'EFO_0001663', 'MONDO_0008315', 'EFO_0006475', 'EFO_0000211', 'EFO_0002428', 'EFO_0004256', 'MONDO_0018906', 'EFO_0000565', 'EFO_0000691', 'EFO_0000540', 'EFO_1001465', 'MONDO_0002158', 'MONDO_0002087', 'EFO_0000756', 'EFO_0000707', 'EFO_0002501', 'MONDO_0015564', 'EFO_0006738', 'MONDO_0008903', 'EFO_0002499', 'EFO_0000673', 'EFO_1001951', 'MONDO_0000873', 'EFO_0000308']",True,True,100,26S proteosome inhibitor ,INHIBITOR ,protein complex 
606,POLATUZUMAB VEDOTIN,CHEMBL3301582,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for diffuse large b-cell lymphoma and neoplasm and has 6 investigational indications.,,4.0,,False,2019,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000007312']","['MONDO_0018906', 'EFO_0000096', 'EFO_1001469', 'EFO_0000095', 'EFO_0000403', 'EFO_0005952', 'EFO_0000574', 'EFO_0000616']",True,False,8,B-cell antigen receptor complex-associated protein beta chain binding agent Tubulin inhibitor ,BINDING AGENT INHIBITOR ,single protein protein complex group 
607,PREXASERTIB,CHEMBL3544911,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 15 investigational indications.,,2.0,,False,no approval year,"['ENSG00000149554', 'ENSG00000183765']","['EFO_0000616', 'MONDO_0001657', 'EFO_0009708', 'EFO_1001779', 'MONDO_0008170', 'EFO_0000198', 'EFO_0000222', 'EFO_0004284', 'EFO_1000158', 'EFO_0004142', 'EFO_0000702', 'EFO_0000708', 'EFO_0002939', 'EFO_0003060', 'MONDO_0004992']",False,False,15,Serine/threonine-protein kinase Chk1 inhibitor Serine/threonine-protein kinase Chk2 inhibitor ,INHIBITOR ,single protein 
608,IBERDOMIDE,CHEMBL3989927,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']","['EFO_0003073', 'MONDO_0018906', 'EFO_0000574', 'MONDO_0019338', 'HP_0000083', 'EFO_0005952', 'EFO_0000403', 'MONDO_0007915', 'EFO_0001421', 'EFO_0001378', 'EFO_0001378']",True,False,11,CRL4(CRBN) E3 ubiquitin ligase modulator ,MODULATOR ,protein complex 
609,CAPMATINIB HYDROCHLORIDE,CHEMBL3989937,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for non-small cell lung carcinoma.,,4.0,,False,2020,['ENSG00000105976'],['EFO_0003060'],False,False,1,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
610,RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2,CHEMBL4298082,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0021063', 'EFO_0001645']",False,False,3,,,
611,THALLOUS CHLORIDE,CHEMBL4302512,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for myocardial infarction and coronary artery disease.,,4.0,,False,1977,[],"['EFO_0000612', 'EFO_0001645']",False,False,2,,,
612,PENICILLIN V,CHEMBL615,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 7 approved and 3 investigational indications.,,4.0,,False,1958,[],"['EFO_0007477', 'EFO_0000544', 'EFO_0003106', 'EFO_0003033', 'EFO_1000830', 'EFO_0000771', 'EFO_0000584', 'EFO_0005856', 'EFO_0003102', 'EFO_0000771']",False,False,10,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
613,MIGLUSTAT,CHEMBL1029,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for gaucher disease type 1 and gaucher disease and has 9 investigational indications.,,4.0,,False,2003,['ENSG00000148154'],"['EFO_0000764', 'Orphanet_365', 'MONDO_0019262', 'Orphanet_77259', 'MONDO_0017720', 'MONDO_0018150', 'MONDO_0018982', 'MONDO_0002412', 'MONDO_0010006', 'MONDO_0009061', 'MONDO_0019064']",False,False,11,Ceramide glucosyltransferase inhibitor ,INHIBITOR ,single protein 
614,PRAVASTATIN,CHEMBL1144,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 38 investigational indications.,,4.0,,False,1991,['ENSG00000113161'],"['EFO_0000319', 'EFO_1001375', 'HP_0001919', 'MONDO_0005147', 'EFO_0000668', 'MONDO_0008310', 'EFO_1000049', 'EFO_0003929', 'EFO_0001645', 'EFO_0000685', 'MONDO_0018473', 'EFO_0004911', 'HP_0003124', 'HP_0002140', 'EFO_0000574', 'EFO_0000565', 'EFO_0000764', 'HP_0002140', 'MONDO_0007915', 'EFO_0000612', 'Orphanet_79211', 'EFO_0000182', 'EFO_0000180', 'EFO_0000612', 'MONDO_0021187', 'MONDO_0021661', 'MONDO_0007254', 'EFO_0000537', 'EFO_0000319', 'EFO_0000400', 'EFO_1000727', 'HP_0003124', 'EFO_0004255', 'EFO_0003884', 'EFO_0000400', 'EFO_0003914', 'Orphanet_79211', 'MONDO_0020732', 'EFO_0003144', 'MONDO_0008903', 'EFO_0006890', 'EFO_0004246', 'Orphanet_309005', 'MONDO_0018076', 'EFO_0000764', 'EFO_0000565', 'EFO_0003106', 'MONDO_0002691', 'EFO_0000313', 'EFO_0004705', 'EFO_1001496']",False,True,51,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
615,DACLIZUMAB,CHEMBL1201605,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for relapsing-remitting multiple sclerosis and immune system disease and has 24 investigational indications. It was withdrawn in at least one region.,,4.0,,False,1997,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']","['EFO_0000198', 'EFO_0001378', 'MONDO_0004979', 'EFO_0000574', 'EFO_0000616', 'MONDO_0001705', 'EFO_0000676', 'HP_0012410', 'EFO_0004683', 'EFO_0000764', 'MONDO_0013730', 'EFO_0000756', 'EFO_0003929', 'MONDO_0018923', 'EFO_0003086', 'EFO_0000729', 'MONDO_0005301', 'EFO_0003884', 'EFO_0000540', 'EFO_0000400', 'HP_0001873', 'EFO_0005297', 'EFO_0000565', 'HP_0001915', 'EFO_1001231', 'MONDO_0005147']",False,True,26,Interleukin-2 receptor inhibitor ,INHIBITOR ,protein complex 
616,"ESTROGENS, CONJUGATED",CHEMBL1201649,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and has 10 approved and 24 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1942,"['ENSG00000140009', 'ENSG00000091831']","['HP_0000938', 'MONDO_0008315', 'EFO_0000612', 'MONDO_0007915', 'EFO_0000712', 'MONDO_0004975', 'EFO_0004288', 'MONDO_0001410', 'EFO_0000400', 'EFO_0001072', 'EFO_1000781', 'HP_0030016', 'HP_0031273', 'MONDO_0002146', 'EFO_0000537', 'HP_0031217', 'MONDO_0043510', 'EFO_1000985', 'EFO_0001663', 'EFO_1001375', 'EFO_0002687', 'EFO_1000096', 'EFO_0003922', 'MONDO_0011962', 'EFO_0003869', 'MONDO_0000831', 'EFO_0001645', 'EFO_0003882', 'HP_0003124', 'MONDO_0007254', 'MONDO_0019499', 'EFO_0004266', 'EFO_0003854', 'MONDO_0005351']",True,True,34,Estrogen receptor agonist ,AGONIST ,protein family 
617,PIRFENIDONE,CHEMBL1256391,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for immune system disease and idiopathic pulmonary fibrosis and has 27 investigational indications.,,4.0,,False,2011,[],"['MONDO_0015926', 'EFO_0000538', 'EFO_0000540', 'EFO_0000768', 'EFO_1002048', 'EFO_0000768', 'EFO_0000717', 'EFO_0000278', 'EFO_0001422', 'EFO_0004244', 'EFO_0003106', 'HP_0000083', 'HP_0000093', 'EFO_0003884', 'MONDO_0018975', 'EFO_0004212', 'EFO_0009448', 'EFO_0007183', 'EFO_0000731', 'EFO_0004255', 'EFO_1001411', 'MONDO_0005301', 'EFO_0009516', 'EFO_1000637', 'EFO_1001459', 'EFO_0003144', 'MONDO_0017853', 'EFO_0004236', 'MONDO_0100096']",False,False,29,,,
618,NITAZOXANIDE,CHEMBL1401,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for diarrhea and has 26 investigational indications.,,4.0,,False,2002,[],"['HP_0002014', 'EFO_0004239', 'EFO_0000694', 'EFO_1001314', 'EFO_0007328', 'EFO_0008572', 'EFO_0000384', 'EFO_0000555', 'EFO_0003047', 'EFO_0008588', 'EFO_0000764', 'EFO_0003086', 'MONDO_0100096', 'EFO_1001463', 'EFO_0001421', 'EFO_1000961', 'EFO_0004220', 'HP_0011950', 'EFO_1000874', 'EFO_0000684', 'EFO_0000685', 'MONDO_0015474', 'EFO_0008533', 'HP_0001298', 'EFO_0007144', 'MONDO_0018076', 'EFO_0000649']",False,False,27,Pyruvate:ferredoxin oxidoreductase inhibitor ,INHIBITOR ,single protein 
619,OSIMERTINIB,CHEMBL3353410,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 10 investigational indications.,,4.0,,False,2015,['ENSG00000146648'],"['EFO_0000313', 'MONDO_0005575', 'EFO_0000707', 'MONDO_0021117', 'EFO_0000519', 'MONDO_0008903', 'EFO_0003060', 'EFO_0003833', 'MONDO_0004992', 'EFO_0000571', 'EFO_0000228', 'MONDO_0008903', 'EFO_0000616', 'EFO_0003060']",False,True,14,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
620,ZUNSEMETINIB,CHEMBL3704901,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0016168', 'EFO_0000685', 'EFO_1000710']",False,False,4,,,
621,DEUTENZALUTAMIDE,CHEMBL4594421,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0008315']",False,False,2,,,
622,CARBOXYAMIDOTRIAZOLE,CHEMBL95431,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000681', 'MONDO_0002367', 'EFO_0003060', 'MONDO_0002158', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0002087', 'EFO_1001465']",False,False,8,,,
623,RANOLAZINE,CHEMBL1404,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for cardiovascular disease and angina pectoris and has 15 investigational indications.,,4.0,,False,2006,"['ENSG00000007314', 'ENSG00000183873']","['MONDO_0004976', 'EFO_0000319', 'EFO_0003913', 'EFO_1001375', 'EFO_0000384', 'MONDO_0005148', 'EFO_1000899', 'EFO_0001361', 'EFO_0004264', 'EFO_0000275', 'EFO_0005672', 'MONDO_0008195', 'EFO_0000407', 'EFO_0001645', 'EFO_0000555', 'EFO_0003086', 'HP_0001657']",False,False,17,Sodium channel protein type V alpha subunit blocker Sodium channel protein type IV alpha subunit blocker ,BLOCKER ,single protein 
624,TENOFOVIR DISOPROXIL FUMARATE,CHEMBL1486,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,[],"['EFO_1001486', 'EFO_0008496', 'EFO_0000764', 'MONDO_0100096', 'EFO_0005741', 'EFO_0000765', 'EFO_1000727', 'EFO_0004197', 'EFO_0000544', 'EFO_0000180', 'EFO_0003047', 'MONDO_0018076', 'EFO_0002614', 'EFO_0001421', 'EFO_0004239', 'EFO_0000574', 'EFO_0007304']",False,False,17,Human immunodeficiency virus type 1 reverse transcriptase inhibitor ,INHIBITOR ,single protein 
625,ANDROGRAPHOLIDE,CHEMBL186141,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000729', 'EFO_0000384', 'EFO_0004142', 'EFO_0008520']",False,False,4,,,
626,LOSARTAN,CHEMBL191,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 6 approved and 43 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,['ENSG00000144891'],"['MP_0001845', 'EFO_0004265', 'EFO_0000319', 'EFO_1000637', 'MONDO_0007254', 'EFO_0006818', 'EFO_0002618', 'EFO_0000546', 'GO_0007568', 'EFO_0007148', 'EFO_0003086', 'MONDO_0005147', 'EFO_0004194', 'EFO_0002618', 'EFO_0003144', 'MONDO_0005149', 'MONDO_0002474', 'EFO_0004236', 'MONDO_0005148', 'MONDO_0009061', 'MONDO_0001134', 'EFO_0003095', 'EFO_0000637', 'EFO_0000401', 'EFO_1001249', 'EFO_0002617', 'MONDO_0007947', 'EFO_0004232', 'EFO_0002517', 'MONDO_0011382', 'EFO_0000537', 'EFO_0000537', 'EFO_0000668', 'EFO_0000694', 'MONDO_0007947', 'EFO_0000712', 'EFO_0003884', 'EFO_0000538', 'EFO_0003884', 'EFO_0003086', 'EFO_0000519', 'EFO_1000653', 'MONDO_0100096', 'EFO_0000764', 'EFO_0000768', 'HP_0000093', 'MONDO_0001134', 'HP_0000093', 'EFO_0004616', 'EFO_0003896', 'EFO_0001358']",True,False,51,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
627,PF-03635659,CHEMBL1910856,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000341'],False,False,1,,,
628,CANAGLIFLOZIN,CHEMBL2048484,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,['ENSG00000140675'],"['EFO_0000401', 'MONDO_0005147', 'HP_0000083', 'EFO_0000400', 'MONDO_0007254', 'EFO_0003144', 'MONDO_0005148', 'EFO_0001073', 'EFO_0000660']",False,False,9,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
629,VIAGENPUMATUCEL-L,CHEMBL3137340,Cell drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
630,ROCILETINIB,CHEMBL3545308,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0003060', 'EFO_0000616']",False,True,2,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
631,ADOMEGLIVANT,CHEMBL3707351,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000215644'],"['EFO_0003884', 'MONDO_0005147', 'MONDO_0005148']",False,False,3,Glucagon receptor antagonist ,ANTAGONIST ,single protein 
632,TIGECYCLINE,CHEMBL376140,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for bacterial disease and infection and has 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,[],"['EFO_0000771', 'MONDO_0021679', 'MONDO_0021678', 'EFO_0000544', 'EFO_1001753', 'EFO_0005681', 'EFO_0000222', 'EFO_1001486', 'EFO_1001272', 'EFO_1001459', 'EFO_0003102', 'EFO_0003884', 'EFO_0000701', 'EFO_0003033']",False,False,14,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
633,RISANKIZUMAB,CHEMBL3990029,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 8 investigational indications.,,4.0,,False,2019,"['ENSG00000113302', 'ENSG00000110944']","['MONDO_0004979', 'MONDO_0002406', 'EFO_0000384', 'EFO_0000676', 'EFO_1000710', 'EFO_0000729', 'EFO_0003898', 'MONDO_0100096', 'EFO_0003778', 'MONDO_0015597', 'EFO_0000540']",True,True,11,Interleukin-23 inhibitor ,INHIBITOR ,protein complex 
634,PLASMALYTE A,CHEMBL4650416,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000556', 'MONDO_0100130', 'EFO_1000812', 'EFO_0000612', 'EFO_0000546']",False,False,5,,,
635,REGDANVIMAB,CHEMBL4650462,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
636,PEGYLATED CARBOXYHEMOGLOBIN (BOVINE),CHEMBL4650504,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['HP_0200042', 'MONDO_0011382', 'HP_0002140', 'EFO_0003884']",False,False,4,,,
637,QUERCETIN,CHEMBL50,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000654', 'MONDO_0100096', 'GO_0007568', 'EFO_0003884', 'MONDO_0005148', 'EFO_0000341', 'MONDO_0005178', 'EFO_0008517', 'EFO_0001645', 'MONDO_0009061', 'EFO_0003948', 'EFO_0001365', 'EFO_0004220', 'MONDO_0019391', 'EFO_0000673', 'EFO_0003868', 'MONDO_0018906']",False,False,17,,,
638,VINORELBINE TARTRATE,CHEMBL538943,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691', 'MONDO_0004992', 'EFO_0006861', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0021063', 'EFO_0000183', 'EFO_0000313', 'MONDO_0008315', 'EFO_0000437', 'MONDO_0002367', 'EFO_0000616', 'EFO_0000621', 'EFO_0000248', 'EFO_1000158', 'MONDO_0001187', 'EFO_0003869', 'EFO_0000565', 'MONDO_0008903', 'EFO_0001416', 'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'MONDO_0007254', 'EFO_0000574']",True,False,28,Tubulin inhibitor ,INHIBITOR ,protein complex group 
639,CEFACLOR,CHEMBL680,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 9 approved and 1 investigational indication.,,4.0,,False,1979,[],"['EFO_0004992', 'EFO_0003103', 'EFO_0009582', 'EFO_0003106', 'MONDO_0002258', 'EFO_0000544', 'HP_0011110', 'EFO_0006505', 'EFO_0003102', 'EFO_0000771']",False,False,10,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
640,PSEUDOEPHEDRINE,CHEMBL1590,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 10 approved and 13 investigational indications.,,4.0,,False,1963,['ENSG00000103546'],"['EFO_0003843', 'EFO_1001417', 'EFO_0003956', 'EFO_0007533', 'MONDO_0005271', 'EFO_0005854', 'EFO_0007328', 'EFO_0007214', 'MONDO_0005277', 'MONDO_0024290', 'HP_0012735', 'EFO_0005252', 'HP_0001742', 'EFO_1001050', 'EFO_0005854', 'HP_0001742', 'MONDO_0024355', 'EFO_0003956', 'MP_0001845', 'EFO_0008521', 'EFO_0005854', 'EFO_0007486', 'EFO_0007214', 'HP_0012735', 'EFO_0003956', 'MONDO_0005271']",False,False,26,Norepinephrine transporter releasing agent ,RELEASING AGENT ,single protein 
641,SIFALIMUMAB,CHEMBL1743069,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000120235', 'ENSG00000120242', 'ENSG00000147873', 'ENSG00000186803', 'ENSG00000188379', 'ENSG00000197919', 'ENSG00000233816', 'ENSG00000214042', 'ENSG00000137080', 'ENSG00000147885', 'ENSG00000228083', 'ENSG00000234829', 'ENSG00000236637']","['EFO_0000676', 'EFO_0000398', 'MONDO_0007915']",False,True,3,Interferon alpha inhibitor ,INHIBITOR ,protein family 
642,VEDOLIZUMAB,CHEMBL1743087,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 8 investigational indications.,,4.0,,False,2014,"['ENSG00000115232', 'ENSG00000139626']","['EFO_0000544', 'EFO_0000764', 'EFO_0000756', 'EFO_0003767', 'EFO_0001060', 'EFO_0000180', 'EFO_0003872', 'MONDO_0005147', 'EFO_0000540', 'EFO_0000384', 'EFO_0000729']",False,True,11,Integrin alpha-4/beta-7 inhibitor ,INHIBITOR ,protein complex 
643,DABRAFENIB,CHEMBL2028663,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 7 approved and 18 investigational indications.,,4.0,,False,2013,['ENSG00000157764'],"['EFO_1000926', 'EFO_0002892', 'EFO_0000756', 'EFO_0003833', 'EFO_0002892', 'EFO_0003086', 'MONDO_0002108', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0008903', 'MONDO_0002108', 'EFO_0002617', 'EFO_0002617', 'EFO_1000926', 'EFO_0000389', 'MONDO_0100342', 'EFO_0000501', 'EFO_0000756', 'EFO_0000641', 'MONDO_0017795', 'EFO_0000616', 'EFO_0001378', 'EFO_0001421', 'EFO_0001378', 'EFO_0006772', 'EFO_0000389']",False,True,26,Serine/threonine-protein kinase B-raf inhibitor ,INHIBITOR ,single protein 
644,CONTUSUGENE LADENOVEC,CHEMBL2108585,Gene drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000141510'],"['EFO_1000158', 'MONDO_0002691', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0007254', 'EFO_0006859', 'MONDO_0004986', 'MONDO_0008170', 'EFO_0003060']",False,True,9,Cellular tumor antigen p53 positive modulator ,POSITIVE MODULATOR ,single protein 
645,ING-1,CHEMBL2109263,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000119888'],['EFO_0000228'],False,False,1,Epithelial cell adhesion molecule other ,OTHER ,single protein 
646,ANETUMAB RAVTANSINE,CHEMBL2109629,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000102854'],"['EFO_0000770', 'EFO_0003060', 'EFO_0002618', 'MONDO_0004992', 'EFO_0000616', 'EFO_0003893', 'MONDO_0021117', 'EFO_0000588']",False,False,8,Mesothelin binding agent ,BINDING AGENT ,single protein 
647,RALIMETINIB,CHEMBL2364626,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000112062'],"['MONDO_0008170', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0000519', 'MONDO_0007254']",True,False,5,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
648,ALVESPIMYCIN,CHEMBL383824,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['MONDO_0001023', 'EFO_0000095', 'MONDO_0007254', 'EFO_0000616']",False,False,4,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
649,AMONAFIDE,CHEMBL428676,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000222', 'MONDO_0007254', 'MONDO_0008315']",False,False,3,,,
650,MUPARFOSTAT,CHEMBL4297163,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000112715', 'ENSG00000173083', 'ENSG00000113578', 'ENSG00000138685']","['EFO_0003060', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000756', 'EFO_0000182', 'MONDO_0008315']",True,False,6,Basic fibroblast growth factor inhibitor Acidic fibroblast growth factor inhibitor Heparanase inhibitor Vascular endothelial growth factor A inhibitor ,INHIBITOR ,single protein 
651,DAROLUTAMIDE,CHEMBL4297185,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 approved and 1 investigational indication.,,4.0,,False,2019,['ENSG00000169083'],"['EFO_0001663', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0004992', 'EFO_0000673', 'EFO_0000196']",True,False,7,Androgen Receptor antagonist ,ANTAGONIST ,single protein 
652,HILTONOL,CHEMBL4297559,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 37 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008170', 'EFO_0001378', 'EFO_0000479', 'EFO_0000199', 'EFO_0003060', 'EFO_0000616', 'MONDO_0008315', 'EFO_0005543', 'EFO_0000632', 'MONDO_0007254', 'EFO_0000305', 'EFO_0002618', 'MONDO_0044903', 'EFO_1000984', 'EFO_0000182', 'EFO_0002913', 'EFO_0001075', 'EFO_0000756', 'EFO_0000222', 'EFO_0000574', 'MONDO_0004992', 'EFO_0000272', 'MONDO_0100342', 'MONDO_0001187', 'MONDO_0002158', 'EFO_0001071', 'EFO_0000389', 'EFO_0000544', 'EFO_1000158', 'EFO_0003833', 'EFO_0000588', 'EFO_0000519', 'EFO_0000630', 'MONDO_0018906', 'EFO_0000180', 'EFO_0005537', 'EFO_0002617']",False,False,37,,,
653,FLUOROESTRADIOL F-18,CHEMBL4594261,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for breast cancer.,,4.0,,False,2020,[],['MONDO_0007254'],False,False,1,,,
654,AFIMOXIFENE,CHEMBL489,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000196482', 'ENSG00000140009', 'ENSG00000091831']","['MONDO_0007254', 'EFO_0000432', 'EFO_1001366']",False,True,3,Estrogen receptor modulator Estrogen-related receptor gamma antagonist ,MODULATOR ANTAGONIST ,protein family single protein 
655,FEXOFENADINE,CHEMBL914,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 12 investigational indications.,,4.0,,False,1996,['ENSG00000196639'],"['EFO_0000401', 'EFO_0003060', 'MONDO_0005271', 'EFO_0004253', 'EFO_0000274', 'EFO_0009373', 'EFO_1001417', 'HP_0000989', 'MONDO_0005271', 'EFO_0003956', 'EFO_0005854', 'EFO_0003956', 'EFO_0005531', 'MONDO_0004979', 'EFO_0000685', 'EFO_0003948', 'EFO_1001417']",True,False,17,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
656,K-777,CHEMBL91704,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
657,LEVOSALBUTAMOL,CHEMBL1002,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for asthma and has 3 investigational indications.,,4.0,,False,1999,['ENSG00000169252'],"['HP_0025428', 'MONDO_0004979', 'MONDO_0004979', 'MONDO_0004979', 'EFO_0000341']",False,False,5,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
658,TRIFLURIDINE,CHEMBL1129,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 8 approved and 7 investigational indications.,,4.0,,False,1980,[],"['MONDO_0044937', 'MONDO_0004768', 'EFO_1001951', 'EFO_0003869', 'EFO_0005221', 'MONDO_0007576', 'EFO_1000657', 'EFO_1002022', 'EFO_0004142', 'EFO_1001888', 'MONDO_0021063', 'MONDO_0005575', 'EFO_0000616', 'EFO_0000365', 'MONDO_0007254']",False,False,15,,,
659,TERBUTALINE,CHEMBL1760,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1974,['ENSG00000169252'],"['HP_0006536', 'HP_0025428', 'EFO_0000341', 'MONDO_0004979', 'EFO_0009661', 'EFO_0005762', 'EFO_0007160', 'EFO_0000341', 'MONDO_0004979', 'MONDO_0005147']",False,False,10,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
660,ONAPRISTONE,CHEMBL1908373,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.,,4.0,,False,no approval year,['ENSG00000082175'],"['EFO_0000616', 'EFO_0000196', 'MONDO_0007254']",False,False,3,Progesterone receptor antagonist ,ANTAGONIST ,single protein 
661,F16IL2,CHEMBL2109583,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000041982'],"['EFO_0000222', 'EFO_1001471', 'MONDO_0007254', 'EFO_0003060']",False,False,4,Tenascin other ,OTHER ,single protein 
662,CENICRIVIROC,CHEMBL2110727,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,"['ENSG00000121807', 'ENSG00000160791']","['EFO_1001249', 'EFO_0003095', 'EFO_0000180', 'EFO_0000180', 'EFO_0000544', 'EFO_0001421', 'EFO_0000764', 'MONDO_0100096', 'EFO_0004268']",True,False,9,C-C chemokine receptor type 2 antagonist C-C chemokine receptor type 5 antagonist ,ANTAGONIST ,single protein 
663,IDELALISIB,CHEMBL2216870,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000171608'],"['EFO_1001469', 'EFO_0000183', 'EFO_0005952', 'MONDO_0018906', 'MONDO_0044903', 'EFO_0005854', 'EFO_0000616', 'EFO_0000574', 'MONDO_0004992', 'EFO_0000403', 'EFO_0002517', 'EFO_0000222', 'EFO_0000095', 'EFO_0001378', 'MONDO_0000432', 'EFO_0009441', 'EFO_1001875', 'EFO_0000096', 'EFO_0000220']",True,False,19,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
664,ACUMAPIMOD,CHEMBL3545226,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000112062'],['EFO_0000341'],False,False,1,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
665,FORMOTEROL FUMARATE,CHEMBL3989798,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 8 investigational indications.,,4.0,,False,2001,['ENSG00000169252'],"['EFO_0009661', 'EFO_0000341', 'MONDO_0004979', 'MONDO_0100096', 'EFO_1000637', 'MONDO_0005271', 'MONDO_0008903', 'HP_0025428', 'HP_0002110', 'EFO_0006505', 'EFO_0003768', 'EFO_0000464', 'EFO_0007183']",True,False,13,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
666,COBALAMIN,CHEMBL4297272,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
667,BALOXAVIR MARBOXIL,CHEMBL4297503,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for viral disease and influenza.,,4.0,,False,2018,[],"['EFO_0000763', 'EFO_0007328']",False,False,2,Polymerase acidic protein inhibitor ,INHIBITOR ,single protein 
668,IRON ISOMALTOSIDE 1000,CHEMBL4298046,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0009579', 'HP_0001891', 'MONDO_0004992', 'EFO_0003767', 'EFO_0004270', 'EFO_0003884', 'EFO_0004272']",False,False,7,,,
669,TAFASITAMAB,CHEMBL4298047,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 6 investigational indications.,,4.0,,False,2020,['ENSG00000177455'],"['EFO_0000403', 'EFO_0000095', 'MONDO_0001023', 'EFO_0000574', 'EFO_0000096', 'MONDO_0018906', 'EFO_0005952', 'EFO_0000616', 'EFO_0000220']",False,False,9,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
670,MESMULOGENE ANCOVACIVEC,CHEMBL4650517,Gene drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
671,ENALAPRIL,CHEMBL578,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,['ENSG00000159640'],"['HP_0000093', 'EFO_0000537', 'EFO_1001482', 'EFO_0003144', 'EFO_0003884', 'EFO_0000668', 'EFO_0001378', 'EFO_0003106', 'EFO_1001375', 'EFO_0000280', 'MONDO_0005147', 'EFO_0007328', 'EFO_0003144', 'EFO_0000756', 'EFO_0000373', 'MONDO_0004992', 'EFO_0008585', 'EFO_0005529', 'MONDO_0100096', 'EFO_0005669', 'EFO_0000318', 'EFO_0000222', 'MONDO_0018638', 'EFO_0004289', 'EFO_0000712', 'EFO_0000537', 'EFO_0004194', 'MONDO_0001134', 'EFO_0004234', 'EFO_0000319', 'EFO_0000556', 'EFO_0000373', 'EFO_0000685', 'EFO_0003777']",False,False,34,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
672,PEGINTERFERON ALFA-2A,CHEMBL1201560,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 23 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,"['ENSG00000142166', 'ENSG00000159110']","['EFO_0002430', 'HP_0012115', 'HP_0001873', 'EFO_0004220', 'EFO_0002429', 'EFO_0001378', 'MONDO_0002050', 'EFO_0000479', 'MONDO_0021063', 'EFO_0004239', 'EFO_0000756', 'EFO_0001422', 'MONDO_0007254', 'EFO_1000026', 'EFO_0004197', 'MONDO_0002367', 'EFO_0000544', 'EFO_0000182', 'EFO_0008496', 'MONDO_0044903', 'EFO_0000095', 'EFO_0000339', 'EFO_0007304', 'EFO_0000764', 'EFO_0003047', 'MONDO_0004992', 'EFO_1000874', 'EFO_0000616']",True,False,28,Interferon alpha/beta receptor agonist ,AGONIST ,protein complex 
673,TEPLIZUMAB,CHEMBL1743078,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000198851'],"['EFO_0002546', 'MONDO_0005147', 'EFO_0000676']",False,False,3,T-cell surface glycoprotein CD3 epsilon chain other ,OTHER ,single protein 
674,TOFACITINIB CITRATE,CHEMBL2103743,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['MONDO_0019558', 'EFO_0003778', 'MONDO_0007915', 'EFO_0000685', 'EFO_0000274']",True,True,5,Janus Kinase (JAK) inhibitor ,INHIBITOR ,protein family 
675,TGN-1412,CHEMBL2109250,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000178562'],"['EFO_0000616', 'MONDO_0007915', 'EFO_0000685', 'EFO_1001494']",True,False,4,T-cell-specific surface glycoprotein CD28 agonist ,AGONIST ,single protein 
676,ANGIOTENSIN,CHEMBL2391146,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000537', 'EFO_0003884']",False,False,2,,,
677,LAS190792,CHEMBL3545272,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,"['ENSG00000133019', 'ENSG00000169252']","['EFO_0000341', 'MONDO_0004979']",True,True,2,Muscarinic acetylcholine receptor M3 antagonist Beta-2 adrenergic receptor agonist ,ANTAGONIST AGONIST ,single protein 
678,CITARINOSTAT,CHEMBL3693786,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0000756', 'EFO_0003060', 'EFO_0001378']",False,False,4,,,
679,FORIGERIMOD ACETATE,CHEMBL3989801,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000109971'],['MONDO_0007915'],False,False,1,Heat shock cognate 71 kDa protein inhibitor ,INHIBITOR ,single protein 
680,SURAMIN HEXASODIUM,CHEMBL413376,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,['ENSG00000113578'],"['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113', 'EFO_1000796', 'HP_0001919', 'EFO_0000673', 'MONDO_0001187', 'EFO_0005044', 'EFO_0007294', 'EFO_0003060', 'EFO_0003756', 'EFO_0001378', 'EFO_1000158', 'EFO_1001951']",False,False,15,Acidic fibroblast growth factor inhibitor ,INHIBITOR ,single protein 
681,APG-2575,CHEMBL4650374,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000171791'],"['EFO_0001378', 'EFO_0000220', 'EFO_1001875', 'EFO_0009441', 'EFO_0004289', 'EFO_0000095', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000222']",True,False,9,Apoptosis regulator Bcl-2 inhibitor ,INHIBITOR ,single protein 
682,TOREMIFENE CITRATE,CHEMBL1200675,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,"['ENSG00000140009', 'ENSG00000091831']","['EFO_0003869', 'EFO_0003931', 'EFO_0000305', 'EFO_0003882', 'MONDO_0007254']",False,True,5,Estrogen receptor modulator ,MODULATOR ,protein family 
683,INDOCYANINE GREEN,CHEMBL1201304,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 22 investigational indications.,,4.0,,False,1959,[],"['MONDO_0008903', 'EFO_0001061', 'MONDO_0019297', 'EFO_0000685', 'EFO_0003897', 'EFO_1001951', 'MONDO_0021117', 'EFO_0000389', 'MONDO_0001056', 'MONDO_0002635', 'EFO_0000681', 'EFO_1000984', 'EFO_0000649', 'MONDO_0007254', 'MONDO_0018309', 'EFO_0003833', 'EFO_1001512', 'EFO_0003060', 'EFO_0000305', 'MONDO_0002038', 'EFO_0003820', 'EFO_1001028']",False,False,22,,,
684,FORETINIB,CHEMBL1230609,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000120156', 'ENSG00000122025', 'ENSG00000105976', 'ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['MONDO_0007254', 'EFO_0000182', 'EFO_0005950', 'MONDO_0008903', 'EFO_0000616', 'EFO_0000681', 'MONDO_0004992']",True,False,7,Tyrosine-protein kinase TIE-2 inhibitor Hepatocyte growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein complex protein family 
685,IMEXON,CHEMBL146428,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000756', 'MONDO_0000432', 'EFO_0003860', 'EFO_0003060', 'EFO_0000095', 'EFO_0001378', 'EFO_0000309', 'MONDO_0018906', 'EFO_0009708', 'EFO_1001469', 'EFO_0000403']",False,False,11,,,
686,CAPECITABINE,CHEMBL1773,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 75 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000176890'],"['EFO_0000182', 'EFO_0001075', 'EFO_0007456', 'EFO_1000657', 'MONDO_0044937', 'EFO_0002938', 'EFO_1001893', 'EFO_0000228', 'EFO_0005774', 'EFO_1001901', 'EFO_0000181', 'EFO_0002617', 'EFO_0002517', 'EFO_0006352', 'MONDO_0021063', 'MONDO_0002691', 'MONDO_0002165', 'MONDO_0002158', 'EFO_1001471', 'EFO_0003860', 'MONDO_0001657', 'EFO_1001949', 'EFO_0000503', 'EFO_0000365', 'EFO_1000158', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0005221', 'EFO_0006859', 'EFO_0003869', 'EFO_0005543', 'MONDO_0002974', 'EFO_0000588', 'EFO_1000251', 'MONDO_0100342', 'EFO_0005922', 'EFO_1001951', 'MONDO_0002087', 'EFO_0003891', 'EFO_0000681', 'MONDO_0002367', 'EFO_0009259', 'EFO_1000984', 'EFO_0008528', 'EFO_0000305', 'MONDO_0004992', 'EFO_0003060', 'EFO_0005537', 'MONDO_0008315', 'EFO_1001956', 'MONDO_0001056', 'MONDO_0002108', 'MONDO_0044926', 'MONDO_0007576', 'EFO_0007416', 'EFO_0000389', 'MONDO_0005575', 'EFO_0000178', 'EFO_0000707', 'EFO_1000045', 'EFO_0004288', 'EFO_0000616', 'EFO_0000519', 'MONDO_0005411', 'EFO_0009708', 'EFO_0004284', 'MONDO_0001879', 'EFO_0002618', 'EFO_1001961', 'MONDO_0003060', 'EFO_0005952', 'EFO_0002916', 'EFO_0000313', 'EFO_0006861', 'EFO_0000756', 'EFO_0003865', 'MONDO_0008170', 'EFO_0003897', 'EFO_0004142', 'MONDO_0002120', 'MONDO_0002898', 'EFO_0004252']",True,False,82,Thymidylate synthase inhibitor ,INHIBITOR ,single protein 
687,ISEGANAN HYDROCHLORIDE,CHEMBL2105862,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003106', 'EFO_1001904']",False,False,2,,,
688,MEPOLIZUMAB,CHEMBL2108429,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 8 investigational indications.,,4.0,,False,2015,['ENSG00000113525'],"['EFO_0004232', 'EFO_0005297', 'EFO_0005531', 'EFO_0000341', 'EFO_0007208', 'EFO_0000274', 'EFO_1000024', 'HP_0001880', 'HP_0006536', 'EFO_1001467', 'EFO_0006803', 'EFO_1000391', 'MONDO_0004979']",False,False,13,Interleukin-5 inhibitor ,INHIBITOR ,single protein 
689,BIIB-022,CHEMBL2109356,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,['ENSG00000140443'],"['EFO_0000616', 'EFO_0003060', 'EFO_0000182']",False,False,3,Insulin-like growth factor I receptor inhibitor ,INHIBITOR ,single protein 
690,APATORSEN,CHEMBL3039556,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000106211'],"['EFO_0000708', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0002618', 'EFO_0000616', 'EFO_0003060']",True,False,6,Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
691,TEMOPORFIN,CHEMBL383675,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 7 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000616', 'EFO_0000313', 'EFO_0006859', 'EFO_0005540', 'EFO_0000181', 'EFO_1001959', 'EFO_0004252']",False,False,8,,,
692,HYDROCORTISONE,CHEMBL389621,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 12 approved and 70 investigational indications.,,4.0,,False,1952,['ENSG00000113580'],"['EFO_0004251', 'MONDO_0019460', 'EFO_0000221', 'MONDO_0100096', 'MONDO_0002406', 'MONDO_0000873', 'EFO_0005251', 'EFO_0000278', 'EFO_0000223', 'EFO_0003027', 'EFO_0003811', 'EFO_0000673', 'EFO_0000094', 'EFO_0000274', 'EFO_1000796', 'EFO_0000403', 'EFO_0009491', 'EFO_0000764', 'MONDO_0015540', 'MONDO_0008728', 'EFO_0007541', 'EFO_0009492', 'HP_0012076', 'EFO_0000275', 'EFO_0001072', 'EFO_0003032', 'EFO_0000574', 'MONDO_0004992', 'EFO_0000546', 'MONDO_0000870', 'EFO_0000198', 'EFO_0000384', 'EFO_0009444', 'EFO_0000220', 'GO_0007568', 'EFO_0005687', 'EFO_0000612', 'EFO_1001779', 'EFO_0000756', 'MONDO_0015129', 'MONDO_0005178', 'EFO_0001378', 'MONDO_0005147', 'EFO_0000565', 'MP_0001845', 'EFO_0001073', 'EFO_0003768', 'EFO_0003025', 'MONDO_0007079', 'HP_0001742', 'HP_0100806', 'EFO_0000544', 'EFO_0005752', 'EFO_0000209', 'EFO_0005611', 'EFO_1000158', 'MONDO_0015128', 'EFO_0007141', 'EFO_0003106', 'EFO_0009560', 'EFO_0006834', 'MONDO_0004979', 'MONDO_0019091', 'EFO_0009552', 'EFO_1001494', 'EFO_0001422', 'EFO_0000218', 'EFO_0004192', 'EFO_1001818', 'EFO_0003144', 'EFO_0007359', 'MONDO_0018479', 'MONDO_0008315', 'EFO_0010702', 'EFO_0007328', 'EFO_1001908', 'HP_0000964', 'EFO_1001347', 'EFO_0002614', 'EFO_0000729', 'EFO_0003802', 'EFO_0000222']",True,False,82,Glucocorticoid receptor agonist ,AGONIST ,single protein 
693,OBATOCLAX,CHEMBL408194,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,"['ENSG00000143384', 'ENSG00000171791', 'ENSG00000258643', 'ENSG00000129473', 'ENSG00000140379', 'ENSG00000171552', 'ENSG00000137875']","['EFO_1001469', 'EFO_0000702', 'EFO_0000702', 'MONDO_0001023', 'EFO_0000222', 'EFO_0000183', 'EFO_0000095', 'MONDO_0044903', 'EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'MONDO_0008903', 'EFO_0002617', 'EFO_0000403', 'MONDO_0018906']",True,False,15,Bcl-2-like protein 10 inhibitor Apoptosis regulator Bcl-2 inhibitor Bcl-2-related protein A1 inhibitor Apoptosis regulator Bcl-X inhibitor Apoptosis regulator Bcl-W inhibitor Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor ,INHIBITOR ,single protein 
694,AR-105,CHEMBL4297696,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003106'],False,False,1,,,
695,FRUQUINTINIB,CHEMBL4303214,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_0002618', 'EFO_1001968', 'MONDO_0001056', 'EFO_1001951', 'MONDO_0007254', 'EFO_0001421', 'MONDO_0011962', 'EFO_0000616', 'EFO_0003060', 'MONDO_0021063', 'MONDO_0008903', 'EFO_0003086', 'EFO_1000657', 'EFO_0000365', 'EFO_0004142']",True,False,15,Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,protein family 
696,SOTROVIMAB,CHEMBL4650524,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000694', 'MONDO_0100096']",False,False,2,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
697,MORPHINE HYDROCHLORIDE,CHEMBL556578,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000768', 'EFO_0000341', 'EFO_0005611', 'EFO_0003843']",False,False,4,,,
698,ERLOTINIB HYDROCHLORIDE,CHEMBL1079742,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 50 investigational indications.,,4.0,,False,2004,['ENSG00000146648'],"['EFO_0003060', 'EFO_0005537', 'EFO_0002501', 'EFO_0000632', 'EFO_0002618', 'MONDO_0002158', 'EFO_0000691', 'MONDO_0007576', 'MONDO_0002974', 'EFO_0005567', 'EFO_0000181', 'MONDO_0004992', 'MONDO_0002367', 'MONDO_0001187', 'EFO_0001422', 'EFO_0000616', 'MONDO_0003268', 'EFO_0000519', 'EFO_1001465', 'EFO_1000657', 'EFO_0000305', 'MONDO_0021063', 'MONDO_0000521', 'EFO_0000182', 'MONDO_0044926', 'MONDO_0008903', 'MONDO_0004986', 'MONDO_0008315', 'EFO_0006859', 'EFO_1000158', 'MONDO_0002898', 'Orphanet_733', 'MONDO_0011962', 'EFO_0000681', 'EFO_0000313', 'EFO_0000756', 'EFO_0003050', 'EFO_0003833', 'EFO_0002499', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0008170', 'EFO_0000588', 'MONDO_0020634', 'EFO_0000308', 'EFO_0000571', 'EFO_0000640', 'EFO_0000365', 'MONDO_0002087', 'MONDO_0002691', 'EFO_0000708']",False,True,51,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
699,CAPTOPRIL,CHEMBL1560,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,['ENSG00000159640'],"['EFO_0005755', 'EFO_0003106', 'EFO_0000537', 'EFO_0000373', 'EFO_1002048', 'EFO_0001361', 'EFO_0002430', 'MONDO_0005148', 'EFO_0000519', 'EFO_0003777', 'EFO_0000616', 'EFO_0000612', 'MONDO_0100096', 'EFO_0000401', 'EFO_0000319', 'EFO_0003770', 'EFO_0003144']",True,False,17,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
700,FORALUMAB,CHEMBL1743020,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']","['EFO_0008520', 'EFO_0000384', 'EFO_0008522', 'EFO_0004599', 'MONDO_0100096']",True,False,5,T cell surface glycoprotein CD3 inhibitor ,INHIBITOR ,protein complex 
701,RAFUTROMBOPAG,CHEMBL4594401,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000117400'],"['EFO_0001421', 'EFO_0000198', 'HP_0001915', 'EFO_0007160', 'HP_0001873', 'MONDO_0007254']",False,False,6,Thrombopoietin receptor agonist ,AGONIST ,single protein 
702,INDOMETHACIN,CHEMBL6,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 12 approved and 23 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1965,"['ENSG00000073756', 'ENSG00000095303']","['MONDO_0003937', 'EFO_0000278', 'EFO_0000199', 'MONDO_0004979', 'EFO_0000685', 'EFO_1001412', 'EFO_0005755', 'EFO_1000652', 'EFO_0010072', 'MONDO_0004975', 'MONDO_0005178', 'MONDO_0100096', 'HP_0002829', 'EFO_1000318', 'EFO_0005252', 'MONDO_0007254', 'EFO_0003843', 'MP_0001914', 'Orphanet_79292', 'EFO_0003898', 'EFO_0003917', 'MP_0001845', 'EFO_0000181', 'MONDO_0024475', 'EFO_0000196', 'EFO_0000342', 'HP_0001643', 'EFO_0000319', 'HP_0003326', 'EFO_0004274', 'EFO_0005752', 'MP_0001845', 'MONDO_0008315', 'EFO_0000389', 'EFO_0000673']",True,False,35,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
703,SEVELAMER CARBONATE,CHEMBL1201799,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic kidney disease and has 4 investigational indications.,,4.0,,False,2007,[],"['HP_0002905', 'EFO_0000401', 'EFO_0000180', 'EFO_1002048', 'EFO_0003884']",False,False,5,,,
704,GIVINOSTAT,CHEMBL1213492,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000183', 'EFO_0002429', 'EFO_0000384', 'MONDO_0010311', 'MONDO_0010679', 'MONDO_0016899', 'EFO_0001378', 'EFO_0004251', 'EFO_0000095', 'EFO_0002609']",False,False,10,,,
705,ALFUZOSIN HYDROCHLORIDE,CHEMBL1723,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 2 investigational indications.,,4.0,,False,2003,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0000284', 'EFO_1001228', 'EFO_0004253']",False,False,3,Adrenergic receptor alpha-1 agonist ,AGONIST ,protein family 
706,AMPICILLIN,CHEMBL174,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 8 approved and 8 investigational indications.,,4.0,,False,1965,[],"['DOID_7551', 'EFO_0000544', 'EFO_0000584', 'EFO_1000831', 'HP_0100806', 'EFO_0003106', 'MONDO_0003441', 'EFO_1001888', 'HP_0100806', 'EFO_1000831', 'EFO_0000764', 'EFO_1001272', 'EFO_0000771', 'EFO_0009948', 'EFO_0000465', 'HP_0000175', 'EFO_0003102', 'EFO_0000544']",False,False,18,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
707,RILOTUMUMAB,CHEMBL1743063,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000019991'],"['EFO_0000702', 'MONDO_0100342', 'EFO_0000681', 'EFO_0000708', 'EFO_0000588', 'MONDO_0001056', 'MONDO_0008315', 'EFO_1001465']",False,False,8,Hepatocyte growth factor inhibitor ,INHIBITOR ,single protein 
708,INFIGRATINIB,CHEMBL1852688,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 11 investigational indications.,,4.0,,False,2021,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']","['EFO_0001668', 'EFO_0000616', 'MONDO_0044704', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0005221', 'MONDO_0007037', 'EFO_0005221', 'EFO_1002027', 'EFO_0000519', 'MONDO_0001187', 'MONDO_0011719', 'EFO_0000756', 'EFO_0001061']",True,True,14,Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family 
709,M170,CHEMBL2109523,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0008315', 'MONDO_0007254']",False,False,2,,,
710,ALECTINIB HYDROCHLORIDE,CHEMBL3707320,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for non-small cell lung carcinoma.,,4.0,,False,2015,"['ENSG00000171094', 'ENSG00000165731', 'ENSG00000143924']",['EFO_0003060'],False,False,1,Tyrosine-protein kinase receptor RET inhibitor ALK tyrosine kinase receptor inhibitor EML4-ALK ,INHIBITOR ,single protein chimeric protein 
711,BRAZIKUMAB,CHEMBL3833372,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113302', 'ENSG00000110944']","['EFO_0000384', 'EFO_0000729']",False,True,2,Interleukin-23 inhibitor ,INHIBITOR ,protein complex 
712,FGFR INHIBITOR DEBIO 1347,CHEMBL3907479,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000077782', 'ENSG00000068078', 'ENSG00000066468']","['MONDO_0007254', 'EFO_0000616']",True,True,2,Fibroblast growth factor receptor 1 inhibitor Fibroblast growth factor receptor 3 inhibitor Fibroblast growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
713,TERAZOSIN HYDROCHLORIDE,CHEMBL3989562,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for benign prostatic hyperplasia.,,4.0,,False,1987,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']",['EFO_0000284'],False,False,1,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
714,ANLOTINIB,CHEMBL4303201,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 53 investigational indications.,,3.0,,False,no approval year,"['ENSG00000037280', 'ENSG00000157404', 'ENSG00000128052', 'ENSG00000113721']","['EFO_0003108', 'MONDO_0002108', 'EFO_0000702', 'EFO_0000616', 'EFO_0003860', 'EFO_0000691', 'MONDO_0004992', 'EFO_0003820', 'EFO_0002618', 'EFO_0000564', 'EFO_0000313', 'EFO_1001972', 'EFO_0003060', 'EFO_0000333', 'MONDO_0005575', 'EFO_0000574', 'EFO_0001071', 'MONDO_0007254', 'EFO_0004252', 'MONDO_0011719', 'EFO_0001376', 'MONDO_0003060', 'EFO_1001512', 'EFO_0003869', 'MONDO_0002912', 'EFO_1001951', 'EFO_0000174', 'MONDO_0002367', 'EFO_0005221', 'EFO_0002916', 'EFO_0000756', 'EFO_1000657', 'MONDO_0024503', 'MONDO_0100342', 'EFO_0005537', 'EFO_0000681', 'EFO_0007143', 'MONDO_0008170', 'MONDO_0021117', 'MONDO_0011962', 'MONDO_0001056', 'EFO_0000621', 'MONDO_0002974', 'EFO_0000707', 'MONDO_0015277', 'EFO_0005922', 'EFO_0000588', 'EFO_0000403', 'EFO_0000182', 'EFO_0000519', 'EFO_1001968', 'EFO_0000181', 'MONDO_0008903']",True,False,53,Vascular endothelial growth factor receptor 3 inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor beta inhibitor Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
715,GOSSYPOL,CHEMBL51483,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
716,DOCETAXEL,CHEMBL92,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 108 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0011719', 'EFO_0003897', 'EFO_0005537', 'HP_0002039', 'EFO_0000313', 'MONDO_0002158', 'EFO_0000466', 'EFO_0006859', 'EFO_0002428', 'EFO_0000756', 'EFO_0000503', 'EFO_0000198', 'MONDO_0001056', 'MONDO_0002974', 'EFO_0004281', 'MONDO_0021117', 'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0007355', 'EFO_0003865', 'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'MONDO_0004986', 'MONDO_0002367', 'MONDO_0008903', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000637', 'MONDO_0001187', 'MONDO_0001528', 'EFO_0000432', 'MONDO_0008315', 'HP_0004326', 'MONDO_0002087', 'MONDO_0002038', 'EFO_0000228', 'EFO_0000181', 'EFO_0001416', 'MONDO_0003060', 'EFO_0000199', 'MONDO_0018364', 'MONDO_0002691', 'EFO_0009708', 'EFO_0004230', 'EFO_1001951', 'EFO_0003893', 'MONDO_0005271', 'EFO_0006911', 'EFO_0008528', 'HP_0012378', 'MONDO_0000521', 'MONDO_0007254', 'EFO_1000043', 'MONDO_0011962', 'EFO_0003891', 'MONDO_0005575', 'MONDO_0004192', 'MONDO_0021310', 'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'EFO_0000691', 'MONDO_0007576', 'Orphanet_145', 'EFO_0000564', 'EFO_0003869', 'EFO_0001663', 'MONDO_0001475', 'EFO_0004252', 'EFO_0001376', 'EFO_1000984', 'EFO_0000196', 'EFO_1000601', 'EFO_0003817', 'MONDO_0021355', 'EFO_0006352', 'MONDO_0004669', 'EFO_0000182', 'EFO_0004284', 'EFO_0000708', 'MONDO_0002120', 'MONDO_0001325', 'EFO_0001075', 'EFO_0002618', 'EFO_0000305', 'EFO_0000174', 'EFO_0000616', 'EFO_0000565', 'EFO_0000702', 'EFO_0003060', 'EFO_1001931', 'EFO_0005577', 'MONDO_0003199', 'EFO_0000574', 'EFO_1001100', 'EFO_0000673', 'EFO_1001214', 'EFO_0003860', 'MONDO_0004992', 'EFO_0000707', 'EFO_0005570', 'EFO_0007362', 'EFO_1000595', 'EFO_0003859', 'EFO_0002916', 'EFO_0005088', 'MONDO_0021063', 'EFO_0000178', 'EFO_0002938', 'EFO_0001378', 'EFO_0000571', 'MONDO_0001402']",True,False,114,Tubulin inhibitor ,INHIBITOR ,protein complex group 
717,BUPIVACAINE,CHEMBL1098,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and hernia and has 72 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1972,['ENSG00000007314'],"['EFO_0003833', 'EFO_0000546', 'HP_0001623', 'HP_0002315', 'EFO_0005251', 'MONDO_0000728', 'EFO_0007490', 'HP_0000175', 'EFO_0003060', 'EFO_0002950', 'HP_0000023', 'EFO_1001792', 'EFO_1000994', 'EFO_0004229', 'EFO_0009615', 'EFO_1000786', 'EFO_1001250', 'EFO_0000342', 'EFO_1001267', 'HP_0001537', 'EFO_1001909', 'EFO_0003869', 'EFO_0009676', 'EFO_0003964', 'MONDO_0002087', 'EFO_0003931', 'HP_0012227', 'EFO_0010072', 'EFO_0005762', 'HP_0012532', 'EFO_0004888', 'EFO_1001331', 'MONDO_0005277', 'HP_0009926', 'EFO_0004616', 'EFO_0004209', 'EFO_0003843', 'EFO_0002618', 'EFO_0003818', 'MONDO_0004992', 'EFO_0001358', 'HP_0030834', 'MONDO_0021117', 'EFO_0000691', 'EFO_1001139', 'HP_0001822', 'MONDO_0008315', 'HP_0002027', 'EFO_0009620', 'MONDO_0004567', 'EFO_0000764', 'MONDO_0005178', 'HP_0000175', 'EFO_1001087', 'HP_0100790', 'HP_0012735', 'EFO_0000275', 'HP_0012532', 'MONDO_0007254', 'EFO_0009314', 'MONDO_0002959', 'HP_0001822', 'EFO_0005323', 'HP_0031217', 'EFO_0001421', 'EFO_0007149', 'MP_0001914', 'EFO_0000616', 'EFO_0009552', 'EFO_1001968', 'EFO_0000546', 'EFO_0009552', 'MONDO_0004992', 'HP_0003419', 'EFO_0007486', 'MONDO_0005178', 'HP_0000023', 'EFO_0000764', 'EFO_1001898', 'EFO_0003843']",False,False,80,Sodium channel protein type IV alpha subunit blocker ,BLOCKER ,single protein 
718,CEPHALEXIN,CHEMBL1200544,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 12 investigational indications.,,4.0,,False,1971,[],"['EFO_0005681', 'EFO_0000701', 'EFO_0000771', 'EFO_0009582', 'MONDO_0001187', 'MONDO_0007254', 'HP_0001742', 'EFO_0000222', 'EFO_0000274', 'EFO_0003830', 'EFO_0003103', 'EFO_1000781', 'EFO_0000544', 'MONDO_0009061', 'HP_0000964', 'MONDO_0024355', 'EFO_0004992', 'EFO_0003035']",False,False,18,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
719,TEMSIROLIMUS,CHEMBL1201182,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 71 investigational indications.,,4.0,,False,2007,['ENSG00000088832'],"['EFO_0000437', 'EFO_0000403', 'EFO_1000292', 'EFO_0000632', 'EFO_0000702', 'EFO_0000181', 'EFO_0000685', 'EFO_1000026', 'EFO_0000756', 'EFO_0003929', 'MONDO_0004992', 'EFO_0000565', 'MONDO_0004192', 'EFO_0000222', 'EFO_0001378', 'MONDO_0002691', 'EFO_0003869', 'EFO_0000616', 'MONDO_0001187', 'EFO_0003833', 'MONDO_0002974', 'EFO_0003060', 'MONDO_0002367', 'EFO_1001187', 'EFO_0007416', 'EFO_1000251', 'EFO_0000313', 'EFO_0000182', 'EFO_0000305', 'MONDO_0003268', 'EFO_0000232', 'EFO_0000248', 'EFO_0000519', 'EFO_0000681', 'EFO_0000228', 'MONDO_0016693', 'EFO_0004265', 'EFO_1001512', 'EFO_1001968', 'EFO_0002501', 'MONDO_0016691', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002158', 'MONDO_0024677', 'MONDO_0002108', 'EFO_0000183', 'EFO_1001469', 'EFO_0000574', 'EFO_0000349', 'EFO_0000673', 'MONDO_0008315', 'EFO_0005952', 'EFO_0000707', 'EFO_0000466', 'EFO_1000158', 'EFO_0000637', 'EFO_0000502', 'EFO_0000621', 'EFO_1001465', 'EFO_0000556', 'MONDO_0007254', 'EFO_0009708', 'EFO_0002499', 'MONDO_0008170', 'EFO_0000339', 'EFO_1001331', 'EFO_0000691', 'EFO_1000613', 'EFO_0000365', 'EFO_0006861', 'EFO_0000389', 'MONDO_0021063', 'MONDO_0011962', 'EFO_0000198']",True,False,75,FK506-binding protein 1A inhibitor ,INHIBITOR ,single protein 
720,ALLOPURINOL,CHEMBL1467,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 4 approved and 37 investigational indications.,,4.0,,False,1966,['ENSG00000158125'],"['EFO_0000565', 'MONDO_0002087', 'EFO_0000319', 'EFO_0009104', 'EFO_1001893', 'EFO_1001793', 'EFO_0005044', 'EFO_0003913', 'MONDO_0005148', 'EFO_0000198', 'EFO_0000729', 'EFO_0000195', 'EFO_0005952', 'EFO_0005207', 'EFO_0000574', 'EFO_0000400', 'EFO_0000095', 'EFO_0004251', 'EFO_0000220', 'EFO_0000702', 'EFO_0000537', 'MONDO_0001134', 'EFO_0003777', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0003884', 'EFO_0000373', 'EFO_0003767', 'EFO_0001073', 'EFO_0001378', 'EFO_0004253', 'MONDO_0005178', 'EFO_1001479', 'EFO_0004274', 'MONDO_0018076', 'EFO_0000094', 'EFO_0003144', 'MONDO_0008170', 'MONDO_0004985', 'EFO_0009582', 'EFO_0000222']",False,False,41,Xanthine dehydrogenase inhibitor ,INHIBITOR ,single protein 
721,TRASTUZUMAB EMTANSINE,CHEMBL1743082,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,"['ENSG00000141736', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_1000984', 'MONDO_0000521', 'EFO_0000305', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0008170', 'EFO_0003869', 'EFO_0009708', 'EFO_0003060', 'MONDO_0004992', 'MONDO_0004669', 'MONDO_0001056', 'MONDO_0011962']",True,True,14,Tubulin inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,protein complex group single protein 
722,NIMOTUZUMAB,CHEMBL2108359,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0004252', 'EFO_0007331', 'EFO_0003060', 'EFO_0002916', 'MONDO_0001325', 'EFO_0000181', 'EFO_0000326', 'EFO_1001931', 'MONDO_0005575', 'EFO_0003897', 'EFO_0000228', 'EFO_1000657', 'MONDO_0007254', 'EFO_0000199', 'EFO_0006859', 'EFO_0000313', 'EFO_0000616', 'EFO_1000026', 'EFO_0000707', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618', 'MONDO_0001056', 'EFO_0002938', 'EFO_1001951', 'MONDO_0002974', 'MONDO_0004992', 'MONDO_0002914', 'EFO_0000519', 'MONDO_0008903']",False,True,30,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
723,XANTHOHUMOL,CHEMBL253896,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000384'],False,False,1,,,
724,LONAFARNIB,CHEMBL298734,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hutchinson-gilford progeria syndrome and progeria and has 17 investigational indications.,,4.0,,False,2020,"['ENSG00000168522', 'ENSG00000257365']","['EFO_1001465', 'MONDO_0004192', 'EFO_0007304', 'MONDO_0007254', 'EFO_0000339', 'EFO_0006859', 'EFO_0009708', 'EFO_0002499', 'MONDO_0008310', 'EFO_0000574', 'EFO_1000158', 'EFO_0000198', 'MONDO_0001187', 'MONDO_0002691', 'MONDO_0008170', 'EFO_0003060', 'MONDO_0020732', 'EFO_1001951', 'EFO_1001779']",True,False,19,Protein farnesyltransferase inhibitor ,INHIBITOR ,protein complex 
725,ERDAFITINIB,CHEMBL3545376,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 10 investigational indications.,,4.0,,False,2019,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']","['EFO_0003863', 'MONDO_0004992', 'EFO_0008528', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000574', 'EFO_0001421', 'EFO_0000294', 'EFO_0001378', 'EFO_0000196', 'MONDO_0001187', 'EFO_0000616', 'EFO_0000708', 'EFO_0000673', 'EFO_0000182']",True,True,15,Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family 
726,TUCIDINOSTAT,CHEMBL3621988,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 32 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0019472', 'EFO_0000096', 'EFO_0000764', 'EFO_0005952', 'EFO_0000403', 'EFO_0000211', 'MONDO_0000873', 'EFO_0000220', 'EFO_1001951', 'EFO_0002913', 'EFO_0000222', 'EFO_0003060', 'EFO_0001416', 'EFO_0000616', 'MONDO_0002120', 'EFO_0005922', 'EFO_0000765', 'HP_0001873', 'EFO_0005537', 'EFO_0003869', 'EFO_0000180', 'EFO_0001378', 'EFO_0000231', 'EFO_0000209', 'EFO_0000574', 'EFO_0000255', 'EFO_0000621', 'MONDO_0007254', 'EFO_0000183', 'MONDO_0000430', 'EFO_0000691', 'MONDO_0001187']",False,False,32,,,
727,GASTRIN,CHEMBL413654,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
728,BIO-11006,CHEMBL4297701,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000277443'],"['EFO_0000341', 'EFO_0003060', 'MONDO_0100130']",True,False,3,Myristoylated alanine-rich C-kinase substrate inhibitor ,INHIBITOR ,single protein 
729,BELUDAVIMAB,CHEMBL4802220,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
730,NALFURAFINE HYDROCHLORIDE,CHEMBL490665,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000082556'],"['EFO_0003884', 'EFO_0001421']",False,False,2,Kappa opioid receptor agonist ,AGONIST ,single protein 
731,ETHINYL ESTRADIOL,CHEMBL691,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 29 investigational indications.,,4.0,,False,2001,['ENSG00000091831'],"['EFO_0000660', 'EFO_0005924', 'MONDO_0005148', 'HP_0100608', 'HP_0100607', 'MONDO_0009061', 'EFO_0000616', 'EFO_0010269', 'MONDO_0004992', 'HP_0000938', 'MONDO_0002050', 'EFO_0008560', 'EFO_1000710', 'EFO_0003047', 'MONDO_0019499', 'MONDO_0007254', 'MONDO_0011962', 'EFO_0003882', 'EFO_0003894', 'MONDO_0004169', 'EFO_0000764', 'MONDO_0005277', 'EFO_0004220', 'EFO_0009006', 'MONDO_0018075', 'EFO_0000095', 'EFO_0004239', 'EFO_1001249', 'EFO_0005204', 'EFO_0000180', 'EFO_0002950', 'MONDO_0005351']",False,True,32,Estrogen receptor alpha agonist ,AGONIST ,single protein 
732,RALOXIFENE,CHEMBL81,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for osteoporosis and breast cancer and has 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000140009'],"['MONDO_0007254', 'EFO_0003854', 'MONDO_0004975', 'EFO_0000660', 'EFO_0000673', 'EFO_0003882', 'EFO_0003882', 'EFO_0005411', 'EFO_0000673', 'EFO_0003922', 'MONDO_0011962', 'EFO_0000694', 'MONDO_0007254', 'HP_0000938', 'MONDO_0005090']",False,False,15,Estrogen receptor beta modulator ,MODULATOR ,single protein 
733,TRANEXAMIC ACID,CHEMBL877,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 55 investigational indications.,,4.0,,False,1986,['ENSG00000122194'],"['HP_0003418', 'EFO_0004273', 'EFO_1000391', 'EFO_0006834', 'MONDO_0004992', 'EFO_0005669', 'HP_0008419', 'EFO_0000731', 'EFO_0000546', 'EFO_0004272', 'HP_0100806', 'EFO_0001645', 'MONDO_0005178', 'EFO_0007440', 'EFO_1000999', 'EFO_0004214', 'HP_0030834', 'MONDO_0010602', 'MONDO_0021148', 'EFO_0001642', 'EFO_0003843', 'MONDO_0044881', 'MONDO_0043510', 'EFO_0003895', 'EFO_0003963', 'EFO_0004710', 'EFO_1001792', 'EFO_1000350', 'EFO_0003833', 'MONDO_0016642', 'HP_0002239', 'MP_0001845', 'EFO_0004198', 'EFO_0009579', 'EFO_0007442', 'HP_0000132', 'HP_0031273', 'EFO_0009314', 'MONDO_0004567', 'EFO_0004616', 'EFO_0004284', 'EFO_0010680', 'EFO_0003931', 'EFO_0000713', 'EFO_0000326', 'MONDO_0019623', 'MONDO_0001187', 'HP_0003040', 'EFO_0000272', 'EFO_1001178', 'EFO_1001801', 'HP_0002105', 'EFO_0005251', 'EFO_0003964', 'MONDO_0019180', 'MP_0001914', 'MONDO_0100096', 'HP_0001873']",True,False,58,Plasminogen inhibitor ,INHIBITOR ,single protein 
734,CLOPIDOGREL BISULFATE,CHEMBL1083385,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000169313'],"['EFO_0004265', 'EFO_0001645', 'EFO_0003869', 'EFO_0000612', 'HP_0002239', 'EFO_0000712', 'EFO_0005672', 'EFO_1000985', 'EFO_0000556']",True,False,9,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
735,INSULIN GLULISINE,CHEMBL1201613,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for diabetes mellitus and has 5 investigational indications.,,4.0,,False,2004,['ENSG00000171105'],"['MONDO_0004975', 'EFO_0001064', 'EFO_0000400', 'EFO_0000612', 'MONDO_0005147', 'MONDO_0005148']",True,False,6,Insulin receptor agonist ,AGONIST ,single protein 
736,TOPOTECAN HYDROCHLORIDE,CHEMBL1607,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 64 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000184428'],"['EFO_0000565', 'EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087', 'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617', 'EFO_0000613', 'EFO_1000158', 'EFO_0000519', 'EFO_0000466', 'MONDO_0008380', 'MONDO_0037745', 'MONDO_0100096', 'EFO_0000305', 'EFO_0000630', 'EFO_1001465', 'EFO_0001416', 'EFO_0000616', 'EFO_0005543', 'EFO_0001378', 'MONDO_0004992', 'EFO_0000621', 'EFO_1001042', 'EFO_1000251', 'EFO_0000681', 'EFO_0000220', 'EFO_0000691', 'MONDO_0019004', 'EFO_0008524', 'EFO_0000198', 'EFO_1001100', 'EFO_0000502', 'EFO_0003893', 'EFO_0002501', 'EFO_0000702', 'MONDO_0007576', 'EFO_1000823', 'EFO_0005561', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254', 'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'MONDO_0008170', 'EFO_0001061', 'EFO_0001075', 'EFO_0005952', 'EFO_0000389', 'EFO_0000313', 'EFO_0003851', 'EFO_0003869', 'MONDO_0021063', 'EFO_0000574', 'MONDO_0011962', 'MONDO_0006058', 'EFO_0000222', 'EFO_1001331', 'MONDO_0018271', 'EFO_0003060', 'MONDO_0002974', 'EFO_0007362', 'MONDO_0018364', 'EFO_1000895', 'MONDO_0008315', 'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043']",False,False,71,"DNA topoisomerase I, mitochondrial inhibitor ",INHIBITOR ,single protein 
737,NAPTUMOMAB ESTAFENATOX,CHEMBL1743045,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000146242'],"['EFO_0000681', 'EFO_0003060']",False,False,2,Trophoblast glycoprotein other ,OTHER ,single protein 
738,SERABELISIB,CHEMBL3935857,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000121879'],"['MONDO_0004992', 'EFO_0000681', 'EFO_0003060', 'EFO_0000616', 'EFO_0004230']",False,False,5,PI3-kinase p110-alpha subunit inhibitor ,INHIBITOR ,single protein 
739,ROGARATINIB,CHEMBL3963485,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']","['MONDO_0007254', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000616', 'MONDO_0001187', 'EFO_0003060']",True,True,6,Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family 
740,ACEBILUSTAT,CHEMBL4297604,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000111144'],"['MONDO_0009061', 'MONDO_0019297', 'EFO_0003894', 'MONDO_0100096']",True,False,4,Leukotriene A4 hydrolase inhibitor ,INHIBITOR ,single protein 
741,CEFTAZIDIME,CHEMBL44354,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 7 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,[],"['EFO_1001849', 'EFO_1001084', 'EFO_1001141', 'EFO_0008588', 'MONDO_0009061', 'EFO_0000701', 'EFO_0003103', 'EFO_0000771', 'EFO_0003106', 'EFO_1001313', 'EFO_0000544', 'EFO_1000831', 'HP_0002571', 'EFO_0003102']",False,False,14,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
742,BMS-986278,CHEMBL5087506,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000768', 'EFO_0009448']",False,False,2,,,
743,UMECLIDINIUM BROMIDE,CHEMBL523299,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 1 investigational indication.,,4.0,,False,2013,['ENSG00000133019'],"['EFO_0000464', 'HP_0006536', 'MONDO_0004979', 'EFO_0006505', 'EFO_0000341']",True,True,5,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
744,FINASTERIDE,CHEMBL710,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 6 investigational indications.,,4.0,,False,1992,['ENSG00000277893'],"['EFO_0003839', 'EFO_0000284', 'EFO_0000673', 'EFO_0004191', 'MONDO_0008315', 'MONDO_0003037', 'MONDO_0004907', 'EFO_0000536', 'EFO_0003060', 'EFO_0003894', 'EFO_0001663', 'MONDO_0002146']",False,False,12,Steroid 5-alpha-reductase 2 inhibitor ,INHIBITOR ,single protein 
745,GLUTAMINE,CHEMBL930,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for sickle cell anemia and primary short bowel syndrome and has 35 investigational indications.,,4.0,,False,2004,[],"['EFO_0008572', 'MONDO_0010679', 'MONDO_0009061', 'EFO_1001904', 'MONDO_0011382', 'EFO_1001892', 'MONDO_0007254', 'MONDO_0018241', 'EFO_0001378', 'EFO_0000616', 'MONDO_0005148', 'EFO_1001373', 'EFO_0001645', 'EFO_0000546', 'EFO_0003884', 'MONDO_0001673', 'EFO_0000555', 'MONDO_0011628', 'MONDO_0100096', 'EFO_0003100', 'EFO_0000384', 'EFO_0004142', 'EFO_0002517', 'EFO_0000400', 'HP_0000964', 'EFO_0003144', 'EFO_0000649', 'MONDO_0008315', 'MONDO_0004992', 'MONDO_0043544', 'EFO_0003917', 'EFO_0000574', 'EFO_1001898', 'EFO_1001996', 'EFO_0009130', 'EFO_0000495', 'HP_0100806']",False,False,37,,,
746,XYLITOL,CHEMBL96783,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007415', 'EFO_0000771', 'EFO_0009869', 'EFO_0004992', 'EFO_0007486', 'EFO_0003819', 'EFO_0000373', 'MONDO_0009061', 'EFO_0003884', 'MONDO_0005271', 'EFO_0000400']",False,False,11,,,
747,IRSOGLADINE MALEATE,CHEMBL1712923,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000217', 'HP_0004398', 'EFO_0009454']",False,False,3,,,
748,AGATOLIMOD,CHEMBL2103792,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,['ENSG00000239732'],"['EFO_0005952', 'EFO_0009441', 'EFO_0003869', 'EFO_0002913', 'EFO_0000403', 'EFO_0000764', 'EFO_0001068', 'EFO_0000756', 'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806', 'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576', 'EFO_0001068', 'EFO_0000313', 'MONDO_0008315', 'EFO_0000191', 'EFO_0003060', 'EFO_1001469']",False,False,22,Toll-like receptor 9 agonist ,AGONIST ,single protein 
749,GLYCEROL PHENYLBUTYRATE,CHEMBL2105745,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for disorder of urea cycle metabolism and ammonia detoxification and urea cycle disorder and has 2 investigational indications.,,4.0,,False,2013,[],"['MONDO_0005180', 'Orphanet_79167', 'MONDO_0004739', 'MONDO_0009061']",False,False,4,,,
750,RADIUM RA 223 DICHLORIDE,CHEMBL2107816,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 3 investigational indications.,,4.0,,False,2013,[],"['MONDO_0008315', 'EFO_0009708', 'EFO_0001663', 'EFO_0003060', 'EFO_0009870', 'EFO_0000196', 'EFO_0000673', 'EFO_0001378', 'EFO_0003869']",False,False,9,,,
751,EFLAPEGRASTIM,CHEMBL3833384,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and has 3 investigational indications.,,4.0,,False,2022,['ENSG00000119535'],"['MONDO_0001475', 'MONDO_0007254', 'EFO_0000574', 'EFO_0000616']",False,False,4,Granulocyte colony stimulating factor receptor agonist ,AGONIST ,single protein 
752,ELEXACAFTOR,CHEMBL4298128,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and has 1 investigational indication.,,4.0,,False,2019,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
753,QUARATUSUGENE OZEPLASMID,CHEMBL4594390,Gene drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
754,INSULIN EFSITORA ALFA,CHEMBL5095357,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005148', 'MONDO_0005147']",False,False,2,,,
755,ERLOTINIB,CHEMBL553,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 100 investigational indications.,,4.0,,False,2004,['ENSG00000146648'],"['EFO_0005537', 'EFO_0000616', 'EFO_0000632', 'EFO_0002501', 'MONDO_0007576', 'EFO_0000313', 'MONDO_0002974', 'MONDO_0004992', 'EFO_0001422', 'EFO_0000616', 'MONDO_0044881', 'EFO_0002429', 'EFO_0000588', 'MONDO_0021117', 'EFO_0000519', 'EFO_0000305', 'EFO_0000514', 'MONDO_0000521', 'EFO_0000681', 'MONDO_0008903', 'EFO_0004252', 'EFO_0000198', 'EFO_0006859', 'MONDO_0008315', 'MONDO_0002898', 'EFO_0000222', 'EFO_1000657', 'EFO_0003050', 'EFO_0000308', 'EFO_0003868', 'EFO_0003893', 'EFO_0000676', 'EFO_1001951', 'MONDO_0008170', 'MONDO_0018531', 'MONDO_0008903', 'MONDO_0016693', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0016691', 'EFO_0000708', 'EFO_0003060', 'MONDO_0002158', 'EFO_0002618', 'MONDO_0002158', 'EFO_0002501', 'EFO_0005577', 'EFO_1000581', 'MONDO_0002898', 'EFO_0003860', 'EFO_1000026', 'EFO_1000158', 'EFO_0000571', 'MONDO_0004992', 'EFO_1001465', 'MONDO_0021063', 'MONDO_0003478', 'EFO_0000182', 'EFO_0000756', 'EFO_0003833', 'MONDO_0007254', 'EFO_0002499', 'EFO_0009708', 'MONDO_0003060', 'EFO_0000588', 'EFO_0002618', 'EFO_0000571', 'MONDO_0021063', 'EFO_0000365', 'MONDO_0007254', 'Orphanet_733', 'EFO_0000691', 'EFO_0001378', 'EFO_0002916', 'EFO_0000519', 'EFO_0000182', 'EFO_1001901', 'MONDO_0001187', 'EFO_0000707', 'EFO_1000657', 'EFO_1000028', 'MONDO_0004986', 'MONDO_0011962', 'EFO_1001951', 'MONDO_0020634', 'EFO_0010282', 'MONDO_0003268', 'EFO_0000565', 'EFO_0006859', 'EFO_0004220', 'MONDO_0002367', 'EFO_0005567', 'EFO_0000181', 'EFO_1001465', 'MONDO_0002367', 'MONDO_0003268', 'EFO_0007243', 'MONDO_0001657', 'MONDO_0002691', 'EFO_0002499', 'MONDO_0044926', 'EFO_0000756', 'EFO_1000158', 'EFO_0000181', 'Orphanet_733', 'EFO_0003060', 'EFO_0000681', 'EFO_0003050', 'EFO_0000313', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0001187', 'EFO_0000349', 'EFO_0000308', 'EFO_0000640', 'MONDO_0007576']",False,True,116,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
756,GABAPENTIN,CHEMBL940,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 58 investigational indications.,,4.0,,False,1993,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']","['EFO_0005687', 'EFO_1002028', 'HP_0000989', 'EFO_0000512', 'MONDO_0041052', 'MONDO_0011382', 'HP_0003419', 'HP_0002013', 'EFO_0003756', 'EFO_0007191', 'EFO_0003917', 'EFO_0001422', 'EFO_0005230', 'EFO_1001931', 'MONDO_0002050', 'EFO_0004777', 'EFO_0005762', 'EFO_0000546', 'HP_0012532', 'EFO_0005611', 'HP_0001250', 'EFO_0005323', 'EFO_0003890', 'EFO_0004710', 'EFO_0009267', 'HP_0031217', 'MONDO_0007254', 'HP_0001337', 'EFO_0000764', 'EFO_0004329', 'EFO_1001800', 'MONDO_0043510', 'EFO_0006859', 'EFO_0006510', 'EFO_0003768', 'EFO_0004698', 'EFO_0003843', 'MONDO_0007079', 'EFO_0004143', 'MONDO_0004986', 'EFO_0004263', 'EFO_1001250', 'HP_0000360', 'EFO_0009430', 'EFO_1000783', 'HP_0008419', 'EFO_0005407', 'EFO_0004888', 'MONDO_0004992', 'EFO_0008568', 'EFO_1001255', 'MONDO_0005090', 'MONDO_0005301', 'EFO_1000971', 'MONDO_0008315', 'EFO_0000474', 'MONDO_0002038', 'EFO_0000279', 'EFO_0008533', 'EFO_0004270', 'EFO_0003818', 'EFO_0004273', 'EFO_1001898']",False,False,63,Voltage-gated calcium channel modulator ,MODULATOR ,protein complex group 
757,ESTETROL,CHEMBL1230314,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pregnancy and has 5 investigational indications.,,4.0,,False,2021,"['ENSG00000140009', 'ENSG00000091831']","['EFO_0000673', 'MONDO_0100096', 'EFO_0003869', 'EFO_0003922', 'EFO_0002950', 'MONDO_0007254']",True,True,6,Estrogen receptor agonist ,AGONIST ,protein family 
758,FAVIPIRAVIR,CHEMBL221722,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000763', 'EFO_0007338', 'EFO_0007243', 'MONDO_0100096', 'EFO_0007541', 'EFO_0000694', 'EFO_0007328', 'EFO_0001421']",False,False,8,RNA-directed RNA polymerase inhibitor ,INHIBITOR ,protein complex 
759,LINOLEIC ACID,CHEMBL267476,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0005148', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0004979', 'EFO_0001073']",False,False,5,,,
760,MIVAVOTINIB CITRATE,CHEMBL4594253,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000165025'],"['EFO_0000222', 'EFO_0005952', 'EFO_0000574', 'EFO_0000403', 'EFO_0001075', 'MONDO_0018906']",False,False,6,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
761,AZD-1390,CHEMBL4594429,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000519', 'EFO_0003060']",False,False,2,,,
762,DEXTRAN SULFATE SODIUM (5000 MW),CHEMBL4594555,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
763,PULRODEMSTAT BESILATE,CHEMBL4650360,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0000673', 'EFO_0005952', 'EFO_0000702', 'EFO_0000565']",False,False,5,,,
764,LOVASTATIN,CHEMBL503,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 27 investigational indications.,,4.0,,False,1987,['ENSG00000113161'],"['MONDO_0021661', 'MONDO_0010726', 'MONDO_0004979', 'EFO_0003777', 'EFO_0000319', 'EFO_1001375', 'EFO_0003914', 'EFO_1000757', 'EFO_0000764', 'Orphanet_309005', 'MONDO_0010383', 'EFO_0000222', 'Orphanet_46724', 'EFO_0000589', 'EFO_0001645', 'EFO_0004705', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004681', 'MP_0001845', 'MONDO_0005180', 'EFO_1000860', 'HP_0100543', 'EFO_0000756', 'MONDO_0018975', 'MONDO_0008948', 'EFO_0000712', 'EFO_0002615', 'EFO_0000341', 'HP_0003124', 'MONDO_0007254', 'EFO_0003876', 'EFO_0000685']",False,False,33,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
765,EPOTHILONE D,CHEMBL96172,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000616', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0008903', 'MONDO_0008315']",True,False,5,Tubulin stabiliser ,STABILISER ,protein complex group 
766,VARESPLADIB,CHEMBL148674,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000188257'],"['EFO_0001645', 'MONDO_0100096', 'MONDO_0011382']",False,False,3,Phospholipase A2 group IIA inhibitor ,INHIBITOR ,single protein 
767,REGORAFENIB,CHEMBL1946170,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000165731', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000066468', 'ENSG00000142627', 'ENSG00000120156', 'ENSG00000185386', 'ENSG00000132155', 'ENSG00000111816', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404', 'ENSG00000097007', 'ENSG00000077782', 'ENSG00000162733', 'ENSG00000198400', 'ENSG00000157764']","['MONDO_0021063', 'EFO_0000569', 'EFO_0000222', 'EFO_0000616', 'EFO_0005540', 'EFO_0000691', 'MONDO_0007576', 'EFO_0004142', 'EFO_0000365', 'EFO_0000637', 'EFO_0003893', 'EFO_0000756', 'EFO_0000313', 'EFO_1001949', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000702', 'MONDO_0008170', 'EFO_1000657', 'MONDO_0004992', 'EFO_0000681', 'EFO_0000519', 'MONDO_0005575', 'EFO_0005221', 'MONDO_0011719', 'MONDO_0001056', 'EFO_0000389', 'MONDO_0003060', 'MONDO_0002108', 'EFO_0002618', 'EFO_0009606', 'EFO_0000231', 'EFO_0003968', 'EFO_1001968', 'EFO_0001075', 'EFO_1001951']",False,False,36,Tyrosine-protein kinase receptor RET inhibitor Ephrin type-A receptor 2 Fibroblast growth factor receptor 2 inhibitor Tyrosine-protein kinase TIE-2 inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase FRK inhibitor Tyrosine-protein kinase ABL inhibitor Serine/threonine-protein kinase B-raf inhibitor MAP kinase p38 beta inhibitor Discoidin domain-containing receptor 2 inhibitor Nerve growth factor receptor Trk-A Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Serine/threonine-protein kinase RAF inhibitor Fibroblast growth factor receptor 1 inhibitor ,INHIBITOR ,single protein protein family protein complex 
768,RIVAROXABAN,CHEMBL198362,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 6 approved and 29 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,['ENSG00000126218'],"['HP_0004419', 'HP_0002140', 'EFO_0009314', 'MONDO_0000831', 'EFO_0000612', 'EFO_0004265', 'EFO_0001378', 'HP_0001907', 'EFO_0001645', 'MONDO_0100096', 'MP_0001914', 'EFO_0003884', 'EFO_0003777', 'EFO_0009531', 'HP_0004936', 'EFO_1001161', 'EFO_0003907', 'HP_0000083', 'EFO_0001074', 'EFO_0000712', 'MONDO_0004992', 'HP_0001873', 'EFO_0005672', 'EFO_0000694', 'MONDO_0005148', 'EFO_0001422', 'EFO_0002689', 'EFO_0004286', 'EFO_0010680', 'EFO_0000275', 'MONDO_0011382', 'EFO_0000616', 'EFO_0000266', 'EFO_0000556', 'EFO_0003827']",False,False,35,Coagulation factor X inhibitor ,INHIBITOR ,single protein 
769,BRILACIDIN,CHEMBL2219413,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
770,NEDAPLATIN,CHEMBL3137685,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002916', 'MONDO_0007576', 'EFO_1000158', 'EFO_0003060', 'EFO_0004252', 'EFO_0000707', 'EFO_0005922', 'MONDO_0002974']",False,False,8,,,
771,NETAZEPIDE,CHEMBL324547,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000110148'],"['EFO_1001095', 'EFO_0004243', 'EFO_0000280', 'EFO_0007549', 'EFO_0008533']",False,False,5,Cholecystokinin B receptor antagonist ,ANTAGONIST ,single protein 
772,LANRAPLENIB,CHEMBL3986824,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000165025'],"['EFO_0000540', 'EFO_0003834', 'EFO_0000699', 'MONDO_0007915', 'EFO_0000222']",False,False,5,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
773,LAROTAXEL,CHEMBL4279455,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000294', 'EFO_0003860', 'EFO_0003869', 'MONDO_0007254']",True,False,4,Tubulin stabiliser ,STABILISER ,protein complex group 
774,DEUTIVACAFTOR,CHEMBL4297603,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
775,MEDI-8852,CHEMBL4298034,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,Hemagglutinin binding agent ,BINDING AGENT ,single protein 
776,ISCALIMAB,CHEMBL4298210,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000101017'],"['EFO_1000710', 'EFO_0004991', 'EFO_0005761', 'MONDO_0005147', 'EFO_0000685', 'EFO_0004599', 'EFO_0004237', 'MONDO_0007915', 'EFO_0000699']",False,True,9,Tumor necrosis factor receptor superfamily member 5 inhibitor ,INHIBITOR ,single protein 
777,METFORMIN,CHEMBL1431,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 163 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,"['ENSG00000115159', 'ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684']","['EFO_0000685', 'EFO_0002617', 'MONDO_0044704', 'EFO_0005537', 'MONDO_0007254', 'EFO_0002618', 'HP_0000842', 'EFO_0004214', 'HP_0003124', 'MONDO_0100096', 'MONDO_0010383', 'MONDO_0018906', 'EFO_0003095', 'EFO_0008522', 'EFO_0000571', 'MONDO_0001941', 'EFO_1001951', 'EFO_0001378', 'MONDO_0010679', 'EFO_0000403', 'EFO_0000182', 'MONDO_0007254', 'EFO_0000673', 'MP_0001845', 'MONDO_0018875', 'EFO_1001496', 'EFO_0000432', 'EFO_0000275', 'EFO_0003914', 'MONDO_0011382', 'MONDO_0021063', 'HP_0001249', 'HP_0003419', 'MONDO_0019391', 'EFO_0001071', 'MONDO_0019353', 'EFO_0004593', 'EFO_0005411', 'EFO_0000305', 'EFO_0003968', 'MONDO_0005148', 'MONDO_0004782', 'EFO_0000673', 'EFO_0000676', 'MONDO_0005090', 'EFO_0000660', 'EFO_0003884', 'EFO_0003770', 'EFO_0009516', 'EFO_0003060', 'EFO_1001121', 'EFO_0000702', 'EFO_0000199', 'MONDO_0011962', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0002950', 'EFO_0000756', 'EFO_1001892', 'Orphanet_309005', 'EFO_0000365', 'MONDO_0021350', 'EFO_0002614', 'EFO_0002618', 'EFO_1001512', 'EFO_0004265', 'HP_0002910', 'EFO_0009637', 'HP_0100543', 'EFO_0000181', 'EFO_0000095', 'MONDO_0002108', 'EFO_0000400', 'EFO_0000280', 'EFO_1000043', 'EFO_0004566', 'EFO_0005672', 'MONDO_0004658', 'EFO_0000694', 'EFO_0000195', 'EFO_1001492', 'EFO_0000341', 'MONDO_0008315', 'MONDO_0002009', 'MONDO_0005148', 'EFO_0004364', 'EFO_0000729', 'EFO_1001459', 'EFO_0001073', 'EFO_1000710', 'EFO_0008520', 'EFO_0003144', 'EFO_0001663', 'EFO_0004142', 'EFO_0006859', 'EFO_0000519', 'EFO_0000196', 'MONDO_0008903', 'EFO_0000228', 'HP_0001268', 'MONDO_0004992', 'MONDO_0005178', 'EFO_0001416', 'EFO_0003884', 'EFO_0006859', 'EFO_0001645', 'EFO_0000466', 'EFO_0000313', 'EFO_0003060', 'EFO_0005922', 'EFO_0001361', 'EFO_0001054', 'MONDO_0005301', 'EFO_0000308', 'Orphanet_733', 'EFO_0000707', 'MONDO_0005277', 'EFO_0000537', 'HP_0001397', 'HP_0001541', 'MONDO_0020121', 'MONDO_0008170', 'MONDO_0002974', 'EFO_1001249', 'EFO_0005762', 'EFO_0003050', 'EFO_0002517', 'EFO_0000571', 'MONDO_0002691', 'EFO_0003863', 'EFO_0001068', 'EFO_0000649', 'MONDO_0005147', 'EFO_0000545', 'EFO_0004593', 'EFO_0001378', 'EFO_1001207', 'EFO_1000045', 'EFO_0003144', 'MONDO_0017975', 'EFO_0003918', 'EFO_0002546', 'EFO_0000195', 'EFO_1001901', 'EFO_0003876', 'MONDO_0001187', 'EFO_0000199', 'MONDO_0015229', 'HP_0012115', 'EFO_1000783', 'MONDO_0007739', 'EFO_1000657', 'MONDO_0005041', 'EFO_0001663', 'EFO_0000400', 'EFO_0000220', 'MONDO_0000396', 'EFO_0000589', 'MONDO_0002087', 'MONDO_0018076', 'MONDO_0021063', 'EFO_0001075', 'MONDO_0017276', 'MONDO_0004985', 'EFO_0000660', 'EFO_0000764', 'EFO_0003833', 'EFO_0001073', 'EFO_0003100', 'HP_0001249', 'EFO_1001465', 'EFO_1001348', 'EFO_0000616', 'EFO_0000319', 'GO_0007568']",True,True,175,Mitochondrial complex I (NADH dehydrogenase) inhibitor Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor ,INHIBITOR ,protein complex single protein 
778,METFORMIN HYDROCHLORIDE,CHEMBL1703,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,"['ENSG00000115159', 'ENSG00000198695', 'ENSG00000130414', 'ENSG00000110717', 'ENSG00000212907', 'ENSG00000184983', 'ENSG00000198888', 'ENSG00000165264', 'ENSG00000189043', 'ENSG00000174886', 'ENSG00000099795', 'ENSG00000198763', 'ENSG00000158864', 'ENSG00000198786', 'ENSG00000119421', 'ENSG00000136521', 'ENSG00000198886', 'ENSG00000198840', 'ENSG00000004779', 'ENSG00000125356', 'ENSG00000164258', 'ENSG00000119013', 'ENSG00000109390', 'ENSG00000131495', 'ENSG00000168653', 'ENSG00000115286', 'ENSG00000145494', 'ENSG00000183648', 'ENSG00000213619', 'ENSG00000170906', 'ENSG00000065518', 'ENSG00000166136', 'ENSG00000090266', 'ENSG00000267855', 'ENSG00000151366', 'ENSG00000140990', 'ENSG00000178127', 'ENSG00000023228', 'ENSG00000167792', 'ENSG00000160194', 'ENSG00000128609', 'ENSG00000139180', 'ENSG00000164182', 'ENSG00000178057', 'ENSG00000185633', 'ENSG00000147123', 'ENSG00000123545', 'ENSG00000186010', 'ENSG00000184752', 'ENSG00000137806', 'ENSG00000147684']","['EFO_0002517', 'EFO_0003884', 'EFO_0000571', 'MONDO_0007254', 'EFO_0002618', 'EFO_0004593', 'EFO_0000199', 'HP_0000842', 'MONDO_0005148', 'EFO_1001459', 'EFO_0003144', 'MONDO_0002158', 'EFO_0000195', 'EFO_0001663', 'EFO_0006859', 'MONDO_0008315', 'EFO_1000783', 'EFO_0001378', 'EFO_0000400', 'EFO_1001512', 'MONDO_0002087', 'MP_0001845', 'EFO_0009637', 'EFO_0000432', 'EFO_0000660', 'EFO_0000466', 'EFO_0003060', 'MONDO_0021063', 'EFO_0001073', 'MONDO_0019391', 'EFO_0001071', 'MONDO_0019353', 'EFO_1000043', 'EFO_1001465', 'HP_0001541', 'EFO_0000673']",True,True,36,Mitochondrial complex I (NADH dehydrogenase) inhibitor Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor ,INHIBITOR ,protein complex single protein 
779,SEPANTRONIUM,CHEMBL2110734,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000403', 'EFO_0000756', 'MONDO_0004992', 'EFO_0001663', 'EFO_0005952']",False,False,8,,,
780,DUVELISIB,CHEMBL3039502,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2018,"['ENSG00000105851', 'ENSG00000171608']","['MONDO_0004979', 'EFO_0000685', 'EFO_0000181', 'MONDO_0004992', 'EFO_0000211', 'MONDO_0100096', 'EFO_0000403', 'EFO_0000616', 'EFO_0000574', 'EFO_1001051', 'EFO_0001421', 'EFO_0000220', 'EFO_1000785', 'MONDO_0044881', 'EFO_0000096', 'EFO_0000756', 'EFO_0000565', 'MONDO_0018906', 'EFO_0000095', 'EFO_0005952']",True,False,20,PI3-kinase p110-delta subunit inhibitor PI3-kinase p110-gamma subunit inhibitor ,INHIBITOR ,single protein 
781,VONAPANITASE,CHEMBL3545070,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000049540'],"['EFO_0003884', 'EFO_0004265']",True,False,2,Elastin proteolytic enzyme ,PROTEOLYTIC ENZYME ,single protein 
782,PERIFOSINE,CHEMBL372764,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 38 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0011719', 'EFO_0000616', 'EFO_0003025', 'EFO_0000209', 'EFO_0003027', 'MONDO_0008315', 'EFO_0009441', 'MONDO_0002367', 'EFO_0000632', 'EFO_0002499', 'EFO_0000224', 'MONDO_0003268', 'EFO_0000198', 'EFO_0003060', 'EFO_1001968', 'EFO_0003833', 'EFO_0002618', 'EFO_0000339', 'EFO_0001378', 'MONDO_0021063', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000519', 'EFO_1001951', 'EFO_0000221', 'EFO_0000095', 'EFO_1001465', 'EFO_0003028', 'EFO_0006859', 'EFO_0000218', 'EFO_0000681', 'EFO_0000673', 'EFO_0000389', 'EFO_0000574', 'EFO_0002501', 'EFO_0000565', 'EFO_0000223']",False,False,38,,,
783,BRENSOCATIB,CHEMBL3900409,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000109861'],"['MONDO_0009061', 'HP_0002110', 'MONDO_0100096']",True,False,3,Dipeptidyl peptidase I inhibitor ,INHIBITOR ,single protein 
784,CDX-1140,CHEMBL4297721,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications.,,2.0,,False,no approval year,['ENSG00000101017'],"['EFO_0005221', 'EFO_0000756', 'EFO_0006859', 'EFO_0003060', 'MONDO_0001056', 'EFO_0000182', 'EFO_0000305', 'EFO_0000681', 'EFO_0002618', 'MONDO_0007576', 'EFO_0000616', 'EFO_1001951', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0002158', 'EFO_0000403', 'EFO_1001469']",False,False,17,Tumor necrosis factor receptor superfamily member 5 agonist ,AGONIST ,single protein 
785,TEPOTINIB HYDROCHLORIDE,CHEMBL4594292,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,4.0,,False,2021,['ENSG00000105976'],"['EFO_0000616', 'EFO_0003060']",False,False,2,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
786,TUNLAMETINIB,CHEMBL5095241,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_1001951', 'EFO_0000756', 'EFO_0000616']",False,False,4,,,
787,ALCOHOL,CHEMBL545,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 38 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001121', 'HP_0002019', 'EFO_0000275', 'EFO_0003894', 'EFO_0004234', 'EFO_1001139', 'HP_0001737', 'MONDO_0007079', 'EFO_0007191', 'EFO_1000889', 'EFO_1001436', 'EFO_1001347', 'EFO_0004364', 'MONDO_0044792', 'MONDO_0002046', 'HP_0000975', 'HP_0012532', 'MONDO_0001134', 'EFO_0000284', 'EFO_0003033', 'EFO_0001065', 'EFO_0000544', 'MONDO_0002009', 'MONDO_0004907', 'EFO_0000537', 'EFO_0005306', 'EFO_0004329', 'MONDO_0100096', 'EFO_0003884', 'EFO_0001422', 'MONDO_0001475', 'EFO_0000621', 'EFO_1000158', 'MONDO_0021201', 'EFO_0009516', 'MONDO_0021698', 'HP_0100607', 'EFO_0001073', 'HP_0001337', 'MONDO_0005148', 'MONDO_0004938']",False,False,41,,,
788,NITROGLYCERIN,CHEMBL730,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 25 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000061918', 'ENSG00000123201', 'ENSG00000152402', 'ENSG00000164116']","['EFO_1000783', 'EFO_1001993', 'EFO_1000657', 'EFO_0004234', 'EFO_0000537', 'EFO_1001375', 'MONDO_0005149', 'EFO_0003913', 'EFO_0000319', 'EFO_0000685', 'EFO_0000373', 'HP_0031273', 'MP_0001845', 'EFO_1001951', 'EFO_0000612', 'HP_0031217', 'EFO_1001395', 'EFO_0003882', 'EFO_0009552', 'MONDO_0004857', 'EFO_1001145', 'EFO_0002687', 'EFO_0004265', 'MONDO_0008903', 'HP_0000938', 'EFO_0000546', 'EFO_0001645', 'EFO_0000544', 'EFO_0003144', 'EFO_0009846', 'EFO_0003843', 'EFO_0005251', 'EFO_0000712', 'EFO_0003060']",True,True,34,Soluble guanylate cyclase activator ,ACTIVATOR ,protein complex group 
789,LOSARTAN POTASSIUM,CHEMBL995,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,['ENSG00000144891'],"['EFO_0003086', 'EFO_0002517', 'EFO_0004232', 'EFO_0002618', 'EFO_0000537', 'HP_0000093', 'MONDO_0001134', 'EFO_0000668', 'EFO_0003095', 'MONDO_0007947', 'EFO_0003896', 'EFO_0000712', 'EFO_0003884']",False,False,13,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
790,IMATINIB MESYLATE,CHEMBL1642,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 75 investigational indications.,,4.0,,False,2001,"['ENSG00000097007', 'ENSG00000186716', 'ENSG00000113721', 'ENSG00000157404']","['EFO_0006861', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0000760', 'EFO_0000756', 'EFO_1001361', 'EFO_0004683', 'EFO_0001361', 'MONDO_0011934', 'MONDO_0004979', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000094', 'EFO_0005952', 'EFO_0000616', 'MONDO_0011382', 'EFO_0004198', 'MONDO_0011719', 'MONDO_0008315', 'EFO_0000717', 'EFO_0000220', 'MONDO_0004992', 'MONDO_0002367', 'MONDO_0002087', 'MONDO_0005301', 'MONDO_0018975', 'EFO_1001951', 'EFO_0000519', 'EFO_1000158', 'MONDO_0005147', 'EFO_1001465', 'MONDO_0002108', 'MONDO_0011705', 'EFO_0000339', 'MONDO_0002158', 'EFO_0000702', 'EFO_0002429', 'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729', 'EFO_0000503', 'EFO_1001467', 'EFO_1001814', 'EFO_0000673', 'EFO_0000658', 'EFO_1001993', 'MONDO_0021063', 'MONDO_0005149', 'EFO_0002430', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000222', 'EFO_0000691', 'MONDO_0008170', 'EFO_0001376', 'EFO_1000657', 'MONDO_0044917', 'EFO_0002428', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313', 'EFO_0004289', 'MONDO_0000873', 'EFO_0000209', 'MONDO_0007254', 'EFO_0000565', 'EFO_0000574', 'EFO_1000613', 'MONDO_0001056', 'EFO_1001471']",True,False,76,Platelet-derived growth factor receptor beta inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase ABL inhibitor Bcr/Abl fusion protein ,INHIBITOR ,single protein chimeric protein 
791,CIXUTUMUMAB,CHEMBL1743001,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 26 investigational indications.,,2.0,,False,no approval year,['ENSG00000140443'],"['EFO_0003050', 'EFO_0000702', 'EFO_0000756', 'EFO_0000571', 'MONDO_0008903', 'MONDO_0021063', 'EFO_1001951', 'EFO_0003060', 'EFO_1001968', 'EFO_0000588', 'EFO_0000181', 'EFO_1000796', 'EFO_1000657', 'MONDO_0008315', 'EFO_0000305', 'EFO_0002618', 'EFO_0000437', 'EFO_0006861', 'EFO_0006859', 'MONDO_0007254', 'EFO_0000637', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000673', 'EFO_0000616', 'EFO_0000248']",False,False,26,Insulin-like growth factor I receptor antagonist ,ANTAGONIST ,single protein 
792,FEVIPIPRANT,CHEMBL3137332,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000183134'],"['HP_0000083', 'EFO_0005854', 'HP_0001880', 'EFO_1000391', 'EFO_0001421', 'EFO_0000274', 'MONDO_0004979', 'EFO_0000341']",False,False,8,G protein-coupled receptor 44 antagonist ,ANTAGONIST ,single protein 
793,SITRAVATINIB,CHEMBL3989926,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0005922', 'EFO_0000199', 'EFO_0000756', 'EFO_0001421', 'EFO_0000707', 'EFO_0003060', 'EFO_0000616', 'EFO_0000681', 'EFO_0000182', 'MONDO_0003060', 'EFO_0000228', 'MONDO_0004992', 'EFO_0000569', 'EFO_0000702', 'EFO_0000349', 'MONDO_0007254', 'MONDO_0011962']",False,False,17,,,
794,TAUROLITHOCHOLIC ACID,CHEMBL408701,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005147', 'MONDO_0004979', 'EFO_1001486', 'MONDO_0004976', 'EFO_0001422', 'MONDO_0005301']",False,False,6,,,
795,MOSUNETUZUMAB,CHEMBL4297788,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286', 'ENSG00000156738']","['EFO_0005952', 'EFO_0000096', 'MONDO_0018906', 'MONDO_0007915', 'EFO_0000403', 'EFO_0000095']",True,False,6,B-lymphocyte antigen CD20 binding agent T cell surface glycoprotein CD3 binding agent ,BINDING AGENT ,single protein protein complex 
796,FE 203799,CHEMBL4563522,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000065325'],"['MONDO_0015183', 'EFO_0003884', 'MONDO_0013730']",False,False,3,Glucagon-like peptide 2 receptor agonist ,AGONIST ,single protein 
797,REGN-3048,CHEMBL4594592,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
798,SAPROPTERIN DIHYDROCHLORIDE,CHEMBL1201775,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for phenylketonuria and hyperphenylalaninemia and has 9 investigational indications.,,4.0,,False,2007,['ENSG00000171759'],"['MONDO_0009861', 'EFO_0003876', 'MONDO_0005090', 'EFO_0000537', 'EFO_0001361', 'EFO_0005411', 'MONDO_0011382', 'Orphanet_238583', 'EFO_0000181', 'EFO_0003884', 'EFO_0001645']",False,False,11,Phenylalanine-4-hydroxylase activator ,ACTIVATOR ,single protein 
799,LINEZOLID,CHEMBL126,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 17 investigational indications.,,4.0,,False,2000,[],"['MONDO_0021108', 'EFO_0005681', 'EFO_0000701', 'EFO_0003030', 'EFO_1001330', 'MONDO_0041806', 'EFO_0000771', 'EFO_0000544', 'EFO_0007381', 'EFO_0003106', 'EFO_0009516', 'MONDO_0021679', 'EFO_0003102', 'EFO_1001272', 'MONDO_0044881', 'EFO_0007504', 'MONDO_0018076', 'EFO_0003033', 'EFO_1000049', 'EFO_0003035', 'MONDO_0009061', 'EFO_1001474']",False,False,22,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
800,GIMERACIL,CHEMBL1730601,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 33 investigational indications.,,3.0,,False,no approval year,['ENSG00000188641'],"['EFO_0000503', 'EFO_0003897', 'EFO_1001951', 'EFO_0003060', 'EFO_0000182', 'MONDO_0007254', 'EFO_0006859', 'EFO_0000228', 'MONDO_0002974', 'EFO_0003860', 'MONDO_0002120', 'EFO_0003086', 'EFO_0001421', 'EFO_0000178', 'EFO_0000702', 'EFO_0000365', 'EFO_0004142', 'MONDO_0001056', 'MONDO_0044937', 'MONDO_0007576', 'EFO_0002618', 'EFO_0005922', 'EFO_0002517', 'EFO_0004252', 'EFO_0000181', 'EFO_0000616', 'MONDO_0005575', 'EFO_0005221', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000657', 'EFO_0002916', 'MONDO_0003060']",False,False,33,Dihydropyrimidine dehydrogenase inhibitor ,INHIBITOR ,single protein 
801,LUNACALCIPOL,CHEMBL2105705,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000111424'],"['EFO_0003884', 'EFO_0000676', 'EFO_0009909', 'EFO_1001173']",True,False,4,Vitamin D receptor agonist ,AGONIST ,single protein 
802,LANCOVUTIDE,CHEMBL2108327,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
803,DIGITOXIN,CHEMBL254219,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication.,,4.0,,False,1982,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']","['EFO_0000319', 'MONDO_0009061']",False,False,2,Sodium/potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex group 
804,SUCROFERRIC OXYHYDROXIDE,CHEMBL3039566,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for chronic kidney disease and has 1 investigational indication.,,4.0,,False,2013,[],"['EFO_0003884', 'HP_0002905']",False,False,2,,,
805,TIOTROPIUM BROMIDE,CHEMBL3545181,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 4 investigational indications.,,4.0,,False,2004,['ENSG00000133019'],"['EFO_1001919', 'HP_0006536', 'HP_0000083', 'HP_0025428', 'MONDO_0009061', 'EFO_0000616', 'EFO_0000341', 'MONDO_0004979', 'EFO_0006505', 'EFO_0000464']",True,True,10,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
806,BIMIRALISIB,CHEMBL4084907,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005952', 'EFO_0000574', 'EFO_0000519', 'EFO_0000616', 'MONDO_0007254']",False,False,5,,,
807,POMALIDOMIDE,CHEMBL43452,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for immune system disease and multiple myeloma and has 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']","['EFO_0003073', 'EFO_0009441', 'EFO_0005952', 'MONDO_0019180', 'MONDO_0015564', 'MONDO_0017816', 'EFO_0002618', 'EFO_0006475', 'EFO_0002430', 'EFO_0000717', 'EFO_0002939', 'EFO_0002429', 'EFO_0004251', 'EFO_0000616', 'EFO_0000702', 'EFO_0000403', 'EFO_0000540', 'EFO_0000558', 'EFO_0004244', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000183', 'EFO_0000309', 'MONDO_0019438', 'MONDO_0013730', 'EFO_0009448', 'EFO_0001378', 'EFO_0006738', 'MONDO_0044903', 'MONDO_0011382']",False,False,30,CRL4(CRBN) E3 ubiquitin ligase inhibitor ,INHIBITOR ,protein complex 
808,ITRACONAZOLE,CHEMBL64391,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 51 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,[],"['EFO_0000616', 'EFO_0000519', 'MONDO_0005341', 'EFO_0000673', 'EFO_0003767', 'EFO_0003144', 'EFO_0007211', 'EFO_0007265', 'EFO_0000660', 'EFO_0007140', 'EFO_0001068', 'EFO_0004197', 'MONDO_0008170', 'EFO_0005762', 'EFO_1001413', 'MONDO_0004975', 'EFO_0002617', 'EFO_0001378', 'HP_0004326', 'EFO_0000222', 'MONDO_0007576', 'EFO_0000198', 'EFO_0007510', 'MONDO_0100096', 'MONDO_0009061', 'EFO_0007494', 'EFO_0007157', 'EFO_0004239', 'EFO_0003060', 'EFO_0009516', 'MONDO_0002026', 'EFO_0000574', 'MONDO_0000831', 'EFO_0001060', 'EFO_0007439', 'EFO_0008525', 'EFO_0007310', 'EFO_0007486', 'EFO_0007174', 'HP_0001871', 'EFO_1001459', 'EFO_0000341', 'EFO_0003818', 'MONDO_0002041', 'EFO_0000384', 'MONDO_0004992', 'EFO_0004193', 'EFO_0005952', 'EFO_0009708', 'EFO_0000544', 'EFO_0007512', 'EFO_0007229', 'MONDO_0008315', 'MONDO_0004979', 'MONDO_0008903', 'EFO_0007228', 'EFO_0004220']",False,False,57,Cytochrome P450 51 inhibitor ,INHIBITOR ,single protein 
809,FOSCARNET,CHEMBL666,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,[],"['EFO_0001062', 'MONDO_0013730', 'EFO_0000763', 'EFO_1002022', 'EFO_0000764', 'EFO_1001302', 'MONDO_0003778', 'EFO_0010282', 'EFO_0003106', 'EFO_0000544', 'EFO_1001302']",False,False,11,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
810,INSULIN,CHEMBL1201631,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 50 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1982,['ENSG00000171105'],"['MONDO_0021187', 'HP_0003074', 'EFO_1000783', 'EFO_1001050', 'HP_0000842', 'MONDO_0005148', 'EFO_0009492', 'EFO_0007430', 'HP_0003124', 'MONDO_0005041', 'HP_0001919', 'EFO_0003840', 'EFO_0001358', 'EFO_0002614', 'EFO_0009267', 'MONDO_0005148', 'HP_0002140', 'EFO_0000373', 'EFO_0000712', 'EFO_1000906', 'EFO_0001645', 'HP_0100543', 'MONDO_0002009', 'EFO_0003768', 'EFO_0003917', 'EFO_1000653', 'EFO_0000400', 'EFO_0008583', 'EFO_0005672', 'EFO_0003929', 'EFO_0000400', 'MONDO_0005180', 'EFO_0003914', 'EFO_0004143', 'EFO_0003843', 'EFO_0001073', 'MONDO_0100096', 'EFO_1000985', 'MONDO_0002146', 'EFO_0000612', 'EFO_0003095', 'EFO_0000546', 'MONDO_0018555', 'EFO_0006834', 'EFO_0009516', 'MONDO_0005147', 'EFO_0004593', 'HP_0001943', 'MONDO_0004985', 'EFO_0000537', 'MONDO_0005090', 'HP_0002153']",True,False,52,Insulin receptor agonist ,AGONIST ,single protein 
811,DOBESILIC ACID,CHEMBL1232131,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and varicose veins and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1000760', 'MONDO_0005148', 'EFO_0000545', 'HP_0000132', 'MP_0001914', 'HP_0002619', 'MONDO_0100096', 'EFO_0009579']",False,False,8,,,
812,AGATOLIMOD SODIUM,CHEMBL2103793,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,['ENSG00000239732'],"['EFO_0005952', 'EFO_0009441', 'EFO_0002913', 'EFO_0003869', 'EFO_0000403', 'EFO_0000764', 'EFO_0001068', 'EFO_0000756', 'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806', 'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576', 'EFO_0000313', 'MONDO_0008315', 'EFO_0000191', 'EFO_0003060', 'EFO_1001469']",False,False,21,Toll-like receptor 9 agonist ,AGONIST ,single protein 
813,AFATINIB DIMALEATE,CHEMBL2105712,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,4.0,,False,2013,"['ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']","['EFO_0003060', 'EFO_0001378']",False,True,2,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
814,MYCOPHENOLATE SODIUM,CHEMBL2106643,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,"['ENSG00000106348', 'ENSG00000178035']","['EFO_0000699', 'EFO_0005761', 'EFO_0005140', 'HP_0001871', 'EFO_1002048', 'EFO_0003884', 'EFO_0004599', 'EFO_0003086']",False,False,8,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor ,INHIBITOR ,protein family 
815,TOSITUMOMAB 131I,CHEMBL3833304,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,['ENSG00000156738'],"['EFO_0000403', 'EFO_0001378', 'MONDO_0000873', 'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000574', 'EFO_0000191', 'MONDO_0018906', 'EFO_1001469', 'EFO_0003032', 'EFO_0000183', 'EFO_0000309', 'EFO_0000095']",False,False,14,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
816,ENCEQUIDAR MESYLATE,CHEMBL4594299,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000616', 'EFO_0003968']",False,False,3,,,
817,ERFONRILIMAB,CHEMBL4650483,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000120217', 'ENSG00000163599']","['EFO_0002517', 'EFO_0000574', 'EFO_0000616', 'EFO_0003060', 'EFO_0005922', 'EFO_0005537', 'EFO_1000576', 'EFO_0000182']",False,False,8,Cytotoxic T-lymphocyte protein 4 inhibitor Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
818,MITOXANTRONE,CHEMBL58,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 46 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,['ENSG00000131747'],"['EFO_0000403', 'EFO_0000211', 'MONDO_0015760', 'MONDO_0019472', 'EFO_0000565', 'EFO_0000182', 'MONDO_0005301', 'EFO_0004289', 'EFO_1001469', 'EFO_0002618', 'MONDO_0008170', 'EFO_0003843', 'EFO_0000220', 'EFO_0000403', 'EFO_0004289', 'MONDO_0018906', 'EFO_0001378', 'EFO_0000616', 'EFO_0004251', 'EFO_0000673', 'EFO_0003929', 'EFO_0000196', 'EFO_0000221', 'EFO_1001830', 'EFO_1001469', 'EFO_0005952', 'EFO_0008522', 'MONDO_0004992', 'EFO_0000224', 'EFO_0000339', 'EFO_0000095', 'MONDO_0008315', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000222', 'EFO_0000178', 'MONDO_0007254', 'EFO_0006859', 'EFO_0000198', 'MONDO_0007254', 'EFO_1000286', 'EFO_0000326', 'EFO_0000574', 'MONDO_0019472', 'EFO_0000211', 'EFO_0000222', 'MONDO_0001023', 'MONDO_0005301', 'EFO_0001378', 'EFO_0000616', 'MONDO_0019460', 'MONDO_0000873', 'EFO_1001052', 'EFO_0000574', 'EFO_0001663']",False,False,55,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
819,SODIUM NITRITE,CHEMBL93268,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for poisoning and has 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,[],"['EFO_0004265', 'MONDO_0011382', 'EFO_0000713', 'EFO_0008583', 'EFO_0001361', 'EFO_0007444', 'MONDO_0009061', 'EFO_0000400', 'EFO_0000537', 'EFO_0003144', 'HP_0001919', 'MONDO_0005149', 'EFO_0003884', 'GO_0007568', 'EFO_0008546', 'EFO_0009492', 'MONDO_0004979', 'EFO_0008585']",False,False,18,,,
820,CEFOXITIN,CHEMBL996,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,[],"['EFO_0002618', 'EFO_0000544', 'EFO_0003106', 'EFO_0000771', 'EFO_0003102']",False,False,5,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
821,AZD-7624,CHEMBL9960,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000112062'],"['MONDO_0004979', 'EFO_0000341', 'MP_0001845']",False,False,3,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
822,SEVELAMER,CHEMBL1201798,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic kidney disease and has 4 investigational indications.,,4.0,,False,2007,[],"['HP_0002905', 'EFO_0000401', 'EFO_0000180', 'EFO_1002048', 'EFO_0003884']",False,False,5,,,
823,PATIROMER,CHEMBL2107875,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['HP_0002153', 'EFO_0003884', 'EFO_0003144']",False,False,3,,,
824,LIXISENATIDE,CHEMBL2108336,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 3 investigational indications.,,4.0,,False,2016,['ENSG00000112164'],"['EFO_0000400', 'MONDO_0005147', 'EFO_0005672', 'MONDO_0005148', 'MONDO_0005180']",False,False,5,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
825,CYCLO(PROLYLGLYCYL),CHEMBL360216,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000694']",False,False,2,,,
826,TRETINOIN,CHEMBL38,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 36 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1971,"['ENSG00000172819', 'ENSG00000077092', 'ENSG00000131759']","['EFO_0000621', 'EFO_0002618', 'EFO_0000231', 'EFO_0000198', 'EFO_0007160', 'EFO_0000616', 'EFO_0003060', 'HP_0001065', 'EFO_0000389', 'EFO_0000464', 'EFO_0004268', 'EFO_0000673', 'EFO_0004193', 'MONDO_0002280', 'EFO_0003963', 'MONDO_0044881', 'EFO_0001378', 'EFO_0000702', 'EFO_0000222', 'EFO_0000574', 'MONDO_0021582', 'EFO_0004826', 'EFO_1000760', 'EFO_0003758', 'MONDO_0004976', 'MONDO_0008903', 'EFO_0000224', 'EFO_0003869', 'EFO_0002496', 'MONDO_0007254', 'EFO_0000707', 'EFO_0000565', 'MONDO_0002367', 'EFO_0003894', 'MONDO_0019098', 'EFO_0004251', 'EFO_0000756', 'HP_0003124', 'MONDO_0100096', 'MONDO_0020077']",True,False,40,Retinoic acid receptor agonist ,AGONIST ,protein family 
827,GLESATINIB,CHEMBL3989914,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105976', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000120156', 'ENSG00000164078']","['EFO_0003060', 'MONDO_0004992']",False,False,2,Vascular endothelial growth factor receptor inhibitor Macrophage-stimulating protein receptor inhibitor Hepatocyte growth factor receptor inhibitor Tyrosine-protein kinase TIE-2 inhibitor ,INHIBITOR ,protein family single protein 
828,PACLITAXEL DOCOSAHEXAENOIC ACID,CHEMBL4297441,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0003060', 'EFO_0000182', 'EFO_0002617']",True,False,3,Tubulin stabiliser ,STABILISER ,protein complex group 
829,GSK-2586881,CHEMBL4297887,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000135744'],"['EFO_0001361', 'EFO_0004610', 'MONDO_0100096']",False,False,3,Angiotensinogen hydrolytic enzyme ,HYDROLYTIC ENZYME ,single protein 
830,BBV-152 ANTIGEN ADJUVATED WITH ALGEL-IMDG,CHEMBL4802199,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
831,EXEMESTANE,CHEMBL1200374,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 10 investigational indications.,,4.0,,False,1999,['ENSG00000137869'],"['MONDO_0011962', 'MONDO_0008315', 'MONDO_0004658', 'EFO_0006861', 'EFO_0000432', 'MONDO_0007254', 'EFO_0000305', 'EFO_0003869', 'EFO_0003060', 'EFO_0000616', 'EFO_0000673', 'EFO_1000098', 'MONDO_0008170', 'EFO_0000574', 'MONDO_0004992']",False,False,15,Cytochrome P450 19A1 inhibitor ,INHIBITOR ,single protein 
832,DOXAZOSIN MESYLATE,CHEMBL1200561,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved indications.,,4.0,,False,1990,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0000537', 'EFO_0000612', 'EFO_0000284']",True,False,3,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
833,SULFUR HEXAFLUORIDE,CHEMBL1796998,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005149', 'EFO_0002517', 'MONDO_0007254', 'HP_0002140']",False,False,4,,,
834,ABEDITEROL,CHEMBL3039530,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000169252'],"['MONDO_0004979', 'EFO_0000341']",False,False,2,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
835,ADAGLOXAD SIMOLENIN,CHEMBL3707279,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000182', 'MONDO_0008170', 'MONDO_0007254']",False,False,3,Hemocyanin 1 vaccine antigen ,VACCINE ANTIGEN ,single protein 
836,GLYBURIDE,CHEMBL472,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications.,,4.0,,False,1984,"['ENSG00000187486', 'ENSG00000006071']","['EFO_0000400', 'EFO_1001919', 'HP_0002140', 'EFO_0000712', 'MONDO_0005147', 'MONDO_0005148', 'EFO_0004593', 'MONDO_0043510', 'EFO_0003913']",False,False,9,"Sulfonylurea receptor 1, Kir6.2 blocker ",BLOCKER ,protein complex 
837,MELPHALAN HYDROCHLORIDE,CHEMBL1200863,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,[],"['EFO_1001469', 'EFO_1001875', 'EFO_0000095', 'MONDO_0018906', 'EFO_0000198', 'EFO_0001378', 'MONDO_0013730', 'MONDO_0008380', 'EFO_0000403', 'EFO_0005952', 'EFO_0000339', 'EFO_0000222', 'EFO_0000326', 'EFO_0000183']",False,False,14,,,
838,CHOLESTYRAMINE,CHEMBL1201625,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 8 investigational indications.,,4.0,,False,1973,[],"['EFO_0004911', 'EFO_0004255', 'EFO_1001375', 'EFO_0004237', 'EFO_0003073', 'EFO_0000319', 'HP_0003124', 'EFO_0000612', 'EFO_0004705', 'Orphanet_309005', 'MONDO_0005301', 'EFO_0003086']",False,False,12,,,
839,FRESOLIMUMAB,CHEMBL1743022,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,"['ENSG00000119699', 'ENSG00000092969', 'ENSG00000105329']","['EFO_0003833', 'EFO_0003060', 'EFO_0000770', 'EFO_0004236', 'EFO_0000768', 'EFO_0000404', 'MONDO_0019019', 'EFO_0000681', 'MONDO_0007254']",True,False,9,Transforming growth factor beta-2 inhibitor Transforming growth factor beta-1 inhibitor Transforming growth factor beta-3 inhibitor ,INHIBITOR ,single protein 
840,CEDIRANIB MALEATE,CHEMBL2103798,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001951', 'EFO_0000702', 'EFO_0006861', 'EFO_1001465', 'EFO_0000389', 'EFO_0000770', 'EFO_0000519', 'EFO_0000349', 'EFO_0003060', 'MONDO_0002974', 'EFO_0002892', 'EFO_0000182', 'EFO_0002617', 'EFO_0000681', 'EFO_0000095', 'EFO_0000673', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0000588']",False,False,19,,,
841,PARSATUZUMAB,CHEMBL2109387,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000172889'],"['EFO_0003060', 'MONDO_0004992']",False,False,2,Epidermal growth factor-like protein 7 inhibitor ,INHIBITOR ,single protein 
842,DAROTROPIUM BROMIDE,CHEMBL2308782,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000133019', 'ENSG00000180720', 'ENSG00000168539', 'ENSG00000181072', 'ENSG00000184984']",['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor antagonist ,ANTAGONIST ,protein family 
843,CEFTAROLINE FOSAMIL ACETATE,CHEMBL3544973,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for chronic kidney disease and bacterial pneumonia.,,4.0,,False,2010,[],"['EFO_0003884', 'EFO_1001272']",False,False,2,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
844,QS-21,CHEMBL4297817,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002087', 'EFO_0000764', 'MONDO_0002158', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000565', 'MONDO_0018906', 'EFO_0001663', 'EFO_1002022', 'MONDO_0004975', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0008170']",False,False,13,,,
845,NINTEDANIB,CHEMBL502835,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 45 investigational indications.,,4.0,,False,2014,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['MONDO_0019180', 'EFO_1001331', 'MONDO_0044937', 'MONDO_0011705', 'EFO_0000222', 'EFO_1001949', 'EFO_0003893', 'MONDO_0011962', 'EFO_0000768', 'EFO_0001378', 'EFO_0000691', 'EFO_0000503', 'EFO_1001465', 'MONDO_0007254', 'EFO_0000681', 'EFO_0000588', 'EFO_0007183', 'EFO_0009448', 'EFO_0000571', 'EFO_0000616', 'MONDO_0008903', 'MONDO_0100096', 'EFO_0008528', 'EFO_0000708', 'EFO_0004284', 'EFO_0000182', 'EFO_0002618', 'EFO_0000717', 'EFO_0000770', 'EFO_0002499', 'EFO_0000519', 'EFO_0001416', 'MONDO_0001235', 'MONDO_0004669', 'MONDO_0015277', 'EFO_0000702', 'MONDO_0008170', 'MONDO_0002158', 'EFO_0000768', 'EFO_0004142', 'EFO_1001951', 'MONDO_0002087', 'EFO_0000673', 'EFO_0000717', 'EFO_0003060', 'EFO_0004243', 'EFO_0000389', 'EFO_0002501', 'EFO_0004244']",True,True,49,Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family protein complex 
846,ATAMPARIB,CHEMBL5095043,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0003060']",False,False,2,,,
847,LIDOCAINE,CHEMBL79,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 22 approved and 103 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1948,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0003943', 'MONDO_0008903', 'EFO_0004273', 'EFO_1001097', 'EFO_0009364', 'MONDO_0001572', 'EFO_0001074', 'Orphanet_365', 'EFO_0002610', 'HP_0003418', 'EFO_0001663', 'EFO_0003843', 'EFO_1000941', 'EFO_0009688', 'HP_0100543', 'HP_0000989', 'EFO_1001434', 'EFO_0004616', 'MONDO_0004992', 'HP_0003419', 'EFO_1001993', 'EFO_0000555', 'EFO_0005856', 'EFO_0009552', 'EFO_0003878', 'EFO_1001896', 'HP_0002315', 'EFO_0003958', 'EFO_0007214', 'EFO_1001250', 'EFO_1000249', 'EFO_0000668', 'EFO_0009660', 'EFO_1001139', 'EFO_1001087', 'EFO_0002970', 'HP_0003394', 'EFO_1001178', 'EFO_1001998', 'MONDO_0007254', 'EFO_0000712', 'EFO_0002618', 'EFO_0009430', 'EFO_0003917', 'HP_0012532', 'MP_0001845', 'HP_0002315', 'EFO_0001073', 'EFO_0004143', 'EFO_0000546', 'EFO_0009620', 'EFO_0007490', 'MONDO_0004567', 'HP_0001907', 'EFO_0003888', 'EFO_1001951', 'HP_0000360', 'EFO_0010582', 'MONDO_0100096', 'EFO_0000519', 'EFO_0003902', 'EFO_1001898', 'EFO_0004142', 'EFO_0003833', 'EFO_0000701', 'EFO_0009492', 'EFO_0000537', 'EFO_0009619', 'EFO_0006834', 'EFO_0005762', 'EFO_0003100', 'HP_0030834', 'HP_0000020', 'HP_0100607', 'MONDO_0002258', 'MP_0001914', 'EFO_0005279', 'EFO_0003777', 'EFO_0003957', 'EFO_1001996', 'EFO_0005687', 'EFO_0003103', 'EFO_0009516', 'EFO_1001219', 'MONDO_0005178', 'EFO_0000545', 'EFO_0005754', 'EFO_0009552', 'EFO_1001054', 'HP_0003418', 'EFO_1001412', 'EFO_0009846', 'EFO_0000616', 'EFO_0000546', 'EFO_0000400', 'MONDO_0005277', 'HP_0000951', 'HP_0004308', 'EFO_0001069', 'HP_0003326', 'EFO_1000910', 'EFO_1000781', 'MONDO_0004992', 'MONDO_0002691', 'EFO_1001904', 'EFO_1000783', 'EFO_0004198', 'EFO_0003901', 'EFO_0000707', 'HP_0000989', 'EFO_0002950', 'EFO_0002950', 'EFO_0001361', 'EFO_1000889', 'HP_0012532', 'EFO_0003843', 'EFO_0009582', 'EFO_0007486', 'EFO_0000305', 'MONDO_0005277', 'HP_0012735', 'EFO_0001365', 'EFO_0004269', 'EFO_0003854', 'EFO_0008507', 'EFO_0005230', 'EFO_0000313', 'EFO_1001887', 'MONDO_0041052', 'EFO_0002496']",True,False,130,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
848,DISULFIRAM,CHEMBL964,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for parasitic infection and alcohol dependence and has 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1951,['ENSG00000111275'],"['EFO_0001378', 'EFO_0002610', 'EFO_0000519', 'EFO_0005611', 'EFO_0001067', 'EFO_0001073', 'EFO_0002617', 'MONDO_0004992', 'EFO_0003060', 'EFO_0004701', 'EFO_0002618', 'EFO_0000756', 'MONDO_0008315', 'HP_0012378', 'EFO_0000691', 'EFO_0000764', 'MONDO_0021698', 'MONDO_0007254', 'MONDO_0007079', 'MONDO_0100096', 'EFO_0000514']",True,False,21,Aldehyde dehydrogenase inhibitor ,INHIBITOR ,single protein 
849,ISOSULFAN BLUE,CHEMBL1200859,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and has 1 investigational indication.,,4.0,,False,1981,[],['MONDO_0007254'],False,False,1,,,
850,METHYLPREDNISOLONE SODIUM SUCCINATE,CHEMBL1201081,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 16 approved and 25 investigational indications.,,4.0,,False,1959,['ENSG00000113580'],"['EFO_0000694', 'MP_0001845', 'MONDO_0004979', 'EFO_0008522', 'MONDO_0002280', 'MONDO_0007915', 'EFO_0000095', 'EFO_1001222', 'EFO_0000540', 'MONDO_0002406', 'EFO_0003894', 'MONDO_0100096', 'EFO_1001119', 'MONDO_0005301', 'EFO_0000220', 'EFO_0003106', 'EFO_0002609', 'EFO_0003843', 'MONDO_0002471', 'MONDO_0002462', 'MONDO_0013730', 'EFO_0003840', 'MONDO_0005178', 'EFO_0000198', 'EFO_0000685', 'EFO_0004194', 'EFO_1001272', 'EFO_0000574', 'EFO_0004599', 'EFO_0000565', 'EFO_0005952', 'EFO_0001379', 'EFO_0007359', 'EFO_0007332', 'EFO_0003778', 'EFO_0007537', 'EFO_0004228', 'EFO_0001378', 'EFO_0000222', 'EFO_0000474', 'EFO_0001063']",True,False,41,Glucocorticoid receptor agonist ,AGONIST ,single protein 
851,INSULIN SUSP ISOPHANE BEEF,CHEMBL1201545,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.,,4.0,,False,1982,['ENSG00000171105'],"['MONDO_0005148', 'MONDO_0005147', 'EFO_0004593']",False,False,3,Insulin receptor agonist ,AGONIST ,single protein 
852,TRASTUZUMAB,CHEMBL1201585,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 65 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000141736'],"['EFO_0003897', 'MONDO_0018364', 'EFO_0009637', 'MONDO_0004192', 'EFO_1000796', 'EFO_0005774', 'MONDO_0003060', 'EFO_0000305', 'MONDO_0002974', 'MONDO_0021311', 'EFO_0000691', 'EFO_0005922', 'MONDO_0003510', 'EFO_0005537', 'EFO_0000183', 'MONDO_0002158', 'EFO_0000616', 'MONDO_0005411', 'MONDO_0003196', 'MONDO_0001402', 'EFO_0000222', 'EFO_1001187', 'EFO_0000641', 'EFO_1001951', 'MONDO_0001528', 'EFO_1001512', 'EFO_0002916', 'MONDO_0008315', 'EFO_1001051', 'EFO_0003968', 'MONDO_0021165', 'MONDO_0011962', 'EFO_0005221', 'EFO_0000501', 'MONDO_0004986', 'MONDO_0004669', 'EFO_0000549', 'EFO_0003863', 'MONDO_0000521', 'EFO_0000701', 'EFO_0000637', 'EFO_1000028', 'EFO_0006861', 'MONDO_0001370', 'EFO_0000228', 'MONDO_0001879', 'EFO_0009708', 'EFO_0000432', 'EFO_0006859', 'EFO_1000984', 'EFO_0006352', 'MONDO_0007254', 'MONDO_0004992', 'MONDO_0007576', 'EFO_0002618', 'MONDO_0002087', 'EFO_0003060', 'MONDO_0044926', 'MONDO_0001187', 'EFO_0000503', 'EFO_0008549', 'EFO_0000313', 'MONDO_0008170', 'MONDO_0008903', 'EFO_0004142', 'EFO_0000565', 'EFO_0006318', 'EFO_0003869', 'EFO_0005952', 'MONDO_0001056']",False,True,70,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
853,MIRVETUXIMAB SORAVTANSINE,CHEMBL3545132,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000110195', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0007254', 'MONDO_0011962', 'EFO_0000616', 'MONDO_0002158', 'MONDO_0008170', 'EFO_0000305']",True,False,6,Tubulin inhibitor Folate receptor alpha binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
854,CIRMTUZUMAB,CHEMBL4297728,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000185483'],"['MONDO_0001056', 'EFO_0002618', 'EFO_0003060', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0000096', 'EFO_0005537', 'EFO_0000403', 'EFO_0000095']",False,False,9,Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor ,INHIBITOR ,single protein 
855,MELATONIN,CHEMBL45,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 65 investigational indications.,,4.0,,False,no approval year,"['ENSG00000168412', 'ENSG00000134640']","['EFO_0003843', 'EFO_0000195', 'EFO_0000555', 'MONDO_0001134', 'HP_0001919', 'MONDO_0100096', 'EFO_0000589', 'EFO_0000616', 'MONDO_0005090', 'EFO_0005800', 'EFO_0005687', 'EFO_0003888', 'EFO_0000729', 'EFO_0000546', 'HP_0100806', 'EFO_0003758', 'EFO_0008568', 'EFO_0009267', 'EFO_1000824', 'EFO_0000275', 'EFO_0000280', 'EFO_0003918', 'HP_0012378', 'MONDO_0002050', 'EFO_0002687', 'HP_0040187', 'EFO_0000474', 'EFO_0003756', 'EFO_0008583', 'MP_0001914', 'EFO_1001216', 'EFO_0000701', 'MONDO_0002009', 'EFO_1001904', 'HP_0100543', 'EFO_0000649', 'EFO_0006859', 'EFO_0003948', 'EFO_0003928', 'EFO_1001121', 'EFO_0009516', 'MONDO_0024290', 'MONDO_0005277', 'EFO_0000756', 'EFO_0000274', 'HP_0031217', 'EFO_0003929', 'EFO_0001666', 'MONDO_0005180', 'HP_0000938', 'EFO_0005547', 'EFO_0000400', 'EFO_0003958', 'MONDO_0021698', 'MONDO_0004992', 'MONDO_0005301', 'EFO_0009579', 'EFO_0000199', 'EFO_0003060', 'MONDO_0007254', 'MONDO_0002635', 'EFO_0004698', 'MONDO_0005299', 'EFO_0000537', 'EFO_0005230']",False,False,65,Melatonin receptor agonist ,AGONIST ,protein family 
856,AZD4205,CHEMBL4577523,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000162434'],"['EFO_0000211', 'EFO_0003060']",False,False,2,Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
857,IZALONTAMAB,CHEMBL5095384,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1001951', 'EFO_0005922', 'EFO_0000181', 'EFO_0003060', 'EFO_0000616']",False,False,5,,,
858,DOVITINIB,CHEMBL522892,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications.,,3.0,,False,no approval year,"['ENSG00000122025', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']","['EFO_0002517', 'EFO_0000182', 'MONDO_0008667', 'EFO_0000222', 'MONDO_0008315', 'EFO_1001465', 'MONDO_0011719', 'EFO_0001378', 'MONDO_0007254', 'MONDO_0001187', 'EFO_0000231', 'EFO_0003060', 'EFO_1000796', 'EFO_0003060', 'MONDO_0002108', 'EFO_0000519', 'EFO_0000756', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0000349', 'MONDO_0011962', 'EFO_0000770', 'EFO_0000681', 'EFO_0003863', 'EFO_0000616']",True,False,25,Vascular endothelial growth factor receptor inhibitor Fibroblast growth factor receptor 3 inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,protein family single protein protein complex 
859,IPILIMUMAB,CHEMBL1789844,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 93 investigational indications.,,4.0,,False,2011,['ENSG00000163599'],"['MONDO_0001056', 'EFO_0000708', 'EFO_0007466', 'EFO_1000984', 'EFO_1001950', 'EFO_0000389', 'EFO_0001416', 'EFO_0004251', 'EFO_0001376', 'EFO_0005952', 'EFO_1001972', 'EFO_0001378', 'EFO_0004288', 'EFO_0002617', 'MONDO_0002087', 'EFO_0002618', 'EFO_0000339', 'EFO_0009709', 'EFO_0008528', 'EFO_0000096', 'MONDO_0007187', 'EFO_0000305', 'EFO_0000403', 'MONDO_0009348', 'EFO_0000756', 'MONDO_0002367', 'EFO_0000681', 'EFO_1001968', 'EFO_0006859', 'EFO_0003085', 'EFO_1001471', 'EFO_0000621', 'EFO_0000181', 'EFO_0000365', 'EFO_0004243', 'MONDO_0011719', 'EFO_0004284', 'EFO_0003891', 'EFO_0000198', 'EFO_0000220', 'MONDO_0004992', 'EFO_1000657', 'EFO_0000228', 'EFO_0000702', 'EFO_0000616', 'MONDO_0002120', 'EFO_0001075', 'MONDO_0001187', 'EFO_0000519', 'EFO_0005543', 'EFO_1001512', 'EFO_0000503', 'EFO_0000588', 'EFO_0004252', 'EFO_0004193', 'EFO_0001061', 'EFO_0000770', 'EFO_0000196', 'MONDO_0011962', 'MONDO_0008903', 'EFO_1000613', 'EFO_1001951', 'MONDO_0024503', 'EFO_0000673', 'MONDO_0020634', 'EFO_0000707', 'EFO_0000571', 'EFO_0000222', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0004142', 'EFO_0000182', 'MONDO_0016642', 'MONDO_0004669', 'EFO_0000558', 'EFO_0002517', 'MONDO_0002547', 'EFO_0000095', 'MONDO_0007576', 'EFO_1000251', 'MONDO_0002898', 'EFO_0000349', 'EFO_0002916', 'MONDO_0100342', 'MONDO_0017582', 'EFO_0001663', 'EFO_0000313', 'MONDO_0021063', 'EFO_0000574', 'EFO_0003863', 'MONDO_0002108', 'EFO_0000691', 'EFO_0008524', 'EFO_1001465', 'EFO_0003060', 'MONDO_0008315', 'EFO_0000764', 'EFO_0000183']",True,False,98,Cytotoxic T-lymphocyte protein 4 inhibitor ,INHIBITOR ,single protein 
860,TRIAPINE,CHEMBL231616,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,"['ENSG00000167325', 'ENSG00000048392']","['EFO_0000616', 'MONDO_0005411', 'MONDO_0008903', 'MONDO_0024503', 'MONDO_0002367', 'EFO_0002618', 'MONDO_0008315', 'EFO_0006861', 'EFO_0003060']",False,False,9,Ribonucleotide reductase inhibitor ,INHIBITOR ,protein complex 
861,PENTAMIDINE ISETHIONATE,CHEMBL361506,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 4 approved and 4 investigational indications.,,4.0,,False,1984,[],"['EFO_0006346', 'EFO_0005044', 'EFO_0003060', 'EFO_0003106', 'EFO_0007448', 'DOID_10113', 'EFO_0000764', 'EFO_0007448']",False,False,8,,,
862,AMISELIMOD HYDROCHLORIDE,CHEMBL3707374,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']","['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729', 'MONDO_0007915', 'EFO_0000384']",True,False,6,Sphingosine 1-phosphate receptor modulator ,MODULATOR ,protein family 
863,NAVAFENTEROL,CHEMBL4297483,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000133019', 'ENSG00000169252']",['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor M3 antagonist Beta-2 adrenergic receptor agonist ,ANTAGONIST AGONIST ,single protein 
864,SY-5609,CHEMBL5090754,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000702', 'EFO_0002618']",False,False,3,,,
865,GONADORELIN ACETATE,CHEMBL1200511,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 9 investigational indications.,,4.0,,False,1989,['ENSG00000109163'],"['MONDO_0018555', 'EFO_0000673', 'EFO_0000196', 'EFO_0001663', 'MONDO_0008315', 'EFO_0000545', 'MONDO_0018800', 'MONDO_0007254', 'MONDO_0002146']",False,False,9,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
866,LEUCOVORIN,CHEMBL1679,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 118 investigational indications.,,4.0,,False,1952,[],"['EFO_0002499', 'EFO_0008549', 'MONDO_0001056', 'EFO_1001961', 'MONDO_0010100', 'EFO_0000681', 'EFO_0002617', 'EFO_0006859', 'EFO_0002618', 'EFO_0003757', 'EFO_0002939', 'MONDO_0003060', 'EFO_0000685', 'MONDO_0002691', 'EFO_0003891', 'EFO_1000657', 'EFO_0000685', 'MONDO_0007254', 'EFO_0000183', 'EFO_0005221', 'EFO_0002893', 'EFO_0000698', 'MONDO_0010006', 'EFO_0000178', 'EFO_0003032', 'EFO_0004142', 'EFO_1001365', 'EFO_0000707', 'EFO_0000181', 'EFO_0002501', 'EFO_1001949', 'EFO_0000365', 'EFO_0000228', 'EFO_0000365', 'EFO_1001100', 'EFO_0002428', 'EFO_0007448', 'EFO_0009534', 'EFO_1000158', 'MONDO_0002120', 'EFO_0000209', 'EFO_1001951', 'EFO_0000389', 'EFO_1000318', 'EFO_0000616', 'MONDO_0001235', 'EFO_1001469', 'MONDO_0002516', 'EFO_0003860', 'EFO_0000182', 'MONDO_0044917', 'MONDO_0007576', 'EFO_0000503', 'MONDO_0004992', 'EFO_0003897', 'EFO_0003833', 'MONDO_0003059', 'EFO_0000756', 'EFO_0002517', 'EFO_0000178', 'EFO_1000657', 'EFO_0005922', 'EFO_0007416', 'EFO_0003060', 'EFO_1001231', 'EFO_0001075', 'MONDO_0003060', 'EFO_1000298', 'EFO_0000220', 'EFO_0000565', 'MONDO_0016717', 'EFO_0004288', 'EFO_0003758', 'EFO_0000309', 'EFO_0000305', 'EFO_0000222', 'EFO_0000198', 'MONDO_0021063', 'EFO_1001471', 'MONDO_0000870', 'EFO_0003897', 'MONDO_0005575', 'EFO_0000616', 'MONDO_0021063', 'EFO_0000403', 'MONDO_0000873', 'EFO_1001901', 'EFO_0004142', 'EFO_0000637', 'MONDO_0008170', 'MONDO_0002087', 'MONDO_0001657', 'EFO_0008528', 'EFO_0000691', 'EFO_0000094', 'EFO_0009708', 'MONDO_0001056', 'EFO_0000313', 'EFO_0003100', 'EFO_0000574', 'EFO_0004252', 'EFO_1000251', 'MONDO_0011719', 'EFO_0005952', 'EFO_0007200', 'EFO_0000211', 'EFO_0000197', 'EFO_0003860', 'EFO_0007517', 'MONDO_0018944', 'EFO_0004252', 'MONDO_0001056', 'EFO_0001064', 'EFO_0005235', 'MONDO_0005835', 'EFO_0002618', 'EFO_0002916', 'MONDO_0044937', 'EFO_0000503', 'EFO_0001378', 'EFO_1001951', 'EFO_1001465', 'EFO_0000182']",False,False,123,,,
867,ETRASIMOD,CHEMBL3358920,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000170989'],"['EFO_0004232', 'EFO_0003767', 'EFO_0000274', 'EFO_1001486', 'EFO_0000729', 'HP_0000999', 'EFO_0000384', 'EFO_0004192']",False,False,8,Sphingosine 1-phosphate receptor Edg-1 agonist ,AGONIST ,single protein 
868,DOCONEXENT,CHEMBL367149,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 47 investigational indications.,,3.0,,False,no approval year,[],"['MP_0001845', 'EFO_0001645', 'HP_0001397', 'MONDO_0001751', 'EFO_0009431', 'MONDO_0011382', 'EFO_0001421', 'MONDO_0002009', 'EFO_1001917', 'EFO_0001073', 'EFO_0003888', 'GO_0007568', 'EFO_0000319', 'EFO_0003095', 'MONDO_0005180', 'EFO_0009606', 'MONDO_0002050', 'MONDO_0019200', 'EFO_0003777', 'MONDO_0004975', 'MONDO_0004979', 'EFO_0003144', 'EFO_0000685', 'MONDO_0005301', 'EFO_0003884', 'EFO_0000474', 'MONDO_0100096', 'HP_0100806', 'MONDO_0007254', 'EFO_0002950', 'MONDO_0009061', 'EFO_0003086', 'MONDO_0001020', 'EFO_0000432', 'EFO_0008509', 'MONDO_0005147', 'EFO_0003917', 'EFO_1000783', 'MONDO_0021165', 'MONDO_0004992', 'HP_0100543', 'EFO_1001158', 'EFO_0005406', 'EFO_0004269', 'MONDO_0007915', 'EFO_0003928', 'EFO_0011023']",False,False,47,,,
869,RECOMBINANT HUMAN THROMBOPOIETIN,CHEMBL4802180,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007160', 'MONDO_0004992', 'HP_0001915', 'EFO_0000222', 'EFO_0000691', 'EFO_0000365', 'HP_0001873', 'EFO_0001422', 'EFO_0003060']",False,False,9,,,
870,AMRUBICIN HYDROCHLORIDE,CHEMBL481958,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000131747'],"['MONDO_0008903', 'EFO_0000702']",True,False,2,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
871,CEFTOBIPROLE,CHEMBL520642,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003106'],False,False,1,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
872,CANNABINOL,CHEMBL74415,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 47 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000474', 'HP_0030833', 'EFO_0000729', 'EFO_1001919', 'MONDO_0007739', 'HP_0012532', 'EFO_0001072', 'EFO_0003778', 'MONDO_0005301', 'EFO_0005762', 'MONDO_0004992', 'EFO_1000710', 'EFO_0003047', 'EFO_0004698', 'EFO_0000765', 'EFO_0010702', 'MONDO_0005180', 'HP_0002027', 'EFO_0005230', 'HP_0000360', 'HP_0003418', 'EFO_0004242', 'EFO_0000694', 'EFO_0007191', 'EFO_0001358', 'EFO_0000384', 'MONDO_0004976', 'MONDO_0043510', 'EFO_1001033', 'MONDO_0005041', 'EFO_0003843', 'MONDO_0100096', 'MONDO_0004985', 'HP_0001250', 'EFO_0005611', 'EFO_1001998', 'EFO_0003758', 'EFO_0004895', 'MONDO_0002050', 'EFO_0003756', 'HP_0001257', 'EFO_0005687', 'EFO_0000519', 'MONDO_0011382', 'EFO_1000783', 'EFO_0004616', 'EFO_0003888']",False,False,47,,,
873,TECHNETIUM TC 99M SULFUR COLLOID,CHEMBL1201529,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000756', 'EFO_0000305', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0009061', 'EFO_0003060']",False,False,6,,,
874,INTERFERON ALFACON-1,CHEMBL1201557,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for neoplasm and has 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,"['ENSG00000142166', 'ENSG00000159110']","['EFO_0004220', 'EFO_0007328', 'EFO_0000616', 'EFO_0003047', 'MONDO_0100096']",True,True,5,Interferon alpha/beta receptor agonist ,AGONIST ,protein complex 
875,ALEFACEPT,CHEMBL1201571,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and has 8 investigational indications.,,4.0,,False,2003,['ENSG00000116824'],"['EFO_0000540', 'EFO_1000726', 'EFO_0000676', 'MONDO_0005147', 'MONDO_0015597', 'EFO_0000574', 'HP_0001915', 'EFO_1002048', 'EFO_0003778']",False,False,9,T-cell surface antigen CD2 inhibitor ,INHIBITOR ,single protein 
876,APROTININ,CHEMBL1201619,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for hemorrhage and has 2 investigational indications. It was withdrawn in at least one region.,,4.0,,False,1993,"['ENSG00000122194', 'ENSG00000164344']","['EFO_0000278', 'MONDO_0007254', 'MP_0001914']",False,False,3,Plasma kallikrein inhibitor Plasminogen inhibitor ,INHIBITOR ,single protein 
877,CANNABIDIOL,CHEMBL190461,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 68 investigational indications.,,4.0,,False,2018,['ENSG00000118432'],"['MONDO_0005180', 'EFO_0005762', 'MONDO_0007739', 'MONDO_0008300', 'HP_0002829', 'EFO_0005230', 'MONDO_0004976', 'EFO_0004242', 'MONDO_0010726', 'EFO_0005411', 'EFO_0008507', 'MONDO_0005351', 'EFO_0001358', 'EFO_0010072', 'MONDO_0016532', 'EFO_0003756', 'EFO_0010702', 'EFO_0000384', 'EFO_0008526', 'HP_0001249', 'EFO_0004599', 'HP_0001397', 'EFO_0005676', 'EFO_0000764', 'EFO_0003843', 'EFO_1000783', 'EFO_0004698', 'EFO_0002610', 'MONDO_0013730', 'EFO_0007191', 'MONDO_0008501', 'MONDO_0005090', 'EFO_0003108', 'MONDO_0002959', 'EFO_0005407', 'EFO_0003778', 'HP_0000938', 'EFO_0003890', 'MONDO_0010826', 'EFO_0000180', 'EFO_0003758', 'HP_0012532', 'MONDO_0007079', 'MONDO_0100062', 'Orphanet_33069', 'Orphanet_93955', 'HP_0012167', 'MONDO_0004985', 'EFO_0000537', 'MONDO_0018097', 'MONDO_0005277', 'EFO_0000673', 'EFO_0004616', 'HP_0100543', 'EFO_0008568', 'EFO_0000729', 'EFO_0005611', 'EFO_0005687', 'EFO_0003086', 'MONDO_0010383', 'EFO_1000634', 'MONDO_0005178', 'MONDO_0008903', 'HP_0001250', 'MONDO_0007254', 'EFO_0003100', 'EFO_0000474', 'EFO_0000616', 'EFO_0004895', 'EFO_0009609', 'EFO_0003768', 'MONDO_0100096', 'EFO_0003144']",True,False,73,Cannabinoid CB1 receptor negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,single protein 
878,TRAMETINIB,CHEMBL2103875,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 38 investigational indications.,,4.0,,False,no approval year,"['ENSG00000126934', 'ENSG00000169032']","['MONDO_0011719', 'MONDO_0008315', 'EFO_1000926', 'MONDO_0015523', 'EFO_0000196', 'EFO_1000657', 'EFO_0000182', 'EFO_0000222', 'MONDO_0004976', 'EFO_0000565', 'MONDO_0008903', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000756', 'MONDO_0017795', 'EFO_0001378', 'EFO_0000305', 'EFO_0002617', 'EFO_1001968', 'EFO_0002517', 'EFO_1001951', 'MONDO_0021063', 'MONDO_0004992', 'HP_0100727', 'EFO_0003868', 'MONDO_0002974', 'EFO_1000849', 'EFO_0000571', 'EFO_0002618', 'MONDO_0001056', 'EFO_0005221', 'EFO_0000389', 'MONDO_0100342', 'EFO_0000501', 'MONDO_0002108', 'EFO_0000641', 'MONDO_0016642', 'EFO_0000365', 'EFO_0006772']",True,False,40,Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor ,INHIBITOR ,protein family 
879,TECHNETIUM TC 99M TILMANOCEPT,CHEMBL2108726,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for breast cancer and squamous cell carcinoma and has 4 investigational indications.,,4.0,,False,2013,[],"['EFO_0000756', 'MONDO_0007254', 'MONDO_0005835', 'MONDO_0011962', 'EFO_0000707', 'EFO_0000474']",False,False,6,,,
880,ABETIMUS SODIUM,CHEMBL2108835,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0005761', 'MONDO_0007915']",False,False,2,,,
881,TASELISIB,CHEMBL2387080,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['MONDO_0008903', 'EFO_0000708', 'EFO_0000305', 'EFO_0005952', 'MONDO_0007254', 'EFO_0001378']",True,False,6,PI3-kinase class I inhibitor ,INHIBITOR ,protein complex group 
882,DALCETRAPIB,CHEMBL313006,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000087237'],"['MONDO_0100096', 'EFO_0000319', 'EFO_0001645', 'MONDO_0021187', 'EFO_0004265', 'EFO_0005672', 'Orphanet_309005', 'HP_0003119']",False,False,8,Cholesteryl ester transfer protein inhibitor ,INHIBITOR ,single protein 
883,LY-3321367,CHEMBL4298022,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000389', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254']",False,False,4,,,
884,PLITIDEPSIN,CHEMBL451930,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000101210'],"['MONDO_0008315', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000574', 'EFO_0003085', 'MONDO_0100096', 'EFO_0001378']",False,False,7,Elongation factor 1-alpha 2 inhibitor ,INHIBITOR ,single protein 
885,MOSAPRIDE,CHEMBL60889,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000166736', 'ENSG00000186038', 'ENSG00000149305', 'ENSG00000186090', 'ENSG00000178084', 'ENSG00000164270']","['MONDO_0004567', 'EFO_0010282', 'EFO_0008533', 'HP_0002014', 'EFO_0000555', 'EFO_0008533', 'EFO_0000217', 'HP_0002019']",False,False,8,Serotonin 3 (5-HT3) receptor antagonist Serotonin 4 (5-HT4) receptor agonist ,ANTAGONIST AGONIST ,protein complex group single protein 
886,IOPAMIDOL,CHEMBL1200932,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for glioma and hypothalamic neoplasm and has 4 investigational indications.,,4.0,,False,1985,[],"['MONDO_0007254', 'EFO_0000681', 'MONDO_0008315', 'EFO_0005543', 'EFO_1000979', 'EFO_0008528']",False,False,6,,,
887,PYRONARIDINE,CHEMBL35228,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007530', 'EFO_0001068', 'EFO_0000222', 'EFO_0007141', 'EFO_0007444', 'MONDO_0100096', 'EFO_0001068', 'EFO_0000220', 'EFO_0007444']",False,False,9,,,
888,ABT-510,CHEMBL386115,Protein drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000183', 'EFO_0003060', 'EFO_0000691', 'EFO_0000389', 'EFO_0000616', 'EFO_0005952', 'EFO_0006859', 'EFO_0000681', 'EFO_0003833']",False,False,9,,,
889,PACMILIMAB,CHEMBL4297563,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000120217'],"['MONDO_0007254', 'EFO_0002617', 'EFO_0000574']",False,False,3,Programmed cell death 1 ligand 1 binding agent ,BINDING AGENT ,single protein 
890,TAVOKINOGENE TELSEPLASMID,CHEMBL4298206,Gene drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000181', 'MONDO_0007254', 'EFO_1001471', 'EFO_0000756', 'EFO_1001051']",False,False,5,,,
891,VEPDEGESTRANT,CHEMBL5095210,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0003869']",False,False,2,,,
892,ELLAGIC ACID,CHEMBL6246,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000195', 'MONDO_0018906']",False,False,2,,,
893,PALIFOSFAMIDE,CHEMBL889,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001968', 'MONDO_0004992', 'EFO_0000702', 'EFO_0000691', 'EFO_0000616', 'MONDO_0007254']",False,False,6,,,
894,"INALIMAREV (CEA, MUC-1, VACCINIA VIRUS)",CHEMBL2108609,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000228', 'MONDO_0007254', 'MONDO_0001187', 'EFO_1001951', 'MONDO_0008170']",False,False,5,,,
895,TETOMILAST,CHEMBL332750,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['EFO_0000341', 'EFO_0000729', 'EFO_0000384']",True,True,3,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
896,ACIPIMOX,CHEMBL345714,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000319', 'EFO_0000195', 'MONDO_0005148', 'EFO_0003144', 'EFO_0005204', 'MONDO_0005147']",False,False,6,,,
897,OLINVACIMAB,CHEMBL4298119,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000128052'],"['EFO_0005537', 'MONDO_0007254', 'EFO_0000519']",False,False,3,Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
898,PLB1003,CHEMBL4650298,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,"['ENSG00000171094', 'ENSG00000143924']",['EFO_0003060'],False,False,1,EML4-ALK  inhibitor ALK tyrosine kinase receptor inhibitor ,INHIBITOR ,chimeric protein single protein 
899,DOPAMINE,CHEMBL59,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 9 investigational indications.,,4.0,,False,no approval year,['ENSG00000043591'],"['EFO_1002048', 'EFO_0005207', 'EFO_0003917', 'EFO_0006834', 'MONDO_0002050', 'EFO_0003144', 'MONDO_0005180', 'EFO_0000612', 'HP_0031273', 'MONDO_0005180', 'EFO_0000373', 'HP_0100543', 'EFO_0000319', 'EFO_0000400']",False,False,14,Beta-1 adrenergic receptor agonist ,AGONIST ,single protein 
900,DIPHENHYDRAMINE,CHEMBL657,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 15 approved and 64 investigational indications.,,4.0,,False,1946,['ENSG00000196639'],"['MONDO_0005271', 'MONDO_0007915', 'EFO_0005592', 'EFO_0000220', 'MONDO_0011962', 'EFO_0000384', 'EFO_0005854', 'EFO_0005761', 'MONDO_0005277', 'MONDO_0002009', 'MONDO_0007915', 'Orphanet_365', 'EFO_0004270', 'EFO_1000783', 'EFO_0005252', 'EFO_0000540', 'EFO_0000616', 'MP_0001845', 'EFO_0005761', 'Orphanet_60', 'HP_0002315', 'EFO_0003086', 'EFO_0003758', 'MONDO_0002367', 'EFO_0000403', 'EFO_0000574', 'HP_0002013', 'EFO_0005230', 'HP_0000989', 'EFO_0006890', 'EFO_0000095', 'EFO_0004698', 'EFO_0009688', 'EFO_0003958', 'EFO_0004239', 'EFO_0008521', 'HP_0001742', 'EFO_0001378', 'EFO_0000222', 'EFO_0005531', 'EFO_1000657', 'EFO_0003938', 'EFO_0009104', 'MONDO_0008903', 'MONDO_0001056', 'EFO_0004599', 'MONDO_0007254', 'EFO_0003843', 'HP_0012735', 'MONDO_0005271', 'MONDO_0008315', 'EFO_0003060', 'EFO_0006928', 'MONDO_0007079', 'MONDO_0002050', 'EFO_0000198', 'EFO_0009516', 'EFO_1001904', 'HP_0002017', 'EFO_0007160', 'HP_0002018', 'EFO_0000701', 'EFO_0009847', 'EFO_0002610', 'EFO_0000403', 'EFO_0000096', 'EFO_0000681', 'MONDO_0004658', 'MONDO_0004992', 'MONDO_0005090', 'HP_0000989', 'EFO_0007359', 'MONDO_0044917', 'EFO_0005952', 'MONDO_0017287', 'EFO_0000274', 'EFO_0007214', 'EFO_0003956', 'EFO_0008520', 'EFO_0005854', 'HP_0012735', 'EFO_0003843']",True,False,82,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
901,ERYTHROMYCIN ETHYLSUCCINATE,CHEMBL1200688,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 3 approved and 2 investigational indications.,,4.0,,False,1965,[],"['EFO_0000650', 'EFO_0000544', 'EFO_0003102', 'EFO_0003894', 'MONDO_0005147']",False,False,5,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
902,RACEMETYROSINE,CHEMBL1330596,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002618', 'MONDO_0007254', 'EFO_0000305', 'EFO_0003758']",False,False,4,,,
903,ETONOGESTREL,CHEMBL1531,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 investigational indications.,,4.0,,False,2001,['ENSG00000082175'],"['EFO_0000764', 'EFO_0000765', 'EFO_0002950', 'EFO_0000284', 'HP_0100607']",False,False,5,Progesterone receptor agonist ,AGONIST ,single protein 
904,RESVERATROL,CHEMBL165,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 37 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0021063', 'EFO_0000407', 'EFO_0002614', 'MONDO_0100096', 'EFO_0000401', 'EFO_0000660', 'MONDO_0002691', 'EFO_0003956', 'MONDO_0005178', 'EFO_0000616', 'EFO_0000365', 'EFO_0003884', 'HP_0001258', 'MONDO_0005148', 'MONDO_0005090', 'EFO_0000195', 'MONDO_0007739', 'MONDO_0005147', 'EFO_0000537', 'EFO_0011023', 'GO_0007568', 'EFO_0001365', 'MONDO_0004975', 'MONDO_0018906', 'MP_0001845', 'MONDO_0005180', 'EFO_1000657', 'EFO_0000545', 'EFO_0000341', 'EFO_0000319', 'EFO_0000694', 'HP_0003124', 'EFO_0001072', 'EFO_0004265', 'MONDO_0011705', 'EFO_0003095', 'MONDO_0100339']",False,False,37,,,
905,SORBITOL,CHEMBL1682,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for constipation and has 8 investigational indications.,,4.0,,False,no approval year,[],"['HP_0002019', 'EFO_0000339', 'MONDO_0015626', 'MONDO_0005178', 'EFO_0003843', 'EFO_0000771', 'EFO_0003095', 'MONDO_0100096', 'EFO_0000546']",False,False,9,,,
906,BECATECARIN,CHEMBL2107313,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000198900', 'ENSG00000131747', 'ENSG00000077097']","['MONDO_0002367', 'EFO_0000574', 'EFO_0006861', 'EFO_1001951', 'MONDO_0008170', 'MONDO_0003060', 'MONDO_0008903', 'EFO_0000616', 'EFO_0000702', 'EFO_0000621']",True,False,10,DNA topoisomerase I inhibitor DNA topoisomerase II inhibitor ,INHIBITOR ,single protein protein family 
907,TERTOMOTIDE,CHEMBL2108308,Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004975', 'EFO_0000284', 'EFO_0003060', 'EFO_0002618', 'EFO_0000756', 'EFO_0000182']",False,False,6,,,
908,"INSULIN, ISOPHANE",CHEMBL2108964,Protein drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.,,4.0,,False,no approval year,['ENSG00000171105'],"['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400', 'HP_0003419']",False,False,4,Insulin receptor agonist ,AGONIST ,single protein 
909,BENFOTIAMINE,CHEMBL3183549,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005147', 'EFO_1000783', 'MONDO_0005148', 'MONDO_0004975']",False,False,4,,,
910,CALCIFEDIOL,CHEMBL3544909,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications.,,4.0,,False,1980,['ENSG00000111424'],"['MONDO_0100096', 'EFO_0003884', 'HP_0001919', 'EFO_0000612', 'EFO_0005754', 'EFO_0003918', 'EFO_1001173', 'EFO_0003762']",True,False,8,Vitamin D receptor agonist ,AGONIST ,single protein 
911,NERATINIB MALEATE,CHEMBL3989921,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 1 investigational indication.,,4.0,,False,2017,"['ENSG00000178568', 'ENSG00000146648', 'ENSG00000141736']","['MONDO_0007254', 'EFO_0000616', 'EFO_0000305']",False,False,3,Receptor protein-tyrosine kinase erbB-2 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
912,NESOLICAFTOR,CHEMBL4297479,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
913,ZILUCOPLAN,CHEMBL4298207,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000106804'],"['EFO_0004991', 'MONDO_0100096', 'MONDO_0004976']",False,False,3,Complement C5 inhibitor ,INHIBITOR ,single protein 
914,PADELIPORFIN,CHEMBL4594284,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 5 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0002367', 'EFO_0003060', 'EFO_0008528', 'EFO_0000616', 'MONDO_0008315', 'EFO_0005221']",False,False,6,,,
915,IZENCITINIB,CHEMBL4650343,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['EFO_0000384', 'EFO_0000729', 'EFO_0003767']",False,True,3,Janus Kinase (JAK) inhibitor ,INHIBITOR ,protein family 
916,COLIMYCIN,CHEMBL507048,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001865', 'MONDO_0009061']",False,False,2,,,
917,AMODIAQUINE,CHEMBL682,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for malaria and has 5 investigational indications.,,4.0,,False,1982,[],"['EFO_0007444', 'MONDO_0100096', 'EFO_0002950', 'EFO_0007445', 'EFO_0001068', 'HP_0001945']",False,False,6,,,
918,FAMOTIDINE,CHEMBL902,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 19 investigational indications.,,4.0,,False,1986,['ENSG00000113749'],"['MONDO_0100096', 'MONDO_0011382', 'EFO_0009454', 'HP_0002239', 'EFO_1001951', 'MONDO_0004992', 'EFO_0000180', 'EFO_0000676', 'MONDO_0043839', 'EFO_0000764', 'EFO_0004607', 'HP_0100633', 'MONDO_0004658', 'EFO_0004232', 'EFO_0006890', 'EFO_0000641', 'MONDO_0005178', 'EFO_0000616', 'HP_0004398', 'HP_0100749', 'MONDO_0001056', 'EFO_0000756', 'MONDO_0017287', 'EFO_0004280', 'EFO_0000685', 'MONDO_0005090', 'EFO_0003060', 'EFO_0003948']",True,False,28,Histamine H2 receptor antagonist ,ANTAGONIST ,single protein 
919,MESNA,CHEMBL1098319,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for thrombocytopenia and has 53 investigational indications.,,4.0,,False,1988,[],"['MONDO_0011382', 'EFO_0000183', 'EFO_0000574', 'MONDO_0005301', 'EFO_0000209', 'EFO_0000095', 'EFO_0004991', 'EFO_0000309', 'EFO_0000384', 'EFO_0000565', 'EFO_0003884', 'EFO_0000094', 'EFO_0003865', 'EFO_0002939', 'EFO_0000182', 'EFO_0001073', 'EFO_0001378', 'EFO_0000096', 'MONDO_0044903', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0003833', 'EFO_0005952', 'EFO_0000756', 'EFO_0000621', 'EFO_0000691', 'EFO_0006803', 'MONDO_0000870', 'EFO_0003929', 'MONDO_0008380', 'EFO_0000403', 'EFO_0009708', 'EFO_0004145', 'HP_0001915', 'EFO_0004256', 'EFO_0000174', 'EFO_0007498', 'EFO_1001968', 'EFO_0000222', 'HP_0001873', 'MONDO_0044881', 'EFO_1001469', 'EFO_0000637', 'HP_0001919', 'EFO_0000220', 'EFO_0002617', 'EFO_0000717', 'EFO_0003869', 'MONDO_0007915', 'EFO_0005088', 'EFO_0000514', 'MONDO_0007254', 'EFO_0000198', 'EFO_0001642']",False,False,54,,,
920,IRON SUCROSE,CHEMBL1200823,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 2 investigational indications.,,4.0,,False,2000,[],"['HP_0001891', 'EFO_0001642', 'EFO_0003884', 'EFO_0001361', 'EFO_0004272']",False,False,5,,,
921,INTERFERON ALFA,CHEMBL2108506,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 42 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0002898', 'EFO_0000691', 'MONDO_0008315', 'EFO_0000349', 'EFO_0001378', 'EFO_1001051', 'EFO_0002618', 'MONDO_0008903', 'MONDO_0007254', 'EFO_1001469', 'EFO_0003047', 'EFO_0000339', 'EFO_0000574', 'EFO_0000565', 'EFO_1000158', 'MONDO_0002691', 'MONDO_0002087', 'MONDO_0018906', 'EFO_0000681', 'MONDO_0004992', 'MONDO_0007576', 'EFO_0000637', 'MONDO_0001056', 'MONDO_0008170', 'EFO_0000640', 'EFO_0000389', 'EFO_0000616', 'EFO_0006859', 'EFO_1000657', 'EFO_0004220', 'EFO_0000588', 'MONDO_0100096', 'EFO_0000544', 'EFO_0002429', 'EFO_0000756', 'EFO_1001901', 'MONDO_0002367', 'EFO_0000182', 'EFO_0002428', 'EFO_1001951', 'MONDO_0005147', 'MONDO_0004986', 'EFO_0000198', 'MONDO_0001187']",False,False,44,,,
922,TOVETUMAB,CHEMBL2364651,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000134853'],"['EFO_0003060', 'MONDO_0004992', 'EFO_0000519']",False,False,3,Platelet-derived growth factor receptor alpha inhibitor ,INHIBITOR ,single protein 
923,MARIMASTAT,CHEMBL279785,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000100985', 'ENSG00000149968', 'ENSG00000137673', 'ENSG00000196611', 'ENSG00000087245', 'ENSG00000262406']","['MONDO_0007254', 'MONDO_0008903']",True,False,2,Matrix metalloproteinase 3 inhibitor Matrix metalloproteinase 7 inhibitor Matrix metalloproteinase-2 inhibitor Matrix metalloproteinase 9 inhibitor Matrix metalloproteinase 12 inhibitor Matrix metalloproteinase-1 inhibitor ,INHIBITOR ,single protein 
924,BREQUINAR SODIUM,CHEMBL300058,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
925,LY-3009120,CHEMBL3545195,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,"['ENSG00000157764', 'ENSG00000078061', 'ENSG00000132155']","['EFO_0004142', 'EFO_0009708', 'EFO_0003060', 'EFO_0000756']",False,True,4,Serine/threonine-protein kinase B-raf inhibitor Serine/threonine-protein kinase A-Raf inhibitor Serine/threonine-protein kinase RAF inhibitor ,INHIBITOR ,single protein 
926,TARLOXOTINIB BROMIDE,CHEMBL4297662,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
927,CRIZOTINIB,CHEMBL601719,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 18 investigational indications.,,4.0,,False,2011,"['ENSG00000171094', 'ENSG00000181163', 'ENSG00000105976', 'ENSG00000143924']","['EFO_1001951', 'EFO_1000026', 'EFO_0000707', 'MONDO_0008903', 'MONDO_0011962', 'EFO_0000571', 'EFO_0000228', 'EFO_0000222', 'EFO_0003060', 'MONDO_0007254', 'EFO_0001378', 'MONDO_0001056', 'MONDO_0015798', 'MONDO_0004992', 'EFO_0000519', 'EFO_0003086', 'MONDO_0007039', 'EFO_0003032', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000640', 'EFO_0000403']",True,False,22,Hepatocyte growth factor receptor inhibitor EML4-ALK ALK tyrosine kinase receptor inhibitor NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) ,INHIBITOR ,single protein chimeric protein 
928,ALENDRONIC ACID,CHEMBL870,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 17 investigational indications.,,4.0,,False,1995,['ENSG00000160752'],"['EFO_0004261', 'EFO_0004260', 'EFO_0003882', 'EFO_0000649', 'MONDO_0005178', 'HP_0000938', 'EFO_0003762', 'EFO_0000589', 'EFO_0003854', 'EFO_0000764', 'EFO_0004261', 'MONDO_0006715', 'MONDO_0004979', 'EFO_0003854', 'EFO_0000266', 'MONDO_0007254', 'EFO_0004197', 'EFO_0003882', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008170', 'MONDO_0008274']",True,False,22,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
929,CHLORTHALIDONE,CHEMBL1055,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 9 approved and 12 investigational indications.,,4.0,,False,1960,['ENSG00000070915'],"['EFO_0004255', 'HP_0003124', 'EFO_0000537', 'EFO_0003144', 'EFO_0000400', 'EFO_0003777', 'EFO_0003763', 'EFO_0004278', 'EFO_0001645', 'MONDO_0005147', 'MONDO_0001134', 'EFO_0003914', 'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'MONDO_0005148', 'MONDO_0002462', 'EFO_0000373', 'EFO_0003884', 'EFO_0000668', 'EFO_0003913']",False,False,21,Thiazide-sensitive sodium-chloride cotransporter inhibitor ,INHIBITOR ,single protein 
930,SODIUM CHLORIDE,CHEMBL1200574,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 approved and 322 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001069', 'HP_0002239', 'EFO_0004143', 'MONDO_0002282', 'EFO_0001358', 'EFO_0000400', 'EFO_0005251', 'EFO_0005669', 'EFO_0009550', 'EFO_0009579', 'HP_0011950', 'EFO_0003060', 'EFO_0000701', 'EFO_1001267', 'HP_0011106', 'EFO_0000182', 'HP_0001541', 'EFO_0004994', 'EFO_0007282', 'EFO_0007541', 'EFO_1000897', 'HP_0001643', 'EFO_1001141', 'EFO_1001139', 'HP_0001945', 'MONDO_0100096', 'MONDO_0019180', 'EFO_0008522', 'EFO_0000319', 'EFO_1001909', 'EFO_1001121', 'EFO_0005531', 'EFO_0005854', 'EFO_1001917', 'HP_0000842', 'EFO_0009840', 'EFO_1000794', 'EFO_0000384', 'HP_0100806', 'HP_0001065', 'EFO_0000772', 'EFO_0008518', 'EFO_0004239', 'EFO_0005549', 'EFO_1000350', 'EFO_0007415', 'EFO_0000612', 'HP_0011868', 'MONDO_0011972', 'EFO_0006834', 'EFO_0004320', 'EFO_0004319', 'EFO_0000756', 'EFO_1001485', 'EFO_0000676', 'EFO_1000657', 'EFO_1001904', 'EFO_0004288', 'EFO_1001068', 'EFO_0004252', 'EFO_0005230', 'MONDO_0003544', 'EFO_0000341', 'HP_0002015', 'EFO_1001887', 'EFO_0009314', 'EFO_1000941', 'MONDO_0002146', 'EFO_0000649', 'MONDO_0005090', 'EFO_0004278', 'EFO_0004232', 'EFO_0009267', 'MONDO_0007254', 'EFO_0004273', 'EFO_0008510', 'MONDO_0005301', 'MONDO_0019297', 'GO_0007568', 'EFO_0003818', 'EFO_0000389', 'MONDO_0100130', 'EFO_0001645', 'EFO_0000694', 'EFO_0000546', 'EFO_0007243', 'EFO_0009619', 'EFO_1002048', 'EFO_1000786', 'EFO_0006346', 'MONDO_0004992', 'EFO_0003819', 'EFO_1001459', 'EFO_0007328', 'EFO_0003958', 'EFO_0000275', 'HP_0002902', 'EFO_0008528', 'EFO_1000880', 'EFO_0008586', 'EFO_0000183', 'HP_0002140', 'EFO_0007149', 'EFO_0000763', 'HP_0000545', 'EFO_0003884', 'EFO_0005547', 'EFO_0000729', 'MONDO_0021108', 'EFO_0005762', 'EFO_0004265', 'MONDO_0019091', 'EFO_0000717', 'MONDO_0005149', 'EFO_0009364', 'MONDO_0005129', 'EFO_0004229', 'EFO_0007332', 'EFO_1001466', 'EFO_1001373', 'EFO_0009444', 'EFO_1001919', 'EFO_0005687', 'MONDO_0005041', 'MONDO_0002491', 'EFO_0003047', 'EFO_0003966', 'EFO_1001434', 'MONDO_0005178', 'EFO_0003843', 'EFO_0009662', 'EFO_1000845', 'MONDO_0009061', 'HP_0000975', 'EFO_0003890', 'MONDO_0005147', 'EFO_0000556', 'HP_0200042', 'MONDO_0004975', 'EFO_0009516', 'HP_0012735', 'EFO_1001476', 'HP_0000083', 'EFO_0002687', 'MONDO_0013730', 'HP_0002571', 'MONDO_0019623', 'EFO_0008521', 'EFO_0003144', 'EFO_0006859', 'EFO_0004599', 'HP_0012532', 'EFO_0000712', 'EFO_0002614', 'MONDO_0008315', 'EFO_0001064', 'HP_0001891', 'HP_0000360', 'HP_0003040', 'MONDO_0001572', 'MONDO_0017276', 'EFO_0003768', 'EFO_0006510', 'EFO_0003833', 'EFO_0000373', 'MONDO_0018076', 'MONDO_0011382', 'EFO_1001097', 'EFO_1000710', 'HP_0003418', 'EFO_0004242', 'Orphanet_365', 'EFO_1001463', 'EFO_0004209', 'MONDO_0018661', 'EFO_0003932', 'EFO_0002610', 'MONDO_0002635', 'HP_0031273', 'EFO_0001068', 'MONDO_0005271', 'EFO_0010282', 'EFO_1001923', 'EFO_0004269', 'MONDO_0021063', 'EFO_0007440', 'MONDO_0009661', 'MONDO_0008170', 'EFO_0000662', 'EFO_1001753', 'EFO_0000407', 'MONDO_0005180', 'EFO_0005323', 'EFO_0000668', 'EFO_0009492', 'EFO_0009609', 'HP_0000989', 'EFO_0001076', 'HP_0002019', 'EFO_0009130', 'MONDO_0005148', 'EFO_0005306', 'HP_0000952', 'MONDO_0002050', 'MONDO_0002471', 'EFO_0007475', 'EFO_0005611', 'EFO_1001494', 'EFO_0005799', 'MONDO_0004976', 'EFO_0003777', 'EFO_0003931', 'MONDO_0008300', 'EFO_1001289', 'EFO_0003106', 'EFO_0004610', 'EFO_0004248', 'HP_0025425', 'EFO_0002618', 'HP_0002110', 'EFO_1000760', 'HP_0000175', 'HP_0000713', 'MONDO_0010674', 'MONDO_0002363', 'EFO_0001074', 'EFO_0000519', 'EFO_0007214', 'EFO_1002000', 'EFO_0000180', 'EFO_1001993', 'MONDO_0003037', 'EFO_1000879', 'MP_0001914', 'EFO_1001145', 'EFO_0001073', 'EFO_0000764', 'MONDO_0016575', 'EFO_0009686', 'EFO_0004282', 'MONDO_0001134', 'EFO_0004234', 'EFO_0003929', 'EFO_0011023', 'MP_0001845', 'EFO_0008590', 'EFO_1001412', 'EFO_1001413', 'HP_0001919', 'EFO_0007454', 'MONDO_0017147', 'EFO_1001896', 'EFO_0009606', 'EFO_0003030', 'EFO_0004227', 'EFO_0004244', 'MONDO_0004907', 'MONDO_0043510', 'EFO_0000713', 'MONDO_0007079', 'EFO_0000222', 'HP_0006554', 'EFO_0005585', 'EFO_0000765', 'HP_0002094', 'EFO_0000616', 'EFO_0009620', 'EFO_0009869', 'EFO_1000906', 'EFO_0004270', 'HP_0002619', 'EFO_0004190', 'HP_0000951', 'EFO_0000699', 'EFO_0007486', 'EFO_0000685', 'EFO_1001496', 'EFO_0000537', 'EFO_0005754', 'EFO_1001518', 'HP_0001943', 'EFO_0003894', 'EFO_1001051', 'EFO_1001060', 'MONDO_0008903', 'MONDO_0004985', 'EFO_0004616', 'EFO_1001134', 'MONDO_0002009', 'HP_0008419', 'EFO_0003876', 'EFO_1001103', 'MONDO_0002691', 'EFO_0003964', 'MONDO_0004979', 'MONDO_0002070', 'EFO_0000771', 'EFO_0004272', 'EFO_0003086', 'MONDO_0004857', 'EFO_0000198', 'EFO_1000668', 'HP_0012227', 'HP_0002315', 'MONDO_0007571', 'MONDO_0010679', 'EFO_0001666', 'EFO_0004888', 'HP_0100543', 'EFO_0007411', 'EFO_1000874', 'HP_0001337', 'HP_0003228', 'EFO_0003756', 'EFO_0005532', 'MONDO_0018088', 'EFO_0001422', 'EFO_1000637', 'EFO_0000731', 'EFO_0000544', 'MONDO_0004001', 'EFO_0001365', 'HP_0003419', 'EFO_0006911', 'HP_0002045', 'EFO_1001474', 'EFO_0008583', 'EFO_0000545', 'EFO_0000284', 'EFO_0007141', 'EFO_0004991']",False,False,331,,,
931,UMIFENOVIR,CHEMBL1214598,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007328', 'EFO_0000763']",False,False,2,Hemagglutinin negative modulator ,NEGATIVE MODULATOR ,single protein 
932,PLATINUM,CHEMBL1235478,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000702', 'MONDO_0021117', 'MONDO_0008903', 'EFO_0003060', 'EFO_0000616', 'EFO_0003869', 'MONDO_0007576', 'EFO_0002938']",False,False,8,,,
933,FLUOROESTRADIOL,CHEMBL1627367,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for breast cancer.,,4.0,,False,2020,[],['MONDO_0007254'],False,False,1,,,
934,CALDARET,CHEMBL2106572,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000373', 'EFO_0000612']",False,False,2,,,
935,CUSTIRSEN,CHEMBL2108309,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000120885'],"['EFO_0003060', 'MONDO_0008315', 'MONDO_0004992']",True,False,3,Clusterin mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
936,TERGENPUMATUCEL-L,CHEMBL2108682,Cell drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
937,552-02,CHEMBL212432,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
938,NAVTEMADLIN,CHEMBL3125702,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 15 investigational indications.,,2.0,,False,no approval year,"['ENSG00000141510', 'ENSG00000135679']","['EFO_0000339', 'EFO_1001471', 'EFO_0000222', 'EFO_0006738', 'EFO_0002429', 'EFO_0000702', 'EFO_0004251', 'MONDO_0004992', 'EFO_1001465', 'EFO_0001378', 'EFO_0000479', 'MONDO_0044903', 'EFO_1001968', 'EFO_0002430', 'EFO_0000756']",False,False,15,Tumour suppressor p53/oncoprotein Mdm2 inhibitor ,INHIBITOR ,protein-protein interaction 
939,MOXIFLOXACIN,CHEMBL32,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 approved and 76 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,[],"['EFO_0000764', 'EFO_0004234', 'EFO_0000474', 'EFO_1001888', 'MONDO_0005090', 'EFO_0007486', 'HP_0001943', 'EFO_0007328', 'EFO_0000616', 'EFO_0000681', 'EFO_0008533', 'MONDO_0005129', 'EFO_0000685', 'MONDO_0016047', 'EFO_0006505', 'EFO_0003102', 'EFO_0003917', 'MONDO_0041806', 'MP_0001845', 'MONDO_0016899', 'EFO_0003030', 'MONDO_0003472', 'EFO_0007445', 'EFO_0000540', 'EFO_0000544', 'MONDO_0005180', 'Orphanet_309005', 'EFO_1001388', 'EFO_0000544', 'EFO_0000537', 'MONDO_0004979', 'EFO_1001272', 'MONDO_0009061', 'EFO_0001645', 'EFO_0003818', 'HP_0030151', 'EFO_0003106', 'MONDO_0100096', 'EFO_0005687', 'EFO_0000765', 'EFO_0007381', 'MONDO_0005148', 'EFO_0005411', 'EFO_0006505', 'MONDO_0007254', 'EFO_0003035', 'MONDO_0007915', 'EFO_1000049', 'EFO_1001289', 'EFO_0004272', 'EFO_0003047', 'EFO_1000829', 'EFO_0007126', 'MONDO_0009861', 'EFO_0000574', 'MONDO_0004976', 'MONDO_0021108', 'HP_0001257', 'EFO_1001388', 'MONDO_0004992', 'EFO_0009560', 'MONDO_0005129', 'EFO_0003106', 'EFO_0000341', 'HP_0002019', 'EFO_0000701', 'EFO_0003843', 'MONDO_0007254', 'MONDO_0004975', 'EFO_0005252', 'EFO_0004992', 'EFO_1001482', 'MONDO_0024355', 'EFO_0004270', 'EFO_0000400', 'EFO_0006911', 'EFO_0005672', 'EFO_1000829', 'EFO_0007486', 'EFO_0005741', 'EFO_0000771', 'EFO_0000373', 'MONDO_0018076', 'MONDO_0013730']",False,False,84,Topoisomerase IV inhibitor Bacterial DNA gyrase inhibitor ,INHIBITOR ,protein complex 
940,LASOFOXIFENE,CHEMBL328190,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,4.0,,False,no approval year,"['ENSG00000140009', 'ENSG00000091831']","['MONDO_0007254', 'EFO_0003882']",False,True,2,Estrogen receptor modulator ,MODULATOR ,protein family 
941,TEZACAFTOR,CHEMBL3544914,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for cystic fibrosis.,,4.0,,False,2018,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
942,AGLATIMAGENE BESADENOVEC,CHEMBL3544993,Gene drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000519', 'EFO_1000028', 'EFO_0003060', 'EFO_0005543', 'MONDO_0008903', 'EFO_0002499', 'MONDO_0008315', 'MONDO_0100342', 'EFO_0000182']",False,False,9,,,
943,TESTOSTERONE,CHEMBL386630,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 4 approved and 31 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1972,['ENSG00000169083'],"['EFO_0000545', 'HP_0001510', 'EFO_0004234', 'EFO_1001919', 'MONDO_0018555', 'MONDO_0005301', 'EFO_0000660', 'EFO_0003964', 'EFO_0001073', 'GO_0007568', 'EFO_0003884', 'EFO_0002970', 'EFO_0000195', 'HP_0030016', 'EFO_0003922', 'EFO_0005088', 'EFO_1001078', 'EFO_0000196', 'Orphanet_325690', 'MONDO_0005351', 'MONDO_0008315', 'EFO_0003144', 'EFO_1000859', 'EFO_0001663', 'EFO_0001645', 'MONDO_0004992', 'HP_0003549', 'Orphanet_145', 'MONDO_0018800', 'EFO_1000653', 'EFO_0004714', 'HP_0000044', 'EFO_1001006', 'EFO_0000765', 'EFO_0002614', 'MONDO_0002146']",True,False,36,Androgen Receptor agonist ,AGONIST ,single protein 
944,KOS-1584,CHEMBL4297296,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']",['EFO_0003060'],True,False,1,Tubulin stabiliser ,STABILISER ,protein complex group 
945,MK-2640,CHEMBL4802175,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
946,BISOPROLOL,CHEMBL645,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for cardiovascular disease and hypertension and has 7 investigational indications.,,4.0,,False,1992,['ENSG00000043591'],"['EFO_0000537', 'Orphanet_79292', 'MONDO_0010679', 'MP_0001914', 'MONDO_0017147', 'MONDO_0007254', 'EFO_0000319', 'EFO_0000537', 'EFO_0001645']",True,False,9,Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
947,TELMISARTAN,CHEMBL1017,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000144891'],"['EFO_0000537', 'Orphanet_309005', 'EFO_0000764', 'EFO_0000612', 'EFO_0008620', 'EFO_0000401', 'EFO_0005762', 'EFO_0004285', 'EFO_0003918', 'EFO_0003777', 'MONDO_0100096', 'EFO_0000319', 'MONDO_0005148', 'MONDO_0001134', 'EFO_0000712', 'EFO_0000180', 'EFO_0003884', 'EFO_0000400', 'MONDO_0004975']",False,False,19,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
948,AMBRISENTAN,CHEMBL1111,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000136160', 'ENSG00000151617']","['MONDO_0005149', 'MONDO_0004933', 'MONDO_0008347', 'EFO_0001361', 'EFO_0000768', 'EFO_0000537', 'EFO_1000782', 'MONDO_0100096', 'EFO_0004264', 'MONDO_0011382', 'MONDO_0004979']",False,False,11,"Endothelin receptor, ET-A/ET-B antagonist ",ANTAGONIST ,protein family 
949,COLESEVELAM HYDROCHLORIDE,CHEMBL1201473,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 7 investigational indications.,,4.0,,False,2000,[],"['EFO_0009523', 'EFO_0003948', 'HP_0003124', 'EFO_1001249', 'EFO_0001421', 'MONDO_0007254', 'EFO_0004911', 'EFO_0000319', 'EFO_0001378', 'MONDO_0005148']",False,False,10,,,
950,SUNITINIB MALATE,CHEMBL1567,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 5 approved and 50 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2006,"['ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000182578', 'ENSG00000122025']","['EFO_0000514', 'EFO_0000222', 'MONDO_0003268', 'MONDO_0002158', 'EFO_1000984', 'MONDO_0002367', 'EFO_1000576', 'EFO_0006861', 'EFO_0002499', 'EFO_0000349', 'MONDO_0044926', 'EFO_0000641', 'EFO_0002618', 'EFO_0000640', 'MONDO_0004192', 'EFO_0000501', 'EFO_0007331', 'MONDO_0008315', 'EFO_1001951', 'EFO_0003865', 'EFO_0002617', 'MONDO_0015277', 'EFO_0000588', 'EFO_0000632', 'EFO_0000095', 'EFO_0000673', 'EFO_0000182', 'MONDO_0018364', 'EFO_1001465', 'EFO_0000220', 'EFO_0000403', 'EFO_1001968', 'EFO_0003897', 'EFO_0003869', 'EFO_0002938', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000681', 'EFO_0000702', 'EFO_1001901', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0007576', 'MONDO_0007254', 'MONDO_0004986', 'EFO_0000519', 'EFO_0006352', 'EFO_0001378', 'MONDO_0002087', 'MONDO_0008667', 'EFO_0000616', 'EFO_0007416', 'EFO_0000558', 'MONDO_0008903']",True,True,55,Stem cell growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Macrophage colony stimulating factor receptor inhibitor ,INHIBITOR ,single protein protein family protein complex 
951,CEFTRIAXONE,CHEMBL161,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 9 approved and 26 investigational indications.,,4.0,,False,1984,[],"['MONDO_0004985', 'EFO_0000544', 'EFO_0005585', 'EFO_0003033', 'EFO_0000584', 'EFO_0003103', 'HP_0100806', 'EFO_1001388', 'DOID_7551', 'EFO_1001388', 'DOID_7551', 'EFO_0008572', 'EFO_0007328', 'EFO_1001312', 'HP_0100806', 'EFO_0005411', 'EFO_0003102', 'EFO_0000771', 'EFO_0004992', 'EFO_1001272', 'MONDO_0005090', 'EFO_0008510', 'EFO_0000729', 'MONDO_0004976', 'EFO_0000616', 'EFO_0007149', 'MONDO_0024355', 'EFO_0003103', 'EFO_1001141', 'MONDO_0005180', 'EFO_0008588', 'HP_0030151', 'MONDO_0100096', 'EFO_0000544', 'EFO_0003106']",False,False,35,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
952,DESIPRAMINE HYDROCHLORIDE,CHEMBL1696,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for unipolar depression and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1964,['ENSG00000103546'],"['EFO_0003761', 'HP_0003418', 'MONDO_0002050', 'EFO_0000702']",False,False,4,Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
953,TASISULAM,CHEMBL2110587,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002158', 'MONDO_0008170', 'EFO_0000691', 'EFO_0002617', 'EFO_0000756', 'MONDO_0007254', 'EFO_0000222', 'EFO_0000574', 'EFO_0000681', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000479']",False,False,13,,,
954,AXL-1717,CHEMBL283120,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000140443'],"['EFO_0002501', 'EFO_0000616', 'EFO_0002499', 'EFO_0000571', 'EFO_0003060', 'EFO_1001465', 'EFO_0001642', 'EFO_0000707']",False,False,8,Insulin-like growth factor I receptor inhibitor ,INHIBITOR ,single protein 
955,C-188-9,CHEMBL3392776,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000182']",False,False,2,,,
956,VELCALCETIDE,CHEMBL3545184,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.,,4.0,,False,2017,['ENSG00000036828'],"['EFO_0003884', 'EFO_0005754', 'EFO_1001173']",True,False,3,Calcium sensing receptor agonist ,AGONIST ,single protein 
957,CP-461,CHEMBL4068108,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000384', 'EFO_0000756', 'MONDO_0008315', 'EFO_0000095', 'EFO_0000681']",False,False,5,,,
958,ETARFOLATIDE,CHEMBL4297280,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000571', 'MONDO_0008170', 'EFO_0003869']",False,False,3,,,
959,DS-2248,CHEMBL5095177,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
960,FLUDARABINE PHOSPHATE,CHEMBL1096882,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 135 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229', 'ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']","['EFO_0000691', 'EFO_0000221', 'EFO_0003060', 'EFO_0009709', 'EFO_0003027', 'EFO_0004256', 'EFO_0000519', 'EFO_0003811', 'EFO_1000026', 'EFO_1000292', 'EFO_0009441', 'MONDO_0008170', 'EFO_0004599', 'EFO_0003778', 'MONDO_0021063', 'EFO_0000309', 'EFO_0004251', 'MONDO_0002334', 'MONDO_0015760', 'EFO_0001642', 'EFO_0002517', 'EFO_1000690', 'EFO_0000389', 'EFO_0000222', 'EFO_0000708', 'MONDO_0001023', 'EFO_0003802', 'EFO_0000255', 'MONDO_0005301', 'EFO_0000196', 'MONDO_0004992', 'Orphanet_848', 'HP_0001915', 'MONDO_0019391', 'EFO_0000339', 'MONDO_0009348', 'MONDO_0021193', 'EFO_0003032', 'EFO_0000565', 'HP_0012410', 'EFO_0005761', 'MONDO_0007576', 'EFO_1001257', 'MONDO_0015277', 'EFO_1000560', 'EFO_0003025', 'MONDO_0002691', 'EFO_0004272', 'EFO_0000403', 'EFO_1001779', 'EFO_0000349', 'MONDO_0018906', 'MONDO_0015253', 'MONDO_0009833', 'MONDO_0019469', 'EFO_0006803', 'EFO_0004252', 'EFO_0001075', 'MONDO_0011382', 'MONDO_0015974', 'EFO_0000621', 'EFO_0005784', 'EFO_0009708', 'MONDO_0019460', 'MONDO_0002158', 'MONDO_0017198', 'EFO_1001051', 'MONDO_0008903', 'EFO_0002617', 'EFO_0000384', 'EFO_0005952', 'MONDO_0000159', 'EFO_0000209', 'EFO_1001465', 'EFO_0000637', 'EFO_1000131', 'EFO_0003869', 'EFO_1001996', 'EFO_0000574', 'MONDO_0044881', 'MONDO_0008315', 'EFO_0000223', 'EFO_0000095', 'MONDO_0002898', 'EFO_1000309', 'EFO_0000183', 'EFO_0000685', 'EFO_0003865', 'MONDO_0000870', 'EFO_0000540', 'EFO_0000096', 'MONDO_0020077', 'EFO_0000211', 'EFO_0006475', 'EFO_0006927', 'EFO_0002429', 'EFO_1001469', 'EFO_0006859', 'MONDO_0007915', 'HP_0002721', 'EFO_0000588', 'EFO_0000094', 'MONDO_0002108', 'EFO_0000182', 'EFO_0000198', 'EFO_0000218', 'EFO_0000220', 'EFO_0002428', 'MONDO_0002087', 'EFO_0000174', 'MONDO_0010518', 'MONDO_0013730', 'EFO_1000956', 'MONDO_0044903', 'EFO_0000717', 'EFO_0001061', 'EFO_0000681', 'EFO_0000756', 'EFO_0000616', 'EFO_1000318', 'HP_0100727', 'MONDO_0019472', 'MONDO_0018305', 'MONDO_0002367', 'EFO_0002430', 'EFO_0005803', 'EFO_0004289', 'EFO_0001378', 'EFO_0000676', 'EFO_1000785', 'MONDO_0000873', 'EFO_1002048', 'MONDO_0019471', 'EFO_1000102', 'EFO_0000326', 'EFO_0000191', 'MONDO_0007254', 'MONDO_0001657']",True,True,138,DNA polymerase (alpha/delta/epsilon) inhibitor Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,protein family protein complex group 
961,SEVOFLURANE,CHEMBL1200694,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 32 investigational indications.,,4.0,,False,1995,"['ENSG00000082482', 'ENSG00000169427', 'ENSG00000145888', 'ENSG00000109738', 'ENSG00000171303', 'ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863', 'ENSG00000100433', 'ENSG00000186795']","['EFO_0009267', 'MONDO_0004992', 'EFO_0003870', 'EFO_0000713', 'EFO_0001074', 'MONDO_0021698', 'EFO_0009686', 'EFO_0005207', 'EFO_1001328', 'HP_0011110', 'HP_0003418', 'EFO_0003884', 'EFO_0001073', 'EFO_0003843', 'EFO_0002687', 'MONDO_0007254', 'MONDO_0007576', 'EFO_0003777', 'EFO_0005323', 'HP_0001919', 'MONDO_0100096', 'EFO_0001645', 'EFO_0008583', 'EFO_0005611', 'EFO_1002048', 'EFO_0000694', 'MONDO_0043510', 'EFO_0006834', 'MP_0001845', 'EFO_1000637', 'EFO_1001951', 'MONDO_0021117']",True,False,32,Potassium channel subfamily K member 9 opener Potassium channel subfamily K member 18 opener Potassium channel subfamily K member 10 opener Glycine receptor (alpha-1/beta) positive modulator GABA-A receptor; anion channel positive allosteric modulator Potassium channel subfamily K member 3 opener Potassium channel subfamily K member 2 opener ,OPENER POSITIVE MODULATOR POSITIVE ALLOSTERIC MODULATOR ,single protein protein complex protein complex group 
962,ARMODAFINIL,CHEMBL1201192,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications.,,4.0,,False,2007,['ENSG00000142319'],"['MONDO_0100342', 'EFO_0003060', 'HP_0012378', 'MONDO_0021107', 'EFO_0003888', 'MONDO_0007576', 'MONDO_0005090', 'EFO_0006859', 'EFO_0003918', 'EFO_0001073', 'MONDO_0016158', 'EFO_0008568', 'MONDO_0002050', 'EFO_0004698', 'MONDO_0043510', 'EFO_0005246', 'EFO_0000712', 'EFO_0000616', 'MONDO_0005301']",False,False,19,Dopamine transporter inhibitor ,INHIBITOR ,single protein 
963,GLATIRAMER ACETATE,CHEMBL1201507,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and multiple sclerosis and has 9 investigational indications.,,4.0,,False,1996,[],"['MONDO_0010726', 'MONDO_0004976', 'EFO_0008522', 'EFO_0000616', 'EFO_0003929', 'EFO_0009606', 'EFO_1001506', 'EFO_0000384', 'EFO_0007405', 'MONDO_0005301', 'EFO_0003840']",False,False,11,,,
964,OSELTAMIVIR,CHEMBL1229,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 10 investigational indications.,,4.0,,False,1999,[],"['EFO_0000544', 'HP_0001873', 'EFO_0005222', 'MONDO_0100096', 'EFO_0000763', 'EFO_0001073', 'EFO_0007328', 'EFO_0007160', 'EFO_0003884', 'EFO_0000763', 'EFO_0003884', 'EFO_0007328', 'EFO_0003106']",False,False,13,Neuraminidase inhibitor ,INHIBITOR ,single protein 
965,MIFEPRISTONE,CHEMBL1276308,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for cushing syndrome and has 35 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2000,"['ENSG00000113580', 'ENSG00000082175']","['EFO_1001110', 'MONDO_0002050', 'MONDO_0001572', 'EFO_0000764', 'MONDO_0007254', 'EFO_0006861', 'EFO_0003060', 'MONDO_0004975', 'EFO_1001757', 'EFO_0000400', 'MONDO_0002158', 'HP_0012076', 'EFO_0001358', 'MONDO_0007079', 'MONDO_0011962', 'EFO_1001255', 'MONDO_0002046', 'MONDO_0016642', 'EFO_0009784', 'MONDO_0002087', 'EFO_0000432', 'EFO_0000673', 'EFO_0003099', 'EFO_0003047', 'EFO_0001065', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0007430', 'MONDO_0002009', 'EFO_0002610', 'EFO_0002950', 'EFO_0000731', 'MONDO_0004985', 'HP_0005268', 'EFO_0003768', 'EFO_0005230']",False,False,36,Progesterone receptor antagonist Glucocorticoid receptor antagonist ,ANTAGONIST ,single protein 
966,IPATASERTIB,CHEMBL2177390,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']","['EFO_0000196', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0000305', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0003893', 'EFO_0003869', 'EFO_0005537', 'EFO_0000503', 'EFO_0003060', 'MONDO_0011962', 'EFO_0000616']",True,False,14,Serine/threonine-protein kinase AKT inhibitor ,INHIBITOR ,protein family 
967,PROPRANOLOL,CHEMBL27,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 8 approved and 73 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1967,"['ENSG00000043591', 'ENSG00000169252']","['EFO_0000712', 'EFO_0001663', 'EFO_0000341', 'EFO_0005687', 'EFO_0009516', 'EFO_0000612', 'MONDO_0004938', 'EFO_0000389', 'EFO_0004319', 'EFO_0009545', 'EFO_1000911', 'HP_0001943', 'EFO_0005252', 'EFO_0001358', 'EFO_0000712', 'EFO_0001422', 'MONDO_0043510', 'EFO_0003756', 'EFO_1000635', 'EFO_0003913', 'MONDO_0001187', 'EFO_0001365', 'MONDO_0021661', 'EFO_1001375', 'EFO_0004329', 'EFO_0001073', 'EFO_0000182', 'HP_0004755', 'HP_0001279', 'EFO_0005223', 'EFO_0001378', 'EFO_0001072', 'MONDO_0005475', 'MONDO_0001056', 'EFO_1001450', 'HP_0030834', 'EFO_1000645', 'EFO_0002610', 'EFO_1001158', 'MONDO_0019297', 'EFO_0000666', 'MONDO_0005147', 'EFO_0005251', 'EFO_0003968', 'EFO_0004280', 'EFO_0000681', 'EFO_0001422', 'EFO_1001968', 'EFO_0003882', 'MONDO_0005277', 'EFO_0004269', 'MONDO_0100431', 'MONDO_0002363', 'EFO_0003918', 'MONDO_0004979', 'MONDO_0002009', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0004262', 'HP_0002315', 'EFO_0004142', 'EFO_0000546', 'EFO_0009444', 'EFO_0001358', 'HP_0001541', 'MONDO_0031037', 'EFO_0000537', 'EFO_0003843', 'EFO_0003086', 'HP_0001636', 'MONDO_0011382', 'EFO_0002610', 'EFO_0000537', 'EFO_1000635', 'EFO_0004287', 'HP_0003419', 'MONDO_0007254', 'EFO_0005230', 'MONDO_0007947', 'EFO_0004278', 'MONDO_0019180', 'EFO_0000756', 'EFO_0000319', 'EFO_0003860']",True,False,84,Beta-1 adrenergic receptor antagonist Beta-2 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
968,FIRIBASTAT,CHEMBL4297511,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000138792'],"['EFO_0003144', 'MONDO_0001134', 'EFO_1002048', 'EFO_0000537', 'EFO_0000612']",False,False,5,Aminopeptidase A inhibitor ,INHIBITOR ,single protein 
969,GILORALIMAB,CHEMBL4594517,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000101017'],"['MONDO_0004992', 'EFO_0002618', 'MONDO_0007254', 'EFO_0006859']",False,False,4,Tumor necrosis factor receptor superfamily member 5 agonist ,AGONIST ,single protein 
970,LEVOCARNITINE,CHEMBL1149,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 26 investigational indications.,,4.0,,False,1985,[],"['EFO_0000764', 'EFO_0009189', 'EFO_0003144', 'EFO_0000765', 'EFO_0000275', 'HP_0001919', 'EFO_0003095', 'HP_0001324', 'MONDO_0005301', 'EFO_0003884', 'EFO_1001141', 'EFO_0000616', 'MONDO_0011382', 'EFO_0000373', 'EFO_0000660', 'EFO_0008525', 'EFO_0001062', 'EFO_1001919', 'EFO_1000653', 'MONDO_0005148', 'EFO_0004265', 'Orphanet_309005', 'EFO_0009686', 'EFO_0003884', 'EFO_0006834', 'MONDO_0011719', 'EFO_0009846', 'HP_0001298', 'EFO_0002618']",False,False,29,,,
971,GOSERELIN ACETATE,CHEMBL1200501,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 11 investigational indications.,,4.0,,False,1989,['ENSG00000109163'],"['EFO_0000305', 'EFO_0006861', 'MONDO_0002087', 'MONDO_0008315', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0000313', 'EFO_0003922', 'MONDO_0002158', 'EFO_0000673', 'EFO_0000545', 'MONDO_0000521', 'EFO_0000195']",False,False,14,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
972,CLINDAMYCIN HYDROCHLORIDE,CHEMBL1200588,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 5 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,1970,[],"['EFO_0003894', 'EFO_0003102', 'EFO_1001314', 'EFO_0003106', 'EFO_0000544']",False,False,5,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
973,CINACALCET,CHEMBL1201284,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 8 investigational indications.,,4.0,,False,2004,['ENSG00000036828'],"['EFO_1001173', 'EFO_1001152', 'MONDO_0024300', 'EFO_1000456', 'EFO_0008519', 'EFO_0003884', 'EFO_0000673', 'EFO_0000313', 'EFO_0003884', 'EFO_0008506', 'EFO_1001173', 'EFO_0005754', 'EFO_0001072']",True,False,13,Calcium sensing receptor positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,single protein 
974,SUPINOXIN,CHEMBL1278118,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
975,PERINDOPRIL,CHEMBL1581,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1993,['ENSG00000159640'],"['EFO_0001358', 'MONDO_0001134', 'EFO_0000537', 'EFO_0004701', 'MONDO_0004975', 'EFO_0000319', 'EFO_0001645', 'MONDO_0007947', 'EFO_1000654', 'EFO_0000612', 'EFO_0000407', 'EFO_0000537', 'EFO_0001645', 'MONDO_0007254', 'MONDO_0002491', 'MONDO_0005148', 'EFO_0004214', 'EFO_0000537']",True,False,18,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
976,BRODALUMAB,CHEMBL1742996,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2017,['ENSG00000177663'],"['EFO_0000540', 'EFO_0000676', 'EFO_0003778', 'EFO_0000384', 'MONDO_0004979', 'MONDO_0015597', 'EFO_1000710', 'EFO_0003898', 'EFO_0000717', 'EFO_1001494', 'EFO_0000685']",False,False,11,Interleukin-17 receptor A antagonist ,ANTAGONIST ,single protein 
977,INFLUENZA VIRUS VACCINE,CHEMBL2109042,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 27 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0002609', 'EFO_0007411', 'MONDO_0004992', 'MONDO_0004979', 'EFO_0007328', 'MONDO_0100096', 'EFO_0000095', 'EFO_1001413', 'EFO_0000544', 'EFO_0000772', 'MONDO_0005301', 'DOID_7551', 'EFO_0005672', 'EFO_1000158', 'EFO_0005226', 'EFO_0002618', 'EFO_0003929', 'EFO_0000632', 'EFO_0006510', 'GO_0007568', 'EFO_0000764', 'EFO_0000220', 'EFO_0000616', 'EFO_0000272', 'EFO_0005222', 'EFO_0000181', 'HP_0001871']",False,False,27,,,
978,SAPANISERTIB,CHEMBL3545097,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 24 investigational indications.,,2.0,,False,no approval year,['ENSG00000198793'],"['MONDO_0008315', 'EFO_0000616', 'EFO_0007416', 'EFO_1001968', 'EFO_0004230', 'EFO_0000182', 'EFO_0000681', 'EFO_1000251', 'MONDO_0007254', 'EFO_0000519', 'EFO_1001471', 'EFO_0001378', 'EFO_0000708', 'EFO_1000045', 'MONDO_0004992', 'EFO_1000043', 'EFO_0003060', 'EFO_0000209', 'EFO_0000466', 'MONDO_0002108', 'EFO_0000574', 'EFO_0009441', 'EFO_1001465', 'EFO_0003869']",False,False,24,Serine/threonine-protein kinase mTOR inhibitor ,INHIBITOR ,single protein 
979,XEN-D0501,CHEMBL3707293,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000196689'],"['EFO_0000341', 'HP_0012735', 'MONDO_0005148']",True,False,3,Vanilloid receptor antagonist ,ANTAGONIST ,single protein 
980,"LACTOSE, ANHYDROUS",CHEMBL417016,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 32 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001145', 'EFO_1000637', 'EFO_0001358', 'EFO_0004197', 'EFO_0003948', 'EFO_0003095', 'EFO_0002610', 'EFO_0003843', 'EFO_0000341', 'EFO_0007328', 'MONDO_0004979', 'EFO_0007183', 'MONDO_0005148', 'EFO_0007303', 'HP_0002014', 'MONDO_0007079', 'MONDO_0024290', 'EFO_0007419', 'EFO_0003768', 'EFO_0003047', 'EFO_0007305', 'EFO_0003762', 'EFO_0003931', 'EFO_0005611', 'EFO_1000781', 'EFO_0004610', 'EFO_0003888', 'MONDO_0018076', 'MONDO_0002050', 'MONDO_0005277', 'EFO_0000649', 'MONDO_0100096']",False,False,32,,,
981,VOPRATELIMAB,CHEMBL4298004,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000163600'],"['EFO_0003060', 'MONDO_0004992']",False,False,2,Inducible T-cell costimulator agonist ,AGONIST ,single protein 
982,OLAPARIB,CHEMBL521686,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 62 investigational indications.,,4.0,,False,2014,"['ENSG00000143799', 'ENSG00000041880', 'ENSG00000129484']","['MONDO_0100342', 'EFO_0000707', 'MONDO_0001056', 'EFO_0000519', 'MONDO_0008315', 'EFO_0003869', 'EFO_0000216', 'EFO_0005221', 'EFO_1001901', 'EFO_0006859', 'EFO_0003893', 'EFO_1001951', 'EFO_0003060', 'EFO_0000294', 'EFO_0003825', 'MONDO_0008903', 'EFO_0000174', 'EFO_0003860', 'EFO_0002617', 'EFO_0000389', 'EFO_0000514', 'EFO_1000251', 'MONDO_0001187', 'EFO_0000574', 'MONDO_0007254', 'MONDO_0003060', 'MONDO_0004986', 'EFO_0001075', 'EFO_0000095', 'MONDO_0004992', 'EFO_0000503', 'EFO_0000616', 'EFO_0003968', 'EFO_1000984', 'EFO_0000702', 'EFO_0002618', 'EFO_0005537', 'EFO_0002918', 'Orphanet_145', 'EFO_0000305', 'EFO_0004230', 'MONDO_0002087', 'MONDO_0002715', 'EFO_1000158', 'EFO_0001663', 'MONDO_0002158', 'MONDO_0008170', 'MONDO_0003059', 'EFO_0009708', 'EFO_1001512', 'MONDO_0011962', 'EFO_0000313', 'EFO_1001100', 'EFO_0000196', 'EFO_0001061', 'EFO_0000673', 'EFO_0002517', 'EFO_0000588', 'EFO_0000637', 'EFO_1001968', 'MONDO_0002974', 'EFO_0000181', 'MONDO_0002928', 'EFO_0000691', 'MONDO_0018364', 'EFO_0000681', 'EFO_0001361']",True,False,67,"PARP 1, 2 and 3 inhibitor ",INHIBITOR ,protein family 
983,ACOLBIFENE,CHEMBL68055,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,"['ENSG00000140009', 'ENSG00000091831']",['MONDO_0007254'],False,True,1,Estrogen receptor modulator ,MODULATOR ,protein family 
984,PHENIRAMINE,CHEMBL1193,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for allergic disease and pruritus and has 3 investigational indications.,,4.0,,False,1994,['ENSG00000196639'],"['EFO_0007214', 'MONDO_0024355', 'MONDO_0005271', 'EFO_0007328', 'EFO_0007214', 'HP_0000989']",False,False,6,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
985,PERFLUTREN,CHEMBL1663,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,[],"['MONDO_0007254', 'HP_0002140', 'EFO_0000612']",False,False,3,,,
986,ENISAMIUM IODIDE,CHEMBL1716983,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007328', 'MONDO_0100096', 'EFO_0000763']",False,False,3,,,
987,BENZYLPENICILLIN,CHEMBL29,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1947,[],"['EFO_0007504', 'EFO_1001161', 'EFO_0003033', 'EFO_1001888', 'EFO_0000676', 'EFO_0000771', 'MONDO_0004992', 'EFO_0000771', 'EFO_0003106', 'EFO_0000764', 'EFO_0000544', 'EFO_0000616', 'MONDO_0002258', 'EFO_0000772', 'EFO_0007504', 'MONDO_0002258', 'EFO_0000181', 'EFO_0000544', 'EFO_0003102', 'EFO_0007548', 'HP_0011110', 'MONDO_0001056']",False,False,22,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
988,INOSINE PRANOBEX,CHEMBL3833405,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for viral disease and has 1 investigational indication.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000763']",False,False,2,,,
989,BELINOSTAT,CHEMBL408513,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 31 investigational indications.,,4.0,,False,2014,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']","['EFO_0000309', 'EFO_1000131', 'EFO_0000403', 'EFO_0000616', 'EFO_0000588', 'EFO_0002913', 'MONDO_0002158', 'EFO_0003060', 'MONDO_0000430', 'EFO_0000222', 'EFO_0005952', 'EFO_0003032', 'EFO_1001469', 'EFO_0000183', 'EFO_0000228', 'EFO_0000466', 'EFO_0001642', 'EFO_1001968', 'MONDO_0019471', 'MONDO_0004992', 'EFO_0000313', 'EFO_0000198', 'MONDO_0015760', 'MONDO_0002087', 'EFO_0000211', 'EFO_1001051', 'EFO_1000581', 'EFO_0008528', 'EFO_0000702', 'EFO_0001378', 'EFO_0000519', 'EFO_0000182', 'EFO_0000574', 'EFO_1000576', 'MONDO_0018906', 'EFO_1000043']",False,False,36,Histone deacetylase inhibitor ,INHIBITOR ,protein family 
990,PRAVASTATIN SODIUM,CHEMBL690,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 9 investigational indications.,,4.0,,False,1991,['ENSG00000113161'],"['EFO_0004705', 'EFO_0000400', 'MONDO_0005147', 'EFO_1000727', 'EFO_0004255', 'EFO_0001645', 'EFO_0004911', 'EFO_0003914', 'HP_0003124', 'HP_0002140', 'Orphanet_79211', 'MONDO_0008903', 'EFO_0000565', 'EFO_0000180', 'EFO_0000612', 'MONDO_0002691', 'EFO_0000764', 'EFO_0000319', 'MONDO_0021661']",False,True,19,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
991,AT-406,CHEMBL2158051,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000181', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000222', 'EFO_0003060', 'EFO_0006859', 'EFO_0000574']",False,False,7,,,
992,BMS-833923,CHEMBL3545403,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000128602'],"['EFO_0000702', 'EFO_0002916', 'EFO_0003897', 'EFO_0000565', 'MONDO_0007187', 'EFO_0004193', 'MONDO_0004992']",False,False,7,Smoothened homolog antagonist ,ANTAGONIST ,single protein 
993,RETASPIMYCIN HYDROCHLORIDE,CHEMBL377559,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['EFO_0002617', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000305', 'EFO_0001378', 'MONDO_0011719', 'MONDO_0004992', 'EFO_0003085', 'MONDO_0007254', 'EFO_0000673']",False,False,10,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
994,SHR-1316,CHEMBL4297828,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000120217'],"['EFO_0000707', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000702']",False,False,7,Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
995,SERPLULIMAB,CHEMBL4594550,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['MONDO_0001056', 'EFO_1001951', 'EFO_0000616', 'MONDO_0002974', 'EFO_0000182', 'EFO_0000702', 'HP_0001541', 'EFO_0005922', 'MONDO_0007254', 'EFO_0000181', 'EFO_0003060']",False,False,11,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
996,IMDEVIMAB,CHEMBL4650249,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
997,VORAPAXAR,CHEMBL493982,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000181104'],"['EFO_0000712', 'EFO_0000612', 'HP_0004419', 'EFO_0004265', 'EFO_0005672', 'EFO_0000764', 'MONDO_0002679']",False,False,7,Proteinase-activated receptor 1 antagonist ,ANTAGONIST ,single protein 
998,CYPROHEPTADINE,CHEMBL516,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 6 investigational indications.,,4.0,,False,1961,['ENSG00000196639'],"['MONDO_0004992', 'HP_0002027', 'MONDO_0005271', 'EFO_0005531', 'EFO_0000712', 'EFO_0007141', 'EFO_0003956', 'HP_0001653', 'MONDO_0007079', 'MONDO_0100096']",False,False,10,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
999,BMS-754807,CHEMBL575448,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000140443', 'ENSG00000171105']","['MONDO_0007254', 'EFO_0000616']",True,False,2,Insulin receptor inhibitor Insulin-like growth factor I receptor inhibitor ,INHIBITOR ,single protein 
1000,DORNASE ALFA,CHEMBL1201431,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for cystic fibrosis and has 18 investigational indications.,,4.0,,False,1993,[],"['MONDO_0004979', 'EFO_1000637', 'MONDO_0100096', 'MONDO_0013730', 'HP_0012735', 'EFO_0000544', 'EFO_0007486', 'EFO_0009444', 'MONDO_0009061', 'EFO_0009637', 'HP_0002140', 'EFO_0000699', 'EFO_0000546', 'EFO_0003097', 'EFO_0009680', 'EFO_0000694', 'EFO_0006859', 'MONDO_0100130', 'EFO_1000906']",False,False,19,,,
1001,TOSITUMOMAB,CHEMBL1201604,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2003,['ENSG00000156738'],"['EFO_0000574', 'EFO_0005952', 'MONDO_0018906', 'EFO_0000096', 'EFO_1001469', 'EFO_0000095']",False,False,6,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
1002,PITAVASTATIN,CHEMBL1201753,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 11 investigational indications.,,4.0,,False,2009,['ENSG00000113161'],"['MONDO_0005148', 'MONDO_0021187', 'Orphanet_309005', 'EFO_0001645', 'MONDO_0005147', 'EFO_0007328', 'HP_0003119', 'MONDO_0021187', 'HP_0000083', 'MONDO_0007254', 'HP_0003119', 'EFO_0000195', 'HP_0002140', 'Orphanet_309005', 'HP_0003119', 'HP_0003124', 'EFO_0004911', 'HP_0003124', 'MONDO_0021187', 'HP_0003124', 'MONDO_0021187', 'EFO_0000319']",True,False,22,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
1003,MEDRONIC ACID,CHEMBL180570,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003854', 'EFO_0003884']",False,False,2,,,
1004,MAGNESIUM SULFATE ANHYDROUS,CHEMBL2021423,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 57 investigational indications.,,4.0,,False,1981,[],"['EFO_1001103', 'EFO_0007294', 'EFO_0006859', 'EFO_1001754', 'HP_0001891', 'EFO_0000713', 'EFO_0002970', 'EFO_0000275', 'MONDO_0100342', 'EFO_0000588', 'EFO_0003833', 'EFO_0004777', 'EFO_1000824', 'EFO_0004142', 'EFO_0007442', 'EFO_0000668', 'MONDO_0005299', 'EFO_0003882', 'EFO_0000612', 'EFO_0000712', 'MONDO_0002258', 'EFO_0005279', 'EFO_0000668', 'EFO_1001254', 'HP_0002315', 'EFO_0008546', 'EFO_0001645', 'EFO_1001412', 'EFO_0002618', 'EFO_0003884', 'EFO_1001029', 'MONDO_0043510', 'EFO_0009505', 'HP_0012532', 'HP_0002019', 'EFO_0004273', 'HP_0002140', 'HP_0002637', 'EFO_0000278', 'EFO_1001375', 'HP_0001250', 'EFO_0003843', 'HP_0011950', 'MONDO_0004979', 'EFO_1000824', 'EFO_0000341', 'EFO_0004149', 'EFO_1000657', 'EFO_0005762', 'EFO_0009846', 'EFO_0004272', 'MONDO_0011382', 'MONDO_0004979', 'EFO_0001070', 'HP_0000360', 'MONDO_0016642', 'EFO_0000537', 'EFO_0003854', 'EFO_0008590', 'EFO_0003917', 'EFO_1000632', 'MP_0001914', 'MONDO_0018896', 'EFO_1001134', 'EFO_1001101']",False,False,65,,,
1005,SIBROTUZUMAB,CHEMBL2108882,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000078098'],['EFO_0003060'],True,False,1,Fibroblast activation protein alpha binding agent ,BINDING AGENT ,single protein 
1006,NAFAMOSTAT MESYLATE,CHEMBL3989553,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1007,7-ETHYL-10-HYDROXYCAMPTOTHECIN,CHEMBL837,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000198900'],"['MONDO_0004992', 'EFO_0000702', 'MONDO_0008903', 'EFO_1001951', 'MONDO_0007254']",False,False,5,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
1008,THIAZOLIDINEDIONE,CHEMBL85398,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002614', 'EFO_0001645', 'MONDO_0005147', 'EFO_0000400', 'MONDO_0005148']",False,False,5,,,
1009,AZD-1480,CHEMBL1231124,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000096968'],"['MONDO_0001056', 'EFO_0003060', 'EFO_0000479', 'EFO_0002430', 'MONDO_0004992']",False,False,5,Tyrosine-protein kinase JAK2 inhibitor ,INHIBITOR ,single protein 
1010,NITROGEN,CHEMBL142438,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 15 investigational indications.,,4.0,,False,2015,[],"['EFO_0000373', 'MONDO_0002009', 'MONDO_0100096', 'EFO_0009516', 'HP_0002093', 'EFO_0004278', 'EFO_0001358', 'MONDO_0004985', 'EFO_0000341', 'MONDO_0009061', 'EFO_0007512', 'EFO_0004242', 'EFO_0002687', 'EFO_1001951', 'EFO_0002496']",False,False,15,,,
1011,CLINDAMYCIN,CHEMBL1753,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1970,[],"['EFO_0000771', 'EFO_0003843', 'MONDO_0007254', 'MONDO_0002234', 'EFO_0007543', 'EFO_0004253', 'EFO_0005681', 'HP_0100806', 'EFO_0003894', 'EFO_0000701', 'EFO_0007448', 'HP_0012424', 'MONDO_0100096', 'EFO_0003894', 'EFO_0003102', 'EFO_1001314', 'HP_0001742', 'EFO_0000544', 'EFO_0003106', 'EFO_1001121', 'EFO_0000544', 'EFO_0003102', 'EFO_1001312', 'EFO_0003932', 'EFO_0001068', 'EFO_1001391']",False,False,26,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1012,TIVANTINIB,CHEMBL2103882,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.,,3.0,,False,no approval year,['ENSG00000105976'],"['EFO_0003060', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000770', 'EFO_0000514', 'MONDO_0002691', 'EFO_0000616', 'EFO_0000305', 'EFO_0003860', 'EFO_0000702', 'MONDO_0007576', 'EFO_0000640', 'EFO_0000673', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000181']",False,False,16,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1013,ORANTINIB,CHEMBL274654,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113721', 'ENSG00000134853', 'ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000128052']","['EFO_0001378', 'EFO_1001951', 'EFO_0000182', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0001056', 'MONDO_0002367']",True,True,10,Platelet-derived growth factor receptor inhibitor Vascular endothelial growth factor receptor 2 inhibitor Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein complex single protein protein family 
1014,PEXIDARTINIB,CHEMBL3813873,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for neoplasm and tenosynovial giant cell tumor and has 16 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2019,"['ENSG00000157404', 'ENSG00000182578', 'ENSG00000122025']","['EFO_0000183', 'MONDO_0008315', 'MONDO_0011719', 'EFO_0000519', 'EFO_0000222', 'EFO_0001421', 'MONDO_0002171', 'EFO_0000616', 'EFO_1000562', 'EFO_0002617', 'EFO_1001106', 'EFO_0003968', 'EFO_0000685', 'EFO_0000760', 'EFO_0000756', 'EFO_0005537', 'MONDO_0007254', 'EFO_0000673']",True,False,18,Macrophage colony stimulating factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Stem cell growth factor receptor inhibitor ,INHIBITOR ,single protein 
1015,ACAPATAMAB,CHEMBL4802258,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0003060']",False,False,2,,,
1016,WATER,CHEMBL1098659,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for multiple sclerosis and primary short bowel syndrome and has 24 investigational indications.,,4.0,,False,2011,[],"['EFO_0001060', 'EFO_0000649', 'EFO_0001358', 'MONDO_0004976', 'EFO_0003894', 'HP_0008419', 'MONDO_0002508', 'MONDO_0005301', 'EFO_0003843', 'EFO_1000905', 'EFO_0004329', 'EFO_1001216', 'MONDO_0004567', 'EFO_0005230', 'HP_0012228', 'EFO_0009552', 'EFO_0000319', 'EFO_0009516', 'EFO_0000544', 'EFO_0000685', 'EFO_0007512', 'EFO_0003819', 'MONDO_0100096', 'EFO_1000710', 'EFO_0007415', 'MONDO_0018241']",False,False,26,,,
1017,CABERGOLINE,CHEMBL1201087,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for parkinson disease and hypothalamic neoplasm and has 11 investigational indications.,,4.0,,False,1996,['ENSG00000149295'],"['EFO_0000400', 'EFO_0000545', 'EFO_0000512', 'MONDO_0002491', 'MONDO_0007254', 'EFO_1001110', 'MONDO_0005180', 'EFO_0001073', 'EFO_0002610', 'MONDO_0011972', 'EFO_1000979', 'EFO_0004270', 'EFO_0001065']",False,False,13,Dopamine D2 receptor agonist ,AGONIST ,single protein 
1018,ICODEXTRIN,CHEMBL1201472,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 2 investigational indications.,,4.0,,False,2002,[],"['EFO_0003884', 'EFO_0000373']",False,False,2,,,
1019,CARBON MONOXIDE,CHEMBL1231840,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000768', 'EFO_0001361', 'MONDO_0100130', 'EFO_0000341', 'EFO_1000637', 'MONDO_0004567']",False,False,6,,,
1020,NICLOSAMIDE,CHEMBL1448,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for helminthiasis and has 8 investigational indications.,,4.0,,False,1982,[],"['MONDO_0021063', 'EFO_1001342', 'EFO_0000196', 'EFO_0000685', 'Orphanet_733', 'EFO_1001951', 'MONDO_0100096', 'EFO_0000222', 'EFO_0000401']",False,False,9,,,
1021,INDOCYANINE GREEN,CHEMBL1646,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 22 investigational indications.,,4.0,,False,1959,[],"['EFO_0001061', 'MONDO_0008903', 'EFO_0003897', 'MONDO_0019297', 'EFO_0000685', 'EFO_1001951', 'MONDO_0021117', 'EFO_0000389', 'MONDO_0001056', 'MONDO_0002635', 'EFO_0000681', 'EFO_1000984', 'EFO_0000649', 'MONDO_0007254', 'MONDO_0018309', 'EFO_0003833', 'EFO_1001512', 'EFO_0003060', 'EFO_0000305', 'MONDO_0002038', 'EFO_0003820', 'EFO_1001028']",False,False,22,,,
1022,ALECTINIB,CHEMBL1738797,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 17 investigational indications.,,4.0,,False,2015,"['ENSG00000171094', 'ENSG00000165731', 'ENSG00000143924']","['EFO_0001421', 'EFO_0000641', 'EFO_0000756', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000691', 'EFO_0003060', 'EFO_0003032', 'EFO_0005221', 'EFO_0003826', 'EFO_0003893', 'EFO_0004142', 'EFO_0000326', 'EFO_0003833', 'MONDO_0021117', 'EFO_1000849', 'EFO_0000616', 'EFO_0003860', 'EFO_0000519', 'EFO_0004284']",False,False,20,Tyrosine-protein kinase receptor RET inhibitor ALK tyrosine kinase receptor inhibitor EML4-ALK ,INHIBITOR ,single protein chimeric protein 
1023,APRICOXIB,CHEMBL1835207,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000073756'],"['EFO_0002618', 'MONDO_0007254', 'EFO_0003060']",False,False,3,Cyclooxygenase-2 inhibitor ,INHIBITOR ,single protein 
1024,MILATAXEL,CHEMBL2107759,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0003060', 'EFO_0004288', 'EFO_1000657', 'EFO_0000588']",True,False,4,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1025,INTERFERON,CHEMBL2108494,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for eye infection and has 27 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0007386', 'EFO_0007549', 'MONDO_0005301', 'MONDO_0100096', 'EFO_1001282', 'EFO_0001422', 'EFO_0007328', 'MONDO_0021063', 'EFO_0000764', 'EFO_0000616', 'EFO_0000681', 'EFO_1001465', 'EFO_0000574', 'EFO_0000630', 'EFO_0003929', 'EFO_0002499', 'MONDO_0100339', 'EFO_0003840', 'EFO_0000756', 'EFO_0009448', 'EFO_0000694', 'MONDO_0002974', 'EFO_0007331', 'EFO_1001888', 'EFO_0000339', 'MONDO_0004992', 'EFO_0004220', 'EFO_0003047']",False,False,28,,,
1026,ONTAMALIMAB,CHEMBL2109511,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000099866'],"['EFO_0000384', 'EFO_0000729']",False,False,2,Mucosal addressin cell adhesion molecule-1 inhibitor ,INHIBITOR ,single protein 
1027,TROSPIUM CHLORIDE,CHEMBL3084748,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urgency urinary incontinence and overactive bladder and has 2 investigational indications.,,4.0,,False,2004,"['ENSG00000133019', 'ENSG00000181072']","['EFO_0006865', 'EFO_0000341', 'EFO_1000781', 'MONDO_0005090']",True,True,4,Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M2 antagonist ,ANTAGONIST ,single protein 
1028,ZENOCUTUZUMAB,CHEMBL4298025,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000065361']",['MONDO_0007254'],False,False,1,ErbB-2/ErbB-3 heterodimer inhibitor ,INHIBITOR ,protein complex 
1029,PROGRAMMED CELL DEATH 1 LIGAND 1,CHEMBL4298070,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0018906', 'EFO_0000182', 'EFO_0003060', 'EFO_0002617', 'EFO_0001378', 'EFO_0000313', 'HP_0001541', 'EFO_0004193']",False,False,8,,,
1030,ONDANSETRON,CHEMBL46,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 34 investigational indications.,,4.0,,False,1991,['ENSG00000166736'],"['EFO_0004888', 'EFO_0003843', 'EFO_0004701', 'HP_0002018', 'HP_0002094', 'MONDO_0005090', 'EFO_0003843', 'HP_0002013', 'EFO_0002618', 'HP_0011110', 'MONDO_0007079', 'Orphanet_79292', 'HP_0002017', 'EFO_0002610', 'HP_0002018', 'MONDO_0100342', 'EFO_1001463', 'EFO_0005611', 'EFO_0004888', 'EFO_0000096', 'EFO_0006911', 'EFO_0003869', 'EFO_1000948', 'MONDO_0004992', 'MONDO_0002046', 'EFO_0001061', 'MONDO_0021148', 'HP_0002013', 'EFO_0005762', 'EFO_0003768', 'EFO_0005774', 'EFO_0000764', 'HP_0001082', 'EFO_0011023', 'EFO_0004242', 'MONDO_0007254', 'EFO_0005952', 'EFO_0006912', 'EFO_0007386', 'EFO_0000555', 'MONDO_0043510', 'EFO_0000691', 'HP_0000738', 'EFO_0005251', 'EFO_0006911']",False,False,45,Serotonin 3a (5-HT3a) receptor antagonist ,ANTAGONIST ,single protein 
1031,CANERTINIB DIHYDROCHLORIDE,CHEMBL545315,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000178568', 'ENSG00000141736', 'ENSG00000146648']","['EFO_0003869', 'MONDO_0021117', 'EFO_0003060']",False,True,3,Receptor protein-tyrosine kinase erbB-4 inhibitor Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1032,METHYLPREDNISOLONE,CHEMBL650,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 13 approved and 123 investigational indications.,,4.0,,False,1957,['ENSG00000113580'],"['MP_0001845', 'Orphanet_77260', 'EFO_1000905', 'EFO_1000391', 'EFO_0004143', 'EFO_0003898', 'HP_0002027', 'EFO_0000685', 'MONDO_0007915', 'EFO_0004256', 'EFO_1000965', 'EFO_0007224', 'MONDO_0011972', 'EFO_0000684', 'HP_0002015', 'EFO_0000403', 'MONDO_0018896', 'EFO_0003777', 'EFO_0000662', 'MONDO_0002135', 'MONDO_0000870', 'EFO_0007160', 'EFO_0004826', 'EFO_1001919', 'EFO_0000384', 'EFO_0004194', 'MONDO_0019391', 'EFO_0007149', 'EFO_0003840', 'EFO_1000784', 'EFO_0003914', 'EFO_0009104', 'EFO_0003060', 'EFO_0007537', 'EFO_0009609', 'EFO_0003103', 'MONDO_0013730', 'MONDO_0016537', 'EFO_1000941', 'EFO_0005761', 'EFO_1001806', 'EFO_0001378', 'HP_0002140', 'HP_0001915', 'EFO_0004991', 'EFO_0000209', 'MONDO_0004750', 'EFO_0005297', 'EFO_0003843', 'HP_0001873', 'EFO_1001435', 'HP_0030834', 'MONDO_0017719', 'EFO_0003929', 'MONDO_0020077', 'MONDO_0100096', 'EFO_0000255', 'EFO_0000211', 'EFO_0009373', 'EFO_0003106', 'MONDO_0019091', 'EFO_0004599', 'MONDO_0017287', 'MONDO_0004979', 'EFO_0000565', 'MONDO_0000873', 'MONDO_0004976', 'MONDO_0004992', 'EFO_1001345', 'EFO_0005952', 'MONDO_0005301', 'EFO_0002428', 'EFO_0000694', 'EFO_0004254', 'EFO_0000540', 'MONDO_0008315', 'EFO_0003032', 'EFO_0007405', 'EFO_0004251', 'MONDO_0009348', 'EFO_0000717', 'EFO_0000557', 'EFO_0000341', 'EFO_1001909', 'EFO_0000198', 'EFO_0000706', 'EFO_0004145', 'MONDO_0100339', 'EFO_1000637', 'MONDO_0018150', 'EFO_0000574', 'MONDO_0007254', 'EFO_0007498', 'EFO_1000809', 'EFO_0000274', 'MONDO_0002158', 'EFO_1001254', 'EFO_0000616', 'EFO_0000196', 'EFO_0009492', 'MONDO_0044881', 'EFO_0007295', 'EFO_0000220', 'EFO_0000756', 'EFO_1001365', 'EFO_0003086', 'MONDO_0016226', 'GO_0007568', 'MONDO_0005180', 'MONDO_0100062', 'MONDO_0009387', 'MONDO_0008170', 'EFO_0000095', 'MONDO_0017276', 'EFO_0003894', 'EFO_0003778', 'EFO_0004278', 'EFO_1001466', 'EFO_1001801', 'EFO_0007448', 'HP_0100543', 'EFO_0001642', 'EFO_0006862', 'EFO_0000309', 'MONDO_0015540', 'MONDO_0018923', 'EFO_0007167', 'EFO_0000729', 'EFO_0003884', 'EFO_0004246', 'EFO_0007486', 'MONDO_0005178', 'EFO_0008520', 'MONDO_0100130', 'EFO_1001139', 'MONDO_0002959']",True,True,136,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1033,CHLOROTHIAZIDE,CHEMBL842,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 8 approved and 5 investigational indications.,,4.0,,False,1958,['ENSG00000070915'],"['EFO_0003777', 'EFO_0003914', 'MONDO_0002462', 'EFO_0004255', 'EFO_0000319', 'EFO_0000537', 'MONDO_0005148', 'EFO_0009373', 'EFO_0003884', 'EFO_0000373', 'EFO_0001645', 'EFO_0000668', 'HP_0003124']",False,False,13,Thiazide-sensitive sodium-chloride cotransporter inhibitor ,INHIBITOR ,single protein 
1034,ZOLEDRONIC ACID,CHEMBL924,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications.,,4.0,,False,2001,['ENSG00000160752'],"['EFO_0000228', 'EFO_0000588', 'EFO_0003820', 'EFO_0000564', 'EFO_0004259', 'MONDO_0008310', 'EFO_0001416', 'EFO_0003863', 'EFO_0005952', 'EFO_0003843', 'EFO_0003882', 'MONDO_0011382', 'EFO_1001998', 'EFO_1001147', 'EFO_0004252', 'EFO_1001919', 'EFO_0000691', 'EFO_0003060', 'EFO_0003869', 'EFO_0000681', 'EFO_0000196', 'MONDO_0019019', 'MONDO_0021165', 'MONDO_0044903', 'MONDO_0008315', 'EFO_0002430', 'MONDO_0002974', 'EFO_0004261', 'EFO_0000182', 'MONDO_0002171', 'EFO_0000685', 'EFO_0003931', 'EFO_0003922', 'EFO_0000673', 'EFO_0009708', 'EFO_0001365', 'MONDO_0008903', 'HP_0000938', 'EFO_0001663', 'EFO_0000637', 'EFO_0001378', 'EFO_0009870', 'MONDO_0020732', 'Orphanet_848', 'HP_0003419', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000333', 'EFO_0003854', 'EFO_0004260', 'EFO_0000621', 'EFO_0000432', 'MONDO_0002367', 'EFO_0000174', 'EFO_1000786']",True,False,55,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
1035,CETYLPYRIDINIUM CHLORIDE,CHEMBL2003538,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0002635', 'EFO_1000653', 'MONDO_0002508']",False,False,4,,,
1036,GENTAMICIN SULFATE,CHEMBL3039594,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 7 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1970,[],"['EFO_1000690', 'EFO_0009450', 'EFO_0000544', 'EFO_1001272', 'MP_0001845', 'DOID_7551', 'EFO_0009449', 'EFO_0003106', 'EFO_0000771', 'EFO_1001753', 'EFO_0005044', 'EFO_0009536', 'MONDO_0009179', 'MONDO_0002406', 'MONDO_0017612', 'EFO_0003102', 'MONDO_0018914']",False,False,17,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1037,COPANLISIB,CHEMBL3218576,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 23 investigational indications.,,4.0,,False,2017,"['ENSG00000121879', 'ENSG00000171608']","['EFO_0000096', 'EFO_0003060', 'EFO_0000305', 'HP_0000083', 'EFO_0000403', 'EFO_0000616', 'EFO_0000616', 'EFO_0005952', 'EFO_0000096', 'MONDO_0018906', 'EFO_0000403', 'EFO_0001378', 'EFO_0000707', 'MONDO_0021063', 'EFO_0004606', 'MONDO_0018906', 'EFO_0000574', 'EFO_0000305', 'MONDO_0008315', 'MONDO_0007254', 'EFO_1001051', 'EFO_1001469', 'EFO_1001469', 'EFO_0000095', 'EFO_0000220', 'EFO_0005221', 'EFO_0000183']",True,False,27,PI3-kinase p110-alpha subunit inhibitor PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
1038,PIBRENTASVIR,CHEMBL3545123,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for chronic hepatitis c virus infection and has 4 investigational indications.,,4.0,,False,2017,[],"['EFO_0001421', 'EFO_0003047', 'EFO_0004220', 'EFO_0003086', 'EFO_0003884']",False,False,5,Nonstructural protein 5A inhibitor ,INHIBITOR ,single protein 
1039,AZD-9496,CHEMBL3623004,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1040,SAMOTOLISIB,CHEMBL4297181,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_0002517', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0008315', 'EFO_0005952', 'EFO_0009708', 'EFO_0004142', 'MONDO_0007254', 'EFO_0000588', 'EFO_0000616', 'EFO_0003060']",True,False,11,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1041,COSIBELIMAB,CHEMBL4297729,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000120217'],"['EFO_0000095', 'EFO_0003060']",False,False,2,Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
1042,ENIBARCIMAB,CHEMBL4650434,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000148926'],"['MONDO_0100096', 'EFO_0003144', 'EFO_0006834']",True,False,3,ADM stabiliser ,STABILISER ,single protein 
1043,VINORELBINE,CHEMBL553025,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for cancer and neoplasm and has 52 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000437', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0021063', 'EFO_0004284', 'EFO_0002918', 'MONDO_0004992', 'EFO_1000895', 'EFO_0003869', 'EFO_0000313', 'MONDO_0009348', 'EFO_0000770', 'EFO_0003050', 'EFO_0003032', 'EFO_1000026', 'EFO_0000571', 'EFO_0000437', 'EFO_0000313', 'MONDO_0002367', 'MONDO_0021117', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000621', 'EFO_0000616', 'EFO_0005537', 'EFO_0005952', 'EFO_0000248', 'EFO_1000158', 'EFO_0003869', 'EFO_0000403', 'EFO_0001071', 'MONDO_0008903', 'MONDO_0002158', 'EFO_0000389', 'MONDO_0007254', 'EFO_0000183', 'EFO_0000248', 'EFO_0002617', 'EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691', 'EFO_0001378', 'EFO_0000691', 'EFO_0006861', 'MONDO_0002974', 'EFO_0000588', 'EFO_0000183', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0008903', 'EFO_0000702', 'MONDO_0001187', 'EFO_0005922', 'EFO_0000565', 'EFO_0001416', 'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'MONDO_0007254', 'EFO_0000574']",True,False,63,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1044,CLOFIBRATE,CHEMBL565,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 2 investigational indications.,,4.0,,False,1967,['ENSG00000186951'],"['EFO_1001375', 'EFO_0000612', 'EFO_0000319']",True,False,3,Peroxisome proliferator-activated receptor alpha agonist ,AGONIST ,single protein 
1045,RILUZOLE,CHEMBL744,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for amyotrophic lateral sclerosis and has 21 investigational indications.,,4.0,,False,1995,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0001358', 'EFO_0003100', 'MONDO_0007739', 'MONDO_0005301', 'MONDO_0004985', 'HP_0002196', 'MONDO_0002050', 'EFO_0000275', 'MONDO_0007254', 'EFO_1001919', 'MONDO_0008458', 'MONDO_0019037', 'MONDO_0004976', 'MONDO_0002009', 'EFO_1001050', 'EFO_0003756', 'EFO_0008522', 'EFO_0008525', 'EFO_0000389', 'MONDO_0000437', 'MONDO_0004975', 'EFO_0004242']",False,False,22,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
1046,RALOXIFENE HYDROCHLORIDE,CHEMBL1116,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for breast cancer and osteoporosis and has 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000140009'],"['MONDO_0007254', 'EFO_0000673', 'EFO_0003882']",False,False,3,Estrogen receptor beta modulator ,MODULATOR ,single protein 
1047,IVERMECTIN,CHEMBL1200633,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 15 investigational indications.,,4.0,,False,1996,[],"['MONDO_0007079', 'EFO_0000544', 'EFO_0004227', 'EFO_0007272', 'EFO_0003894', 'EFO_0005547', 'EFO_1001342', 'EFO_0003106', 'EFO_0009536', 'EFO_0007501', 'EFO_0007402', 'EFO_0007328', 'EFO_0000305', 'EFO_0000274', 'MONDO_0100096', 'EFO_1000760', 'EFO_0001068', 'MONDO_0003472', 'EFO_0007524', 'EFO_0000694']",False,False,20,Glutamate-gated chloride channel modulator ,MODULATOR ,single protein 
1048,PREDNISOLONE,CHEMBL131,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 58 approved and 91 investigational indications.,,4.0,,False,1955,['ENSG00000113580'],"['MONDO_0000873', 'MONDO_0015128', 'EFO_0005319', 'EFO_0007486', 'HP_0001742', 'EFO_1001345', 'EFO_0004254', 'EFO_0008997', 'EFO_0005558', 'EFO_1001321', 'EFO_1001205', 'EFO_0000341', 'HP_0002315', 'EFO_0004190', 'EFO_1001968', 'EFO_0005761', 'EFO_0000565', 'EFO_0000768', 'EFO_0005297', 'HP_0001915', 'EFO_0000222', 'EFO_0003872', 'EFO_0000673', 'MONDO_0100096', 'EFO_0000182', 'EFO_1001139', 'EFO_0001663', 'EFO_0007257', 'EFO_0009609', 'EFO_0000685', 'EFO_0005854', 'HP_0003072', 'EFO_0000545', 'EFO_1001896', 'EFO_1001231', 'MONDO_0018906', 'EFO_1001069', 'MONDO_0005090', 'EFO_0007537', 'MONDO_0005129', 'EFO_0003938', 'EFO_1000684', 'EFO_0007427', 'EFO_0004236', 'MONDO_0015540', 'EFO_0009456', 'EFO_0000274', 'MONDO_0004992', 'EFO_0004274', 'EFO_0000384', 'EFO_0000196', 'EFO_0004194', 'EFO_0004237', 'EFO_0003106', 'HP_0002140', 'EFO_0003884', 'EFO_0000209', 'EFO_1000941', 'MONDO_0004750', 'MONDO_0019338', 'EFO_0007520', 'EFO_0000764', 'MONDO_0002462', 'EFO_0004246', 'EFO_0001378', 'EFO_0009491', 'MONDO_0001705', 'MP_0001845', 'EFO_0000255', 'EFO_1001194', 'EFO_0003778', 'EFO_1000764', 'HP_0004398', 'EFO_0000211', 'EFO_0003898', 'EFO_1001110', 'EFO_1001467', 'EFO_0000096', 'EFO_1000694', 'HP_0001873', 'EFO_0002609', 'EFO_0007227', 'EFO_0000676', 'MONDO_0007254', 'EFO_0000398', 'EFO_0004826', 'MONDO_0005148', 'MONDO_0004979', 'EFO_1000726', 'EFO_1000680', 'MONDO_0007915', 'EFO_0000220', 'EFO_0003086', 'EFO_0000717', 'EFO_1001051', 'MONDO_0010679', 'EFO_1000997', 'EFO_0007141', 'MONDO_0018097', 'EFO_0001054', 'EFO_0001365', 'EFO_1000954', 'EFO_0000756', 'MONDO_0000870', 'MONDO_0008315', 'MONDO_0005271', 'EFO_0000403', 'EFO_0000183', 'EFO_1001222', 'EFO_0003032', 'HP_0012424', 'EFO_0007160', 'EFO_1000784', 'EFO_0007208', 'HP_0001094', 'EFO_0009449', 'EFO_1001209', 'MONDO_0005178', 'EFO_1000749', 'EFO_0001060', 'MONDO_0008867', 'HP_0000964', 'EFO_0005752', 'EFO_1001887', 'EFO_0004255', 'EFO_1000049', 'EFO_0005952', 'EFO_1000635', 'EFO_1001435', 'EFO_1001264', 'MONDO_0018896', 'MONDO_0005301', 'MONDO_0005041', 'EFO_1001119', 'EFO_0007403', 'EFO_0000574', 'MONDO_0008728', 'EFO_0000729', 'MONDO_0020290', 'EFO_0007405', 'EFO_1001888', 'MONDO_0001280', 'EFO_0007140', 'EFO_0000759', 'EFO_0009552', 'EFO_1001077', 'EFO_0008518', 'MONDO_0009387', 'EFO_1000039']",True,True,149,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1049,BRIAKINUMAB,CHEMBL1742995,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113302', 'ENSG00000110944', 'ENSG00000168811']","['EFO_0000676', 'EFO_0000384', 'EFO_0000540', 'MONDO_0005301']",False,True,4,Interleukin-12 inhibitor Interleukin-23 inhibitor ,INHIBITOR ,protein complex 
1050,SAPACITABINE,CHEMBL2105681,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002913', 'EFO_0000565', 'MONDO_0007254', 'EFO_0000222', 'EFO_0000616', 'EFO_0003060']",False,False,6,,,
1051,CARRAGEENAN,CHEMBL2108264,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0001668', 'EFO_0008571']",False,False,3,,,
1052,EPRATUZUMAB 90Y,CHEMBL2108357,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000012124'],['EFO_1001938'],False,False,1,CD22 binding agent ,BINDING AGENT ,single protein 
1053,GLUCAGON,CHEMBL266481,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for hypoglycemia and diabetes mellitus and has 6 investigational indications.,,4.0,,False,1998,['ENSG00000215644'],"['HP_0001943', 'EFO_0001073', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0017182', 'EFO_0007214', 'MONDO_0005147', 'EFO_0007318']",False,False,8,Glucagon receptor agonist ,AGONIST ,single protein 
1054,DIRIDAVUMAB,CHEMBL3137350,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005226', 'EFO_0007328']",False,False,2,Hemagglutinin inhibitor ,INHIBITOR ,single protein 
1055,LMB-100,CHEMBL4297777,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000102854', 'ENSG00000167658']","['MONDO_0004992', 'EFO_0000571', 'EFO_0000588', 'EFO_0003860']",True,False,4,Elongation factor 2 disrupting agent Mesothelin binding agent ,DISRUPTING AGENT BINDING AGENT ,single protein 
1056,DS-1062,CHEMBL4297939,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000184292', 'ENSG00000198900']","['MONDO_0008903', 'EFO_0003869', 'MONDO_0007254', 'EFO_0003060']",False,False,4,DNA topoisomerase I inhibitor Tumor-associated calcium signal transducer 2 binding agent ,INHIBITOR BINDING AGENT ,single protein 
1057,TRASTUZUMAB DUOCARMAZINE,CHEMBL4298178,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,['ENSG00000141736'],"['MONDO_0007254', 'MONDO_0001056', 'EFO_0004243', 'EFO_0000616', 'EFO_0001075', 'EFO_0003968', 'MONDO_0011962', 'MONDO_0001187', 'MONDO_0021251', 'EFO_0005537']",False,False,10,Receptor protein-tyrosine kinase erbB-2 binding agent ,BINDING AGENT ,single protein 
1058,BALIXAFORTIDE,CHEMBL4802129,Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000121966'],"['EFO_0000339', 'EFO_0000612', 'EFO_0000198', 'MONDO_0007254', 'EFO_0000222', 'EFO_0001378', 'EFO_0000095']",True,False,7,C-X-C chemokine receptor type 4 antagonist ,ANTAGONIST ,single protein 
1059,DALPICICLIB,CHEMBL4802161,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0005922', 'EFO_0003869']",False,False,3,,,
1060,NIACIN,CHEMBL573,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 11 approved and 31 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000319', 'MONDO_0005148', 'HP_0031284', 'EFO_0005407', 'MONDO_0011382', 'EFO_0000764', 'EFO_0001358', 'EFO_0005672', 'EFO_0003768', 'EFO_1001207', 'HP_0002140', 'EFO_0003894', 'Orphanet_79211', 'EFO_0000195', 'EFO_0003914', 'EFO_0005952', 'MONDO_0018076', 'EFO_0000519', 'EFO_0003781', 'MONDO_0004992', 'EFO_0000612', 'EFO_0003884', 'HP_0003124', 'MONDO_0002009', 'MONDO_0021187', 'EFO_0000180', 'EFO_0000712', 'EFO_0004911', 'EFO_0004272', 'Orphanet_309005', 'EFO_1000860', 'EFO_1001157', 'EFO_1001375', 'EFO_0001645', 'HP_0001891', 'EFO_0001073', 'EFO_0004242', 'HP_0002027', 'EFO_0003876', 'EFO_0003144', 'EFO_0000266', 'EFO_0009783']",False,False,42,,,
1061,RAMIPRIL,CHEMBL1168,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,['ENSG00000159640'],"['EFO_0003884', 'EFO_0000401', 'EFO_0000400', 'EFO_0004285', 'EFO_0001645', 'EFO_0003914', 'EFO_0000319', 'EFO_0000195', 'EFO_0008583', 'EFO_0003911', 'MONDO_0002462', 'EFO_0003086', 'EFO_0003777', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000712', 'EFO_0000589', 'EFO_0000537', 'EFO_0000275', 'MONDO_0007915', 'EFO_1001375', 'EFO_0000612', 'HP_0003124', 'EFO_0000373', 'EFO_0002546', 'EFO_0003144', 'MONDO_0005147', 'MONDO_0005148']",True,False,28,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
1062,AMINOLEVULINIC ACID HYDROCHLORIDE,CHEMBL1200582,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 15 investigational indications.,,4.0,,False,1999,[],"['MONDO_0100342', 'HP_0002745', 'EFO_0006859', 'EFO_0002496', 'EFO_0000616', 'EFO_0000574', 'EFO_0003833', 'MONDO_0004647', 'EFO_0000519', 'EFO_0000729', 'EFO_0003894', 'MONDO_0007254', 'MONDO_0018975', 'EFO_0000565', 'EFO_1001051']",False,False,15,,,
1063,SODIUM CITRATE,CHEMBL1355,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for anemia (phenotype) and unipolar depression and has 9 investigational indications.,,4.0,,False,1983,[],"['MONDO_0005147', 'EFO_0004599', 'EFO_1000811', 'EFO_0004272', 'EFO_0003761', 'HP_0004936', 'EFO_1000906', 'MONDO_0005129', 'MONDO_0005178', 'MONDO_0011628', 'EFO_1001496']",False,False,11,,,
1064,TROSPIUM,CHEMBL1888176,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications.,,4.0,,False,2004,"['ENSG00000133019', 'ENSG00000181072']","['EFO_0006865', 'HP_0000020', 'EFO_0000341', 'EFO_1000781', 'HP_0000103', 'MONDO_0005090', 'EFO_1000781']",True,True,7,Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M2 antagonist ,ANTAGONIST ,single protein 
1065,SELENIOUS ACID,CHEMBL2009089,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 7 investigational indications.,,4.0,,False,2019,[],"['EFO_0000673', 'MONDO_0008315', 'MONDO_0019297', 'EFO_0009492', 'EFO_0003777', 'EFO_0003869', 'MONDO_0100096']",False,False,7,,,
1066,EMPAGLIFLOZIN,CHEMBL2107830,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 25 investigational indications.,,4.0,,False,2014,['ENSG00000140675'],"['EFO_0003095', 'EFO_1000982', 'EFO_0003884', 'EFO_0004593', 'HP_0002902', 'HP_0001943', 'MONDO_0005147', 'EFO_0000660', 'EFO_0003086', 'EFO_0008583', 'EFO_0000401', 'EFO_0000612', 'MONDO_0017147', 'EFO_1001482', 'Orphanet_364', 'EFO_0000384', 'EFO_0000729', 'HP_0001541', 'EFO_0003144', 'EFO_0002614', 'EFO_0000694', 'EFO_0000666', 'EFO_0004253', 'MONDO_0005148', 'EFO_1001121', 'HP_0001919', 'EFO_0000400']",False,False,27,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1067,SEMAGLUTIDE,CHEMBL2108724,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2017,['ENSG00000112164'],"['EFO_0003095', 'MONDO_0004979', 'EFO_0000400', 'MONDO_0005148', 'MONDO_0005180', 'EFO_0001645', 'EFO_0001073', 'HP_0000938', 'MONDO_0002009', 'MONDO_0005147', 'MONDO_0004975', 'EFO_1001249']",False,False,12,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
1068,CAMOTESKIMAB,CHEMBL2109604,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,['ENSG00000150782'],"['EFO_0000341', 'EFO_0001378', 'EFO_0007135']",False,False,3,Interleukin-18 cross-linking agent ,CROSS-LINKING AGENT ,single protein 
1069,PINATUZUMAB VEDOTIN,CHEMBL3301585,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000012124']","['MONDO_0018906', 'EFO_0000095', 'EFO_0000403']",True,False,3,CD22 binding agent Tubulin inhibitor ,BINDING AGENT INHIBITOR ,single protein protein complex group 
1070,DEPATUXIZUMAB,CHEMBL3707294,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_0000616', 'EFO_0000228']",False,False,2,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1071,EFINEPTAKIN ALFA,CHEMBL4594590,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000181', 'EFO_1001465', 'MONDO_0100096', 'EFO_0007455']",False,False,5,,,
1072,TRIPTOLIDE,CHEMBL463763,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000544', 'EFO_0000764', 'EFO_0003060', 'EFO_1001496']",False,False,4,,,
1073,ECLITASERTIB,CHEMBL4861471,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0003834']",False,False,2,,,
1074,DIPYRIDAMOLE,CHEMBL932,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 13 investigational indications.,,4.0,,False,1961,"['ENSG00000138735', 'ENSG00000065989', 'ENSG00000172572', 'ENSG00000139053', 'ENSG00000185527', 'ENSG00000186642', 'ENSG00000205268', 'ENSG00000115252', 'ENSG00000160191', 'ENSG00000133256', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000156973', 'ENSG00000132915', 'ENSG00000152270', 'ENSG00000095464', 'ENSG00000113231', 'ENSG00000112541', 'ENSG00000123360', 'ENSG00000105650', 'ENSG00000154678', 'ENSG00000073417', 'ENSG00000171408', 'ENSG00000112759']","['EFO_0001645', 'MONDO_0100096', 'EFO_0000685', 'EFO_1002000', 'MONDO_0008170', 'MONDO_0011382', 'EFO_0000764', 'EFO_0003777', 'EFO_0000712', 'EFO_0003913', 'EFO_0002615', 'EFO_1000965', 'EFO_0000537', 'HP_0004419', 'EFO_1001375', 'EFO_0002618']",True,False,16,"Equilibrative nucleoside transporter 1 inhibitor 3',5'-cyclic phosphodiesterase inhibitor ",INHIBITOR ,single protein protein family 
1075,SELENOMETHIONINE,CHEMBL113178,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 8 investigational indications.,,4.0,,False,1973,[],"['EFO_1001951', 'EFO_0000349', 'EFO_0003779', 'EFO_0005406', 'MONDO_0008315', 'MONDO_0008903', 'EFO_0000365', 'MONDO_0018906']",False,False,8,,,
1076,PORFIMER SODIUM,CHEMBL1201481,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for neoplasm and has 14 investigational indications.,,4.0,,False,1995,[],"['MONDO_0001187', 'MONDO_0007576', 'EFO_0000702', 'EFO_0000588', 'MONDO_0008903', 'MONDO_0002038', 'EFO_1001959', 'EFO_0006859', 'EFO_1000158', 'EFO_0000616', 'EFO_0000770', 'EFO_0003060', 'EFO_0005540', 'EFO_0003833', 'MONDO_0005411']",False,False,15,,,
1077,"GLOBULIN, IMMUNE",CHEMBL1201599,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 66 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001050', 'HP_0031047', 'EFO_0000717', 'EFO_0002950', 'EFO_0000474', 'MONDO_0015977', 'EFO_1000318', 'MONDO_0020077', 'Orphanet_308', 'MONDO_0003778', 'EFO_0005252', 'EFO_0000540', 'EFO_0004719', 'EFO_0003144', 'EFO_0009538', 'MONDO_0004979', 'EFO_0004256', 'EFO_0005762', 'EFO_0000650', 'EFO_0003884', 'EFO_0003782', 'EFO_0004276', 'EFO_0000398', 'HP_0100543', 'EFO_0007498', 'EFO_0007187', 'MONDO_0008867', 'EFO_0007332', 'MONDO_0000437', 'HP_0040187', 'EFO_0000341', 'EFO_0008583', 'MONDO_0007915', 'EFO_0004246', 'HP_0002140', 'EFO_0007160', 'EFO_0000544', 'HP_0002110', 'EFO_1000868', 'MONDO_0015517', 'MONDO_0019956', 'EFO_0004149', 'EFO_0009606', 'EFO_0004991', 'EFO_1000906', 'EFO_0000565', 'EFO_0003834', 'EFO_0004145', 'EFO_0000764', 'EFO_1000749', 'EFO_0003929', 'EFO_0000778', 'EFO_1000954', 'EFO_0004599', 'EFO_0001378', 'MONDO_0004975', 'EFO_0007454', 'EFO_0007328', 'MONDO_0005301', 'MONDO_0015540', 'MONDO_0000465', 'EFO_0000198', 'EFO_0000621', 'MONDO_0100096', 'MONDO_0007571', 'EFO_0007292']",False,False,66,,,
1078,NESIRITIDE,CHEMBL1201668,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for cardiovascular disease and has 17 investigational indications.,,4.0,,False,2001,['ENSG00000169418'],"['EFO_0001073', 'EFO_0000537', 'EFO_0000756', 'EFO_0000373', 'EFO_0000701', 'EFO_0000319', 'EFO_0008583', 'EFO_0003086', 'EFO_0000318', 'EFO_0000400', 'EFO_0003144', 'EFO_0005672', 'EFO_0000612', 'HP_0000842', 'EFO_1002048', 'HP_0030680', 'HP_0001919', 'HP_0002094']",False,False,18,Atrial natriuretic peptide receptor A agonist ,AGONIST ,single protein 
1079,BLEOMYCIN A6,CHEMBL1231529,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000708'],False,False,1,,,
1080,SELUMETINIB,CHEMBL1614701,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 44 investigational indications.,,4.0,,False,2020,"['ENSG00000169032', 'ENSG00000126934']","['EFO_0000389', 'EFO_0000272', 'EFO_0000501', 'EFO_0000403', 'EFO_0009254', 'EFO_0003060', 'EFO_0005537', 'EFO_1001956', 'MONDO_0018975', 'EFO_0000756', 'MONDO_0001187', 'EFO_0008514', 'EFO_0000365', 'EFO_0000305', 'MONDO_0007254', 'EFO_0000760', 'EFO_0000558', 'MONDO_0003060', 'EFO_0002617', 'EFO_0000339', 'EFO_1001951', 'MONDO_0002367', 'EFO_0000228', 'EFO_1001950', 'EFO_0000220', 'EFO_0001378', 'EFO_0002618', 'EFO_0000503', 'MONDO_0018975', 'EFO_0002618', 'MONDO_0016691', 'EFO_0000707', 'EFO_0000616', 'EFO_0000182', 'EFO_0000641', 'EFO_0004606', 'EFO_0000708', 'EFO_1001968', 'EFO_0000389', 'MONDO_0004992', 'EFO_0004142', 'EFO_0000658', 'EFO_1000657', 'EFO_0002617', 'MONDO_0021063', 'MONDO_0002108', 'MONDO_0018531', 'MONDO_0008903', 'EFO_0005221']",True,False,49,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor ,INHIBITOR ,single protein protein family 
1081,ERAVACYCLINE,CHEMBL1951095,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for bacterial disease and infection and has 4 investigational indications.,,4.0,,False,2018,[],"['EFO_0001421', 'EFO_0003103', 'EFO_0000771', 'EFO_0003884', 'EFO_0000544', 'EFO_0000544']",False,False,6,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1082,ABT-751,CHEMBL20684,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000258947', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000173213']","['EFO_0000681', 'EFO_0001642', 'EFO_1001951', 'EFO_0000621', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0000870', 'EFO_0003060']",True,False,8,Tubulin beta inhibitor ,INHIBITOR ,protein family 
1083,KBPA-101,CHEMBL2109535,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003106'],False,False,1,,,
1084,NOGAPENDEKIN ALFA,CHEMBL4297690,Protein drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005835', 'EFO_0001378', 'EFO_0000365', 'EFO_0000196', 'EFO_0002618', 'MONDO_0100096', 'MONDO_0001187', 'EFO_0000707', 'EFO_0000181', 'EFO_0008528', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0003060', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000182', 'EFO_0000756', 'EFO_0000198', 'EFO_0000764', 'EFO_0000765', 'MONDO_0002158', 'MONDO_0008978', 'EFO_1001471', 'EFO_0005952', 'EFO_1001951', 'EFO_0000222']",False,False,26,,,
1085,FERRIC DERISOMALTOSE,CHEMBL4298187,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for iron deficiency anemia and anemia and has 1 investigational indication.,,4.0,,False,2020,[],"['EFO_0003884', 'HP_0001891', 'MONDO_0002280']",False,False,3,,,
1086,SIBOFIMLOC,CHEMBL4594305,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0000384'],False,False,1,,,
1087,MEGESTROL ACETATE,CHEMBL1201139,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 13 investigational indications.,,4.0,,False,1971,['ENSG00000082175'],"['EFO_0000341', 'EFO_0003859', 'MONDO_0002715', 'MONDO_0002691', 'EFO_0004230', 'HP_0031217', 'HP_0002039', 'EFO_1001512', 'HP_0004326', 'EFO_0000765', 'MONDO_0004992', 'EFO_0007312', 'EFO_0006859', 'MONDO_0007254', 'MONDO_0011962', 'MONDO_0003778', 'EFO_0000616', 'MONDO_0024474', 'EFO_0003869']",False,False,19,Progesterone receptor agonist ,AGONIST ,single protein 
1088,PAZOPANIB HYDROCHLORIDE,CHEMBL1201733,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,"['ENSG00000077782', 'ENSG00000182866', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113263', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000182578']","['MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0000501', 'MONDO_0001187', 'MONDO_0015277', 'EFO_1001465', 'MONDO_0008903', 'EFO_1000613', 'MONDO_0004192', 'EFO_0000349', 'MONDO_0002158', 'EFO_0003968', 'MONDO_0004986', 'EFO_0000588', 'EFO_0001663', 'EFO_0000641', 'MONDO_0008315', 'EFO_0000640', 'MONDO_0008667', 'MONDO_0007254', 'EFO_1001968', 'EFO_0000616', 'EFO_0000691', 'EFO_0006861', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170']",True,False,28,Macrophage colony stimulating factor receptor inhibitor Tyrosine-protein kinase ITK/TSK inhibitor Platelet-derived growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor Fibroblast growth factor receptor 1 inhibitor Tyrosine-protein kinase LCK inhibitor Stem cell growth factor receptor inhibitor Fibroblast growth factor receptor 3 inhibitor ,INHIBITOR ,single protein protein complex protein family 
1089,GOLIMUMAB,CHEMBL1201833,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000232810'],"['EFO_0000384', 'EFO_0002609', 'EFO_0000706', 'EFO_0009672', 'EFO_0000540', 'MONDO_0004979', 'EFO_0000685', 'EFO_0003778', 'MONDO_0019338', 'MONDO_0005147', 'MONDO_0005178', 'EFO_0003898', 'EFO_0000729', 'MONDO_0003937']",False,True,14,TNF-alpha inhibitor ,INHIBITOR ,single protein 
1090,LADARIXIN,CHEMBL189475,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000180871', 'ENSG00000163464']","['MONDO_0005147', 'EFO_0007187']",False,False,2,Interleukin-8 receptor A modulator Interleukin-8 receptor B modulator ,MODULATOR ,single protein 
1091,TEDIZOLID PHOSPHATE,CHEMBL2105669,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 7 investigational indications.,,4.0,,False,2014,[],"['EFO_0000701', 'EFO_0000771', 'EFO_0003106', 'EFO_0003086', 'EFO_0001421', 'MONDO_0021679', 'EFO_0000544']",False,False,7,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1092,IMETELSTAT SODIUM,CHEMBL2108702,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000164362'],"['EFO_0001378', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008903']",False,False,4,Telomerase reverse transcriptase inhibitor ,INHIBITOR ,single protein 
1093,MENATETRENONE,CHEMBL259223,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000182', 'EFO_0003882', 'EFO_0003884', 'MONDO_0000831', 'EFO_0003854']",False,False,5,,,
1094,CEFIDEROCOL,CHEMBL3989974,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 5 investigational indications.,,4.0,,False,2019,[],"['EFO_0003106', 'EFO_0003103', 'EFO_1001272', 'EFO_0000771', 'HP_0100806', 'EFO_1001272', 'EFO_0000544', 'EFO_0003103']",False,False,8,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1095,FLUORESCEIN,CHEMBL4297067,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 6 investigational indications.,,4.0,,False,1976,[],"['MONDO_0002070', 'EFO_0000701', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0003822', 'EFO_0000693']",False,False,6,,,
1096,TARLOXOTINIB,CHEMBL4297661,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361']","['EFO_0003060', 'EFO_0003060']",False,True,2,Epidermal growth factor receptor inhibitor ,INHIBITOR ,protein family 
1097,FERMAGATE,CHEMBL4297751,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003884'],False,False,1,,,
1098,ABIVERTINIB MALEATE,CHEMBL4297866,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000146648', 'ENSG00000010671']","['EFO_0000096', 'EFO_0003060', 'MONDO_0100096']",False,True,3,Epidermal growth factor receptor erbB1 inhibitor Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1099,VOLAGIDEMAB,CHEMBL4298213,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000215644'],"['HP_0003074', 'MONDO_0005148', 'MONDO_0005147']",False,False,3,Glucagon receptor inhibitor ,INHIBITOR ,single protein 
1100,VEBRELTINIB,CHEMBL4650443,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1101,SAB-185,CHEMBL5095291,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1102,NADOLOL,CHEMBL649,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1979,"['ENSG00000043591', 'ENSG00000169252']","['MONDO_0004979', 'EFO_1000635', 'EFO_0000612', 'EFO_0003913', 'EFO_0000319', 'EFO_0004319', 'EFO_0000537', 'EFO_0000712']",False,False,8,Beta-2 adrenergic receptor antagonist Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
1103,MITOMYCIN,CHEMBL105,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 40 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,[],"['MONDO_0001056', 'EFO_0000588', 'MONDO_0001187', 'EFO_0000313', 'EFO_0004190', 'MONDO_0004647', 'HP_0007957', 'MONDO_0007254', 'EFO_0006859', 'MONDO_0003060', 'MONDO_0002691', 'EFO_0004268', 'MONDO_0008903', 'EFO_0009708', 'MONDO_0015486', 'HP_0000545', 'EFO_0000294', 'EFO_0000228', 'EFO_0000182', 'EFO_0000616', 'EFO_0003835', 'EFO_0003060', 'MONDO_0001235', 'EFO_0005221', 'EFO_1000601', 'MONDO_0001879', 'EFO_0000691', 'EFO_0008528', 'MONDO_0005041', 'EFO_0003884', 'EFO_0000565', 'MONDO_0004992', 'HP_0012227', 'EFO_0000678', 'EFO_1001951', 'EFO_0004252', 'MONDO_0004986', 'EFO_0002618', 'MONDO_0002974', 'MONDO_0021117', 'EFO_1001060', 'MONDO_0003199', 'EFO_0000181', 'HP_0010450']",False,False,44,,,
1104,MERCAPTOPURINE,CHEMBL1200751,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 4 approved and 19 investigational indications.,,4.0,,False,1953,['ENSG00000128059'],"['EFO_0000574', 'MONDO_0019460', 'EFO_0000565', 'EFO_0000224', 'EFO_0003833', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729', 'EFO_0004289', 'MONDO_0000870', 'EFO_0000209', 'EFO_0000616', 'MONDO_0044917', 'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872', 'MONDO_0000873', 'EFO_0002499', 'EFO_1000318', 'EFO_0000220', 'EFO_0000222', 'EFO_0000309']",False,False,23,Amidophosphoribosyltransferase inhibitor ,INHIBITOR ,single protein 
1105,COLESTIPOL HYDROCHLORIDE,CHEMBL1201474,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for hypercholesterolemia and cardiovascular disease and has 5 investigational indications.,,4.0,,False,1977,[],"['EFO_1001375', 'EFO_0003781', 'EFO_1000860', 'MONDO_0001676', 'HP_0003124', 'EFO_0000319', 'MONDO_0007254']",False,False,7,,,
1106,CERTOLIZUMAB PEGOL,CHEMBL1201831,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2008,['ENSG00000232810'],"['EFO_0000540', 'EFO_0000384', 'MP_0001845', 'EFO_0003898', 'EFO_0002609', 'EFO_0000676', 'EFO_0000685', 'EFO_0000729', 'EFO_0003778', 'EFO_1000869']",False,True,10,TNF-alpha inhibitor ,INHIBITOR ,single protein 
1107,RACOTUMOMAB,CHEMBL1743059,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000621', 'EFO_0003060']",False,False,2,,,
1108,EDRATIDE,CHEMBL2107743,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007915'],False,False,1,,,
1109,TENECTEPLASE,CHEMBL2108791,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications.,,4.0,,False,2000,['ENSG00000122194'],"['EFO_0003827', 'EFO_0009637', 'EFO_0000712', 'MONDO_0002679', 'HP_0002140', 'EFO_1000637', 'HP_0004419', 'EFO_0008583', 'EFO_0000618', 'MONDO_0005299', 'EFO_0000612', 'MONDO_0000831', 'EFO_0004278', 'EFO_0008585', 'EFO_1001154']",False,True,15,Plasminogen activator ,ACTIVATOR ,single protein 
1110,ELUBRIXIN TOSYLATE,CHEMBL3039524,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0000341'],False,False,1,,,
1111,BEMIPARIN,CHEMBL3707365,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000126218'],"['EFO_0001422', 'HP_0000083', 'EFO_0000702', 'EFO_1001459', 'MONDO_0100096', 'HP_0004419']",False,False,6,Coagulation factor X inhibitor ,INHIBITOR ,single protein 
1112,COBOLIMAB,CHEMBL4298123,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000135077'],"['MONDO_0002691', 'EFO_0000616', 'EFO_0000756', 'EFO_0003060']",False,False,4,Hepatitis A virus cellular receptor 2 inhibitor ,INHIBITOR ,single protein 
1113,ENMD-2076,CHEMBL482968,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000128052', 'ENSG00000182578', 'ENSG00000122025', 'ENSG00000087586', 'ENSG00000068078', 'ENSG00000178999']","['EFO_0001642', 'MONDO_0004992', 'EFO_0000348', 'EFO_1001968', 'MONDO_0002087', 'EFO_1000251', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000182']",True,False,10,Macrophage colony stimulating factor receptor inhibitor Serine/threonine-protein kinase Aurora-A inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Vascular endothelial growth factor receptor 2 inhibitor Stem cell growth factor receptor inhibitor Fibroblast growth factor receptor 3 inhibitor Serine/threonine-protein kinase Aurora-B inhibitor ,INHIBITOR ,single protein 
1114,KETOTIFEN,CHEMBL534,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for allergic disease and eye allergy and has 11 investigational indications.,,4.0,,False,1999,['ENSG00000196639'],"['EFO_1001417', 'EFO_0005687', 'MONDO_0005271', 'MONDO_0002406', 'EFO_0008533', 'EFO_0007141', 'HP_0012532', 'EFO_1001417', 'EFO_0007141', 'EFO_0000274', 'MONDO_0100096', 'HP_0001371', 'EFO_0003931', 'EFO_0007425', 'EFO_0005751']",False,False,15,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
1115,METHYLENE BLUE,CHEMBL550495,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for urinary tract infection and has 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2016,[],"['EFO_0001358', 'MONDO_0100096', 'EFO_0007444', 'EFO_0000694', 'HP_0000952', 'EFO_0006834', 'MONDO_0004975', 'EFO_0000546', 'HP_0100806', 'EFO_1001216', 'EFO_0001068', 'EFO_0007287', 'EFO_0003901', 'EFO_0003030', 'MONDO_0004985', 'EFO_0003103']",False,False,16,,,
1116,MOMELOTINIB,CHEMBL1078178,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000162434', 'ENSG00000096968']","['EFO_0000479', 'EFO_0002517', 'EFO_0002429', 'EFO_0002430', 'EFO_0003060', 'MONDO_0044903']",False,False,6,Tyrosine-protein kinase JAK1 inhibitor Tyrosine-protein kinase JAK2 inhibitor ,INHIBITOR ,single protein 
1117,AZATHIOPRINE,CHEMBL1542,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for rheumatoid arthritis and immune system disease and has 35 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1968,['ENSG00000128059'],"['EFO_0000318', 'EFO_0003818', 'EFO_0003884', 'EFO_0000729', 'MONDO_0007915', 'EFO_0005761', 'EFO_0004826', 'EFO_0000545', 'EFO_0000384', 'HP_0001873', 'EFO_0005297', 'MONDO_0011382', 'EFO_0000685', 'EFO_1001857', 'EFO_0004719', 'EFO_0000182', 'EFO_0007208', 'EFO_0004274', 'EFO_0004244', 'EFO_0009448', 'MONDO_0019249', 'EFO_0006803', 'EFO_0005676', 'EFO_0004256', 'EFO_0003767', 'EFO_0007187', 'EFO_1000784', 'EFO_0001423', 'EFO_0004991', 'HP_0000964', 'EFO_0000222', 'EFO_1000749', 'EFO_0000768', 'EFO_0000540', 'EFO_0004194', 'EFO_0005531', 'EFO_0000198']",False,False,37,Amidophosphoribosyltransferase inhibitor ,INHIBITOR ,single protein 
1118,TIGATUZUMAB,CHEMBL1743080,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000120889'],"['MONDO_0004992', 'MONDO_0008170', 'EFO_0000574', 'EFO_0004142', 'EFO_0003060', 'EFO_0002618', 'EFO_0000182']",False,False,7,Tumor necrosis factor receptor superfamily member 10B agonist ,AGONIST ,single protein 
1119,NIVOLUMAB,CHEMBL2108738,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 13 approved and 133 investigational indications.,,4.0,,False,2015,['ENSG00000188389'],"['MONDO_0001657', 'EFO_0000305', 'MONDO_0002691', 'MONDO_0011962', 'EFO_1001972', 'EFO_1001949', 'EFO_0009709', 'EFO_0003968', 'MONDO_0007187', 'MONDO_0002158', 'EFO_0004243', 'EFO_0004197', 'EFO_0000183', 'MONDO_0002120', 'EFO_0000691', 'MONDO_0021148', 'EFO_0000096', 'EFO_0000565', 'EFO_0000403', 'EFO_0005537', 'EFO_0000519', 'EFO_0002618', 'EFO_0006859', 'EFO_0003891', 'EFO_0000198', 'EFO_0000621', 'EFO_0000211', 'EFO_0000228', 'EFO_0000180', 'EFO_0000770', 'MONDO_0021117', 'EFO_1001469', 'MONDO_0008170', 'EFO_1001951', 'MONDO_0007254', 'EFO_0001061', 'EFO_1001931', 'MONDO_0002928', 'EFO_1001465', 'MONDO_0100342', 'EFO_0000182', 'EFO_1000613', 'HP_0100806', 'EFO_0002916', 'EFO_0002617', 'EFO_0000708', 'MONDO_0016642', 'MONDO_0008903', 'MONDO_0002547', 'MONDO_0015760', 'EFO_0000294', 'MONDO_0002367', 'EFO_1001051', 'EFO_0000632', 'MONDO_0017582', 'MONDO_0100096', 'EFO_0000365', 'EFO_0000339', 'EFO_0005543', 'EFO_0000181', 'EFO_0001642', 'EFO_0000637', 'MONDO_0003060', 'MONDO_0001187', 'EFO_0000220', 'EFO_0000571', 'MONDO_0024503', 'MONDO_0002108', 'EFO_0000588', 'HP_0002745', 'EFO_0008524', 'EFO_0002517', 'EFO_0000616', 'EFO_0007541', 'EFO_0007466', 'EFO_1000984', 'EFO_1001950', 'EFO_0001416', 'MONDO_0001056', 'EFO_0003833', 'MONDO_0008315', 'EFO_0003032', 'EFO_1000251', 'MONDO_0002087', 'EFO_0000196', 'EFO_0002892', 'EFO_0003085', 'EFO_0005221', 'EFO_0004142', 'EFO_0000564', 'MONDO_0011719', 'EFO_1001512', 'MONDO_0002038', 'EFO_0000707', 'EFO_1000657', 'EFO_0003050', 'EFO_0005922', 'EFO_0004239', 'MONDO_0044704', 'EFO_0001075', 'EFO_0000349', 'EFO_1001471', 'MONDO_0007576', 'MONDO_0002898', 'EFO_0000503', 'EFO_0000326', 'EFO_0000514', 'MONDO_0009348', 'EFO_1001968', 'EFO_0000199', 'EFO_0001378', 'EFO_0003060', 'EFO_0005952', 'EFO_0000702', 'EFO_0000756', 'MONDO_0020634', 'EFO_0003016', 'EFO_0000389', 'MONDO_0018906', 'EFO_0008528', 'MONDO_0004669', 'EFO_0000558', 'EFO_0000681', 'EFO_1000796', 'EFO_0000640', 'EFO_0000574', 'MONDO_0004986', 'EFO_1000209', 'EFO_0004193', 'EFO_0004284', 'MONDO_0000870', 'EFO_0000095', 'EFO_0000673', 'EFO_0007304', 'EFO_0000313', 'MONDO_0004992', 'MONDO_0021063', 'EFO_1000785', 'EFO_0004252', 'MONDO_0044881', 'EFO_0003863', 'MONDO_0008978', 'EFO_0000335', 'EFO_1000026', 'EFO_0000222', 'MONDO_0002974']",True,False,146,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
1120,CALCIUM,CHEMBL2146121,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 43 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001073', 'MONDO_0004985', 'EFO_0007319', 'EFO_0007176', 'EFO_0005406', 'EFO_0000660', 'EFO_0008519', 'EFO_0003884', 'EFO_0004288', 'MONDO_0002171', 'EFO_0003777', 'EFO_0003762', 'EFO_0000537', 'EFO_0000574', 'EFO_0003843', 'EFO_0004142', 'EFO_0004261', 'EFO_0000668', 'EFO_0003931', 'MONDO_0011972', 'MONDO_0005271', 'EFO_0003922', 'EFO_0003964', 'EFO_1001375', 'MONDO_0005180', 'EFO_0003854', 'MONDO_0004992', 'MONDO_0007254', 'HP_0000938', 'EFO_0009451', 'EFO_1001951', 'EFO_0003869', 'HP_0002901', 'MONDO_0019019', 'EFO_0002609', 'EFO_0000764', 'EFO_0000546', 'EFO_0000565', 'EFO_0003819', 'MONDO_0008315', 'EFO_0002618', 'EFO_0003144', 'EFO_0003882']",False,False,43,,,
1121,SITAXENTAN,CHEMBL282724,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for hypertension and has 6 investigational indications. It was withdrawn in at least one region.,,4.0,,False,2006,"['ENSG00000136160', 'ENSG00000151617']","['MONDO_0005149', 'EFO_0000537', 'HP_0000093', 'EFO_1000899', 'EFO_0001361', 'MONDO_0004979', 'EFO_0003884']",False,False,7,"Endothelin receptor, ET-A/ET-B antagonist ",ANTAGONIST ,protein family 
1122,AZD-3759,CHEMBL3623290,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1123,FULACIMSTAT,CHEMBL4297596,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000092009'],"['EFO_0000612', 'EFO_0000401', 'EFO_0003144']",False,False,3,Chymase inhibitor ,INHIBITOR ,single protein 
1124,HYDROCHLOROTHIAZIDE,CHEMBL435,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 11 approved and 13 investigational indications.,,4.0,,False,1959,['ENSG00000070915'],"['EFO_0001422', 'EFO_0003913', 'EFO_0000319', 'EFO_0000400', 'MONDO_0005148', 'Orphanet_79292', 'EFO_0003884', 'EFO_0000668', 'EFO_0004278', 'EFO_0009373', 'EFO_0000537', 'EFO_0001645', 'EFO_0000612', 'HP_0003124', 'EFO_0004255', 'EFO_0003914', 'EFO_0004253', 'EFO_0000195', 'MONDO_0001134', 'EFO_0003086', 'EFO_1001496', 'EFO_0000668', 'EFO_0000373', 'MONDO_0002462']",False,False,24,Thiazide-sensitive sodium-chloride cotransporter inhibitor ,INHIBITOR ,single protein 
1125,PUCOTENLIMAB,CHEMBL4650472,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000756', 'EFO_0000182', 'MONDO_0001056', 'EFO_0000616', 'MONDO_0001187', 'MONDO_0002108', 'EFO_0003060']",False,False,7,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
1126,INIPARIB,CHEMBL1170047,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008170', 'EFO_0003060', 'EFO_0000708', 'MONDO_0007254', 'EFO_1000613', 'EFO_0000616']",False,False,6,,,
1127,MARAVIROC,CHEMBL1201187,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,['ENSG00000160791'],"['EFO_0000198', 'EFO_0000764', 'MONDO_0100096', 'EFO_0000685', 'EFO_0000403', 'EFO_0000183', 'EFO_0000544', 'EFO_0000339', 'EFO_0002608', 'MONDO_0018906', 'MONDO_0044881', 'EFO_0000095', 'EFO_0000765', 'EFO_0000558', 'EFO_0000712', 'MONDO_0013730', 'EFO_0004211', 'EFO_0000763', 'EFO_0000180', 'HP_0100543', 'MONDO_0021094']",True,False,21,C-C chemokine receptor type 5 antagonist ,ANTAGONIST ,single protein 
1128,IPRATROPIUM,CHEMBL1621597,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 10 approved and 6 investigational indications.,,4.0,,False,1986,['ENSG00000133019'],"['MONDO_0005180', 'HP_0025428', 'HP_0002307', 'EFO_0008590', 'EFO_0006505', 'EFO_0000464', 'HP_0001742', 'Orphanet_1764', 'EFO_0000341', 'EFO_0003956', 'EFO_0000341', 'EFO_0001361', 'EFO_0007214', 'HP_0006536', 'EFO_0000274', 'MONDO_0004979']",True,True,16,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1129,COLESTILAN CHLORIDE,CHEMBL2103800,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005148', 'EFO_0003884']",False,False,2,,,
1130,IMETELSTAT,CHEMBL2107856,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000164362'],"['MONDO_0044903', 'EFO_0000621', 'EFO_0000479', 'EFO_0001378', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000198', 'EFO_0000574', 'EFO_0002429']",False,True,9,Telomerase reverse transcriptase inhibitor ,INHIBITOR ,single protein 
1131,SERELAXIN,CHEMBL2108358,Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000171509', 'ENSG00000133105']","['EFO_0001421', 'EFO_0000668', 'EFO_0001645', 'EFO_0003144', 'EFO_0000319', 'EFO_0003884']",False,False,6,Relaxin receptor 1 activator Relaxin receptor 2 activator ,ACTIVATOR ,single protein 
1132,DEMCIZUMAB,CHEMBL2109384,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000128917'],"['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'EFO_0000616']",False,False,4,Delta-like protein 4 inhibitor ,INHIBITOR ,single protein 
1133,VOCLOSPORIN,CHEMBL2218919,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for lupus nephritis and immune system disease and has 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2021,['ENSG00000138814'],"['EFO_1000986', 'EFO_1000811', 'EFO_1001119', 'EFO_1000906', 'EFO_1001082', 'EFO_0003086', 'EFO_1001231', 'MONDO_0007915', 'EFO_0005761', 'EFO_0004236', 'EFO_0000540', 'EFO_0000676']",False,True,12,"Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor ",INHIBITOR ,single protein 
1134,ERTEBEREL,CHEMBL278703,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000140009'],"['MONDO_0005090', 'EFO_0000284']",False,False,2,Estrogen receptor beta agonist ,AGONIST ,single protein 
1135,TIPIFARNIB,CHEMBL289228,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 44 investigational indications.,,3.0,,False,no approval year,"['ENSG00000168522', 'ENSG00000257365']","['EFO_0005235', 'EFO_0000565', 'EFO_0002430', 'MONDO_0002108', 'EFO_0000305', 'MONDO_0001187', 'EFO_0000218', 'EFO_1001951', 'EFO_0002429', 'EFO_0003869', 'EFO_1000984', 'EFO_0001378', 'EFO_1001779', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'EFO_0003028', 'EFO_1000309', 'EFO_0000632', 'MONDO_0004992', 'MONDO_0008903', 'MONDO_0007254', 'EFO_0003060', 'EFO_0002428', 'EFO_0006861', 'EFO_1000158', 'EFO_0000756', 'EFO_0000198', 'EFO_0002939', 'EFO_0000479', 'EFO_0008528', 'EFO_0003027', 'MONDO_0019469', 'MONDO_0021633', 'EFO_0000222', 'EFO_0000223', 'EFO_0000095', 'EFO_1001465', 'EFO_0000181', 'EFO_1001469', 'EFO_1001933', 'EFO_0000519', 'MONDO_0021310', 'EFO_0000339']",True,False,44,Protein farnesyltransferase inhibitor ,INHIBITOR ,protein complex 
1136,URIDINE TRIPHOSPHATE,CHEMBL336296,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004244', 'MONDO_0008903']",False,False,2,,,
1137,DOVITINIB LACTATE,CHEMBL4297063,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0002517']",False,False,2,,,
1138,CLN-081,CHEMBL4650281,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1139,ICENTICAFTOR,CHEMBL4650318,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000001626'],"['HP_0001399', 'EFO_0000341', 'MONDO_0009061']",False,True,3,Cystic fibrosis transmembrane conductance regulator activator ,ACTIVATOR ,single protein 
1140,FESOMERSEN SODIUM,CHEMBL5095313,Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003884'],False,False,1,,,
1141,"LACTOFERRIN, BOVINE",CHEMBL5095320,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['HP_0040187', 'HP_0002014', 'MONDO_0100096']",False,False,3,,,
1142,PYRUVATE,CHEMBL1162144,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000673', 'MONDO_0007254', 'MONDO_0004979', 'MONDO_0009061']",False,False,4,,,
1143,EFALIZUMAB,CHEMBL1201575,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and has 9 investigational indications. It was withdrawn in at least one region.,,4.0,,False,2003,"['ENSG00000005844', 'ENSG00000160255']","['EFO_1000710', 'EFO_0001365', 'EFO_0003778', 'EFO_0000676', 'EFO_0003884', 'EFO_0000699', 'EFO_0000274', 'MONDO_0005147', 'EFO_0000540', 'EFO_0000685']",True,False,10,Integrin alpha-L/beta-2 (LFA-1) inhibitor ,INHIBITOR ,protein complex 
1144,FULVESTRANT,CHEMBL1358,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 28 investigational indications.,,4.0,,False,2002,"['ENSG00000140009', 'ENSG00000091831']","['MONDO_0004992', 'EFO_0008528', 'MONDO_0011962', 'MONDO_0007915', 'MONDO_0008903', 'EFO_1001951', 'MONDO_0000088', 'MONDO_0008315', 'EFO_0000432', 'EFO_0003859', 'EFO_0002618', 'EFO_0000616', 'EFO_1000919', 'EFO_0000313', 'EFO_0003869', 'MONDO_0007254', 'EFO_0009708', 'EFO_0000305', 'MONDO_0018919', 'EFO_0000553', 'EFO_0001361', 'Orphanet_145', 'EFO_0005952', 'EFO_0006318', 'EFO_0000588', 'MONDO_0008170', 'EFO_0000574', 'EFO_0000181', 'EFO_1001512', 'EFO_0000702', 'EFO_1001331', 'EFO_0003060', 'EFO_0000673']",False,True,33,Estrogen receptor antagonist ,ANTAGONIST ,protein family 
1145,NIROGACESTAT,CHEMBL1770916,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000117362', 'ENSG00000205155', 'ENSG00000138613', 'ENSG00000080815', 'ENSG00000162736', 'ENSG00000143801']","['EFO_0003869', 'EFO_0001378', 'EFO_0002618', 'EFO_0009907', 'EFO_0000616', 'MONDO_0007254']",True,False,6,Gamma-secretase inhibitor ,INHIBITOR ,protein complex 
1146,DACTOLISIB,CHEMBL1879463,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461', 'ENSG00000198793']","['MONDO_0007254', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0100096', 'MONDO_0008315', 'EFO_1000045', 'EFO_0000544', 'MONDO_0002367', 'MONDO_0011962', 'EFO_1000601']",True,False,10,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1147,MARGETUXIMAB,CHEMBL2364649,Antibody drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for breast cancer. This drug has a black box warning from the FDA.,,4.0,,True,2020,['ENSG00000141736'],['MONDO_0007254'],False,False,1,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1148,BERBERINE,CHEMBL295124,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001121', 'EFO_0000729', 'MONDO_0005148', 'EFO_0005406', 'EFO_0003095', 'Orphanet_79211', 'EFO_0000571', 'EFO_0000400']",False,False,8,,,
1149,MUREPAVADIN,CHEMBL3946483,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003106', 'EFO_0003086']",False,False,2,LPS-assembly protein LptD inhibitor ,INHIBITOR ,single protein 
1150,UPAMOSTAT,CHEMBL4206119,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0100096']",False,False,2,,,
1151,CILENGITIDE,CHEMBL429876,Protein drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.,,3.0,,False,no approval year,"['ENSG00000138448', 'ENSG00000082781', 'ENSG00000259207']","['EFO_0006861', 'MONDO_0008315', 'EFO_0000198', 'EFO_0000756', 'EFO_1000026', 'MONDO_0021633', 'EFO_0000519', 'EFO_0002428', 'EFO_1001465', 'EFO_0003086', 'EFO_0003060', 'EFO_0001378', 'EFO_0000326', 'EFO_0002499', 'EFO_0002501', 'EFO_0000565', 'EFO_0000707', 'EFO_1000158', 'EFO_0000691', 'EFO_0000616']",False,False,20,Integrin alpha-V/beta-3 antagonist Integrin alpha-V/beta-5 antagonist ,ANTAGONIST ,protein complex 
1152,VADIMEZAN,CHEMBL71263,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000616', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0008528', 'EFO_0003060']",False,False,5,,,
1153,TERBINAFINE,CHEMBL822,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for tinea and has 4 investigational indications.,,4.0,,False,1992,[],"['EFO_0007512', 'EFO_0000384', 'EFO_0007512', 'MONDO_0002041', 'EFO_0007510', 'EFO_0000729']",False,False,6,Squalene monooxygenase inhibitor ,INHIBITOR ,single protein 
1154,ROSIGLITAZONE,CHEMBL121,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 43 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,,4.0,,True,1999,['ENSG00000132170'],"['MONDO_0004992', 'HP_0001952', 'EFO_1001373', 'MONDO_0004979', 'MONDO_0007254', 'EFO_0000400', 'HP_0003124', 'MONDO_0005148', 'EFO_0000691', 'EFO_1001051', 'EFO_0003914', 'EFO_0000616', 'EFO_0006911', 'EFO_0001068', 'MONDO_0005148', 'EFO_0003914', 'HP_0100543', 'EFO_0000764', 'Orphanet_309005', 'EFO_1001110', 'EFO_0007444', 'EFO_0004236', 'EFO_0000195', 'EFO_0000373', 'EFO_0000589', 'EFO_0004272', 'EFO_0002614', 'EFO_1000785', 'HP_0002745', 'EFO_0000685', 'EFO_0004234', 'EFO_0000764', 'EFO_1000158', 'EFO_0000729', 'EFO_0001065', 'EFO_0001645', 'EFO_1001249', 'EFO_0000400', 'EFO_0002546', 'EFO_1001121', 'EFO_1000783', 'EFO_0003095', 'MONDO_0004975', 'EFO_0000537', 'EFO_0006859', 'EFO_0000673', 'EFO_0002614']",True,False,47,Peroxisome proliferator-activated receptor gamma agonist ,AGONIST ,single protein 
1155,CHLOROQUINE SULPHATE,CHEMBL2095223,Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication.,,4.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1156,PEGINTERFERON LAMBDA-1A,CHEMBL2108723,Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000243646', 'ENSG00000185436']","['EFO_0000694', 'EFO_0004220', 'EFO_0007304', 'MONDO_0100096', 'EFO_0004197', 'EFO_0004239', 'EFO_0003047']",True,True,7,Interferon lambda receptor agonist ,AGONIST ,protein complex 
1157,AZD2423,CHEMBL3545221,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000121807'],"['EFO_0003843', 'EFO_0000341', 'EFO_0005762']",False,False,3,C-C chemokine receptor type 2 antagonist ,ANTAGONIST ,single protein 
1158,MAVELERTINIB,CHEMBL3989970,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1159,VERAPAMIL,CHEMBL6966,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 17 investigational indications.,,4.0,,False,1981,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['HP_0004308', 'Orphanet_33069', 'EFO_0004616', 'MONDO_0005148', 'EFO_0003843', 'MP_0001914', 'EFO_0000384', 'EFO_0000275', 'MONDO_0100096', 'EFO_0003890', 'EFO_0000319', 'EFO_0004269', 'EFO_0000319', 'EFO_1001413', 'EFO_0000400', 'MONDO_0005147', 'EFO_0003144', 'EFO_0000183', 'EFO_0000275', 'HP_0002140', 'MONDO_0004985', 'EFO_0000537']",False,True,22,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1160,QUINIDINE,CHEMBL1294,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1950,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0001068', 'EFO_0004278', 'HP_0004308', 'EFO_0004287', 'HP_0002019', 'EFO_0000275', 'EFO_0004269', 'MONDO_0004976', 'EFO_1001413', 'EFO_0000612', 'MONDO_0004976', 'MONDO_0002050', 'MONDO_0005277', 'MONDO_0002009', 'MONDO_0005301', 'EFO_1001249', 'EFO_0003758', 'EFO_0004197']",False,False,18,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
1161,FLUTICASONE FUROATE,CHEMBL1676,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 7 approved and 2 investigational indications.,,4.0,,False,2007,['ENSG00000113580'],"['MONDO_0004979', 'EFO_0008521', 'EFO_0007533', 'HP_0001742', 'HP_0006536', 'EFO_1001417', 'EFO_0003956', 'EFO_0005854', 'EFO_0000341']",False,True,9,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1162,CARLUMAB,CHEMBL1742999,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000108691'],"['EFO_0009448', 'MONDO_0008315', 'MONDO_0004992']",False,False,3,C-C motif chemokine 2 inhibitor ,INHIBITOR ,single protein 
1163,EVEROLIMUS,CHEMBL1908360,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 19 approved and 115 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000088832'],"['EFO_0000389', 'HP_0001871', 'EFO_0004224', 'EFO_0002618', 'EFO_0000339', 'EFO_0000681', 'EFO_0000519', 'EFO_0000349', 'MONDO_0001422', 'EFO_0000691', 'MONDO_0017623', 'EFO_0000770', 'EFO_0002499', 'EFO_0000326', 'EFO_1000312', 'MONDO_0005411', 'MONDO_0015277', 'MONDO_0007576', 'EFO_0000365', 'EFO_0002916', 'EFO_0005220', 'EFO_0003060', 'MONDO_0018975', 'EFO_0000305', 'EFO_0001378', 'EFO_1000630', 'EFO_0003897', 'MONDO_0002898', 'EFO_1000634', 'EFO_0000474', 'EFO_0003833', 'MONDO_0011962', 'MONDO_0002120', 'MONDO_0018076', 'MONDO_0007039', 'EFO_0000231', 'EFO_0002913', 'EFO_0000574', 'EFO_0003047', 'EFO_0000272', 'MONDO_0000873', 'MONDO_0100342', 'MONDO_0002367', 'EFO_0009708', 'EFO_0005672', 'MONDO_0001056', 'EFO_0000632', 'EFO_0001365', 'EFO_0000222', 'EFO_0008620', 'EFO_0004243', 'MONDO_0008280', 'MONDO_0008170', 'MONDO_0024503', 'EFO_1002048', 'EFO_0001071', 'MONDO_0021054', 'EFO_1001496', 'EFO_1000852', 'MONDO_0009348', 'MONDO_0002087', 'MONDO_0003268', 'EFO_0000702', 'EFO_0004599', 'MONDO_0013730', 'EFO_0002617', 'EFO_0000403', 'EFO_1000601', 'MONDO_0008903', 'EFO_1001469', 'EFO_0000630', 'EFO_0000183', 'EFO_0000565', 'EFO_0007331', 'EFO_0003884', 'MONDO_0003478', 'EFO_1001901', 'EFO_0005952', 'EFO_0000637', 'MONDO_0002974', 'EFO_0009441', 'EFO_0000182', 'MONDO_0020732', 'EFO_0000544', 'EFO_1001231', 'EFO_0003860', 'EFO_0006861', 'MONDO_0018364', 'EFO_0000228', 'EFO_0000558', 'MONDO_0001187', 'EFO_1001968', 'MONDO_0021063', 'EFO_0004289', 'EFO_0005221', 'EFO_0004252', 'MONDO_0011719', 'MONDO_0007254', 'EFO_1000045', 'MONDO_0016586', 'EFO_0000313', 'MONDO_0011705', 'EFO_0006859', 'MONDO_0002715', 'EFO_0001376', 'EFO_0003086', 'MONDO_0004992', 'EFO_0000333', 'MONDO_0002108', 'MONDO_0002158', 'EFO_0005543', 'EFO_0001062', 'EFO_0002626', 'EFO_0000181', 'MONDO_0002603', 'MONDO_0001734', 'MONDO_0002691', 'MONDO_0008315', 'EFO_0000514', 'MONDO_0020290', 'EFO_1000158', 'EFO_1000026', 'EFO_0000760', 'EFO_0000540', 'MONDO_0016642', 'EFO_1001951', 'MONDO_0016693', 'EFO_0000616', 'EFO_0003869', 'HP_0009720', 'EFO_0000220', 'EFO_0000198', 'EFO_0000588', 'EFO_0005537']",True,False,134,FK506-binding protein 1A inhibitor ,INHIBITOR ,single protein 
1164,LUCINACTANT,CHEMBL1963685,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 investigational indications.,,4.0,,False,2012,[],"['EFO_1000644', 'EFO_1000637', 'EFO_1001037', 'EFO_0009686', 'MONDO_0009061']",False,False,5,,,
1165,GANETESPIB,CHEMBL2103879,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.,,3.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['EFO_0000616', 'MONDO_0001056', 'EFO_0000702', 'MONDO_0008903', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021063', 'EFO_0002916', 'MONDO_0007254', 'MONDO_0011719', 'EFO_0001378', 'EFO_0003060', 'EFO_1000657', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000756', 'MONDO_0008170', 'EFO_0000198', 'EFO_0000222', 'EFO_0000571', 'EFO_0000760', 'EFO_0003968', 'EFO_0000770', 'EFO_0005537']",True,False,24,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
1166,TREBANANIB,CHEMBL2108568,Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,"['ENSG00000091879', 'ENSG00000154188']","['MONDO_0008170', 'EFO_0000673', 'EFO_1001465', 'EFO_0000632', 'MONDO_0002158', 'EFO_0008528', 'EFO_0000616', 'EFO_0003060', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0002087', 'EFO_1000158', 'EFO_0000681', 'EFO_0003968']",True,False,14,Angiopoietin-2 inhibitor Angiopoietin-1 inhibitor ,INHIBITOR ,single protein 
1167,PERILLYL ALCOHOL,CHEMBL236687,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0002618', 'EFO_0002496', 'EFO_0000519', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000574', 'MONDO_0016642']",False,False,7,,,
1168,VANDETANIB,CHEMBL24828,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 7 approved and 41 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,"['ENSG00000142627', 'ENSG00000133216', 'ENSG00000145242', 'ENSG00000116106', 'ENSG00000070886', 'ENSG00000080224', 'ENSG00000135333', 'ENSG00000182580', 'ENSG00000044524', 'ENSG00000154928', 'ENSG00000196411', 'ENSG00000146904', 'ENSG00000106123', 'ENSG00000183317', 'ENSG00000120156', 'ENSG00000197122', 'ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361', 'ENSG00000165731', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000101213']","['EFO_0000588', 'MONDO_0008627', 'EFO_1001951', 'MONDO_0100342', 'EFO_0009708', 'EFO_0000349', 'EFO_0000641', 'MONDO_0008315', 'EFO_0000616', 'MONDO_0007254', 'EFO_0001663', 'EFO_0000182', 'EFO_0007535', 'MONDO_0002367', 'EFO_0000702', 'MONDO_0008903', 'EFO_1000026', 'EFO_0003060', 'EFO_0003869', 'EFO_0002501', 'EFO_1000657', 'EFO_0002916', 'MONDO_0011719', 'EFO_0000519', 'EFO_0003897', 'MONDO_0001187', 'MONDO_0008170', 'EFO_0001378', 'MONDO_0002108', 'EFO_0006859', 'EFO_1000158', 'EFO_0002499', 'MONDO_0004992', 'MONDO_0015277', 'EFO_0000501', 'MONDO_0002087', 'EFO_0002618', 'EFO_0003841', 'MONDO_0001056', 'EFO_0000222', 'MONDO_0004192', 'EFO_0000630', 'MONDO_0002158', 'EFO_0000181', 'EFO_1001465', 'EFO_0000621', 'EFO_0002892', 'EFO_0000365']",True,True,48,Vascular endothelial growth factor receptor inhibitor Tyrosine-protein kinase receptor RET inhibitor Ephrin receptor inhibitor Tyrosine-protein kinase TIE-2 inhibitor Tyrosine-protein kinase SRC inhibitor Tyrosine-protein kinase BRK inhibitor Epidermal growth factor receptor inhibitor ,INHIBITOR ,protein family single protein 
1169,NBI-6024,CHEMBL4297306,Protein drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1170,BREPOCITINIB,CHEMBL4297477,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105397', 'ENSG00000162434']","['EFO_0000384', 'EFO_1000710', 'EFO_0003778', 'EFO_0000274', 'EFO_0000398', 'EFO_0000676', 'EFO_0000729', 'MONDO_0007915', 'EFO_0004192', 'EFO_0003086', 'EFO_1002028']",False,True,11,Tyrosine-protein kinase TYK2 inhibitor Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
1171,PATRITUMAB DERUXTECAN,CHEMBL4594611,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000065361', 'ENSG00000198900']","['MONDO_0007254', 'EFO_0003060']",False,False,2,DNA topoisomerase I inhibitor Receptor tyrosine-protein kinase erbB-3 binding agent ,INHIBITOR BINDING AGENT ,single protein 
1172,CDX-301,CHEMBL4650387,Protein drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.,,2.0,,False,no approval year,['ENSG00000122025'],"['EFO_0005221', 'MONDO_0008315', 'EFO_0006859', 'EFO_0002617', 'MONDO_0007254', 'MONDO_0001056', 'EFO_0000182', 'EFO_0003060', 'EFO_0000681', 'EFO_0000574', 'EFO_0002618', 'MONDO_0007576', 'EFO_1001951', 'MONDO_0008170', 'EFO_0000756', 'MONDO_0002158', 'EFO_1001469', 'EFO_0000403']",True,False,18,Tyrosine-protein kinase receptor FLT3 agonist ,AGONIST ,single protein 
1173,DEFEROXAMINE,CHEMBL556,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 14 investigational indications.,,4.0,,False,1968,[],"['EFO_0005669', 'EFO_1001459', 'EFO_1001996', 'EFO_0000713', 'EFO_1001012', 'HP_0001919', 'MONDO_0007254', 'EFO_0005669', 'EFO_0000182', 'MONDO_0005147', 'EFO_1000642', 'Orphanet_848', 'MONDO_0011382', 'MONDO_0100096', 'HP_0002140']",False,False,15,,,
1174,LORATADINE,CHEMBL998,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 11 investigational indications.,,4.0,,False,1993,['ENSG00000196639'],"['EFO_0004232', 'HP_0003418', 'MONDO_0004979', 'EFO_0005531', 'EFO_0000685', 'EFO_0001378', 'MONDO_0005271', 'MONDO_0011705', 'MONDO_0005301', 'MONDO_0007254', 'EFO_0003956', 'HP_0000989', 'EFO_1001417', 'MONDO_0100096', 'EFO_0005854', 'EFO_0000574', 'EFO_0000274']",False,False,17,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
1175,CLOPIDOGREL,CHEMBL1771,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 49 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000169313'],"['EFO_0000712', 'MONDO_0000831', 'EFO_0003777', 'EFO_0003764', 'EFO_0008583', 'EFO_1000985', 'EFO_0005672', 'EFO_0000764', 'EFO_0003106', 'EFO_0003144', 'EFO_1000860', 'EFO_0001645', 'EFO_0007328', 'EFO_0006859', 'EFO_0000275', 'EFO_0002615', 'EFO_0004265', 'EFO_0004264', 'HP_0002140', 'EFO_0005672', 'EFO_0002950', 'EFO_0000180', 'EFO_0000717', 'EFO_0003914', 'EFO_0004277', 'EFO_0003869', 'MONDO_0004979', 'EFO_0009315', 'HP_0030680', 'EFO_0004265', 'MONDO_0002009', 'EFO_0003875', 'EFO_0008585', 'EFO_0000556', 'EFO_0000712', 'EFO_0003870', 'EFO_0000266', 'EFO_0003913', 'EFO_0002429', 'EFO_0004286', 'EFO_0000319', 'EFO_0009686', 'MONDO_0007915', 'EFO_0001645', 'EFO_0009086', 'MONDO_0100096', 'MP_0001914', 'EFO_0007541', 'HP_0002239', 'EFO_0003876', 'EFO_0001361', 'EFO_0003884', 'EFO_0000556', 'EFO_0000612', 'EFO_0000612', 'MONDO_0005148', 'HP_0004419']",True,False,57,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
1176,TALOTREXIN AMMONIUM,CHEMBL2104985,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000565', 'EFO_0000616']",False,False,3,,,
1177,RETEPLASE,CHEMBL2107885,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 2 investigational indications.,,4.0,,False,1996,['ENSG00000122194'],"['EFO_0000712', 'EFO_0008585', 'EFO_0003144', 'HP_0004419', 'EFO_0000612']",False,True,5,Plasminogen activator ,ACTIVATOR ,single protein 
1178,CAPIVASERTIB,CHEMBL2325741,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']","['MONDO_0011962', 'EFO_0000707', 'EFO_0000096', 'MONDO_0008170', 'EFO_0003060', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0001056', 'MONDO_0008315', 'MONDO_0002974', 'EFO_1000251', 'EFO_0001378', 'EFO_0000616', 'EFO_0000305', 'MONDO_0004992', 'EFO_0000503', 'EFO_0000228', 'EFO_0003869', 'EFO_0001642', 'MONDO_0016642', 'Orphanet_145']",True,False,21,Serine/threonine-protein kinase AKT inhibitor ,INHIBITOR ,protein family 
1179,GLYCOPYRRONIUM TOSYLATE,CHEMBL3707243,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved indications.,,4.0,,False,2018,[],"['EFO_0006505', 'EFO_1000632', 'EFO_0000341', 'HP_0000975', 'EFO_0004269', 'MONDO_0004247']",False,False,6,,,
1180,PEMLIMOGENE MEROLISBAC,CHEMBL4297241,Gene drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000571', 'EFO_0003060']",False,False,2,,,
1181,LINRODOSTAT,CHEMBL4297598,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,['ENSG00000131203'],"['EFO_0000756', 'MONDO_0002898', 'MONDO_0004992', 'EFO_0006859', 'EFO_0000519', 'EFO_0000199', 'EFO_0003060', 'MONDO_0001056', 'EFO_0000294', 'EFO_0000182']",True,False,10,"Indoleamine 2,3-dioxygenase inhibitor ",INHIBITOR ,single protein 
1182,DOSTARLIMAB,CHEMBL4298124,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for neoplasm and endometrial cancer and has 22 investigational indications.,,4.0,,False,2021,['ENSG00000188389'],"['EFO_0001378', 'MONDO_0002691', 'MONDO_0008170', 'Orphanet_145', 'MONDO_0007254', 'EFO_0000756', 'EFO_0003893', 'EFO_1000657', 'EFO_0000616', 'MONDO_0002974', 'MONDO_0018944', 'EFO_0002517', 'EFO_0000691', 'EFO_0003060', 'EFO_0006859', 'MONDO_0021063', 'EFO_0000702', 'EFO_0002618', 'MONDO_0011962', 'EFO_1001951', 'EFO_0003968', 'EFO_0001061', 'EFO_0005537', 'EFO_0000588']",False,False,24,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
1183,MTI-31,CHEMBL4594431,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1184,MESALAMINE,CHEMBL704,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for proctitis and ulcerative colitis and has 15 investigational indications.,,4.0,,False,1987,"['ENSG00000132170', 'ENSG00000012779', 'ENSG00000073756', 'ENSG00000095303']","['EFO_0005628', 'EFO_0007168', 'EFO_1001293', 'MONDO_0005835', 'EFO_0008572', 'EFO_0009959', 'EFO_0000729', 'HP_0002253', 'EFO_1001951', 'EFO_0000555', 'EFO_0004232', 'EFO_0003872', 'EFO_0000384', 'EFO_0005406', 'EFO_1001294', 'EFO_1001460', 'EFO_0000764']",True,False,17,Arachidonate 5-lipoxygenase inhibitor Peroxisome proliferator-activated receptor gamma agonist Cyclooxygenase inhibitor ,INHIBITOR AGONIST ,single protein protein family 
1185,SORAFENIB TOSYLATE,CHEMBL1200485,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 54 investigational indications.,,4.0,,False,2005,"['ENSG00000157764', 'ENSG00000122025', 'ENSG00000132155', 'ENSG00000113721', 'ENSG00000165731', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']","['MONDO_0004192', 'MONDO_0011719', 'EFO_0000691', 'EFO_0000349', 'EFO_0006352', 'EFO_1001968', 'EFO_0006861', 'EFO_0000756', 'EFO_0002501', 'EFO_0000389', 'EFO_0000641', 'MONDO_0002367', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0000182', 'EFO_0007535', 'EFO_0000220', 'EFO_0002618', 'EFO_0000616', 'EFO_1000613', 'EFO_1001465', 'EFO_1000657', 'MONDO_0021063', 'EFO_0002938', 'MONDO_0044926', 'EFO_0002499', 'EFO_0000588', 'EFO_1001469', 'EFO_0000501', 'EFO_0000673', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0004986', 'MONDO_0044937', 'EFO_0003060', 'EFO_0001378', 'EFO_0000224', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0002108', 'EFO_0003833', 'EFO_1001951', 'EFO_0000640', 'EFO_0000519', 'EFO_0009907', 'EFO_0000702', 'EFO_1000158', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000681', 'EFO_0000222', 'MONDO_0001187', 'EFO_0000403', 'EFO_0000637', 'EFO_0000335', 'EFO_0003871', 'EFO_0002892', 'EFO_0003032', 'MONDO_0002158']",True,True,61,Vascular endothelial growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Serine/threonine-protein kinase RAF inhibitor Serine/threonine-protein kinase B-raf inhibitor Tyrosine-protein kinase receptor RET inhibitor Platelet-derived growth factor receptor beta inhibitor ,INHIBITOR ,protein family single protein 
1186,ISOSORBIDE,CHEMBL1200660,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 12 investigational indications.,,4.0,,False,1974,[],"['EFO_0000702', 'EFO_0003913', 'MONDO_0008315', 'EFO_0000181', 'EFO_0000403', 'EFO_1001469', 'EFO_0000673', 'EFO_0000095', 'MONDO_0018906', 'EFO_0000537', 'MONDO_0002358', 'MONDO_0004992']",False,False,12,,,
1187,CORTISONE ACETATE,CHEMBL1650,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 44 approved and 2 investigational indications.,,4.0,,False,1950,['ENSG00000113580'],"['EFO_1001896', 'HP_0004398', 'EFO_1001435', 'EFO_0004276', 'EFO_1001205', 'EFO_0008997', 'EFO_1001119', 'EFO_1000764', 'EFO_0007403', 'EFO_0000274', 'EFO_0007160', 'EFO_0000398', 'EFO_1000694', 'EFO_0004255', 'EFO_0005752', 'EFO_1000039', 'HP_0001094', 'HP_0003072', 'EFO_0000685', 'EFO_0003778', 'MONDO_0008728', 'EFO_1000049', 'MONDO_0043579', 'MONDO_0007915', 'MONDO_0005178', 'EFO_1001194', 'EFO_0003106', 'EFO_1000941', 'EFO_0000565', 'EFO_0005319', 'HP_0001873', 'MONDO_0018479', 'MONDO_0015128', 'EFO_0005558', 'EFO_0002609', 'EFO_1001250', 'EFO_0004274', 'EFO_1000684', 'EFO_0005532', 'EFO_0009456', 'EFO_0000574', 'EFO_0003063', 'HP_0001915', 'EFO_1000997', 'MONDO_0004979', 'MONDO_0005271']",False,False,46,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1188,FLUOROURACIL,CHEMBL185,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 6 approved and 97 investigational indications.,,4.0,,False,1962,['ENSG00000176890'],"['EFO_0001075', 'EFO_0002618', 'EFO_1000720', 'EFO_1001471', 'MONDO_0003060', 'EFO_0000198', 'EFO_0007363', 'EFO_1001365', 'EFO_0002617', 'MONDO_0007576', 'EFO_0000228', 'EFO_0004252', 'EFO_0000313', 'EFO_0003060', 'EFO_1001901', 'EFO_0005952', 'MONDO_0021063', 'EFO_0004288', 'EFO_1000910', 'EFO_0005577', 'EFO_0000365', 'EFO_1001951', 'EFO_0003860', 'EFO_0008528', 'EFO_0002938', 'EFO_0000181', 'EFO_0000305', 'EFO_0005950', 'EFO_0003866', 'MONDO_0002358', 'EFO_0000182', 'EFO_0002517', 'MONDO_0002038', 'MONDO_0002974', 'EFO_0004284', 'EFO_0000294', 'MONDO_0000831', 'EFO_0003897', 'EFO_0000503', 'EFO_0003869', 'EFO_0000698', 'EFO_0003859', 'MONDO_0004992', 'EFO_0000616', 'EFO_1000292', 'MONDO_0004192', 'EFO_0010282', 'MONDO_0004986', 'MONDO_0002691', 'EFO_1001129', 'EFO_0000707', 'MONDO_0008170', 'EFO_1001949', 'MONDO_0002087', 'EFO_1001961', 'EFO_0009259', 'EFO_1000028', 'MONDO_0024475', 'MONDO_0001056', 'EFO_0000178', 'EFO_0009708', 'EFO_0002496', 'EFO_0003835', 'MONDO_0007254', 'MONDO_0003199', 'MONDO_0002367', 'EFO_0002428', 'EFO_0000326', 'MONDO_0044704', 'MONDO_0005575', 'EFO_0003100', 'EFO_0000574', 'EFO_0005221', 'EFO_1000251', 'MONDO_0011719', 'EFO_0000389', 'MONDO_0002516', 'MONDO_0001187', 'EFO_0000197', 'MONDO_0002120', 'EFO_0006859', 'MONDO_0021355', 'MONDO_0005835', 'MONDO_0005041', 'MONDO_0001879', 'EFO_0003817', 'MONDO_0044937', 'EFO_1000657', 'EFO_0000199', 'EFO_0001378', 'EFO_0008549', 'EFO_0002916', 'MONDO_0003059', 'EFO_0000756', 'EFO_1000984', 'EFO_0005570', 'EFO_1001100', 'EFO_0003891', 'EFO_0000681', 'EFO_0004193', 'EFO_0004142', 'EFO_0007416', 'EFO_0005922']",True,False,103,Thymidylate synthase inhibitor ,INHIBITOR ,single protein 
1189,MITUMOMAB,CHEMBL2108442,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000702', 'MONDO_0008903']",False,False,2,,,
1190,ASPIRIN,CHEMBL25,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 19 approved and 138 investigational indications.,,4.0,,False,1950,"['ENSG00000073756', 'ENSG00000095303']","['EFO_0000495', 'MONDO_0007576', 'EFO_0000180', 'EFO_0001645', 'Orphanet_733', 'EFO_0003870', 'EFO_0002615', 'EFO_0008586', 'EFO_0003144', 'EFO_0007328', 'MONDO_0002009', 'EFO_0003843', 'MONDO_0004247', 'EFO_0000266', 'EFO_0000275', 'EFO_0009364', 'HP_0012378', 'EFO_0003770', 'EFO_0000519', 'MONDO_0005277', 'EFO_0004607', 'EFO_1001157', 'EFO_0000339', 'MONDO_0011962', 'EFO_0004698', 'EFO_0003106', 'EFO_0005411', 'EFO_1001161', 'MP_0001845', 'EFO_0003914', 'EFO_0000571', 'MONDO_0005178', 'EFO_0003060', 'EFO_0004277', 'MONDO_0008170', 'EFO_0009315', 'EFO_0008573', 'EFO_0000389', 'MONDO_0005090', 'EFO_0010282', 'EFO_1000637', 'EFO_0000764', 'EFO_1001951', 'MONDO_0043839', 'MONDO_0005835', 'MONDO_0010888', 'EFO_0005406', 'MONDO_0004979', 'EFO_1001375', 'HP_0005521', 'EFO_0000195', 'MONDO_0007254', 'EFO_0001378', 'MONDO_0005129', 'MP_0001914', 'EFO_0000673', 'EFO_0007443', 'EFO_0000266', 'EFO_0003931', 'EFO_0009606', 'EFO_0001361', 'EFO_0000545', 'MONDO_0041052', 'HP_0100806', 'EFO_0005856', 'EFO_0007541', 'HP_0002239', 'MONDO_0100096', 'MONDO_0018076', 'EFO_0004610', 'MONDO_0001056', 'EFO_0004286', 'EFO_1000860', 'EFO_0000182', 'HP_0004398', 'EFO_0007214', 'MONDO_0004985', 'EFO_0000537', 'EFO_0003893', 'EFO_0008585', 'EFO_0000668', 'EFO_0003764', 'EFO_0003913', 'HP_0003326', 'EFO_0004259', 'EFO_0000280', 'EFO_0000341', 'EFO_0000612', 'HP_0003394', 'EFO_0007129', 'HP_0002140', 'EFO_0000616', 'EFO_0003763', 'EFO_0000707', 'EFO_0001663', 'EFO_0003875', 'EFO_0006859', 'EFO_0003869', 'EFO_0002429', 'EFO_0003884', 'HP_0002315', 'EFO_0004264', 'EFO_1001154', 'EFO_0003777', 'EFO_0000400', 'EFO_0002950', 'EFO_0000649', 'EFO_1000954', 'HP_0100607', 'EFO_0009854', 'EFO_0000479', 'EFO_0000729', 'EFO_0009314', 'EFO_0000319', 'Orphanet_309005', 'MONDO_0005301', 'EFO_0000556', 'EFO_1000657', 'MONDO_0011382', 'EFO_0009454', 'EFO_1002022', 'EFO_0000538', 'GO_0007568', 'HP_0002745', 'EFO_0003762', 'EFO_0005407', 'EFO_0003768', 'EFO_0000694', 'HP_0003418', 'EFO_0004252', 'EFO_0009846', 'MONDO_0021108', 'EFO_0000546', 'MONDO_0002679', 'HP_0000618', 'EFO_0009686', 'HP_0004936', 'MONDO_0021063', 'MONDO_0002974', 'MONDO_0007915', 'MONDO_0004992', 'HP_0001945', 'HP_0004419', 'MONDO_0002258', 'EFO_0004265', 'MONDO_0008315', 'EFO_0005672', 'HP_0003419', 'EFO_0010072', 'HP_0012228', 'EFO_0008583', 'EFO_1001923', 'HP_0003124', 'EFO_0000712', 'MONDO_0005148', 'EFO_0004246', 'MONDO_0000831', 'EFO_0004211']",True,False,158,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
1191,BRIGATINIB,CHEMBL3545311,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for non-small cell lung carcinoma and neoplasm and has 1 investigational indication.,,4.0,,False,2017,"['ENSG00000171094', 'ENSG00000146648']","['EFO_0003060', 'EFO_0000616', 'EFO_0003032']",False,True,3,ALK tyrosine kinase receptor inhibitor Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1192,MONALIZUMAB,CHEMBL4297787,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000134545'],"['MONDO_0004992', 'EFO_0000095', 'MONDO_0007254', 'EFO_0004284', 'EFO_0000616', 'EFO_0003060', 'EFO_0000707', 'EFO_0000181', 'MONDO_0100096', 'MONDO_0021148', 'EFO_0000199']",False,False,11,NKG2-A/NKG2-B type II integral membrane protein inhibitor ,INHIBITOR ,single protein 
1193,BAMLANIVIMAB,CHEMBL4650379,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
1194,TOZINAMERAN,CHEMBL4650429,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000544', 'EFO_0000694', 'MONDO_0004992', 'MONDO_0005271', 'MONDO_0100096']",False,False,5,,,
1195,ALISERTIB,CHEMBL483158,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.,,3.0,,False,no approval year,['ENSG00000087586'],"['EFO_0001378', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000222', 'EFO_1001469', 'MONDO_0008903', 'EFO_0006859', 'MONDO_0007254', 'EFO_0000621', 'MONDO_0018906', 'EFO_0000574', 'EFO_0000198', 'MONDO_0002158', 'EFO_0000211', 'EFO_0000181', 'MONDO_0002087', 'EFO_0000702', 'EFO_0000305', 'EFO_0001075', 'EFO_0000673', 'EFO_0000616', 'EFO_0000309', 'MONDO_0002516', 'EFO_0000403']",False,False,24,Serine/threonine-protein kinase Aurora-A inhibitor ,INHIBITOR ,single protein 
1196,ILOPROST,CHEMBL494,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 13 investigational indications.,,4.0,,False,2004,['ENSG00000160013'],"['EFO_0000341', 'EFO_0001071', 'MONDO_0005149', 'MONDO_0008903', 'EFO_0006834', 'EFO_0000717', 'MONDO_0100130', 'EFO_0003943', 'HP_0004419', 'MONDO_0004979', 'EFO_0009492', 'EFO_0000612', 'EFO_0003884', 'EFO_1001373', 'EFO_0001361', 'EFO_1001145']",True,False,16,Prostanoid IP receptor agonist ,AGONIST ,single protein 
1197,GLIPIZIDE,CHEMBL1073,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications.,,4.0,,False,1984,"['ENSG00000187486', 'ENSG00000006071']","['EFO_0003914', 'MONDO_0005148', 'EFO_0003884', 'EFO_0000400']",False,False,4,"Sulfonylurea receptor 1, Kir6.2 blocker ",BLOCKER ,protein complex 
1198,POTASSIUM CHLORIDE,CHEMBL1200731,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and cardiac arrhythmia and has 11 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000612', 'MP_0001914', 'EFO_1000985', 'EFO_0000537', 'EFO_0003777', 'EFO_1000899', 'EFO_0000266', 'EFO_0003144', 'EFO_0003833', 'HP_0002019', 'EFO_0006834', 'EFO_0004269', 'EFO_0000373']",False,False,13,,,
1199,PEGLOTICASE,CHEMBL1237025,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for gout and has 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,2010,[],"['EFO_0003884', 'EFO_0004274']",False,False,2,,,
1200,MOSEDIPIMOD,CHEMBL157366,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0009688', 'MONDO_0001475']",False,False,3,,,
1201,EUCALYPTUS OIL,CHEMBL2108406,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1202,OXITROPIUM,CHEMBL4297364,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 1 investigational indication.,,4.0,,False,no approval year,[],"['EFO_0000341', 'HP_0006536']",False,False,2,,,
1203,EMERAMIDE,CHEMBL4297510,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000341', 'EFO_1001810', 'MONDO_0016486']",False,False,3,,,
1204,PEMRAMETOSTAT,CHEMBL4466233,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000100462'],"['MONDO_0007254', 'EFO_0000616']",True,False,2,Protein arginine N-methyltransferase 5 inhibitor ,INHIBITOR ,single protein 
1205,ELSUBRUTINIB,CHEMBL4594348,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000010671'],"['EFO_0000685', 'MONDO_0007915']",False,False,2,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1206,MITOQUINOL CATION,CHEMBL4594414,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1207,RETINOIC ACID RECEPTOR .GAMMA.,CHEMBL4594589,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000464'],False,False,1,,,
1208,BEBTELOVIMAB,CHEMBL4802210,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
1209,DOXAZOSIN,CHEMBL707,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved and 15 investigational indications.,,4.0,,False,1990,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0002610', 'EFO_0000537', 'EFO_0000284', 'HP_0003124', 'EFO_0000400', 'EFO_0004234', 'EFO_0000537', 'EFO_0004253', 'MONDO_0002491', 'EFO_0003144', 'EFO_1001375', 'EFO_0000612', 'EFO_0001358', 'MONDO_0007079', 'EFO_0000612', 'EFO_0003777', 'EFO_0003890', 'EFO_0000284', 'EFO_0003768']",True,False,19,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
1210,DENOSUMAB,CHEMBL1237023,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 approved and 31 investigational indications.,,4.0,,False,2010,['ENSG00000120659'],"['EFO_0000400', 'MONDO_0005271', 'EFO_0007176', 'EFO_0000685', 'EFO_1000318', 'EFO_0000756', 'EFO_0009870', 'EFO_0000616', 'EFO_1000984', 'EFO_1000786', 'EFO_0001378', 'EFO_0000681', 'MONDO_0005351', 'EFO_0004248', 'MONDO_0002108', 'EFO_0009708', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000637', 'EFO_0004274', 'EFO_0003882', 'EFO_0000389', 'EFO_0000305', 'MONDO_0007254', 'MONDO_0019019', 'HP_0003072', 'EFO_0000384', 'MONDO_0000845', 'EFO_1001951', 'EFO_0004260', 'EFO_0003931', 'EFO_0000313', 'EFO_0000266', 'EFO_0003854', 'EFO_0003086', 'MONDO_0008315', 'EFO_0001075', 'EFO_0003869', 'MONDO_0002171', 'HP_0000938']",True,True,40,Tumor necrosis factor ligand superfamily member 11 inhibitor ,INHIBITOR ,single protein 
1211,TAZOBACTAM SODIUM,CHEMBL1439,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 9 approved and 1 investigational indication.,,4.0,,False,1993,[],"['EFO_0003106', 'EFO_0003103', 'EFO_0000544', 'EFO_1001312', 'EFO_1001388', 'EFO_1001459', 'EFO_0003035', 'EFO_0000544', 'EFO_0008588', 'EFO_0007149']",False,False,10,Bacterial beta-lactamase TEM inhibitor ,INHIBITOR ,single protein 
1212,PEPPERMINT,CHEMBL2108553,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1213,TRIMETHOPRIM,CHEMBL22,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 approved and 29 investigational indications.,,4.0,,False,1973,[],"['EFO_0003103', 'EFO_0003833', 'EFO_0005681', 'EFO_0003033', 'HP_0100806', 'EFO_0001068', 'EFO_0000274', 'EFO_0007448', 'EFO_0003106', 'EFO_0000768', 'EFO_0005297', 'HP_0000964', 'EFO_0004992', 'EFO_0007399', 'MONDO_0018076', 'EFO_0003102', 'EFO_1002025', 'EFO_0003030', 'EFO_1001141', 'EFO_0000616', 'MONDO_0005147', 'MONDO_0018998', 'EFO_0000544', 'EFO_0000341', 'EFO_0000094', 'EFO_1001365', 'EFO_0002499', 'EFO_0000519', 'EFO_0003086', 'MONDO_0009061', 'EFO_0000764', 'EFO_1000690', 'EFO_0004272', 'EFO_0000771']",False,False,34,Bacterial dihydrofolate reductase inhibitor ,INHIBITOR ,single protein 
1214,PAXALISIB,CHEMBL3813842,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_0000519', 'EFO_1000158', 'MONDO_0007254']",True,False,3,PI3-kinase class I inhibitor ,INHIBITOR ,protein complex group 
1215,AZD-8835,CHEMBL3894518,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1216,BMX-010,CHEMBL4297709,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000760', 'MONDO_0005147', 'EFO_0000676', 'EFO_0000274', 'EFO_0003894']",False,False,5,,,
1217,IERAMILIMAB,CHEMBL4298009,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000089692'],"['MONDO_0007254', 'EFO_0000616', 'EFO_0005537', 'EFO_0000756']",False,False,4,Lymphocyte activation gene 3 protein inhibitor ,INHIBITOR ,single protein 
1218,ADAGRASIB,CHEMBL4594350,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000133703'],"['EFO_0000616', 'EFO_0003060', 'EFO_0009709']",False,False,3,GTPase KRas inhibitor ,INHIBITOR ,single protein 
1219,AMG-404,CHEMBL4594522,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000220', 'MONDO_0008315', 'MONDO_0100342', 'EFO_0000616', 'EFO_0000702']",False,False,5,,,
1220,METHADONE,CHEMBL651,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1947,['ENSG00000112038'],"['EFO_0005611', 'MONDO_0041052', 'EFO_0000228', 'EFO_0003843', 'EFO_0004240', 'EFO_0010702', 'HP_0012532', 'EFO_0000764', 'EFO_0003890', 'EFO_0003917', 'EFO_0003843', 'EFO_0004273', 'EFO_0005611', 'EFO_0003047', 'EFO_0003884', 'HP_0008419', 'EFO_0005799', 'EFO_0000180', 'EFO_0003890', 'MONDO_0004992', 'EFO_0000764', 'EFO_0004270', 'EFO_0005762', 'EFO_0002610']",False,False,24,Mu opioid receptor agonist ,AGONIST ,single protein 
1221,AN-9,CHEMBL100014,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000095', 'EFO_0000756']",False,False,3,,,
1222,ONALESPIB,CHEMBL1214827,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['MONDO_0007254', 'EFO_0003060', 'EFO_0000305', 'EFO_0003060', 'EFO_0000616', 'MONDO_0008315']",False,False,6,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
1223,NAPHAZOLINE HYDROCHLORIDE,CHEMBL1706,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 3 investigational indications.,,4.0,,False,1971,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']","['EFO_0000678', 'MP_0001845', 'HP_0001742', 'EFO_0007328', 'EFO_0003956', 'EFO_0007214', 'EFO_0007486']",False,False,7,Adrenergic receptor alpha agonist ,AGONIST ,protein family 
1224,STREPTOKINASE,CHEMBL2108147,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for recurrent thrombophlebitis and has 6 investigational indications.,,4.0,,False,1997,['ENSG00000122194'],"['EFO_1000652', 'EFO_1001375', 'HP_0004419', 'EFO_0000612', 'HP_0002140', 'EFO_0008583', 'HP_0004936']",False,True,7,Plasminogen activator ,ACTIVATOR ,single protein 
1225,CAROTUXIMAB,CHEMBL2109321,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,['ENSG00000106991'],"['MONDO_0007254', 'EFO_1001968', 'MONDO_0004992', 'EFO_0000349', 'EFO_0000640', 'EFO_0002499', 'MONDO_0008315', 'MONDO_0003268', 'EFO_0003968', 'MONDO_0008903', 'EFO_1001111', 'EFO_0003060', 'EFO_1001465', 'EFO_0000681', 'EFO_0009708', 'EFO_0002893', 'EFO_0000519', 'EFO_0001365', 'EFO_0000616', 'EFO_0002501', 'EFO_0000182']",True,False,21,Endoglin inhibitor ,INHIBITOR ,single protein 
1226,IMD-1041,CHEMBL3545168,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000104365'],['EFO_0000341'],False,False,1,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor ,INHIBITOR ,single protein 
1227,PEPINEMAB,CHEMBL4297884,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000187764'],"['MONDO_0004975', 'MONDO_0007739', 'EFO_0000181', 'EFO_0003060', 'EFO_0000389', 'MONDO_0007254', 'EFO_0000637', 'MONDO_0005301', 'EFO_0000616']",True,False,9,Semaphorin-4D inhibitor ,INHIBITOR ,single protein 
1228,P,CHEMBL4300766,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000738', 'EFO_0003884', 'EFO_0000401']",False,False,3,,,
1229,BELZUTIFAN,CHEMBL4585668,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 6 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2021,['ENSG00000116016'],"['EFO_1000045', 'EFO_0000616', 'EFO_0001421', 'EFO_0003884', 'EFO_0000349', 'EFO_0000681', 'MONDO_0016748', 'MONDO_0008667']",False,False,8,Endothelial PAS domain-containing protein 1 inhibitor ,INHIBITOR ,single protein 
1230,CBX-129801,CHEMBL4594533,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0005147', 'EFO_1000783']",False,False,2,,,
1231,PIPERACILLIN,CHEMBL702,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 8 approved and 20 investigational indications.,,4.0,,False,1981,[],"['EFO_0000771', 'EFO_0001076', 'EFO_0006834', 'EFO_1001312', 'EFO_0002618', 'MONDO_0044881', 'EFO_0007328', 'EFO_1001289', 'EFO_1001388', 'EFO_1001459', 'EFO_1001141', 'EFO_0003035', 'HP_0100806', 'EFO_0003102', 'EFO_1001272', 'EFO_1001313', 'EFO_0003106', 'EFO_0003030', 'EFO_0003103', 'EFO_0008588', 'EFO_1001459', 'EFO_0000544', 'EFO_0003106', 'MONDO_0013730', 'EFO_0000544', 'EFO_0004992', 'EFO_0007149', 'MONDO_0100096', 'EFO_0005741']",False,False,29,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1232,CEFOTAXIME SODIUM,CHEMBL1010,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication.,,4.0,,False,1981,[],"['EFO_0000544', 'DOID_7551', 'EFO_0003106', 'EFO_0003102']",False,False,4,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1233,RIGOSERTIB,CHEMBL1241855,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0009179', 'EFO_0000198', 'EFO_0000339', 'EFO_0000198', 'MONDO_0008170', 'EFO_1001779', 'EFO_0000222', 'EFO_0000181', 'EFO_0000708', 'EFO_0003811', 'EFO_0005922', 'EFO_0003811', 'EFO_0000095', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000616']",False,False,16,,,
1234,TIVOZANIB,CHEMBL1289494,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for renal cell carcinoma and neoplasm and has 13 investigational indications.,,4.0,,False,2021,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113721']","['EFO_0005221', 'MONDO_0002158', 'EFO_0001421', 'EFO_0000681', 'EFO_1001951', 'EFO_0000519', 'MONDO_0008315', 'EFO_0000182', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001968', 'MONDO_0007254', 'EFO_0000681', 'EFO_0000616', 'EFO_0003060']",True,False,15,Vascular endothelial growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor beta inhibitor ,INHIBITOR ,protein family single protein 
1235,PIOGLITAZONE HYDROCHLORIDE,CHEMBL1715,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for type 2 diabetes mellitus and liver disease and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,['ENSG00000132170'],"['HP_0002745', 'EFO_0002618', 'MONDO_0004976', 'MONDO_0005148', 'EFO_0003095', 'EFO_0001421', 'EFO_0003884', 'MONDO_0002009', 'EFO_0003060']",True,False,9,Peroxisome proliferator-activated receptor gamma agonist ,AGONIST ,single protein 
1236,CEPHALEXIN,CHEMBL1727,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 12 investigational indications.,,4.0,,False,1971,[],"['EFO_0005681', 'EFO_0000701', 'EFO_0000771', 'EFO_0009582', 'MONDO_0007254', 'MONDO_0001187', 'HP_0001742', 'EFO_0000222', 'EFO_0000274', 'EFO_0003830', 'EFO_0003103', 'EFO_1000781', 'EFO_0000544', 'HP_0000964', 'MONDO_0009061', 'MONDO_0024355', 'EFO_0004992', 'EFO_0003035']",False,False,18,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1237,MOGAMULIZUMAB,CHEMBL1743041,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 8 investigational indications.,,4.0,,False,2018,['ENSG00000183813'],"['EFO_0000313', 'EFO_0000616', 'EFO_0002913', 'EFO_0007527', 'MONDO_0004979', 'EFO_0003060', 'EFO_1000785', 'EFO_0000182', 'MONDO_0019471', 'EFO_1001051', 'EFO_0000211']",False,False,11,C-C chemokine receptor type 4 cross-linking agent ,CROSS-LINKING AGENT ,single protein 
1238,DAUNORUBICIN,CHEMBL178,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 3 approved and 40 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1979,['ENSG00000131747'],"['MONDO_0044881', 'EFO_0000222', 'EFO_0000220', 'EFO_0000565', 'MONDO_0000873', 'EFO_0000558', 'MONDO_0004643', 'EFO_0003028', 'EFO_0000565', 'EFO_0003811', 'EFO_0000209', 'EFO_0004251', 'EFO_0000218', 'EFO_0000198', 'EFO_0003802', 'MONDO_0000870', 'EFO_0000224', 'EFO_0003025', 'EFO_0000221', 'MONDO_0000870', 'MONDO_0007254', 'EFO_0000691', 'EFO_0000094', 'EFO_0003884', 'EFO_0000094', 'MONDO_0044917', 'MONDO_0044903', 'EFO_0000574', 'EFO_0000616', 'EFO_0000565', 'EFO_0000223', 'EFO_0004239', 'EFO_0000198', 'EFO_0004289', 'EFO_0000479', 'EFO_0005952', 'EFO_0000220', 'EFO_0000339', 'EFO_0003029', 'EFO_0000691', 'EFO_0002429', 'EFO_0003027', 'EFO_0000222', 'EFO_1001779', 'EFO_0003802', 'EFO_1001052']",False,False,46,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
1239,ENZASTAURIN HYDROCHLORIDE,CHEMBL2107337,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000519', 'EFO_0000621', 'MONDO_0002087', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0004288', 'EFO_0003869', 'EFO_1000158', 'MONDO_0008315', 'EFO_0000616', 'EFO_0003060', 'EFO_0000403']",False,False,12,,,
1240,VISTUSERTIB,CHEMBL2336325,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 20 investigational indications.,,2.0,,False,no approval year,['ENSG00000198793'],"['EFO_0000616', 'EFO_0000707', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0005537', 'EFO_0000702', 'EFO_0003897', 'EFO_1000251', 'MONDO_0016642', 'MONDO_0001187', 'EFO_0000708', 'MONDO_0008315', 'EFO_0000519', 'EFO_0000349', 'EFO_0000228', 'EFO_0003060', 'EFO_1001512', 'EFO_0000503', 'EFO_0000403', 'Orphanet_145']",False,False,20,Serine/threonine-protein kinase mTOR inhibitor ,INHIBITOR ,single protein 
1241,TILARGININE,CHEMBL256147,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000089250', 'ENSG00000007171', 'ENSG00000164867']","['MONDO_0007254', 'EFO_0004272', 'EFO_0600064', 'EFO_1000859', 'EFO_0000764', 'EFO_1000653', 'MONDO_0011382', 'MONDO_0021187', 'HP_0031273', 'EFO_0009444']",True,False,10,Nitric oxide synthase inhibitor ,INHIBITOR ,protein family 
1242,TEGAVIVINT,CHEMBL3601411,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000565', 'EFO_0009907', 'EFO_0003060']",False,False,3,,,
1243,NEOMYCIN,CHEMBL3989751,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1957,[],"['EFO_0007315', 'MP_0001845', 'EFO_0000616', 'EFO_1001888', 'MONDO_0100096', 'EFO_0000384', 'EFO_0003033', 'EFO_0003106', 'EFO_0009516', 'EFO_0000544', 'EFO_1001121', 'EFO_0000771', 'EFO_0000544', 'EFO_0003102']",False,False,14,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1244,CM-4307,CHEMBL4297490,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003891', 'EFO_0005221', 'MONDO_0002108', 'EFO_0000222', 'EFO_0000616', 'MONDO_0007576', 'EFO_0004252', 'MONDO_0001056', 'EFO_0003060', 'EFO_0002618', 'EFO_0000182']",False,False,11,,,
1245,BEMPEGALDESLEUKIN,CHEMBL4298058,Protein drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000681', 'EFO_0000691', 'EFO_0000756', 'MONDO_0100096', 'EFO_0002617', 'MONDO_0004992', 'EFO_0005952', 'EFO_0003060', 'MONDO_0001187', 'EFO_0000616', 'EFO_0000389', 'EFO_0006859', 'MONDO_0008315']",False,False,13,,,
1246,SELPERCATINIB,CHEMBL4559134,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 5 approved and 2 investigational indications.,,4.0,,False,2020,"['ENSG00000165731', 'ENSG00000108091', 'ENSG00000170759']","['EFO_0001421', 'EFO_0000616', 'MONDO_0015277', 'EFO_0003060', 'MONDO_0004992', 'HP_0000083', 'MONDO_0002108']",False,False,7,Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor RET inhibitor Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor ,INHIBITOR ,chimeric protein single protein 
1247,EPINEPHRINE,CHEMBL679,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 19 approved and 34 investigational indications.,,4.0,,False,1976,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000043591', 'ENSG00000169252', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286', 'ENSG00000188778']","['MONDO_0001056', 'MONDO_0003061', 'EFO_0000319', 'EFO_0005532', 'HP_0002105', 'EFO_0003060', 'EFO_0007355', 'MONDO_0007254', 'EFO_1001250', 'EFO_0004198', 'EFO_0000544', 'HP_0011950', 'HP_0002239', 'EFO_0003956', 'EFO_0006834', 'EFO_0004278', 'MONDO_0004979', 'EFO_0004209', 'HP_0001742', 'MP_0001914', 'EFO_0003843', 'EFO_0000400', 'EFO_0007149', 'EFO_1001139', 'EFO_1001087', 'EFO_0004616', 'EFO_0005251', 'HP_0100543', 'MONDO_0100053', 'EFO_0004287', 'HP_0011499', 'EFO_0009676', 'HP_0006536', 'EFO_0000546', 'EFO_0004610', 'EFO_0005854', 'HP_0012532', 'EFO_0003843', 'EFO_0009492', 'MONDO_0005271', 'MONDO_0005041', 'EFO_0009840', 'EFO_0003144', 'MONDO_0005178', 'HP_0031273', 'EFO_0005306', 'EFO_1001417', 'EFO_0005531', 'EFO_0009846', 'EFO_0007486', 'EFO_0004278', 'MONDO_0002050', 'EFO_1001222']",True,False,53,Adrenergic receptor agonist ,AGONIST ,protein family 
1248,CYCLOPHOSPHAMIDE,CHEMBL88,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 10 approved and 237 investigational indications.,,4.0,,False,1959,[],"['MONDO_0019391', 'EFO_0000313', 'EFO_0008498', 'EFO_0002087', 'EFO_0001642', 'EFO_1001779', 'MONDO_0009348', 'HP_0002721', 'EFO_0003032', 'EFO_0003811', 'EFO_0004255', 'MONDO_0015760', 'EFO_1000026', 'EFO_1000292', 'EFO_0006475', 'EFO_0006861', 'EFO_0007147', 'MONDO_0008903', 'EFO_1000749', 'MONDO_0018076', 'EFO_1000309', 'EFO_0002939', 'EFO_0005761', 'MONDO_0000873', 'MONDO_0003060', 'MONDO_0005301', 'Orphanet_145', 'EFO_0009441', 'EFO_0002618', 'MONDO_0007576', 'EFO_0000637', 'MONDO_0011382', 'EFO_0000095', 'EFO_0000220', 'MONDO_0010006', 'EFO_0005561', 'EFO_0003025', 'MONDO_0009254', 'MONDO_0001718', 'EFO_0009259', 'EFO_0009448', 'MONDO_0000870', 'EFO_0004252', 'EFO_0003840', 'EFO_0000588', 'EFO_0006803', 'EFO_0009708', 'EFO_0000222', 'MONDO_0017198', 'EFO_0000309', 'EFO_0000181', 'MONDO_0010100', 'EFO_0002617', 'MONDO_0017816', 'HP_0001871', 'EFO_1001380', 'MONDO_0002380', 'EFO_0003802', 'EFO_0000691', 'EFO_0001376', 'MONDO_0044881', 'MONDO_0008380', 'EFO_0000764', 'MONDO_0019019', 'MONDO_0002691', 'EFO_0000223', 'MONDO_0037745', 'EFO_1000895', 'MONDO_0000432', 'EFO_0003869', 'MONDO_0002898', 'EFO_0000621', 'MONDO_0006058', 'EFO_0004826', 'EFO_0000305', 'EFO_0004145', 'MONDO_0004095', 'EFO_1000158', 'MONDO_0018906', 'MONDO_0020077', 'EFO_0005543', 'EFO_1001042', 'EFO_0000174', 'EFO_1000131', 'MONDO_0013730', 'MONDO_0019472', 'EFO_1000251', 'EFO_0000702', 'EFO_0000182', 'EFO_0000209', 'EFO_0000349', 'EFO_0000502', 'EFO_1000690', 'MONDO_0018149', 'EFO_0003833', 'MONDO_0018944', 'MONDO_0019148', 'MONDO_0019338', 'MONDO_0008315', 'EFO_0005803', 'MONDO_0001657', 'MONDO_0044903', 'MONDO_0019438', 'EFO_0002918', 'EFO_0006859', 'EFO_0003929', 'EFO_0000218', 'EFO_0005952', 'EFO_1002048', 'MONDO_0008978', 'EFO_0002430', 'EFO_0000765', 'EFO_0001378', 'EFO_1001469', 'EFO_0000384', 'EFO_0000221', 'EFO_1001471', 'MONDO_0001187', 'MONDO_0008170', 'EFO_0009709', 'EFO_0000389', 'EFO_0000613', 'EFO_0005537', 'EFO_0003027', 'EFO_0003922', 'EFO_1000965', 'MONDO_0016717', 'EFO_0000768', 'MONDO_0021063', 'MONDO_0002334', 'EFO_0003865', 'MONDO_0002108', 'EFO_0002517', 'EFO_0004719', 'EFO_1001968', 'EFO_0001075', 'EFO_0004272', 'EFO_1001996', 'EFO_0000574', 'MONDO_0024475', 'EFO_1001993', 'EFO_0000545', 'MONDO_0019262', 'MONDO_0004992', 'MONDO_0000159', 'EFO_0000183', 'EFO_0005235', 'MONDO_0018868', 'EFO_1001951', 'MONDO_0015277', 'MONDO_0016537', 'EFO_0005784', 'EFO_0000756', 'EFO_0003060', 'EFO_1000785', 'MONDO_0018544', 'EFO_0004991', 'EFO_0003780', 'EFO_0000339', 'MONDO_0015540', 'HP_0001873', 'EFO_1001465', 'HP_0001915', 'EFO_0000519', 'EFO_0000255', 'EFO_0007160', 'EFO_1000657', 'MONDO_0100342', 'MONDO_0003751', 'MONDO_0003478', 'MONDO_0001705', 'EFO_0000708', 'EFO_0005570', 'EFO_0005297', 'EFO_0000685', 'EFO_0000514', 'MONDO_0018271', 'MONDO_0002367', 'EFO_1000984', 'MONDO_0002087', 'EFO_0000540', 'EFO_0004194', 'EFO_0004254', 'EFO_0009538', 'EFO_0004256', 'EFO_0000191', 'EFO_0006738', 'EFO_0002428', 'EFO_0000616', 'MONDO_0015564', 'EFO_1001365', 'EFO_0000094', 'EFO_0000248', 'EFO_0000437', 'HP_0002017', 'MONDO_0001023', 'EFO_0000403', 'EFO_1000576', 'EFO_1000784', 'EFO_0000228', 'EFO_0007498', 'MONDO_0011962', 'MONDO_0018305', 'EFO_0000717', 'EFO_0000096', 'MONDO_0016700', 'MONDO_0019471', 'EFO_1001857', 'EFO_0000707', 'EFO_0008528', 'MONDO_0009499', 'EFO_1001051', 'EFO_0004236', 'EFO_0004281', 'MONDO_0000430', 'EFO_0000211', 'MONDO_0007254', 'EFO_1000318', 'EFO_0000326', 'EFO_1001901', 'MONDO_0019004', 'MONDO_0001475', 'EFO_1000028', 'EFO_1001875', 'EFO_0003893', 'EFO_0004251', 'MONDO_0007915', 'EFO_0003086', 'MONDO_0002974', 'EFO_0000198', 'MONDO_0018150', 'EFO_0000681', 'MONDO_0002158', 'EFO_1000581', 'EFO_0000569', 'EFO_0000565', 'EFO_0000196', 'EFO_0006911', 'EFO_0001061', 'EFO_0000673', 'EFO_0000199', 'EFO_0006927', 'EFO_0000770', 'EFO_0004289', 'MONDO_0004658', 'MONDO_0044917', 'EFO_0003884']",False,False,247,,,
1249,BUMETANIDE,CHEMBL1072,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1983,['ENSG00000074803'],"['HP_0001250', 'EFO_0003086', 'MONDO_0005148', 'EFO_0003758', 'EFO_0000373', 'EFO_0004255', 'EFO_0003144', 'MONDO_0008223', 'EFO_0000319', 'EFO_0000182', 'EFO_0003884', 'EFO_0003756']",False,False,12,Sodium-(potassium)-chloride cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1250,TANESPIMYCIN,CHEMBL109480,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 38 investigational indications.,,3.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['MONDO_0001187', 'MONDO_0002367', 'EFO_0002428', 'EFO_0000565', 'MONDO_0008903', 'EFO_0000333', 'EFO_1000785', 'EFO_0009441', 'EFO_0000616', 'EFO_0000403', 'EFO_0001378', 'EFO_0000183', 'MONDO_0015277', 'EFO_0000637', 'MONDO_0018906', 'MONDO_0001056', 'MONDO_0019471', 'MONDO_0000873', 'EFO_1001365', 'EFO_0000255', 'EFO_0000191', 'EFO_0000309', 'EFO_0006859', 'EFO_0000641', 'EFO_0000673', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000756', 'EFO_0000095', 'EFO_0000574', 'MONDO_0001023', 'EFO_0003032', 'EFO_1001051', 'EFO_0000389', 'MONDO_0008315', 'MONDO_0007254', 'MONDO_0008170', 'EFO_1001469']",False,False,38,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
1251,ABCIXIMAB,CHEMBL1201584,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for recurrent thrombophlebitis and intermediate coronary syndrome and has 7 investigational indications.,,4.0,,False,1993,"['ENSG00000259207', 'ENSG00000005961', 'ENSG00000138448']","['MONDO_0005299', 'EFO_0003913', 'EFO_0008583', 'EFO_0000712', 'EFO_0000612', 'EFO_0002615', 'EFO_0008585', 'HP_0004419', 'EFO_1000985']",True,True,9,Integrin alpha-V/beta-3 inhibitor Integrin alpha-IIb/beta-3 inhibitor ,INHIBITOR ,protein complex 
1252,METRELEPTIN,CHEMBL2107857,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for liver disease and lipodystrophy and has 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000116678'],"['EFO_0001073', 'MONDO_0020088', 'EFO_0003095', 'EFO_0002614', 'EFO_0001421', 'MONDO_0005147', 'EFO_1000728', 'EFO_0000195', 'EFO_1001348', 'EFO_0010269', 'EFO_1000727']",False,False,11,Leptin receptor agonist ,AGONIST ,single protein 
1253,FERRIC CARBOXYMALTOSE,CHEMBL2108597,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 8 investigational indications.,,4.0,,False,2013,[],"['MONDO_0021148', 'EFO_0003144', 'EFO_1000984', 'MONDO_0002280', 'EFO_0004540', 'EFO_0000178', 'EFO_0000341', 'EFO_0004270', 'EFO_0004272', 'HP_0001891', 'EFO_0003964']",False,False,11,,,
1254,NIZATIDINE,CHEMBL3183075,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 2 investigational indications.,,4.0,,False,1988,['ENSG00000113749'],"['EFO_0000217', 'EFO_1000948', 'HP_0004398', 'HP_0100633', 'EFO_0004607', 'EFO_0003948']",False,False,6,Histamine H2 receptor antagonist ,ANTAGONIST ,single protein 
1255,CLINDAMYCIN PHOSPHATE,CHEMBL3184512,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 17 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1972,[],"['EFO_0003097', 'EFO_0003102', 'EFO_0003030', 'EFO_1001240', 'EFO_1001312', 'EFO_1000760', 'EFO_0003106', 'EFO_0008588', 'EFO_0000555', 'EFO_0003932', 'HP_0100806', 'EFO_0009549', 'EFO_1001753', 'EFO_1001084', 'EFO_1001362', 'EFO_0000544', 'MONDO_0024355', 'EFO_1001314', 'EFO_0003894']",False,False,19,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1256,TELACEBEC,CHEMBL3298910,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0018076', 'MONDO_0100096']",False,False,2,,,
1257,FUROSEMIDE,CHEMBL35,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 7 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1966,['ENSG00000074803'],"['EFO_0002617', 'MONDO_0019091', 'MONDO_0005090', 'EFO_0001422', 'EFO_0000400', 'EFO_0009373', 'EFO_0000319', 'HP_0003124', 'HP_0011950', 'MONDO_0004992', 'EFO_0000565', 'EFO_0003144', 'EFO_0009840', 'EFO_1000391', 'EFO_0003086', 'EFO_0008583', 'MONDO_0001134', 'EFO_0009662', 'EFO_1001134', 'EFO_0000668', 'HP_0002094', 'EFO_1002048', 'EFO_0000373', 'EFO_0003827', 'EFO_0004610', 'EFO_0003917', 'EFO_0001645', 'EFO_0000222', 'EFO_0003914', 'MONDO_0005148', 'MONDO_0024664', 'EFO_0000537', 'EFO_0004255', 'EFO_0003818', 'HP_0001919', 'EFO_0002496', 'EFO_0003884']",False,False,37,Sodium-(potassium)-chloride cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1258,PRALSETINIB,CHEMBL4582651,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved indications.,,4.0,,False,2020,"['ENSG00000165731', 'ENSG00000108091', 'ENSG00000170759']","['MONDO_0015277', 'EFO_0000616', 'EFO_0003060', 'MONDO_0004992']",False,False,4,Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor RET inhibitor ,INHIBITOR ,chimeric protein single protein 
1259,AMINOGLUTETHIMIDE,CHEMBL488,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for neoplasm and has 2 investigational indications.,,4.0,,False,1980,"['ENSG00000137869', 'ENSG00000140459']","['MONDO_0008315', 'EFO_0000616', 'MONDO_0007254']",False,False,3,Cytochrome P450 11A1 inhibitor Cytochrome P450 19A1 inhibitor ,INHIBITOR ,single protein 
1260,UK432097,CHEMBL1096896,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000128271'],['EFO_0000341'],False,False,1,Adenosine A2a receptor agonist ,AGONIST ,single protein 
1261,SOMATROPIN,CHEMBL1201621,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 13 approved and 32 investigational indications.,,4.0,,False,1976,['ENSG00000112964'],"['MONDO_0019019', 'Orphanet_665', 'EFO_0003944', 'EFO_0000319', 'EFO_0001379', 'EFO_0001380', 'EFO_0000400', 'MONDO_0019499', 'EFO_0000180', 'HP_0100543', 'MONDO_0010674', 'MONDO_0009061', 'EFO_0000495', 'Orphanet_269', 'MONDO_0015183', 'HP_0001510', 'EFO_1001109', 'EFO_0000545', 'MONDO_0007078', 'EFO_0001073', 'EFO_0000764', 'EFO_0001379', 'MONDO_0043510', 'EFO_0003884', 'EFO_1001434', 'MONDO_0001967', 'EFO_0009607', 'HP_0004326', 'MONDO_0015514', 'MONDO_0008300', 'EFO_0007312', 'MONDO_0018241', 'EFO_1001919', 'EFO_0008560', 'MONDO_0009661', 'EFO_0001422', 'EFO_0009516', 'EFO_1000653', 'EFO_0003144', 'MONDO_0004976', 'EFO_0000384', 'EFO_0004616', 'MONDO_0018997', 'EFO_0008525', 'GO_0007568']",False,False,45,Growth hormone receptor agonist ,AGONIST ,single protein 
1262,SARGRAMOSTIM,CHEMBL1201670,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 100 investigational indications.,,4.0,,False,1991,"['ENSG00000198223', 'ENSG00000100368']","['EFO_1001469', 'EFO_0000199', 'EFO_0006475', 'MONDO_0004992', 'EFO_1001465', 'HP_0001945', 'EFO_0003869', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000756', 'MONDO_0018906', 'EFO_0004142', 'EFO_0000681', 'EFO_0001378', 'EFO_1000657', 'MONDO_0005180', 'EFO_0004239', 'EFO_0000198', 'EFO_0000565', 'MONDO_0002158', 'EFO_1000251', 'EFO_0000621', 'EFO_0000313', 'EFO_0001075', 'MONDO_0015667', 'MONDO_0002087', 'EFO_0002618', 'EFO_0005543', 'EFO_0000685', 'EFO_0000095', 'EFO_0000389', 'MONDO_0004975', 'MONDO_0021063', 'MONDO_0001475', 'EFO_1001042', 'EFO_0000649', 'EFO_0002428', 'MONDO_0044881', 'EFO_0005537', 'EFO_0004265', 'EFO_1001951', 'MONDO_0007254', 'EFO_0000574', 'EFO_0000183', 'EFO_0003811', 'EFO_0000309', 'EFO_0001663', 'EFO_0000339', 'MONDO_0007576', 'MONDO_0005411', 'EFO_0003086', 'MONDO_0008170', 'MONDO_0005575', 'EFO_0000384', 'EFO_0000180', 'EFO_0000544', 'EFO_1000043', 'HP_0100806', 'EFO_0000220', 'EFO_0000403', 'EFO_0005046', 'EFO_1000984', 'EFO_0003921', 'EFO_0002918', 'MONDO_0100096', 'EFO_0000228', 'EFO_0004991', 'EFO_0000502', 'EFO_0000519', 'EFO_0002617', 'MONDO_0001437', 'EFO_0000764', 'EFO_1001302', 'EFO_0000637', 'EFO_0000694', 'EFO_0000691', 'MONDO_0001187', 'MONDO_0002691', 'EFO_0009708', 'MONDO_0100130', 'Orphanet_264675', 'MONDO_0013730', 'MONDO_0020077', 'MONDO_0100342', 'EFO_1000158', 'MONDO_0008903', 'EFO_0000466', 'EFO_0003891', 'MONDO_0011962', 'EFO_0000616', 'MONDO_0002367', 'EFO_0000305', 'EFO_0003893', 'EFO_0001064', 'EFO_0003833', 'MONDO_0001056', 'EFO_0005952', 'EFO_0000181', 'EFO_0000222', 'HP_0001871', 'EFO_0000432', 'EFO_0006861', 'EFO_0000182']",True,True,104,Granulocyte-macrophage colony-stimulating factor receptor agonist ,AGONIST ,protein complex 
1263,IVACAFTOR,CHEMBL2010601,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for cystic fibrosis and respiratory system disease and has 6 investigational indications.,,4.0,,False,2012,['ENSG00000001626'],"['EFO_0007486', 'MONDO_0016575', 'EFO_0001421', 'EFO_0000341', 'MONDO_0009061', 'MONDO_0009061', 'EFO_0006505', 'EFO_0000684']",False,True,8,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
1264,EPRATUZUMAB,CHEMBL2108404,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,['ENSG00000012124'],"['MONDO_0000870', 'EFO_0009441', 'MONDO_0007915', 'EFO_0000403', 'EFO_0005952', 'EFO_0000220', 'MONDO_0004992', 'EFO_0000574', 'EFO_0000094', 'EFO_0000565']",True,False,10,CD22 inhibitor ,INHIBITOR ,single protein 
1265,OMEGA-3-CARBOXYLIC ACIDS,CHEMBL3137327,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications.,,4.0,,False,2014,[],"['EFO_0004211', 'EFO_0000384']",False,False,2,,,
1266,TISAGENLECLEUCEL,CHEMBL3301574,Cell drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 14 investigational indications.,,4.0,,False,no approval year,['ENSG00000177455'],"['EFO_0002618', 'EFO_0000183', 'MONDO_0018906', 'EFO_0000616', 'EFO_0000096', 'EFO_0001378', 'EFO_0005952', 'MONDO_0000873', 'EFO_0000222', 'EFO_0000565', 'EFO_0000220', 'EFO_0000574', 'EFO_0000094', 'EFO_0000095', 'EFO_0000403']",False,False,15,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
1267,UMBRALISIB,CHEMBL3948730,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 19 investigational indications.,,4.0,,False,2021,"['ENSG00000213923', 'ENSG00000171608', 'ENSG00000097007']","['EFO_0000183', 'MONDO_0044903', 'MONDO_0001056', 'EFO_1000630', 'MONDO_0018906', 'MONDO_0007576', 'EFO_0000095', 'EFO_0000095', 'EFO_1001469', 'EFO_1001469', 'EFO_0002618', 'EFO_1001951', 'EFO_0000183', 'MONDO_0011719', 'EFO_0000403', 'EFO_1000657', 'EFO_0000096', 'EFO_0002429', 'EFO_0000403', 'EFO_0009441', 'EFO_0000211', 'MONDO_0018906']",True,False,22,Casein kinase I epsilon inhibitor Tyrosine-protein kinase ABL inhibitor PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
1268,ENDOSTATIN,CHEMBL4297747,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000756', 'EFO_0004284', 'EFO_0009254', 'EFO_0000182', 'EFO_0004252', 'EFO_0004142', 'MONDO_0008903', 'EFO_0000616']",False,False,9,,,
1269,ZB-716,CHEMBL4526356,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1270,INAVOLISIB,CHEMBL4650215,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000121879'],"['MONDO_0007254', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0000616']",False,False,4,PI3-kinase p110-alpha subunit inhibitor ,INHIBITOR ,single protein 
1271,PAZOPANIB,CHEMBL477772,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 9 approved and 64 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,"['ENSG00000077782', 'ENSG00000182866', 'ENSG00000068078', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404', 'ENSG00000113263', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000182578']","['EFO_1001465', 'EFO_0000182', 'MONDO_0004986', 'EFO_0005543', 'MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'MONDO_0011719', 'EFO_0007143', 'MONDO_0015277', 'EFO_1001465', 'EFO_0003869', 'MONDO_0008903', 'EFO_1000613', 'MONDO_0004192', 'MONDO_0008170', 'MONDO_0002158', 'MONDO_0019297', 'MONDO_0004986', 'MONDO_0000521', 'EFO_0003893', 'EFO_0000637', 'EFO_0000691', 'EFO_1001968', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0008315', 'EFO_0000333', 'EFO_0002618', 'MONDO_0004992', 'MONDO_0008667', 'EFO_0003968', 'EFO_0000564', 'MONDO_0002367', 'MONDO_0007254', 'EFO_1001100', 'EFO_0000616', 'EFO_0000519', 'MONDO_0011934', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0019180', 'EFO_0003060', 'EFO_0000574', 'EFO_0000702', 'EFO_0000222', 'EFO_0000501', 'EFO_0002892', 'MONDO_0001187', 'MONDO_0001187', 'EFO_0000181', 'EFO_0000349', 'EFO_0000349', 'MONDO_0002087', 'EFO_0003968', 'MONDO_0008315', 'EFO_0000588', 'EFO_0001663', 'EFO_0009606', 'MONDO_0002974', 'EFO_0000641', 'EFO_0000365', 'EFO_0000640', 'MONDO_0002158', 'EFO_0000681', 'MONDO_0016238', 'EFO_1000880', 'EFO_1001968', 'MONDO_0008903', 'EFO_0000691', 'EFO_0000756', 'EFO_0000673', 'EFO_0000569', 'EFO_0000514', 'EFO_0000676', 'EFO_1001901', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170']",True,False,79,Macrophage colony stimulating factor receptor inhibitor Tyrosine-protein kinase ITK/TSK inhibitor Platelet-derived growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor Fibroblast growth factor receptor 1 inhibitor Tyrosine-protein kinase LCK inhibitor Stem cell growth factor receptor inhibitor Fibroblast growth factor receptor 3 inhibitor ,INHIBITOR ,single protein protein complex protein family 
1272,CUDC-101,CHEMBL598797,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.,,1.0,,False,no approval year,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429', 'ENSG00000146648', 'ENSG00000141736']","['EFO_0000616', 'EFO_0006859', 'EFO_0003060', 'MONDO_0002691', 'MONDO_0001056', 'MONDO_0007254', 'MONDO_0004992']",True,True,7,Receptor protein-tyrosine kinase erbB-2 inhibitor Epidermal growth factor receptor erbB1 inhibitor Histone deacetylase inhibitor ,INHIBITOR ,single protein protein family 
1273,RANITIDINE,CHEMBL1790041,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 18 investigational indications.,,4.0,,False,1983,['ENSG00000113749'],"['EFO_0009454', 'HP_0004398', 'EFO_0009454', 'MONDO_0015277', 'Orphanet_2314', 'EFO_0003948', 'HP_0012735', 'MONDO_0005301', 'EFO_0005592', 'HP_0004398', 'EFO_0009579', 'EFO_0000540', 'EFO_0005252', 'EFO_1000961', 'EFO_0004607', 'MONDO_0044917', 'MONDO_0004992', 'EFO_1001095', 'MONDO_0043839', 'MONDO_0007254', 'EFO_0000280', 'EFO_0000681', 'MONDO_0004658', 'EFO_0003948', 'EFO_0000764']",True,False,25,Histamine H2 receptor antagonist ,ANTAGONIST ,single protein 
1274,POLYGLYCONATE,CHEMBL2107966,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0007328'],False,False,1,,,
1275,MCS-110,CHEMBL2109512,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000184371'],"['MONDO_0001056', 'MONDO_0007254', 'EFO_0000756']",False,False,3,Macrophage colony-stimulating factor 1 inhibitor ,INHIBITOR ,single protein 
1276,NALFURAFINE,CHEMBL267495,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000082556'],"['EFO_0003884', 'EFO_0001421']",False,False,2,Kappa opioid receptor agonist ,AGONIST ,single protein 
1277,VELEDIMEX,CHEMBL3039523,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000519', 'EFO_1000026', 'EFO_1001361', 'MONDO_0007254', 'EFO_0000756']",False,False,5,,,
1278,DOXORUBICIN HYDROCHLORIDE,CHEMBL359744,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 21 approved and 80 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1974,['ENSG00000131747'],"['EFO_0003869', 'EFO_1000796', 'EFO_0000564', 'EFO_0003893', 'MONDO_0002974', 'EFO_1001042', 'MONDO_0011934', 'MONDO_0003175', 'EFO_1001951', 'EFO_0003060', 'EFO_0005561', 'EFO_1000292', 'EFO_0000223', 'MONDO_0006058', 'EFO_0001376', 'EFO_0000403', 'MONDO_0021054', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0004986', 'EFO_0007143', 'EFO_0000437', 'EFO_0000198', 'EFO_0003144', 'MONDO_0018364', 'MONDO_0005094', 'EFO_1000984', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000239', 'EFO_0000309', 'EFO_0000702', 'EFO_0000183', 'MONDO_0002367', 'EFO_0000094', 'MONDO_0017387', 'MONDO_0008315', 'EFO_0000691', 'MONDO_0000870', 'EFO_0000588', 'EFO_0000621', 'EFO_0000220', 'EFO_0000565', 'EFO_0000211', 'EFO_1001365', 'MONDO_0008903', 'EFO_0003032', 'EFO_0000760', 'EFO_1000131', 'EFO_0000174', 'EFO_0000637', 'EFO_0000569', 'EFO_0007160', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0006475', 'EFO_0000305', 'MONDO_0000873', 'MONDO_0008170', 'EFO_0000502', 'MONDO_0002158', 'EFO_0003968', 'EFO_0000222', 'MONDO_0004192', 'EFO_1000158', 'MONDO_0004986', 'EFO_0001378', 'EFO_0003859', 'EFO_1001469', 'MONDO_0001187', 'EFO_0005537', 'MONDO_0009348', 'EFO_0000096', 'EFO_0000574', 'MONDO_0002678', 'MONDO_0020077', 'EFO_0000248', 'EFO_0000182', 'EFO_0009708', 'EFO_0006859', 'MONDO_0008380', 'EFO_0005952', 'EFO_1001100', 'EFO_0000681', 'MONDO_0007576', 'MONDO_0015540', 'EFO_1000251', 'EFO_0001075', 'EFO_1001968', 'EFO_0000616', 'MONDO_0018906', 'EFO_0002918', 'MONDO_0011962', 'MONDO_0002691', 'EFO_0000209', 'EFO_1000595', 'EFO_0000558', 'EFO_0000313', 'EFO_0000765', 'MONDO_0004658', 'MONDO_0044917']",True,False,101,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
1279,REVEFENACIN,CHEMBL3833319,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chronic obstructive pulmonary disease and airway obstruction and has 2 investigational indications.,,4.0,,False,2018,['ENSG00000133019'],"['EFO_0001421', 'EFO_0000341', 'HP_0006536', 'EFO_0003086']",True,True,4,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1280,"ENDOSTATIN, N-TERMINAL-MGGSHHHHH",CHEMBL4297946,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 22 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000621', 'MONDO_0002974', 'MONDO_0000831', 'EFO_1001951', 'MONDO_0007254', 'MONDO_0021117', 'EFO_0000637', 'EFO_0000574', 'MONDO_0001056', 'EFO_1001968', 'EFO_0003060', 'EFO_0000702', 'EFO_0005922', 'MONDO_0008903', 'MONDO_0005575', 'EFO_0000182', 'EFO_1001411', 'EFO_0004252', 'EFO_0000211', 'EFO_0002618', 'EFO_0001061', 'MONDO_0007576']",False,False,22,,,
1281,ADINTREVIMAB,CHEMBL4802187,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
1282,CALCITRIOL,CHEMBL846,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 31 investigational indications.,,4.0,,False,1978,['ENSG00000111424'],"['EFO_0002424', 'EFO_1001121', 'EFO_0000537', 'EFO_1001152', 'EFO_0003884', 'EFO_0000401', 'EFO_0003888', 'MONDO_0008315', 'Orphanet_733', 'HP_0002901', 'HP_0100806', 'EFO_0003854', 'EFO_0003868', 'EFO_0005221', 'MONDO_0024300', 'EFO_0002617', 'EFO_0003882', 'EFO_0009451', 'EFO_1001494', 'MONDO_0005147', 'Orphanet_89936', 'EFO_0003869', 'EFO_1000158', 'MONDO_0007915', 'HP_0001919', 'EFO_0000673', 'EFO_0000616', 'EFO_0002618', 'EFO_0000676', 'EFO_1001006', 'EFO_0000384', 'MONDO_0017198', 'EFO_0004193', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000198']",True,False,36,Vitamin D receptor agonist ,AGONIST ,single protein 
1283,MOMETASONE FUROATE,CHEMBL1161,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 8 approved and 17 investigational indications.,,4.0,,False,1987,['ENSG00000113580'],"['EFO_0000676', 'EFO_0004232', 'HP_0001742', 'HP_0100582', 'EFO_0007486', 'EFO_0007415', 'EFO_1000391', 'HP_0006536', 'EFO_1001919', 'EFO_0000341', 'EFO_0000274', 'MONDO_0011382', 'EFO_0003918', 'MONDO_0005271', 'MONDO_0004979', 'EFO_1001417', 'EFO_0002460', 'EFO_0004192', 'EFO_0007187', 'MONDO_0007254', 'MONDO_0100096', 'EFO_0003956', 'EFO_0005854', 'EFO_0000701', 'EFO_1001494']",True,True,25,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1284,THALLOUS CHLORIDE TL 201,CHEMBL1200535,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for myocardial infarction and coronary artery disease.,,4.0,,False,1977,[],"['EFO_0000612', 'EFO_0001645']",False,False,2,,,
1285,REPAGLINIDE,CHEMBL1272,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 11 investigational indications.,,4.0,,False,1997,"['ENSG00000187486', 'ENSG00000006071']","['MONDO_0009061', 'MONDO_0008315', 'EFO_0003914', 'MONDO_0005180', 'MONDO_0044970', 'EFO_0001068', 'EFO_0000685', 'MONDO_0005148', 'EFO_0000537', 'EFO_0000400', 'EFO_0001645', 'HP_0003124', 'MONDO_0011719']",False,False,13,"Sulfonylurea receptor 1, Kir6.2 blocker ",BLOCKER ,protein complex 
1286,NECITUMUMAB,CHEMBL1743047,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and non-small cell lung carcinoma and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,['ENSG00000146648'],"['EFO_0000708', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060', 'EFO_0009708']",False,True,5,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1287,DIGOXIN,CHEMBL1751,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 32 investigational indications.,,4.0,,False,1975,"['ENSG00000163399', 'ENSG00000129244', 'ENSG00000143153', 'ENSG00000018625', 'ENSG00000069849', 'ENSG00000105409', 'ENSG00000132681', 'ENSG00000137731']","['EFO_1001249', 'EFO_0006911', 'MONDO_0002009', 'EFO_0003047', 'EFO_0000400', 'EFO_0000222', 'EFO_0001062', 'MP_0001845', 'MONDO_0008667', 'EFO_0000764', 'EFO_0003890', 'MONDO_0001134', 'EFO_0000474', 'EFO_0000685', 'EFO_0000373', 'EFO_0000558', 'EFO_0006859', 'EFO_0003869', 'MONDO_0002050', 'EFO_0002618', 'EFO_0000275', 'EFO_0003060', 'EFO_0007328', 'HP_0004755', 'EFO_0000198', 'EFO_0000544', 'EFO_0003144', 'EFO_0000756', 'EFO_0000616', 'MONDO_0008315', 'MONDO_0019623', 'EFO_0000319', 'EFO_0002496', 'MONDO_0005148', 'MONDO_0007254', 'EFO_0004239']",True,False,36,Sodium/potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex group 
1288,DROTRECOGIN ALFA (ACTIVATED),CHEMBL2109065,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for recurrent thrombophlebitis and has 8 investigational indications. It was withdrawn in at least one region.,,4.0,,False,2001,"['ENSG00000198734', 'ENSG00000185010']","['EFO_0005251', 'EFO_0006834', 'EFO_0003827', 'HP_0002140', 'HP_0100806', 'EFO_0000712', 'EFO_0003884', 'MONDO_0100130', 'HP_0004419']",False,False,9,Coagulation factor VIII inhibitor Coagulation factor V inhibitor ,INHIBITOR ,single protein 
1289,MM-121,CHEMBL2109402,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000065361'],"['MONDO_0007254', 'MONDO_0008170', 'MONDO_0002087', 'EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'MONDO_0002158']",False,False,7,Receptor tyrosine-protein kinase erbB-3 antagonist ,ANTAGONIST ,single protein 
1290,PEGVORHYALURONIDASE ALFA,CHEMBL3989976,Enzyme drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0002618', 'EFO_0000228', 'EFO_0000503', 'EFO_0002916', 'EFO_0005221', 'EFO_0002517']",False,False,7,,,
1291,SIROLIMUS,CHEMBL413,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for immune system disease and eye disease and has 133 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,['ENSG00000088832'],"['EFO_1002048', 'Orphanet_77260', 'EFO_0007323', 'EFO_0000760', 'MONDO_0004976', 'MONDO_0013730', 'EFO_1001465', 'MONDO_0018848', 'Orphanet_365', 'MONDO_0002280', 'EFO_1000749', 'EFO_1000475', 'EFO_0000514', 'EFO_1000637', 'EFO_0000182', 'EFO_1001968', 'EFO_0000519', 'MONDO_0007079', 'HP_0001915', 'EFO_0008620', 'Orphanet_122', 'Orphanet_733', 'EFO_0000637', 'MONDO_0011705', 'EFO_0000180', 'EFO_0001365', 'EFO_1000986', 'MONDO_0001734', 'MONDO_0000873', 'EFO_0004599', 'MONDO_0007915', 'HP_0003124', 'EFO_0000681', 'EFO_1000906', 'EFO_0000565', 'EFO_0008514', 'MONDO_0005147', 'EFO_0000220', 'EFO_0003086', 'MONDO_0004992', 'EFO_0004610', 'EFO_0008517', 'EFO_0003144', 'GO_0007568', 'MONDO_0018975', 'Orphanet_848', 'EFO_0001378', 'EFO_0000183', 'HP_0002721', 'EFO_0002913', 'MONDO_0021121', 'EFO_0000095', 'EFO_0001075', 'EFO_0000717', 'EFO_1001119', 'MONDO_0017719', 'EFO_0006475', 'EFO_0004236', 'MONDO_0011382', 'EFO_0003060', 'EFO_1001469', 'MONDO_0002691', 'MONDO_0100096', 'EFO_1000811', 'EFO_0003929', 'EFO_0000198', 'MONDO_0044881', 'EFO_0000196', 'EFO_0004194', 'HP_0001871', 'EFO_0000222', 'MONDO_0019313', 'MONDO_0001718', 'MONDO_0016471', 'EFO_0000574', 'EFO_0003870', 'EFO_1001050', 'MONDO_0007254', 'MONDO_0002177', 'MONDO_0015974', 'EFO_0000571', 'EFO_0000401', 'EFO_0000616', 'EFO_0000174', 'EFO_1001996', 'EFO_0002618', 'EFO_0000540', 'EFO_0003966', 'EFO_0009661', 'EFO_0003770', 'EFO_0005952', 'MONDO_0004986', 'EFO_0000339', 'EFO_0000708', 'EFO_1000251', 'EFO_1001496', 'EFO_0002424', 'MONDO_0018150', 'MONDO_0008501', 'MONDO_0019338', 'EFO_0006927', 'MONDO_0001187', 'Orphanet_46724', 'MONDO_0002898', 'EFO_1000312', 'EFO_0000621', 'EFO_0000702', 'EFO_0004208', 'MONDO_0018531', 'EFO_0009708', 'MONDO_0002108', 'EFO_0009259', 'EFO_1000657', 'EFO_1001466', 'EFO_0005761', 'MONDO_0005180', 'MONDO_0008094', 'EFO_1000158', 'EFO_0004683', 'MONDO_0017276', 'EFO_0003884', 'HP_0001626', 'MONDO_0002050', 'EFO_0000537', 'MONDO_0018305', 'EFO_1000653', 'MONDO_0008903', 'EFO_0000691', 'MONDO_0005149', 'EFO_0000403', 'EFO_0006888', 'MONDO_0019391', 'MONDO_0008315', 'MONDO_0015564', 'EFO_0009907']",True,False,135,FK506-binding protein 1A inhibitor ,INHIBITOR ,single protein 
1292,VELIPARIB,CHEMBL506871,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications.,,3.0,,False,no approval year,"['ENSG00000143799', 'ENSG00000041880', 'ENSG00000129484']","['EFO_0002617', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0008170', 'EFO_0000616', 'EFO_0006861', 'EFO_0000708', 'Orphanet_145', 'MONDO_0002898', 'EFO_0000305', 'EFO_0005537', 'EFO_0001075', 'MONDO_0015760', 'MONDO_0001056', 'EFO_1000158', 'EFO_0000182', 'EFO_0002618', 'EFO_0000519', 'EFO_0005088', 'EFO_1000657', 'EFO_1001951', 'MONDO_0004992', 'EFO_0000466', 'EFO_0005952', 'EFO_0000702', 'EFO_1001465', 'EFO_0002499', 'MONDO_0002158', 'EFO_1001469', 'EFO_0001663', 'EFO_0003060', 'EFO_0003968', 'EFO_0006772', 'EFO_0000574']",True,False,34,"PARP 1, 2 and 3 inhibitor ",INHIBITOR ,protein family 
1293,TIRAPAZAMINE,CHEMBL50882,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008903', 'EFO_0004284', 'EFO_0000702', 'MONDO_0002087', 'EFO_0001416', 'EFO_0000181', 'MONDO_0002974', 'EFO_0002918', 'MONDO_0008170', 'EFO_0000182', 'EFO_0000616']",False,False,11,,,
1294,TARLATAMAB,CHEMBL5095292,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0000702']",False,False,2,,,
1295,IMATINIB,CHEMBL941,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 105 investigational indications.,,4.0,,False,2001,"['ENSG00000097007', 'ENSG00000186716', 'ENSG00000113721', 'ENSG00000157404']","['EFO_0004288', 'EFO_0006861', 'MONDO_0002108', 'EFO_0000717', 'EFO_0000756', 'EFO_0000760', 'EFO_1001361', 'MONDO_0005575', 'EFO_0003032', 'EFO_0001361', 'MONDO_0011934', 'EFO_0000756', 'MONDO_0004979', 'MONDO_0004643', 'EFO_0000685', 'MONDO_0008978', 'EFO_0004198', 'EFO_0000717', 'EFO_0000220', 'MONDO_0005301', 'MONDO_0018975', 'MONDO_0005147', 'EFO_1001465', 'MONDO_0002108', 'EFO_0000702', 'EFO_0002429', 'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729', 'EFO_0002617', 'MONDO_0021063', 'MONDO_0005149', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000691', 'MONDO_0008170', 'EFO_1000657', 'EFO_1000895', 'MONDO_0008903', 'MONDO_0007254', 'EFO_0000641', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313', 'EFO_0009907', 'EFO_0000209', 'MONDO_0007254', 'EFO_1000613', 'MONDO_0001056', 'EFO_1001471', 'MONDO_0018076', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0002618', 'EFO_0000616', 'EFO_0004683', 'EFO_0001361', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000519', 'EFO_0000497', 'EFO_0000094', 'EFO_0005952', 'EFO_0001422', 'EFO_0000616', 'MONDO_0011382', 'MONDO_0011719', 'EFO_0007444', 'MONDO_0008315', 'EFO_0002087', 'MONDO_0004992', 'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158', 'EFO_1001951', 'MONDO_0013730', 'EFO_0000519', 'MONDO_0000873', 'MONDO_0044881', 'MONDO_0005149', 'MONDO_0011719', 'MONDO_0011705', 'EFO_0000339', 'MONDO_0002158', 'EFO_0000503', 'EFO_1001467', 'EFO_0000712', 'EFO_1001814', 'MONDO_0004992', 'EFO_1001467', 'EFO_0000673', 'EFO_0000658', 'EFO_1000576', 'EFO_1001993', 'EFO_0000691', 'EFO_0002430', 'EFO_0000365', 'EFO_0000222', 'EFO_0004610', 'EFO_0001376', 'EFO_0003956', 'MONDO_0044917', 'EFO_0002428', 'MONDO_0100096', 'EFO_0000565', 'EFO_0005952', 'EFO_1001919', 'EFO_0004289', 'EFO_0000220', 'EFO_0000339', 'EFO_0000349', 'MONDO_0000873', 'EFO_0000565', 'EFO_0000574', 'EFO_0003897', 'EFO_0000222']",True,False,122,Platelet-derived growth factor receptor beta inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase ABL inhibitor Bcr/Abl fusion protein ,INHIBITOR ,single protein chimeric protein 
1296,EZETIMIBE,CHEMBL1138,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 16 investigational indications.,,4.0,,False,2002,['ENSG00000015520'],"['HP_0003124', 'EFO_0007304', 'EFO_0000764', 'EFO_0000195', 'MONDO_0019052', 'EFO_0000537', 'MONDO_0008315', 'EFO_0001645', 'EFO_0004220', 'EFO_0000266', 'Orphanet_309005', 'EFO_0003914', 'MONDO_0021187', 'EFO_0004211', 'EFO_0003095', 'EFO_0004911', 'EFO_0000612', 'EFO_0000319', 'MONDO_0005148', 'MONDO_0018328', 'EFO_0000400']",False,False,21,Niemann-Pick C1-like protein 1 inhibitor ,INHIBITOR ,single protein 
1297,FORMOTEROL,CHEMBL1256786,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved and 11 investigational indications.,,4.0,,False,2001,['ENSG00000169252'],"['EFO_0000341', 'EFO_1000637', 'MONDO_0005271', 'MONDO_0008903', 'HP_0002110', 'EFO_0000341', 'EFO_0003768', 'EFO_0009661', 'MONDO_0004975', 'MONDO_0004979', 'MONDO_0100096', 'HP_0006536', 'MONDO_0004979', 'HP_0025428', 'EFO_0006505', 'EFO_0000464', 'EFO_0007183']",True,False,17,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1298,RONTALIZUMAB,CHEMBL1743066,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000120235', 'ENSG00000120242', 'ENSG00000147873', 'ENSG00000186803', 'ENSG00000188379', 'ENSG00000197919', 'ENSG00000233816', 'ENSG00000214042', 'ENSG00000137080', 'ENSG00000147885', 'ENSG00000228083', 'ENSG00000234829', 'ENSG00000236637']",['MONDO_0007915'],False,True,1,Interferon alpha inhibitor ,INHIBITOR ,protein family 
1299,CICLESONIDE,CHEMBL2040682,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 4 investigational indications.,,4.0,,False,2006,['ENSG00000113580'],"['MONDO_0100096', 'EFO_0003956', 'EFO_1000024', 'MONDO_0005271', 'HP_0006536', 'HP_0001742', 'EFO_0005854', 'MONDO_0004979', 'EFO_1001417', 'EFO_0000341']",True,True,10,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1300,VARLITINIB,CHEMBL2103842,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000146648']","['MONDO_0001056', 'EFO_0000182', 'EFO_0000616', 'EFO_0005221', 'MONDO_0003060', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0002618']",False,False,8,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1301,CANFOSFAMIDE HYDROCHLORIDE,CHEMBL2107319,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002158', 'MONDO_0008903', 'MONDO_0002087', 'EFO_0003869', 'MONDO_0008170', 'EFO_0003893', 'EFO_0003060']",False,False,7,,,
1302,FLUOXETINE,CHEMBL41,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 33 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,['ENSG00000108576'],"['EFO_0003761', 'HP_0002140', 'EFO_0004262', 'MONDO_0100096', 'EFO_0003768', 'MONDO_0024290', 'HP_0011868', 'MONDO_0005147', 'EFO_1001917', 'EFO_1001050', 'EFO_0001361', 'HP_0100543', 'EFO_0003761', 'EFO_0001073', 'MONDO_0004985', 'EFO_0000694', 'EFO_0000712', 'EFO_0003948', 'MONDO_0002009', 'EFO_0003758', 'MONDO_0005090', 'EFO_0002610', 'EFO_0005230', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004985', 'EFO_0009854', 'EFO_0008623', 'EFO_0007328', 'EFO_0004242', 'EFO_0000546', 'MONDO_0002050', 'EFO_0009963', 'EFO_0008522', 'EFO_0001358', 'MONDO_0002050', 'EFO_0005669', 'EFO_0000474', 'EFO_0007191', 'EFO_0004242']",False,False,40,Serotonin transporter inhibitor ,INHIBITOR ,single protein 
1303,DIACEREIN,CHEMBL41286,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 11 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1000786', 'HP_0001873', 'MONDO_0017612', 'Orphanet_303', 'MONDO_0100096', 'EFO_0005755', 'MONDO_0017610', 'MONDO_0005178', 'MONDO_0005148', 'EFO_0004616', 'EFO_0004274', 'EFO_0000685']",False,False,12,,,
1304,ELX-02,CHEMBL4297744,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']","['EFO_0000508', 'MONDO_0009061', 'MONDO_0016239', 'EFO_0003086', 'MONDO_0018965']",True,False,5,80S Ribosome modulator ,MODULATOR ,protein nucleic-acid complex 
1305,SINTILIMAB,CHEMBL4297829,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 52 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000313', 'EFO_0005221', 'EFO_0000616', 'EFO_0000702', 'EFO_0003860', 'EFO_1001961', 'EFO_0004252', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0011962', 'EFO_1000657', 'EFO_0000707', 'EFO_0002913', 'EFO_0000211', 'EFO_0000183', 'EFO_0000621', 'EFO_0000348', 'EFO_0000365', 'EFO_1001901', 'EFO_0004142', 'EFO_0000255', 'MONDO_0003060', 'EFO_0000574', 'EFO_1001968', 'MONDO_0007254', 'EFO_0000199', 'EFO_0005570', 'EFO_0003968', 'EFO_0002618', 'MONDO_0021117', 'MONDO_0002120', 'EFO_0000349', 'EFO_0000182', 'EFO_1001972', 'MONDO_0004669', 'EFO_0001416', 'EFO_0005922', 'MONDO_0001056', 'EFO_0002916', 'EFO_0003060', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0019472', 'EFO_0000691', 'EFO_0000181', 'EFO_0000503', 'MONDO_0009348', 'MONDO_0008903', 'EFO_0000681', 'MONDO_0044704', 'EFO_0000403', 'MONDO_0008170']",False,False,52,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
1306,ZALIFRELIMAB,CHEMBL4297876,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000163599'],"['EFO_0000294', 'MONDO_0004992', 'EFO_0003060', 'EFO_1000026', 'EFO_0003968', 'EFO_0002517', 'EFO_1001968', 'MONDO_0002974']",False,False,8,Cytotoxic T-lymphocyte protein 4 inhibitor ,INHIBITOR ,single protein 
1307,ETESEVIMAB,CHEMBL4650488,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
1308,AZITHROMYCIN,CHEMBL529,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 19 approved and 64 investigational indications.,,4.0,,False,1991,[],"['EFO_0007444', 'EFO_0005585', 'EFO_0007486', 'HP_0002239', 'HP_0011950', 'EFO_0000764', 'EFO_0007224', 'EFO_1001466', 'EFO_0004242', 'EFO_0007205', 'MONDO_0004992', 'EFO_0009429', 'EFO_0001645', 'EFO_0007324', 'EFO_0001068', 'EFO_1000829', 'EFO_0006505', 'EFO_0000694', 'EFO_0003818', 'HP_0040187', 'EFO_0003102', 'MONDO_0002258', 'EFO_0009582', 'EFO_0004992', 'HP_0012735', 'EFO_0007460', 'EFO_0007361', 'EFO_0007503', 'EFO_0007548', 'EFO_0007200', 'EFO_0003106', 'EFO_0007541', 'EFO_1001388', 'HP_0030160', 'EFO_0000650', 'EFO_0008572', 'MONDO_0043839', 'EFO_0003917', 'EFO_1001888', 'MONDO_0002041', 'EFO_0000612', 'EFO_0003878', 'HP_0002013', 'MONDO_0100096', 'MONDO_0011382', 'EFO_1002018', 'EFO_0007183', 'HP_0002014', 'HP_0002110', 'EFO_0000341', 'EFO_0000384', 'EFO_0002950', 'EFO_0010282', 'EFO_0009536', 'EFO_0009686', 'DOID_7551', 'EFO_0003966', 'EFO_0007243', 'EFO_1002047', 'EFO_0001073', 'EFO_0007386', 'HP_0001945', 'EFO_0007402', 'MONDO_0009061', 'MONDO_0004979', 'EFO_1001413', 'EFO_0000771', 'EFO_0006890', 'MONDO_0019338', 'HP_0002027', 'EFO_0000649', 'MONDO_0005301', 'HP_0100806', 'EFO_1000948', 'EFO_0007504', 'HP_0011110', 'MP_0001845', 'EFO_1000637', 'EFO_0000540', 'EFO_0003894', 'MONDO_0019091', 'MONDO_0018076', 'EFO_0000544']",False,False,83,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1309,DEXTROTHYROXINE,CHEMBL559,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 3 investigational indications.,,4.0,,False,1967,"['ENSG00000126351', 'ENSG00000151090']","['EFO_0000319', 'EFO_1001375', 'EFO_0000612', 'EFO_0001064']",False,False,4,Thyroid hormone receptor agonist ,AGONIST ,protein complex 
1310,ALPRAZOLAM,CHEMBL661,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']","['EFO_0006788', 'MONDO_0005147', 'EFO_0003890', 'EFO_0000474', 'EFO_1001917', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0005090', 'EFO_1001892', 'HP_0001250', 'EFO_0004262', 'EFO_0001358', 'MONDO_0005277', 'MONDO_0004979']",False,True,14,GABA-A receptor; anion channel positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,protein complex group 
1311,PAMIDRONIC ACID,CHEMBL834,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for bone disease and has 6 investigational indications.,,4.0,,False,1991,['ENSG00000160752'],"['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'EFO_0003882', 'MONDO_0007254', 'HP_0003419', 'EFO_0001378', 'MONDO_0019019', 'EFO_0004260']",True,False,9,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
1312,IOHEXOL,CHEMBL1200455,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,[],"['MONDO_0007254', 'HP_0001919', 'HP_0000083', 'EFO_0000764', 'EFO_1001375', 'MONDO_0010526', 'EFO_0003086', 'EFO_0000616']",False,False,8,,,
1313,MIGLITOL,CHEMBL1561,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication.,,4.0,,False,1996,"['ENSG00000257335', 'ENSG00000171298']","['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400']",False,False,3,Maltase-glucoamylase inhibitor Lysosomal alpha-glucosidase inhibitor ,INHIBITOR ,single protein 
1314,EDETATE DISODIUM,CHEMBL1749,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for eye disease and has 4 investigational indications.,,4.0,,False,1982,[],"['EFO_0000400', 'EFO_0000556', 'EFO_0003966', 'EFO_0000612', 'EFO_0004265']",False,False,5,,,
1315,DIMESNA,CHEMBL2009034,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000571']",False,False,2,,,
1316,CM-082,CHEMBL3545427,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000122025', 'ENSG00000113721', 'ENSG00000128052']","['EFO_0001365', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000616', 'EFO_0000681', 'EFO_0000702']",False,False,7,Vascular endothelial growth factor receptor 2 inhibitor Platelet-derived growth factor receptor beta inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,single protein 
1317,EPCORITAMAB,CHEMBL4650393,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000156738', 'ENSG00000198851', 'ENSG00000160654', 'ENSG00000167286']","['EFO_0000403', 'EFO_0000095', 'MONDO_0018906', 'EFO_1001469', 'EFO_0005952', 'EFO_0000096']",True,False,6,T cell surface glycoprotein CD3 binding agent B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,protein complex single protein 
1318,SOTALOL,CHEMBL471,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and cardiovascular disease and has 6 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,"['ENSG00000043591', 'ENSG00000055118', 'ENSG00000169252']","['HP_0004308', 'EFO_0004278', 'EFO_0000319', 'EFO_0000275', 'EFO_0000612', 'EFO_0004287', 'EFO_0003144', 'EFO_0000275', 'EFO_0005306']",False,False,9,Beta-1 adrenergic receptor antagonist Beta-2 adrenergic receptor antagonist HERG blocker ,ANTAGONIST BLOCKER ,single protein 
1319,TERBUTALINE SULFATE,CHEMBL1315867,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,1974,['ENSG00000169252'],"['HP_0025428', 'EFO_0000341', 'MONDO_0004979', 'EFO_0009661']",False,False,4,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1320,"WAX, EMULSIFYING",CHEMBL2108813,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005301', 'MONDO_0100096', 'MONDO_0004975', 'EFO_0008507', 'EFO_1001904', 'EFO_0001054', 'EFO_0003756']",False,False,7,,,
1321,FGI-101-1A6,CHEMBL2109593,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000074319'],['EFO_0007328'],False,False,1,Tumor susceptibility gene 101 protein inhibitor ,INHIBITOR ,single protein 
1322,SEMAXANIB,CHEMBL276711,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']","['EFO_1000158', 'EFO_1000657', 'EFO_1001951', 'MONDO_0002974', 'EFO_0001378', 'EFO_0000588', 'EFO_0000616', 'EFO_0006859', 'MONDO_0007254', 'MONDO_0021063', 'EFO_0000389', 'EFO_0000681', 'MONDO_0002367', 'EFO_0000756', 'EFO_0000365', 'MONDO_0008315', 'EFO_0000691']",True,False,17,Stem cell growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein family 
1323,FEXAPOTIDE TRIFLUTATE,CHEMBL3707309,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000284', 'MONDO_0008315']",False,False,2,,,
1324,FELZARTAMAB,CHEMBL4594579,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000004468'],"['EFO_0001378', 'MONDO_0002462', 'MONDO_0007915', 'EFO_0004194', 'EFO_0003086', 'EFO_0004254']",True,False,6,Lymphocyte differentiation antigen CD38 inhibitor ,INHIBITOR ,single protein 
1325,ACLIDINIUM,CHEMBL1194325,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 2 investigational indications.,,4.0,,False,2012,['ENSG00000133019'],"['EFO_0000341', 'EFO_0000464', 'EFO_0006505', 'MONDO_0004979', 'EFO_0000341', 'HP_0006536', 'EFO_0003768']",True,True,7,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1326,ZINC ION,CHEMBL1236970,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003758', 'MONDO_0004907', 'EFO_0000181', 'HP_0002014', 'EFO_0000763', 'EFO_0003922', 'HP_0000360', 'EFO_0000694', 'EFO_1001347', 'EFO_0000764', 'HP_0100806', 'EFO_0010282', 'EFO_0000684', 'EFO_1001996', 'EFO_1001345', 'MONDO_0100096', 'EFO_0001068', 'EFO_0003047', 'EFO_0002950', 'MONDO_0018076', 'EFO_1000049', 'MONDO_0011382', 'MONDO_0001673', 'EFO_0000544', 'EFO_0003106', 'EFO_0000199']",False,False,26,,,
1327,OXIGLUTATIONE,CHEMBL1372,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 investigational indications.,,4.0,,False,2008,['ENSG00000104687'],"['EFO_0003060', 'EFO_0000565', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0000198']",False,False,5,Glutathione reductase  ,OTHER ,single protein 
1328,TOBRAMYCIN,CHEMBL1747,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 6 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1975,[],"['EFO_1000906', 'HP_0002110', 'EFO_1001272', 'EFO_0000544', 'EFO_0007141', 'EFO_0007486', 'EFO_1001459', 'EFO_0003106', 'EFO_0001076', 'MONDO_0009061', 'EFO_0003884', 'EFO_1000829', 'EFO_0003931', 'EFO_1001888', 'EFO_0000771', 'EFO_0009536', 'MP_0001845', 'MONDO_0019091', 'MONDO_0005129', 'EFO_0003102']",False,False,20,70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1329,PLECONARIL,CHEMBL29609,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['HP_0100806', 'EFO_0000763', 'MONDO_0005147']",False,False,3,VP1 capsid protein disrupting agent ,DISRUPTING AGENT ,single protein 
1330,EMIBETUZUMAB,CHEMBL3301578,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000105976'],"['EFO_0003060', 'MONDO_0004992', 'MONDO_0001056']",False,False,3,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1331,MSC-2360844,CHEMBL3683575,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0005952', 'MONDO_0044903', 'EFO_0003060']",False,False,3,,,
1332,IBERDOMIDE HYDROCHLORIDE,CHEMBL3989912,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003073', 'MONDO_0018906', 'EFO_0000574', 'MONDO_0019338', 'EFO_0005952', 'EFO_0000403', 'MONDO_0007915', 'EFO_0001421', 'EFO_0001378']",False,False,9,,,
1333,PANOBINOSTAT,CHEMBL483254,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 48 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']","['EFO_0002892', 'EFO_0000349', 'EFO_0003060', 'EFO_0000673', 'EFO_0004252', 'MONDO_0007254', 'EFO_0000519', 'EFO_0002617', 'EFO_1000026', 'MONDO_0001056', 'EFO_0006475', 'EFO_0000403', 'EFO_0000681', 'EFO_0000574', 'EFO_0001378', 'EFO_0002618', 'EFO_1001469', 'EFO_0009441', 'EFO_0000756', 'EFO_0000220', 'EFO_0002429', 'EFO_0002430', 'EFO_0000616', 'EFO_0000565', 'EFO_0006738', 'MONDO_0011382', 'MONDO_0002898', 'MONDO_0044881', 'EFO_0000183', 'MONDO_0004992', 'MONDO_0044903', 'EFO_0005952', 'EFO_1001901', 'EFO_0000339', 'EFO_1001951', 'EFO_0000764', 'MONDO_0100342', 'EFO_0000182', 'EFO_0000198', 'EFO_1000657', 'EFO_0005543', 'EFO_0000222', 'MONDO_0008903', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0009348', 'MONDO_0021063', 'EFO_1001779', 'EFO_0002913', 'MONDO_0013730']",True,False,51,Histone deacetylase inhibitor ,INHIBITOR ,protein family 
1334,REMINERTANT,CHEMBL506981,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000101188'],['EFO_0000702'],False,False,1,Neurotensin receptor 1 antagonist ,ANTAGONIST ,single protein 
1335,QUINACRINE,CHEMBL7568,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000681', 'EFO_0004226', 'MONDO_0008315', 'EFO_0000365', 'EFO_0003060']",False,False,5,,,
1336,RUBITECAN,CHEMBL77305,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['MONDO_0001187', 'MONDO_0011962', 'MONDO_0004192', 'EFO_0000389', 'MONDO_0008170', 'MONDO_0008903', 'EFO_1001951', 'MONDO_0002087', 'EFO_0002618', 'MONDO_0007254', 'EFO_0000616', 'EFO_1000158']",False,False,12,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
1337,L-SULFORAPHANE,CHEMBL1627201,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000341'],False,False,1,,,
1338,TABALUMAB,CHEMBL1743075,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000102524'],"['EFO_0001378', 'EFO_0000685', 'EFO_0003884', 'MONDO_0007915', 'EFO_0003929']",True,False,5,Tumor necrosis factor ligand superfamily member 13B inhibitor ,INHIBITOR ,single protein 
1339,GARLIC,CHEMBL2108463,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['HP_0003124', 'EFO_0004192', 'EFO_1000893', 'MONDO_0018906']",False,False,4,,,
1340,VADADUSTAT,CHEMBL3646221,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000129521', 'ENSG00000135766', 'ENSG00000269858']","['EFO_0001421', 'EFO_0003884', 'EFO_0004272']",False,False,3,Egl nine homolog 3 inhibitor Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor Egl nine homolog 1 inhibitor ,INHIBITOR ,single protein 
1341,STREPTOMYCIN,CHEMBL372795,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 8 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1946,[],"['EFO_0009425', 'EFO_0003103', 'EFO_0007291', 'EFO_1001444', 'EFO_0000544', 'EFO_0000771', 'MONDO_0000327', 'EFO_0003106', 'EFO_0003102', 'EFO_0007481', 'EFO_0007386', 'MONDO_0018076']",False,False,12,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1342,SATRAPLATIN,CHEMBL3833367,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004992', 'MONDO_0008315', 'MONDO_0008903', 'EFO_0000616', 'EFO_0003060', 'MONDO_0007254']",False,False,6,,,
1343,DORDAVIPRONE,CHEMBL4297310,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000519', 'EFO_0005543', 'EFO_0000616', 'MONDO_0011962', 'EFO_0000198', 'EFO_1001465', 'MONDO_0007254', 'EFO_0000222', 'EFO_1000026', 'EFO_0000220', 'EFO_1001901', 'EFO_0001378']",False,False,12,,,
1344,OLACAFTOR,CHEMBL4297649,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
1345,AMLODIPINE BENZOATE,CHEMBL4594262,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 approved indications.,,4.0,,False,2019,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['EFO_0000400', 'EFO_0003144', 'EFO_0000712', 'EFO_0001645', 'EFO_0000612', 'EFO_0000537']",True,False,6,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1346,INTERFERON ALFA-2B KINOID,CHEMBL4650474,Protein drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007915'],False,False,1,,,
1347,LANINAMIVIR OCTANOATE,CHEMBL467058,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007328', 'MONDO_0004979']",False,False,2,Neuraminidase inhibitor ,INHIBITOR ,single protein 
1348,CARBOPLATIN,CHEMBL1351,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 6 approved and 175 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1989,[],"['MONDO_0002928', 'MONDO_0005147', 'EFO_0000181', 'EFO_1000796', 'EFO_1000292', 'EFO_0002939', 'EFO_0000691', 'EFO_0000681', 'EFO_0003859', 'EFO_1001961', 'EFO_0000196', 'MONDO_0021043', 'EFO_1001951', 'EFO_0000707', 'MONDO_0002367', 'MONDO_0016717', 'MONDO_0021311', 'EFO_0005088', 'MONDO_0004992', 'EFO_0000673', 'EFO_0008524', 'MONDO_0016700', 'MONDO_0002108', 'MONDO_0004669', 'EFO_0007535', 'MONDO_0021364', 'MONDO_0001402', 'MONDO_0000831', 'EFO_1001931', 'EFO_0002499', 'EFO_0000222', 'EFO_0000466', 'EFO_0005537', 'EFO_0003032', 'EFO_0000308', 'Orphanet_145', 'MONDO_0021657', 'EFO_0003863', 'EFO_0003817', 'MONDO_0000873', 'EFO_0004272', 'EFO_0000571', 'MONDO_0008903', 'EFO_1000043', 'EFO_0000537', 'EFO_0001663', 'EFO_0004252', 'EFO_0000549', 'EFO_0002916', 'MONDO_0008627', 'EFO_0004281', 'MONDO_0001187', 'MONDO_0002691', 'EFO_1001471', 'MONDO_0004192', 'MONDO_0021092', 'EFO_0001061', 'MONDO_0001370', 'EFO_1000028', 'EFO_0000228', 'EFO_0004230', 'EFO_0003869', 'MONDO_0004986', 'EFO_0000326', 'EFO_1000613', 'EFO_0003826', 'EFO_1000158', 'MONDO_0011962', 'MONDO_0003478', 'EFO_1001469', 'EFO_0000305', 'EFO_0000198', 'EFO_0004284', 'MONDO_0002974', 'EFO_0008528', 'EFO_0004149', 'EFO_1001465', 'EFO_0000588', 'EFO_1000576', 'EFO_0002618', 'MONDO_0001879', 'MONDO_0007254', 'EFO_0001416', 'MONDO_0018364', 'EFO_0006861', 'MONDO_0001056', 'MONDO_0003510', 'MONDO_0005411', 'EFO_0003060', 'EFO_0006352', 'EFO_0000272', 'EFO_1001331', 'EFO_0009637', 'EFO_0000708', 'EFO_0000432', 'MONDO_0008315', 'EFO_0005952', 'EFO_0003050', 'EFO_0009254', 'MONDO_0003751', 'EFO_0007416', 'MONDO_0024503', 'EFO_0005950', 'EFO_0001378', 'EFO_0000702', 'MONDO_0002087', 'MONDO_0002715', 'EFO_0005543', 'MONDO_0002038', 'EFO_0003893', 'EFO_0002617', 'MONDO_0003196', 'EFO_0000770', 'EFO_0000183', 'EFO_0001075', 'EFO_0003100', 'MONDO_0003001', 'EFO_1001187', 'EFO_0000403', 'EFO_0000309', 'MONDO_0002358', 'EFO_1001767', 'EFO_0005567', 'MONDO_0002158', 'EFO_0000637', 'EFO_0000389', 'EFO_0005235', 'EFO_0004243', 'EFO_1000251', 'EFO_0000616', 'MONDO_0019004', 'MONDO_0002120', 'EFO_0000501', 'EFO_0005221', 'EFO_0000514', 'EFO_1001100', 'EFO_0002501', 'EFO_0000701', 'EFO_1000984', 'MONDO_0021117', 'MONDO_0044926', 'MONDO_0100342', 'EFO_0000564', 'EFO_1000581', 'EFO_0000502', 'MONDO_0009348', 'EFO_0003868', 'EFO_0000519', 'EFO_0000313', 'MONDO_0018944', 'EFO_0000621', 'EFO_0003833', 'EFO_0000199', 'MONDO_0011719', 'EFO_0005922', 'EFO_0002938', 'EFO_1001512', 'EFO_1001968', 'EFO_1001956', 'MONDO_0001657', 'MONDO_0007576', 'MONDO_0008170', 'EFO_0000096', 'MONDO_0002898', 'EFO_0000630', 'EFO_0002428', 'EFO_0000641', 'EFO_0003897', 'EFO_0003843', 'MONDO_0044704', 'EFO_0000565', 'EFO_0006859', 'EFO_0000574', 'MONDO_0018906', 'MONDO_0001528', 'MONDO_0019471', 'MONDO_0008380', 'EFO_0006772', 'EFO_0000764', 'EFO_0000756', 'EFO_0000182']",False,False,181,,,
1349,NIFEDIPINE,CHEMBL193,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 15 investigational indications.,,4.0,,False,1981,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['MONDO_0018479', 'HP_0000093', 'EFO_1001145', 'EFO_0000401', 'EFO_0003917', 'EFO_1001375', 'EFO_0003890', 'EFO_0004263', 'EFO_0009660', 'EFO_0007442', 'HP_0012390', 'MONDO_0005149', 'EFO_0000668', 'EFO_0003884', 'EFO_0004225', 'EFO_0000319', 'EFO_0000537', 'EFO_0004253']",True,False,18,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1350,DEXAMETHASONE SODIUM PHOSPHATE,CHEMBL2021430,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 69 approved and 12 investigational indications.,,4.0,,False,1959,['ENSG00000113580'],"['EFO_1000941', 'EFO_1000684', 'MONDO_0007915', 'EFO_0000556', 'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719', 'EFO_1000039', 'EFO_1000764', 'MONDO_0002406', 'EFO_1002022', 'EFO_1000997', 'EFO_1001896', 'EFO_0000574', 'HP_0001915', 'EFO_0000676', 'EFO_0001642', 'EFO_1001051', 'MONDO_0005178', 'HP_0012424', 'EFO_0005558', 'HP_0001873', 'EFO_0005854', 'EFO_0007257', 'MONDO_0100096', 'EFO_0004276', 'EFO_1001250', 'EFO_0006738', 'EFO_0005319', 'EFO_0000729', 'EFO_1000049', 'EFO_0007141', 'EFO_0009491', 'EFO_0001378', 'EFO_0009552', 'EFO_0003929', 'EFO_0005752', 'EFO_0004265', 'HP_0000559', 'EFO_0007490', 'EFO_0008997', 'EFO_1000845', 'EFO_1001194', 'EFO_0007403', 'EFO_0004255', 'EFO_0004274', 'MONDO_0015128', 'EFO_1001119', 'EFO_0003778', 'EFO_0003898', 'EFO_0000694', 'EFO_0002609', 'EFO_0000565', 'MONDO_0003005', 'MONDO_0019338', 'EFO_1001222', 'EFO_0003956', 'MONDO_0004992', 'EFO_0003106', 'EFO_0000685', 'EFO_0000384', 'MP_0001845', 'EFO_0009456', 'HP_0004398', 'HP_0003072', 'EFO_0003894', 'EFO_0007405', 'MONDO_0004979', 'EFO_0005539', 'EFO_0009449', 'EFO_0007520', 'HP_0001094', 'EFO_1001205', 'HP_0001742', 'MONDO_0001280', 'HP_0003040', 'EFO_1000694', 'EFO_0007160', 'EFO_1001435', 'EFO_0000274']",True,False,81,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1351,VITESPEN,CHEMBL2108060,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000158', 'MONDO_0018906', 'EFO_0000095', 'EFO_0000756', 'EFO_0000681', 'EFO_0002618', 'EFO_1000028', 'EFO_0000519', 'EFO_0003060', 'EFO_1001465', 'MONDO_0016700', 'EFO_0000691']",False,False,12,,,
1352,DILTIAZEM,CHEMBL23,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 24 investigational indications.,,4.0,,False,1982,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['EFO_0002687', 'EFO_0000701', 'MONDO_0000831', 'EFO_1001375', 'EFO_0000195', 'HP_0003124', 'EFO_0003890', 'EFO_0000537', 'EFO_0000537', 'EFO_0009660', 'EFO_0000538', 'EFO_0003144', 'EFO_1001951', 'EFO_0000275', 'EFO_0009552', 'EFO_0004225', 'EFO_0007328', 'EFO_0001645', 'MONDO_0004992', 'EFO_0003914', 'HP_0012390', 'EFO_0000319', 'MONDO_0100096', 'MONDO_0005148', 'EFO_0000275', 'EFO_0005251', 'HP_0012390', 'EFO_0003913', 'EFO_0000764', 'HP_0002019']",False,False,30,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1353,RIBOCICLIB,CHEMBL3545110,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 34 investigational indications.,,4.0,,False,2017,"['ENSG00000135446', 'ENSG00000105810']","['MONDO_0002158', 'EFO_0003085', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000569', 'EFO_0000519', 'EFO_0002499', 'EFO_0000182', 'EFO_0005701', 'EFO_0000220', 'EFO_1001968', 'EFO_0000574', 'MONDO_0007254', 'EFO_0000313', 'EFO_0000181', 'EFO_0000305', 'EFO_0001075', 'EFO_0000196', 'MONDO_0004992', 'EFO_1001901', 'EFO_0002626', 'EFO_0000305', 'EFO_1001100', 'EFO_0000756', 'EFO_0000616', 'EFO_0003859', 'EFO_1000251', 'EFO_0003869', 'MONDO_0002601', 'EFO_0003086', 'EFO_0005220', 'EFO_1000026', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0007254', 'EFO_0000621']",True,False,37,Cyclin-dependent kinase 4 inhibitor Cyclin-dependent kinase 6 inhibitor ,INHIBITOR ,single protein 
1354,TEZEPELUMAB,CHEMBL3707229,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for asthma and airway obstruction and has 4 investigational indications.,,4.0,,False,2021,['ENSG00000145777'],"['MONDO_0004979', 'EFO_0000274', 'EFO_0005531', 'EFO_0000341', 'HP_0006536', 'MONDO_0005271']",False,False,6,Thymic stromal lymphopoietin inhibitor ,INHIBITOR ,single protein 
1355,LENABASUM,CHEMBL456341,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000398', 'EFO_0000404', 'MONDO_0007915', 'MONDO_0009061']",False,False,4,,,
1356,CSL-324,CHEMBL4650461,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000119535'],['MONDO_0100096'],True,False,1,Granulocyte colony stimulating factor receptor antagonist ,ANTAGONIST ,single protein 
1357,DFP-13318,CHEMBL5095369,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0004992', 'EFO_0000702']",False,False,2,,,
1358,AMIODARONE,CHEMBL633,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,['ENSG00000055118'],"['EFO_0004269', 'EFO_0004287', 'EFO_0000373', 'EFO_0007243', 'HP_0004755', 'MONDO_0100096', 'EFO_0001645', 'EFO_0005529', 'MONDO_0019438', 'EFO_0005306', 'EFO_0003911', 'EFO_0000612', 'EFO_0009492', 'EFO_0004287', 'EFO_0003144', 'EFO_0004278', 'EFO_0005306', 'EFO_0000275', 'HP_0004308', 'EFO_0000275', 'HP_0004308', 'EFO_0000318']",False,False,22,HERG blocker ,BLOCKER ,single protein 
1359,OLMESARTAN MEDOXOMIL,CHEMBL1200692,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,['ENSG00000144891'],"['MONDO_0002462', 'EFO_0000401', 'EFO_0000319', 'EFO_0003086', 'EFO_0003144', 'EFO_0000400', 'EFO_0003914', 'HP_0000093', 'MONDO_0001134', 'EFO_0000712', 'EFO_0000537', 'EFO_0000612']",False,False,12,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
1360,IRSOGLADINE,CHEMBL136497,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000217', 'HP_0004398', 'EFO_0009454']",False,False,3,,,
1361,MINOCYCLINE,CHEMBL1434,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 9 approved and 66 investigational indications.,,4.0,,False,1971,[],"['EFO_0002615', 'EFO_0009854', 'EFO_0000771', 'EFO_0008517', 'EFO_1000714', 'EFO_0000649', 'EFO_1001919', 'EFO_0004240', 'EFO_0000685', 'MP_0001914', 'MONDO_0004979', 'MONDO_0009061', 'EFO_0003929', 'EFO_0000519', 'EFO_0001378', 'EFO_1001951', 'EFO_0009430', 'MONDO_0010383', 'EFO_0000649', 'EFO_0003102', 'MONDO_0043510', 'EFO_1000760', 'EFO_0004364', 'EFO_0004268', 'EFO_1001390', 'EFO_0000544', 'MONDO_0008903', 'MONDO_0005180', 'MONDO_0005090', 'EFO_0005407', 'EFO_0002618', 'EFO_0000768', 'EFO_0001072', 'EFO_0000701', 'EFO_0006859', 'EFO_0005687', 'EFO_0003758', 'EFO_0005773', 'EFO_0003756', 'EFO_0000305', 'EFO_0007410', 'EFO_0009450', 'EFO_0003761', 'HP_0002107', 'EFO_0003106', 'MONDO_0007935', 'EFO_0003894', 'MONDO_0019200', 'EFO_0000764', 'MONDO_0002050', 'EFO_1001931', 'MONDO_0007113', 'EFO_0001365', 'MONDO_0100342', 'EFO_1002047', 'MONDO_0005301', 'EFO_0005411', 'EFO_0004242', 'EFO_0003060', 'EFO_0003894', 'MONDO_0007079', 'MONDO_0004985', 'MONDO_0007576', 'EFO_1001391', 'EFO_0000544', 'EFO_0000275', 'EFO_0000712', 'EFO_1001157', 'MONDO_0002009', 'EFO_0000326', 'MONDO_0007739', 'MONDO_0024355', 'EFO_0000537', 'EFO_0005669', 'MONDO_0004976', 'HP_0012532', 'EFO_1000760']",False,False,77,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1362,CEFTOBIPROLE MEDOCARIL,CHEMBL1652606,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001849', 'EFO_0000544', 'EFO_0000771', 'EFO_0003033', 'MONDO_0021108', 'EFO_0000701', 'EFO_0000771', 'EFO_0005681', 'EFO_0003106']",False,False,9,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1363,ALICAFORSEN,CHEMBL2108326,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000090339'],"['EFO_0003767', 'EFO_0000729', 'EFO_0000384', 'EFO_0003921']",False,False,4,Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
1364,BEDORADRINE SULFATE,CHEMBL2218893,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000169252'],"['MONDO_0004979', 'EFO_0000341', 'EFO_0008590']",False,False,3,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1365,LY2452473,CHEMBL3542265,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000169083'],"['MONDO_0008315', 'EFO_0004234', 'EFO_0000284']",False,False,3,Androgen Receptor modulator ,MODULATOR ,single protein 
1366,NARSOPLIMAB,CHEMBL4298195,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000009724'],"['MONDO_0016244', 'EFO_0005761', 'MONDO_0100096', 'EFO_0004194']",False,False,4,Mannan-binding lectin serine protease 2 inhibitor ,INHIBITOR ,single protein 
1367,ICOSAPENT,CHEMBL460026,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 48 investigational indications.,,3.0,,False,no approval year,[],"['MP_0001845', 'EFO_0001645', 'EFO_0009431', 'HP_0001397', 'MONDO_0001751', 'EFO_0005411', 'EFO_0001421', 'MONDO_0002009', 'EFO_0006861', 'EFO_1001917', 'EFO_0003890', 'EFO_0001073', 'EFO_0000432', 'GO_0007568', 'MONDO_0007254', 'EFO_0000673', 'EFO_1001951', 'EFO_0003095', 'MONDO_0002050', 'HP_0004326', 'EFO_0003756', 'EFO_0004220', 'EFO_0003144', 'Orphanet_733', 'EFO_0000685', 'MONDO_0005301', 'EFO_0004194', 'EFO_0003884', 'EFO_0000474', 'MONDO_0018906', 'MONDO_0100096', 'EFO_0005203', 'EFO_0000339', 'MONDO_0004985', 'EFO_0003086', 'EFO_0004211', 'MONDO_0004979', 'EFO_0000319', 'EFO_0001378', 'EFO_0008509', 'EFO_1000783', 'MONDO_0004992', 'MONDO_0005090', 'EFO_0011023', 'EFO_0000565', 'EFO_0005406', 'MONDO_0007915', 'HP_0002039']",False,False,48,,,
1368,ESTRAMUSTINE PHOSPHATE SODIUM,CHEMBL1200721,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for neoplasm and carcinoma and has 5 investigational indications.,,4.0,,False,1981,['ENSG00000140009'],"['EFO_0000673', 'MONDO_0008315', 'EFO_0000574', 'EFO_0000616', 'MONDO_0002367', 'MONDO_0007254', 'EFO_0000313']",False,False,7,Estrogen receptor beta modulator ,MODULATOR ,single protein 
1369,PRAZOSIN,CHEMBL2,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for hypertension and diabetes mellitus and has 9 investigational indications.,,4.0,,False,1976,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0004777', 'EFO_0004701', 'EFO_0000537', 'EFO_0000537', 'EFO_0003768', 'EFO_0000400', 'MONDO_0100096', 'EFO_0005230', 'MONDO_0007079', 'HP_0000011', 'EFO_0001358', 'EFO_0004253']",False,False,12,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
1370,LITRONESIB,CHEMBL2105661,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,2.0,,False,no approval year,['ENSG00000138160'],"['EFO_1001951', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000565', 'EFO_0000702', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0008315', 'EFO_0006859', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0004992']",False,False,12,Kinesin-like protein 1 inhibitor ,INHIBITOR ,single protein 
1371,ETIPREDNOL DICLOACETATE,CHEMBL2107614,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000384'],False,False,1,,,
1372,ROXADUSTAT,CHEMBL2338329,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anemia (phenotype) and has 4 investigational indications.,,4.0,,False,no approval year,"['ENSG00000269858', 'ENSG00000178467', 'ENSG00000135766', 'ENSG00000129521']","['EFO_0004272', 'EFO_0000198', 'EFO_0003086', 'EFO_0008585', 'EFO_0003884']",False,False,5,Hypoxia-inducible factor prolyl hydroxylase inhibitor ,INHIBITOR ,protein family 
1373,VELSECORAT,CHEMBL3666807,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000113580'],"['EFO_0000341', 'MONDO_0004979']",False,True,2,Glucocorticoid receptor modulator ,MODULATOR ,single protein 
1374,VIS-410,CHEMBL4594613,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,Hemagglutinin inhibitor ,INHIBITOR ,single protein 
1375,CISPLATIN,CHEMBL11359,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for cancer and neoplasm and has 178 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,[],"['MONDO_0002715', 'MONDO_0002108', 'MONDO_0003060', 'EFO_1000796', 'EFO_0000182', 'EFO_0000183', 'EFO_0005950', 'EFO_1000437', 'EFO_0005922', 'EFO_0000365', 'MONDO_0004992', 'EFO_0003866', 'EFO_1000564', 'EFO_0009637', 'MONDO_0002601', 'EFO_0008524', 'EFO_0000621', 'EFO_0000096', 'MONDO_0002358', 'EFO_1001961', 'MONDO_0003751', 'EFO_0006859', 'EFO_1001898', 'EFO_0003859', 'EFO_0000181', 'EFO_0000616', 'MONDO_0021657', 'EFO_0000466', 'EFO_1000292', 'MONDO_0004986', 'EFO_0003860', 'EFO_0003833', 'EFO_0008549', 'MONDO_0001187', 'EFO_0004230', 'MONDO_0001325', 'MONDO_0002087', 'EFO_0000574', 'EFO_0005235', 'MONDO_0019472', 'EFO_0000502', 'EFO_0000503', 'EFO_0001378', 'MONDO_0021310', 'EFO_1000574', 'EFO_0003050', 'EFO_1002017', 'EFO_0004284', 'EFO_0000681', 'EFO_0000211', 'MONDO_0044903', 'EFO_0003817', 'EFO_0000389', 'MONDO_0003478', 'EFO_0004281', 'EFO_0005577', 'EFO_0005088', 'EFO_0005537', 'EFO_0000326', 'EFO_0000770', 'EFO_0000255', 'EFO_0001068', 'MONDO_0001879', 'EFO_0004272', 'MONDO_0044704', 'MONDO_0003001', 'MONDO_0001528', 'MONDO_0007254', 'EFO_0007362', 'MONDO_0001056', 'EFO_0002617', 'MONDO_0008315', 'EFO_0001416', 'EFO_0005570', 'EFO_1001931', 'EFO_0003869', 'EFO_1001959', 'EFO_0004252', 'EFO_0002938', 'EFO_0003863', 'EFO_0008528', 'MONDO_0002974', 'EFO_0000565', 'EFO_1000251', 'EFO_1001100', 'EFO_0004142', 'EFO_0003032', 'EFO_1001469', 'EFO_0003826', 'MONDO_0021364', 'EFO_0000514', 'EFO_0000756', 'MONDO_0004669', 'MONDO_0021355', 'MONDO_0011962', 'EFO_0003868', 'MONDO_0016717', 'EFO_0000178', 'EFO_0000707', 'EFO_1000984', 'EFO_1001960', 'MONDO_0009348', 'EFO_0007416', 'EFO_0000228', 'EFO_0000313', 'EFO_0006911', 'MONDO_0100342', 'MONDO_0002038', 'EFO_1001471', 'MONDO_0003199', 'HP_0002017', 'EFO_0002618', 'EFO_0009869', 'EFO_0000198', 'MONDO_0002120', 'EFO_0005543', 'EFO_0005221', 'MONDO_0002367', 'EFO_0009688', 'EFO_1000415', 'EFO_0010282', 'EFO_0002939', 'EFO_0002626', 'MONDO_0021148', 'EFO_0001071', 'MONDO_0004192', 'MONDO_0021117', 'EFO_0004606', 'EFO_0004243', 'EFO_0003060', 'MONDO_0016700', 'EFO_0002916', 'EFO_0003897', 'MONDO_0007576', 'EFO_1001951', 'MONDO_0044926', 'EFO_0000199', 'MONDO_0001657', 'EFO_1001365', 'EFO_0000637', 'EFO_0000588', 'EFO_0009708', 'MONDO_0008170', 'EFO_1001956', 'EFO_1000158', 'EFO_0000403', 'EFO_0001061', 'MONDO_0008903', 'EFO_0005952', 'EFO_0000571', 'MONDO_0018944', 'MONDO_0005411', 'EFO_0000294', 'EFO_0003086', 'EFO_0001421', 'EFO_1001904', 'MONDO_0002898', 'EFO_0000691', 'EFO_0002918', 'MONDO_0011719', 'MONDO_0019471', 'EFO_0002517', 'MONDO_0008380', 'EFO_1001968', 'EFO_0003893', 'EFO_0000708', 'MONDO_0002158', 'MONDO_0005575', 'EFO_0000305', 'EFO_0001075', 'EFO_0004193', 'EFO_0000702', 'EFO_1000576', 'EFO_0003871', 'MONDO_0002691', 'EFO_0006352', 'EFO_0003891', 'EFO_0006772', 'EFO_1000581', 'EFO_1000043']",False,False,180,,,
1376,IPRAGLIFLOZIN,CHEMBL2018096,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000140675'],"['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400']",False,False,3,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1377,PATRITUMAB,CHEMBL2109406,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000065361'],"['EFO_0000181', 'EFO_0003060', 'EFO_0004284', 'EFO_0003968', 'EFO_0000616', 'EFO_0005537']",False,False,6,Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
1378,AZD4818,CHEMBL2178570,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000163823'],['EFO_0000341'],False,False,1,C-C chemokine receptor type 1 antagonist ,ANTAGONIST ,single protein 
1379,ZANUBRUTINIB,CHEMBL3936761,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 14 investigational indications.,,4.0,,False,2019,['ENSG00000010671'],"['MONDO_0015540', 'EFO_0004256', 'MONDO_0004992', 'EFO_0005761', 'EFO_0000096', 'MONDO_0017287', 'EFO_1001469', 'EFO_0000403', 'EFO_0000616', 'EFO_0000095', 'MONDO_0015564', 'EFO_0007160', 'MONDO_0100096', 'EFO_0009441', 'MONDO_0018906', 'EFO_0000565', 'EFO_0000574']",True,False,17,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1380,PERAMIVIR,CHEMBL3989402,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for influenza.,,4.0,,False,2014,[],['EFO_0007328'],False,False,1,Neuraminidase inhibitor ,INHIBITOR ,single protein 
1381,BICALUTAMIDE,CHEMBL409,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for carcinoma and neoplasm and has 16 investigational indications.,,4.0,,False,1995,['ENSG00000169083'],"['EFO_0000196', 'MONDO_0002087', 'MONDO_0001187', 'EFO_0000313', 'EFO_0003869', 'MONDO_0000088', 'MONDO_0002158', 'EFO_0000694', 'MONDO_0008170', 'EFO_0000305', 'MONDO_0100096', 'EFO_0001663', 'EFO_0000673', 'MONDO_0008315', 'HP_0000771', 'EFO_0000616', 'MONDO_0004669', 'MONDO_0007254']",True,False,18,Androgen Receptor antagonist ,ANTAGONIST ,single protein 
1382,LANSOPRAZOLE,CHEMBL480,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 21 investigational indications.,,4.0,,False,1995,"['ENSG00000105675', 'ENSG00000186009']","['MONDO_0007254', 'MONDO_0011962', 'EFO_0000095', 'EFO_0000768', 'EFO_1001355', 'EFO_0003843', 'EFO_0000574', 'EFO_0004274', 'EFO_0003917', 'EFO_0004607', 'EFO_0000616', 'EFO_1001095', 'MONDO_0005178', 'EFO_0007456', 'EFO_1000961', 'EFO_0003948', 'MONDO_0005147', 'EFO_1000657', 'EFO_0009454', 'HP_0004398', 'MONDO_0002974', 'EFO_0004232', 'MONDO_0009061', 'EFO_0000217']",False,False,24,Potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex 
1383,PAQUINIMOD,CHEMBL67776,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007915', 'EFO_0000717']",False,False,2,,,
1384,MEDROXYPROGESTERONE ACETATE,CHEMBL717,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 6 approved and 26 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1959,['ENSG00000082175'],"['MONDO_0011962', 'EFO_0000536', 'MONDO_0007915', 'EFO_0000198', 'EFO_0000545', 'EFO_0000400', 'EFO_0000616', 'HP_0031217', 'HP_0000132', 'EFO_0001065', 'EFO_0000180', 'EFO_0000764', 'EFO_1001375', 'HP_0008209', 'EFO_0003843', 'EFO_0000681', 'EFO_0000537', 'EFO_0003882', 'MONDO_0019499', 'EFO_0002890', 'MP_0001914', 'MONDO_0002367', 'EFO_0000673', 'MONDO_0000831', 'EFO_0001645', 'HP_0003124', 'EFO_0004230', 'EFO_0003877', 'MONDO_0004975', 'EFO_0002950', 'EFO_0003777', 'EFO_0003922']",False,False,32,Progesterone receptor agonist ,AGONIST ,single protein 
1385,PANITUMUMAB,CHEMBL1201827,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 24 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2006,['ENSG00000146648'],"['EFO_0000616', 'EFO_0000181', 'EFO_0000707', 'MONDO_0007576', 'EFO_1000657', 'EFO_0006859', 'MONDO_0008170', 'EFO_1000852', 'EFO_0000681', 'EFO_0000503', 'EFO_0000365', 'MONDO_0021063', 'MONDO_0008903', 'EFO_0000313', 'EFO_0005922', 'EFO_0002618', 'MONDO_0005575', 'EFO_0004142', 'EFO_0005221', 'MONDO_0002158', 'MONDO_0002974', 'MONDO_0008315', 'MONDO_0002367', 'MONDO_0004992', 'EFO_1001951', 'MONDO_0001187', 'MONDO_0007254', 'EFO_0002916', 'EFO_0000305', 'EFO_0003060']",False,True,30,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1386,SORAFENIB,CHEMBL1336,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 9 approved and 107 investigational indications.,,4.0,,False,2005,"['ENSG00000157764', 'ENSG00000122025', 'ENSG00000132155', 'ENSG00000113721', 'ENSG00000165731', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']","['MONDO_0004192', 'EFO_0000691', 'EFO_0000673', 'EFO_0001061', 'EFO_0000198', 'EFO_1001968', 'EFO_0000756', 'MONDO_0018531', 'EFO_0000641', 'EFO_0004212', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0008903', 'EFO_0000182', 'EFO_0008524', 'EFO_0000756', 'MONDO_0008170', 'EFO_0000182', 'EFO_0000691', 'EFO_0003060', 'EFO_0001361', 'EFO_1001968', 'EFO_1001465', 'EFO_0000574', 'EFO_0003833', 'MONDO_0000831', 'EFO_1000657', 'MONDO_0004992', 'MONDO_0002108', 'EFO_0002499', 'EFO_0000588', 'EFO_1001469', 'EFO_0000501', 'EFO_0000313', 'EFO_1000796', 'EFO_0000702', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0044937', 'EFO_0003891', 'EFO_0000666', 'EFO_0000095', 'EFO_0001378', 'EFO_0000224', 'EFO_0000196', 'MONDO_0008315', 'EFO_0002618', 'EFO_0003833', 'EFO_0000519', 'EFO_0002499', 'EFO_0000640', 'EFO_0000565', 'EFO_0000221', 'MONDO_0007576', 'MONDO_0011719', 'EFO_0009907', 'EFO_0000558', 'EFO_1001465', 'EFO_0000621', 'EFO_0000702', 'EFO_1000158', 'EFO_0000095', 'MONDO_0001187', 'EFO_1001901', 'MONDO_0002087', 'EFO_1001346', 'EFO_0000222', 'EFO_1000657', 'EFO_0000501', 'EFO_0003865', 'EFO_0003893', 'MONDO_0015277', 'MONDO_0001187', 'EFO_0000403', 'EFO_0003841', 'MONDO_0002691', 'EFO_0000335', 'EFO_0000637', 'MONDO_0011719', 'EFO_0000349', 'EFO_0006352', 'EFO_0006861', 'EFO_0002501', 'EFO_0000389', 'MONDO_0007254', 'MONDO_0002367', 'EFO_0004142', 'MONDO_0004992', 'EFO_0002918', 'EFO_0000224', 'EFO_0007535', 'EFO_1000292', 'MONDO_0008315', 'EFO_0000220', 'EFO_0000228', 'EFO_0000222', 'MONDO_0008903', 'EFO_0000616', 'EFO_0002618', 'EFO_0000616', 'EFO_0002618', 'MONDO_0001056', 'EFO_1000613', 'EFO_0003860', 'MONDO_0021063', 'EFO_0005221', 'EFO_0002938', 'EFO_0000182', 'EFO_0000707', 'MONDO_0044926', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000339', 'MONDO_0004986', 'EFO_0000641', 'EFO_0003060', 'EFO_0004284', 'EFO_0001421', 'MONDO_0007254', 'EFO_0002501', 'MONDO_0002108', 'EFO_0000222', 'EFO_0000681', 'EFO_1001951', 'MONDO_0002108', 'EFO_0000519', 'EFO_0000588', 'MONDO_0002367', 'EFO_0003086', 'EFO_0003060', 'EFO_0002892', 'EFO_0004252', 'EFO_0000616', 'EFO_0000681', 'EFO_0005088', 'EFO_0000637', 'EFO_0001378', 'EFO_0003871', 'EFO_0002892', 'EFO_0004252', 'EFO_0003032', 'EFO_0000220', 'MONDO_0002158']",True,True,143,Vascular endothelial growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Serine/threonine-protein kinase RAF inhibitor Serine/threonine-protein kinase B-raf inhibitor Tyrosine-protein kinase receptor RET inhibitor Platelet-derived growth factor receptor beta inhibitor ,INHIBITOR ,protein family single protein 
1387,LIOTHYRONINE,CHEMBL1544,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1956,"['ENSG00000126351', 'ENSG00000151090']","['EFO_0003144', 'EFO_1000931', 'EFO_0006859', 'EFO_0004705', 'MONDO_0008315', 'EFO_0003929', 'EFO_0003840', 'MONDO_0007254', 'EFO_0000275', 'EFO_0003841', 'HP_0030680', 'MONDO_0002050', 'EFO_0004705', 'EFO_0005207', 'EFO_0006834', 'HP_0030680', 'EFO_1001465', 'EFO_1002017', 'EFO_0003761', 'MONDO_0004985', 'EFO_1001055', 'MONDO_0005301']",True,False,22,Thyroid hormone receptor agonist ,AGONIST ,protein complex 
1388,TALAPORFIN SODIUM,CHEMBL2107806,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002499', 'EFO_0000519', 'EFO_0004683', 'EFO_0000284', 'EFO_0000182']",False,False,5,,,
1389,TOFIMILAST,CHEMBL217899,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['EFO_0000341', 'MONDO_0004979']",True,False,2,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
1390,MOCETINOSTAT,CHEMBL272980,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications.,,2.0,,False,no approval year,"['ENSG00000147099', 'ENSG00000163517', 'ENSG00000196591', 'ENSG00000171720', 'ENSG00000116478']","['EFO_0000574', 'EFO_0000183', 'EFO_0003060', 'MONDO_0018906', 'EFO_0008528', 'EFO_0000222', 'EFO_0000565', 'EFO_0000095', 'EFO_0000616', 'EFO_0000198', 'EFO_0002918', 'EFO_0000199', 'EFO_0000564', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0008903']",False,False,16,Histone deacetylase 3 inhibitor Histone deacetylase 8 inhibitor Histone deacetylase 2 inhibitor Histone deacetylase 11 inhibitor Histone deacetylase 1 inhibitor ,INHIBITOR ,single protein 
1391,TALAZOPARIB,CHEMBL3137320,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 24 investigational indications.,,4.0,,False,2018,"['ENSG00000143799', 'ENSG00000129484']","['EFO_0000196', 'EFO_0008528', 'EFO_0005537', 'EFO_0003869', 'EFO_0005537', 'Orphanet_145', 'EFO_0003869', 'MONDO_0008170', 'EFO_0003060', 'EFO_0000222', 'EFO_0000616', 'MONDO_0007254', 'EFO_0000519', 'EFO_0001075', 'EFO_0000708', 'EFO_1001901', 'EFO_0003060', 'EFO_0000305', 'MONDO_0008315', 'EFO_0000681', 'EFO_0000565', 'EFO_0000616', 'MONDO_0007254', 'EFO_1001951', 'EFO_0000702', 'EFO_0000673', 'EFO_0002618', 'EFO_0000222', 'MONDO_0011962', 'EFO_0003968', 'MONDO_0004992', 'MONDO_0044881']",True,False,32,Poly [ADP-ribose] polymerase 2 inhibitor Poly [ADP-ribose] polymerase-1 inhibitor ,INHIBITOR ,single protein 
1392,ROCAPULDENCEL-T,CHEMBL3545128,Cell drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000681', 'EFO_0003060']",False,False,2,,,
1393,GEDIVUMAB,CHEMBL4298040,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,Hemagglutinin inhibitor ,INHIBITOR ,single protein 
1394,AG0302-COVID19,CHEMBL4650372,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1395,NIRMATRELVIR,CHEMBL4802135,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003086', 'EFO_0001421', 'MONDO_0100096']",False,False,3,,,
1396,REBIMASTAT,CHEMBL76222,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000118113', 'ENSG00000157227', 'ENSG00000137745', 'ENSG00000196611', 'ENSG00000100985', 'ENSG00000087245']","['MONDO_0008903', 'MONDO_0007254', 'EFO_0000673', 'EFO_0000691']",True,False,4,Matrix metalloproteinase 13 inhibitor Matrix metalloproteinase 8 inhibitor Matrix metalloproteinase-1 inhibitor Matrix metalloproteinase 14 inhibitor Matrix metalloproteinase-2 inhibitor Matrix metalloproteinase 9 inhibitor ,INHIBITOR ,single protein 
1397,IFOSFAMIDE,CHEMBL1024,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 5 approved and 69 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1988,[],"['EFO_0000564', 'EFO_1001042', 'MONDO_0011934', 'EFO_0005088', 'EFO_0002428', 'EFO_0005561', 'EFO_1001365', 'EFO_0000574', 'EFO_0001376', 'EFO_0002618', 'EFO_0000637', 'EFO_0000220', 'EFO_0000198', 'MONDO_0000870', 'EFO_0007143', 'EFO_0000437', 'MONDO_0007254', 'MONDO_0005094', 'MONDO_0008170', 'EFO_0000239', 'MONDO_0002974', 'EFO_0000222', 'MONDO_0002087', 'EFO_0009708', 'MONDO_0002715', 'EFO_0000760', 'EFO_1001968', 'MONDO_0017387', 'MONDO_0002158', 'EFO_0000569', 'EFO_0003060', 'EFO_0003032', 'MONDO_0000873', 'EFO_1001469', 'EFO_0000183', 'MONDO_0002601', 'MONDO_0019004', 'EFO_0000621', 'EFO_0000691', 'EFO_0000326', 'MONDO_0018906', 'EFO_1000158', 'MONDO_0003751', 'EFO_0000174', 'EFO_0003968', 'EFO_0000702', 'EFO_0000209', 'MONDO_0009348', 'EFO_0002918', 'MONDO_0003510', 'MONDO_0001325', 'MONDO_0002678', 'EFO_0004252', 'EFO_0000514', 'EFO_0000248', 'EFO_0005952', 'MONDO_0001187', 'EFO_1000251', 'EFO_0000403', 'EFO_1000613', 'EFO_0000211', 'MONDO_0004992', 'EFO_0004281', 'EFO_0007362', 'EFO_0000096', 'MONDO_0008903', 'EFO_0000309', 'MONDO_0004192', 'MONDO_0011962', 'EFO_0000313', 'EFO_0000616', 'EFO_0001378', 'MONDO_0002367', 'EFO_0000565']",False,False,74,,,
1398,MITOQUINONE CATION,CHEMBL1229093,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000407', 'MONDO_0005180', 'EFO_0004220', 'MONDO_0100096', 'EFO_0003095', 'GO_0007568', 'EFO_0000729']",False,False,7,,,
1399,APREPITANT,CHEMBL1471,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 5 approved and 17 investigational indications.,,4.0,,False,2003,['ENSG00000115353'],"['EFO_0006911', 'HP_0002013', 'EFO_0004888', 'EFO_0002610', 'HP_0002017', 'EFO_0005611', 'EFO_0000514', 'MONDO_0100096', 'HP_0000989', 'EFO_0000519', 'HP_0002018', 'EFO_0004240', 'EFO_0003060', 'EFO_0007191', 'EFO_0000764', 'EFO_0000222', 'EFO_1000948', 'EFO_0001378', 'MONDO_0004992', 'EFO_0003843', 'MONDO_0007079', 'MONDO_0002009']",False,False,22,Neurokinin 1 receptor antagonist ,ANTAGONIST ,single protein 
1400,SOMATOSTATIN,CHEMBL1823872,Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,"['ENSG00000162009', 'ENSG00000180616', 'ENSG00000132671', 'ENSG00000139874', 'ENSG00000278195']","['MONDO_0005147', 'EFO_0004606', 'HP_0001399', 'EFO_0000666', 'HP_0004398', 'EFO_1000045', 'EFO_1001496', 'EFO_1000652', 'EFO_0004243', 'EFO_0000182', 'HP_0001943', 'EFO_0000673']",False,False,12,Somatostatin receptor agonist ,AGONIST ,protein family 
1401,METOPROLOL TARTRATE,CHEMBL2062335,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,['ENSG00000043591'],"['EFO_0000712', 'EFO_0000612', 'EFO_0003913', 'EFO_0003144', 'EFO_0000537', 'EFO_0000275', 'EFO_0003777']",False,False,7,Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
1402,LANTHANUM CARBONATE,CHEMBL2096647,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for chronic kidney disease and has 2 investigational indications.,,4.0,,False,2004,[],"['EFO_0003884', 'EFO_0003086', 'HP_0002905']",False,False,3,,,
1403,BARICITINIB,CHEMBL2105759,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for immune system disease and rheumatoid arthritis and has 23 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2018,"['ENSG00000096968', 'ENSG00000162434']","['EFO_1001486', 'EFO_0000699', 'EFO_0000540', 'EFO_1000726', 'EFO_0000694', 'EFO_0000783', 'EFO_0003884', 'EFO_0004192', 'EFO_1001231', 'MONDO_0005147', 'EFO_0000401', 'EFO_0007160', 'EFO_0003106', 'EFO_0000764', 'EFO_0000676', 'EFO_1001209', 'EFO_0000685', 'EFO_0000398', 'EFO_0000274', 'MONDO_0007915', 'EFO_0004208', 'EFO_1000668', 'MONDO_0013730', 'EFO_0002609', 'MONDO_0100096']",True,True,25,Tyrosine-protein kinase JAK2 inhibitor Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
1404,SAW PALMETTO,CHEMBL2108769,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000284', 'MONDO_0008315']",False,False,2,,,
1405,BCG VACCINE,CHEMBL2108905,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.,,3.0,,False,no approval year,[],"['HP_0100806', 'EFO_0000764', 'EFO_0000389', 'EFO_0000684', 'EFO_0000180', 'EFO_1001951', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0100096', 'EFO_0000621', 'EFO_0000691', 'MONDO_0018076', 'MONDO_0004986', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0008903', 'MONDO_0001187', 'EFO_0000544']",False,False,18,,,
1406,FLUVASTATIN,CHEMBL2220442,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 12 investigational indications.,,4.0,,False,1993,['ENSG00000113161'],"['HP_0003124', 'EFO_0004911', 'Orphanet_309005', 'EFO_0003047', 'HP_0003124', 'EFO_0004220', 'EFO_0002689', 'HP_0000802', 'EFO_0005543', 'MONDO_0008315', 'EFO_0000266', 'EFO_0000756', 'MONDO_0007254', 'EFO_0000319', 'MONDO_0018965']",False,False,15,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
1407,RABUSERTIB,CHEMBL3039517,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000149554'],"['EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'EFO_0003860']",False,False,4,Serine/threonine-protein kinase Chk1 inhibitor ,INHIBITOR ,single protein 
1408,TREOSULFAN,CHEMBL455186,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 16 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001642', 'EFO_0005952', 'MONDO_0008170', 'MONDO_0009833', 'MONDO_0000159', 'EFO_0000198', 'EFO_0000616', 'EFO_0000708', 'EFO_0000222', 'EFO_0000183', 'EFO_0000756', 'EFO_0000220', 'EFO_0001378', 'EFO_0003060', 'HP_0012410', 'EFO_0000174', 'MONDO_0013730']",False,False,17,,,
1409,CLEVUDINE,CHEMBL458875,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004197', 'EFO_0000763', 'EFO_0004239', 'MONDO_0100096']",False,False,4,Protein P inhibitor ,INHIBITOR ,single protein 
1410,TOPOTECAN,CHEMBL84,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 9 approved and 72 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000184428'],"['EFO_0000565', 'EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087', 'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617', 'EFO_0000613', 'EFO_0000519', 'EFO_1000158', 'EFO_0000466', 'MONDO_0008380', 'MONDO_0037745', 'MONDO_0100096', 'EFO_0000305', 'EFO_1001465', 'EFO_0000630', 'EFO_0001416', 'EFO_0000616', 'MONDO_0008170', 'EFO_0005543', 'MONDO_0002974', 'EFO_0001378', 'EFO_0000621', 'MONDO_0004992', 'EFO_1001042', 'EFO_1000251', 'EFO_0000681', 'EFO_0003833', 'EFO_0000220', 'EFO_0000691', 'EFO_0008524', 'MONDO_0019004', 'EFO_0000198', 'EFO_1001100', 'EFO_0000502', 'EFO_0003893', 'MONDO_0004992', 'EFO_0002501', 'EFO_0000702', 'EFO_0000616', 'EFO_1000823', 'MONDO_0007576', 'EFO_0005561', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254', 'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'MONDO_0008170', 'EFO_0001075', 'EFO_0001061', 'EFO_0005952', 'EFO_0000313', 'EFO_0000389', 'EFO_0003851', 'EFO_0003060', 'EFO_0003869', 'MONDO_0021063', 'EFO_0000574', 'MONDO_0011962', 'EFO_0000702', 'MONDO_0006058', 'EFO_0000222', 'EFO_1001331', 'EFO_0000621', 'MONDO_0018271', 'EFO_0003060', 'EFO_0003893', 'MONDO_0002974', 'EFO_0007362', 'EFO_0003859', 'MONDO_0018364', 'MONDO_0018364', 'EFO_1000895', 'MONDO_0008315', 'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043']",False,False,82,"DNA topoisomerase I, mitochondrial inhibitor ",INHIBITOR ,single protein 
1411,PYRAZOLOACRIDINE,CHEMBL118841,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000389', 'MONDO_0008903', 'EFO_0000621', 'MONDO_0007254', 'EFO_1000158']",False,False,5,,,
1412,NORKETOTIFEN,CHEMBL1197564,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,,,
1413,HEPARIN SODIUM,CHEMBL1201657,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 9 approved and 49 investigational indications.,,4.0,,False,1939,['ENSG00000117601'],"['MONDO_0005147', 'HP_0000083', 'EFO_0001645', 'HP_0004936', 'EFO_0003964', 'HP_0001907', 'EFO_0000668', 'EFO_1000985', 'HP_0004419', 'EFO_1001904', 'MONDO_0004992', 'EFO_0003103', 'EFO_0002950', 'EFO_0000712', 'EFO_0003033', 'EFO_0000365', 'EFO_0003907', 'EFO_0003106', 'EFO_0000713', 'EFO_0000612', 'MONDO_0002243', 'EFO_0003777', 'EFO_0001073', 'HP_0001919', 'EFO_0000616', 'EFO_1000637', 'EFO_0008585', 'MP_0001914', 'EFO_0006834', 'EFO_0000319', 'HP_0100806', 'EFO_1001129', 'HP_0031273', 'EFO_0000275', 'HP_0004418', 'HP_0002619', 'EFO_0003913', 'EFO_1001375', 'EFO_0003884', 'EFO_0004286', 'EFO_0003966', 'EFO_0003827', 'EFO_0000546', 'MONDO_0021148', 'MONDO_0100096', 'EFO_1001951', 'EFO_0000544', 'EFO_0000266', 'MONDO_0005148', 'MONDO_0000831', 'EFO_0008583', 'EFO_0000771', 'EFO_1002048', 'EFO_0008507', 'EFO_0009516', 'EFO_0000545', 'EFO_0000694', 'EFO_0005672']",False,False,58,Antithrombin-III activator ,ACTIVATOR ,single protein 
1414,EDOXABAN,CHEMBL1269025,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,['ENSG00000126218'],"['EFO_0000275', 'EFO_0000612', 'EFO_0004265', 'EFO_0003827', 'EFO_0000712', 'EFO_0000266', 'EFO_0000694', 'EFO_0009314', 'EFO_0000275', 'EFO_0000712', 'HP_0004419', 'MONDO_0100096', 'EFO_0001645', 'EFO_0004286', 'MP_0001914', 'EFO_0003907', 'EFO_0003777', 'MONDO_0000831', 'HP_0002140', 'EFO_0004286']",False,False,20,Coagulation factor X inhibitor ,INHIBITOR ,single protein 
1415,PYRIDOXINE,CHEMBL1364,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 8 approved and 21 investigational indications.,,4.0,,False,1985,[],"['EFO_1000049', 'HP_0001891', 'EFO_0001378', 'EFO_0004280', 'MONDO_0004975', 'EFO_1001375', 'MONDO_0001437', 'EFO_0000764', 'EFO_0003095', 'EFO_0000612', 'MONDO_0018076', 'MONDO_0018097', 'MONDO_0004992', 'EFO_0003914', 'EFO_0003882', 'EFO_0000474', 'EFO_0003884', 'MONDO_0002280', 'MONDO_0005148', 'EFO_0001070', 'EFO_0003888', 'EFO_1001893', 'MONDO_0018076', 'EFO_0000574', 'HP_0002017', 'EFO_1001951', 'EFO_0005407', 'EFO_0004272', 'EFO_0003144', 'HP_0002017']",False,False,30,,,
1416,BELATACEPT,CHEMBL1742990,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for immune system disease and has 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,"['ENSG00000121594', 'ENSG00000114013']","['HP_0000093', 'EFO_0000540', 'EFO_0004599', 'EFO_0000685', 'MONDO_0005147', 'EFO_0003884']",False,False,6,T-lymphocyte activation antigen CD80 inhibitor T-lymphocyte activation antigen CD86 inhibitor ,INHIBITOR ,single protein 
1417,REMOGLIFLOZIN ETABONATE,CHEMBL2028665,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000140675'],"['MONDO_0005147', 'MONDO_0005148']",False,False,2,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1418,MALTODEXTRIN,CHEMBL2107951,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 25 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0003095', 'GO_0007568', 'MONDO_0100096', 'EFO_0000729', 'EFO_0002622', 'EFO_0000195', 'HP_0002019', 'EFO_0002614', 'EFO_0010282', 'MONDO_0005180', 'EFO_0004599', 'EFO_0000555', 'EFO_0003921', 'MONDO_0002009', 'EFO_1000653', 'EFO_0000544', 'EFO_0003144', 'EFO_1001121', 'HP_0040187', 'MONDO_0043544', 'EFO_0009784', 'HP_0100806', 'HP_0002014', 'EFO_0000274', 'EFO_0003758']",False,False,25,,,
1419,SERIBANTUMAB,CHEMBL3545071,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000065361'],"['MONDO_0007254', 'EFO_0002618']",False,False,2,Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
1420,LITIFILIMAB,CHEMBL3833308,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000198178'],"['EFO_0003834', 'MONDO_0007915']",True,False,2,C-type lectin domain family 4 member C inhibitor ,INHIBITOR ,single protein 
1421,DASIGLUCAGON,CHEMBL4297741,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000215644'],"['MONDO_0005147', 'EFO_0007318', 'MONDO_0017182', 'HP_0001943']",False,False,4,Glucagon receptor agonist ,AGONIST ,single protein 
1422,TIRAGOLUMAB,CHEMBL4298050,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,['ENSG00000181847'],"['MONDO_0004992', 'MONDO_0018906', 'MONDO_0002974', 'EFO_1000657', 'EFO_1001513', 'EFO_0003060', 'EFO_0000702', 'EFO_0000756', 'EFO_0008528', 'EFO_0000181', 'EFO_0000616', 'EFO_0005537', 'MONDO_0001187', 'EFO_0005922', 'EFO_0000503', 'MONDO_0011962', 'EFO_0002916', 'EFO_0000389', 'MONDO_0007576']",True,False,19,T-cell immunoreceptor with Ig and ITIM domains inhibitor ,INHIBITOR ,single protein 
1423,ASTEGOLIMAB,CHEMBL4594385,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000196083', 'ENSG00000115602']","['MONDO_0004979', 'EFO_0000341', 'MONDO_0100096', 'EFO_0000274']",True,False,4,IL-33 receptor (ST2) inhibitor ,INHIBITOR ,protein complex 
1424,BEXMARILIMAB,CHEMBL4594544,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000681', 'MONDO_0004992', 'EFO_0003060']",False,False,3,,,
1425,IODINE,CHEMBL1201225,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 10 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0002108', 'EFO_0003841', 'EFO_0000684', 'EFO_0001378', 'EFO_1000581', 'MONDO_0018531', 'EFO_0003144', 'MONDO_0007254', 'EFO_0004142']",False,False,10,,,
1426,ANAKINRA,CHEMBL1201570,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 55 investigational indications.,,4.0,,False,2001,['ENSG00000115594'],"['EFO_0009672', 'EFO_0000540', 'MONDO_0005301', 'EFO_0000685', 'EFO_0004274', 'EFO_0000398', 'EFO_0009609', 'MONDO_0004979', 'EFO_0003106', 'EFO_0004246', 'MONDO_0007254', 'EFO_0001378', 'EFO_0002609', 'EFO_0007328', 'EFO_0003073', 'EFO_0000694', 'EFO_0000764', 'EFO_0009507', 'EFO_1001806', 'MONDO_0008315', 'EFO_0007427', 'EFO_0000096', 'MONDO_0019338', 'EFO_0000660', 'MONDO_0043510', 'EFO_0001065', 'EFO_0003884', 'MONDO_0100096', 'MONDO_0005178', 'EFO_0003843', 'EFO_0007135', 'EFO_0000095', 'MONDO_0005147', 'EFO_1000657', 'MONDO_0011776', 'EFO_0004238', 'EFO_1001209', 'EFO_1000668', 'EFO_0009536', 'MONDO_0005149', 'EFO_0004540', 'EFO_0005669', 'EFO_0007323', 'Orphanet_47045', 'EFO_0003144', 'EFO_0000400', 'HP_0001943', 'MONDO_0004976', 'EFO_0000195', 'EFO_1000710', 'EFO_0000544', 'EFO_1001345', 'MONDO_0018088', 'EFO_0008583', 'EFO_1001231', 'EFO_0000616', 'MONDO_0018305', 'EFO_0001361', 'EFO_0002618']",True,False,59,Interleukin-1 receptor antagonist ,ANTAGONIST ,single protein 
1427,PANTHENOL,CHEMBL1371937,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007214', 'EFO_1001459', 'EFO_0007328']",False,False,3,,,
1428,LEBRIKIZUMAB,CHEMBL1743035,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000169194'],"['EFO_0000768', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000274']",False,False,4,Interleukin-13 inhibitor ,INHIBITOR ,single protein 
1429,ALVELESTAT,CHEMBL3617964,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000197561'],"['MONDO_0044881', 'HP_0002110', 'EFO_0000341', 'MONDO_0009061', 'MONDO_0100096']",True,False,5,Leukocyte elastase inhibitor ,INHIBITOR ,single protein 
1430,PRAMLINTIDE ACETATE,CHEMBL3833353,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,"['ENSG00000004948', 'ENSG00000132329', 'ENSG00000131477', 'ENSG00000122679']","['EFO_0001073', 'MONDO_0005148', 'MONDO_0005147']",False,False,3,"Amylin receptor AMY3; CALCR/RAMP3 agonist Amylin receptor AMY2; CALCR/RAMP2 agonist Amylin receptor AMY1, CALCR/RAMP1 agonist ",AGONIST ,protein complex 
1431,GLEPAGLUTIDE,CHEMBL4297761,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000384', 'EFO_0003086', 'MONDO_0015183']",False,False,3,,,
1432,RUCAPARIB,CHEMBL1173055,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 4 approved and 19 investigational indications.,,4.0,,False,2016,"['ENSG00000143799', 'ENSG00000041880', 'ENSG00000129484']","['EFO_0003060', 'EFO_0002517', 'MONDO_0002087', 'MONDO_0002158', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000702', 'MONDO_0001056', 'MONDO_0008170', 'MONDO_0003060', 'EFO_0000616', 'EFO_0000616', 'Orphanet_145', 'MONDO_0002974', 'EFO_0002618', 'EFO_1000613', 'EFO_0000564', 'EFO_0000673', 'MONDO_0011962', 'EFO_0000588', 'EFO_0001075']",True,False,24,"PARP 1, 2 and 3 inhibitor ",INHIBITOR ,protein family 
1433,"ESTROGENS, ESTERIFIED",CHEMBL1201468,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,1977,"['ENSG00000140009', 'ENSG00000091831']","['EFO_1000096', 'EFO_0004266', 'EFO_0003922', 'MONDO_0002146', 'MONDO_0007254']",False,True,5,Estrogen receptor agonist ,AGONIST ,protein family 
1434,HYALURONIDASE (HUMAN RECOMBINANT),CHEMBL1201718,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 20 investigational indications.,,4.0,,False,2005,[],"['EFO_1000668', 'MONDO_0005147', 'EFO_0003882', 'MONDO_0003778', 'MONDO_0005148', 'EFO_0000400', 'EFO_1000868', 'MONDO_0005301', 'MONDO_0001187', 'EFO_0000756', 'HP_0003124', 'MONDO_0019623', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000764', 'EFO_0003843', 'EFO_0003060', 'EFO_0000349', 'EFO_0001378', 'EFO_0000676']",False,False,20,,,
1435,PRASUGREL,CHEMBL1201772,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000169313'],"['EFO_0003777', 'EFO_0000612', 'EFO_0000612', 'MONDO_0004979', 'EFO_0008585', 'MP_0001914', 'EFO_0003884', 'EFO_0000275', 'EFO_0000764', 'EFO_0003106', 'HP_0004419', 'MONDO_0011382', 'EFO_0007328', 'EFO_0005672', 'EFO_0001645', 'EFO_0005672', 'MONDO_0100096']",True,False,17,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
1436,PF-04691502,CHEMBL1234354,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_0003869', 'MONDO_0007254', 'MONDO_0004992']",True,False,3,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1437,FOLIC ACID,CHEMBL1622,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 10 approved and 61 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001231', 'EFO_0003060', 'MONDO_0002280', 'EFO_1000657', 'MONDO_0008903', 'MONDO_0002087', 'EFO_0000305', 'EFO_0003894', 'MONDO_0004975', 'EFO_1001375', 'EFO_0004272', 'HP_0000175', 'EFO_0002913', 'EFO_0000545', 'HP_0001891', 'EFO_0000612', 'MONDO_0008315', 'MONDO_0002050', 'EFO_0000211', 'MONDO_0002507', 'MONDO_0002974', 'EFO_0001070', 'EFO_0000537', 'MONDO_0007576', 'EFO_0001645', 'MONDO_0007915', 'EFO_0003032', 'EFO_0006859', 'EFO_0000685', 'EFO_0003777', 'MONDO_0100096', 'MONDO_0004992', 'EFO_0000574', 'EFO_0004248', 'EFO_0004284', 'EFO_0000588', 'EFO_0004142', 'MONDO_0005147', 'EFO_0001068', 'MONDO_0002158', 'EFO_1001012', 'EFO_1000954', 'EFO_0000474', 'MONDO_0001437', 'MONDO_0005575', 'EFO_0003761', 'EFO_0003869', 'MONDO_0005148', 'MONDO_0018076', 'EFO_0000764', 'MONDO_0018075', 'MP_0001914', 'EFO_0003914', 'EFO_0000660', 'EFO_0003882', 'MONDO_0011382', 'EFO_1000785', 'EFO_0003884', 'EFO_0000616', 'EFO_1001951', 'EFO_0000401', 'EFO_0003758', 'EFO_1001518', 'EFO_0003884', 'MONDO_0008170', 'EFO_0005407', 'EFO_0003959', 'EFO_1001898', 'EFO_0003144', 'EFO_1001051', 'HP_0000155']",False,False,71,,,
1438,ERIBULIN MESYLATE,CHEMBL1683544,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 17 investigational indications.,,4.0,,False,2010,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0003060', 'MONDO_0001187', 'EFO_0000616', 'MONDO_0004992', 'EFO_0008528', 'MONDO_0004669', 'EFO_0006859', 'EFO_0000574', 'EFO_0000637', 'EFO_1001968', 'MONDO_0004192', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'EFO_0000305', 'MONDO_0002974', 'MONDO_0007254', 'EFO_0005537', 'EFO_0003869', 'MONDO_0008315']",True,False,20,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1439,RUXOLITINIB,CHEMBL1789941,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 61 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,"['ENSG00000162434', 'ENSG00000096968']","['EFO_0003086', 'EFO_0000222', 'HP_0011974', 'EFO_0000181', 'EFO_0000685', 'EFO_0000220', 'EFO_0000616', 'HP_0004326', 'EFO_0003060', 'EFO_0000339', 'EFO_0000574', 'MONDO_0002158', 'MONDO_0013730', 'EFO_0000305', 'EFO_0002517', 'EFO_0004208', 'MONDO_0002406', 'EFO_0002618', 'EFO_0000274', 'EFO_0001068', 'EFO_1001951', 'EFO_1000710', 'EFO_0002430', 'EFO_1000738', 'EFO_1000984', 'EFO_0000676', 'EFO_0003106', 'EFO_0000676', 'EFO_0000274', 'EFO_0000222', 'EFO_1001467', 'MONDO_0008903', 'EFO_1001806', 'EFO_0002429', 'EFO_0000095', 'EFO_0000565', 'EFO_0000694', 'EFO_0001378', 'EFO_1001779', 'EFO_0000479', 'EFO_0000305', 'MONDO_0009348', 'EFO_0004251', 'EFO_0001421', 'EFO_0000220', 'MONDO_0007254', 'EFO_0004192', 'EFO_0000466', 'EFO_0007183', 'EFO_0002430', 'EFO_0004192', 'MONDO_0004992', 'EFO_0000209', 'EFO_0004192', 'EFO_1000726', 'EFO_0005952', 'EFO_0001642', 'EFO_0000764', 'EFO_0000519', 'MONDO_0044903', 'EFO_0002429', 'MONDO_0019558', 'HP_0000964', 'MONDO_0100096', 'EFO_0000095', 'EFO_0000183', 'EFO_0004599', 'MONDO_0008315', 'MONDO_0015540', 'MONDO_0016486']",True,False,70,Tyrosine-protein kinase JAK2 inhibitor Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
1440,METENKEFALIN,CHEMBL2108291,Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000182', 'EFO_0003929', 'MONDO_0100096', 'EFO_0002618']",False,False,4,,,
1441,EPOETIN BETA,CHEMBL2109092,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anemia (phenotype) and has 44 investigational indications.,,4.0,,False,no approval year,['ENSG00000187266'],"['EFO_1001919', 'EFO_1002048', 'EFO_0000712', 'EFO_0001068', 'EFO_0000198', 'MONDO_0043510', 'EFO_1001330', 'MP_0001914', 'EFO_0004247', 'MONDO_0005180', 'EFO_0000183', 'MONDO_0004976', 'EFO_1000632', 'EFO_0004220', 'EFO_0004272', 'MONDO_0008170', 'EFO_1001375', 'EFO_1001779', 'EFO_1000824', 'EFO_0003964', 'HP_0002140', 'MONDO_0002135', 'EFO_0001061', 'EFO_0000713', 'MONDO_0005301', 'EFO_0008583', 'MONDO_0004992', 'EFO_1001100', 'EFO_0003928', 'EFO_0000403', 'MONDO_0003608', 'EFO_0000612', 'MONDO_0005299', 'EFO_0002687', 'MONDO_0002158', 'EFO_0000574', 'EFO_0005676', 'EFO_0006859', 'HP_0001919', 'EFO_1000809', 'EFO_0007405', 'EFO_0004273', 'EFO_0003917', 'EFO_0000546', 'EFO_0003884']",False,False,45,Erythropoietin receptor agonist ,AGONIST ,single protein 
1442,CYANOCOBALAMIN,CHEMBL2110563,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 approved and 36 investigational indications.,,4.0,,False,no approval year,[],"['HP_0001891', 'MONDO_0002050', 'MONDO_0008903', 'EFO_0000574', 'EFO_0000588', 'HP_0003419', 'HP_0001742', 'EFO_0002950', 'EFO_0004284', 'HP_0002829', 'MONDO_0002158', 'EFO_1001012', 'EFO_0000305', 'MONDO_0002087', 'MONDO_0004975', 'EFO_1001375', 'MONDO_0004976', 'MONDO_0001437', 'EFO_0000764', 'MONDO_0005148', 'EFO_0002913', 'EFO_0000612', 'EFO_1000783', 'EFO_0000676', 'EFO_0003060', 'EFO_0003914', 'MONDO_0008315', 'EFO_0003882', 'EFO_0003758', 'EFO_1000785', 'EFO_0003884', 'EFO_0000211', 'MONDO_0100096', 'EFO_0001070', 'EFO_0004272', 'EFO_0004252', 'EFO_0000734', 'MONDO_0008170', 'EFO_0005407', 'EFO_0003032', 'EFO_0006859', 'MONDO_0042976', 'MONDO_0002280', 'EFO_0003144', 'EFO_1001051']",False,False,45,,,
1443,SAGOPILONE,CHEMBL2304041,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0007254', 'EFO_0000519', 'EFO_0003893', 'EFO_1000158', 'EFO_0003060', 'EFO_0000616', 'EFO_0000756', 'EFO_0003869', 'EFO_0000702', 'MONDO_0008315']",True,False,10,Tubulin stabiliser ,STABILISER ,protein complex group 
1444,IDASANUTLIN,CHEMBL2402737,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,"['ENSG00000141510', 'ENSG00000135679']","['EFO_0005952', 'EFO_0000403', 'EFO_1001951', 'MONDO_0007254', 'MONDO_0018906', 'EFO_0000616', 'EFO_0002429', 'EFO_0000222', 'EFO_0000519', 'EFO_0000479', 'EFO_0001378']",True,True,11,Tumour suppressor p53/oncoprotein Mdm2 inhibitor ,INHIBITOR ,protein-protein interaction 
1445,SURAMIN,CHEMBL265502,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,['ENSG00000113578'],"['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113', 'EFO_1000796', 'EFO_0003060', 'HP_0001919', 'EFO_0000673', 'MONDO_0001187', 'EFO_0005044', 'EFO_0007294', 'EFO_0003756', 'EFO_0001378', 'EFO_0003060', 'EFO_1000158', 'EFO_1001951']",False,False,16,Acidic fibroblast growth factor inhibitor ,INHIBITOR ,single protein 
1446,POZIOTINIB,CHEMBL3545154,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000146648', 'ENSG00000178568', 'ENSG00000065361']","['EFO_0000616', 'MONDO_0001056', 'EFO_0004284', 'EFO_0005922', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000571', 'MONDO_0004992']",True,True,8,Epidermal growth factor receptor inhibitor ,INHIBITOR ,protein family 
1447,TALC,CHEMBL3989756,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for pleural effusion and has 4 investigational indications.,,4.0,,False,1997,[],"['EFO_1000786', 'EFO_0003957', 'EFO_0003060', 'EFO_0009637', 'EFO_0004616']",False,False,5,,,
1448,PAMIPARIB,CHEMBL4112930,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000143799', 'ENSG00000129484']","['MONDO_0008170', 'MONDO_0008315', 'MONDO_0001056', 'EFO_0000616', 'EFO_1000158', 'MONDO_0004992', 'MONDO_0007254', 'MONDO_0003060', 'EFO_0000702', 'EFO_0000519']",True,False,10,Poly [ADP-ribose] polymerase-1 inhibitor Poly [ADP-ribose] polymerase 2 inhibitor ,INHIBITOR ,single protein 
1449,MM-111,CHEMBL4297556,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000065361']",['MONDO_0007254'],False,False,1,ErbB-2/ErbB-3 heterodimer inhibitor ,INHIBITOR ,protein complex 
1450,SPARTALIZUMAB,CHEMBL4297831,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000389', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000756', 'EFO_0005537', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000681', 'EFO_0000181', 'MONDO_0011719', 'MONDO_0001056', 'EFO_0003060', 'EFO_0005922', 'MONDO_0008903', 'EFO_0004252', 'EFO_0000182', 'EFO_0002517', 'EFO_0000574', 'MONDO_0002120']",False,False,19,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
1451,TRASTUZUMAB DERUXTECAN,CHEMBL4297844,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2019,"['ENSG00000198900', 'ENSG00000141736']","['EFO_0000503', 'MONDO_0007254', 'EFO_0003060', 'EFO_0009708', 'EFO_0000637', 'EFO_0000616', 'EFO_0004142', 'EFO_0000305', 'MONDO_0005575', 'EFO_0003869', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0008549']",False,True,13,DNA topoisomerase I inhibitor Receptor protein-tyrosine kinase erbB-2 binding agent ,INHIBITOR BINDING AGENT ,single protein 
1452,BINTRAFUSP ALFA,CHEMBL4298024,Protein drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105329', 'ENSG00000092969', 'ENSG00000119699', 'ENSG00000120217']","['EFO_0003863', 'MONDO_0008903', 'EFO_0003869', 'EFO_1000581', 'MONDO_0002974', 'EFO_0000365', 'EFO_0000196', 'EFO_1001961', 'MONDO_0008170', 'EFO_0001416', 'MONDO_0001056', 'EFO_0002618', 'EFO_0000588', 'EFO_0005221', 'EFO_0000305', 'EFO_0000702', 'EFO_0003060', 'MONDO_0007254', 'EFO_0002916', 'EFO_0001663', 'EFO_0000616', 'EFO_1001968', 'MONDO_0008315', 'EFO_0000558', 'EFO_0000181']",True,False,25,Programmed cell death 1 ligand 1 binding agent Transforming growth factor beta binding agent ,BINDING AGENT ,single protein protein family 
1453,AZOXIMER BROMIDE,CHEMBL4650378,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1454,GOFLIKICEPT,CHEMBL4650513,Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0018088', 'EFO_0007427', 'EFO_0000612', 'EFO_1001165', 'EFO_0007135', 'MONDO_0100096']",False,False,6,,,
1455,IBUPROFEN,CHEMBL521,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 21 approved and 58 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1974,"['ENSG00000073756', 'ENSG00000095303']","['EFO_0002609', 'EFO_0009582', 'EFO_0007328', 'EFO_1000652', 'HP_0003326', 'MONDO_0002009', 'EFO_0000546', 'HP_0012228', 'EFO_0003869', 'HP_0004398', 'EFO_0009615', 'EFO_0005252', 'HP_0003419', 'EFO_0002970', 'MONDO_0004975', 'EFO_1001158', 'EFO_0003843', 'EFO_0000685', 'EFO_0009516', 'EFO_0009846', 'EFO_0001068', 'EFO_0003917', 'EFO_0007214', 'EFO_0005854', 'HP_0001643', 'EFO_1000632', 'EFO_0000537', 'MONDO_0024290', 'EFO_0006803', 'EFO_0005279', 'EFO_0003938', 'EFO_0000649', 'EFO_0004263', 'EFO_0003918', 'EFO_0004209', 'EFO_0003958', 'HP_0001945', 'HP_0100543', 'EFO_0000706', 'EFO_0010072', 'EFO_0003944', 'EFO_0004616', 'EFO_0005856', 'MONDO_0007254', 'EFO_1000843', 'EFO_0000464', 'EFO_0003843', 'MONDO_0019091', 'EFO_1000637', 'EFO_1001139', 'MONDO_0005301', 'MP_0001914', 'HP_0012532', 'EFO_0000544', 'MONDO_0005147', 'EFO_0006834', 'EFO_0000668', 'MONDO_0005277', 'HP_0030833', 'MONDO_0010679', 'HP_0003418', 'EFO_0003931', 'EFO_0005755', 'HP_0001643', 'EFO_1000782', 'EFO_0007486', 'EFO_0000764', 'EFO_1000854', 'MONDO_0100342', 'EFO_0009610', 'MONDO_0002258', 'MONDO_0005178', 'HP_0002315', 'EFO_1001216', 'EFO_0005757', 'EFO_0000319', 'HP_0100607', 'MONDO_0018076', 'MONDO_0018305', 'HP_0002829']",True,False,80,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
1456,ZAFIRLUKAST,CHEMBL603,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for airway obstruction and asthma and has 2 investigational indications.,,4.0,,False,1996,['ENSG00000173198'],"['HP_0006536', 'MONDO_0007254', 'MONDO_0004979', 'MONDO_0008170']",False,False,4,Cysteinyl leukotriene receptor 1 antagonist ,ANTAGONIST ,single protein 
1457,CHOLECALCIFEROL,CHEMBL1042,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 100 investigational indications.,,4.0,,False,1999,['ENSG00000111424'],"['MONDO_0002508', 'EFO_0003929', 'MONDO_0003778', 'EFO_0005406', 'MONDO_0008315', 'EFO_0000365', 'MONDO_0005301', 'MONDO_0004979', 'MONDO_0008170', 'MONDO_0007915', 'EFO_0003095', 'EFO_0000765', 'EFO_0003047', 'EFO_0000616', 'GO_0007568', 'EFO_0000660', 'EFO_0001073', 'MONDO_0005271', 'MONDO_0007254', 'EFO_0003767', 'EFO_0009516', 'EFO_0003884', 'EFO_0007141', 'HP_0011950', 'EFO_0002950', 'EFO_0005531', 'EFO_0000432', 'EFO_0007328', 'HP_0100543', 'MONDO_0002898', 'EFO_0003854', 'EFO_0000676', 'EFO_0000274', 'EFO_0000694', 'MONDO_0004647', 'MONDO_0021063', 'EFO_0005681', 'Orphanet_145', 'EFO_0004272', 'EFO_0002609', 'EFO_0000400', 'MONDO_0004992', 'EFO_0008572', 'Orphanet_309005', 'EFO_0000222', 'MONDO_0011382', 'EFO_0000474', 'EFO_0007405', 'EFO_0000764', 'MONDO_0005148', 'EFO_0000729', 'EFO_1000049', 'MONDO_0002050', 'EFO_0000544', 'EFO_0000095', 'EFO_0009686', 'EFO_0003106', 'MONDO_0005180', 'EFO_0000756', 'HP_0001891', 'EFO_0000180', 'EFO_1000961', 'MONDO_0002363', 'HP_0000938', 'EFO_0000319', 'EFO_0004593', 'EFO_0003931', 'HP_0001742', 'MONDO_0005090', 'MONDO_0002146', 'MONDO_0018975', 'EFO_0000341', 'EFO_0004261', 'EFO_1001951', 'MONDO_0100096', 'EFO_0007214', 'EFO_0003964', 'EFO_1000653', 'EFO_0002546', 'EFO_0000519', 'EFO_0000555', 'MONDO_0044881', 'EFO_0003944', 'EFO_0003758', 'MONDO_0018076', 'EFO_0008506', 'EFO_0002496', 'MONDO_0021187', 'EFO_0003762', 'EFO_1001121', 'EFO_0004248', 'MONDO_0005147', 'EFO_0000384', 'EFO_1000657', 'EFO_0000196', 'EFO_0000280', 'EFO_0003882', 'EFO_0005411', 'EFO_0000195', 'EFO_0000673', 'EFO_0003144', 'Orphanet_43', 'EFO_0003103']",True,False,103,Vitamin D receptor agonist ,AGONIST ,single protein 
1458,MK-2206,CHEMBL1079175,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 21 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105221', 'ENSG00000117020', 'ENSG00000142208']","['MONDO_0008903', 'EFO_0000756', 'MONDO_0011962', 'EFO_0001663', 'EFO_0000308', 'EFO_0000403', 'MONDO_0021063', 'EFO_0000681', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0004252', 'EFO_0000095', 'EFO_0003060', 'EFO_0000181', 'EFO_0006861', 'EFO_0000182', 'EFO_1000657', 'EFO_0000305', 'EFO_0000616', 'EFO_0003050', 'MONDO_0100342']",True,False,21,Serine/threonine-protein kinase AKT inhibitor ,INHIBITOR ,protein family 
1459,BASILIXIMAB,CHEMBL1201439,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for immune system disease and has 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,"['ENSG00000134460', 'ENSG00000147168', 'ENSG00000100385']","['EFO_0000222', 'EFO_0000183', 'EFO_1000794', 'EFO_0003884', 'EFO_0004236', 'MONDO_0018923', 'EFO_0000616', 'MONDO_0019472', 'EFO_1001226', 'EFO_1001231', 'EFO_0002687', 'EFO_0000544', 'EFO_0000464', 'EFO_0004599', 'EFO_0000729', 'EFO_0001378', 'EFO_0000540', 'MONDO_0005147', 'MONDO_0004976', 'EFO_0000519', 'EFO_0003086']",True,True,21,Interleukin-2 receptor inhibitor ,INHIBITOR ,protein complex 
1460,GANITUMAB,CHEMBL1743024,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,['ENSG00000140443'],"['EFO_0000702', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000174', 'EFO_0003060', 'EFO_0003893', 'EFO_0002918', 'EFO_0000691', 'EFO_0002618', 'EFO_0003968', 'EFO_0000616', 'EFO_0005537']",False,False,12,Insulin-like growth factor I receptor antagonist ,ANTAGONIST ,single protein 
1461,ICRUCUMAB,CHEMBL1743030,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000102755'],"['MONDO_0007254', 'MONDO_0021063', 'EFO_0000616', 'EFO_1000657']",True,False,4,Vascular endothelial growth factor receptor 1 antagonist ,ANTAGONIST ,single protein 
1462,LUCATUMUMAB,CHEMBL1743038,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000101017'],"['EFO_0005952', 'EFO_0001378', 'MONDO_0018906', 'EFO_0000183', 'EFO_0000095']",False,False,5,Tumor necrosis factor receptor superfamily member 5 antagonist ,ANTAGONIST ,single protein 
1463,NEMIRALISIB,CHEMBL2216859,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000171608'],['EFO_0000341'],False,False,1,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
1464,OGLEMILAST,CHEMBL4297520,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['MONDO_0004979', 'EFO_0000341']",True,False,2,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
1465,LADIRATUZUMAB VEDOTIN,CHEMBL4298101,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000141424']","['EFO_0003968', 'EFO_0003869', 'EFO_0005537', 'MONDO_0007254']",True,False,4,Tubulin inhibitor Zinc transporter ZIP6 binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
1466,SULFAMETHOXAZOLE,CHEMBL443,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 26 investigational indications.,,4.0,,False,1973,[],"['EFO_0000771', 'EFO_0003833', 'EFO_0005681', 'EFO_0003033', 'HP_0100806', 'EFO_0001068', 'EFO_0000274', 'EFO_0003106', 'EFO_0007448', 'EFO_0005297', 'EFO_0000768', 'HP_0000964', 'EFO_0007399', 'MONDO_0018076', 'EFO_0003102', 'EFO_1002025', 'EFO_0003030', 'EFO_1001141', 'MONDO_0005147', 'EFO_0000616', 'EFO_0000544', 'EFO_0000341', 'EFO_0003086', 'EFO_0000094', 'EFO_1001365', 'EFO_0002499', 'EFO_0000519', 'MONDO_0009061', 'EFO_0000764', 'EFO_0003103']",False,False,30,Bacterial dihydropteroate synthase inhibitor ,INHIBITOR ,single protein 
1467,AT-1501,CHEMBL4594460,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000102245'],"['MONDO_0004976', 'EFO_0004194', 'MONDO_0005147']",False,False,3,CD40 ligand inhibitor ,INHIBITOR ,single protein 
1468,NM-21-1480,CHEMBL4650496,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1469,NEZULCITINIB,CHEMBL4802163,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['EFO_0004610', 'MONDO_0100096']",True,True,2,Janus Kinase (JAK) inhibitor ,INHIBITOR ,protein family 
1470,JDQ-443,CHEMBL5077861,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000702']",False,False,2,,,
1471,BACITRACIN,CHEMBL1200558,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1948,[],"['EFO_0003106', 'EFO_0000544', 'EFO_0009516', 'EFO_0000771', 'EFO_0009481', 'EFO_0003102', 'EFO_0004269', 'MP_0001845']",False,False,8,,,
1472,PANTOPRAZOLE,CHEMBL1502,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 22 investigational indications.,,4.0,,False,2000,"['ENSG00000105675', 'ENSG00000186009']","['EFO_0003948', 'EFO_0000771', 'HP_0002239', 'EFO_0003948', 'MONDO_0008315', 'EFO_0007549', 'MONDO_0003523', 'MONDO_0043839', 'EFO_0000616', 'MONDO_0005090', 'HP_0100633', 'MONDO_0005148', 'EFO_0007157', 'EFO_0007549', 'HP_0100633', 'EFO_1001355', 'MONDO_0005147', 'Orphanet_79292', 'MONDO_0005301', 'EFO_0000400', 'HP_0004398', 'MP_0001914', 'EFO_0000280', 'EFO_1000961', 'EFO_0005672', 'EFO_0009544', 'EFO_0000373']",False,False,27,Potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex 
1473,ETROLIZUMAB,CHEMBL1743015,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000139626'],"['EFO_0000384', 'EFO_0000729']",False,False,2,Integrin beta-7 antagonist ,ANTAGONIST ,single protein 
1474,DEXTRAN SULFATE SODIUM,CHEMBL2108952,Oligosaccharide drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1475,SARACATINIB,CHEMBL217092,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.,,3.0,,False,no approval year,"['ENSG00000097007', 'ENSG00000197122']","['MONDO_0021063', 'EFO_0000637', 'EFO_0006861', 'MONDO_0011705', 'EFO_0000616', 'MONDO_0007606', 'EFO_0000365', 'MONDO_0008315', 'MONDO_0002158', 'EFO_1000581', 'EFO_0002618', 'MONDO_0007254', 'EFO_0004329', 'MONDO_0008170', 'MONDO_0007079', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000756', 'EFO_1000657', 'MONDO_0004975']",False,False,20,Tyrosine-protein kinase ABL inhibitor Tyrosine-protein kinase SRC inhibitor ,INHIBITOR ,single protein 
1476,ETIRINOTECAN PEGOL,CHEMBL3039558,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['EFO_0000616', 'EFO_0002499', 'EFO_0002501', 'EFO_0003060', 'EFO_0000519', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001951', 'MONDO_0004992']",False,False,9,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
1477,MBX-2982,CHEMBL3260505,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000147262'],"['MONDO_0005147', 'EFO_0000400']",False,False,2,Glucose-dependent insulinotropic receptor agonist ,AGONIST ,single protein 
1478,ETALOCIB,CHEMBL329123,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000132170', 'ENSG00000213903']","['EFO_0002618', 'EFO_0000616', 'EFO_0003060']",False,False,3,Leukotriene B4 receptor 1 antagonist Peroxisome proliferator-activated receptor gamma agonist ,ANTAGONIST AGONIST ,single protein 
1479,TEICOPLANIN,CHEMBL4297166,Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 4 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000544', 'EFO_0003102', 'MONDO_0009061', 'EFO_0000771', 'EFO_0000701']",False,False,5,,,
1480,AMCENESTRANT,CHEMBL4475463,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000091831'],"['EFO_0003968', 'EFO_0005537', 'MONDO_0007254']",False,True,3,Estrogen receptor alpha degrader ,DEGRADER ,single protein 
1481,OLODATEROL,CHEMBL605846,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications.,,4.0,,False,2014,['ENSG00000169252'],"['EFO_0006505', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000464', 'EFO_0000341', 'HP_0006536', 'EFO_0001421']",False,False,7,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1482,PATUPILONE,CHEMBL94657,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0008170', 'EFO_0000182', 'EFO_0003865', 'EFO_0004243', 'MONDO_0004992', 'EFO_0000673', 'EFO_0000756', 'MONDO_0007254', 'EFO_0003060', 'EFO_0003869', 'EFO_0000616', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0000519', 'EFO_0004288', 'EFO_1001100', 'MONDO_0021063']",True,False,17,Tubulin stabiliser ,STABILISER ,protein complex group 
1483,RETINOL,CHEMBL986,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 11 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0008572', 'HP_0000979', 'MONDO_0019200', 'EFO_0000544', 'EFO_0003966', 'EFO_0001067', 'EFO_1001237', 'HP_0001742', 'MONDO_0100096', 'EFO_0001068', 'MONDO_0018076', 'MONDO_0001673', 'EFO_0003894', 'EFO_0003144']",False,False,14,,,
1484,ARFORMOTEROL,CHEMBL1363,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 6 investigational indications.,,4.0,,False,2006,['ENSG00000169252'],"['EFO_0009661', 'EFO_0000341', 'EFO_0006505', 'EFO_0000341', 'EFO_0006505', 'EFO_0000464', 'HP_0025428', 'MONDO_0004979', 'EFO_0000464']",False,False,9,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1485,SELICICLIB,CHEMBL14762,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000136807', 'ENSG00000170312', 'ENSG00000123374', 'ENSG00000134058', 'ENSG00000164885']","['MONDO_0009061', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616', 'EFO_1001110']",False,False,5,Cyclin-dependent kinase 9 inhibitor Cyclin-dependent kinase 7 inhibitor Cyclin-dependent kinase 5 inhibitor Cyclin-dependent kinase 2 inhibitor Cyclin-dependent kinase 1 inhibitor ,INHIBITOR ,single protein 
1486,GLEMBATUMUMAB VEDOTIN,CHEMBL1743028,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000136235', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000637', 'EFO_0000756', 'EFO_0000708', 'MONDO_0007254']",True,False,4,Transmembrane glycoprotein NMB binding agent Tubulin inhibitor ,BINDING AGENT INHIBITOR ,single protein protein complex group 
1487,AUS-131,CHEMBL198877,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000140009'],"['MONDO_0004975', 'EFO_0003922', 'EFO_0000284', 'MONDO_0007254']",False,False,4,Estrogen receptor beta agonist ,AGONIST ,single protein 
1488,CISPLATIN,CHEMBL2068237,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for cancer and neoplasm and has 178 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,[],"['MONDO_0002715', 'MONDO_0002108', 'MONDO_0003060', 'EFO_1000796', 'EFO_0000182', 'EFO_0000183', 'EFO_0005922', 'EFO_1000437', 'EFO_0005950', 'EFO_0000365', 'MONDO_0004992', 'EFO_0003866', 'EFO_1000564', 'EFO_0009637', 'MONDO_0002601', 'EFO_0008524', 'EFO_0000621', 'EFO_0000096', 'MONDO_0002358', 'EFO_1001961', 'MONDO_0003751', 'EFO_0006859', 'EFO_1001898', 'EFO_0003859', 'EFO_0000181', 'EFO_0000616', 'MONDO_0021657', 'EFO_0000466', 'EFO_1000292', 'MONDO_0004986', 'EFO_0008549', 'EFO_0004230', 'EFO_0003833', 'MONDO_0001187', 'EFO_0003860', 'MONDO_0002087', 'MONDO_0001325', 'EFO_0000574', 'EFO_0005235', 'MONDO_0019472', 'EFO_0000502', 'EFO_0000503', 'EFO_0001378', 'MONDO_0021310', 'EFO_1000574', 'EFO_0003050', 'EFO_1002017', 'EFO_0004284', 'EFO_0000681', 'EFO_0000211', 'MONDO_0044903', 'EFO_0003817', 'EFO_0000389', 'MONDO_0003478', 'EFO_0004281', 'EFO_0005577', 'EFO_0005088', 'EFO_0005537', 'EFO_0000326', 'EFO_0000770', 'EFO_0000255', 'EFO_0001068', 'MONDO_0001879', 'EFO_0004272', 'MONDO_0044704', 'MONDO_0003001', 'MONDO_0001528', 'MONDO_0007254', 'EFO_0007362', 'MONDO_0001056', 'EFO_0002617', 'MONDO_0008315', 'EFO_0001416', 'EFO_0005570', 'EFO_1001931', 'EFO_0003869', 'EFO_1001959', 'EFO_0004252', 'EFO_0002938', 'EFO_0003863', 'EFO_0008528', 'MONDO_0002974', 'EFO_0000565', 'EFO_0004142', 'EFO_1000251', 'EFO_1001100', 'EFO_0003032', 'EFO_1001469', 'EFO_0003826', 'MONDO_0021364', 'EFO_0000514', 'EFO_0000756', 'MONDO_0004669', 'MONDO_0021355', 'MONDO_0011962', 'EFO_0003868', 'MONDO_0016717', 'EFO_0000178', 'EFO_0000707', 'EFO_1000984', 'EFO_1001960', 'MONDO_0009348', 'EFO_0007416', 'EFO_0000228', 'EFO_0000313', 'EFO_0006911', 'MONDO_0100342', 'MONDO_0002038', 'EFO_1001471', 'MONDO_0003199', 'HP_0002017', 'EFO_0002618', 'EFO_0009869', 'EFO_0000198', 'MONDO_0002120', 'EFO_0005543', 'EFO_0005221', 'EFO_0009688', 'MONDO_0002367', 'EFO_1000415', 'EFO_0010282', 'EFO_0002939', 'EFO_0002626', 'MONDO_0021148', 'EFO_0001071', 'MONDO_0004192', 'MONDO_0021117', 'EFO_0004606', 'EFO_0004243', 'EFO_0003060', 'MONDO_0016700', 'EFO_0002916', 'EFO_0003897', 'MONDO_0007576', 'EFO_1001951', 'MONDO_0044926', 'EFO_0000199', 'MONDO_0001657', 'EFO_1001365', 'EFO_0000637', 'EFO_0000588', 'EFO_0009708', 'MONDO_0008170', 'EFO_1001956', 'EFO_1000158', 'EFO_0000403', 'EFO_0001061', 'MONDO_0008903', 'EFO_0005952', 'EFO_0000571', 'MONDO_0018944', 'MONDO_0005411', 'EFO_0000294', 'EFO_0003086', 'EFO_0001421', 'EFO_1001904', 'MONDO_0002898', 'EFO_0000691', 'EFO_0002918', 'MONDO_0011719', 'MONDO_0019471', 'EFO_0002517', 'MONDO_0008380', 'EFO_1001968', 'EFO_0003893', 'EFO_0000708', 'MONDO_0002158', 'MONDO_0005575', 'EFO_0000305', 'EFO_0001075', 'EFO_0004193', 'EFO_0000702', 'EFO_1000576', 'EFO_0003871', 'MONDO_0002691', 'EFO_0006352', 'EFO_0003891', 'EFO_0006772', 'EFO_1000581', 'EFO_1000043']",False,False,180,,,
1489,REPAGERMANIUM,CHEMBL2107883,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1490,INOTUZUMAB OZOGAMICIN,CHEMBL2108611,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2017,['ENSG00000012124'],"['EFO_1000131', 'EFO_0000616', 'EFO_0000094', 'EFO_0000220', 'MONDO_0044881', 'EFO_0000096', 'EFO_0000094', 'EFO_0005952', 'EFO_0000403', 'MONDO_0018906', 'MONDO_0000873', 'EFO_0000574', 'EFO_0000309']",False,False,13,CD22 binding agent ,BINDING AGENT ,single protein 
1491,MAGNESIUM CHLORIDE,CHEMBL2219642,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005147', 'MP_0001914', 'EFO_0000712', 'EFO_0000574', 'EFO_0003833']",False,False,5,,,
1492,FUTIBATINIB,CHEMBL3701238,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 4 investigational indications.,,4.0,,False,2022,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']","['EFO_0000182', 'EFO_0000616', 'MONDO_0007254', 'EFO_1001968', 'EFO_0005221', 'MONDO_0004992', 'EFO_0003060']",True,True,7,Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family 
1493,BUDIGALIMAB,CHEMBL4297858,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000188389'],"['EFO_1001951', 'EFO_0000764', 'EFO_0000616', 'EFO_0000180', 'EFO_0000702', 'MONDO_0007254', 'MONDO_0008170', 'MONDO_0004992', 'EFO_0006859']",False,False,9,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
1494,DHES-0815A,CHEMBL4297933,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1495,ETOPOSIDE PHOSPHATE,CHEMBL1200645,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 20 investigational indications.,,4.0,,False,1996,['ENSG00000131747'],"['MONDO_0002158', 'EFO_0000183', 'EFO_0008524', 'EFO_0000616', 'EFO_0000574', 'EFO_0000094', 'EFO_0002939', 'EFO_0000621', 'EFO_1000158', 'EFO_0000096', 'MONDO_0000873', 'EFO_0005952', 'EFO_0000222', 'EFO_0000220', 'MONDO_0008903', 'EFO_0000313', 'EFO_0000565', 'EFO_0002918', 'EFO_0000702', 'MONDO_0002087', 'EFO_0002501', 'MONDO_0100342', 'MONDO_0008170', 'EFO_0001378']",True,False,24,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
1496,LEUPROLIDE,CHEMBL1201199,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 7 approved and 29 investigational indications.,,4.0,,False,1985,['ENSG00000109163'],"['EFO_0000731', 'MONDO_0004975', 'EFO_0004248', 'EFO_0000616', 'EFO_0005204', 'MONDO_0008170', 'EFO_0000731', 'MONDO_0000088', 'EFO_0000673', 'EFO_0000196', 'EFO_0003869', 'EFO_0000756', 'EFO_0000764', 'MONDO_0008315', 'MONDO_0008315', 'MONDO_0004992', 'EFO_0003843', 'EFO_0001065', 'EFO_0001065', 'EFO_0000545', 'MONDO_0008315', 'EFO_0009029', 'HP_0100543', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000537', 'MONDO_0003061', 'EFO_0003922', 'EFO_0009006', 'EFO_0001073', 'EFO_1001469', 'MONDO_0007254', 'EFO_0000673', 'EFO_0000196', 'EFO_0001073', 'EFO_0000183', 'EFO_0001663', 'EFO_0001663', 'MONDO_0002146', 'EFO_0007453']",False,False,40,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
1497,ALTEPLASE,CHEMBL1201593,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 24 investigational indications.,,4.0,,False,1996,['ENSG00000122194'],"['EFO_0000712', 'EFO_0009680', 'EFO_1000637', 'MONDO_0000831', 'EFO_0003966', 'EFO_1001157', 'EFO_0003907', 'EFO_0000616', 'MONDO_0005299', 'MONDO_0100096', 'EFO_0000618', 'HP_0004418', 'HP_0002140', 'MONDO_0002679', 'EFO_0000713', 'EFO_0003913', 'EFO_1001375', 'HP_0004419', 'EFO_0003144', 'EFO_1001753', 'EFO_0003827', 'EFO_1001154', 'EFO_0009661', 'EFO_0000694', 'EFO_0000612', 'MP_0001914', 'EFO_0003030', 'EFO_0005669', 'EFO_0003097', 'EFO_0000373', 'MONDO_0004992', 'HP_0000016']",True,True,32,Plasminogen activator ,ACTIVATOR ,single protein 
1498,PENICILLIN G POTASSIUM,CHEMBL1223,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 11 investigational indications.,,4.0,,False,1947,[],"['EFO_0003033', 'EFO_0000616', 'MONDO_0002258', 'EFO_0000772', 'MONDO_0004992', 'EFO_0000181', 'EFO_0000544', 'EFO_0003102', 'HP_0011110', 'EFO_0003106', 'MONDO_0001056']",False,False,11,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1499,PF-00610355,CHEMBL1240967,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000169252'],"['EFO_0000341', 'MONDO_0004979', 'EFO_0003818']",False,False,3,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1500,OBATOCLAX MESYLATE,CHEMBL2107358,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,"['ENSG00000143384', 'ENSG00000171791', 'ENSG00000258643', 'ENSG00000129473', 'ENSG00000140379', 'ENSG00000171552', 'ENSG00000137875']","['EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'EFO_1001469', 'EFO_0000702', 'MONDO_0001023', 'MONDO_0008903', 'EFO_0002617', 'EFO_0000403', 'EFO_0000183', 'EFO_0000095', 'MONDO_0044903', 'MONDO_0018906']",True,False,13,Bcl-2-like protein 10 inhibitor Apoptosis regulator Bcl-2 inhibitor Bcl-2-related protein A1 inhibitor Apoptosis regulator Bcl-X inhibitor Apoptosis regulator Bcl-W inhibitor Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor ,INHIBITOR ,single protein 
1501,PANCRELIPASE,CHEMBL2108074,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 investigational indications.,,4.0,,False,1996,[],"['MONDO_0009061', 'MONDO_0001684', 'EFO_0000342', 'MONDO_0005147', 'EFO_0002618', 'HP_0001943', 'EFO_0000278']",False,False,7,,,
1502,ROSIPTOR,CHEMBL3989954,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000168918'],"['EFO_0000341', 'EFO_0000274', 'EFO_1000869', 'EFO_0008507']",True,False,4,"Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator ",ACTIVATOR ,single protein 
1503,ENARODUSTAT,CHEMBL4297619,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000135766'],['EFO_0003884'],False,False,1,Egl nine homolog 1 inhibitor ,INHIBITOR ,single protein 
1504,NIPOCALIMAB,CHEMBL4594310,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000104870'],"['EFO_1001264', 'EFO_0004991', 'EFO_0000699', 'MONDO_0007915', 'EFO_1000868', 'EFO_0005761', 'EFO_0000783', 'EFO_0000685']",True,False,8,IgG receptor FcRn large subunit p51 antagonist ,ANTAGONIST ,single protein 
1505,CHLORPROMAZINE,CHEMBL71,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1957,"['ENSG00000149295', 'ENSG00000151577', 'ENSG00000069696', 'ENSG00000102468']","['EFO_0009267', 'HP_0002017', 'MONDO_0021063', 'EFO_0000519', 'EFO_0004216', 'EFO_0005407', 'MONDO_0005090', 'MONDO_0100096', 'EFO_0000677', 'MONDO_0037939', 'EFO_0005799']",False,False,11,D2-like dopamine receptor antagonist Serotonin 2a (5-HT2a) receptor antagonist ,ANTAGONIST ,protein family single protein 
1506,TEPROTUMUMAB,CHEMBL1743079,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and graves ophthalmopathy and has 5 investigational indications.,,4.0,,False,2020,['ENSG00000140443'],"['EFO_0003060', 'EFO_0000616', 'MONDO_0007254', 'EFO_0000540', 'EFO_1001466', 'EFO_0000404', 'EFO_0000691']",False,False,7,Insulin-like growth factor I receptor antagonist ,ANTAGONIST ,single protein 
1507,AMUVATINIB,CHEMBL2103851,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000122025', 'ENSG00000105976', 'ENSG00000134853', 'ENSG00000157404']","['EFO_0000616', 'EFO_0000702']",False,False,2,Stem cell growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Platelet-derived growth factor receptor alpha inhibitor Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1508,SELICRELUMAB,CHEMBL2109477,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications.,,1.0,,False,no approval year,['ENSG00000101017'],"['EFO_0000616', 'EFO_1001951', 'EFO_0000096', 'EFO_0003860', 'EFO_0000756', 'MONDO_0007254']",False,False,6,Tumor necrosis factor receptor superfamily member 5 agonist ,AGONIST ,single protein 
1509,VANCOMYCIN,CHEMBL262777,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 11 approved and 41 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1964,[],"['EFO_1001849', 'HP_0100806', 'EFO_0002617', 'EFO_0003033', 'EFO_0003884', 'EFO_0003035', 'EFO_1000874', 'EFO_0000384', 'EFO_1001849', 'EFO_0000701', 'MP_0001845', 'MONDO_0000565', 'HP_0002014', 'MONDO_0009061', 'EFO_0005681', 'EFO_0000729', 'EFO_0000771', 'MONDO_0044881', 'HP_0003040', 'EFO_0000544', 'MONDO_0021201', 'EFO_0003060', 'EFO_0000544', 'MONDO_0043544', 'EFO_0003030', 'EFO_0004599', 'EFO_0000182', 'EFO_0009130', 'EFO_1001865', 'MONDO_0021679', 'EFO_0007486', 'EFO_0000701', 'EFO_0009130', 'EFO_1000829', 'EFO_1001888', 'EFO_0003106', 'EFO_0003756', 'EFO_1001272', 'EFO_0003030', 'EFO_0003102', 'EFO_0001073', 'MONDO_0005178', 'EFO_0007496', 'EFO_0000771', 'MONDO_0024355', 'EFO_1001121', 'EFO_0008588', 'MONDO_0009061', 'EFO_1001481', 'EFO_0000465', 'HP_0002019', 'EFO_1002048', 'EFO_1001459', 'HP_0040187', 'EFO_0003035', 'EFO_0004268']",False,False,56,,,
1510,GSK159802,CHEMBL3545087,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000169252'],['EFO_0000341'],False,False,1,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1511,OXALIPLATIN,CHEMBL414804,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for neoplasm and cancer and has 93 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,[],"['MONDO_0002087', 'EFO_0000228', 'EFO_1001100', 'EFO_0004288', 'EFO_1000657', 'MONDO_0002974', 'EFO_0002617', 'EFO_0002916', 'EFO_0003060', 'EFO_1001956', 'EFO_0000305', 'EFO_0005952', 'MONDO_0044937', 'EFO_0000222', 'EFO_0004142', 'EFO_1000292', 'EFO_0002517', 'EFO_0000681', 'EFO_1000158', 'MONDO_0007576', 'EFO_0000183', 'MONDO_0005575', 'EFO_1001961', 'EFO_1001901', 'MONDO_0001879', 'EFO_0000178', 'EFO_0000698', 'EFO_0003859', 'EFO_0004243', 'EFO_0000707', 'MONDO_0019472', 'EFO_0009708', 'MONDO_0001056', 'EFO_0000616', 'MONDO_0003060', 'EFO_0000182', 'MONDO_0002158', 'EFO_0000514', 'MONDO_0002601', 'EFO_1001949', 'MONDO_0005411', 'EFO_0005922', 'EFO_0000198', 'EFO_0002913', 'EFO_0003869', 'EFO_0004284', 'EFO_0005221', 'MONDO_0007254', 'EFO_0010282', 'MONDO_0008170', 'EFO_0000313', 'EFO_0003100', 'MONDO_0018906', 'MONDO_0011719', 'MONDO_0002038', 'MONDO_0002516', 'EFO_0000197', 'EFO_1000601', 'EFO_0004252', 'MONDO_0011962', 'EFO_0000403', 'MONDO_0019471', 'EFO_0000389', 'EFO_0000621', 'EFO_1001465', 'MONDO_0008315', 'MONDO_0005835', 'EFO_0001421', 'EFO_0003891', 'MONDO_0021063', 'MONDO_0018364', 'EFO_0001075', 'EFO_0007416', 'MONDO_0001187', 'EFO_0000702', 'EFO_0000574', 'MONDO_0004992', 'EFO_0003897', 'MONDO_0008903', 'EFO_0000365', 'EFO_0008528', 'MONDO_0003059', 'EFO_0003860', 'EFO_0000565', 'EFO_0004281', 'EFO_0000588', 'MONDO_0002120', 'EFO_0000096', 'EFO_1000251', 'MONDO_0044881', 'EFO_1001951', 'EFO_0006859', 'MONDO_0002691', 'EFO_0000503', 'EFO_0002618']",False,False,95,,,
1512,MONTMORILLONITE,CHEMBL4298106,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'HP_0002014']",False,False,2,,,
1513,REPOTRECTINIB,CHEMBL4298138,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0004992', 'EFO_0003060', 'EFO_0000616']",False,False,3,,,
1514,DACARBAZINE,CHEMBL476,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1975,[],"['EFO_0000574', 'MONDO_0002898', 'EFO_1001968', 'EFO_0000183', 'EFO_0007143', 'EFO_1001901', 'MONDO_0002367', 'EFO_0000691', 'EFO_0000211', 'EFO_0000616', 'MONDO_0002108', 'EFO_0000621', 'EFO_1000045', 'MONDO_0007254', 'EFO_0001376', 'EFO_0000389', 'MONDO_0021063', 'EFO_0000756', 'EFO_0002617', 'MONDO_0009348', 'MONDO_0004992', 'MONDO_0008903', 'EFO_0000564']",False,False,23,,,
1515,LAPATINIB,CHEMBL554,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 44 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000146648', 'ENSG00000141736']","['MONDO_0004992', 'MONDO_0008315', 'EFO_0000228', 'EFO_0006859', 'EFO_0005543', 'MONDO_0044926', 'EFO_0005774', 'EFO_1000478', 'EFO_1001465', 'EFO_0000616', 'MONDO_0004986', 'EFO_0000707', 'MONDO_0004986', 'EFO_1001951', 'EFO_1000158', 'EFO_1001512', 'MONDO_0007254', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618', 'EFO_0003869', 'EFO_0005950', 'EFO_0000181', 'EFO_1001968', 'MONDO_0011962', 'MONDO_0001056', 'EFO_0003884', 'EFO_0000365', 'EFO_0006352', 'EFO_0000305', 'EFO_0000305', 'EFO_0002892', 'EFO_0002938', 'EFO_0003869', 'EFO_0000616', 'EFO_0002618', 'MONDO_0002974', 'MONDO_0002087', 'MONDO_0001187', 'MONDO_0008315', 'EFO_0003060', 'EFO_0000574', 'MONDO_0008170', 'EFO_0006859', 'EFO_0000756', 'EFO_0006318', 'MONDO_0007254', 'EFO_0006861', 'EFO_0000681', 'MONDO_0001657']",True,True,50,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1516,FAROPENEM,CHEMBL556262,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0018076', 'EFO_0003106', 'EFO_0000771', 'EFO_1000049']",False,False,4,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1517,OMBRABULIN,CHEMBL572284,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000691', 'EFO_0000616', 'EFO_0003060', 'MONDO_0008170']",True,False,4,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1518,CILASTATIN,CHEMBL766,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 9 investigational indications.,,4.0,,False,1985,['ENSG00000015413'],"['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_0003106', 'EFO_0000465', 'EFO_0000771', 'HP_0100806', 'EFO_0003103', 'MONDO_0044881', 'EFO_1001865', 'EFO_0000544', 'EFO_1001272', 'EFO_0003102', 'EFO_1001141']",False,False,14,Renal dipeptidase inhibitor ,INHIBITOR ,single protein 
1519,OCTREOTIDE ACETATE,CHEMBL1200480,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 17 investigational indications.,,4.0,,False,1988,"['ENSG00000162009', 'ENSG00000180616', 'ENSG00000132671', 'ENSG00000139874', 'ENSG00000278195']","['MONDO_0008300', 'EFO_1002048', 'EFO_1000852', 'EFO_1001901', 'MONDO_0043579', 'EFO_0009708', 'EFO_0000616', 'HP_0002019', 'MONDO_0004565', 'EFO_0003770', 'MONDO_0017611', 'EFO_0002626', 'HP_0002014', 'EFO_0004243', 'EFO_1001485', 'EFO_0001073', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0017182', 'EFO_0000574']",False,False,21,Somatostatin receptor agonist ,AGONIST ,protein family 
1520,CABAZITAXEL,CHEMBL1201748,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2010,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0003085', 'MONDO_0007254', 'EFO_0001663', 'EFO_0005088', 'EFO_0003060', 'EFO_0000326', 'EFO_1001094', 'EFO_1000796', 'EFO_0006859', 'MONDO_0008315', 'EFO_0000519', 'EFO_1000601', 'MONDO_0008170', 'MONDO_0001657', 'EFO_0000702', 'EFO_0000181', 'EFO_0000196', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0001056', 'MONDO_0004986', 'EFO_0000673', 'EFO_0000616', 'EFO_0008528']",True,False,24,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1521,ESCITALOPRAM,CHEMBL1508,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 29 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,['ENSG00000108576'],"['EFO_0003761', 'EFO_0003761', 'EFO_0000712', 'MONDO_0004992', 'EFO_0004262', 'EFO_0003047', 'EFO_0001358', 'MONDO_0004985', 'EFO_1001892', 'EFO_0000313', 'EFO_0003890', 'EFO_0009963', 'EFO_0002610', 'EFO_0004242', 'HP_0002381', 'MONDO_0002009', 'EFO_1001908', 'EFO_0005230', 'MONDO_0004975', 'MONDO_0002050', 'EFO_0002517', 'EFO_1001892', 'MONDO_0002009', 'EFO_0003884', 'MONDO_0005149', 'MONDO_0002491', 'MONDO_0002050', 'HP_0012076', 'EFO_0005687', 'EFO_1001917', 'EFO_0010282', 'EFO_1001919', 'MONDO_0005090', 'EFO_0006788', 'EFO_0000685']",False,False,35,Serotonin transporter inhibitor ,INHIBITOR ,single protein 
1522,AMANTADINE HYDROCHLORIDE,CHEMBL1569,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 7 investigational indications.,,4.0,,False,1968,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']","['EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328', 'EFO_0003047', 'MONDO_0005301', 'MONDO_0005090', 'EFO_0000544', 'EFO_1001402', 'EFO_1000860', 'MONDO_0043510', 'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411']",False,False,14,Glutamate [NMDA] receptor antagonist Matrix protein 2 inhibitor ,ANTAGONIST INHIBITOR ,protein complex group single protein 
1523,KARENITECIN,CHEMBL1743260,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['EFO_0003833', 'EFO_1000158', 'EFO_0000756', 'MONDO_0008170', 'MONDO_0008903', 'EFO_0003060']",False,False,6,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
1524,ZALUTUMUMAB,CHEMBL2107861,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0000707', 'EFO_0004284', 'EFO_0003060', 'EFO_0006859', 'EFO_1001951']",False,True,5,Epidermal growth factor receptor erbB1 antagonist ,ANTAGONIST ,single protein 
1525,UBLITUXIMAB,CHEMBL2108354,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000156738'],"['EFO_0009441', 'EFO_0004256', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000403', 'EFO_0000095', 'EFO_0000096', 'EFO_0003929', 'MONDO_0005301']",False,False,9,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
1526,"GINSENG, AMERICAN",CHEMBL2109196,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0005301', 'EFO_0000565', 'EFO_0000765', 'EFO_0000095', 'EFO_0000537', 'MONDO_0005148', 'MONDO_0007254', 'HP_0003074']",False,False,8,,,
1527,BROMHEXINE,CHEMBL253376,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001068', 'MONDO_0100096']",False,False,2,,,
1528,SNK01,CHEMBL4650287,Cell drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000676']",False,False,2,,,
1529,DESIDUSTAT,CHEMBL4650314,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0009909', 'EFO_0003884']",False,False,3,,,
1530,ODANACATIB,CHEMBL481611,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000143387'],"['EFO_0003854', 'MONDO_0005178', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0003882', 'HP_0000083']",True,False,6,Cathepsin K inhibitor ,INHIBITOR ,single protein 
1531,VENLAFAXINE HYDROCHLORIDE,CHEMBL1201066,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1993,"['ENSG00000108576', 'ENSG00000103546']","['MONDO_0005180', 'EFO_0003761', 'EFO_1001917', 'MONDO_0002009', 'EFO_0004242', 'EFO_0004262', 'EFO_0006862', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090', 'MONDO_0004985', 'EFO_1001919', 'EFO_0009854', 'MONDO_0002050', 'EFO_1002014', 'HP_0030833', 'EFO_0002610', 'EFO_0005230', 'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'HP_0031217', 'EFO_0005687', 'MONDO_0004975', 'EFO_0006788', 'EFO_1001892']",True,False,26,Serotonin transporter inhibitor Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
1532,URELUMAB,CHEMBL1743085,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,['ENSG00000049249'],"['EFO_0001378', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000756', 'EFO_0002618', 'EFO_0000096', 'EFO_1001465', 'EFO_0003060', 'EFO_0000565']",True,False,10,Tumor necrosis factor receptor superfamily member 9 agonist ,AGONIST ,single protein 
1533,ARZOXIFENE HYDROCHLORIDE,CHEMBL2105949,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008170', 'MONDO_0011962', 'Orphanet_145', 'MONDO_0002087', 'MONDO_0007254']",False,False,5,,,
1534,CANGRELOR,CHEMBL334966,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for recurrent thrombophlebitis and myocardial infarction and has 4 investigational indications.,,4.0,,False,2015,['ENSG00000169313'],"['EFO_0005672', 'HP_0004419', 'EFO_0000556', 'EFO_0008585', 'EFO_0001645', 'HP_0004419', 'EFO_0000612']",True,False,7,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
1535,CAMRELIZUMAB,CHEMBL4297715,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 63 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000637', 'MONDO_0005147', 'EFO_0000294', 'EFO_0000181', 'MONDO_0008170', 'EFO_0000756', 'EFO_0005537', 'MONDO_0021355', 'EFO_0000182', 'EFO_0000519', 'EFO_1001012', 'EFO_0002916', 'MONDO_0021117', 'EFO_0000365', 'MONDO_0002120', 'EFO_0004252', 'EFO_0000708', 'EFO_0000707', 'EFO_1001961', 'MONDO_0009348', 'EFO_1000657', 'EFO_0000178', 'EFO_0003868', 'MONDO_0003060', 'EFO_0005952', 'EFO_0000403', 'EFO_0002618', 'MONDO_0020669', 'EFO_1001951', 'EFO_0004142', 'EFO_0000537', 'EFO_0003060', 'MONDO_0021063', 'MONDO_0005575', 'EFO_0009637', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0001378', 'EFO_0000313', 'MONDO_0019472', 'EFO_0000616', 'EFO_0002938', 'EFO_0001061', 'MONDO_0001056', 'EFO_0000349', 'EFO_0001071', 'EFO_0000222', 'EFO_1001968', 'EFO_0000702', 'MONDO_0002108', 'MONDO_0002974', 'MONDO_0018944', 'EFO_0000574', 'EFO_0000199', 'EFO_0005221', 'EFO_1000796', 'MONDO_0002691', 'EFO_0000503', 'EFO_0000183', 'EFO_0000691', 'MONDO_0007254', 'MONDO_0007576', 'EFO_0005922']",True,False,63,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
1536,PROPAFENONE,CHEMBL631,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1989,"['ENSG00000043591', 'ENSG00000169252', 'ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0000275', 'HP_0004308', 'EFO_0004278', 'EFO_0000612', 'EFO_0003144', 'EFO_0004287', 'EFO_0004269', 'EFO_0000275']",False,False,8,Sodium channel alpha subunit blocker Beta-1 adrenergic receptor antagonist Beta-2 adrenergic receptor antagonist ,BLOCKER ANTAGONIST ,protein family single protein 
1537,CEFOXITIN SODIUM,CHEMBL1200530,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for infection and pneumonia. This drug has a black box warning from the FDA.,,4.0,,True,1978,[],"['EFO_0000544', 'EFO_0003106']",False,False,2,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1538,TRIPTORELIN,CHEMBL1201334,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 17 investigational indications.,,4.0,,False,2000,['ENSG00000109163'],"['MONDO_0011972', 'MONDO_0000088', 'EFO_0000196', 'EFO_0000574', 'EFO_0001663', 'MONDO_0000088', 'EFO_0001663', 'EFO_0000616', 'MONDO_0008170', 'EFO_0000180', 'EFO_1001757', 'EFO_0009029', 'EFO_0000673', 'EFO_0001065', 'EFO_0009029', 'MONDO_0008315', 'EFO_0000545', 'MONDO_0008315', 'EFO_0000305', 'EFO_0000673', 'EFO_0001065', 'MONDO_0007254', 'MONDO_0004669', 'MONDO_0007254']",False,False,24,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
1539,TINZAPARIN SODIUM,CHEMBL1201414,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for deep vein thrombosis and recurrent thrombophlebitis and has 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2000,['ENSG00000117601'],"['EFO_0003907', 'EFO_0000365', 'EFO_0003106', 'HP_0002140', 'MONDO_0002367', 'EFO_0001378', 'MONDO_0100096', 'EFO_0003060', 'HP_0001907', 'HP_0004419', 'MONDO_0008170']",False,False,11,Antithrombin-III activator ,ACTIVATOR ,single protein 
1540,INTERFERON GAMMA-1B,CHEMBL1201564,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 39 investigational indications.,,4.0,,False,1999,"['ENSG00000159128', 'ENSG00000027697']","['EFO_1001231', 'MONDO_0018305', 'EFO_0000588', 'EFO_0000574', 'EFO_0002918', 'EFO_0009869', 'MONDO_0009061', 'EFO_0000676', 'EFO_0000616', 'MONDO_0018364', 'EFO_0007460', 'EFO_0007386', 'EFO_0000174', 'MONDO_0002158', 'MONDO_0007254', 'EFO_0000756', 'EFO_0005952', 'MONDO_0017198', 'EFO_0009448', 'MONDO_0002087', 'EFO_1001359', 'EFO_0000637', 'EFO_0000764', 'MONDO_0004580', 'EFO_0000621', 'Orphanet_53', 'EFO_0000389', 'EFO_1001051', 'EFO_0009429', 'EFO_0004220', 'EFO_0001422', 'EFO_0003830', 'EFO_0001378', 'EFO_1000811', 'EFO_0000768', 'EFO_0007228', 'EFO_1001282', 'EFO_0007183', 'EFO_0000565', 'MONDO_0008315', 'EFO_0007147', 'MONDO_0008170', 'MONDO_0100339']",True,False,43,Interferon gamma receptor agonist ,AGONIST ,protein complex 
1541,IBRITUMOMAB TIUXETAN,CHEMBL1201606,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 16 investigational indications.,,4.0,,False,2002,['ENSG00000156738'],"['MONDO_0013730', 'EFO_0000191', 'EFO_0000183', 'EFO_0000095', 'EFO_0009441', 'EFO_0000565', 'EFO_0000096', 'EFO_0001378', 'EFO_0000403', 'MONDO_0018906', 'EFO_0000574', 'EFO_0000309', 'EFO_1001365', 'EFO_0005952', 'EFO_1001469', 'MONDO_0000873']",False,False,16,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
1542,RILONACEPT,CHEMBL1201830,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 7 investigational indications.,,4.0,,False,2008,['ENSG00000125538'],"['EFO_0000404', 'MONDO_0016168', 'EFO_0000540', 'Orphanet_47045', 'EFO_0007427', 'EFO_0002609', 'EFO_0004274', 'MONDO_0018088', 'EFO_0004238', 'MONDO_0005147', 'MONDO_0008633', 'EFO_1001345']",False,False,12,Interleukin-1 beta inhibitor ,INHIBITOR ,single protein 
1543,INSULIN DEGLUDEC,CHEMBL2107869,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for diabetes mellitus and has 2 investigational indications.,,4.0,,False,2015,['ENSG00000171105'],"['EFO_0000400', 'MONDO_0005147', 'MONDO_0005148']",False,False,3,Insulin receptor agonist ,AGONIST ,single protein 
1544,PEMETREXED DISODIUM,CHEMBL2360464,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 34 investigational indications.,,4.0,,False,2004,"['ENSG00000228716', 'ENSG00000176890', 'ENSG00000159131']","['EFO_0003050', 'MONDO_0011962', 'MONDO_0002158', 'MONDO_0008315', 'EFO_1001951', 'EFO_0000308', 'EFO_0000365', 'EFO_0000571', 'EFO_0006859', 'EFO_0002618', 'MONDO_0021117', 'MONDO_0004192', 'MONDO_0008903', 'EFO_0003060', 'EFO_0000708', 'EFO_0000574', 'MONDO_0000521', 'MONDO_0004992', 'MONDO_0002087', 'MONDO_0018944', 'EFO_0003860', 'MONDO_0007254', 'MONDO_0001187', 'EFO_0008528', 'EFO_0000691', 'MONDO_0002974', 'MONDO_0008170', 'MONDO_0001056', 'EFO_0009708', 'EFO_1000576', 'EFO_0000770', 'EFO_0000588', 'EFO_0003863', 'EFO_1000581', 'EFO_0000616']",True,False,35,Thymidylate synthase inhibitor Dihydrofolate reductase inhibitor GAR transformylase inhibitor ,INHIBITOR ,single protein 
1545,XL-281,CHEMBL3545027,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000132155', 'ENSG00000157764']","['EFO_0000756', 'EFO_0000641', 'EFO_1001951', 'EFO_0003060']",False,True,4,Serine/threonine-protein kinase B-raf inhibitor Serine/threonine-protein kinase RAF inhibitor ,INHIBITOR ,single protein 
1546,BERZOSERTIB,CHEMBL3989870,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.,,2.0,,False,no approval year,['ENSG00000175054'],"['EFO_0001075', 'EFO_1000251', 'EFO_0000199', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000702', 'EFO_0006352', 'EFO_0000616', 'EFO_0000305', 'EFO_0002618', 'EFO_0000564', 'EFO_0000196', 'MONDO_0008170', 'EFO_0003893', 'EFO_0001416', 'EFO_0000365', 'EFO_1001960', 'MONDO_0044704']",False,False,18,Serine-protein kinase ATR inhibitor ,INHIBITOR ,single protein 
1547,OLITIGALTIN,CHEMBL4297442,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000131981'],"['EFO_0000768', 'MONDO_0100096']",True,False,2,Galectin-3 inhibitor ,INHIBITOR ,single protein 
1548,TRV-120027,CHEMBL4297447,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000144891'],"['MONDO_0100096', 'EFO_0003144']",False,False,2,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
1549,PEMIGATINIB,CHEMBL4297522,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 10 investigational indications.,,4.0,,False,2020,"['ENSG00000077782', 'ENSG00000068078', 'ENSG00000066468']","['EFO_0000519', 'EFO_0003863', 'EFO_0004251', 'MONDO_0004992', 'EFO_0003060', 'EFO_1001951', 'MONDO_0011962', 'EFO_0008528', 'EFO_0000222', 'MONDO_0001187', 'EFO_0005221', 'EFO_0002618', 'EFO_0000616']",False,False,13,Fibroblast growth factor receptor 3 inhibitor Fibroblast growth factor receptor 2 inhibitor Fibroblast growth factor receptor 1 inhibitor ,INHIBITOR ,single protein 
1550,CHLORHEXIDINE,CHEMBL790,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 5 approved and 31 investigational indications.,,4.0,,False,1976,[],"['EFO_0003106', 'EFO_1001898', 'EFO_0003819', 'EFO_0007543', 'MONDO_0100096', 'MONDO_0002508', 'EFO_1001904', 'EFO_0005681', 'EFO_0006859', 'EFO_0000764', 'HP_0040187', 'MONDO_0043771', 'EFO_0000544', 'EFO_1001865', 'EFO_0000341', 'HP_0100806', 'EFO_1001888', 'EFO_0007126', 'EFO_1001459', 'EFO_1000874', 'EFO_0003033', 'MONDO_0002635', 'EFO_0000649', 'MONDO_0100096', 'EFO_0007126', 'MONDO_0002258', 'MONDO_0002258', 'EFO_0000544', 'MONDO_0002508', 'EFO_1001390', 'EFO_0003030', 'EFO_0000649', 'MONDO_0001475', 'EFO_0005741', 'MONDO_0009061', 'EFO_0000771', 'EFO_0003819', 'EFO_0003106', 'EFO_1001390']",False,False,39,,,
1551,CALCIFEDIOL,CHEMBL1040,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications.,,4.0,,False,1980,['ENSG00000111424'],"['MONDO_0100096', 'EFO_0003884', 'HP_0001919', 'EFO_0000612', 'EFO_0005754', 'EFO_0003918', 'EFO_1001173', 'EFO_0003762']",True,False,8,Vitamin D receptor agonist ,AGONIST ,single protein 
1552,DECITABINE,CHEMBL1201129,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 52 investigational indications.,,4.0,,False,2006,"['ENSG00000130816', 'ENSG00000119772']","['EFO_0000096', 'EFO_0000224', 'EFO_0000326', 'EFO_0000403', 'EFO_0000220', 'MONDO_0011382', 'MONDO_0003660', 'MONDO_0007254', 'EFO_0002913', 'EFO_1000131', 'MONDO_0000870', 'EFO_0003869', 'EFO_0000621', 'EFO_1001996', 'EFO_0003811', 'EFO_1001830', 'MONDO_0003659', 'EFO_0000756', 'EFO_0007160', 'MONDO_0019472', 'EFO_0000183', 'EFO_0000641', 'EFO_0002428', 'EFO_0003060', 'EFO_0004251', 'MONDO_0008170', 'EFO_0002617', 'MONDO_0013730', 'EFO_0000681', 'EFO_0000565', 'EFO_0000501', 'EFO_0001663', 'EFO_0000198', 'HP_0001915', 'MONDO_0002158', 'EFO_0000222', 'EFO_0000196', 'EFO_0000180', 'EFO_0000211', 'MONDO_0002280', 'EFO_0005952', 'EFO_0006859', 'EFO_0000616', 'EFO_1001779', 'EFO_0000339', 'EFO_0001642', 'HP_0001873', 'MONDO_0004992', 'MONDO_0002087', 'EFO_0000389', 'EFO_0002939', 'MONDO_0000430', 'EFO_0001378', 'EFO_0000574', 'EFO_0005922', 'EFO_0000309', 'EFO_1001469', 'MONDO_0100096']",True,False,58,DNA (cytosine-5)-methyltransferase 1 inhibitor DNA (cytosine-5)-methyltransferase 3A inhibitor ,INHIBITOR ,single protein 
1553,LAPATINIB DITOSYLATE,CHEMBL1201179,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000146648', 'ENSG00000141736']","['EFO_0002892', 'EFO_0000305', 'MONDO_0008315', 'EFO_0002938', 'MONDO_0044926', 'EFO_0000616', 'EFO_1001465', 'MONDO_0004986', 'MONDO_0001187', 'EFO_1000158', 'EFO_1001512', 'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0002618', 'EFO_0006861', 'EFO_0003869', 'EFO_0006352']",False,False,18,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1554,ESOMEPRAZOLE,CHEMBL1201320,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 10 approved and 29 investigational indications.,,4.0,,False,2001,"['ENSG00000105675', 'ENSG00000186009']","['HP_0004398', 'EFO_1000961', 'EFO_0009454', 'EFO_0000342', 'MONDO_0004247', 'EFO_0000337', 'EFO_1000961', 'MONDO_0004247', 'EFO_1001095', 'MONDO_0005178', 'HP_0100633', 'HP_0002239', 'EFO_0000574', 'EFO_0009454', 'EFO_0003948', 'MONDO_0004247', 'EFO_0004232', 'EFO_0002609', 'EFO_0003869', 'MONDO_0009061', 'EFO_0003948', 'MONDO_0007576', 'MP_0001914', 'EFO_0009454', 'EFO_0000217', 'MONDO_0004979', 'EFO_0000668', 'EFO_0004607', 'EFO_0005762', 'EFO_0000616', 'EFO_0003948', 'MONDO_0005148', 'EFO_0001361', 'EFO_0007549', 'EFO_0007549', 'MONDO_0005178', 'EFO_0003948', 'EFO_0010282', 'EFO_0004239', 'EFO_0004607', 'MONDO_0043839', 'EFO_0003758', 'EFO_0008533', 'HP_0002018', 'EFO_0003898', 'EFO_0000685', 'EFO_0004607', 'EFO_0003756']",False,False,48,Potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex 
1555,ONABOTULINUMTOXINA,CHEMBL1201574,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 100 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,['ENSG00000132639'],"['EFO_1001896', 'EFO_1001887', 'HP_0030834', 'EFO_0003897', 'EFO_1001434', 'EFO_1001466', 'GO_0007568', 'EFO_0009550', 'EFO_0005422', 'EFO_1001993', 'EFO_0008521', 'MONDO_0005180', 'HP_0012532', 'HP_0000565', 'HP_0002307', 'EFO_0003899', 'EFO_0001073', 'MONDO_0043839', 'HP_0000951', 'EFO_0000618', 'HP_0003419', 'HP_0001347', 'HP_0012390', 'HP_0000020', 'HP_0000016', 'EFO_1000781', 'EFO_1000999', 'EFO_0004212', 'EFO_0009523', 'HP_0000473', 'EFO_1000657', 'EFO_1000391', 'EFO_0005762', 'EFO_1000948', 'EFO_0004616', 'EFO_1001054', 'EFO_0003877', 'EFO_0004234', 'MONDO_0005301', 'MONDO_0043510', 'EFO_0009453', 'HP_0001257', 'EFO_0004270', 'EFO_0009619', 'HP_0002315', 'HP_0000989', 'EFO_0003894', 'MONDO_0004001', 'EFO_0000275', 'EFO_1001250', 'EFO_0007159', 'MONDO_0002050', 'EFO_1000632', 'EFO_1001092', 'EFO_0002618', 'HP_0000486', 'EFO_0002970', 'EFO_0000284', 'EFO_0003843', 'EFO_0004143', 'EFO_0004273', 'HP_0001337', 'EFO_0006346', 'EFO_0002916', 'MONDO_0002471', 'HP_0009926', 'EFO_0004269', 'EFO_0005306', 'EFO_1001219', 'HP_0012228', 'MONDO_0005178', 'EFO_0009846', 'EFO_0009625', 'EFO_0000546', 'EFO_1000850', 'EFO_0004191', 'HP_0000975', 'MONDO_0041052', 'EFO_0003911', 'EFO_0006865', 'EFO_0009430', 'MONDO_0005277', 'EFO_0003830', 'HP_0003549', 'EFO_0003108', 'EFO_1001145', 'HP_0000011', 'EFO_0000712', 'EFO_0007507', 'EFO_1001919', 'HP_0001605', 'Orphanet_93955', 'MONDO_0002009', 'EFO_0008507', 'EFO_1001909', 'EFO_1001494', 'HP_0032252', 'EFO_0001074', 'EFO_1000906', 'MONDO_0002507']",False,False,100,Synaptosomal-associated protein 25 inhibitor ,INHIBITOR ,single protein 
1556,DEFIBROTIDE,CHEMBL2108396,Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0004599', 'MONDO_0011382', 'EFO_0001378', 'MONDO_0019514', 'HP_0004419', 'EFO_0004246', 'MONDO_0100096']",False,False,7,,,
1557,CARBOXYMETHYLCELLULOSE SODIUM,CHEMBL2109001,Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 25 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000479', 'EFO_0003060', 'HP_0000539', 'EFO_0000305', 'MONDO_0001187', 'EFO_0000389', 'EFO_1000158', 'MONDO_0007935', 'MONDO_0044903', 'EFO_0000616', 'EFO_0008571', 'EFO_0003833', 'EFO_0002618', 'EFO_0000588', 'EFO_0000182', 'EFO_0000519', 'EFO_0002913', 'EFO_1000984', 'EFO_0005543', 'EFO_1000906', 'EFO_0001075', 'EFO_0000756', 'MONDO_0018906', 'EFO_0005537', 'EFO_0000222']",False,False,25,,,
1558,HYALURONATE,CHEMBL2110674,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for skin ulcer and nasal congestion and has 21 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001250', 'MONDO_0004986', 'EFO_0010822', 'EFO_1001178', 'EFO_0004143', 'EFO_0000341', 'MONDO_0005178', 'EFO_0005802', 'MONDO_0008315', 'EFO_1001345', 'EFO_1001818', 'MONDO_0005178', 'EFO_1000906', 'HP_0011107', 'EFO_1000906', 'HP_0200042', 'EFO_0004616', 'MONDO_0001330', 'EFO_0000546', 'HP_0001742', 'EFO_1000786', 'EFO_0004616', 'EFO_0004192', 'EFO_0009582', 'EFO_0000649', 'HP_0008419']",False,False,26,,,
1559,BGT-226,CHEMBL3218578,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['MONDO_0016063', 'MONDO_0007254', 'MONDO_0004992']",True,False,3,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1560,DOCETAXEL,CHEMBL3545252,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 108 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0011719', 'EFO_0003897', 'EFO_0005537', 'HP_0002039', 'EFO_0000313', 'MONDO_0002158', 'EFO_0000466', 'EFO_0006859', 'EFO_0002428', 'EFO_0000756', 'EFO_0000503', 'EFO_0000198', 'MONDO_0001056', 'MONDO_0002974', 'EFO_0004281', 'MONDO_0021117', 'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0007355', 'EFO_0003865', 'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'MONDO_0004986', 'MONDO_0002367', 'MONDO_0008903', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000637', 'MONDO_0001187', 'MONDO_0001528', 'EFO_0000432', 'MONDO_0008315', 'HP_0004326', 'MONDO_0002087', 'MONDO_0002038', 'EFO_0000228', 'EFO_0000181', 'EFO_0001416', 'MONDO_0003060', 'EFO_0000199', 'MONDO_0018364', 'MONDO_0002691', 'EFO_0009708', 'EFO_0004230', 'EFO_1001951', 'EFO_0003893', 'MONDO_0005271', 'EFO_0006911', 'EFO_0008528', 'HP_0012378', 'MONDO_0000521', 'MONDO_0007254', 'EFO_1000043', 'MONDO_0011962', 'EFO_0003891', 'MONDO_0005575', 'MONDO_0004192', 'MONDO_0021310', 'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'EFO_0000691', 'MONDO_0007576', 'Orphanet_145', 'EFO_0000564', 'EFO_0003869', 'EFO_0001663', 'MONDO_0001475', 'EFO_0004252', 'EFO_0001376', 'EFO_1000984', 'EFO_0000196', 'EFO_1000601', 'EFO_0003817', 'MONDO_0021355', 'EFO_0006352', 'MONDO_0004669', 'EFO_0000182', 'EFO_0004284', 'EFO_0000708', 'MONDO_0002120', 'MONDO_0001325', 'EFO_0001075', 'EFO_0002618', 'EFO_0000305', 'EFO_0000174', 'EFO_0000616', 'EFO_0000565', 'EFO_0000702', 'EFO_0003060', 'EFO_1001931', 'EFO_0005577', 'MONDO_0003199', 'EFO_0000574', 'EFO_1001100', 'EFO_0000673', 'EFO_1001214', 'EFO_0003860', 'MONDO_0004992', 'EFO_0000707', 'EFO_0005570', 'EFO_0007362', 'EFO_1000595', 'EFO_0003859', 'EFO_0002916', 'EFO_0005088', 'MONDO_0021063', 'EFO_0000178', 'EFO_0002938', 'EFO_0000571', 'EFO_0001378', 'MONDO_0001402']",True,False,114,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1561,IANALUMAB,CHEMBL4594357,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,['ENSG00000159958'],"['EFO_0000768', 'EFO_0000699', 'EFO_0005676', 'EFO_0000685', 'MONDO_0018906', 'EFO_0000095', 'MONDO_0007915', 'MONDO_0005301', 'EFO_0000403', 'EFO_1001469', 'EFO_0004719', 'EFO_0005761', 'EFO_1000630']",False,False,13,Tumor necrosis factor receptor superfamily member 13C binding agent ,BINDING AGENT ,single protein 
1562,DOMVANALIMAB,CHEMBL4650392,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000181847'],"['EFO_0003060', 'EFO_0000756', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000519']",True,False,5,T-cell immunoreceptor with Ig and ITIM domains inhibitor ,INHIBITOR ,single protein 
1563,ICARITIN,CHEMBL498485,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000182', 'EFO_0000616', 'MONDO_0007254']",False,False,3,,,
1564,MIDAZOLAM,CHEMBL655,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 105 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']","['MONDO_0018076', 'HP_0001623', 'EFO_0009686', 'EFO_0000662', 'EFO_0005741', 'EFO_1001328', 'MONDO_0043510', 'HP_0011110', 'HP_0000083', 'EFO_1001413', 'MONDO_0002050', 'EFO_1001249', 'EFO_0000685', 'EFO_0000274', 'EFO_0003768', 'EFO_0003929', 'EFO_0001073', 'MONDO_0005129', 'EFO_0001378', 'EFO_0004320', 'MONDO_0004992', 'EFO_0009854', 'MONDO_0002050', 'EFO_0000544', 'EFO_0000384', 'EFO_0007157', 'EFO_0006834', 'MONDO_0007606', 'EFO_0004272', 'EFO_0008525', 'EFO_0002617', 'MONDO_0002009', 'EFO_0003931', 'EFO_0003843', 'EFO_0009513', 'EFO_0007328', 'HP_0012378', 'HP_0000989', 'EFO_0003869', 'EFO_0003047', 'EFO_0000588', 'MONDO_0007254', 'MONDO_0002009', 'HP_0100806', 'MONDO_0100096', 'EFO_0004220', 'MONDO_0004975', 'EFO_1001454', 'EFO_0003914', 'MONDO_0005180', 'EFO_0001358', 'EFO_0002610', 'EFO_0003890', 'MONDO_0004976', 'EFO_1000049', 'MONDO_0004985', 'EFO_0000676', 'HP_0012076', 'EFO_0000274', 'MONDO_0005148', 'EFO_0000713', 'HP_0003419', 'EFO_0003863', 'EFO_0001068', 'EFO_0000616', 'MONDO_0005148', 'EFO_0005251', 'EFO_1001494', 'HP_0030833', 'EFO_0003144', 'EFO_0000616', 'EFO_0003060', 'EFO_0000319', 'EFO_0003854', 'EFO_0008526', 'EFO_0000701', 'EFO_0000545', 'EFO_0004242', 'EFO_0000546', 'EFO_0006911', 'EFO_0009267', 'EFO_0000222', 'EFO_0004239', 'EFO_0008526', 'EFO_0005411', 'EFO_0001422', 'EFO_0000673', 'EFO_0000764', 'EFO_0000618', 'MONDO_0044970', 'EFO_0000474', 'MONDO_0011719', 'EFO_0000537', 'MONDO_0005090', 'MONDO_0004985', 'EFO_0005952', 'HP_0002140', 'EFO_0005762', 'EFO_0005230', 'EFO_0000729', 'MP_0001914', 'EFO_0000095', 'HP_0001250', 'EFO_0001065', 'MONDO_0018076', 'MONDO_0008315', 'HP_0012532', 'EFO_0004888', 'EFO_0003015', 'HP_0000023', 'EFO_1001454', 'MONDO_0011382', 'HP_0012735']",True,False,113,GABA-A receptor; anion channel positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,protein complex group 
1565,MONTELUKAST,CHEMBL787,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 31 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000173198'],"['HP_0040187', 'MONDO_0004979', 'EFO_0007183', 'EFO_1001417', 'EFO_0003918', 'MONDO_0011382', 'EFO_0003917', 'EFO_0005854', 'EFO_0000694', 'HP_0012735', 'EFO_0000540', 'HP_0011950', 'EFO_0003843', 'EFO_0004227', 'EFO_0003877', 'MONDO_0100096', 'EFO_0000684', 'EFO_0000222', 'EFO_0003956', 'EFO_0008521', 'EFO_0000220', 'EFO_0004232', 'EFO_0000341', 'EFO_0008590', 'EFO_1001417', 'EFO_0000764', 'EFO_0005854', 'EFO_1001249', 'EFO_0000685', 'HP_0100806', 'EFO_0000401', 'EFO_0001378', 'EFO_0003956', 'MONDO_0004979', 'MONDO_0004975', 'MONDO_0019091', 'HP_0006536', 'EFO_0004232', 'EFO_0009715']",True,False,39,Cysteinyl leukotriene receptor 1 antagonist ,ANTAGONIST ,single protein 
1566,AMINOSALICYLIC ACID,CHEMBL1169,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for tuberculosis and has 4 investigational indications.,,4.0,,False,1950,[],"['MONDO_0018076', 'EFO_0000384', 'MONDO_0018076', 'EFO_0000729', 'MONDO_0018076', 'EFO_0003102']",False,False,6,Dihydrofolate reductase inhibitor ,INHIBITOR ,single protein 
1567,CARVEDILOL PHOSPHATE,CHEMBL1201167,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for myocardial infarction and hypertension and has 1 investigational indication.,,4.0,,False,2006,"['ENSG00000043591', 'ENSG00000169252', 'ENSG00000188778', 'ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0000373', 'EFO_0000612', 'EFO_0000537']",True,False,3,Adrenergic receptor alpha-1 antagonist Adrenergic receptor beta antagonist ,ANTAGONIST ,protein family 
1568,POVIDONE-IODINE,CHEMBL1201724,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 14 investigational indications.,,4.0,,False,1985,[],"['EFO_0000544', 'EFO_0007126', 'MONDO_0021201', 'EFO_0003894', 'EFO_0007149', 'EFO_0000771', 'EFO_0003106', 'EFO_0008571', 'EFO_1001888', 'EFO_0003819', 'EFO_0000546', 'MONDO_0100096', 'EFO_0009560', 'EFO_1001904', 'EFO_0009449', 'MONDO_0005178', 'EFO_0007486', 'EFO_0009516']",False,False,18,,,
1569,DEXLANSOPRAZOLE,CHEMBL1201863,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 2 investigational indications.,,4.0,,False,2009,"['ENSG00000105675', 'ENSG00000186009']","['EFO_0000280', 'EFO_0003948', 'EFO_1001095', 'HP_0004398', 'EFO_0009454', 'EFO_0004607', 'HP_0100633']",False,False,7,Potassium-transporting ATPase inhibitor ,INHIBITOR ,protein complex 
1570,LISOFYLLINE,CHEMBL1411,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1571,ATOVAQUONE,CHEMBL1450,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for malaria and pneumocystosis and has 6 investigational indications.,,4.0,,False,1992,[],"['EFO_0007444', 'EFO_0007200', 'EFO_0001068', 'EFO_0007448', 'EFO_0003060', 'MONDO_0100096', 'EFO_0000222', 'EFO_0003948']",False,False,8,Cytochrome b inhibitor ,INHIBITOR ,single protein 
1572,HONEY,CHEMBL2108391,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007486', 'MONDO_0100096', 'EFO_1001216', 'MONDO_0005147', 'EFO_0009094', 'EFO_0007305', 'EFO_0000546', 'MONDO_0007254', 'HP_0003074', 'EFO_0008517']",False,False,10,,,
1573,CAPMATINIB,CHEMBL3188267,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for non-small cell lung carcinoma and neoplasm and has 10 investigational indications.,,4.0,,False,2020,['ENSG00000105976'],"['MONDO_0008903', 'MONDO_0007254', 'EFO_0000182', 'EFO_0003060', 'EFO_0003060', 'MONDO_0002367', 'EFO_0000389', 'EFO_0000756', 'EFO_1001968', 'EFO_0000519', 'EFO_0000616', 'EFO_0001421']",True,False,12,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1574,OSUGACESTAT,CHEMBL4297269,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_1001830', 'EFO_0000231', 'MONDO_0004992']",False,False,4,,,
1575,TALACOTUZUMAB,CHEMBL4297837,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000185291'],"['EFO_0000198', 'MONDO_0007915', 'EFO_0000222']",True,False,3,Interleukin-3 receptor subunit alpha binding agent ,BINDING AGENT ,single protein 
1576,DV-281,CHEMBL4594538,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1577,GANULAMERAN,CHEMBL4650455,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1578,PROMETHAZINE,CHEMBL643,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 9 approved and 14 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1951,['ENSG00000196639'],"['EFO_0003843', 'EFO_0005230', 'HP_0002013', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0005531', 'MONDO_0005271', 'HP_0002017', 'EFO_1000971', 'EFO_0003843', 'MONDO_0004900', 'EFO_0006928', 'EFO_0003956', 'MONDO_0005475', 'EFO_0004698', 'MONDO_0100431', 'EFO_0000384', 'EFO_0000274', 'HP_0000989', 'HP_0002018', 'MONDO_0005271', 'EFO_1000948', 'EFO_0007141']",False,False,23,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
1579,NAPROXEN,CHEMBL154,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 25 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1976,"['ENSG00000073756', 'ENSG00000095303']","['EFO_0003898', 'MONDO_0100096', 'HP_0003419', 'MONDO_0005277', 'EFO_0005856', 'MONDO_0002258', 'EFO_0010072', 'MONDO_0005277', 'EFO_0004274', 'EFO_0003843', 'EFO_0003898', 'EFO_0004616', 'EFO_0002609', 'MONDO_0004975', 'MONDO_0005178', 'MONDO_0007254', 'EFO_0002609', 'MONDO_0002471', 'EFO_0000546', 'HP_0003418', 'EFO_0005757', 'MONDO_0005178', 'HP_0002829', 'MONDO_0005301', 'EFO_0009637', 'EFO_1000941', 'EFO_1000786', 'MONDO_0003937', 'MONDO_0004975', 'HP_0100607', 'EFO_0009454', 'HP_0003418', 'EFO_0007214', 'EFO_0009454', 'EFO_0000673', 'EFO_0004274', 'EFO_0005755', 'HP_0100607', 'HP_0001945', 'EFO_0005762', 'EFO_0000685', 'EFO_0010072', 'EFO_0004616', 'EFO_0004607', 'EFO_0000685', 'MONDO_0005835', 'EFO_0009846', 'HP_0004398', 'EFO_1001434', 'MP_0001845', 'MONDO_0004857', 'MONDO_0010870', 'EFO_0003843', 'HP_0003326', 'HP_0002315']",True,False,55,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
1580,TENOFOVIR ALAFENAMIDE,CHEMBL2107825,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,[],"['EFO_0000180', 'EFO_0000095', 'EFO_0000765', 'EFO_0004239', 'EFO_0007304', 'EFO_0002614', 'EFO_0000180', 'EFO_0004239', 'MONDO_0004976', 'EFO_0000764', 'EFO_0004197', 'MONDO_0100096', 'EFO_0000764', 'EFO_0000763']",False,False,14,Human immunodeficiency virus type 1 reverse transcriptase inhibitor ,INHIBITOR ,single protein 
1581,SGN-15,CHEMBL2109502,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003893', 'MONDO_0007254', 'EFO_0000673', 'EFO_0003060']",False,False,4,,,
1582,RIMIDUCID,CHEMBL269259,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0008315', 'MONDO_0007254', 'EFO_0000220', 'EFO_0000198', 'MONDO_0044881', 'EFO_0000222', 'EFO_0000196', 'MONDO_0004992', 'EFO_0000095', 'EFO_0001378']",False,False,10,,,
1583,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,CHEMBL3707314,Protein drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 1 investigational indication.,,4.0,,False,no approval year,['ENSG00000187266'],"['EFO_0004272', 'MONDO_0002280', 'EFO_0003884', 'EFO_0003086']",False,False,4,Erythropoietin receptor agonist ,AGONIST ,single protein 
1584,ALOBRESIB,CHEMBL3982690,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0008315', 'MONDO_0007254', 'EFO_0000574']",False,False,3,,,
1585,LOBAPLATIN,CHEMBL4594256,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004252', 'EFO_0000182', 'EFO_0002916', 'MONDO_0007576', 'EFO_0000616', 'EFO_0000181', 'MONDO_0007254', 'EFO_0000702']",False,False,8,,,
1586,DIROCAFTOR,CHEMBL4594297,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
1587,GC-4711,CHEMBL4650307,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0002618', 'EFO_0003060']",False,False,2,,,
1588,ZORECIMERAN,CHEMBL4802204,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000694', 'MONDO_0100096']",False,False,2,,,
1589,THIOTEPA,CHEMBL671,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 5 approved and 42 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1959,[],"['EFO_0000502', 'EFO_0003833', 'MONDO_0013730', 'MONDO_0010518', 'EFO_0002428', 'MONDO_0002691', 'EFO_0000616', 'EFO_0004251', 'EFO_1000984', 'EFO_0000313', 'MONDO_0011382', 'EFO_0000228', 'EFO_0000198', 'EFO_0000565', 'EFO_0000574', 'EFO_0001378', 'EFO_1001968', 'MONDO_0002087', 'EFO_0005803', 'EFO_0000637', 'EFO_0000339', 'MONDO_0002158', 'MONDO_0008380', 'MONDO_0004992', 'MONDO_0008978', 'EFO_0004272', 'MONDO_0044903', 'MONDO_0015974', 'EFO_0000384', 'MONDO_0007254', 'EFO_0000183', 'EFO_0006861', 'EFO_0000326', 'EFO_0000220', 'MONDO_0008170', 'MONDO_0003751', 'EFO_1000158', 'EFO_0005235', 'EFO_0000403', 'MONDO_0002367', 'EFO_0000621', 'MONDO_0021193', 'EFO_0002939', 'EFO_0000691', 'EFO_0000305', 'EFO_0001642', 'EFO_0000222']",False,False,47,,,
1590,PROGESTERONE,CHEMBL103,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for amenorrhea and hemorrhage and has 41 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1976,['ENSG00000082175'],"['HP_0000938', 'MONDO_0005351', 'MONDO_0022394', 'MONDO_0005147', 'EFO_0010269', 'EFO_0000545', 'MP_0001914', 'EFO_1000623', 'EFO_0000731', 'EFO_0005204', 'EFO_0002950', 'EFO_0000474', 'EFO_0001645', 'EFO_0000400', 'EFO_0003869', 'EFO_0000180', 'EFO_0007453', 'EFO_0000668', 'MONDO_0100096', 'MONDO_0007254', 'MONDO_0004975', 'EFO_1000645', 'EFO_0004701', 'EFO_0000537', 'EFO_0008560', 'MONDO_0011972', 'EFO_0003917', 'EFO_0007442', 'EFO_0007191', 'EFO_1000985', 'EFO_0003768', 'EFO_0000660', 'EFO_0003922', 'EFO_1001465', 'MONDO_0000831', 'MONDO_0043510', 'MONDO_0011962', 'EFO_1001375', 'EFO_0003882', 'EFO_0001072', 'HP_0003124', 'EFO_0002610', 'EFO_0003893']",False,False,43,Progesterone receptor agonist ,AGONIST ,single protein 
1591,LEUPROLIDE ACETATE,CHEMBL1200775,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 approved and 15 investigational indications.,,4.0,,False,1985,['ENSG00000109163'],"['EFO_0001378', 'MONDO_0004975', 'EFO_0004248', 'EFO_0005204', 'EFO_0000731', 'EFO_0000537', 'MONDO_0000088', 'EFO_0000196', 'EFO_0003869', 'EFO_1001469', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000673', 'MONDO_0004992', 'EFO_0001073', 'EFO_0000183', 'EFO_0001663', 'EFO_0001065', 'EFO_0009029', 'HP_0100543', 'EFO_0007453']",False,False,21,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
1592,GLP-1,CHEMBL1240772,Protein drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005669', 'EFO_0001073', 'HP_0001943', 'MONDO_0005147', 'MONDO_0005148', 'EFO_0010282', 'EFO_0003913']",False,False,7,,,
1593,CEFEPIME,CHEMBL186,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 11 investigational indications.,,4.0,,False,1996,[],"['EFO_0003103', 'EFO_0000544', 'EFO_0003086', 'HP_0031217', 'EFO_0006834', 'HP_0001945', 'MONDO_0001475', 'EFO_0003106', 'EFO_0000771', 'EFO_0009582', 'MONDO_0044881', 'EFO_0003033', 'EFO_0003102', 'EFO_0003103', 'EFO_1001313', 'EFO_1001141', 'EFO_0005741']",False,False,17,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1594,CABOZANTINIB,CHEMBL2105717,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 8 approved and 60 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000105976', 'ENSG00000128052']","['EFO_0000519', 'EFO_0000681', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000501', 'EFO_1001949', 'EFO_0000640', 'EFO_0001421', 'EFO_0003968', 'EFO_0000239', 'EFO_0000640', 'EFO_0000313', 'EFO_0000616', 'EFO_1001512', 'EFO_0000681', 'MONDO_0007254', 'EFO_1001968', 'MONDO_0002974', 'EFO_0005220', 'EFO_1001951', 'EFO_0000326', 'EFO_0000272', 'EFO_0000616', 'EFO_0000673', 'EFO_1000796', 'EFO_1001465', 'EFO_0000389', 'MONDO_0002120', 'EFO_0004243', 'EFO_0002618', 'EFO_1000251', 'EFO_0000305', 'EFO_1000657', 'MONDO_0011719', 'EFO_0008528', 'EFO_0000349', 'EFO_0000641', 'EFO_0000222', 'EFO_0002617', 'EFO_1000613', 'MONDO_0004669', 'MONDO_0001187', 'EFO_0000519', 'EFO_1001465', 'EFO_0003016', 'EFO_0000756', 'EFO_0000641', 'EFO_0000182', 'EFO_0002892', 'EFO_0001378', 'MONDO_0002108', 'MONDO_0008315', 'EFO_0000637', 'MONDO_0002108', 'MONDO_0004986', 'EFO_0000707', 'MONDO_0002367', 'MONDO_0016642', 'MONDO_0004992', 'EFO_0000501', 'EFO_0003060', 'EFO_0003863', 'EFO_0000182', 'EFO_0003060', 'EFO_0000335', 'EFO_0000349', 'EFO_0008524', 'EFO_0000673', 'EFO_1001901', 'EFO_0002499', 'MONDO_0015277', 'EFO_1001961']",True,False,72,Vascular endothelial growth factor receptor 2 inhibitor Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1595,TIFACOGIN,CHEMBL2108792,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003106'],False,False,1,,,
1596,DACOMITINIB,CHEMBL2110732,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 14 investigational indications.,,4.0,,False,2018,"['ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']","['EFO_0004284', 'EFO_1001951', 'MONDO_0001657', 'EFO_0009708', 'EFO_0000707', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000616', 'EFO_0000519', 'EFO_0000181', 'EFO_0003060', 'EFO_0003833', 'EFO_1001094', 'EFO_0000313', 'EFO_0001421', 'MONDO_0008903', 'EFO_0005570']",False,True,17,Receptor protein-tyrosine kinase erbB-2 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1597,NALOXEGOL,CHEMBL2219418,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 4 investigational indications.,,4.0,,False,2014,['ENSG00000112038'],"['MONDO_0002203', 'HP_0002019', 'MONDO_0043510', 'EFO_0005611', 'EFO_0003060', 'MONDO_0004567', 'EFO_0003843']",False,False,7,Mu opioid receptor antagonist ,ANTAGONIST ,single protein 
1598,MERIMEPODIB,CHEMBL304087,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000106348'],['MONDO_0100096'],True,False,1,Inosine-5'-monophosphate dehydrogenase 1 inhibitor ,INHIBITOR ,single protein 
1599,CETYLPYRIDINIUM,CHEMBL305906,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0002635', 'EFO_1000653', 'MONDO_0002508']",False,False,4,,,
1600,FINGOLIMOD,CHEMBL314854,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications.,,4.0,,False,2010,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']","['EFO_0008520', 'EFO_0000540', 'MONDO_0010726', 'EFO_1000868', 'HP_0000083', 'EFO_0002499', 'MONDO_0005090', 'EFO_1001231', 'MONDO_0004979', 'EFO_0000712', 'EFO_0007405', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0003840', 'EFO_0003929', 'EFO_0000519', 'MONDO_0004976', 'MONDO_0005301', 'EFO_0000305', 'EFO_0003929']",True,False,20,Sphingosine 1-phosphate receptor binding agent Sphingosine 1-phosphate receptor agonist ,BINDING AGENT AGONIST ,protein family 
1601,SACITUZUMAB GOVITECAN,CHEMBL3545262,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2020,"['ENSG00000184292', 'ENSG00000198900']","['EFO_0003060', 'MONDO_0004992', 'EFO_0005537', 'EFO_0000519', 'EFO_0000305', 'EFO_0000702', 'EFO_0003863', 'MONDO_0008315', 'EFO_0008528', 'MONDO_0007254', 'EFO_1001512', 'EFO_0000616', 'MONDO_0001187']",False,False,13,Tumor-associated calcium signal transducer 2 binding agent DNA topoisomerase I inhibitor ,BINDING AGENT INHIBITOR ,single protein 
1602,ORNITHINE,CHEMBL446143,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002939', 'HP_0006554', 'EFO_0004198', 'EFO_0001422', 'MONDO_0005147', 'HP_0006554', 'EFO_0000621', 'MONDO_0011628', 'HP_0001298']",False,False,9,,,
1603,ENSIFENTRINE,CHEMBL4594287,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650', 'ENSG00000172572', 'ENSG00000152270']","['MONDO_0100096', 'MONDO_0009061', 'EFO_0000341', 'MONDO_0004979']",True,False,4,Phosphodiesterase 3 inhibitor Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
1604,CHLORPHENIRAMINE,CHEMBL505,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 6 investigational indications.,,4.0,,False,1950,['ENSG00000196639'],"['EFO_0005854', 'HP_0012735', 'EFO_0007328', 'MONDO_0005271', 'EFO_0003956', 'EFO_0007486', 'EFO_0003956', 'EFO_0003958', 'EFO_0004239']",False,False,9,Histamine H1 receptor antagonist ,ANTAGONIST ,single protein 
1605,NAPHAZOLINE,CHEMBL761,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 7 investigational indications.,,4.0,,False,1971,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']","['EFO_0007214', 'EFO_0000678', 'MP_0001845', 'EFO_0007141', 'EFO_0000616', 'HP_0001742', 'EFO_0003822', 'EFO_0007328', 'EFO_0003956', 'EFO_0005751', 'EFO_0007214', 'EFO_0007486', 'HP_0001742']",False,False,13,Adrenergic receptor alpha agonist ,AGONIST ,protein family 
1606,METOLAZONE,CHEMBL878,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 approved and 1 investigational indication.,,4.0,,False,1973,['ENSG00000070915'],"['EFO_0000373', 'EFO_0000319', 'EFO_0003884', 'EFO_0000537', 'EFO_0003144', 'EFO_0000668']",False,False,6,Thiazide-sensitive sodium-chloride cotransporter inhibitor ,INHIBITOR ,single protein 
1607,BEVACIZUMAB,CHEMBL1201583,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 19 approved and 181 investigational indications.,,4.0,,False,2004,['ENSG00000112715'],"['EFO_0003050', 'EFO_1000613', 'EFO_0000174', 'EFO_1000796', 'EFO_0006859', 'EFO_0003828', 'MONDO_0008903', 'EFO_0003016', 'EFO_1000052', 'MONDO_0002363', 'EFO_1001961', 'EFO_0007224', 'MONDO_0018364', 'MONDO_0100342', 'EFO_0002893', 'EFO_0001061', 'EFO_0002618', 'EFO_1000783', 'MONDO_0002158', 'EFO_0009708', 'MONDO_0001056', 'EFO_0003106', 'EFO_0003884', 'EFO_0009637', 'EFO_0003060', 'EFO_0008528', 'EFO_0004243', 'EFO_1001187', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0000756', 'EFO_0000698', 'EFO_1001100', 'EFO_1000158', 'EFO_0000349', 'MONDO_0005575', 'MONDO_0011719', 'MONDO_0001280', 'MONDO_0003005', 'MONDO_0020634', 'EFO_0000770', 'EFO_0000630', 'EFO_1001231', 'EFO_0000678', 'EFO_1001465', 'EFO_0009606', 'HP_0001541', 'EFO_0000095', 'EFO_1000895', 'EFO_1000984', 'MONDO_0024677', 'EFO_0000365', 'EFO_0005577', 'EFO_0002087', 'EFO_1000581', 'EFO_0001416', 'EFO_0002892', 'EFO_0002517', 'MONDO_0001576', 'MONDO_0002974', 'EFO_0000198', 'EFO_0000693', 'EFO_0000673', 'EFO_0000564', 'MONDO_0018906', 'EFO_0000519', 'MONDO_0009937', 'EFO_0000588', 'MONDO_0011962', 'EFO_0000272', 'MONDO_0044903', 'EFO_0000707', 'MONDO_0008315', 'EFO_1001949', 'EFO_0009448', 'MONDO_0003268', 'EFO_0003833', 'EFO_0005543', 'EFO_0000182', 'EFO_0000503', 'EFO_0002499', 'MONDO_0008170', 'EFO_0004212', 'EFO_0004284', 'EFO_0000305', 'EFO_0002617', 'EFO_1001111', 'EFO_0003893', 'EFO_0005753', 'EFO_0004264', 'MONDO_0044937', 'MP_0001914', 'EFO_0000335', 'EFO_0005537', 'EFO_0000616', 'EFO_0000640', 'MONDO_0002989', 'MONDO_0002108', 'EFO_1000657', 'MONDO_0019472', 'EFO_0000574', 'EFO_0001376', 'EFO_0000248', 'EFO_0001365', 'EFO_1000043', 'EFO_0000621', 'EFO_1000251', 'EFO_0000571', 'EFO_0001065', 'MONDO_0002120', 'EFO_0001075', 'MONDO_0002691', 'EFO_1001951', 'EFO_1001158', 'EFO_0000183', 'EFO_0004683', 'EFO_0000348', 'EFO_0002916', 'EFO_0002918', 'EFO_0006772', 'EFO_0000339', 'EFO_1001471', 'MONDO_0016700', 'EFO_0005773', 'EFO_0002939', 'EFO_0000569', 'EFO_0005952', 'EFO_1000809', 'EFO_0000096', 'EFO_0007143', 'EFO_0000632', 'MP_0001845', 'EFO_0007416', 'EFO_0009784', 'EFO_1001469', 'EFO_1001157', 'EFO_1000475', 'EFO_1000026', 'EFO_1001968', 'EFO_0000514', 'EFO_0000232', 'EFO_0004252', 'EFO_0003839', 'MONDO_0001657', 'EFO_0005567', 'EFO_0000681', 'MONDO_0003060', 'MONDO_0021632', 'EFO_0000389', 'MONDO_0016642', 'EFO_1000028', 'MONDO_0005041', 'EFO_0000228', 'EFO_0000558', 'EFO_0000403', 'EFO_0004251', 'EFO_1000823', 'MONDO_0007254', 'MONDO_0018271', 'EFO_0010282', 'MONDO_0021063', 'EFO_0000466', 'MONDO_0018092', 'MONDO_0008667', 'EFO_0001378', 'EFO_0006861', 'EFO_1001901', 'MONDO_0100096', 'EFO_0003770', 'EFO_0000313', 'EFO_1001512', 'EFO_1001513', 'EFO_0000691', 'EFO_0000694', 'EFO_0005221', 'MONDO_0002087', 'EFO_0000565', 'EFO_0004142', 'MONDO_0007576', 'EFO_0000178', 'MONDO_0005835', 'MONDO_0019297', 'EFO_0003860', 'MONDO_0007935', 'EFO_0004256', 'HP_0000545', 'EFO_0003968', 'EFO_0000196', 'MONDO_0019180', 'EFO_0000760', 'EFO_0000702', 'EFO_0008626', 'MONDO_0002367', 'EFO_0002501', 'EFO_0004288', 'EFO_0000181', 'MONDO_0043510', 'EFO_0003869', 'EFO_1000880', 'EFO_0000326']",True,True,200,Vascular endothelial growth factor A inhibitor ,INHIBITOR ,single protein 
1608,HYDROXYCHLOROQUINE,CHEMBL1535,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for malaria and rheumatoid arthritis and has 78 investigational indications.,,4.0,,False,1955,"['ENSG00000239732', 'ENSG00000196664']","['DOID_13406', 'EFO_0000616', 'EFO_0002618', 'EFO_0009001', 'EFO_0001068', 'EFO_0004244', 'MONDO_0005178', 'MONDO_0004992', 'EFO_0007448', 'MONDO_0100096', 'EFO_0003840', 'EFO_0000519', 'MONDO_0100130', 'EFO_1000158', 'MONDO_0008903', 'EFO_0002689', 'MONDO_0011705', 'EFO_0000389', 'EFO_0000565', 'EFO_0007328', 'EFO_0003818', 'EFO_0004616', 'EFO_0000729', 'MONDO_0005147', 'EFO_0007224', 'EFO_0001378', 'MONDO_0100096', 'EFO_0003834', 'EFO_0000198', 'MONDO_0007915', 'MONDO_0008315', 'EFO_0002614', 'EFO_0001068', 'EFO_0000694', 'EFO_0001663', 'EFO_0000228', 'MONDO_0005148', 'EFO_0005221', 'EFO_0000182', 'MONDO_0010520', 'EFO_0009686', 'MONDO_0007254', 'EFO_0000756', 'EFO_0002950', 'MONDO_0013730', 'EFO_0004220', 'EFO_0000681', 'EFO_1000710', 'EFO_0000095', 'EFO_0000685', 'EFO_0000389', 'EFO_0000637', 'EFO_0000384', 'EFO_0005221', 'Orphanet_912', 'EFO_0000702', 'EFO_0007224', 'EFO_0005755', 'EFO_0000349', 'EFO_0000685', 'EFO_0000691', 'EFO_1001209', 'MONDO_0015104', 'EFO_0003047', 'EFO_0004244', 'HP_0001873', 'EFO_0000668', 'EFO_0000222', 'EFO_0007541', 'EFO_0003106', 'MONDO_0009061', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000764', 'EFO_1000954', 'EFO_1000726', 'MONDO_0019200', 'EFO_0000544', 'EFO_1001951', 'EFO_0000699', 'MONDO_0007915', 'MONDO_0100342', 'EFO_1000637', 'EFO_0002689', 'EFO_0003060', 'EFO_0002618']",True,True,86,Toll-like receptor 7 antagonist Toll-like receptor 9 antagonist ,ANTAGONIST ,single protein 
1609,TIBOLONE,CHEMBL2103774,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0003882', 'EFO_0004714', 'MONDO_0002009', 'MONDO_0007254', 'EFO_0003922']",False,False,5,,,
1610,ST. JOHN'S WORT,CHEMBL2108102,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001145', 'MONDO_0007254', 'EFO_0003761', 'EFO_0003888', 'EFO_0003843', 'MONDO_0002050', 'EFO_0007355', 'EFO_0003865', 'EFO_0000555', 'EFO_0006859', 'EFO_0003768']",False,False,11,,,
1611,FUTUXIMAB,CHEMBL2109388,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['MONDO_0100342', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060']",False,True,4,Epidermal growth factor receptor erbB1 antagonist ,ANTAGONIST ,single protein 
1612,VINFLUNINE,CHEMBL2110725,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 13 investigational indications.,,4.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0001056', 'EFO_0008528', 'EFO_0000702', 'MONDO_0004992', 'EFO_1001094', 'MONDO_0007254', 'EFO_0003060', 'MONDO_0002038', 'MONDO_0008903', 'EFO_1000601', 'EFO_0000616', 'MONDO_0001187', 'MONDO_0004986', 'EFO_0003863', 'MONDO_0008315']",True,False,15,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1613,TASIDOTIN,CHEMBL2111109,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000756', 'MONDO_0008315', 'EFO_0003060']",False,False,3,,,
1614,ARSENIC TRIOXIDE,CHEMBL2362016,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2000,['ENSG00000198431'],"['EFO_0000182', 'EFO_1001512', 'EFO_0003060', 'EFO_0000224', 'EFO_0000479', 'MONDO_0002974', 'EFO_0000339', 'EFO_0000222', 'EFO_0002429', 'MONDO_0004992', 'EFO_1001951', 'EFO_1000158', 'EFO_0000095', 'MONDO_0008627', 'MONDO_0007254', 'EFO_0000565', 'EFO_0000616', 'EFO_0000765', 'EFO_1001465', 'EFO_0000702', 'MONDO_0007915', 'EFO_0000574', 'MONDO_0002367', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0000621', 'MONDO_0002691', 'EFO_0001378', 'MONDO_0044903', 'EFO_0002430', 'EFO_0002617', 'MONDO_0004192', 'EFO_0002618', 'MONDO_0004986', 'EFO_0000198', 'MONDO_0005341', 'MONDO_0001657']",True,False,37,Thioredoxin reductase 1 inhibitor ,INHIBITOR ,single protein 
1615,NAFAMOSTAT,CHEMBL273264,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['HP_0001919', 'MONDO_0100096', 'MONDO_0100096']",False,False,3,,,
1616,NAZARTINIB,CHEMBL3787344,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_0000616', 'MONDO_0008903', 'EFO_1000849', 'EFO_0003060']",False,True,4,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1617,CHLORHEXIDINE GLUCONATE,CHEMBL4297088,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved and 16 investigational indications. It was withdrawn in at least one region.,,4.0,,False,1976,[],"['EFO_0003106', 'EFO_1001898', 'MONDO_0002258', 'MONDO_0002508', 'EFO_0003030', 'EFO_1001390', 'EFO_0003819', 'EFO_0007543', 'MONDO_0100096', 'EFO_0000649', 'EFO_1001904', 'EFO_0006859', 'EFO_0000764', 'MONDO_0043771', 'EFO_0000544', 'HP_0100806', 'MONDO_0009061', 'EFO_0007126', 'EFO_1000874']",False,False,19,,,
1618,PARSACLISIB,CHEMBL4297615,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,['ENSG00000171608'],"['EFO_0000574', 'EFO_0000211', 'MONDO_0000430', 'EFO_0004719', 'MONDO_0007254', 'EFO_0000756', 'MONDO_0011962', 'EFO_0000403', 'EFO_0000095', 'EFO_0004251', 'EFO_1001469', 'MONDO_0004992', 'MONDO_0018906', 'EFO_0000096', 'EFO_0000616', 'EFO_1001264', 'EFO_0000699']",True,False,17,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
1619,CADISEGLIATIN,CHEMBL5095262,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1620,NIMESULIDE,CHEMBL56367,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 2 investigational indications. It was withdrawn in at least one region.,,4.0,,False,no approval year,[],"['EFO_0003843', 'HP_0002829', 'HP_0003326', 'EFO_0005755', 'MONDO_0007254']",False,False,5,,,
1621,ARTEMISININ,CHEMBL567597,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for malaria and has 2 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001068', 'MONDO_0100096', 'MONDO_0005090']",False,False,3,,,
1622,MELOXICAM,CHEMBL599,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2000,['ENSG00000073756'],"['HP_0030834', 'EFO_0000685', 'EFO_0002609', 'MONDO_0018076', 'MONDO_0002258', 'MONDO_0005277', 'EFO_0000673', 'EFO_0010072', 'MONDO_0005178', 'MONDO_0007915', 'HP_0003419', 'EFO_0003898', 'HP_0100607', 'EFO_0005755', 'EFO_0003843']",True,False,15,Cyclooxygenase-2 inhibitor ,INHIBITOR ,single protein 
1623,HYDROGEN PEROXIDE,CHEMBL71595,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 8 investigational indications.,,4.0,,False,2017,[],"['EFO_0000544', 'MONDO_0100096', 'EFO_0003894', 'EFO_0004193', 'EFO_1001216', 'MONDO_0002258', 'MONDO_0002508', 'EFO_0005584', 'EFO_0009662', 'MONDO_0007254', 'EFO_0003819', 'EFO_0000546']",False,False,12,,,
1624,ROFECOXIB,CHEMBL122,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for rheumatic disease and has 12 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,,4.0,,True,1999,['ENSG00000073756'],"['EFO_0005755', 'MONDO_0005178', 'EFO_0003833', 'MONDO_0008315', 'EFO_0005406', 'EFO_0005543', 'EFO_0004616', 'EFO_0003843', 'EFO_0003897', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004975', 'HP_0003040']",False,False,13,Cyclooxygenase-2 inhibitor ,INHIBITOR ,single protein 
1625,AVIPTADIL,CHEMBL1981592,Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000120907', 'ENSG00000150594', 'ENSG00000184160', 'ENSG00000171873', 'ENSG00000170214', 'ENSG00000274286']","['MONDO_0100096', 'EFO_0004610', 'EFO_1000637']",True,False,3,Adrenergic receptor alpha antagonist ,ANTAGONIST ,protein family 
1626,DACOMITINIB,CHEMBL2105719,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for non-small cell lung carcinoma.,,4.0,,False,2018,"['ENSG00000146648', 'ENSG00000178568', 'ENSG00000141736']",['EFO_0003060'],False,True,1,Receptor protein-tyrosine kinase erbB-2 inhibitor Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor ,INHIBITOR ,single protein 
1627,BOSUTINIB,CHEMBL288441,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for chronic myelogenous leukemia and neoplasm and has 18 investigational indications.,,4.0,,False,2010,"['ENSG00000097007', 'ENSG00000186716', 'ENSG00000101336', 'ENSG00000197122', 'ENSG00000254087']","['EFO_0000222', 'EFO_0000339', 'MONDO_0002974', 'EFO_1000131', 'EFO_0002618', 'EFO_0000616', 'EFO_1001496', 'MONDO_0002087', 'EFO_1000581', 'MONDO_0007254', 'EFO_0000519', 'EFO_0003060', 'EFO_0000565', 'MONDO_0001187', 'MONDO_0002586', 'EFO_0000220', 'EFO_0000305', 'EFO_0000588', 'MONDO_0004976', 'MONDO_0008170']",True,False,20,Bcr/Abl fusion protein Tyrosine-protein kinase ABL inhibitor Tyrosine-protein kinase Lyn inhibitor Tyrosine-protein kinase SRC inhibitor Tyrosine-protein kinase HCK inhibitor ,INHIBITOR ,chimeric protein single protein 
1628,XL-999,CHEMBL3545285,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468', 'ENSG00000122025', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000157404']","['EFO_1001951', 'EFO_0000222', 'EFO_0000681', 'EFO_0003060', 'MONDO_0008170', 'MONDO_0004992', 'EFO_0001378']",False,False,7,Fibroblast growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,protein family single protein protein complex 
1629,SULANEMADLIN,CHEMBL5095209,Protein drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000211', 'EFO_0003060', 'EFO_0000198', 'EFO_0000702', 'EFO_0000222']",False,False,5,,,
1630,ATROPINE,CHEMBL517712,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 7 approved and 23 investigational indications.,,4.0,,False,1960,"['ENSG00000168539', 'ENSG00000181072', 'ENSG00000133019']","['HP_0000545', 'HP_0002315', 'EFO_1001865', 'EFO_0008546', 'EFO_0004209', 'HP_0001943', 'EFO_0002614', 'HP_0004398', 'MONDO_0007254', 'MONDO_0005180', 'EFO_0005252', 'EFO_0003956', 'MONDO_0004976', 'EFO_0005323', 'EFO_0009314', 'MONDO_0001020', 'EFO_0010282', 'EFO_0003843', 'EFO_1001109', 'EFO_0009492', 'HP_0000545', 'HP_0011499', 'HP_0012803', 'MP_0001914', 'EFO_1000645', 'EFO_0005854', 'HP_0001662', 'EFO_0003956', 'EFO_1001121', 'HP_0000486', 'EFO_0010581', 'HP_0011499']",False,False,32,Muscarinic acetylcholine receptor M1 antagonist Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M2 antagonist ,ANTAGONIST ,single protein 
1631,VOSAROXIN,CHEMBL68117,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000131747', 'ENSG00000077097']","['EFO_0000565', 'EFO_0000220', 'EFO_0003060', 'EFO_0000702', 'EFO_0000339', 'EFO_0000198', 'EFO_0000616', 'EFO_0000222']",True,False,8,DNA topoisomerase II inhibitor ,INHIBITOR ,protein family 
1632,MUPIROCIN,CHEMBL719,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved and 10 investigational indications.,,4.0,,False,1987,[],"['EFO_0005681', 'EFO_0007486', 'EFO_0000544', 'EFO_1000714', 'EFO_0003895', 'EFO_0000544', 'EFO_0000546', 'EFO_1000635', 'MONDO_0043771', 'HP_0001742', 'MONDO_0009061', 'EFO_0003102', 'MONDO_0019180', 'EFO_0005681']",False,False,14,Isoleucyl-tRNA synthetase inhibitor ,INHIBITOR ,single protein 
1633,AMILORIDE,CHEMBL945,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']","['EFO_0000537', 'MONDO_0009061', 'EFO_0000319', 'EFO_0008519', 'EFO_0000373', 'EFO_0003888', 'EFO_0001645', 'EFO_0007405', 'EFO_0008522', 'EFO_0004269', 'MONDO_0005475', 'MONDO_0009061', 'EFO_0000537', 'HP_0011096']",False,False,14,"Amiloride-sensitive sodium channel, ENaC blocker ",BLOCKER ,protein complex 
1634,AMIFOSTINE,CHEMBL1006,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 35 investigational indications.,,4.0,,False,1995,[],"['EFO_0000691', 'MONDO_0011962', 'MONDO_0021310', 'EFO_0000673', 'EFO_0000183', 'EFO_1000292', 'EFO_0009869', 'MONDO_0019391', 'MONDO_0002691', 'EFO_0000621', 'MONDO_0008170', 'EFO_1001951', 'EFO_1000657', 'EFO_0001378', 'EFO_0003833', 'EFO_0000181', 'EFO_0000565', 'EFO_0000770', 'EFO_0003100', 'MONDO_0008380', 'MONDO_0007254', 'MONDO_0001187', 'EFO_1000158', 'MONDO_0008978', 'EFO_0005952', 'EFO_0000574', 'MONDO_0008903', 'EFO_0002428', 'MONDO_0008315', 'EFO_1001219', 'MONDO_0002974', 'EFO_0000198', 'MONDO_0003751', 'EFO_0000222', 'MONDO_0002367', 'EFO_0006859', 'EFO_0000616', 'MONDO_0002087', 'MONDO_0002158']",False,False,39,,,
1635,ROPIVACAINE,CHEMBL1077896,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 31 investigational indications.,,4.0,,False,1996,"['ENSG00000144285', 'ENSG00000183873', 'ENSG00000007314', 'ENSG00000136546', 'ENSG00000136531', 'ENSG00000169432', 'ENSG00000153253', 'ENSG00000168356', 'ENSG00000196876', 'ENSG00000185313']","['EFO_0003843', 'HP_0012532', 'EFO_0007355', 'MONDO_0005178', 'MONDO_0001572', 'EFO_0003869', 'EFO_0003931', 'EFO_0009507', 'EFO_0009620', 'MONDO_0001056', 'HP_0003040', 'HP_0003470', 'MONDO_0004992', 'EFO_0009676', 'EFO_0003843', 'MONDO_0008170', 'EFO_0005251', 'HP_0000138', 'EFO_0006859', 'MONDO_0007254', 'HP_0001822', 'HP_0000023', 'HP_0000023', 'EFO_0007149', 'HP_0030834', 'EFO_0001358', 'HP_0002027', 'MONDO_0005178', 'HP_0002017', 'EFO_0002950', 'EFO_1001909', 'EFO_0004616', 'EFO_1001250']",False,False,33,Sodium channel alpha subunit blocker ,BLOCKER ,protein family 
1636,FLUDEOXYGLUCOSE,CHEMBL1086863,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 32 investigational indications.,,4.0,,False,1994,[],"['MONDO_0001187', 'EFO_0000183', 'EFO_0000519', 'MONDO_0008903', 'MONDO_0018906', 'MONDO_0002367', 'EFO_0000641', 'EFO_0000685', 'EFO_0000349', 'MONDO_0008667', 'MONDO_0004992', 'MONDO_0009348', 'EFO_0001642', 'EFO_0000574', 'EFO_0004142', 'EFO_0001416', 'EFO_0002618', 'EFO_0003968', 'EFO_0000616', 'EFO_0000691', 'MONDO_0004192', 'EFO_0000756', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000503', 'EFO_0006859', 'MONDO_0004975', 'EFO_1001051', 'EFO_0003060', 'EFO_0000501', 'EFO_1001465', 'MONDO_0002974', 'EFO_0003060']",False,False,33,,,
1637,ERYTHROMYCIN LACTOBIONATE,CHEMBL1200506,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 2 investigational indications.,,4.0,,False,1964,[],"['EFO_0003102', 'MONDO_0005147']",False,False,2,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1638,ALBENDAZOLE,CHEMBL1483,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 13 investigational indications.,,4.0,,False,1996,[],"['EFO_0000764', 'EFO_0007402', 'MONDO_0016075', 'EFO_0007501', 'EFO_1001342', 'EFO_0001067', 'EFO_0008572', 'EFO_0007314', 'EFO_0007231', 'EFO_0007272', 'EFO_0007231', 'EFO_0007524', 'EFO_0007516', 'MONDO_0100096', 'EFO_0000544', 'EFO_0001068']",False,False,16,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1639,DEXRAZOXANE,CHEMBL1738,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 22 investigational indications.,,4.0,,False,1995,"['ENSG00000131747', 'ENSG00000077097']","['EFO_0000502', 'EFO_0000691', 'EFO_1001968', 'MONDO_0000870', 'EFO_1000292', 'MONDO_0005301', 'EFO_0000565', 'EFO_0000209', 'EFO_0000616', 'EFO_1000158', 'EFO_0000174', 'EFO_0000318', 'HP_0030680', 'EFO_0000637', 'EFO_0000220', 'EFO_1000984', 'EFO_0000198', 'EFO_0000574', 'EFO_0000621', 'MONDO_0004992', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000222', 'EFO_0002918']",False,False,24,DNA topoisomerase II inhibitor ,INHIBITOR ,protein family 
1640,ITOLIZUMAB,CHEMBL1743033,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000013725'],"['MONDO_0004979', 'MONDO_0100096', 'EFO_0004599']",True,False,3,T-cell differentiation antigen CD6 inhibitor ,INHIBITOR ,single protein 
1641,METHYLENE BLUE,CHEMBL191083,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for urinary tract infection and has 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2016,[],"['EFO_0001358', 'MONDO_0100096', 'EFO_0007444', 'EFO_0000694', 'EFO_0006834', 'HP_0000952', 'MONDO_0004975', 'EFO_0000546', 'EFO_1001216', 'HP_0100806', 'EFO_0001068', 'EFO_0007287', 'EFO_0003901', 'EFO_0003030', 'MONDO_0004985', 'EFO_0003103']",False,False,16,,,
1642,ASTUPROTIMUT-R,CHEMBL2108705,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000221867'],"['EFO_0001378', 'EFO_0000389', 'EFO_0000181', 'EFO_0000756', 'EFO_0003060', 'MONDO_0001187']",False,False,6,Melanoma-associated antigen 3 vaccine antigen ,VACCINE ANTIGEN ,single protein 
1643,SAVOLITINIB,CHEMBL3334567,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,['ENSG00000105976'],"['EFO_0003863', 'EFO_0000313', 'EFO_1000657', 'MONDO_0004992', 'EFO_0000681', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000503', 'MONDO_0008315', 'EFO_0000640', 'EFO_0000616', 'EFO_1001951', 'EFO_1001949']",False,False,14,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1644,EFATUTAZONE,CHEMBL3545280,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000132170'],"['MONDO_0004992', 'EFO_1001951', 'EFO_0000616', 'EFO_0000569', 'EFO_0003060', 'MONDO_0002108', 'EFO_0001378', 'EFO_0000365']",False,False,8,Peroxisome proliferator-activated receptor gamma agonist ,AGONIST ,single protein 
1645,FOSTAMATINIB DISODIUM,CHEMBL3989516,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for autoimmune thrombocytopenic purpura and thrombocytopenia and has 5 investigational indications.,,4.0,,False,2018,['ENSG00000165025'],"['EFO_0007160', 'MONDO_0007915', 'EFO_0000574', 'EFO_0004194', 'EFO_0000685', 'HP_0001873', 'EFO_1001264']",False,False,7,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
1646,PCS-499,CHEMBL4297371,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000738', 'EFO_0003884', 'EFO_0000401']",False,False,3,,,
1647,CEMIPLIMAB,CHEMBL4297723,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 22 investigational indications.,,4.0,,False,2018,['ENSG00000188389'],"['EFO_0000519', 'EFO_0000756', 'MONDO_0002158', 'EFO_0003060', 'EFO_1000026', 'MONDO_0002898', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0002618', 'MONDO_0044926', 'EFO_0004197', 'EFO_0000616', 'EFO_0000764', 'EFO_0004193', 'MONDO_0002974', 'MONDO_0008903', 'EFO_0005537', 'EFO_0000681', 'EFO_0000181', 'EFO_0000707', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000183', 'MONDO_0008315', 'EFO_0009709', 'EFO_0003968', 'EFO_1001471', 'EFO_0000574']",False,False,28,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
1648,MRX-2843,CHEMBL4650408,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1649,ALPROSTADIL,CHEMBL495,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000125384', 'ENSG00000160951']","['HP_0001919', 'EFO_0000319', 'MONDO_0008315', 'EFO_0004714', 'EFO_1000809', 'EFO_0004234', 'EFO_0009606', 'MONDO_0100096', 'EFO_0003144', 'HP_0001643', 'EFO_0004265', 'EFO_0003875', 'MONDO_0100130', 'EFO_1000820']",True,False,14,Prostanoid EP1 receptor agonist Prostanoid EP2 receptor agonist ,AGONIST ,single protein 
1650,AMINOLEVULINIC ACID,CHEMBL601,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 34 investigational indications.,,4.0,,False,no approval year,[],"['EFO_1001051', 'HP_0002745', 'EFO_0002501', 'MONDO_0007187', 'EFO_0000616', 'MONDO_0018975', 'EFO_0000519', 'EFO_0005543', 'EFO_0000729', 'EFO_0003894', 'EFO_0002496', 'EFO_0000384', 'EFO_1001465', 'EFO_0000544', 'MONDO_0018975', 'EFO_0003894', 'EFO_1000764', 'MONDO_0100342', 'EFO_0006859', 'EFO_0002496', 'EFO_0000574', 'EFO_0000519', 'EFO_0003833', 'MONDO_0004647', 'MONDO_0021632', 'MONDO_0021063', 'EFO_0004193', 'MONDO_0003268', 'EFO_0003833', 'MONDO_0001657', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0100342', 'EFO_0009907', 'EFO_0000565', 'EFO_0002499']",False,False,36,,,
1651,LOXAPINE,CHEMBL831,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1975,"['ENSG00000102468', 'ENSG00000147246', 'ENSG00000149295', 'ENSG00000151577', 'ENSG00000069696']","['EFO_0000341', 'HP_0000713', 'MONDO_0004979', 'EFO_0009267', 'EFO_0005407', 'EFO_0003768', 'MONDO_0005090', 'MONDO_0005277', 'EFO_0005762', 'EFO_0009963', 'EFO_0005230']",False,False,11,Serotonin 2a (5-HT2a) receptor antagonist Serotonin 2c (5-HT2c) receptor antagonist D2-like dopamine receptor antagonist ,ANTAGONIST ,single protein protein family 
1652,PREDNISOLONE PHOSPHORIC ACID,CHEMBL1201231,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 4 investigational indications.,,4.0,,False,1973,['ENSG00000113580'],"['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0003929', 'MP_0001845', 'EFO_0007126', 'MONDO_0004979', 'EFO_0000768', 'EFO_1001226', 'EFO_0000341', 'HP_0000559', 'EFO_0009448', 'EFO_0000565', 'EFO_0007308', 'EFO_0005854', 'EFO_0007141', 'EFO_0004255', 'EFO_0007415']",False,True,18,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1653,RAMELTEON,CHEMBL1218,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for insomnia and has 12 investigational indications.,,4.0,,False,2005,"['ENSG00000168412', 'ENSG00000134640']","['EFO_0000341', 'MONDO_0004985', 'EFO_0004698', 'EFO_0003768', 'EFO_0008568', 'MONDO_0005475', 'EFO_0009516', 'MONDO_0100096', 'MONDO_0100431', 'EFO_0003890', 'MONDO_0002050', 'EFO_0007191', 'EFO_0003918']",False,False,13,Melatonin receptor agonist ,AGONIST ,protein family 
1654,FUSIDIC ACID,CHEMBL374975,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and eye infection and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000544', 'EFO_0000771', 'EFO_0004212', 'EFO_0000701', 'EFO_1001459', 'EFO_1001888', 'EFO_0000544', 'EFO_0003060']",False,False,8,Elongation factor G inhibitor ,INHIBITOR ,single protein 
1655,THYMOSIN,CHEMBL412531,Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0008583', 'MONDO_0100096', 'EFO_0008585', 'EFO_0007067', 'EFO_0002626', 'EFO_1001923', 'EFO_1000906', 'EFO_1000690']",False,False,8,,,
1656,BALOXAVIR,CHEMBL4297215,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,Polymerase acidic protein inhibitor ,INHIBITOR ,single protein 
1657,LODAPOLIMAB,CHEMBL4298020,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000389', 'EFO_0000616', 'MONDO_0004992', 'EFO_0002618', 'MONDO_0007254']",False,False,5,,,
1658,ZELPULTIDE ALFA,CHEMBL4650375,Protein drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0100096', 'MONDO_0019091']",False,False,2,,,
1659,NOVAFERON,CHEMBL4650410,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001901', 'EFO_0000305', 'MONDO_0100096']",False,False,3,,,
1660,PRASTERONE,CHEMBL90593,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 8 approved and 26 investigational indications.,,4.0,,False,2016,[],"['EFO_0001378', 'EFO_0009491', 'EFO_0001376', 'EFO_0003922', 'MONDO_0007915', 'EFO_0003843', 'EFO_0004714', 'EFO_0000685', 'EFO_0005800', 'MONDO_0005351', 'MONDO_0002050', 'MONDO_0002146', 'HP_0100607', 'EFO_0004234', 'GO_0007568', 'EFO_1001271', 'EFO_0004266', 'EFO_0005422', 'MONDO_0015129', 'EFO_1001006', 'MONDO_0021148', 'EFO_0000764', 'MONDO_0005147', 'EFO_1001078', 'EFO_0000545', 'HP_0008209', 'EFO_0001358', 'MONDO_0005178', 'MONDO_0016107', 'EFO_0001068', 'MONDO_0007254', 'EFO_0000384', 'EFO_0000616', 'HP_0031217']",False,False,34,,,
1661,VALSPODAR,CHEMBL1086218,Protein drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.,,3.0,,False,no approval year,['ENSG00000085563'],"['EFO_0000218', 'EFO_0000223', 'EFO_0003027', 'EFO_0003025', 'EFO_0000691', 'EFO_0000565', 'EFO_0003028', 'EFO_0003029', 'EFO_0000681', 'MONDO_0007254', 'EFO_0009708', 'EFO_0004251', 'EFO_0000198', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000574', 'EFO_0003865', 'EFO_0000221']",True,False,18,P-glycoprotein 1 inhibitor ,INHIBITOR ,single protein 
1662,GALLIUM NITRATE,CHEMBL1200983,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,"['ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']","['EFO_0009429', 'EFO_0000691', 'EFO_0000574', 'EFO_0000621', 'EFO_1000158', 'MONDO_0009061', 'EFO_0005952']",False,False,7,Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,protein complex group 
1663,LEUCOVORIN CALCIUM,CHEMBL1201138,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 104 investigational indications.,,4.0,,False,1952,[],"['EFO_0002499', 'EFO_0008549', 'EFO_0003060', 'EFO_1001231', 'EFO_0001075', 'EFO_1001961', 'MONDO_0003060', 'MONDO_0010100', 'EFO_1000298', 'EFO_0000220', 'EFO_0000565', 'EFO_0000681', 'EFO_0002617', 'EFO_0006859', 'MONDO_0016717', 'EFO_0004288', 'EFO_0003757', 'EFO_0003758', 'EFO_0000309', 'EFO_0000305', 'EFO_0000222', 'EFO_0000198', 'MONDO_0021063', 'EFO_1001471', 'EFO_0002939', 'EFO_0000685', 'MONDO_0002691', 'MONDO_0000870', 'EFO_0003891', 'EFO_1000657', 'MONDO_0007254', 'EFO_0000183', 'EFO_0005221', 'EFO_0003897', 'EFO_0002893', 'EFO_0000698', 'MONDO_0010006', 'EFO_0000178', 'MONDO_0005575', 'EFO_0000403', 'MONDO_0000873', 'EFO_1001365', 'EFO_0003032', 'EFO_1001901', 'EFO_0004142', 'EFO_0000707', 'EFO_0000637', 'MONDO_0008170', 'EFO_0000181', 'MONDO_0002087', 'EFO_1001949', 'EFO_0000365', 'EFO_0002501', 'MONDO_0001657', 'EFO_0008528', 'EFO_1001100', 'EFO_0000691', 'EFO_0000094', 'EFO_0002428', 'EFO_0007448', 'EFO_1000158', 'EFO_0009708', 'MONDO_0002120', 'EFO_0000313', 'EFO_0003100', 'EFO_0000574', 'EFO_0000209', 'EFO_0004252', 'EFO_1000251', 'MONDO_0011719', 'EFO_0005952', 'EFO_0007200', 'EFO_0000389', 'EFO_1000318', 'EFO_0000616', 'MONDO_0001235', 'EFO_1001469', 'MONDO_0002516', 'EFO_0003860', 'EFO_0007517', 'EFO_0000211', 'MONDO_0018944', 'EFO_0000197', 'EFO_0000182', 'MONDO_0001056', 'EFO_0001064', 'EFO_0005235', 'MONDO_0044917', 'MONDO_0007576', 'EFO_0000503', 'MONDO_0005835', 'EFO_0002618', 'EFO_0002916', 'MONDO_0004992', 'MONDO_0044937', 'EFO_0003833', 'MONDO_0003059', 'EFO_0001378', 'EFO_0000756', 'EFO_1001951', 'EFO_1001465', 'EFO_0002517', 'EFO_0005922', 'EFO_0007416']",False,False,104,,,
1664,"GONADOTROPIN, CHORIONIC",CHEMBL1201509,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 10 investigational indications.,,4.0,,False,1973,['ENSG00000138039'],"['MONDO_0018555', 'MONDO_0002259', 'EFO_0002950', 'MONDO_0007254', 'MONDO_0002146', 'MONDO_0002775', 'EFO_0004599', 'EFO_0000279', 'EFO_0000545', 'EFO_0000660']",False,False,10,Luteinizing hormone/Choriogonadotropin receptor agonist ,AGONIST ,single protein 
1665,ABATACEPT,CHEMBL1201823,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 35 investigational indications.,,4.0,,False,2006,"['ENSG00000121594', 'ENSG00000114013']","['EFO_1001148', 'MONDO_0100096', 'EFO_0004192', 'EFO_0009609', 'EFO_0004255', 'EFO_1001494', 'EFO_0004599', 'EFO_0000699', 'EFO_0000729', 'EFO_0000384', 'MONDO_0019338', 'EFO_0003780', 'MONDO_0017287', 'EFO_1001996', 'EFO_1001231', 'EFO_0005297', 'EFO_1001209', 'EFO_0004991', 'EFO_0004208', 'EFO_0002609', 'MONDO_0013730', 'EFO_0003929', 'EFO_0000685', 'MONDO_0005301', 'EFO_0000404', 'EFO_0000537', 'EFO_0000540', 'MONDO_0007915', 'EFO_0003778', 'EFO_0008518', 'EFO_0007425', 'EFO_0003898', 'EFO_0005761', 'EFO_0000398', 'EFO_1001857', 'EFO_0001378', 'EFO_0000676', 'EFO_0004826', 'MONDO_0005147']",True,True,39,T-lymphocyte activation antigen CD80 inhibitor T-lymphocyte activation antigen CD86 inhibitor ,INHIBITOR ,single protein 
1666,ANASTROZOLE,CHEMBL1399,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 23 investigational indications.,,4.0,,False,1995,['ENSG00000137869'],"['EFO_0000195', 'EFO_0000313', 'MONDO_0004992', 'GO_0007568', 'EFO_0000305', 'MONDO_0008315', 'MONDO_0000088', 'EFO_0006861', 'MONDO_0008170', 'MONDO_0018919', 'EFO_1001512', 'MONDO_0002146', 'HP_0000771', 'MONDO_0011962', 'EFO_0003869', 'EFO_0005537', 'EFO_0001361', 'EFO_0000553', 'MONDO_0002775', 'MONDO_0007254', 'EFO_0000432', 'EFO_0000537', 'MONDO_0018800', 'EFO_0001065', 'EFO_0000616', 'EFO_0001380', 'EFO_0000673', 'EFO_1001100']",False,False,28,Cytochrome P450 19A1 inhibitor ,INHIBITOR ,single protein 
1667,OLARATUMAB,CHEMBL1743049,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 8 investigational indications.,,4.0,,False,2016,['ENSG00000134853'],"['EFO_0000564', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000519', 'EFO_0003893', 'EFO_0003060', 'EFO_0000691', 'MONDO_0011719', 'EFO_0000616', 'EFO_0002618', 'EFO_0009708']",False,False,11,Platelet-derived growth factor receptor alpha antagonist ,ANTAGONIST ,single protein 
1668,MORPHINE SULFATE,CHEMBL2103744,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1984,['ENSG00000112038'],"['EFO_0010702', 'EFO_0000768', 'EFO_0004616', 'HP_0001822', 'HP_0003419', 'HP_0012532', 'HP_0000989', 'EFO_0005799', 'EFO_0003843', 'EFO_0003918', 'EFO_0000612', 'EFO_0001361', 'EFO_0005611', 'EFO_0003890', 'MONDO_0011382', 'MONDO_0004992']",False,False,16,Mu opioid receptor agonist ,AGONIST ,single protein 
1669,CLAZAKIZUMAB,CHEMBL2108589,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000136244'],"['HP_0004326', 'MONDO_0100096', 'HP_0012378', 'EFO_1001904', 'EFO_0000384', 'EFO_0000685', 'MONDO_0004979', 'EFO_0004599', 'EFO_0003778']",True,True,9,Interleukin-6 inhibitor ,INHIBITOR ,single protein 
1670,AMG-888,CHEMBL2109396,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000065361'],"['EFO_0003060', 'EFO_0000616', 'MONDO_0007254']",False,False,3,Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
1671,COBIMETINIB,CHEMBL2146883,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 21 investigational indications.,,4.0,,False,2015,"['ENSG00000169032', 'ENSG00000126934']","['MONDO_0008170', 'EFO_1001779', 'EFO_1001956', 'EFO_1000209', 'EFO_0003060', 'EFO_0000756', 'MONDO_0002898', 'Orphanet_46724', 'EFO_0002892', 'EFO_0002916', 'EFO_1001951', 'EFO_0001378', 'EFO_0000305', 'EFO_0000389', 'EFO_0000222', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000616', 'EFO_0002617', 'EFO_0000503', 'EFO_0000691', 'EFO_0002617', 'EFO_0009259', 'EFO_0002517']",True,False,24,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Dual specificity mitogen-activated protein kinase kinase 1 inhibitor ,INHIBITOR ,single protein 
1672,GUADECITABINE,CHEMBL3544916,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004251', 'MONDO_0008170', 'EFO_0000349', 'EFO_0000182', 'EFO_0000702', 'EFO_0000514', 'EFO_0000222', 'EFO_0000365', 'EFO_0008528', 'EFO_0000198', 'EFO_0002617', 'MONDO_0008903']",False,False,12,,,
1673,TAZOBACTAM,CHEMBL404,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 10 approved and 22 investigational indications.,,4.0,,False,1993,[],"['EFO_0001076', 'EFO_0003106', 'EFO_0000544', 'EFO_0006834', 'EFO_1001312', 'EFO_1001141', 'EFO_0000771', 'EFO_0002618', 'EFO_0003103', 'MONDO_0044881', 'EFO_0007328', 'EFO_1001289', 'EFO_1001388', 'EFO_1001459', 'EFO_0003035', 'HP_0100806', 'EFO_0003102', 'EFO_1001313', 'EFO_1001272', 'EFO_0003086', 'EFO_1001865', 'EFO_0003103', 'EFO_0003030', 'EFO_0008588', 'EFO_1001459', 'EFO_0000544', 'EFO_0003106', 'MONDO_0013730', 'EFO_0000544', 'EFO_0004992', 'EFO_0007149', 'MONDO_0100096', 'EFO_0005741']",False,False,33,Bacterial beta-lactamase TEM inhibitor ,INHIBITOR ,single protein 
1674,AMIKACIN SULFATE,CHEMBL4208954,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,[],"['EFO_0003103', 'EFO_0000584', 'EFO_0000544', 'EFO_1001272', 'EFO_0008588', 'HP_0100806', 'EFO_0005681', 'EFO_0003818', 'EFO_0003102', 'EFO_0000341']",False,False,10,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
1675,EMB-01,CHEMBL4594472,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000105976', 'ENSG00000146648']",['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1676,TEBOTELIMAB,CHEMBL4594578,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000089692', 'ENSG00000188389']","['MONDO_0007254', 'EFO_1001512', 'EFO_0000182', 'MONDO_0001056', 'EFO_0000181']",False,False,5,Lymphocyte activation gene 3 protein inhibitor Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
1677,PELITINIB,CHEMBL607707,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000146648'],"['EFO_1000657', 'EFO_0003060', 'EFO_0000616', 'EFO_0004288']",False,True,4,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1678,VALPROIC ACID,CHEMBL109,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 12 approved and 82 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,['ENSG00000112294'],"['HP_0000713', 'EFO_0002939', 'MONDO_0019200', 'EFO_0004247', 'MONDO_0007254', 'MONDO_0001187', 'EFO_1000158', 'MONDO_0019188', 'HP_0001250', 'MONDO_0004985', 'HP_0001250', 'EFO_0005762', 'MONDO_0004985', 'EFO_0005762', 'EFO_0004252', 'EFO_0000095', 'MONDO_0005277', 'EFO_0000181', 'MONDO_0019037', 'EFO_0005230', 'MONDO_0100342', 'MONDO_0044970', 'EFO_0000616', 'EFO_0000717', 'EFO_0009430', 'EFO_0000519', 'MONDO_0002050', 'EFO_0000474', 'EFO_0008526', 'MONDO_0004975', 'EFO_0003833', 'EFO_0000095', 'EFO_0000691', 'EFO_0008525', 'EFO_0006859', 'MONDO_0004976', 'EFO_0009267', 'MONDO_0010826', 'HP_0000713', 'EFO_1001951', 'HP_0002121', 'EFO_0000180', 'MONDO_0007079', 'EFO_0000546', 'MONDO_0004975', 'EFO_0004191', 'EFO_1000877', 'EFO_0001358', 'Orphanet_83419', 'EFO_0002618', 'EFO_0003758', 'EFO_0000198', 'HP_0007359', 'EFO_0002499', 'EFO_1000877', 'MONDO_0008170', 'MONDO_0005277', 'EFO_1001968', 'EFO_0003761', 'EFO_0000616', 'EFO_0008526', 'MONDO_0043510', 'EFO_0000519', 'MONDO_0008903', 'MONDO_0004992', 'EFO_0003758', 'EFO_0008525', 'EFO_0000574', 'MONDO_0002974', 'EFO_0000403', 'MONDO_0018105', 'EFO_0000474', 'EFO_0000616', 'MONDO_0005277', 'MONDO_0007254', 'MONDO_0004975', 'MONDO_0004985', 'MONDO_0007739', 'EFO_0000565', 'HP_0002121', 'EFO_0007527', 'MONDO_0007079', 'EFO_0000198', 'EFO_0009963', 'EFO_0000702', 'EFO_0000764', 'HP_0010865', 'MONDO_0005090', 'EFO_0003841', 'EFO_0003060', 'MONDO_0003478', 'EFO_0000756', 'HP_0002013', 'HP_0001250', 'MONDO_0008315', 'EFO_0004192', 'EFO_0000474', 'MONDO_0009293', 'MONDO_0005090', 'HP_0031273', 'EFO_0009963', 'EFO_0001075', 'EFO_0000222', 'EFO_0000339', 'EFO_0000309', 'EFO_0000403', 'EFO_1001469', 'HP_0002039']",False,False,108,Succinate semialdehyde dehydrogenase inhibitor ,INHIBITOR ,single protein 
1679,SOFOSBUVIR,CHEMBL1259059,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,[],"['EFO_0003047', 'EFO_0004197', 'EFO_0004220', 'EFO_0000694', 'EFO_0000574', 'MONDO_0100096', 'EFO_0000763', 'EFO_0000544']",False,False,8,Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor ,INHIBITOR ,single protein 
1680,OCTREOTIDE PAMOATE,CHEMBL2105834,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1681,METHYLCELLULOSE,CHEMBL2109198,Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for constipation and has 2 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005129', 'EFO_0003884', 'HP_0002019']",False,False,3,,,
1682,MEDI-565,CHEMBL2109372,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,"['ENSG00000105388', 'ENSG00000198851']",['EFO_0000228'],False,False,1,Carcinoembryonic antigen-related cell adhesion molecule 5 cross-linking agent T-cell surface glycoprotein CD3 epsilon chain cross-linking agent ,CROSS-LINKING AGENT ,single protein 
1683,GIMSILUMAB,CHEMBL2109430,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000164400'],"['EFO_0000685', 'MONDO_0100096']",True,False,2,Granulocyte-macrophage colony-stimulating factor inhibitor ,INHIBITOR ,single protein 
1684,SUBSTANCE P,CHEMBL235363,Protein drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003956', 'MONDO_0005147']",False,False,2,,,
1685,PEGARGIMINASE,CHEMBL3137346,Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000389', 'EFO_1001968', 'EFO_0002618', 'EFO_0005952', 'EFO_0000222', 'EFO_0000770', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000182', 'EFO_0000519', 'EFO_0000588']",False,False,11,,,
1686,BEMCENTINIB,CHEMBL3809489,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.,,2.0,,False,no approval year,['ENSG00000167601'],"['MONDO_0100096', 'EFO_0000571', 'EFO_0002618', 'EFO_1000984', 'EFO_0000756', 'EFO_0003060', 'EFO_0000222', 'EFO_0000198', 'EFO_1000158', 'EFO_0000588']",True,False,10,Tyrosine-protein kinase receptor UFO inhibitor ,INHIBITOR ,single protein 
1687,CAFICRESTAT,CHEMBL4297455,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000085662'],['MONDO_0100096'],True,False,1,Aldose reductase inhibitor ,INHIBITOR ,single protein 
1688,EFLEPEDOCOKIN ALFA,CHEMBL4594542,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000243646', 'ENSG00000142677']","['MONDO_0100096', 'EFO_1001345', 'MONDO_0013730']",False,True,3,IL22 Receptor agonist ,AGONIST ,protein complex 
1689,DEUCRAVACITINIB,CHEMBL4596392,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 8 investigational indications.,,4.0,,False,2022,['ENSG00000105397'],"['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540', 'EFO_0003086', 'EFO_0000676', 'EFO_0005761', 'HP_0001410', 'MONDO_0007915']",False,True,9,Tyrosine-protein kinase TYK2 inhibitor Tyrosine-protein kinase TYK2 negative allosteric modulator ,INHIBITOR NEGATIVE ALLOSTERIC MODULATOR ,single protein 
1690,NENDRATAREOTIDE UZATANSINE,CHEMBL4650335,Protein drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0000702'],False,False,1,,,
1691,VOLASERTIB,CHEMBL1233528,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000166851'],"['EFO_0003893', 'EFO_1001257', 'EFO_0003060', 'EFO_0002913', 'EFO_0000198', 'EFO_0000574', 'EFO_0000616', 'EFO_0000221', 'EFO_0000222', 'EFO_0000565', 'MONDO_0000430']",False,False,11,Serine/threonine-protein kinase PLK1 inhibitor ,INHIBITOR ,single protein 
1692,TRIAMCINOLONE,CHEMBL1451,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved and 33 investigational indications.,,4.0,,False,1957,['ENSG00000113580'],"['EFO_0005762', 'EFO_0000274', 'EFO_0007486', 'EFO_1000391', 'EFO_0005752', 'HP_0002027', 'EFO_0005854', 'MONDO_0005178', 'EFO_1000786', 'HP_0001742', 'HP_0006536', 'EFO_1000662', 'EFO_1001157', 'EFO_1000879', 'MONDO_0003005', 'MONDO_0002959', 'EFO_0000701', 'EFO_0004683', 'EFO_0003843', 'EFO_0001365', 'EFO_0004208', 'EFO_1001250', 'EFO_0004212', 'EFO_0004264', 'EFO_0003963', 'HP_0030834', 'EFO_0009552', 'EFO_0004616', 'EFO_1001417', 'EFO_0000342', 'EFO_1001077', 'EFO_1000809', 'EFO_0000341', 'EFO_0000676', 'EFO_0008517', 'EFO_0003770', 'EFO_0000756', 'EFO_0004192']",False,True,38,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1693,IBRUTINIB,CHEMBL1873475,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 40 investigational indications.,,4.0,,False,2013,['ENSG00000010671'],"['EFO_0007359', 'EFO_0000183', 'MONDO_0100096', 'EFO_0001421', 'EFO_1000560', 'MONDO_0021063', 'MONDO_0007576', 'EFO_0000220', 'EFO_0000096', 'EFO_1001890', 'EFO_0000222', 'EFO_0005952', 'EFO_0003060', 'EFO_0000309', 'MONDO_0007254', 'EFO_1001264', 'EFO_1001469', 'EFO_0001378', 'EFO_0000181', 'EFO_1000630', 'EFO_0000574', 'EFO_0000616', 'EFO_0000389', 'EFO_0000198', 'EFO_0000095', 'EFO_0009441', 'EFO_0004243', 'MONDO_0100053', 'MONDO_0008903', 'MONDO_0001023', 'MONDO_0044881', 'MONDO_0009348', 'EFO_0004289', 'EFO_0000519', 'MONDO_0008315', 'EFO_0002617', 'EFO_0000403', 'EFO_0002616', 'MONDO_0018906', 'EFO_1001875', 'MONDO_0004992', 'MONDO_0013730', 'EFO_0000565', 'EFO_1001951', 'EFO_1000956', 'EFO_0000681']",True,False,46,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1694,IROSUSTAT,CHEMBL286738,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000101846'],"['MONDO_0007254', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0008315']",False,False,4,Steryl-sulfatase inhibitor ,INHIBITOR ,single protein 
1695,PERINDOPRIL ARGININE,CHEMBL3544986,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 1 investigational indication.,,4.0,,False,2015,['ENSG00000159640'],"['EFO_0000612', 'EFO_0000537', 'EFO_0001645', 'EFO_0004214']",True,False,4,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
1696,MERESTINIB,CHEMBL3545307,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000105976'],"['EFO_0000389', 'MONDO_0003060', 'EFO_1001469', 'EFO_0003060', 'EFO_0002618', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0007254']",True,False,8,Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1697,GS-9901,CHEMBL3928407,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000095', 'MONDO_0018906']",False,False,2,,,
1698,EXATECAN MESYLATE,CHEMBL3989759,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0000565', 'MONDO_0002158', 'EFO_0002618', 'MONDO_0008170', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002691', 'EFO_1000158', 'MONDO_0002974', 'EFO_0000691', 'EFO_0000616', 'EFO_0000198', 'MONDO_0007254', 'EFO_0000574']",False,False,15,,,
1699,SRT-2104,CHEMBL4297436,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000096717'],"['EFO_1000096', 'EFO_0000341', 'EFO_0000676', 'EFO_0009851', 'HP_0100806', 'EFO_0000729', 'MONDO_0005148']",True,False,7,NAD-dependent deacetylase sirtuin 1 activator ,ACTIVATOR ,single protein 
1700,HUMAN C1-ESTERASE INHIBITOR,CHEMBL4297549,Enzyme drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hereditary angioedema and has 5 investigational indications.,,4.0,,False,no approval year,"['ENSG00000182326', 'ENSG00000131187', 'ENSG00000088926', 'ENSG00000164344']","['EFO_1002048', 'EFO_0005532', 'EFO_0003884', 'MONDO_0100096', 'MONDO_0019623', 'EFO_0004256']",True,False,6,Complement C1s inhibitor Coagulation factor XII inhibitor Plasma kallikrein inhibitor Coagulation factor XI inhibitor ,INHIBITOR ,single protein 
1701,PIPENDOXIFENE,CHEMBL44426,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1702,PANCREATIC POLYPEPTIDE,CHEMBL4540843,Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1703,TIXAGEVIMAB,CHEMBL4650265,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1704,CANGRELOR TETRASODIUM,CHEMBL1097279,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for recurrent thrombophlebitis and myocardial infarction.,,4.0,,False,2015,['ENSG00000169313'],"['HP_0004419', 'EFO_0000612']",True,False,2,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
1705,EPIRUBICIN HYDROCHLORIDE,CHEMBL1200981,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 29 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,[],"['MONDO_0002691', 'MONDO_0001056', 'EFO_1000984', 'EFO_0000220', 'MONDO_0007576', 'EFO_0000616', 'EFO_0002916', 'EFO_0006861', 'EFO_0000565', 'EFO_0000691', 'EFO_0005537', 'EFO_0002618', 'EFO_1001968', 'EFO_0000702', 'MONDO_0002087', 'EFO_0000574', 'EFO_0000182', 'EFO_0000313', 'EFO_0000389', 'EFO_0000588', 'EFO_0000503', 'MONDO_0002158', 'MONDO_0001187', 'EFO_0000305', 'EFO_0000211', 'EFO_0003897', 'EFO_0003869', 'MONDO_0008170', 'MONDO_0008903', 'MONDO_0011962', 'EFO_0000228', 'MONDO_0008315', 'MONDO_0007254']",False,False,33,,,
1706,CETUXIMAB,CHEMBL1201577,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 12 approved and 60 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,['ENSG00000146648'],"['MONDO_0001056', 'EFO_0004142', 'EFO_0007535', 'EFO_0000571', 'MONDO_0002974', 'EFO_0000519', 'EFO_0009430', 'MONDO_0007576', 'EFO_0004284', 'EFO_0004252', 'EFO_1001931', 'MONDO_0002358', 'EFO_0002916', 'MONDO_0008315', 'EFO_0000231', 'EFO_0001061', 'EFO_0000616', 'EFO_0002938', 'EFO_0000503', 'EFO_0003060', 'EFO_0003897', 'MONDO_0021355', 'EFO_0005922', 'EFO_0003817', 'EFO_1000657', 'EFO_0001378', 'MONDO_0004992', 'MONDO_0001187', 'MONDO_0021364', 'EFO_0000182', 'MONDO_0002691', 'EFO_0003871', 'MONDO_0007254', 'EFO_0003835', 'EFO_0000673', 'MONDO_0001023', 'MONDO_0044926', 'MONDO_0005575', 'EFO_0006859', 'MONDO_0008978', 'MONDO_0001879', 'EFO_0006352', 'MONDO_0044704', 'EFO_0004198', 'MONDO_0021310', 'EFO_0009708', 'MONDO_0021063', 'EFO_0002618', 'MONDO_0100342', 'EFO_0003869', 'EFO_0000365', 'MONDO_0002087', 'EFO_1001949', 'EFO_1001100', 'EFO_0000707', 'EFO_1001951', 'MONDO_0008903', 'MONDO_0011962', 'EFO_1000251', 'MONDO_0001657', 'EFO_0002499', 'MONDO_0008170', 'MONDO_0002038', 'EFO_0000313', 'EFO_0000691', 'EFO_0003891', 'EFO_0000228', 'EFO_0005221', 'EFO_0003868', 'EFO_1001998', 'EFO_0000181', 'EFO_1001950']",False,True,72,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1707,METOPROLOL,CHEMBL13,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 35 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,['ENSG00000043591'],"['HP_0004308', 'EFO_0008585', 'EFO_0005252', 'EFO_0001073', 'EFO_0003913', 'EFO_0008586', 'HP_0003124', 'EFO_0003917', 'EFO_0000612', 'EFO_0000676', 'EFO_0000319', 'EFO_0003144', 'EFO_0000275', 'EFO_0000612', 'EFO_0000274', 'EFO_0000537', 'EFO_0000266', 'EFO_0003777', 'EFO_0000373', 'EFO_0003777', 'MONDO_0005148', 'EFO_0003144', 'Orphanet_79292', 'MONDO_0010679', 'EFO_0004287', 'EFO_0000712', 'EFO_0000537', 'EFO_0001068', 'EFO_0000275', 'EFO_0000764', 'HP_0001653', 'EFO_0000275', 'EFO_0001645', 'Orphanet_848', 'EFO_0000616', 'EFO_0003914', 'EFO_0008583', 'EFO_0000341', 'EFO_0003144', 'EFO_0003913', 'MONDO_0008300', 'EFO_0000538', 'EFO_0004278', 'EFO_0005306', 'EFO_0000373', 'MONDO_0007254', 'EFO_0000537']",True,False,47,Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
1708,TOREMIFENE,CHEMBL1655,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,"['ENSG00000140009', 'ENSG00000091831']","['EFO_0009907', 'MONDO_0008315', 'EFO_0003931', 'MONDO_0100096', 'EFO_0003869', 'EFO_0003882', 'EFO_1001366', 'MONDO_0007254', 'MONDO_0007254', 'EFO_0000616', 'EFO_0003869', 'MONDO_0008170', 'EFO_0000305', 'EFO_0002621', 'EFO_0003931']",True,True,15,Estrogen receptor modulator ,MODULATOR ,protein family 
1709,BRENTUXIMAB VEDOTIN,CHEMBL1742994,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 23 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,"['ENSG00000120949', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0019473', 'EFO_0000616', 'EFO_0000095', 'EFO_0002913', 'EFO_0001642', 'EFO_0000565', 'EFO_0000183', 'EFO_1000785', 'EFO_0000096', 'EFO_0004599', 'EFO_0000764', 'EFO_1001051', 'EFO_0000574', 'MONDO_0019471', 'EFO_0005952', 'MONDO_0018906', 'EFO_0000211', 'EFO_0000514', 'EFO_0000222', 'EFO_0003032', 'MONDO_0009348', 'MONDO_0007915', 'EFO_0000403', 'EFO_0000588', 'MONDO_0013730', 'EFO_0007359', 'EFO_0000404']",True,False,27,Tumor necrosis factor receptor superfamily member 8 inhibitor Tubulin inhibitor ,INHIBITOR ,single protein protein complex group 
1710,GLEMBATUMUMAB,CHEMBL2108707,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,['ENSG00000136235'],"['EFO_0000756', 'MONDO_0007254']",True,False,2,Transmembrane glycoprotein NMB binding agent ,BINDING AGENT ,single protein 
1711,TIPIRACIL,CHEMBL235668,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 20 investigational indications.,,4.0,,False,2015,['ENSG00000025708'],"['MONDO_0044937', 'MONDO_0001187', 'EFO_0000365', 'EFO_0003869', 'EFO_1001949', 'EFO_0005221', 'EFO_1000657', 'EFO_0000616', 'EFO_0000365', 'EFO_1000657', 'EFO_0002618', 'EFO_0000708', 'MONDO_0001056', 'MONDO_0005575', 'EFO_1001951', 'MONDO_0021063', 'EFO_0003860', 'EFO_0004142', 'MONDO_0007254', 'EFO_0000702', 'EFO_0004252']",True,False,21,Thymidine phosphorylase inhibitor ,INHIBITOR ,single protein 
1712,BAMOCAFTOR,CHEMBL4297849,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
1713,RADAVIRSEN,CHEMBL4297897,Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0007328'],False,False,1,,,
1714,IMLIFIDASE,CHEMBL4297981,Enzyme drug with a maximum clinical trial phase of IV (across all indications) and is indicated for immune system disease and has 4 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000540', 'EFO_0007290', 'EFO_0003884', 'EFO_0007160', 'EFO_0004599']",False,False,5,,,
1715,ADENOSINE,CHEMBL477,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 18 investigational indications.,,4.0,,False,1989,"['ENSG00000163485', 'ENSG00000170425', 'ENSG00000282608', 'ENSG00000128271']","['EFO_0000556', 'EFO_1001450', 'EFO_0008583', 'EFO_1000637', 'MONDO_0006715', 'EFO_0008585', 'EFO_0003843', 'EFO_0000318', 'EFO_0000612', 'EFO_0000275', 'EFO_0000095', 'EFO_0009493', 'MONDO_0004992', 'EFO_0001645', 'EFO_0000319', 'EFO_1002000', 'EFO_0000616', 'EFO_1001375', 'EFO_0005306', 'EFO_0003913', 'MP_0001845']",True,True,21,Adenosine receptor agonist ,AGONIST ,protein family 
1716,TEMAZEPAM,CHEMBL967,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for insomnia and has 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000022355', 'ENSG00000145864', 'ENSG00000113327', 'ENSG00000166206', 'ENSG00000109158', 'ENSG00000182256', 'ENSG00000268089', 'ENSG00000011677', 'ENSG00000094755', 'ENSG00000187730', 'ENSG00000163285', 'ENSG00000163288', 'ENSG00000102287', 'ENSG00000151834', 'ENSG00000186297', 'ENSG00000145863']","['EFO_0005230', 'EFO_0004698', 'EFO_0000341', 'MONDO_0002050', 'MONDO_0005090']",True,False,5,GABA-A receptor; anion channel positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,protein complex group 
1717,FOLITIXORIN,CHEMBL117348,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0021063', 'EFO_1000657']",False,False,3,,,
1718,BIVALIRUDIN,CHEMBL2103749,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications.,,4.0,,False,2000,['ENSG00000180210'],"['HP_0004419', 'HP_0001871', 'EFO_0008583', 'EFO_0000266', 'HP_0001873', 'EFO_0000713', 'EFO_1000985', 'EFO_0003777', 'EFO_0005672', 'MP_0001914', 'EFO_0003907', 'EFO_0000612', 'EFO_0001645', 'EFO_0000319', 'MONDO_0000831']",False,False,15,Thrombin inhibitor ,INHIBITOR ,single protein 
1719,DILMAPIMOD,CHEMBL2103838,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000112062'],"['EFO_0004610', 'EFO_0001645', 'EFO_0005762', 'EFO_0000341', 'EFO_0000685']",False,False,5,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
1720,LABETUZUMAB,CHEMBL2108501,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000105388'],"['EFO_1000657', 'EFO_1001951', 'MONDO_0007254', 'EFO_0000365', 'EFO_0004142', 'MONDO_0021063', 'EFO_0003860']",False,False,7,Carcinoembryonic antigen-related cell adhesion molecule 5 other ,OTHER ,single protein 
1721,APIXABAN,CHEMBL231779,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,['ENSG00000126218'],"['EFO_0003884', 'EFO_0003144', 'EFO_0009314', 'EFO_0000266', 'MONDO_0000831', 'EFO_1002000', 'MONDO_0004992', 'HP_0002140', 'EFO_0003907', 'EFO_0004286', 'MP_0001914', 'HP_0000083', 'EFO_0000556', 'EFO_0004255', 'EFO_0003827', 'EFO_0001422', 'EFO_0003911', 'MONDO_0011382', 'HP_0001907', 'EFO_0005672', 'EFO_0000220', 'EFO_0010680', 'HP_0004419', 'EFO_0000275', 'HP_0001655', 'HP_0004936', 'EFO_0000712', 'MONDO_0100096']",False,False,28,Coagulation factor X inhibitor ,INHIBITOR ,single protein 
1722,LUMINESPIB,CHEMBL252164,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications.,,2.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['EFO_0000574', 'EFO_0000571', 'EFO_0003060', 'EFO_0000708', 'EFO_0000616', 'EFO_0001378', 'MONDO_0001056', 'EFO_0000365', 'EFO_0004251', 'MONDO_0011719', 'MONDO_0021063', 'EFO_1000657', 'MONDO_0007254']",True,False,13,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
1723,MSC-2364447,CHEMBL3545193,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000010671'],['MONDO_0007915'],False,False,1,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1724,LB-100,CHEMBL4297300,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000104695', 'ENSG00000011485', 'ENSG00000113575']","['MONDO_0004992', 'EFO_0000632', 'EFO_0000198', 'EFO_0000702', 'EFO_0000519']",True,False,5,"Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor Serine/threonine-protein phosphatase 5 inhibitor Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor ",INHIBITOR ,single protein 
1725,LURBINECTEDIN,CHEMBL4297516,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and small cell lung carcinoma and has 16 investigational indications.,,4.0,,False,2020,[],"['MONDO_0024503', 'EFO_0000178', 'EFO_0003060', 'EFO_0002618', 'EFO_0001075', 'MONDO_0008170', 'EFO_0000616', 'EFO_1001951', 'EFO_0000519', 'EFO_0000564', 'EFO_0000174', 'EFO_0000691', 'EFO_0000702', 'EFO_0000770', 'EFO_0000565', 'EFO_1001512', 'MONDO_0007254', 'EFO_0000588']",False,False,18,,,
1726,ELGEMTUMAB,CHEMBL4298013,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,['ENSG00000065361'],"['EFO_0000181', 'EFO_0005922', 'MONDO_0007254']",False,False,3,Receptor tyrosine-protein kinase erbB-3 inhibitor ,INHIBITOR ,single protein 
1727,LAZERTINIB,CHEMBL4558324,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['MONDO_0021117', 'EFO_0001421', 'MONDO_0004992', 'EFO_0003060']",False,True,4,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1728,ATULIFLAPON,CHEMBL4802195,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0005672', 'EFO_0003884', 'MONDO_0004979', 'EFO_0001645', 'EFO_0000319']",False,False,5,,,
1729,CYTARABINE,CHEMBL803,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 10 approved and 68 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1969,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229']","['MONDO_0044881', 'EFO_0000339', 'EFO_0000309', 'EFO_1001779', 'MONDO_0019460', 'EFO_0003811', 'EFO_1000781', 'EFO_0000220', 'MONDO_0001475', 'EFO_0003028', 'EFO_0000096', 'MONDO_0007915', 'EFO_0003025', 'EFO_0000095', 'EFO_0000519', 'EFO_0007498', 'EFO_1001257', 'MONDO_0008315', 'EFO_0000691', 'EFO_0000211', 'MONDO_0044903', 'MONDO_0018906', 'EFO_0000223', 'EFO_0003802', 'MONDO_0000870', 'EFO_0000574', 'EFO_0002939', 'EFO_0004991', 'EFO_0006475', 'EFO_0003833', 'MONDO_0044917', 'EFO_0000198', 'EFO_0009538', 'EFO_0004191', 'EFO_0002429', 'EFO_0001378', 'EFO_0003029', 'EFO_1001052', 'MONDO_0013730', 'EFO_1001365', 'EFO_1000131', 'EFO_0002428', 'EFO_1001012', 'EFO_0000094', 'EFO_0000183', 'EFO_1000823', 'MONDO_0000873', 'MONDO_0009348', 'EFO_0004256', 'EFO_0000616', 'EFO_0003929', 'EFO_1000318', 'EFO_0000209', 'EFO_0000218', 'EFO_0000756', 'EFO_0000403', 'EFO_0000221', 'EFO_1000158', 'EFO_0000222', 'EFO_1000309', 'MONDO_0019471', 'EFO_0003884', 'EFO_0004289', 'MONDO_0004992', 'EFO_0003027', 'EFO_0000222', 'EFO_0001068', 'MONDO_0007254', 'EFO_0000565', 'EFO_0000224', 'EFO_1001469', 'EFO_1000286', 'EFO_0003032', 'EFO_0000479', 'EFO_0004251', 'EFO_0005952', 'EFO_1001383', 'MONDO_0008170']",True,True,78,DNA polymerase (alpha/delta/epsilon) inhibitor ,INHIBITOR ,protein family 
1730,TORSEMIDE,CHEMBL1148,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 2 investigational indications.,,4.0,,False,1993,['ENSG00000074803'],"['EFO_0000712', 'EFO_0000612', 'EFO_0000373', 'EFO_0003144', 'EFO_0000319', 'MONDO_0005148', 'EFO_0000668', 'EFO_0000537']",False,False,8,Sodium-(potassium)-chloride cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1731,ATAZANAVIR,CHEMBL1163,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 6 investigational indications.,,4.0,,False,2003,[],"['EFO_0000763', 'EFO_0000544', 'EFO_0000764', 'EFO_0000180', 'EFO_0000765', 'MONDO_0100096', 'EFO_0000764', 'MONDO_0005147', 'EFO_0001642', 'EFO_0000180']",False,False,10,Human immunodeficiency virus type 1 protease inhibitor ,INHIBITOR ,single protein 
1732,TRIPTORELIN PAMOATE,CHEMBL1200554,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 3 investigational indications.,,4.0,,False,2000,['ENSG00000109163'],"['EFO_0001065', 'MONDO_0008315', 'EFO_0001663', 'EFO_0000673', 'MONDO_0000088', 'EFO_0009029', 'MONDO_0007254']",False,False,7,Gonadotropin-releasing hormone receptor agonist ,AGONIST ,single protein 
1733,SOLITHROMYCIN,CHEMBL1232510,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001249', 'EFO_0000341', 'DOID_7551', 'EFO_1001272', 'EFO_0000771']",False,False,5,,,
1734,MITOXANTRONE HYDROCHLORIDE,CHEMBL1417019,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 approved and 36 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,['ENSG00000131747'],"['EFO_0001663', 'EFO_0000211', 'MONDO_0015760', 'MONDO_0019472', 'EFO_0000565', 'EFO_0000182', 'MONDO_0005301', 'EFO_0004289', 'MONDO_0008170', 'EFO_0003843', 'EFO_0000220', 'MONDO_0018906', 'EFO_0000616', 'EFO_0004251', 'EFO_0000673', 'EFO_0003929', 'EFO_0000196', 'EFO_0000221', 'EFO_0005952', 'EFO_1001830', 'EFO_1001469', 'EFO_0008522', 'MONDO_0004992', 'EFO_0000224', 'EFO_0000339', 'EFO_0000095', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000222', 'EFO_0000178', 'EFO_0006859', 'EFO_0000198', 'MONDO_0007254', 'EFO_1000286', 'EFO_0000574', 'MONDO_0001023', 'EFO_0001378', 'MONDO_0019460', 'MONDO_0000873', 'EFO_1001052', 'EFO_0000403']",False,False,41,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
1735,HEPATITIS B VIRUS VACCINE INACTIVATED,CHEMBL2109163,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001476', 'EFO_0004197', 'EFO_0001668', 'EFO_0001068', 'EFO_0000764', 'EFO_0003884']",False,False,6,,,
1736,PELAREOREP,CHEMBL3545069,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0002617', 'EFO_0000708', 'EFO_0000389', 'MONDO_0007254', 'EFO_0001378', 'EFO_0005537', 'EFO_0000707']",False,False,7,,,
1737,HEMAY-022,CHEMBL3545111,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000141736'],['MONDO_0007254'],False,False,1,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1738,ISOFLAVONE,CHEMBL366460,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0006859', 'EFO_0003922', 'EFO_0000571', 'EFO_0003884', 'MONDO_0007254', 'MONDO_0008315']",False,False,6,,,
1739,GREMUBAMAB,CHEMBL4298031,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003106'],False,False,1,Low calcium response locus protein V inhibitor ,INHIBITOR ,single protein 
1740,DASIGLUCAGON HYDROCHLORIDE,CHEMBL4650274,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for type 1 diabetes mellitus and hypoglycemia.,,4.0,,False,2021,['ENSG00000215644'],"['MONDO_0005147', 'HP_0001943']",False,False,2,Glucagon receptor agonist ,AGONIST ,single protein 
1741,AUMOLERTINIB,CHEMBL4761468,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0001421', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000707', 'EFO_0000571', 'EFO_0000313', 'MONDO_0004992', 'EFO_0000616']",False,True,8,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1742,ALENDRONATE SODIUM,CHEMBL675,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 2 investigational indications.,,4.0,,False,1995,['ENSG00000160752'],"['MONDO_0007254', 'EFO_0003762', 'EFO_0000589', 'EFO_0003882', 'EFO_0003854', 'EFO_0004261']",True,False,6,Farnesyl diphosphate synthase inhibitor ,INHIBITOR ,single protein 
1743,FOSCARNET SODIUM,CHEMBL754,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,[],"['MONDO_0013730', 'EFO_1002022', 'EFO_0000764', 'MONDO_0003778', 'EFO_0010282', 'EFO_0003106', 'EFO_1001302']",False,False,7,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
1744,OMALIZUMAB,CHEMBL1201589,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2003,['ENSG00000211891'],"['EFO_0007486', 'MONDO_0021063', 'EFO_0000274', 'EFO_0007187', 'EFO_0009482', 'Orphanet_2314', 'MONDO_0001085', 'EFO_1001890', 'MONDO_0100096', 'EFO_0000540', 'EFO_0009661', 'EFO_0005532', 'EFO_0007425', 'MONDO_0005271', 'EFO_0007369', 'EFO_0008507', 'EFO_0005854', 'MONDO_0007915', 'EFO_0003956', 'EFO_0005531', 'HP_0006536', 'EFO_1001463', 'MONDO_0004979', 'EFO_0000341', 'EFO_0004232']",True,False,25,Ig epsilon chain C region inhibitor ,INHIBITOR ,single protein 
1745,BAVITUXIMAB,CHEMBL1742989,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000657', 'EFO_0006861', 'EFO_0000673', 'EFO_0000519', 'EFO_0000616', 'EFO_0000182', 'EFO_0002618', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000313', 'EFO_0000756', 'EFO_0000707', 'EFO_0003047', 'EFO_0005537']",False,False,14,,,
1746,RINTATOLIMOD,CHEMBL2107862,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,['ENSG00000164342'],"['EFO_0000756', 'MONDO_0044881', 'MONDO_0100096', 'EFO_0000673', 'MONDO_0007254', 'EFO_0006861', 'EFO_0000764', 'MONDO_0002158', 'EFO_0002618', 'EFO_0004540', 'MONDO_0008170', 'MONDO_0004658', 'EFO_0001423']",False,False,13,Toll-like receptor 3 agonist ,AGONIST ,single protein 
1747,NEOSTIGMINE,CHEMBL278020,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and glaucoma and has 9 investigational indications.,,4.0,,False,2013,['ENSG00000087085'],"['EFO_0004209', 'EFO_0004991', 'EFO_1000948', 'MONDO_0007254', 'HP_0025267', 'EFO_0001074', 'EFO_0009516', 'HP_0002315', 'MONDO_0005041', 'EFO_0004888', 'EFO_0003843']",False,False,11,Acetylcholinesterase inhibitor ,INHIBITOR ,single protein 
1748,VERCIRNON SODIUM,CHEMBL3039505,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0000384'],False,False,1,,,
1749,AXP-107-11,CHEMBL3545214,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000228'],False,False,1,,,
1750,FLUZOPARIB,CHEMBL3930624,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004992', 'EFO_0004252', 'MONDO_0008315', 'EFO_0002618', 'EFO_0000616', 'EFO_0000702', 'EFO_0003060', 'EFO_0001421', 'MONDO_0007254', 'MONDO_0001056', 'MONDO_0008170', 'EFO_0003086', 'EFO_0000681']",False,False,13,,,
1751,ENSARTINIB,CHEMBL4113131,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000171094'],"['MONDO_0008903', 'EFO_0003060', 'EFO_0000756']",False,False,3,ALK tyrosine kinase receptor inhibitor ,INHIBITOR ,single protein 
1752,SURUFATINIB,CHEMBL4297190,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.,,3.0,,False,no approval year,"['ENSG00000077782', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_0000503', 'EFO_0002618', 'EFO_0003860', 'MONDO_0002120', 'EFO_0003086', 'EFO_0003060', 'EFO_0001421', 'EFO_0000616', 'EFO_0006859', 'MONDO_0007254', 'EFO_0004142', 'EFO_1001901', 'EFO_0000691', 'EFO_1001951', 'MONDO_0005575', 'EFO_0002892', 'EFO_0000702', 'MONDO_0003060', 'EFO_0000182', 'EFO_0004252', 'MONDO_0002108']",True,False,21,Fibroblast growth factor receptor 1 inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein family 
1753,ELACESTRANT,CHEMBL4297509,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000091831'],"['MONDO_0007254', 'HP_0031217', 'EFO_0000305']",False,True,3,Estrogen receptor alpha degrader ,DEGRADER ,single protein 
1754,ENCEQUIDAR,CHEMBL4594298,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000085563'],"['MONDO_0007254', 'EFO_0003968', 'EFO_0000616', 'EFO_0005537', 'EFO_0003968']",True,False,5,P-glycoprotein 1 inhibitor ,INHIBITOR ,single protein 
1755,PULRODEMSTAT,CHEMBL4651180,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0000673', 'EFO_0005952', 'EFO_0000702', 'EFO_0000565']",False,False,5,,,
1756,NIDANILIMAB,CHEMBL5095365,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1757,QUETIAPINE,CHEMBL716,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 37 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,"['ENSG00000147246', 'ENSG00000102468', 'ENSG00000149295']","['MONDO_0005301', 'EFO_0004242', 'MONDO_0002009', 'EFO_0002610', 'EFO_0004698', 'EFO_0005411', 'EFO_0009963', 'EFO_0007191', 'EFO_0003918', 'EFO_0003761', 'MONDO_0005090', 'EFO_0009854', 'MONDO_0005351', 'EFO_0009963', 'MONDO_0005180', 'MONDO_0002050', 'EFO_0005407', 'Orphanet_79292', 'EFO_0004247', 'EFO_0003888', 'MONDO_0002050', 'MONDO_0007079', 'EFO_0000677', 'MONDO_0004985', 'EFO_1001892', 'EFO_0005230', 'EFO_0005411', 'EFO_0003884', 'MONDO_0002046', 'EFO_0004242', 'HP_0000713', 'HP_0012076', 'EFO_1001917', 'MONDO_0002009', 'EFO_1000904', 'MONDO_0005090', 'EFO_0005407', 'EFO_0009964', 'EFO_0005230', 'MONDO_0007079', 'EFO_0004701', 'EFO_0009267', 'MONDO_0004985', 'EFO_1001917', 'EFO_0004257', 'HP_0012076', 'EFO_0001358', 'EFO_0003761', 'EFO_0007453']",True,False,49,Serotonin 2a (5-HT2a) receptor antagonist Dopamine D2 receptor antagonist Serotonin 2c (5-HT2c) receptor antagonist ,ANTAGONIST ,single protein 
1758,EPTIFIBATIDE,CHEMBL1174,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for acute coronary syndrome and recurrent thrombophlebitis and has 11 investigational indications.,,4.0,,False,1998,"['ENSG00000259207', 'ENSG00000005961']","['MONDO_0011382', 'EFO_0008583', 'EFO_0001645', 'EFO_0000319', 'EFO_0000712', 'HP_0002140', 'EFO_0005672', 'EFO_0006834', 'HP_0004419', 'EFO_0003106', 'EFO_0000612', 'EFO_0008585', 'EFO_0004277']",True,True,13,Integrin alpha-IIb/beta-3 inhibitor ,INHIBITOR ,protein complex 
1759,BIMOSIAMOSE,CHEMBL1215923,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188404', 'ENSG00000007908', 'ENSG00000174175']","['EFO_0000341', 'EFO_0000676']",False,False,2,Selectin inhibitor ,INHIBITOR ,protein family 
1760,FAMITINIB,CHEMBL1278146,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000128052', 'ENSG00000037280', 'ENSG00000102755', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000122025']","['MONDO_0024503', 'EFO_0003869', 'EFO_0003060', 'EFO_0005537', 'EFO_0000756', 'EFO_0004252', 'EFO_0002618', 'EFO_0000681', 'EFO_0001071', 'EFO_0005922', 'EFO_1001961', 'MONDO_0002974', 'MONDO_0011719', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000365']",True,False,17,Tyrosine-protein kinase receptor FLT3 inhibitor Vascular endothelial growth factor receptor 2 inhibitor Vascular endothelial growth factor receptor 3 inhibitor Vascular endothelial growth factor receptor 1 inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor ,INHIBITOR ,single protein protein complex 
1761,ALGINIC ACID,CHEMBL2108894,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0007536', 'MONDO_0009061', 'HP_0004398', 'EFO_0003843', 'EFO_0001073', 'EFO_0003948']",False,False,6,,,
1762,OZONE,CHEMBL2447938,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000400', 'EFO_0008507', 'MONDO_0100096', 'EFO_0001645']",False,False,4,,,
1763,MOTEXAFIN GADOLINIUM,CHEMBL3544910,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,"['ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848', 'ENSG00000198431']","['EFO_0009708', 'EFO_0000095', 'EFO_1000158', 'EFO_0000681', 'EFO_0000632', 'EFO_0000228', 'EFO_0005952', 'EFO_0000519', 'EFO_0002618', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378', 'EFO_0003863', 'MONDO_0005411', 'MONDO_0002367', 'EFO_1001465', 'EFO_0003833']",False,False,17,Thioredoxin reductase 1 inhibitor Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,single protein protein complex group 
1764,COFETUZUMAB PELIDOTIN,CHEMBL3989983,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1765,SOTORASIB,CHEMBL4535757,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 5 investigational indications.,,4.0,,False,2021,['ENSG00000133703'],"['EFO_0000571', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001421', 'EFO_0002618', 'EFO_0000616', 'EFO_0000365']",False,False,7,GTPase KRas inhibitor ,INHIBITOR ,single protein 
1766,REGN-4659,CHEMBL4594596,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1767,SALMETEROL XINAFOATE,CHEMBL1082607,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000169252'],"['EFO_0001073', 'EFO_0006505', 'EFO_0000341', 'EFO_0007183', 'HP_0025428', 'MONDO_0004979', 'EFO_0000464']",False,False,7,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1768,PH-797804,CHEMBL1088751,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000112062'],"['EFO_0000341', 'MONDO_0005178', 'MONDO_0041052', 'EFO_0003843', 'EFO_0000685']",False,False,5,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
1769,NEMONOXACIN,CHEMBL1213456,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['HP_0001410', 'EFO_0003106', 'EFO_1001272', 'EFO_0000771', 'EFO_0000544', 'EFO_0003086']",False,False,6,Bacterial DNA gyrase inhibitor Topoisomerase IV inhibitor ,INHIBITOR ,protein complex 
1770,LORVOTUZUMAB MERTANSINE,CHEMBL1743037,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000149294', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000565', 'EFO_0000702', 'MONDO_0006058', 'EFO_0002918', 'EFO_0000760', 'EFO_0001378', 'EFO_0001376', 'EFO_0000621']",True,False,8,Tubulin inhibitor Neural cell adhesion molecule 1 binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
1771,THEOPHYLLINE,CHEMBL190,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1940 and has 3 approved and 24 investigational indications.,,4.0,,False,1940,"['ENSG00000163485', 'ENSG00000170425', 'ENSG00000282608', 'ENSG00000128271', 'ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650', 'ENSG00000172572', 'ENSG00000152270']","['MONDO_0019992', 'HP_0001919', 'EFO_1000782', 'MONDO_0007078', 'HP_0002104', 'Orphanet_665', 'EFO_0003060', 'EFO_0000222', 'MONDO_0001187', 'HP_0002315', 'HP_0006536', 'EFO_0000565', 'EFO_0009492', 'EFO_0001361', 'EFO_0000341', 'MONDO_0004979', 'EFO_0003917', 'EFO_0001361', 'MONDO_0002009', 'HP_0006536', 'HP_0006536', 'EFO_0000763', 'EFO_0006505', 'EFO_0009686', 'EFO_1000782', 'HP_0006536', 'MONDO_0002050', 'EFO_0003086', 'MONDO_0004979', 'EFO_0003884', 'EFO_0001663']",True,True,31,Phosphodiesterase 3 inhibitor Adenosine receptor antagonist Phosphodiesterase 4 inhibitor ,INHIBITOR ANTAGONIST ,protein family 
1772,ALDOXORUBICIN,CHEMBL2107818,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000131747'],"['EFO_0000182', 'EFO_0000702', 'EFO_0003060', 'MONDO_0008978', 'EFO_0000519', 'MONDO_0007254', 'EFO_0002618', 'EFO_0000616', 'EFO_0000707', 'EFO_0002517', 'EFO_1001968']",True,False,11,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
1773,AVADOMIDE,CHEMBL3989934,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000095', 'MONDO_0018906', 'EFO_0000182', 'EFO_0000403', 'HP_0000083', 'EFO_0005952', 'EFO_0000096', 'EFO_0000756']",False,False,8,,,
1774,CANAGLIFLOZIN,CHEMBL4594217,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,['ENSG00000140675'],"['EFO_0000401', 'MONDO_0005147', 'HP_0000083', 'EFO_0000400', 'MONDO_0007254', 'EFO_0003144', 'MONDO_0005148', 'EFO_0001073', 'EFO_0000660']",False,False,9,Sodium/glucose cotransporter 2 inhibitor ,INHIBITOR ,single protein 
1775,INUPADENANT,CHEMBL4650331,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000616']",False,False,2,,,
1776,TARAGARESTRANT,CHEMBL5095327,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1777,ATOMOXETINE,CHEMBL641,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for attention deficit hyperactivity disorder and has 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,['ENSG00000103546'],"['EFO_1001917', 'HP_0010865', 'EFO_0004895', 'EFO_0003758', 'MONDO_0007079', 'EFO_0003918', 'EFO_0003888', 'MONDO_0002491', 'EFO_0003768', 'EFO_0004701', 'EFO_0005611', 'EFO_1000645', 'HP_0100543', 'MONDO_0004992', 'EFO_0002610', 'EFO_0005252', 'MONDO_0005147', 'MONDO_0005180', 'EFO_0004701', 'EFO_0003888', 'MONDO_0004975', 'EFO_0003877', 'EFO_0003918', 'EFO_0007191', 'MONDO_0005090']",False,False,25,Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
1778,FENRETINIDE,CHEMBL7301,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1001465', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000389', 'MONDO_0008903', 'MONDO_0004992', 'EFO_1000158', 'EFO_0000222', 'EFO_0000211', 'EFO_0002428', 'EFO_0006859', 'MONDO_0009061', 'MONDO_0005090', 'EFO_0000673', 'EFO_0000565', 'MONDO_0001187', 'EFO_0000616', 'MONDO_0002974', 'EFO_0000621', 'EFO_0005411', 'MONDO_0002367', 'MONDO_0008315', 'EFO_0000220', 'EFO_0000574']",False,False,24,,,
1779,TESTOSTERONE ENANTHATE,CHEMBL1200335,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for hypogonadotropic hypogonadism and hypogonadism and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1953,['ENSG00000169083'],"['EFO_0000341', 'HP_0000044', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000196', 'EFO_0007312', 'MONDO_0002146', 'HP_0001824', 'Orphanet_269']",False,False,9,Androgen Receptor agonist ,AGONIST ,single protein 
1780,ALUMINUM HYDROXIDE,CHEMBL1200706,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 21 investigational indications.,,4.0,,False,1983,[],"['EFO_0007328', 'MONDO_0005147', 'EFO_0000778', 'EFO_0005046', 'HP_0031273', 'EFO_0000544', 'EFO_0009688', 'EFO_1001413', 'EFO_0003768', 'EFO_1001474', 'EFO_0009425', 'EFO_0000764', 'EFO_0005222', 'EFO_1001475', 'EFO_0005681', 'EFO_0007444', 'EFO_0000180', 'EFO_0001068', 'EFO_0005547', 'EFO_0000694', 'EFO_0007314']",False,False,21,,,
1781,SILMITASERTIB,CHEMBL1230165,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000101266'],"['EFO_0004193', 'EFO_0002939', 'EFO_0005221', 'MONDO_0100096', 'EFO_0001378']",False,False,5,Casein kinase II alpha inhibitor ,INHIBITOR ,single protein 
1782,CLODRONATE DISODIUM,CHEMBL1520188,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0003843']",False,False,2,,,
1783,BELNACASAN,CHEMBL2107819,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000137752'],"['EFO_0000676', 'EFO_0000474', 'MONDO_0100096', 'EFO_0004263']",True,False,4,Caspase-1 inhibitor ,INHIBITOR ,single protein 
1784,PROINSULIN HUMAN,CHEMBL2109212,Protein drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
1785,TOL-101,CHEMBL2109591,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000211810', 'ENSG00000277734', 'ENSG00000278030', 'ENSG00000211699']",['EFO_0003884'],False,False,1,T-cell receptor inhibitor ,INHIBITOR ,protein complex 
1786,COLISTIN,CHEMBL2221249,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 9 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000771', 'EFO_1001272', 'MONDO_0004992', 'EFO_0000544', 'EFO_0003106', 'EFO_0003033', 'EFO_0009661', 'EFO_0003102', 'MONDO_0009061', 'HP_0001298']",False,False,10,,,
1787,EFAVALEUKIN ALFA,CHEMBL4298204,Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000729', 'EFO_0000540', 'EFO_0000685', 'MONDO_0007915']",False,False,4,,,
1788,BAZEDOXIFENE,CHEMBL46740,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for postmenopausal osteoporosis and has 7 investigational indications.,,4.0,,False,2009,"['ENSG00000140009', 'ENSG00000091831']","['EFO_0000432', 'EFO_0003854', 'EFO_0003922', 'MONDO_0007254', 'EFO_0003922', 'EFO_0003882', 'EFO_0003854', 'EFO_0003929', 'EFO_0003882']",False,True,9,Estrogen receptor modulator ,MODULATOR ,protein family 
1789,BIOTIN,CHEMBL857,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 6 investigational indications.,,4.0,,False,1985,[],"['HP_0001891', 'EFO_0003884', 'MONDO_0005148', 'MONDO_0007739', 'MONDO_0004976', 'MONDO_0005301', 'MONDO_0011382', 'EFO_0004272', 'MONDO_0001240', 'EFO_0003144']",False,False,10,,,
1790,GAMMA-AMINOBUTYRIC ACID,CHEMBL96,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0005147', 'EFO_0000474']",False,False,2,,,
1791,ZINC SULFATE,CHEMBL1200929,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved and 12 investigational indications.,,4.0,,False,1987,[],"['EFO_1001345', 'EFO_0003938', 'HP_0011950', 'EFO_0001070', 'EFO_0000545', 'EFO_0003884', 'EFO_0001073', 'HP_0001891', 'HP_0002014', 'HP_0100806', 'EFO_1001898', 'MONDO_0011382', 'MONDO_0021187', 'EFO_0003106', 'EFO_0004272']",False,False,15,,,
1792,AMLODIPINE,CHEMBL1491,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 13 approved and 30 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['EFO_0003913', 'EFO_0000319', 'MONDO_0016486', 'HP_0000093', 'EFO_1001145', 'EFO_0001421', 'EFO_0000712', 'EFO_0004911', 'EFO_0003144', 'MONDO_0000477', 'EFO_0000537', 'HP_0003124', 'MONDO_0021187', 'EFO_0000278', 'EFO_0000712', 'HP_0003124', 'EFO_0000373', 'Orphanet_79292', 'EFO_0007148', 'EFO_0000612', 'EFO_0003086', 'MONDO_0001422', 'MONDO_0002050', 'EFO_0000764', 'EFO_0000612', 'EFO_0000400', 'EFO_0000612', 'EFO_0003144', 'EFO_0000537', 'EFO_1000013', 'EFO_0001645', 'MONDO_0021187', 'EFO_0000400', 'EFO_0000373', 'EFO_0001645', 'EFO_0004234', 'MONDO_0005148', 'MONDO_0001134', 'MONDO_0007254', 'EFO_0003914', 'EFO_1001375', 'EFO_1001996', 'MONDO_0001134', 'EFO_0003777', 'EFO_0000537', 'EFO_0000538', 'EFO_0001645', 'EFO_0004214']",True,False,48,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1793,RAMUCIRUMAB,CHEMBL1743062,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 34 investigational indications.,,4.0,,False,2014,['ENSG00000128052'],"['EFO_0000588', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000519', 'EFO_0004243', 'EFO_0000681', 'EFO_0008528', 'EFO_0000708', 'EFO_1000895', 'MONDO_0003060', 'EFO_0000228', 'EFO_0001376', 'EFO_1000657', 'EFO_0002916', 'EFO_1001951', 'EFO_0000616', 'EFO_1001961', 'MONDO_0007254', 'EFO_0000181', 'MONDO_0007576', 'MONDO_0021063', 'MONDO_0008315', 'EFO_0000178', 'EFO_0000389', 'EFO_0000326', 'EFO_1000576', 'EFO_0003897', 'EFO_0003060', 'MONDO_0005411', 'EFO_0000182', 'EFO_0005922', 'EFO_1001469', 'EFO_1000581', 'EFO_0000503', 'EFO_0005952', 'EFO_0002618', 'MONDO_0001056']",False,False,37,Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
1794,GISADENAFIL,CHEMBL1928262,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000138735'],"['EFO_0000341', 'EFO_0000284', 'HP_0000802', 'EFO_1000781']",False,False,4,Phosphodiesterase 5A inhibitor ,INHIBITOR ,single protein 
1795,YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN,CHEMBL2108666,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000012124'],"['EFO_0000094', 'MONDO_0018906', 'EFO_0000403', 'EFO_0000096']",False,False,4,CD22 inhibitor ,INHIBITOR ,single protein 
1796,BELLADONNA,CHEMBL2108906,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0010282', 'MONDO_0007254']",False,False,2,,,
1797,FLUVASTATIN SODIUM,CHEMBL2218894,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for familial hypercholesterolemia and hypercholesterolemia and has 1 investigational indication.,,4.0,,False,1993,['ENSG00000113161'],"['EFO_0004911', 'HP_0003124', 'MONDO_0007254']",False,False,3,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
1798,FERRIC PYROPHOSPHATE CITRATE,CHEMBL3833317,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chronic kidney disease and has 2 investigational indications.,,4.0,,False,2015,[],"['EFO_0003884', 'EFO_1002048', 'HP_0001891']",False,False,3,,,
1799,DAPANSUTRILE,CHEMBL3989943,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000162711'],"['MONDO_0100096', 'EFO_0000756', 'EFO_1001165', 'EFO_1001207']",True,False,4,"NACHT, LRR and PYD domains-containing protein 3 inhibitor ",INHIBITOR ,single protein 
1800,PEMETREXED TROMETHAMINE,CHEMBL3989962,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for large cell lung carcinoma and adenocarcinoma.,,4.0,,False,2022,"['ENSG00000228716', 'ENSG00000159131']","['EFO_0003050', 'EFO_0000228']",False,False,2,Dihydrofolate reductase inhibitor Thymidylate synthase inhibitor GAR transformylase inhibitor ,INHIBITOR ,single protein 
1801,ST-101,CHEMBL4297437,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0004975', 'MONDO_0007254', 'EFO_0000196', 'MONDO_0001657', 'EFO_0000519', 'EFO_0002617', 'EFO_0003108']",False,False,7,,,
1802,GLYCYRRHIZIN,CHEMBL441687,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003884', 'MONDO_0005178']",False,False,2,,,
1803,PLUTAVIMAB,CHEMBL4650460,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1804,TADALAFIL,CHEMBL779,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 5 approved and 31 investigational indications.,,4.0,,False,2003,['ENSG00000138735'],"['EFO_0003060', 'EFO_0009200', 'EFO_0000616', 'EFO_0001361', 'EFO_0004714', 'EFO_0004244', 'EFO_0002614', 'MONDO_0000153', 'MONDO_0005148', 'EFO_0002499', 'HP_0030680', 'MONDO_0005149', 'HP_0000802', 'EFO_0000373', 'HP_0001952', 'EFO_0004284', 'EFO_1000948', 'EFO_0000284', 'EFO_0000181', 'EFO_0004718', 'EFO_0003099', 'EFO_0004234', 'EFO_0002618', 'EFO_0001073', 'EFO_0000537', 'MONDO_0020121', 'EFO_0000712', 'MONDO_0010679', 'MONDO_0002009', 'EFO_0001378', 'EFO_0000717', 'MONDO_0001134', 'HP_0200023', 'MONDO_0004992', 'EFO_0000519', 'EFO_1001145']",False,False,36,Phosphodiesterase 5A inhibitor ,INHIBITOR ,single protein 
1805,PIPERACILLIN SODIUM,CHEMBL1200820,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 2 investigational indications.,,4.0,,False,1981,[],"['EFO_0003106', 'EFO_1001312', 'EFO_1001388', 'EFO_1001459', 'EFO_0003035', 'EFO_0008588', 'EFO_0000544', 'EFO_0007149', 'EFO_0003102']",False,False,9,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1806,SITAGLIPTIN,CHEMBL1422,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 5 approved and 22 investigational indications.,,4.0,,False,2006,['ENSG00000197635'],"['EFO_1001459', 'EFO_1001121', 'EFO_0000612', 'EFO_0000400', 'EFO_0004599', 'MONDO_0005147', 'MONDO_0009061', 'EFO_0002546', 'EFO_0000373', 'MONDO_0021187', 'EFO_0000712', 'EFO_0003884', 'EFO_0003047', 'MONDO_0005148', 'MONDO_0005148', 'EFO_0000400', 'HP_0000083', 'MONDO_0021187', 'MONDO_0013730', 'EFO_0000180', 'EFO_0001073', 'EFO_0000182', 'MONDO_0100096', 'EFO_0003095', 'HP_0001952', 'EFO_0000676', 'EFO_0008583']",True,False,27,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
1807,FLUOXYMESTERONE,CHEMBL1445,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 1 investigational indication.,,4.0,,False,1956,['ENSG00000169083'],"['EFO_1001078', 'MONDO_0007254', 'MONDO_0002146', 'EFO_0000616']",True,False,4,Androgen Receptor agonist ,AGONIST ,single protein 
1808,IXEKIZUMAB,CHEMBL1743034,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 4 approved and 10 investigational indications.,,4.0,,False,2016,['ENSG00000112115'],"['MONDO_0002009', 'MONDO_0005147', 'EFO_0006818', 'EFO_0003778', 'EFO_0003898', 'EFO_0007187', 'MONDO_0100096', 'EFO_0000540', 'HP_0000999', 'EFO_0009856', 'EFO_1001494', 'EFO_0000676', 'MONDO_0100017', 'EFO_0000685']",False,False,14,Interleukin 17A inhibitor ,INHIBITOR ,single protein 
1809,CABOZANTINIB S-MALATE,CHEMBL2103868,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000105976', 'ENSG00000128052']","['EFO_0000519', 'EFO_0000681', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000326', 'EFO_0000272', 'EFO_0000501', 'EFO_0000673', 'EFO_1001465', 'EFO_0000641', 'EFO_0003060', 'EFO_0003968', 'EFO_0000182', 'EFO_0000239', 'EFO_0002892', 'EFO_0000640', 'MONDO_0002108', 'EFO_1000251', 'EFO_0000616', 'EFO_1001512', 'EFO_0000305', 'EFO_0008524', 'EFO_0000349']",False,False,23,Vascular endothelial growth factor receptor 2 inhibitor Hepatocyte growth factor receptor inhibitor ,INHIBITOR ,single protein 
1810,GATAPARSEN,CHEMBL2219774,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000089685'],"['EFO_0000182', 'MONDO_0008315', 'EFO_0000222', 'EFO_0003060']",True,False,4,Survivin mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
1811,DDO-3055,CHEMBL4162752,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003884'],False,False,1,,,
1812,TALOTREXIN,CHEMBL590985,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000565', 'EFO_0000616']",False,False,3,,,
1813,VALACYCLOVIR,CHEMBL1349,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 29 investigational indications.,,4.0,,False,1995,[],"['MONDO_0004985', 'EFO_0007307', 'EFO_0000764', 'EFO_1001347', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0002499', 'MONDO_0100342', 'MONDO_0019956', 'EFO_0006510', 'EFO_1002022', 'EFO_0002950', 'EFO_0001062', 'EFO_0004220', 'EFO_0000519', 'EFO_0005411', 'EFO_1000811', 'EFO_0007326', 'EFO_0007204', 'EFO_0000763', 'MONDO_0041052', 'EFO_1000028', 'MONDO_0005090', 'EFO_0000673', 'MONDO_0004992', 'EFO_0009441', 'EFO_0000616', 'EFO_0001062', 'EFO_1002022', 'EFO_0000095', 'EFO_0006510', 'EFO_0000341', 'MONDO_0005090', 'EFO_0007282', 'EFO_0005407', 'EFO_0005543', 'EFO_0007282', 'EFO_1001347']",False,False,38,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
1814,DESMOPRESSIN,CHEMBL1429,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,"['ENSG00000126895', 'ENSG00000166148', 'ENSG00000198049']","['EFO_0005669', 'MONDO_0004782', 'EFO_1000781', 'MP_0001914', 'EFO_1001412', 'MONDO_0024290', 'MONDO_0004782', 'MONDO_0007254', 'HP_0001742', 'MONDO_0024574', 'HP_0031364', 'MONDO_0024290', 'MP_0001914', 'EFO_0009505', 'MONDO_0008315', 'HP_0000863', 'EFO_0000537', 'EFO_0007344']",False,False,18,Vasopressin receptor agonist ,AGONIST ,protein family 
1815,FLUTEMETAMOL F 18,CHEMBL2042122,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for alzheimer disease and cognitive impairment and has 1 investigational indication.,,4.0,,False,2013,[],"['MONDO_0004975', 'HP_0100543', 'EFO_0000318']",False,False,3,,,
1816,VOLOCIXIMAB,CHEMBL2108061,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000150093', 'ENSG00000161638']","['MONDO_0008903', 'EFO_0003060', 'EFO_0000756', 'EFO_0002618', 'MONDO_0008170', 'EFO_0001365', 'EFO_1001100']",False,False,7,Integrin alpha-5/beta-1 antagonist ,ANTAGONIST ,protein complex 
1817,VILOBELIMAB,CHEMBL2109636,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000106804'],"['EFO_1000784', 'EFO_1000710', 'HP_0000999', 'MONDO_0100096', 'EFO_0005297', 'EFO_0006834', 'HP_0100806', 'MP_0001845', 'EFO_0000717']",False,False,9,Complement C5 inhibitor ,INHIBITOR ,single protein 
1818,LINIFANIB,CHEMBL223360,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000182578', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000122025']","['EFO_0000681', 'EFO_1000657', 'EFO_0000365', 'EFO_0003060', 'MONDO_0021063', 'EFO_0000182', 'EFO_0001365', 'EFO_0001065', 'EFO_0000616', 'MONDO_0007254']",True,False,10,Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Macrophage colony stimulating factor receptor inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,protein family protein complex single protein 
1819,ENZASTAURIN,CHEMBL300138,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 36 investigational indications.,,3.0,,False,no approval year,['ENSG00000166501'],"['MONDO_0008315', 'EFO_0001378', 'EFO_1001465', 'EFO_0004288', 'EFO_0002913', 'EFO_1001951', 'EFO_0009441', 'MONDO_0018906', 'EFO_1001469', 'EFO_1000158', 'EFO_0000096', 'MONDO_0008315', 'EFO_0003060', 'EFO_0000403', 'EFO_0000403', 'MONDO_0002087', 'EFO_0004289', 'EFO_0000365', 'MONDO_0008170', 'MONDO_0020066', 'MONDO_0004992', 'EFO_0003860', 'EFO_0005543', 'EFO_0000681', 'EFO_1001100', 'EFO_0000519', 'MONDO_0100342', 'MONDO_0008903', 'EFO_0000702', 'EFO_0005952', 'MONDO_0008903', 'EFO_0003869', 'EFO_1000251', 'EFO_0003060', 'EFO_0000621', 'EFO_0000519', 'EFO_0000574', 'EFO_0000326', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0007254']",True,False,41,Protein kinase C beta inhibitor ,INHIBITOR ,single protein 
1820,ONALESPIB LACTATE,CHEMBL3301599,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1821,BPI-9016,CHEMBL3545236,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,"['ENSG00000167601', 'ENSG00000105976']","['EFO_0003060', 'EFO_0000616']",False,False,2,Hepatocyte growth factor receptor inhibitor Tyrosine-protein kinase receptor UFO inhibitor ,INHIBITOR ,single protein 
1822,NEDISERTIB,CHEMBL4297629,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications.,,1.0,,False,no approval year,[],"['EFO_1000657', 'EFO_0000222', 'EFO_0000616', 'EFO_1001465', 'EFO_1001901', 'EFO_0000196', 'EFO_0000702', 'EFO_0000095']",False,False,8,,,
1823,PIOGLITAZONE,CHEMBL595,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 73 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,['ENSG00000132170'],"['EFO_0000756', 'EFO_0004265', 'EFO_0000712', 'EFO_0000400', 'MONDO_0005148', 'EFO_0000384', 'MONDO_0002108', 'HP_0012115', 'HP_0003124', 'EFO_0002546', 'EFO_0000544', 'HP_0002745', 'EFO_0000339', 'MONDO_0004975', 'EFO_0003929', 'EFO_0001421', 'EFO_0000616', 'MONDO_0018305', 'EFO_0001361', 'MP_0001845', 'EFO_0001421', 'MONDO_0004976', 'EFO_0003085', 'MONDO_0015339', 'MONDO_0100339', 'EFO_0000707', 'EFO_0001073', 'EFO_0003884', 'Orphanet_43', 'EFO_0000708', 'EFO_0001645', 'EFO_0003914', 'MONDO_0005301', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0008903', 'MONDO_0007915', 'EFO_0000519', 'EFO_0000613', 'EFO_0003095', 'EFO_0003047', 'EFO_1000948', 'EFO_0000537', 'EFO_0000685', 'MONDO_0002009', 'EFO_0004272', 'HP_0100543', 'EFO_0002618', 'EFO_0002499', 'EFO_0003756', 'MONDO_0001437', 'EFO_0005611', 'EFO_0003060', 'MONDO_0007079', 'MONDO_0009061', 'EFO_1001249', 'EFO_1001348', 'EFO_0000676', 'MONDO_0005148', 'EFO_0000673', 'EFO_0008620', 'EFO_0003060', 'MONDO_0004976', 'MONDO_0004979', 'EFO_0000319', 'EFO_0000660', 'EFO_0005669', 'EFO_0000195', 'EFO_0003884', 'HP_0001397', 'MONDO_0005180', 'EFO_0001378', 'EFO_0003095', 'MONDO_0016642', 'EFO_0004220', 'MONDO_0005147', 'EFO_0000222', 'MONDO_0001657']",True,False,78,Peroxisome proliferator-activated receptor gamma agonist ,AGONIST ,single protein 
1824,GEMCITABINE HYDROCHLORIDE,CHEMBL1637,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 48 investigational indications.,,4.0,,False,1996,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229', 'ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']","['MONDO_0008170', 'MONDO_0008627', 'EFO_0006859', 'EFO_0000183', 'Orphanet_145', 'EFO_0000574', 'EFO_0006475', 'EFO_0000681', 'EFO_1000613', 'EFO_0000616', 'EFO_1000043', 'EFO_0000313', 'EFO_0000096', 'EFO_0001075', 'EFO_0000565', 'EFO_0003859', 'MONDO_0011962', 'EFO_0000691', 'MONDO_0002087', 'EFO_1000251', 'MONDO_0004192', 'MONDO_0016537', 'EFO_0006861', 'EFO_1001961', 'EFO_0006738', 'EFO_0000305', 'EFO_0000588', 'MONDO_0002158', 'EFO_0004252', 'MONDO_0015760', 'MONDO_0001056', 'MONDO_0005411', 'MONDO_0004992', 'EFO_0008528', 'MONDO_0004986', 'EFO_1001951', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0002367', 'EFO_0001416', 'HP_0001907', 'EFO_0000466', 'EFO_1001469', 'EFO_1001051', 'EFO_1001959', 'EFO_0002517', 'EFO_0001378', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0008903', 'MONDO_0001187', 'EFO_0002618', 'MONDO_0002691', 'EFO_0005537']",True,True,54,DNA polymerase (alpha/delta/epsilon) inhibitor Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,protein family protein complex group 
1825,RELMAPIRAZIN,CHEMBL1949708,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003884', 'HP_0001919']",False,False,2,,,
1826,TAFAMIDIS MEGLUMINE,CHEMBL2105675,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 2 investigational indications.,,4.0,,False,2019,['ENSG00000118271'],"['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438', 'EFO_0004129']",False,True,5,Transthyretin stabiliser ,STABILISER ,single protein 
1827,BGT-226,CHEMBL3545096,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['MONDO_0016063', 'MONDO_0004992', 'MONDO_0007254']",True,False,3,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1828,AZD3199,CHEMBL3545103,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000169252'],"['EFO_0000341', 'MONDO_0004979']",False,False,2,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1829,ASM-024,CHEMBL3707249,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000175344', 'ENSG00000117971', 'ENSG00000080644', 'ENSG00000181072', 'ENSG00000133019', 'ENSG00000168539']","['MONDO_0004979', 'EFO_0000341']",True,True,2,Neuronal acetylcholine receptor; alpha3/beta4 antagonist Muscarinic acetylcholine receptor M1 antagonist Muscarinic acetylcholine receptor M3 antagonist Neuronal acetylcholine receptor protein alpha-7 subunit modulator Muscarinic acetylcholine receptor M2 antagonist ,ANTAGONIST MODULATOR ,protein complex single protein 
1830,VIBOSTOLIMAB,CHEMBL4297785,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000181847'],"['MONDO_0008315', 'EFO_0000702', 'EFO_0003060', 'EFO_0000681', 'EFO_0000756', 'EFO_0001642', 'EFO_1001951', 'EFO_0000616']",True,False,8,T-cell immunoreceptor with Ig and ITIM domains antagonist ,ANTAGONIST ,single protein 
1831,PICTILISIB,CHEMBL521851,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['MONDO_0007254', 'MONDO_0004992', 'EFO_0005952', 'EFO_0003060', 'EFO_0000616']",True,False,5,PI3-kinase class I inhibitor ,INHIBITOR ,protein complex group 
1832,BAICALEIN,CHEMBL8260,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0007328'],False,False,1,,,
1833,MELPHALAN,CHEMBL852,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 4 approved and 104 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1964,[],"['EFO_1001469', 'MONDO_0002158', 'MONDO_0019471', 'EFO_0000220', 'MONDO_0013730', 'MONDO_0010518', 'EFO_0000191', 'EFO_1000785', 'MONDO_0018906', 'EFO_0000309', 'EFO_0007331', 'EFO_0000198', 'EFO_0001378', 'MONDO_0019469', 'EFO_0000313', 'MONDO_0015760', 'EFO_1001996', 'EFO_0000403', 'MONDO_0002334', 'MONDO_0017816', 'EFO_0005952', 'EFO_0007498', 'HP_0001915', 'EFO_0000574', 'EFO_0000183', 'HP_0002110', 'MONDO_0000870', 'EFO_0000326', 'MONDO_0004992', 'EFO_0006738', 'MONDO_0008170', 'EFO_1001257', 'EFO_0004272', 'EFO_0000095', 'EFO_1001469', 'EFO_0005803', 'EFO_0000616', 'EFO_0000255', 'EFO_0006861', 'EFO_0002430', 'EFO_0000095', 'MONDO_0008380', 'EFO_1001968', 'EFO_0004991', 'MONDO_0013730', 'EFO_0006475', 'MONDO_0002087', 'EFO_0002429', 'EFO_0000621', 'MONDO_0011382', 'MONDO_0008380', 'EFO_1000309', 'EFO_0000756', 'EFO_0000691', 'MONDO_0021193', 'EFO_0009538', 'MONDO_0044903', 'EFO_0003032', 'EFO_0000339', 'EFO_1001951', 'EFO_0000339', 'EFO_0000502', 'EFO_1001875', 'EFO_0002939', 'MONDO_0002367', 'EFO_0000198', 'MONDO_0015974', 'MONDO_0007254', 'EFO_0000681', 'EFO_0002428', 'EFO_1000956', 'MONDO_0009833', 'EFO_0004256', 'EFO_0000565', 'EFO_1000984', 'EFO_0000403', 'EFO_0003929', 'EFO_0000222', 'EFO_0001378', 'MONDO_0019438', 'EFO_0000096', 'EFO_1000318', 'MONDO_0000873', 'MONDO_0015253', 'HP_0100727', 'EFO_0009441', 'MONDO_0019472', 'MONDO_0044881', 'EFO_0005952', 'MONDO_0002691', 'EFO_0000222', 'EFO_0000183', 'EFO_1001051', 'EFO_0000211', 'MONDO_0008978', 'MONDO_0020077', 'MONDO_0002120', 'MONDO_0018906', 'EFO_0000389', 'EFO_0000174', 'EFO_0000384', 'EFO_0003073', 'MONDO_0008315', 'EFO_1000158', 'MONDO_0003751', 'EFO_1001779', 'EFO_0005088', 'EFO_1001383', 'EFO_0003833', 'EFO_0002501', 'EFO_1000131', 'EFO_0001642', 'Orphanet_848']",False,False,113,,,
1834,RIMANTADINE,CHEMBL959,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved indications.,,4.0,,False,1993,[],"['EFO_0000763', 'EFO_0000544', 'EFO_0007328']",False,False,3,Influenza virus A matrix protein M2 inhibitor ,INHIBITOR ,single protein 
1835,FONDAPARINUX,CHEMBL1201202,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2001,['ENSG00000117601'],"['HP_0001907', 'HP_0004936', 'EFO_0000275', 'EFO_0003907', 'EFO_0004286', 'EFO_0003827', 'EFO_0007541', 'EFO_0001074', 'EFO_0005672', 'HP_0004419', 'HP_0004936', 'EFO_0004286', 'HP_0001873', 'MONDO_0100096', 'HP_0000083', 'EFO_0009686', 'HP_0001907', 'EFO_0001075']",False,False,18,Antithrombin-III activator ,ACTIVATOR ,single protein 
1836,TREPROSTINIL,CHEMBL1237119,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 15 investigational indications.,,4.0,,False,2002,['ENSG00000160013'],"['MONDO_0005149', 'MONDO_0005147', 'EFO_0000717', 'EFO_0000768', 'EFO_0000341', 'MONDO_0001999', 'EFO_0000556', 'EFO_1001145', 'MONDO_0100130', 'EFO_1001103', 'EFO_0003875', 'EFO_0002687', 'EFO_0001361', 'EFO_1001459', 'EFO_0005207', 'EFO_0001361', 'HP_0004419', 'EFO_0000717']",False,False,18,Prostanoid IP receptor agonist ,AGONIST ,single protein 
1837,SODIUM BICARBONATE,CHEMBL1353,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for pain and gastroesophageal reflux disease and has 25 investigational indications.,,4.0,,False,1985,[],"['MONDO_0004992', 'MONDO_0001056', 'EFO_1000845', 'EFO_0003106', 'MONDO_0100096', 'EFO_1000910', 'EFO_0000764', 'EFO_0003086', 'EFO_0003884', 'EFO_1000014', 'MONDO_0009061', 'HP_0002239', 'EFO_0004253', 'EFO_0003843', 'HP_0012228', 'EFO_0003777', 'EFO_1002048', 'HP_0001919', 'HP_0000020', 'EFO_0003948', 'HP_0001871', 'EFO_1001139', 'EFO_0002618', 'MONDO_0002492', 'HP_0002019', 'EFO_1001931', 'EFO_0000546']",False,False,27,,,
1838,FLUVOXAMINE MALEATE,CHEMBL1409,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for obsessive-compulsive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000108576'],"['EFO_0000694', 'EFO_0004262', 'MONDO_0100096', 'EFO_0004242']",False,False,4,Serotonin transporter inhibitor ,INHIBITOR ,single protein 
1839,DOXEPIN,CHEMBL1628227,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 7 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1969,['ENSG00000103546'],"['EFO_0003761', 'MONDO_0007079', 'EFO_0005230', 'EFO_0003761', 'EFO_0005531', 'EFO_0004698', 'MONDO_0005090', 'EFO_1001904', 'MONDO_0004985', 'HP_0000989', 'EFO_0008568', 'EFO_0003843', 'EFO_0000555', 'MONDO_0007254', 'MONDO_0002050', 'EFO_0000274']",False,False,16,Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
1840,ERDOSTEINE,CHEMBL1697744,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000341', 'EFO_0006505']",False,False,2,,,
1841,ORTERONEL,CHEMBL1921976,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000148795'],"['MONDO_0008315', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000673']",False,False,4,Cytochrome P450 17A1 inhibitor ,INHIBITOR ,single protein 
1842,GSK2879552,CHEMBL3786182,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000198', 'EFO_0000702', 'EFO_0000565']",False,False,3,,,
1843,FORIGERIMOD,CHEMBL3989409,Protein drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000109971'],"['MONDO_0007915', 'MONDO_0007915']",False,False,2,Heat shock cognate 71 kDa protein inhibitor ,INHIBITOR ,single protein 
1844,DAS-181,CHEMBL4297932,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0007419', 'EFO_0000544', 'EFO_0007328']",False,False,4,,,
1845,EMVODODSTAT,CHEMBL4650336,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000102967'],"['MONDO_0004992', 'EFO_0000222', 'MONDO_0007254', 'MONDO_0007039']",True,False,4,Dihydroorotate dehydrogenase inhibitor ,INHIBITOR ,single protein 
1846,ABDAVOMERAN,CHEMBL4650454,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein vaccine antigen ,VACCINE ANTIGEN ,single protein 
1847,COFIRASERSEN,CHEMBL4650476,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000166828', 'ENSG00000111319', 'ENSG00000168447']","['EFO_0006505', 'MONDO_0009061']",False,False,2,"Amiloride-sensitive sodium channel, ENaC mRNA antisense inhibitor ",ANTISENSE INHIBITOR ,nucleic-acid 
1848,DEXMEDETOMIDINE,CHEMBL778,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 67 investigational indications.,,4.0,,False,1999,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']","['EFO_0003918', 'EFO_0002460', 'HP_0030834', 'EFO_0006834', 'EFO_1002048', 'EFO_0005774', 'EFO_0004698', 'EFO_0003777', 'EFO_0009516', 'EFO_0001074', 'EFO_0005279', 'MONDO_0004976', 'EFO_0003843', 'HP_0000713', 'MP_0001845', 'EFO_0003957', 'EFO_0001645', 'EFO_0001073', 'EFO_0003843', 'EFO_0002950', 'EFO_0004888', 'MONDO_0007254', 'HP_0012532', 'EFO_0000668', 'MONDO_0005090', 'EFO_0005207', 'MONDO_0001056', 'HP_0012735', 'EFO_0000275', 'EFO_0009267', 'EFO_0005762', 'HP_0001919', 'EFO_0005323', 'HP_0002093', 'EFO_0003833', 'EFO_0005411', 'EFO_0000474', 'EFO_0009267', 'EFO_0005230', 'EFO_0000239', 'EFO_0002610', 'MONDO_0002258', 'EFO_0000546', 'MONDO_0005149', 'MONDO_0003544', 'MONDO_0004992', 'EFO_0004273', 'HP_0000713', 'HP_0100543', 'MONDO_0004975', 'EFO_0000537', 'EFO_0009686', 'EFO_0000677', 'EFO_0009620', 'MONDO_0005299', 'MONDO_0043510', 'HP_0000175', 'EFO_0005611', 'EFO_0003756', 'EFO_0010282', 'EFO_0003931', 'EFO_0000713', 'MONDO_0043510', 'EFO_0004264', 'HP_0002315', 'EFO_1001454', 'HP_0001337', 'HP_0000023']",True,False,68,Adrenergic receptor alpha-2 agonist ,AGONIST ,protein family 
1849,DUTASTERIDE,CHEMBL1200969,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 9 investigational indications.,,4.0,,False,2001,"['ENSG00000145545', 'ENSG00000277893', 'ENSG00000128039']","['EFO_0001663', 'MONDO_0002146', 'MONDO_0004976', 'EFO_0000284', 'EFO_0004191', 'MONDO_0008315', 'EFO_0003830', 'MONDO_0004907', 'MONDO_0010735', 'MONDO_0100096', 'GO_0007568', 'EFO_0000673']",True,False,12,Steroid 5-alpha-reductase inhibitor ,INHIBITOR ,protein family 
1850,NILOTINIB HYDROCHLORIDE MONOHYDRATE,CHEMBL1201740,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic myelogenous leukemia and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000097007', 'ENSG00000186716']","['MONDO_0005180', 'MONDO_0007254', 'EFO_0000339', 'EFO_0000717']",False,False,4,Bcr/Abl fusion protein Tyrosine-protein kinase ABL inhibitor ,INHIBITOR ,chimeric protein single protein 
1851,INDOLE-3-CARBINOL,CHEMBL155625,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0001073', 'MONDO_0007254', 'EFO_0003768', 'EFO_0000616']",False,False,4,,,
1852,ARFORMOTEROL TARTRATE,CHEMBL1951071,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 1 investigational indication.,,4.0,,False,2006,['ENSG00000169252'],"['EFO_0009661', 'EFO_0000341', 'EFO_0006505', 'EFO_0000464']",False,False,4,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1853,EDODEKIN ALFA,CHEMBL2109059,Protein drug with a maximum clinical trial phase of II (across all indications) and has 58 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0001378', 'MONDO_0018364', 'MONDO_0001187', 'EFO_0009637', 'EFO_1000796', 'EFO_0002428', 'EFO_0000389', 'MONDO_0021311', 'EFO_0000691', 'MONDO_0001056', 'EFO_0000403', 'MONDO_0003510', 'MONDO_0002158', 'EFO_0000191', 'MONDO_0005411', 'MONDO_0007254', 'MONDO_0003196', 'MONDO_0004992', 'MONDO_0001402', 'EFO_1001051', 'EFO_0000621', 'EFO_1001187', 'MONDO_0004192', 'EFO_0000641', 'MONDO_0018944', 'MONDO_0007576', 'EFO_0000181', 'MONDO_0001528', 'EFO_1001512', 'MONDO_0002367', 'EFO_0000501', 'EFO_0003060', 'EFO_0000549', 'MONDO_0008315', 'EFO_0000701', 'EFO_0000616', 'MONDO_0018906', 'MONDO_0001370', 'EFO_0000095', 'EFO_0004281', 'MONDO_0001879', 'EFO_0000574', 'EFO_0006352', 'MONDO_0002087', 'MONDO_0044926', 'EFO_0002618', 'EFO_0000565', 'MONDO_0008170', 'EFO_0009441', 'EFO_0006861', 'MONDO_0002974', 'EFO_1001469', 'EFO_0000198', 'EFO_1000984', 'EFO_0000756', 'MONDO_0004669', 'EFO_1000785', 'EFO_0000183']",False,False,58,,,
1854,CAL,CHEMBL2109562,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000087494'],"['EFO_0000764', 'MONDO_0007254']",False,True,2,Parathyroid hormone-related protein inhibitor ,INHIBITOR ,single protein 
1855,TAMIBAROTENE,CHEMBL25202,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000077092', 'ENSG00000131759']","['MONDO_0004975', 'EFO_0007527', 'EFO_0002618', 'EFO_0000198', 'EFO_0005761', 'EFO_0000224', 'EFO_0000222', 'EFO_0000384']",False,False,8,Retinoic acid receptor beta agonist Retinoic acid receptor alpha agonist ,AGONIST ,single protein 
1856,S-3304,CHEMBL297792,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000616']",False,False,2,,,
1857,ATEZOLIZUMAB,CHEMBL3707227,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 7 approved and 75 investigational indications.,,4.0,,False,2016,['ENSG00000120217'],"['EFO_1001465', 'EFO_1001513', 'MONDO_0008315', 'EFO_0003863', 'EFO_0007143', 'EFO_0001378', 'MONDO_0044881', 'EFO_0000756', 'EFO_0000339', 'EFO_0004288', 'EFO_0006859', 'EFO_0000096', 'EFO_1001951', 'EFO_0001061', 'EFO_0005922', 'MONDO_0001187', 'EFO_1001100', 'EFO_0000640', 'EFO_1000251', 'EFO_0005537', 'MONDO_0011962', 'EFO_0008524', 'EFO_0000503', 'MONDO_0008170', 'MONDO_0003060', 'EFO_0003869', 'EFO_0000196', 'EFO_1001956', 'EFO_0000673', 'EFO_0000403', 'MONDO_0002367', 'EFO_0000313', 'EFO_0002517', 'EFO_0005567', 'EFO_0002617', 'EFO_0000691', 'EFO_1000657', 'EFO_0002618', 'EFO_0000095', 'MONDO_0002974', 'MONDO_0011719', 'EFO_0001075', 'EFO_1000613', 'EFO_0000702', 'MONDO_0002158', 'MONDO_0007576', 'EFO_0000588', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000183', 'MONDO_0002898', 'EFO_0002892', 'EFO_0008528', 'EFO_1001512', 'EFO_0009708', 'EFO_0003893', 'EFO_0000181', 'MONDO_0008903', 'EFO_0003060', 'MONDO_0001879', 'MONDO_0100342', 'EFO_0000637', 'EFO_0002916', 'EFO_0004142', 'EFO_1001051', 'EFO_0008528', 'EFO_0000305', 'EFO_0005221', 'EFO_0005952', 'EFO_1001961', 'EFO_0004284', 'EFO_0000182', 'EFO_0000574', 'MONDO_0018906', 'EFO_0000198', 'EFO_0000770', 'EFO_0000389', 'MONDO_0004992', 'EFO_0000519', 'EFO_1000785', 'EFO_0000222', 'EFO_0000681']",False,False,82,Programmed cell death 1 ligand 1 inhibitor ,INHIBITOR ,single protein 
1858,ASPARTYL-ALANYL-DIKETOPIPERAZINE,CHEMBL4297349,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0004616']",False,False,2,,,
1859,RELDESEMTIV,CHEMBL4297600,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000130598', 'ENSG00000130595', 'ENSG00000101470']","['EFO_0000341', 'MONDO_0004976', 'EFO_0008525']",False,False,3,Fast skeletal troponin complex activator ,ACTIVATOR ,protein complex 
1860,BMS-986012,CHEMBL4297704,Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000702'],False,False,1,,,
1861,TORIPALIMAB,CHEMBL4297843,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 47 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000569', 'EFO_0000691', 'EFO_0005922', 'EFO_1001951', 'MONDO_0004986', 'EFO_0000707', 'EFO_0006859', 'EFO_1001972', 'EFO_0000181', 'EFO_0001416', 'EFO_1001968', 'MONDO_0007576', 'EFO_0000616', 'EFO_0000756', 'EFO_0003826', 'EFO_0002617', 'EFO_0000199', 'MONDO_0007254', 'MONDO_0002108', 'EFO_0003891', 'MONDO_0021358', 'MONDO_0003060', 'EFO_0003897', 'EFO_0000769', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0003060', 'MONDO_0002120', 'MONDO_0002974', 'MONDO_0000831', 'EFO_0005221', 'EFO_0002916', 'MONDO_0019472', 'EFO_0000182', 'MONDO_0008903', 'EFO_0004252', 'EFO_0000702', 'EFO_0000770', 'EFO_0000574', 'EFO_0005537', 'EFO_0003868', 'EFO_0000178', 'EFO_0000503', 'EFO_1001961', 'EFO_0008528', 'EFO_0004288', 'MONDO_0001056']",False,False,47,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
1862,LENALIDOMIDE,CHEMBL848,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 81 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']","['MONDO_0100342', 'EFO_1000657', 'EFO_0000180', 'EFO_1001779', 'EFO_0000574', 'MONDO_0002280', 'EFO_0000403', 'MONDO_0002158', 'EFO_1001469', 'EFO_0003758', 'EFO_1001951', 'MONDO_0044903', 'MONDO_0004992', 'MONDO_0002367', 'EFO_0000681', 'EFO_0000621', 'EFO_0006475', 'HP_0004326', 'EFO_0002618', 'EFO_0000673', 'MONDO_0004095', 'EFO_1001115', 'EFO_0000479', 'MONDO_0001187', 'EFO_0000616', 'MONDO_0008170', 'EFO_1001465', 'EFO_0000384', 'EFO_0000182', 'EFO_0004142', 'MONDO_0021063', 'EFO_0000209', 'MONDO_0002087', 'EFO_0005952', 'EFO_0002892', 'EFO_0000183', 'EFO_1000630', 'EFO_0000222', 'MONDO_0019471', 'EFO_1001998', 'EFO_0000191', 'EFO_0004272', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0017816', 'EFO_0000294', 'EFO_0002517', 'EFO_0002499', 'EFO_0000540', 'MONDO_0001023', 'EFO_0000198', 'EFO_0000339', 'EFO_0000756', 'EFO_0002430', 'EFO_0000211', 'EFO_0003841', 'EFO_0000095', 'MONDO_0044881', 'EFO_1000026', 'EFO_0000707', 'EFO_0009708', 'MONDO_0019438', 'EFO_0000196', 'EFO_0000096', 'MONDO_0015760', 'EFO_0000309', 'EFO_0002913', 'EFO_0006738', 'MONDO_0018906', 'MONDO_0002691', 'EFO_1000158', 'MONDO_0004192', 'MONDO_0013730', 'EFO_0000764', 'EFO_0003073', 'EFO_0000558', 'EFO_0001378', 'EFO_0000769', 'EFO_0004251', 'MONDO_0002959', 'EFO_0009441', 'MONDO_0006412', 'EFO_0002429', 'EFO_0000565', 'EFO_0000220', 'HP_0001871', 'MONDO_0000430']",True,False,87,CRL4(CRBN) E3 ubiquitin ligase inhibitor ,INHIBITOR ,protein complex 
1863,IMIPENEM,CHEMBL148,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 8 investigational indications.,,4.0,,False,1985,[],"['EFO_0001642', 'EFO_0000771', 'EFO_0000544', 'MONDO_0044881', 'EFO_1001865', 'HP_0100806', 'EFO_0000465', 'EFO_1001272', 'EFO_0003102', 'EFO_0003106', 'EFO_0003103', 'EFO_1001313', 'EFO_1001141']",False,False,13,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1864,KETOCONAZOLE,CHEMBL157101,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 5 approved and 34 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.,,4.0,,True,1981,[],"['EFO_0009516', 'MONDO_0005148', 'MONDO_0005301', 'EFO_0000540', 'EFO_0003047', 'EFO_0007510', 'MONDO_0001134', 'EFO_0004234', 'EFO_1001494', 'EFO_0000574', 'EFO_0005952', 'MONDO_0008315', 'EFO_1000764', 'MONDO_0002406', 'MONDO_0004975', 'EFO_0000341', 'EFO_0000756', 'EFO_1000948', 'EFO_0000519', 'EFO_0001663', 'EFO_0003932', 'EFO_0007174', 'EFO_0003882', 'MONDO_0007254', 'EFO_0000621', 'MONDO_0002146', 'EFO_0000616', 'MONDO_0004979', 'EFO_0007512', 'EFO_0007543', 'MONDO_0004992', 'EFO_0003917', 'EFO_0000095', 'EFO_0003894', 'EFO_0000673', 'EFO_0002614', 'EFO_0005539', 'MONDO_0100130', 'EFO_0006911']",False,False,39,Cytochrome P450 51 inhibitor ,INHIBITOR ,single protein 
1865,ONVANSERTIB,CHEMBL1738758,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000166851'],"['EFO_1000984', 'EFO_0000702', 'EFO_0000616', 'EFO_0000222', 'EFO_0002517', 'MONDO_0008315']",False,False,6,Serine/threonine-protein kinase PLK1 inhibitor ,INHIBITOR ,single protein 
1866,NILOTINIB,CHEMBL255863,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 24 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000097007', 'ENSG00000186716']","['MONDO_0005180', 'EFO_0002617', 'EFO_0000616', 'MONDO_0005180', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000339', 'EFO_0000693', 'EFO_0000220', 'EFO_0005543', 'MONDO_0000437', 'EFO_0000756', 'MONDO_0004643', 'MONDO_0007739', 'EFO_1001968', 'MONDO_0021063', 'MONDO_0004975', 'MONDO_0013730', 'EFO_0001361', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000717', 'EFO_0000389', 'MONDO_0008978', 'EFO_1001106', 'EFO_0000339', 'MONDO_0002171', 'MONDO_0011719']",False,False,28,Bcr/Abl fusion protein Tyrosine-protein kinase ABL inhibitor ,INHIBITOR ,chimeric protein single protein 
1867,TAFENOQUINE,CHEMBL298470,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for plasmodium vivax malaria and malaria and has 3 investigational indications.,,4.0,,False,2018,[],"['EFO_0007445', 'EFO_0007444', 'MONDO_0100096', 'EFO_0001068', 'EFO_0007445', 'EFO_0001068']",False,False,6,,,
1868,ROMIDEPSIN,CHEMBL343448,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 36 investigational indications.,,4.0,,False,2009,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']","['EFO_0006861', 'EFO_0000183', 'EFO_0002499', 'EFO_0000224', 'EFO_0002517', 'EFO_0000403', 'EFO_1001051', 'EFO_0000565', 'EFO_1001951', 'EFO_1000785', 'MONDO_0004192', 'EFO_0003032', 'MONDO_0008170', 'EFO_0000569', 'EFO_1001465', 'EFO_0000764', 'EFO_1000984', 'EFO_0000255', 'EFO_0003060', 'EFO_1001469', 'EFO_0000641', 'EFO_0005537', 'EFO_0000095', 'EFO_0000180', 'EFO_0002913', 'EFO_0000574', 'EFO_0000211', 'EFO_0001378', 'EFO_0000616', 'EFO_0002618', 'EFO_0000702', 'MONDO_0001187', 'MONDO_0018906', 'EFO_0000503', 'MONDO_0004992', 'MONDO_0015760', 'EFO_0000756', 'EFO_0000501', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0000430', 'EFO_0002501']",False,False,42,Histone deacetylase inhibitor ,INHIBITOR ,protein family 
1869,TTC-352,CHEMBL3763743,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1870,DAPTOMYCIN,CHEMBL387675,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 15 investigational indications.,,4.0,,False,2003,[],"['EFO_1002048', 'EFO_0000465', 'MONDO_0000565', 'MONDO_0021679', 'EFO_0005681', 'EFO_1000830', 'EFO_0000544', 'HP_0100806', 'EFO_0003033', 'EFO_0000771', 'EFO_1001459', 'EFO_1001114', 'MONDO_0044881', 'EFO_0003102', 'EFO_1001272', 'EFO_0000701', 'EFO_0003884', 'MONDO_0043544', 'MONDO_0021108']",False,False,19,,,
1871,OMAVELOXOLONE,CHEMBL4303525,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000116044'],"['EFO_0001421', 'MONDO_0007254', 'EFO_0000756', 'MONDO_0100339']",False,False,4,Nuclear factor erythroid 2-related factor 2 activator ,ACTIVATOR ,single protein 
1872,LUFOTRELVIR,CHEMBL4802214,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000763']",False,False,2,,,
1873,TELAVANCIN,CHEMBL507870,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,[],"['EFO_0003033', 'MONDO_0021679', 'EFO_0000544', 'EFO_1001272', 'EFO_1001849', 'EFO_0000771', 'EFO_0003884', 'EFO_0000544', 'EFO_1001272']",False,False,9,,,
1874,INSULIN GLARGINE,CHEMBL1201497,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 12 investigational indications.,,4.0,,False,2000,['ENSG00000171105'],"['EFO_0000574', 'EFO_0000565', 'MONDO_0005148', 'EFO_0003770', 'EFO_0000400', 'MONDO_0009061', 'EFO_1000897', 'EFO_0001645', 'EFO_1001121', 'HP_0003124', 'EFO_0003914', 'HP_0003074', 'EFO_0000537', 'EFO_0000612', 'MONDO_0005147']",True,False,15,Insulin receptor agonist ,AGONIST ,single protein 
1875,GALIDESIVIR,CHEMBL1236524,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0007358', 'MONDO_0100096', 'HP_0001945']",False,False,3,Replicase polyprotein 1ab inhibitor RNA-directed RNA polymerase L inhibitor Genome polyprotein inhibitor ,INHIBITOR ,single protein 
1876,MAGNESIUM SULFATE,CHEMBL3989857,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 54 investigational indications.,,4.0,,False,1981,[],"['EFO_1001103', 'EFO_0007294', 'EFO_0006859', 'EFO_1001754', 'HP_0001891', 'EFO_0000713', 'EFO_0002970', 'EFO_0000275', 'MONDO_0100342', 'EFO_0000588', 'EFO_0003833', 'EFO_0004777', 'EFO_0004142', 'EFO_0007442', 'MONDO_0005299', 'EFO_0003882', 'EFO_0000612', 'EFO_0000712', 'MONDO_0002258', 'EFO_0005279', 'EFO_0000668', 'EFO_1001254', 'HP_0002315', 'EFO_1001412', 'EFO_0001645', 'EFO_0008546', 'EFO_0002618', 'EFO_0003884', 'EFO_1001029', 'MONDO_0043510', 'EFO_0009505', 'EFO_0004273', 'HP_0002637', 'HP_0012532', 'HP_0002140', 'HP_0002019', 'EFO_0000278', 'EFO_1001375', 'HP_0001250', 'EFO_0003843', 'HP_0011950', 'EFO_1000824', 'EFO_0000341', 'EFO_0004149', 'EFO_1000657', 'EFO_0005762', 'EFO_0009846', 'EFO_0004272', 'MONDO_0011382', 'MONDO_0004979', 'EFO_0001070', 'HP_0000360', 'MONDO_0016642', 'EFO_0000537', 'EFO_0003854', 'EFO_0008590', 'EFO_0003917', 'EFO_1000632', 'MP_0001914', 'EFO_1001134', 'EFO_1001101']",False,False,61,,,
1877,PLONMARLIMAB,CHEMBL4650518,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000164400'],"['MONDO_0100096', 'EFO_0000685']",True,False,2,Granulocyte-macrophage colony-stimulating factor antagonist ,ANTAGONIST ,single protein 
1878,NITROUS ACID,CHEMBL1161681,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for poisoning and has 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2011,[],"['EFO_0004265', 'MONDO_0011382', 'EFO_0000713', 'EFO_0008583', 'EFO_0001361', 'EFO_0007444', 'MONDO_0009061', 'EFO_0009492', 'EFO_0000537', 'EFO_0000400', 'EFO_0003144', 'HP_0001919', 'MONDO_0005149', 'EFO_0003884', 'GO_0007568', 'EFO_0008546', 'EFO_0009492', 'MONDO_0004979', 'EFO_0008585']",False,False,19,,,
1879,ROFLUMILAST,CHEMBL193240,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 17 investigational indications.,,4.0,,False,2011,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']","['EFO_0006505', 'MONDO_0002009', 'MONDO_0010383', 'HP_0006536', 'EFO_0000341', 'EFO_1000760', 'EFO_0000401', 'EFO_0000274', 'EFO_0003095', 'MONDO_0004979', 'MONDO_0002406', 'EFO_0000574', 'EFO_0000676', 'MONDO_0005090', 'MONDO_0100130', 'HP_0002110', 'EFO_0001073', 'MONDO_0004992', 'EFO_0000618', 'MONDO_0005148']",True,False,20,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
1880,[18F]FLUOROMISONIDAZOLE,CHEMBL2037002,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1881,ALVOCIDIB HYDROCHLORIDE,CHEMBL2105698,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0001378', 'MONDO_0001023', 'EFO_1001469', 'EFO_0000403', 'EFO_0009441', 'EFO_0000095', 'MONDO_0018906', 'EFO_0000222', 'EFO_0000191']",False,False,9,,,
1882,ENTINOSTAT,CHEMBL27759,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.,,3.0,,False,no approval year,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000094631', 'ENSG00000196591', 'ENSG00000108840', 'ENSG00000061273', 'ENSG00000147099', 'ENSG00000163517', 'ENSG00000068024', 'ENSG00000048052', 'ENSG00000100429']","['EFO_0000349', 'EFO_0000222', 'EFO_0000756', 'EFO_0002618', 'EFO_0006861', 'MONDO_0008170', 'EFO_1000657', 'EFO_0000681', 'EFO_0003086', 'EFO_0000673', 'EFO_0000305', 'MONDO_0002367', 'MONDO_0002158', 'EFO_0000198', 'EFO_1001951', 'EFO_0005537', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0004992', 'MONDO_0002087', 'EFO_0000183', 'EFO_0000326', 'MONDO_0001187', 'EFO_1001901', 'EFO_0000616', 'EFO_0003060', 'MONDO_0021063', 'EFO_0000574']",True,False,28,Histone deacetylase inhibitor ,INHIBITOR ,protein family 
1883,CANERTINIB,CHEMBL31965,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000178568', 'ENSG00000141736', 'ENSG00000146648']","['EFO_0003869', 'MONDO_0021117', 'EFO_0003060']",False,True,3,Receptor protein-tyrosine kinase erbB-4 inhibitor Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
1884,METHOXSALEN,CHEMBL416,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for psoriasis and t-cell non-hodgkin lymphoma and has 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1954,[],"['EFO_0000685', 'EFO_0002618', 'EFO_0000676', 'EFO_0000404', 'EFO_0001642', 'EFO_0004599', 'EFO_0000174', 'MONDO_0013730', 'EFO_0000574', 'EFO_0000384', 'MONDO_0015760', 'EFO_1000785', 'EFO_1001051', 'EFO_1000691']",False,False,14,,,
1885,EFINOPEGDUTIDE,CHEMBL4297576,Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000112164', 'ENSG00000215644']","['MONDO_0005148', 'EFO_0001073', 'EFO_0003884', 'EFO_1001249']",False,False,4,Glucagon receptor agonist Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
1886,SUGEMALIMAB,CHEMBL4594535,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000120217'],"['EFO_0000503', 'EFO_0000574', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000183', 'EFO_0000616', 'EFO_0000702', 'EFO_0000182']",False,False,8,Programmed cell death 1 ligand 1 binding agent ,BINDING AGENT ,single protein 
1887,HYDROXYTYROSOL,CHEMBL485747,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1888,BEMNIFOSBUVIR SULFATE,CHEMBL5095037,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0004220', 'MONDO_0100096']",False,False,2,,,
1889,IMLUNESTRANT,CHEMBL5095183,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1890,DEXTROMETHORPHAN,CHEMBL52440,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 7 approved and 41 investigational indications.,,4.0,,False,1982,"['ENSG00000183454', 'ENSG00000147955']","['HP_0001742', 'HP_0002315', 'EFO_0007486', 'EFO_0000384', 'EFO_0005611', 'EFO_0001068', 'HP_0012735', 'MONDO_0004985', 'MONDO_0004976', 'EFO_0005762', 'EFO_0002460', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000764', 'EFO_0003100', 'EFO_0001062', 'MONDO_0010726', 'EFO_0003929', 'MONDO_0005180', 'HP_0012735', 'MONDO_0002009', 'EFO_0000676', 'MONDO_0005148', 'MONDO_0005277', 'MONDO_0005148', 'MONDO_0004976', 'HP_0000093', 'EFO_0000616', 'HP_0100543', 'EFO_0003758', 'EFO_0003890', 'EFO_0002617', 'EFO_0007214', 'EFO_0009430', 'MONDO_0044970', 'MONDO_0005271', 'EFO_1000783', 'HP_0001945', 'MONDO_0002009', 'EFO_0003756', 'MONDO_0004975', 'EFO_0009692', 'MONDO_0005090', 'EFO_0000729', 'EFO_0000616', 'EFO_0005687', 'MONDO_0002050', 'EFO_0000555', 'EFO_0007214', 'EFO_0001663', 'MONDO_0005301']",False,False,51,Glutamate [NMDA] receptor subunit epsilon 1 antagonist Sigma opioid receptor agonist ,ANTAGONIST AGONIST ,single protein 
1891,VENLAFAXINE,CHEMBL637,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1993,"['ENSG00000108576', 'ENSG00000103546']","['MONDO_0005180', 'EFO_0006788', 'MONDO_0002050', 'MONDO_0002009', 'EFO_0006862', 'MONDO_0004985', 'EFO_0009854', 'HP_0031217', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004975', 'EFO_0006788', 'EFO_1001892', 'EFO_0003761', 'EFO_1001917', 'EFO_0004242', 'EFO_0004262', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090', 'EFO_1001919', 'MONDO_0002050', 'EFO_1002014', 'HP_0030833', 'EFO_0002610', 'EFO_0005230', 'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009', 'EFO_0003761']",True,False,31,Serotonin transporter inhibitor Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
1892,IXABEPILONE,CHEMBL1201752,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2007,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000756', 'MONDO_0004992', 'MONDO_0004192', 'EFO_1001968', 'EFO_0003897', 'EFO_1001465', 'EFO_1000613', 'EFO_0006861', 'MONDO_0044926', 'EFO_0000305', 'EFO_1001469', 'MONDO_0011962', 'MONDO_0004986', 'EFO_0000403', 'EFO_0000349', 'EFO_0000565', 'EFO_0000309', 'MONDO_0008903', 'EFO_0002499', 'EFO_0000681', 'EFO_0003869', 'MONDO_0018906', 'EFO_0000673', 'EFO_0000616', 'MONDO_0002158', 'EFO_0002938', 'EFO_0002618', 'EFO_0003871', 'EFO_0003032', 'EFO_0000574', 'EFO_0003060', 'EFO_0006859', 'MONDO_0002087', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0006352', 'EFO_0007535', 'EFO_1001951', 'MONDO_0008315']",True,False,39,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1893,THIAMINE,CHEMBL1547,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 13 investigational indications.,,4.0,,False,1985,[],"['EFO_0003777', 'HP_0001298', 'HP_0100806', 'EFO_0003144', 'EFO_0003884', 'HP_0001891', 'HP_0100806', 'MONDO_0007739', 'EFO_1000971', 'EFO_0008569', 'EFO_0006834', 'EFO_0009686', 'EFO_0009492', 'EFO_1000036', 'EFO_0004272', 'MONDO_0005301', 'EFO_1000837', 'EFO_0004272', 'EFO_0006834']",False,False,19,,,
1894,EXATECAN,CHEMBL1614650,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,['ENSG00000198900'],"['MONDO_0008315', 'MONDO_0002158', 'EFO_0000565', 'EFO_0002618', 'MONDO_0008170', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002691', 'EFO_1000158', 'MONDO_0002974', 'EFO_0000691', 'EFO_0000616', 'EFO_0000198', 'MONDO_0007254', 'EFO_0000574']",False,False,15,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
1895,GANCICLOVIR,CHEMBL182,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 7 approved and 19 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1989,[],"['MONDO_0008170', 'EFO_0000182', 'EFO_1001302', 'EFO_1000158', 'EFO_0000763', 'EFO_0000765', 'EFO_0000588', 'EFO_0000389', 'MONDO_0002087', 'EFO_0009708', 'EFO_0000544', 'EFO_0001062', 'MONDO_0005147', 'EFO_0000574', 'MONDO_0013730', 'EFO_0003086', 'EFO_0000621', 'MONDO_0003778', 'EFO_0003833', 'MONDO_0002708', 'EFO_0009450', 'MONDO_0002158', 'EFO_0000519', 'EFO_1000811', 'EFO_0000764', 'EFO_1001888']",False,False,26,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
1896,PROFLAVINE SULFATE,CHEMBL1964546,Small molecule drug with a maximum clinical trial phase of I (Early) (across all indications) and has 2 investigational indications.,,0.5,,False,no approval year,[],"['EFO_0000280', 'MONDO_0021400']",False,False,2,,,
1897,OCRELIZUMAB,CHEMBL2108041,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 4 investigational indications.,,4.0,,False,2017,['ENSG00000156738'],"['EFO_0003840', 'EFO_0005952', 'EFO_0000540', 'MONDO_0005301', 'MONDO_0007915', 'EFO_0008520', 'EFO_0003929', 'EFO_0000685', 'EFO_0007332']",True,False,9,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
1898,NAVARIXIN,CHEMBL216981,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000180871', 'ENSG00000163464']","['EFO_0000341', 'MONDO_0004979', 'EFO_0000676']",False,True,3,Interleukin-8 receptor B antagonist Interleukin-8 receptor A antagonist ,ANTAGONIST ,single protein 
1899,MAGNESIUM VALPROATE,CHEMBL2315212,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0002974', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0000616']",False,False,4,,,
1900,ABIRATERONE ACETATE,CHEMBL271227,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 6 approved and 7 investigational indications.,,4.0,,False,2011,['ENSG00000148795'],"['MONDO_0018479', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0003826', 'MONDO_0008728', 'MONDO_0008315', 'EFO_0000616', 'EFO_0001663', 'HP_0000083', 'EFO_0003060', 'EFO_0000196', 'EFO_0000673', 'EFO_0001421']",False,False,13,Cytochrome P450 17A1 inhibitor ,INHIBITOR ,single protein 
1901,LY2623091,CHEMBL3545275,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000151623'],"['EFO_0003884', 'MONDO_0001134']",False,False,2,Mineralocorticoid receptor antagonist ,ANTAGONIST ,single protein 
1902,SENICAPOC,CHEMBL405821,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000104783'],"['EFO_0000694', 'MONDO_0100096', 'MONDO_0004979', 'MONDO_0011382']",False,False,4,Intermediate conductance calcium-activated potassium channel protein 4 blocker ,BLOCKER ,single protein 
1903,552-02,CHEMBL4297254,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
1904,ETRUMADENANT,CHEMBL4740383,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000128271', 'ENSG00000170425']","['EFO_1001951', 'EFO_1000657', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008315']",True,False,5,Adenosine A2b receptor antagonist Adenosine A2a receptor antagonist ,ANTAGONIST ,single protein 
1905,VORINOSTAT,CHEMBL98,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 84 investigational indications.,,4.0,,False,2006,"['ENSG00000116478', 'ENSG00000171720', 'ENSG00000196591', 'ENSG00000094631']","['MONDO_0008903', 'EFO_1001951', 'EFO_0000096', 'MONDO_0004992', 'EFO_0000220', 'EFO_0002913', 'EFO_0000691', 'EFO_0000191', 'EFO_0003828', 'EFO_0006352', 'EFO_1000026', 'MONDO_0004975', 'MONDO_0015760', 'EFO_0000616', 'EFO_1001830', 'EFO_0004198', 'EFO_0000574', 'EFO_0000621', 'EFO_1001110', 'MONDO_0002158', 'EFO_0000641', 'EFO_0003833', 'MONDO_0007254', 'MONDO_0003268', 'EFO_0007535', 'MONDO_0005090', 'EFO_0000309', 'MONDO_0011382', 'EFO_0000365', 'EFO_0000565', 'EFO_0000222', 'MONDO_0019460', 'EFO_0000764', 'EFO_0000224', 'EFO_1001380', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0001657', 'EFO_0005774', 'EFO_0000349', 'EFO_0002429', 'EFO_0000180', 'EFO_0002939', 'EFO_0000211', 'MONDO_0007576', 'EFO_0000198', 'EFO_0000519', 'EFO_1000785', 'EFO_0003893', 'EFO_0000479', 'EFO_0000339', 'MONDO_0015277', 'EFO_1001968', 'MONDO_0018364', 'EFO_0002618', 'EFO_0003869', 'MONDO_0044926', 'EFO_1000657', 'EFO_0000183', 'EFO_0000702', 'EFO_1001465', 'EFO_0002938', 'EFO_1001469', 'MONDO_0018906', 'EFO_1000309', 'MONDO_0001879', 'EFO_0000756', 'MONDO_0002087', 'EFO_0001378', 'EFO_0000588', 'EFO_0000681', 'MONDO_0021063', 'MONDO_0008170', 'MONDO_0000873', 'EFO_0000095', 'MONDO_0002691', 'EFO_0002501', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000384', 'EFO_0000770', 'EFO_0000403', 'EFO_0002499', 'EFO_0005952', 'MONDO_0004986', 'EFO_1001051', 'EFO_0006861', 'MONDO_0000870']",False,False,88,Histone deacetylase 6 inhibitor Histone deacetylase 1 inhibitor Histone deacetylase 2 inhibitor Histone deacetylase 3 inhibitor ,INHIBITOR ,single protein 
1906,BEXAROTENE,CHEMBL1023,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 22 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,"['ENSG00000204231', 'ENSG00000143171', 'ENSG00000186350']","['EFO_0000676', 'EFO_0004192', 'EFO_0000565', 'MONDO_0005090', 'EFO_0000574', 'EFO_1001051', 'EFO_0000222', 'MONDO_0020077', 'EFO_1001110', 'EFO_0003060', 'MONDO_0004975', 'EFO_0002913', 'EFO_0000305', 'EFO_0000198', 'MONDO_0008903', 'EFO_1000785', 'EFO_0005411', 'EFO_0000616', 'EFO_1000747', 'MONDO_0002108', 'EFO_0003032', 'EFO_0001378', 'MONDO_0015760', 'EFO_0000432', 'MONDO_0007254']",True,False,25,Retinoid X receptor agonist ,AGONIST ,protein family 
1907,USTEKINUMAB,CHEMBL1201835,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 22 investigational indications.,,4.0,,False,2009,"['ENSG00000113302', 'ENSG00000110944', 'ENSG00000168811']","['EFO_0000540', 'EFO_1001486', 'MONDO_0007915', 'EFO_1001494', 'MONDO_0019269', 'EFO_0000685', 'EFO_1000710', 'MONDO_0044881', 'EFO_0000676', 'EFO_0003778', 'EFO_1001209', 'EFO_0007187', 'EFO_0003780', 'EFO_0000729', 'MONDO_0013730', 'EFO_0003898', 'EFO_1001231', 'MONDO_0019338', 'EFO_0003921', 'MONDO_0005147', 'MONDO_0005301', 'EFO_0003872', 'EFO_0000398', 'EFO_0000274', 'EFO_0002609', 'EFO_0000384', 'EFO_1001857']",False,True,27,Interleukin-23 inhibitor Interleukin-12 inhibitor ,INHIBITOR ,protein complex 
1908,XENON,CHEMBL1236802,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 14 investigational indications.,,4.0,,False,1982,[],"['EFO_0009267', 'EFO_0001645', 'EFO_0004262', 'MONDO_0002009', 'MONDO_0009061', 'HP_0002140', 'HP_0002045', 'MONDO_0004985', 'EFO_0001073', 'EFO_0000341', 'MONDO_0005299', 'EFO_0004242', 'MONDO_0004975', 'MONDO_0043510']",False,False,14,,,
1909,BUDESONIDE,CHEMBL1370,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 11 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000113580'],"['HP_0025267', 'HP_0002014', 'EFO_1000391', 'HP_0001742', 'EFO_1001223', 'EFO_0000464', 'EFO_0004194', 'EFO_1001486', 'EFO_0005854', 'EFO_0004232', 'EFO_0003918', 'EFO_1000637', 'EFO_1000782', 'EFO_0000684', 'EFO_0007140', 'MONDO_0100096', 'EFO_1001294', 'EFO_0000384', 'MONDO_0013730', 'EFO_0007183', 'EFO_0000694', 'EFO_0000729', 'EFO_0007486', 'MONDO_0019091', 'EFO_0004268', 'MONDO_0004979', 'EFO_1001411', 'EFO_0008572', 'MONDO_0005271', 'EFO_0000756', 'EFO_0000341', 'EFO_0005628', 'EFO_0003956', 'HP_0002043', 'EFO_0004599', 'MONDO_0008903', 'EFO_0006505', 'EFO_1001417', 'EFO_0008590', 'EFO_0001378', 'EFO_1001295', 'HP_0006536', 'MONDO_0007254', 'EFO_0005676', 'EFO_1001293']",True,True,45,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1910,RIBOFLAVIN,CHEMBL1534,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 15 investigational indications.,,4.0,,False,1993,[],"['MONDO_0002974', 'EFO_0004272', 'HP_0001891', 'EFO_1000783', 'EFO_0003884', 'EFO_0011023', 'HP_0000545', 'HP_0012532', 'EFO_0000612', 'MONDO_0004892', 'EFO_0000676', 'EFO_0001070', 'MONDO_0015486', 'EFO_1000036', 'HP_0000540', 'MONDO_0005301', 'HP_0001871', 'EFO_0003966', 'HP_0000483', 'EFO_0003144']",False,False,20,,,
1911,SOLIFENACIN,CHEMBL1734,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications.,,4.0,,False,2004,"['ENSG00000181072', 'ENSG00000133019']","['EFO_0006865', 'EFO_1000781', 'EFO_1000781', 'EFO_0000284', 'HP_0000020', 'EFO_0006865', 'HP_0000103', 'EFO_0000284']",False,False,8,Muscarinic acetylcholine receptor M2 antagonist Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1912,VISILIZUMAB,CHEMBL2108811,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000198851'],"['EFO_0000384', 'EFO_0000729', 'EFO_0004599', 'MONDO_0013730', 'EFO_0000222', 'EFO_0000574']",False,False,6,T-cell surface glycoprotein CD3 epsilon chain inhibitor ,INHIBITOR ,single protein 
1913,IXAZOMIB,CHEMBL2141296,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 19 investigational indications.,,4.0,,False,no approval year,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']","['EFO_1001264', 'EFO_0000565', 'EFO_0000220', 'EFO_0009441', 'MONDO_0019438', 'MONDO_0044881', 'EFO_0005537', 'EFO_0005761', 'EFO_0000681', 'EFO_0006738', 'EFO_0000764', 'MONDO_0004992', 'EFO_0000574', 'EFO_0000616', 'EFO_0007160', 'EFO_0000222', 'EFO_1001469', 'MONDO_0000873', 'EFO_0003884', 'EFO_0001378', 'MONDO_0018906']",True,False,21,26S proteasome inhibitor ,INHIBITOR ,protein complex 
1914,BINIMETINIB,CHEMBL3187723,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 21 investigational indications.,,4.0,,False,2018,"['ENSG00000126934', 'ENSG00000169032']","['EFO_0001421', 'EFO_0000565', 'MONDO_0004992', 'EFO_0000616', 'EFO_0002617', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000685', 'MONDO_0021063', 'EFO_1001951', 'EFO_0000389', 'EFO_1000956', 'MONDO_0002158', 'MONDO_0011719', 'MONDO_0008170', 'EFO_0002503', 'EFO_0003833', 'EFO_0000313', 'EFO_0000305', 'EFO_0002892', 'EFO_0001378', 'MONDO_0008903', 'EFO_0000756', 'EFO_0002618', 'EFO_1000657', 'MONDO_0002087']",True,False,26,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Dual specificity mitogen-activated protein kinase kinase 1 inhibitor ,INHIBITOR ,single protein 
1915,TESNATILIMAB,CHEMBL4594564,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000384', 'EFO_0004192']",False,False,2,,,
1916,SULFORAPHANE,CHEMBL48802,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0008315', 'MONDO_0005148', 'EFO_0003884', 'MONDO_0008903', 'GO_0007568', 'MONDO_0002050', 'EFO_0003758', 'MONDO_0001187', 'EFO_0003756', 'EFO_0005411', 'MONDO_0005090', 'EFO_0008528', 'MONDO_0007254', 'EFO_0005422', 'MONDO_0005180', 'EFO_0000756', 'EFO_0000673']",False,False,17,,,
1917,GLUCOSAMINE,CHEMBL493287,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 6 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0001073', 'EFO_0005755', 'MONDO_0007254', 'EFO_0000649', 'EFO_0004616', 'EFO_0000555', 'MONDO_0005178', 'EFO_0004616', 'MONDO_0005178']",False,False,9,,,
1918,VINCRISTINE SULFATE,CHEMBL501867,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 57 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1963,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000174', 'EFO_0000272', 'EFO_0000094', 'EFO_0000248', 'EFO_0000220', 'MONDO_0006058', 'MONDO_0008380', 'MONDO_0018975', 'EFO_0006859', 'EFO_1001469', 'MONDO_0018906', 'EFO_0000558', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289', 'EFO_0003032', 'EFO_0000574', 'EFO_1001042', 'EFO_0000403', 'EFO_0000756', 'EFO_0000621', 'EFO_0000096', 'MONDO_0008903', 'MONDO_0002367', 'EFO_1000131', 'EFO_0000616', 'EFO_0001378', 'EFO_0005235', 'EFO_1000292', 'MONDO_0000430', 'EFO_1001951', 'EFO_0000095', 'MONDO_0000870', 'EFO_0000209', 'MONDO_0015540', 'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'MONDO_0002974', 'EFO_1000158', 'HP_0001871', 'EFO_0000565', 'EFO_0000588', 'EFO_0000211', 'MONDO_0000873', 'MONDO_0009348', 'EFO_0000222', 'EFO_1001365', 'MONDO_0018271', 'EFO_0009441', 'EFO_0003833', 'EFO_0000309', 'MONDO_0019471', 'EFO_0000765', 'EFO_0002918', 'MONDO_0044917', 'EFO_0000437']",True,False,57,Tubulin inhibitor ,INHIBITOR ,protein complex group 
1919,CALCIUM ACETATE,CHEMBL1200800,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 1 investigational indication.,,4.0,,False,1982,[],"['HP_0002905', 'EFO_1002048', 'EFO_0003884', 'GO_0007568']",False,False,4,,,
1920,INSULIN PORK,CHEMBL1201539,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 5 investigational indications.,,4.0,,False,1966,['ENSG00000171105'],"['EFO_0002614', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0001645', 'EFO_0000400']",False,False,5,Insulin receptor agonist ,AGONIST ,single protein 
1921,THIOSULFURIC ACID,CHEMBL1208642,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 15 investigational indications.,,4.0,,False,1992,[],"['EFO_0005672', 'MONDO_0100096', 'MONDO_0002123', 'EFO_0004238', 'EFO_0003837', 'EFO_1000292', 'EFO_0006859', 'EFO_0006951', 'EFO_0003884', 'EFO_0000398', 'EFO_0002501', 'EFO_0002918', 'MONDO_0100342', 'EFO_0000770', 'EFO_0002939']",False,False,15,,,
1922,ICOTINIB,CHEMBL2087361,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['EFO_0000708', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0007254', 'EFO_0004252', 'EFO_0003060', 'MONDO_0007576', 'EFO_1000849', 'EFO_0002618', 'EFO_0005922', 'EFO_0000313', 'EFO_0000676', 'EFO_0000571']",False,True,13,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1923,GSK-1070806,CHEMBL2109606,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000150782'],"['EFO_0000274', 'EFO_0003767', 'EFO_0003780', 'EFO_0000400', 'EFO_0000384']",False,False,5,Interleukin-18 inhibitor ,INHIBITOR ,single protein 
1924,"THIOUREA, N-(5-BROMO-2-PYRIDINYL)-N'-(2-(2-CHLORO-3-ETHOXY-6-FLUOROPHENYL)ETHYL)-",CHEMBL398891,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003863', 'EFO_0000673', 'EFO_1000581', 'EFO_0003060', 'EFO_0001378', 'MONDO_0003060', 'EFO_0000616']",False,False,7,,,
1925,MUPADOLIMAB,CHEMBL4802200,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
1926,CLODRONIC ACID,CHEMBL12318,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0004260', 'EFO_1000844', 'EFO_0003843']",False,False,4,,,
1927,AZD-9164,CHEMBL1921904,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000133019'],['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1928,PU-H71,CHEMBL200102,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000574', 'MONDO_0007254']",False,False,2,,,
1929,ELINOGREL,CHEMBL2103828,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000169313'],"['EFO_0000612', 'EFO_0003086']",True,False,2,Purinergic receptor P2Y12 antagonist ,ANTAGONIST ,single protein 
1930,TALIMOGENE LAHERPAREPVEC,CHEMBL2108727,Gene drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 13 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000756', 'MONDO_0017387', 'EFO_1000657', 'EFO_0002618', 'EFO_0000616', 'MONDO_0002038', 'EFO_0000558', 'EFO_0000432', 'MONDO_0007254', 'EFO_1001968', 'EFO_0000389', 'EFO_0000326', 'EFO_0003968', 'EFO_0000305']",False,False,14,,,
1931,LERONLIMAB,CHEMBL2109343,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000160791'],"['MONDO_0013730', 'MONDO_0100096', 'EFO_0003869', 'EFO_0000616', 'EFO_0000764', 'EFO_1001249', 'EFO_0000180']",True,False,7,C-C chemokine receptor type 5 antagonist ,ANTAGONIST ,single protein 
1932,PASIREOTIDE,CHEMBL3039583,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for acromegaly and has 31 investigational indications.,,4.0,,False,2012,"['ENSG00000278195', 'ENSG00000162009', 'ENSG00000139874', 'ENSG00000180616']","['MONDO_0016642', 'EFO_0000182', 'MONDO_0004992', 'EFO_0003843', 'EFO_0001378', 'EFO_1001485', 'EFO_0007331', 'HP_0003074', 'EFO_0000673', 'EFO_0004243', 'EFO_0000432', 'EFO_0001642', 'EFO_1001471', 'EFO_1001110', 'EFO_1000581', 'EFO_0005323', 'EFO_0008549', 'EFO_1001901', 'EFO_0000702', 'MONDO_0002108', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0015277', 'EFO_1001256', 'EFO_0003086', 'EFO_1001485', 'MONDO_0024503', 'EFO_0000232', 'EFO_0001071', 'EFO_0003099', 'EFO_1001307', 'MONDO_0008315']",False,False,32,Somatostatin receptor 2 agonist Somatostatin receptor 1 agonist Somatostatin receptor 3 agonist Somatostatin receptor 5 agonist ,AGONIST ,single protein 
1933,AZD-4547,CHEMBL3184679,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,2.0,,False,no approval year,"['ENSG00000068078', 'ENSG00000077782', 'ENSG00000160867', 'ENSG00000066468']","['EFO_0000707', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000228', 'EFO_0000708', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000326', 'MONDO_0001187', 'EFO_0001378']",True,True,11,Fibroblast growth factor receptor inhibitor ,INHIBITOR ,protein family 
1934,FERRIC CITRATE,CHEMBL3301597,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications.,,4.0,,False,2014,[],"['MONDO_0002280', 'HP_0002905', 'EFO_0003884']",False,False,3,,,
1935,EMAPALUMAB,CHEMBL3989977,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications.,,4.0,,False,2018,['ENSG00000111537'],"['EFO_1001806', 'Orphanet_158038', 'MONDO_0100096', 'EFO_0007135', 'MONDO_0007915', 'MONDO_0018305', 'EFO_0004599', 'MONDO_0015540', 'EFO_0000540']",True,False,9,Interferon gamma inhibitor ,INHIBITOR ,single protein 
1936,AXICABTAGENE CILOLEUCEL,CHEMBL3989989,Gene drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 6 investigational indications.,,4.0,,False,no approval year,['ENSG00000177455'],"['EFO_0001642', 'EFO_1001469', 'EFO_0000403', 'EFO_0000616', 'EFO_0000096', 'MONDO_0018906', 'EFO_0000574']",False,False,7,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
1937,TRILACICLIB DIHYDROCHLORIDE,CHEMBL4650272,Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for small cell lung carcinoma.,,4.0,,False,2021,"['ENSG00000105810', 'ENSG00000135446']",['EFO_0000702'],True,False,1,Cyclin-dependent kinase 6 inhibitor Cyclin-dependent kinase 4 inhibitor ,INHIBITOR ,single protein 
1938,BEFOTERTINIB,CHEMBL5095167,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003060'],False,False,1,,,
1939,OBETICHOLIC ACID,CHEMBL566315,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2016,['ENSG00000012504'],"['EFO_0003095', 'EFO_1001486', 'MONDO_0020088', 'Orphanet_733', 'EFO_1001345', 'EFO_0004268', 'HP_0002014', 'MONDO_0001751', 'EFO_0001421', 'EFO_0000280', 'EFO_1001249', 'EFO_0001073', 'EFO_0004267', 'HP_0030151', 'HP_0000989']",True,False,15,Bile acid receptor FXR agonist ,AGONIST ,single protein 
1940,ALCLOMETASONE DIPROPIONATE,CHEMBL1200989,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for eye inflammation and skin disease and has 1 investigational indication.,,4.0,,False,1982,['ENSG00000113580'],"['EFO_0003060', 'EFO_0005752', 'EFO_0000701']",False,False,3,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1941,ETANERCEPT,CHEMBL1201572,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 8 approved and 45 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000232810'],"['EFO_0000676', 'HP_0002039', 'MONDO_0004979', 'MONDO_0003937', 'MONDO_0013730', 'EFO_0009688', 'EFO_0003884', 'EFO_0005279', 'EFO_0004208', 'EFO_0005297', 'EFO_0007323', 'MONDO_0019391', 'EFO_0000616', 'EFO_1000726', 'HP_0100727', 'EFO_0004719', 'MONDO_0005147', 'EFO_0000398', 'EFO_0000713', 'EFO_0004246', 'HP_0000360', 'EFO_0000341', 'EFO_0005761', 'HP_0011868', 'HP_0004326', 'MONDO_0024280', 'MONDO_0017816', 'EFO_0002609', 'EFO_1001494', 'EFO_0009448', 'EFO_0000565', 'EFO_0003898', 'EFO_0000699', 'EFO_0002687', 'EFO_0007430', 'EFO_0000764', 'EFO_0003106', 'EFO_0000685', 'EFO_0000095', 'MONDO_0008315', 'MONDO_0004975', 'EFO_0000540', 'EFO_0000198', 'EFO_0003778', 'MP_0001845', 'EFO_0003834', 'EFO_0000195', 'EFO_0004599', 'EFO_0008997', 'EFO_1000710', 'EFO_0008518', 'MONDO_0002959', 'EFO_0004276']",False,False,53,TNF-alpha inhibitor ,INHIBITOR ,single protein 
1942,TOCILIZUMAB,CHEMBL1237022,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 5 approved and 65 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,['ENSG00000160712'],"['EFO_1001513', 'EFO_0000565', 'MONDO_0000845', 'EFO_0000540', 'EFO_0000095', 'EFO_1000926', 'EFO_0000222', 'EFO_0007328', 'EFO_0001378', 'EFO_0000094', 'EFO_0003818', 'EFO_0008586', 'EFO_0003780', 'EFO_1000986', 'MONDO_0007915', 'EFO_0000474', 'EFO_0004256', 'HP_0001945', 'EFO_0007135', 'EFO_0008518', 'MONDO_0100096', 'EFO_0004991', 'EFO_0008528', 'EFO_1000637', 'EFO_1001165', 'EFO_1001209', 'EFO_0007541', 'EFO_0000519', 'EFO_0003106', 'EFO_1001119', 'MONDO_0005147', 'MONDO_0015564', 'EFO_0000685', 'EFO_0000717', 'EFO_0000673', 'EFO_1001951', 'EFO_1001148', 'EFO_0000403', 'EFO_0000764', 'EFO_0000694', 'EFO_1001806', 'MONDO_0013730', 'EFO_0003060', 'MONDO_0002009', 'EFO_0000756', 'MONDO_0004976', 'EFO_0000220', 'EFO_0003898', 'EFO_0000398', 'MONDO_0008170', 'EFO_0000182', 'MONDO_0044881', 'EFO_1001857', 'MONDO_0005090', 'MONDO_0007254', 'MONDO_0018088', 'EFO_0002618', 'EFO_0000574', 'EFO_0000096', 'EFO_1001466', 'EFO_0001361', 'EFO_0004599', 'EFO_0000616', 'EFO_0002609', 'MONDO_0001187', 'EFO_0005952', 'EFO_1001231', 'MONDO_0018906', 'EFO_0003884', 'MONDO_0015540']",True,True,70,Interleukin-6 receptor alpha subunit inhibitor ,INHIBITOR ,single protein 
1943,SILTUXIMAB,CHEMBL1743070,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 12 investigational indications.,,4.0,,False,2014,['ENSG00000136244'],"['EFO_0000565', 'EFO_0000673', 'EFO_1001332', 'EFO_0001663', 'MONDO_0100096', 'MONDO_0005147', 'EFO_0000540', 'EFO_0000198', 'EFO_0000203', 'EFO_0000681', 'MONDO_0015564', 'MONDO_0008315', 'MONDO_0005090', 'EFO_0001378', 'MONDO_0002367']",True,False,15,Interleukin-6 inhibitor ,ANTAGONIST ,single protein 
1944,T-DM1,CHEMBL2109399,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000141736'],['MONDO_0007254'],False,False,1,Receptor protein-tyrosine kinase erbB-2 binding agent ,BINDING AGENT ,single protein 
1945,MEDI-570,CHEMBL2109449,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000163600'],['MONDO_0007915'],True,False,1,Inducible T-cell costimulator inhibitor ,INHIBITOR ,single protein 
1946,SABIZABULIN,CHEMBL2163631,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0008315', 'MONDO_0100130', 'EFO_0000694']",False,False,4,,,
1947,FLOXACILLIN,CHEMBL222645,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 5 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0005681', 'EFO_0003884', 'EFO_0000544', 'EFO_0000701', 'EFO_0000771', 'EFO_0003102']",False,False,6,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
1948,RIBOCICLIB SUCCINATE,CHEMBL3707266,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.,,4.0,,False,2017,"['ENSG00000135446', 'ENSG00000105810']","['EFO_0000305', 'EFO_0000616', 'MONDO_0007254']",False,False,3,Cyclin-dependent kinase 4 inhibitor Cyclin-dependent kinase 6 inhibitor ,INHIBITOR ,single protein 
1949,GDC-0927,CHEMBL4297758,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
1950,DAXDILIMAB,CHEMBL4594330,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000239961'],"['EFO_0004610', 'EFO_0004192', 'MONDO_0007915']",True,False,3,Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor ,INHIBITOR ,single protein 
1951,ENPATORAN,CHEMBL4802159,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000101916', 'ENSG00000196664']","['MONDO_0007915', 'EFO_0003834', 'MONDO_0100096']",True,True,3,Toll-like receptor 7 antagonist Toll-like receptor 8 antagonist ,ANTAGONIST ,single protein 
1952,EZABENLIMAB,CHEMBL4802172,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,[],"['EFO_1001951', 'EFO_0003060', 'EFO_0000616', 'EFO_0000181', 'EFO_0000519']",False,False,5,,,
1953,SIMEPREVIR,CHEMBL501849,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for chronic hepatitis c virus infection and viral disease and has 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,[],"['EFO_0004220', 'EFO_0000763', 'EFO_0003884', 'EFO_0003047']",False,False,4,"Hepatitis C virus serine protease, NS3/NS4A inhibitor ",INHIBITOR ,protein complex 
1954,CHLOROQUINE PHOSPHATE,CHEMBL58510,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for malaria and has 7 investigational indications.,,4.0,,False,1949,[],"['MONDO_0100096', 'MONDO_0007915', 'EFO_0000694', 'EFO_0000764', 'EFO_0001068', 'EFO_0000275', 'EFO_0007541', 'EFO_0000685']",False,False,8,,,
1955,CANDESARTAN CILEXETIL,CHEMBL1014,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 8 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000144891'],"['EFO_0003843', 'EFO_0003913', 'MONDO_0005147', 'EFO_0000612', 'EFO_0000537', 'EFO_0003144', 'EFO_0001645', 'HP_0000093', 'EFO_1001150', 'HP_0003124', 'MONDO_0007254', 'EFO_0000373', 'EFO_0000400', 'EFO_0000319', 'EFO_0003914', 'MONDO_0001134', 'MONDO_0005148', 'EFO_1001153', 'MONDO_0100096', 'EFO_0000712']",True,False,20,Type-1 angiotensin II receptor antagonist ,ANTAGONIST ,single protein 
1956,EPOPROSTENOL,CHEMBL1139,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for recurrent thrombophlebitis and pulmonary arterial hypertension and has 6 investigational indications.,,4.0,,False,1995,['ENSG00000160013'],"['EFO_0002687', 'HP_0004419', 'MONDO_0005149', 'EFO_0001361', 'EFO_0000713', 'MONDO_0043510', 'MONDO_0100096', 'EFO_0001361']",True,False,8,Prostanoid IP receptor agonist ,AGONIST ,single protein 
1957,UMECLIDINIUM,CHEMBL1187833,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 4 investigational indications.,,4.0,,False,2013,['ENSG00000133019'],"['MONDO_0004979', 'EFO_0000464', 'EFO_0000341', 'HP_0006536', 'MONDO_0004979', 'HP_0000975', 'EFO_0000341', 'EFO_0006505']",True,True,8,Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
1958,AMLODIPINE BESYLATE,CHEMBL1200402,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 10 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,"['ENSG00000151067', 'ENSG00000081248', 'ENSG00000157388', 'ENSG00000102001']","['EFO_0003913', 'HP_0003124', 'EFO_0000612', 'Orphanet_79292', 'HP_0000093', 'EFO_0004911', 'EFO_1000013', 'EFO_0000537', 'MONDO_0021187', 'EFO_0000373', 'EFO_0000712', 'MONDO_0001134', 'EFO_0001645']",True,False,13,Voltage-gated L-type calcium channel blocker ,BLOCKER ,protein family 
1959,PREDNISOLONE SODIUM PHOSPHATE,CHEMBL1201014,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 3 investigational indications.,,4.0,,False,1973,['ENSG00000113580'],"['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0007126', 'EFO_0003929', 'MP_0001845', 'MONDO_0004979', 'EFO_1001226', 'EFO_0000768', 'EFO_0000341', 'HP_0000559', 'EFO_0009448', 'EFO_0000565', 'EFO_0005854', 'EFO_0007141', 'EFO_0004255', 'EFO_0007415']",False,True,17,Glucocorticoid receptor agonist ,AGONIST ,single protein 
1960,AMILORIDE HYDROCHLORIDE,CHEMBL1398126,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000111319', 'ENSG00000168447', 'ENSG00000166828']","['EFO_0004269', 'MONDO_0009061', 'EFO_0000537', 'EFO_0000373']",False,False,4,"Amiloride-sensitive sodium channel, ENaC blocker ",BLOCKER ,protein complex 
1961,ESTRAMUSTINE,CHEMBL1575,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000673', 'MONDO_0007254', 'EFO_0000196', 'EFO_0000616', 'MONDO_0008315']",False,False,5,,,
1962,PANTOTHENIC ACID,CHEMBL1594,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for chronic kidney disease and has 2 investigational indications.,,4.0,,False,1993,[],"['EFO_0003884', 'HP_0200042', 'EFO_0003144']",False,False,3,,,
1963,TASIDOTIN HYDROCHLORIDE,CHEMBL2107376,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000756', 'MONDO_0008315', 'EFO_0003060']",False,False,3,,,
1964,PACLITAXEL POLIGLUMEX,CHEMBL2108628,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0006772', 'MONDO_0008170', 'MONDO_0002158', 'MONDO_0008315', 'EFO_0000466', 'MONDO_0005575', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003060', 'MONDO_0002087', 'EFO_0000673', 'EFO_0003833', 'MONDO_0008903', 'EFO_0000707']",True,False,14,Tubulin stabiliser ,STABILISER ,protein complex group 
1965,LURTOTECAN,CHEMBL305666,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003893', 'EFO_0006859', 'EFO_0000702', 'EFO_0000616', 'MONDO_0002158', 'MONDO_0002087', 'MONDO_0008170']",False,False,7,,,
1966,MAGNESIUM CHLORIDE,CHEMBL3185229,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005147', 'MP_0001914', 'EFO_0000712', 'EFO_0000574', 'EFO_0003833']",False,False,5,,,
1967,ONATASERTIB,CHEMBL3586404,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,['ENSG00000198793'],"['EFO_1001901', 'EFO_0001378', 'EFO_0003060', 'EFO_0000519', 'EFO_0000182', 'EFO_0000403', 'MONDO_0007254', 'EFO_0000616']",False,False,8,Serine/threonine-protein kinase mTOR inhibitor ,INHIBITOR ,single protein 
1968,VOROLANIB,CHEMBL4297587,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0001365', 'EFO_0000702']",False,False,2,,,
1969,ABIVERTINIB,CHEMBL4297865,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,"['ENSG00000146648', 'ENSG00000010671']","['EFO_0000096', 'MONDO_0100096', 'EFO_0003060', 'EFO_0003060', 'MONDO_0100096', 'MONDO_0008315']",False,True,6,Epidermal growth factor receptor erbB1 inhibitor Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
1970,OBEXELIMAB,CHEMBL4298134,Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000072694', 'ENSG00000177455']",['MONDO_0007915'],True,True,1,B-lymphocyte antigen CD19 inhibitor Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor ,INHIBITOR ,single protein 
1971,LOPINAVIR,CHEMBL729,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for hiv-1 infection and hiv infection and has 15 investigational indications.,,4.0,,False,2000,[],"['EFO_0000558', 'EFO_0003047', 'EFO_0003835', 'EFO_0007224', 'EFO_0002950', 'EFO_0000765', 'MONDO_0018076', 'EFO_0003106', 'EFO_0000180', 'EFO_1000637', 'EFO_0002614', 'EFO_0007328', 'MONDO_0100096', 'EFO_0000694', 'EFO_0000764', 'EFO_0000544', 'MONDO_0100116']",False,False,17,Human immunodeficiency virus type 1 protease inhibitor ,INHIBITOR ,single protein 
1972,EPLERENONE,CHEMBL1095097,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 10 investigational indications.,,4.0,,False,2002,['ENSG00000151623'],"['EFO_0000401', 'EFO_0003884', 'EFO_0000612', 'EFO_0008519', 'EFO_0000275', 'MONDO_0010679', 'EFO_0009784', 'EFO_0003144', 'MONDO_0005148', 'EFO_0000318', 'EFO_0000319', 'EFO_0000537', 'MONDO_0007254', 'EFO_0000712', 'MONDO_0001134', 'EFO_0000373']",True,False,16,Mineralocorticoid receptor antagonist ,ANTAGONIST ,single protein 
1973,AXITINIB,CHEMBL1289926,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 36 investigational indications.,,4.0,,False,2012,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_0004142', 'MONDO_0004669', 'EFO_0000673', 'EFO_0000198', 'EFO_0000616', 'MONDO_0011719', 'MONDO_0011962', 'MONDO_0002367', 'EFO_1001951', 'EFO_0009708', 'EFO_0003860', 'EFO_0003841', 'EFO_1001465', 'EFO_0003060', 'EFO_0000231', 'EFO_1001968', 'EFO_0003865', 'EFO_0004198', 'EFO_0000681', 'MONDO_0004992', 'EFO_0000222', 'EFO_0002517', 'EFO_1000131', 'EFO_0004252', 'EFO_0000640', 'EFO_0000313', 'EFO_0003869', 'EFO_0000181', 'EFO_1000796', 'EFO_0000349', 'EFO_0000770', 'EFO_0002890', 'EFO_0004243', 'EFO_0007143', 'EFO_0003891', 'MONDO_0008315', 'EFO_0000756', 'EFO_0000519', 'MONDO_0016238', 'MONDO_0001056', 'EFO_0001065', 'EFO_0000182']",False,False,42,Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,protein family 
1974,GEVOKIZUMAB,CHEMBL1743026,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,['ENSG00000125538'],"['MONDO_0005148', 'HP_0000999', 'MONDO_0021063', 'EFO_0009672', 'EFO_0003780', 'MONDO_0001718', 'MONDO_0005147', 'MONDO_0005178', 'EFO_0003894', 'EFO_0000685', 'EFO_1001231']",False,False,11,Interleukin-1 beta negative allosteric modulator ,NEGATIVE ALLOSTERIC MODULATOR ,single protein 
1975,TYPHOID VACCINE,CHEMBL2108822,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000764', 'EFO_0001068', 'EFO_0003891', 'EFO_0007305', 'MONDO_0002009', 'EFO_0000319', 'EFO_0006789', 'EFO_0000182', 'EFO_0003106']",False,False,9,,,
1976,DAPIROLIZUMAB PEGOL,CHEMBL2109478,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000102245'],['MONDO_0007915'],True,False,1,CD40 ligand inhibitor ,INHIBITOR ,single protein 
1977,VERTEPORFIN,CHEMBL2218885,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for wet macular degeneration and ocular vascular disease and has 13 investigational indications.,,4.0,,False,2000,[],"['EFO_0004683', 'MONDO_0007187', 'EFO_0009606', 'EFO_0002618', 'EFO_0004207', 'EFO_0005753', 'EFO_0007310', 'MONDO_0007254', 'EFO_0009637', 'EFO_0000519', 'MONDO_0008315', 'EFO_0001365', 'EFO_0004193', 'EFO_1000158', 'EFO_0000389']",False,False,15,,,
1978,TOFACITINIB,CHEMBL221959,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 33 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,"['ENSG00000105639', 'ENSG00000162434', 'ENSG00000096968', 'ENSG00000105397']","['MONDO_0019472', 'EFO_0000685', 'EFO_0003778', 'EFO_0000274', 'EFO_0003884', 'EFO_0000398', 'MONDO_0018305', 'MONDO_0019338', 'EFO_0000274', 'EFO_0000783', 'EFO_0003921', 'EFO_0000546', 'MONDO_0007915', 'EFO_0008518', 'EFO_0000699', 'EFO_0002609', 'EFO_1000906', 'EFO_0003778', 'EFO_0000540', 'EFO_0000676', 'MONDO_0100096', 'EFO_0003834', 'EFO_0000729', 'EFO_0003106', 'EFO_0004991', 'MONDO_0019558', 'EFO_1001494', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872', 'MONDO_0007915', 'EFO_0004192', 'EFO_0000717', 'EFO_0003898', 'EFO_0000685', 'EFO_0003086']",True,True,36,Janus Kinase (JAK) inhibitor ,INHIBITOR ,protein family 
1979,BRILANESTRANT,CHEMBL3581693,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000091831'],['MONDO_0007254'],False,True,1,Estrogen receptor alpha antagonist ,ANTAGONIST ,single protein 
1980,DANVATIRSEN,CHEMBL4297739,Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,['ENSG00000168610'],"['EFO_0000182', 'EFO_0000403', 'EFO_0000181', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0001187']",False,False,7,STAT-3 mRNA 3'UTR antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
1981,TAZEMETOSTAT HYDROBROMIDE,CHEMBL4594260,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sarcoma and follicular lymphoma and has 1 investigational indication.,,4.0,,False,2020,['ENSG00000106462'],"['EFO_0000691', 'EFO_0000702', 'MONDO_0018906']",False,False,3,Histone-lysine N-methyltransferase EZH2 inhibitor ,INHIBITOR ,single protein 
1982,MOBOCERTINIB,CHEMBL4650319,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2021,['ENSG00000146648'],"['EFO_0003086', 'EFO_0001421', 'EFO_0003060', 'EFO_0003060']",False,True,4,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1983,ENSOVIBEP,CHEMBL4802171,Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
1984,GEFITINIB,CHEMBL939,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 45 investigational indications.,,4.0,,False,2003,['ENSG00000146648'],"['EFO_0000514', 'EFO_0000702', 'EFO_0000182', 'EFO_0000222', 'EFO_0003869', 'MONDO_0001187', 'EFO_0000708', 'MONDO_0007254', 'EFO_0000196', 'EFO_1000158', 'MONDO_0008315', 'EFO_0000616', 'MONDO_0002367', 'EFO_0000313', 'MONDO_0004992', 'EFO_0000681', 'EFO_0004252', 'EFO_0003859', 'EFO_0000588', 'EFO_1001951', 'EFO_0000571', 'EFO_0002618', 'EFO_0000691', 'EFO_0000181', 'MONDO_0004192', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0004669', 'EFO_0001071', 'EFO_0000308', 'EFO_0000707', 'EFO_0000519', 'MONDO_0021117', 'EFO_0006861', 'EFO_0000621', 'MONDO_0002898', 'MONDO_0002087', 'EFO_1000251', 'MONDO_0007576', 'MONDO_0002974', 'MONDO_0008903', 'EFO_0006859', 'EFO_1001100', 'EFO_1001465', 'EFO_0000178', 'EFO_0004284', 'EFO_0003897', 'MONDO_0008170']",False,True,48,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
1985,CURCUMIN,CHEMBL116438,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 47 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000826', 'EFO_0000649', 'EFO_1001818', 'EFO_0007430', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0004975', 'MONDO_0005301', 'EFO_0002913', 'MONDO_0043771', 'EFO_0000095', 'EFO_0001378', 'EFO_0000729', 'MONDO_0004979', 'MONDO_0007915', 'EFO_0003884', 'MONDO_0008315', 'EFO_0004268', 'EFO_0000616', 'MONDO_0005147', 'Orphanet_733', 'HP_0100543', 'MONDO_0010788', 'HP_0000155', 'EFO_0002618', 'EFO_0003768', 'EFO_0001416', 'EFO_1001898', 'EFO_0003060', 'MONDO_0011962', 'EFO_1001904', 'EFO_0001365', 'MONDO_0004985', 'EFO_1001801', 'EFO_0000198', 'EFO_0000220', 'HP_0000093', 'EFO_1000910', 'EFO_0008517', 'MONDO_0007254', 'MONDO_0021063', 'MONDO_0044937', 'EFO_0004288', 'MONDO_0002974', 'MONDO_0005575', 'MONDO_0022394', 'EFO_0000384']",False,False,47,,,
1986,EPOETIN ALFA,CHEMBL1201565,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 32 investigational indications.,,4.0,,False,1989,['ENSG00000187266'],"['MONDO_0008170', 'EFO_0000764', 'HP_0012378', 'EFO_0003047', 'EFO_0000612', 'MONDO_0007254', 'EFO_0003884', 'EFO_0009492', 'EFO_0003917', 'EFO_1001459', 'EFO_0002618', 'EFO_0001645', 'EFO_0009909', 'EFO_0003100', 'MONDO_0011382', 'EFO_0001663', 'EFO_0006859', 'EFO_1001100', 'MONDO_0004992', 'EFO_1001779', 'MONDO_0100339', 'MONDO_0043510', 'MONDO_0002280', 'EFO_0001416', 'EFO_0000712', 'MONDO_0008903', 'EFO_0004272', 'MONDO_0001240', 'EFO_0000198', 'Orphanet_848', 'EFO_0003890', 'EFO_0008585', 'EFO_0009446', 'MONDO_0005299', 'EFO_0000222', 'HP_0004936']",True,False,36,Erythropoietin receptor agonist ,AGONIST ,single protein 
1987,SALMETEROL,CHEMBL1263,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1994,['ENSG00000169252'],"['EFO_0001073', 'EFO_1001919', 'MONDO_0004979', 'EFO_0006505', 'HP_0006536', 'EFO_0000464', 'EFO_0000341', 'EFO_0007183', 'EFO_0006505', 'HP_0025428', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000464']",False,False,13,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
1988,DOPAMINE HYDROCHLORIDE,CHEMBL1557,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 3 approved and 1 investigational indication.,,4.0,,False,1974,['ENSG00000043591'],"['MONDO_0005180', 'EFO_0000612', 'EFO_0000373', 'EFO_1002048']",False,False,4,Beta-1 adrenergic receptor agonist ,AGONIST ,single protein 
1989,DUSIGITUMAB,CHEMBL2109355,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000167244', 'ENSG00000017427']","['MONDO_0007254', 'MONDO_0004992', 'EFO_0000182']",False,False,3,Insulin-like growth factor I inhibitor Insulin-like growth factor II inhibitor ,INHIBITOR ,single protein 
1990,PF-04236921,CHEMBL2109613,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000136244'],"['EFO_0000384', 'MONDO_0007915']",True,True,2,Interleukin-6 inhibitor ,INHIBITOR ,single protein 
1991,TENAPANOR,CHEMBL3304485,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2019,['ENSG00000066230'],"['EFO_0003884', 'MONDO_0002203', 'HP_0002905', 'EFO_0000555', 'EFO_0000555', 'HP_0002905', 'HP_0002019']",False,False,7,Sodium/hydrogen exchanger 3 inhibitor ,INHIBITOR ,single protein 
1992,TIOMOLIBDATE ION,CHEMBL4297444,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000768', 'MONDO_0007254', 'EFO_0000182', 'EFO_1001951', 'MONDO_0010200', 'EFO_0003060', 'MONDO_0008315', 'EFO_1001486', 'EFO_0002916', 'EFO_0000676']",False,False,10,,,
1993,CT-7001,CHEMBL4297488,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0004992', 'MONDO_0007254']",False,False,2,,,
1994,AVDORALIMAB,CHEMBL4594463,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000197405'],"['MONDO_0100096', 'EFO_0000616', 'EFO_0007187']",True,False,3,C5a anaphylatoxin chemotactic receptor inhibitor ,INHIBITOR ,single protein 
1995,PEGIPANERMIN,CHEMBL4802208,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0004975', 'MONDO_0100096']",False,False,2,,,
1996,GEDATOLISIB,CHEMBL592445,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['EFO_0000198', 'MONDO_0004992', 'EFO_0005537', 'EFO_0004230', 'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000616']",True,False,8,Serine/threonine-protein kinase mTOR inhibitor PI3-kinase class I inhibitor ,INHIBITOR ,single protein protein complex group 
1997,SULINDAC,CHEMBL15770,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1978,"['ENSG00000073756', 'ENSG00000095303']","['EFO_0000389', 'MONDO_0021074', 'EFO_0004142', 'EFO_1001951', 'MONDO_0007254', 'Orphanet_733', 'EFO_0009907', 'EFO_0000222', 'EFO_0000181', 'MONDO_0005178', 'EFO_0005755', 'EFO_0000685', 'MONDO_0010383', 'MONDO_0003937']",True,False,14,Cyclooxygenase inhibitor ,INHIBITOR ,protein family 
1998,FARLETUZUMAB,CHEMBL1743016,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000110195'],"['MONDO_0002158', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000571', 'EFO_1001100']",True,False,5,Folate receptor alpha inhibitor ,INHIBITOR ,single protein 
1999,SODIUM THIOSULFATE,CHEMBL2096650,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 15 investigational indications.,,4.0,,False,1992,[],"['EFO_0004238', 'MONDO_0100096', 'MONDO_0002123', 'EFO_0005672', 'EFO_0003837', 'EFO_1000292', 'EFO_0006859', 'EFO_0006951', 'EFO_0003884', 'EFO_0000398', 'MONDO_0100342', 'EFO_0002501', 'EFO_0000770', 'EFO_0002918', 'EFO_0002939']",False,False,15,,,
2000,REMESTEMCEL-L,CHEMBL2108046,Cell drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004599', 'EFO_0000384', 'EFO_1000637', 'EFO_0000729', 'MONDO_0100096']",False,False,5,,,
2001,LINAGLIPTIN,CHEMBL237500,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 8 investigational indications.,,4.0,,False,2011,['ENSG00000197635'],"['EFO_0000684', 'EFO_0003060', 'EFO_0000503', 'MONDO_0100096', 'EFO_0000537', 'MONDO_0005090', 'EFO_0002916', 'EFO_0000400', 'HP_0000083', 'MONDO_0005148']",True,False,10,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
2002,APABETALONE,CHEMBL2393130,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']","['EFO_0003884', 'MONDO_0010526', 'MONDO_0100096', 'EFO_0001361', 'EFO_0000400', 'EFO_0001645']",True,False,6,Bromodomain and extra-terminal motif (BET) inhibitor ,INHIBITOR ,protein family 
2003,TELAGLENASTAT,CHEMBL3639788,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.,,2.0,,False,no approval year,['ENSG00000115419'],"['MONDO_0008315', 'EFO_0000222', 'EFO_0000349', 'EFO_0000220', 'EFO_0000272', 'EFO_0000198', 'EFO_0005537', 'EFO_1001779', 'EFO_0003060', 'EFO_0001378', 'EFO_0000760', 'EFO_0000681']",False,False,12,"Glutaminase kidney isoform, mitochondrial inhibitor ",INHIBITOR ,single protein 
2004,AK-01,CHEMBL4594367,Unknown drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000702', 'MONDO_0007254', 'EFO_0000621', 'EFO_0003060']",False,False,4,,,
2005,GIREDESTRANT,CHEMBL4650316,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000091831'],"['MONDO_0007254', 'MONDO_0008170']",False,True,2,Estrogen receptor alpha degrader ,DEGRADER ,single protein 
2006,ACASUNLIMAB,CHEMBL5095337,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0003060']",False,False,2,,,
2007,FLUDROCORTISONE ACETATE,CHEMBL1201010,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 9 investigational indications.,,4.0,,False,1955,['ENSG00000151623'],"['MONDO_0002050', 'EFO_1001176', 'MONDO_0015128', 'MONDO_0018479', 'MONDO_0015898', 'MONDO_0100096', 'EFO_0000694', 'EFO_0006834', 'MONDO_0015129', 'MONDO_0005180', 'EFO_0000756', 'MONDO_0011972']",True,False,12,Mineralocorticoid receptor agonist ,AGONIST ,single protein 
2008,IMIQUIMOD,CHEMBL1282,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 48 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000196664'],"['MONDO_0024475', 'EFO_0000565', 'EFO_0000389', 'MONDO_0008094', 'EFO_0001061', 'EFO_0002627', 'EFO_0002913', 'EFO_0004197', 'EFO_1001968', 'EFO_0000707', 'MONDO_0100342', 'EFO_0002499', 'EFO_0003868', 'EFO_1000026', 'EFO_0000220', 'EFO_0000095', 'EFO_1000249', 'MONDO_0022394', 'MONDO_0021582', 'EFO_0007444', 'EFO_0007328', 'MONDO_0002974', 'EFO_0005222', 'EFO_1000720', 'MONDO_0021054', 'MONDO_0008315', 'EFO_0000756', 'EFO_0000673', 'MONDO_0008170', 'MONDO_0004992', 'EFO_1001361', 'EFO_0002939', 'MONDO_0002158', 'MONDO_0002102', 'EFO_0001422', 'MONDO_0005341', 'EFO_1000028', 'MONDO_0024474', 'EFO_1002048', 'EFO_1001951', 'EFO_0000519', 'EFO_0002496', 'MONDO_0001657', 'EFO_1000635', 'EFO_0000763', 'EFO_0004212', 'EFO_0003835', 'EFO_0007147', 'EFO_0001668', 'EFO_0005046', 'EFO_0003060', 'MONDO_0007254', 'EFO_0004193']",True,False,53,Toll-like receptor 7 agonist ,AGONIST ,single protein 
2009,TP-271,CHEMBL2057236,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003106', 'EFO_0000771']",False,False,2,,,
2010,IC14,CHEMBL2109330,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000170458'],"['EFO_1000637', 'MONDO_0004976', 'MONDO_0100130', 'MONDO_0100096', 'EFO_0005547']",True,False,5,Monocyte differentiation antigen CD14 inhibitor ,INHIBITOR ,single protein 
2011,IMGATUZUMAB,CHEMBL2109389,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000203747', 'ENSG00000146648']","['EFO_1001951', 'EFO_0000616', 'EFO_0003060', 'EFO_0006859']",False,True,4,Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent Epidermal growth factor receptor erbB1 inhibitor ,CROSS-LINKING AGENT INHIBITOR ,single protein 
2012,VERCIRNON,CHEMBL2178578,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000173585'],"['EFO_0000729', 'EFO_0001060', 'EFO_0000384', 'EFO_0000384']",True,False,4,C-C chemokine receptor type 9 antagonist ,ANTAGONIST ,single protein 
2013,UK-500001,CHEMBL3113734,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0000341'],False,False,1,Phosphodiesterase isozyme 4 inhibitor ,INHIBITOR ,single protein 
2014,AZD-1656,CHEMBL3219124,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000106633'],"['MONDO_0005147', 'MONDO_0005148', 'MONDO_0100096']",False,False,3,Hexokinase type IV activator ,ACTIVATOR ,single protein 
2015,ENILURACIL,CHEMBL355200,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,['ENSG00000188641'],"['EFO_0000574', 'EFO_0006859', 'EFO_1001951', 'EFO_0000365', 'EFO_1000657', 'MONDO_0007254', 'MONDO_0021063', 'MONDO_0004992']",False,False,8,Dihydropyrimidine dehydrogenase inhibitor ,INHIBITOR ,single protein 
2016,2X-121,CHEMBL3644587,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000107854', 'ENSG00000173273', 'ENSG00000143799', 'ENSG00000129484']","['MONDO_0008170', 'EFO_0000305', 'MONDO_0007254']",True,False,3,Tankyrase 1/2 inhibitor Poly [ADP-ribose] polymerase-1 inhibitor Poly [ADP-ribose] polymerase 2 inhibitor ,INHIBITOR ,protein family single protein 
2017,RONICICLIB,CHEMBL4442620,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000170312', 'ENSG00000135446', 'ENSG00000123374', 'ENSG00000164885', 'ENSG00000105810', 'ENSG00000134058', 'ENSG00000250506', 'ENSG00000102225', 'ENSG00000117266', 'ENSG00000132964', 'ENSG00000059758', 'ENSG00000248333', 'ENSG00000138395', 'ENSG00000155111', 'ENSG00000058091', 'ENSG00000136807', 'ENSG00000185324', 'ENSG00000065883', 'ENSG00000156345', 'ENSG00000167258']","['EFO_0003060', 'EFO_0000616', 'EFO_0000702']",True,False,3,Cyclin-dependent kinase inhibitor ,INHIBITOR ,protein family 
2018,L-DOS47,CHEMBL4594480,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0002618', 'EFO_0003060', 'EFO_0000571']",False,False,3,,,
2019,PIMIVALIMAB,CHEMBL4650482,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000188389'],"['EFO_0003060', 'MONDO_0004992']",False,False,2,Programmed cell death protein 1 inhibitor ,INHIBITOR ,single protein 
2020,BEMARITUZUMAB,CHEMBL4802165,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000066468'],"['MONDO_0001056', 'EFO_0000616', 'EFO_0003060', 'EFO_0000228']",False,False,4,Fibroblast growth factor receptor 2 antagonist ,ANTAGONIST ,single protein 
2021,PRIMAQUINE,CHEMBL506,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for malaria and has 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1952,[],"['EFO_0007444', 'EFO_0001068', 'EFO_0007287', 'EFO_0007444', 'EFO_0001073', 'EFO_0007448', 'MONDO_0100096', 'EFO_0007445', 'EFO_0001068', 'EFO_0007445']",False,False,10,,,
2022,ALBUTEROL,CHEMBL714,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,['ENSG00000169252'],"['EFO_0010581', 'EFO_0003818', 'MONDO_0005149', 'HP_0025428', 'MONDO_0004979', 'EFO_0001072', 'HP_0006536', 'MONDO_0002009', 'Orphanet_1764', 'EFO_0003818', 'Orphanet_590', 'MONDO_0100130', 'EFO_0000319', 'EFO_0001361', 'MONDO_0017147', 'HP_0011950', 'MONDO_0016575', 'MONDO_0004979', 'EFO_0009686', 'EFO_0008590', 'MONDO_0011705', 'EFO_0000373', 'HP_0012735', 'EFO_0008590', 'MONDO_0005271', 'Orphanet_365', 'EFO_0000400', 'EFO_1001134', 'EFO_0009840', 'EFO_0003956', 'EFO_0000341', 'EFO_0000768', 'HP_0025428', 'EFO_0000341', 'EFO_1001919']",False,False,35,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
2023,DESIPRAMINE,CHEMBL72,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for unipolar depression and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1964,['ENSG00000103546'],"['EFO_0003761', 'MONDO_0002009', 'EFO_0004234', 'EFO_0003918', 'EFO_0002610', 'EFO_0001358', 'MONDO_0002050', 'MONDO_0007079', 'HP_0011868', 'EFO_0000702', 'MONDO_0004992', 'MONDO_0010726', 'EFO_0003761', 'EFO_0003948', 'HP_0003418', 'MONDO_0002050']",False,False,16,Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
2024,SITAGLIPTIN PHOSPHATE,CHEMBL1201174,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications.,,4.0,,False,2006,['ENSG00000197635'],"['EFO_0000612', 'MONDO_0005148', 'EFO_0000400', 'HP_0000083', 'MONDO_0021187', 'EFO_0000712']",False,False,6,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
2025,CERAMIDE,CHEMBL155886,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000222', 'MONDO_0007254', 'EFO_0000313']",False,False,3,,,
2026,CEFTOLOZANE,CHEMBL2103872,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for urinary tract infection and infection and has 6 investigational indications.,,4.0,,False,2014,[],"['EFO_0003103', 'EFO_0003103', 'EFO_0000544', 'EFO_1001865', 'EFO_1001141', 'EFO_0000544', 'EFO_0005741', 'EFO_0003106']",False,False,8,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
2027,DEXTRIN,CHEMBL2108197,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000764', 'MONDO_0008315', 'EFO_0000319', 'EFO_0000702', 'EFO_0007160']",False,False,5,,,
2028,CETHROMYCIN,CHEMBL3989904,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003106'],False,False,1,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2029,UPROLESELAN,CHEMBL3989971,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000007908'],"['EFO_0003907', 'EFO_0000222', 'EFO_0001378', 'MONDO_0100096']",False,False,4,Selectin E antagonist ,ANTAGONIST ,single protein 
2030,SPESOLIMAB,CHEMBL4297911,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 4 investigational indications.,,4.0,,False,2022,"['ENSG00000115598', 'ENSG00000196083']","['MONDO_0015597', 'EFO_1000710', 'EFO_0000274', 'EFO_0000540', 'EFO_0000676', 'EFO_0000729', 'EFO_0000384']",True,False,7,IL36 receptor antagonist ,ANTAGONIST ,protein complex 
2031,CARFILZOMIB,CHEMBL451887,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 24 investigational indications.,,4.0,,False,2009,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']","['EFO_0000222', 'MONDO_0004992', 'MONDO_0002120', 'EFO_0006475', 'EFO_1000785', 'MONDO_0018906', 'MONDO_0008315', 'EFO_0006738', 'EFO_0009441', 'EFO_0000574', 'EFO_0000616', 'EFO_0000095', 'EFO_0000211', 'EFO_0000220', 'MONDO_0001023', 'MONDO_0017816', 'MONDO_0002367', 'EFO_0000702', 'EFO_0000565', 'EFO_0001378', 'EFO_0000096', 'EFO_0005952', 'EFO_0000403', 'EFO_1001469', 'EFO_1001875', 'EFO_0000183', 'EFO_1001051']",True,True,27,26S proteosome inhibitor ,INHIBITOR ,protein complex 
2032,ROMLUSEVIMAB,CHEMBL4650383,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
2033,EBSELEN,CHEMBL51085,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0004985', 'EFO_0004238', 'MONDO_0002050', 'EFO_0006862', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0006951', 'MONDO_0100096']",False,False,8,,,
2034,MECASERMIN,CHEMBL1201716,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for hypothyroidism and growth delay and has 14 investigational indications.,,4.0,,False,2005,['ENSG00000140443'],"['EFO_0004260', 'EFO_1001348', 'EFO_0000400', 'MONDO_0002177', 'MONDO_0010726', 'MONDO_0015892', 'EFO_1001158', 'EFO_0000384', 'EFO_0004705', 'MONDO_0005301', 'MONDO_0005351', 'EFO_1001434', 'MONDO_0004976', 'GO_0007568', 'MONDO_0018997', 'HP_0001510']",True,False,16,Insulin-like growth factor I receptor agonist ,AGONIST ,single protein 
2035,RITONAVIR,CHEMBL163,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,"['ENSG00000160868', 'ENSG00000106258', 'ENSG00000021461', 'ENSG00000160870']","['EFO_0000558', 'EFO_0000764', 'EFO_0000691', 'EFO_0002950', 'EFO_0004234', 'EFO_0000519', 'EFO_0001068', 'EFO_0003106', 'EFO_0004220', 'EFO_0009708', 'EFO_0007328', 'EFO_0003086', 'MONDO_0004976', 'EFO_0001361', 'EFO_0000694', 'MONDO_0100116', 'EFO_0003047', 'EFO_0000763', 'EFO_0003835', 'EFO_0000765', 'EFO_0000180', 'EFO_0007224', 'MONDO_0100096', 'MONDO_0018076', 'EFO_0007386', 'EFO_0001421', 'EFO_0000537', 'EFO_0004197', 'MONDO_0004992', 'EFO_0000544', 'EFO_1000637', 'EFO_0002614', 'EFO_0007304']",True,False,33,Cytochrome P450 3A inhibitor Human immunodeficiency virus type 1 protease inhibitor ,INHIBITOR ,protein family single protein 
2036,REPARIXIN,CHEMBL191413,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,"['ENSG00000180871', 'ENSG00000163464']","['MONDO_0005147', 'EFO_0003106', 'MONDO_0100096', 'EFO_0002687', 'MONDO_0007254', 'EFO_0000342', 'EFO_0007541', 'MONDO_0100130']",True,False,8,Interleukin-8 receptor B modulator Interleukin-8 receptor A modulator ,MODULATOR ,single protein 
2037,20-HYDROXYECDYSONE,CHEMBL224128,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1000653', 'DOID_10718', 'MONDO_0100096']",False,False,3,,,
2038,SODIUM DICHLOROACETATE,CHEMBL306823,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.,,4.0,,False,no approval year,"['ENSG00000005882', 'ENSG00000067992', 'ENSG00000004799', 'ENSG00000152256']","['EFO_0003777', 'MONDO_0019169', 'EFO_0001361', 'EFO_1000036', 'EFO_0000519', 'EFO_0000181', 'MONDO_0007254', 'MONDO_0008903']",True,False,8,Pyruvate dehydrogenase kinase inhibitor ,INHIBITOR ,protein family 
2039,NEOMYCIN SULFATE,CHEMBL3989769,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1957,[],"['EFO_0007315', 'MP_0001845', 'EFO_0009516', 'MONDO_0100096', 'EFO_0000544']",False,False,5,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2040,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,CHEMBL4297879,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 9 investigational indications.,,4.0,,False,no approval year,['ENSG00000197561'],"['MP_0001845', 'EFO_0000342', 'EFO_0000341', 'EFO_0008583', 'MP_0001914', 'Orphanet_60', 'MONDO_0100096', 'MONDO_0013730', 'MONDO_0009061', 'MONDO_0005147']",True,False,10,Leukocyte elastase inhibitor ,INHIBITOR ,single protein 
2041,NVX-COV2373,CHEMBL5095387,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000694']",False,False,2,,,
2042,BECLOMETHASONE DIPROPIONATE,CHEMBL1200500,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 6 approved and 16 investigational indications.,,4.0,,False,1976,['ENSG00000113580'],"['HP_0006536', 'EFO_0005854', 'EFO_0000702', 'EFO_0003956', 'MONDO_0004979', 'EFO_0007227', 'MONDO_0019091', 'HP_0002110', 'MONDO_0043579', 'EFO_1000391', 'EFO_1001417', 'EFO_0004599', 'EFO_1000644', 'EFO_1000702', 'EFO_0000768', 'HP_0001742', 'MONDO_0013730', 'EFO_0000544', 'EFO_0007486', 'EFO_0004232', 'MONDO_0100096', 'EFO_0000341']",True,True,22,Glucocorticoid receptor agonist ,AGONIST ,single protein 
2043,NATALIZUMAB,CHEMBL1201607,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,"['ENSG00000115232', 'ENSG00000139626', 'ENSG00000150093']","['MONDO_0013730', 'EFO_0008522', 'MONDO_0005090', 'EFO_0000637', 'MP_0001845', 'EFO_0000685', 'EFO_0000384', 'EFO_0004599', 'MONDO_0005301', 'EFO_0000540', 'EFO_0003929', 'EFO_0001378', 'EFO_0008520', 'EFO_0007323', 'HP_0002140']",True,True,15,Integrin alpha-4/beta-7 inhibitor Integrin alpha-4/beta-1 inhibitor ,INHIBITOR ,protein complex 
2044,RIFAXIMIN,CHEMBL1617,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 27 investigational indications.,,4.0,,False,2004,[],"['EFO_0000384', 'EFO_0008588', 'EFO_1000657', 'EFO_0004268', 'MONDO_0004992', 'HP_0001298', 'EFO_0003884', 'EFO_1001460', 'EFO_1000988', 'MONDO_0011382', 'EFO_0008533', 'EFO_1001207', 'EFO_1000961', 'EFO_0000305', 'MONDO_0005180', 'MONDO_0004975', 'EFO_0000555', 'EFO_1000874', 'EFO_0003047', 'EFO_0000764', 'EFO_1000760', 'HP_0002014', 'EFO_1001293', 'EFO_1001345', 'EFO_0007430', 'EFO_0000180', 'EFO_0000544', 'EFO_0003932', 'HP_0001399', 'EFO_0001422']",False,False,30,Bacterial DNA-directed RNA polymerase inhibitor ,INHIBITOR ,protein complex 
2045,ONARTUZUMAB,CHEMBL1743051,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000105976'],"['EFO_0000182', 'MONDO_0008903', 'MONDO_0004992', 'MONDO_0001056', 'MONDO_0007254', 'EFO_0000519', 'EFO_0003060', 'EFO_0000616', 'EFO_1001951']",True,False,9,Hepatocyte growth factor receptor antagonist ,ANTAGONIST ,single protein 
2046,TOLVAPTAN,CHEMBL344159,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 9 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000126895'],"['EFO_0000319', 'EFO_0001422', 'EFO_1001771', 'HP_0002094', 'EFO_0000313', 'EFO_1000982', 'EFO_0003884', 'HP_0002902', 'EFO_0003086', 'EFO_0008620', 'EFO_0000373', 'EFO_0003144', 'EFO_0004253', 'EFO_1001496']",False,False,14,Vasopressin V2 receptor antagonist ,ANTAGONIST ,single protein 
2047,OXYTOCIN,CHEMBL395429,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for uterine inertia and hemorrhage and has 47 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1980,['ENSG00000180914'],"['EFO_0002610', 'EFO_1000948', 'MONDO_0008300', 'MONDO_0007079', 'EFO_0001073', 'EFO_0004242', 'GO_0007568', 'MONDO_0100096', 'EFO_0003918', 'EFO_0003758', 'EFO_0000668', 'MONDO_0005090', 'MONDO_0017276', 'MONDO_0002491', 'EFO_0004714', 'EFO_0004616', 'EFO_0010702', 'EFO_0005411', 'EFO_0009579', 'MONDO_0002009', 'MP_0001845', 'EFO_0004566', 'EFO_0003888', 'MONDO_0002025', 'EFO_0004247', 'EFO_0000612', 'MONDO_0005351', 'EFO_0004777', 'EFO_0005611', 'EFO_1001271', 'MONDO_0002050', 'HP_0012532', 'EFO_0003843', 'EFO_1000911', 'EFO_1001863', 'EFO_0003756', 'EFO_0000432', 'EFO_0003877', 'EFO_1000096', 'EFO_0001072', 'EFO_0005762', 'EFO_1001917', 'EFO_0001358', 'MONDO_0004782', 'MONDO_0005178', 'EFO_0010642', 'EFO_0004269', 'MONDO_0010383', 'MP_0001914']",True,False,49,Oxytocin receptor agonist ,AGONIST ,single protein 
2048,RIFABUTIN,CHEMBL444633,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 approved and 6 investigational indications.,,4.0,,False,1992,[],"['EFO_0000544', 'EFO_1000049', 'MONDO_0002041', 'EFO_0009429', 'MONDO_0018076', 'EFO_0000384', 'EFO_0003102', 'EFO_0007386', 'EFO_0000764', 'EFO_0000180']",False,False,10,Bacterial DNA-directed RNA polymerase inhibitor ,INHIBITOR ,protein complex 
2049,SENAPARIB,CHEMBL4802152,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000129484', 'ENSG00000143799']","['EFO_0000702', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0008315']",True,False,6,Poly [ADP-ribose] polymerase-1 inhibitor Poly [ADP-ribose] polymerase 2 inhibitor ,INHIBITOR ,single protein 
2050,BENDAMUSTINE,CHEMBL487253,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 38 investigational indications.,,4.0,,False,2008,[],"['MONDO_0002334', 'MONDO_0019438', 'MONDO_0008903', 'MONDO_0008170', 'MONDO_0018906', 'EFO_0000702', 'EFO_0000565', 'EFO_0000211', 'EFO_0000616', 'EFO_0000565', 'EFO_0000339', 'EFO_0000220', 'EFO_0000222', 'EFO_0005952', 'EFO_0000095', 'MONDO_0009348', 'EFO_0002499', 'EFO_0002501', 'EFO_0000255', 'EFO_0000096', 'EFO_0000183', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000574', 'EFO_1001465', 'EFO_0001378', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000198', 'EFO_0001378', 'MONDO_0004992', 'EFO_0000095', 'MONDO_0044881', 'EFO_1000630', 'EFO_0000403', 'EFO_0000183', 'EFO_0009441', 'EFO_1000956', 'EFO_0000191', 'EFO_0006475', 'EFO_0000403', 'EFO_0000574', 'MONDO_0019438', 'MONDO_0007254', 'EFO_1001469', 'MONDO_0009348', 'EFO_0000096']",False,False,47,,,
2051,LYCOPENE,CHEMBL501174,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,[],"['EFO_1000726', 'EFO_0000649', 'EFO_0000284', 'EFO_0003914', 'EFO_0000673', 'EFO_0002621', 'MONDO_0008315', 'EFO_0001645', 'EFO_1001393']",False,False,9,,,
2052,MAVORIXAFOR,CHEMBL518924,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000121966'],"['EFO_0000349', 'EFO_0000756', 'EFO_0000764', 'MONDO_0007254', 'MONDO_0001475', 'EFO_0009441']",True,False,6,C-X-C chemokine receptor type 4 antagonist ,ANTAGONIST ,single protein 
2053,INTERFERON BETA-1A,CHEMBL1201562,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and multiple sclerosis and has 14 investigational indications.,,4.0,,False,1996,"['ENSG00000142166', 'ENSG00000159110']","['EFO_0000384', 'MONDO_0100130', 'EFO_1001373', 'EFO_0003929', 'EFO_0000616', 'EFO_0000729', 'EFO_0000712', 'EFO_0003047', 'EFO_0003106', 'MONDO_0004979', 'MONDO_0004975', 'EFO_1000868', 'EFO_0007328', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0000341']",True,True,16,Interferon alpha/beta receptor agonist ,AGONIST ,protein complex 
2054,SAPROPTERIN,CHEMBL1201774,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for phenylketonuria and hyperphenylalaninemia and has 20 investigational indications.,,4.0,,False,2007,['ENSG00000171759'],"['MONDO_0009861', 'MONDO_0010298', 'MONDO_0005090', 'MONDO_0043771', 'EFO_0000537', 'Orphanet_238583', 'EFO_0000181', 'EFO_0003884', 'EFO_0003144', 'EFO_0001645', 'EFO_0003876', 'EFO_0000341', 'EFO_0003884', 'EFO_0003758', 'EFO_0001361', 'MONDO_0004975', 'EFO_0005411', 'MONDO_0043579', 'MONDO_0011382', 'EFO_0000666', 'MONDO_0009861', 'EFO_0001422', 'EFO_0000537']",False,False,23,Phenylalanine-4-hydroxylase activator ,ACTIVATOR ,single protein 
2055,DULANERMIN,CHEMBL2107846,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000104689', 'ENSG00000120889']","['EFO_1001951', 'EFO_0005952', 'EFO_0003060']",False,False,3,TRAIL receptor-1 agonist Tumor necrosis factor receptor superfamily member 10B agonist ,AGONIST ,single protein 
2056,ARZOXIFENE,CHEMBL226267,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,"['ENSG00000140009', 'ENSG00000091831']","['MONDO_0008170', 'MONDO_0007254', 'MONDO_0011962', 'EFO_0003854', 'EFO_0003869', 'EFO_0003882', 'MONDO_0002087', 'Orphanet_145', 'MONDO_0007254']",False,True,9,Estrogen receptor modulator ,MODULATOR ,protein family 
2057,EVOLOCUMAB,CHEMBL2364655,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 12 investigational indications.,,4.0,,False,2015,['ENSG00000169174'],"['EFO_0000712', 'EFO_0000319', 'EFO_0003144', 'MONDO_0018328', 'EFO_0000519', 'HP_0003124', 'EFO_0003060', 'EFO_0008585', 'EFO_0001645', 'MONDO_0008903', 'Orphanet_79211', 'MONDO_0100096', 'EFO_0005672', 'Orphanet_309005', 'EFO_0000612', 'MONDO_0021187', 'HP_0100806', 'EFO_0004911']",False,True,18,Subtilisin/kexin type 9 inhibitor ,INHIBITOR ,single protein 
2058,CFI-400945,CHEMBL3408947,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000142731'],"['MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254']",False,False,3,Serine/threonine-protein kinase PLK4 inhibitor ,INHIBITOR ,single protein 
2059,OSIMERTINIB MESYLATE,CHEMBL3545063,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.,,4.0,,False,2015,['ENSG00000146648'],"['EFO_0003060', 'MONDO_0008903']",False,True,2,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
2060,LISINOPRIL,CHEMBL419213,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,['ENSG00000159640'],"['EFO_0000537', 'EFO_0000612', 'EFO_0000373', 'EFO_0000712', 'EFO_0000400', 'EFO_0003144', 'EFO_0000319']",True,False,7,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
2061,FDL169,CHEMBL5095180,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0009061'],False,False,1,,,
2062,RETLIRAFUSP ALFA,CHEMBL5095383,Protein drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0002618', 'EFO_0000756', 'EFO_0004252', 'EFO_0000616', 'EFO_0000181', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000574', 'MONDO_0007254']",False,False,9,,,
2063,TERAZOSIN,CHEMBL611,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 7 investigational indications.,,4.0,,False,1987,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0000284', 'EFO_0003914', 'MONDO_0005180', 'MONDO_0005148', 'EFO_0000537', 'EFO_0000284', 'EFO_0001645', 'EFO_0002615', 'HP_0003124']",False,False,9,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
2064,FLUCONAZOLE,CHEMBL106,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 4 approved and 32 investigational indications.,,4.0,,False,1990,[],"['EFO_0007228', 'MONDO_0002041', 'EFO_0007512', 'EFO_0000764', 'EFO_0000544', 'EFO_0007174', 'EFO_0000616', 'EFO_1001283', 'MONDO_0002026', 'EFO_1000781', 'EFO_0007310', 'EFO_0007494', 'EFO_0005046', 'EFO_1001282', 'MONDO_0004975', 'EFO_0000574', 'EFO_1001240', 'EFO_0000384', 'EFO_0003103', 'EFO_0000341', 'EFO_0007543', 'MONDO_0002234', 'EFO_1000992', 'EFO_0003917', 'MONDO_0004992', 'MONDO_0013730', 'EFO_0004233', 'EFO_0003932', 'EFO_0000771', 'EFO_1001413', 'EFO_0007406', 'EFO_0009365', 'EFO_0007157', 'EFO_0000222', 'EFO_1001249', 'EFO_0007211']",False,False,36,Cytochrome P450 51 inhibitor ,INHIBITOR ,single protein 
2065,FLUDEOXYGLUCOSE F 18,CHEMBL1092067,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 31 investigational indications.,,4.0,,False,1994,[],"['MONDO_0001187', 'EFO_0000183', 'EFO_0000519', 'MONDO_0008903', 'MONDO_0018906', 'MONDO_0002367', 'EFO_0000641', 'EFO_0000685', 'EFO_0000349', 'MONDO_0008667', 'MONDO_0004992', 'MONDO_0009348', 'EFO_0001642', 'EFO_0000574', 'EFO_0001416', 'EFO_0002618', 'EFO_0003968', 'EFO_0000616', 'EFO_0000691', 'MONDO_0004192', 'EFO_0000756', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000503', 'EFO_0006859', 'MONDO_0004975', 'EFO_1001051', 'EFO_0000501', 'EFO_1001465', 'MONDO_0002974', 'EFO_0003060']",False,False,31,,,
2066,OMEGA-3-ACID ETHYL ESTERS,CHEMBL1200711,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 61 investigational indications.,,4.0,,False,2004,[],"['HP_0100543', 'EFO_0003894', 'EFO_0000649', 'Orphanet_309005', 'MP_0001845', 'EFO_0003144', 'EFO_0003756', 'EFO_1001375', 'MONDO_0005090', 'EFO_0004211', 'EFO_0003884', 'EFO_0000220', 'EFO_0004705', 'EFO_1001471', 'EFO_0007453', 'MONDO_0005148', 'EFO_0002614', 'EFO_0005425', 'EFO_0000319', 'EFO_1001141', 'HP_0000155', 'EFO_0004911', 'EFO_0000195', 'EFO_0005407', 'EFO_0003777', 'EFO_0003758', 'EFO_0003876', 'MONDO_0007254', 'EFO_0000181', 'Orphanet_79211', 'EFO_0004194', 'EFO_0008528', 'EFO_0003888', 'MONDO_0004975', 'EFO_1001951', 'MONDO_0008170', 'MONDO_0002050', 'EFO_0000537', 'MONDO_0004985', 'EFO_0000764', 'EFO_1001904', 'MONDO_0005147', 'EFO_0008623', 'EFO_1000906', 'MONDO_0100096', 'EFO_0005529', 'EFO_1000653', 'EFO_0003060', 'EFO_0000400', 'EFO_0000275', 'EFO_0004265', 'EFO_0005952', 'MONDO_0002009', 'EFO_0008517', 'EFO_0000756', 'EFO_0003015', 'EFO_0000783', 'EFO_0000546', 'EFO_0002618', 'HP_0003124', 'EFO_0000474', 'HP_0001397', 'EFO_0003095', 'EFO_0000612', 'MONDO_0004658']",False,False,65,,,
2067,OFATUMUMAB,CHEMBL1201836,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2009,['ENSG00000156738'],"['EFO_0004255', 'MONDO_0005301', 'EFO_0000565', 'EFO_0000540', 'EFO_0000574', 'EFO_0004289', 'EFO_0009441', 'EFO_0000309', 'EFO_0000403', 'MONDO_0001023', 'MONDO_0018906', 'MONDO_0004992', 'EFO_0000183', 'EFO_1000749', 'EFO_0000756', 'EFO_1001469', 'MONDO_0000873', 'MONDO_0000870', 'EFO_0000616', 'EFO_0000685', 'EFO_0000095', 'EFO_0000765', 'EFO_0004719', 'EFO_0005952', 'EFO_0000220']",False,False,25,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
2068,INDACATEROL MALEATE,CHEMBL1789842,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 1 investigational indication.,,4.0,,False,2011,['ENSG00000169252'],"['EFO_0000341', 'EFO_0006505', 'MONDO_0004979', 'EFO_0000464']",False,False,4,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
2069,ANTINEOPLASTON A10,CHEMBL1980825,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 41 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0005235', 'EFO_1000028', 'MONDO_0002691', 'MONDO_0021063', 'EFO_0000272', 'EFO_0009441', 'EFO_0003833', 'EFO_0000574', 'EFO_0000702', 'EFO_0002499', 'EFO_0001378', 'MONDO_0100342', 'MONDO_0003268', 'EFO_0000519', 'EFO_0000616', 'EFO_0005701', 'MONDO_0008903', 'EFO_0000756', 'MONDO_0016642', 'EFO_1001968', 'EFO_0000365', 'MONDO_0008170', 'EFO_0000178', 'EFO_0000326', 'EFO_1001469', 'MONDO_0008315', 'MONDO_0002367', 'MONDO_0001657', 'EFO_0005952', 'EFO_0000588', 'EFO_0000621', 'EFO_0002618', 'EFO_0000313', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000632', 'EFO_1000796', 'EFO_0000673', 'MONDO_0001187', 'EFO_0000196', 'EFO_0006859']",False,False,41,,,
2070,LEMUTEPORFIN,CHEMBL2107756,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000284', 'EFO_0003894']",False,False,2,,,
2071,LENZILUMAB,CHEMBL3707325,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000164400'],"['EFO_0003106', 'EFO_0000096', 'EFO_1001779', 'EFO_0000685', 'MONDO_0004979', 'MONDO_0100096']",True,False,6,Granulocyte-macrophage colony-stimulating factor inhibitor ,INHIBITOR ,single protein 
2072,CENERIMOD,CHEMBL4297505,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000170989'],"['EFO_0003086', 'MONDO_0007915', 'EFO_0001421']",False,False,3,Sphingosine 1-phosphate receptor Edg-1 modulator ,MODULATOR ,single protein 
2073,IVUXOLIMAB,CHEMBL4297883,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000186827'],"['MONDO_0018906', 'EFO_0000349', 'MONDO_0004992', 'EFO_0000222', 'EFO_0000616', 'EFO_0000305', 'EFO_0000196']",True,False,7,Tumor necrosis factor receptor superfamily member 4 agonist ,AGONIST ,single protein 
2074,LIFASTUZUMAB VEDOTIN,CHEMBL4297938,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014', 'ENSG00000157765']","['EFO_0003060', 'MONDO_0008170']",True,False,2,Sodium-dependent phosphate transport protein 2B binding agent Tubulin inhibitor ,BINDING AGENT INHIBITOR ,single protein protein complex group 
2075,LIFILEUCEL,CHEMBL4298200,Cell drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000181', 'EFO_0003060', 'EFO_0000389', 'EFO_0001061', 'EFO_0000588', 'MONDO_0007254', 'MONDO_0002974', 'EFO_0002617']",False,False,8,,,
2076,PRINABEREL,CHEMBL450940,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000140009'],"['HP_0001657', 'EFO_0001065', 'EFO_0000384']",False,False,3,Estrogen receptor beta agonist ,AGONIST ,single protein 
2077,RADEZOLID,CHEMBL455461,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['EFO_0003106'],False,False,1,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2078,BIIB021,CHEMBL467399,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['EFO_0000616', 'EFO_0000574', 'MONDO_0011719', 'MONDO_0007254', 'EFO_0000095']",False,False,5,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
2079,MITIPERSTAT,CHEMBL5095218,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003086', 'EFO_0000341', 'EFO_0000319', 'EFO_0003144']",False,False,4,,,
2080,SUNITINIB,CHEMBL535,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 7 approved and 92 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2006,"['ENSG00000165731', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000157404', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000182578', 'ENSG00000122025']","['EFO_0000222', 'EFO_0000313', 'MONDO_0011719', 'MONDO_0003268', 'EFO_0000181', 'EFO_0005221', 'EFO_0000228', 'EFO_1000251', 'MONDO_0002367', 'EFO_0002499', 'EFO_0000349', 'EFO_0006861', 'MONDO_0001056', 'MONDO_0044926', 'EFO_1000581', 'EFO_0000641', 'EFO_0000640', 'MONDO_0004192', 'EFO_0000640', 'EFO_0003869', 'EFO_0000673', 'EFO_0007331', 'EFO_0000681', 'EFO_0000702', 'EFO_0000514', 'EFO_0002617', 'MONDO_0015277', 'EFO_0000294', 'EFO_0000095', 'EFO_0000673', 'EFO_0000220', 'EFO_0000403', 'MONDO_0002367', 'EFO_0003897', 'EFO_0003869', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000702', 'EFO_0003833', 'EFO_0003897', 'EFO_0003060', 'MONDO_0007254', 'EFO_0004142', 'EFO_0000519', 'EFO_0008528', 'EFO_0006352', 'EFO_0001378', 'EFO_0000182', 'MONDO_0008170', 'EFO_0002618', 'MONDO_0002087', 'MONDO_0007254', 'MONDO_0008667', 'EFO_0000239', 'EFO_0000616', 'MONDO_0008903', 'EFO_0000558', 'MONDO_0008667', 'EFO_0007416', 'EFO_0000514', 'EFO_0000222', 'EFO_0000519', 'MONDO_0002158', 'EFO_0004243', 'MONDO_0007576', 'EFO_0003060', 'MONDO_0002158', 'EFO_1001951', 'EFO_1000984', 'MONDO_0001187', 'EFO_1000796', 'MONDO_0008903', 'EFO_0000616', 'EFO_0000756', 'EFO_1000576', 'EFO_0003863', 'EFO_1001465', 'EFO_0000196', 'EFO_0000501', 'EFO_1000045', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0002087', 'EFO_0000632', 'EFO_0000588', 'EFO_0003865', 'EFO_0007243', 'EFO_0004252', 'EFO_0000637', 'EFO_0000691', 'EFO_0000182', 'HP_0001541', 'EFO_1001465', 'EFO_0000349', 'EFO_1001968', 'MONDO_0018364', 'EFO_0007143', 'EFO_0002938', 'EFO_1001968', 'MONDO_0008315', 'EFO_0000681', 'EFO_1001901', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0007416', 'MONDO_0004992', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0002892', 'EFO_1000576', 'EFO_0002617', 'EFO_1001901']",True,True,113,Stem cell growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor Tyrosine-protein kinase receptor RET inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor Macrophage colony stimulating factor receptor inhibitor ,INHIBITOR ,single protein protein family protein complex 
2081,LOSMAPIMOD,CHEMBL1088752,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.,,3.0,,False,no approval year,"['ENSG00000185386', 'ENSG00000112062']","['EFO_0004236', 'Orphanet_269', 'MONDO_0100096', 'EFO_0000319', 'EFO_0005762', 'EFO_0005672', 'EFO_0000685', 'EFO_0000341', 'EFO_0003914', 'MONDO_0002009', 'Orphanet_309005']",False,False,11,MAP kinase p38 beta inhibitor MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
2082,CILASTATIN SODIUM,CHEMBL1201057,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved indications.,,4.0,,False,1985,['ENSG00000015413'],"['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_0003106', 'EFO_0000465']",False,False,5,Renal dipeptidase inhibitor ,INHIBITOR ,single protein 
2083,LAMIVUDINE,CHEMBL141,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 9 approved and 13 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1995,[],"['EFO_0004239', 'EFO_0000558', 'EFO_0007527', 'EFO_0000702', 'MONDO_0018076', 'MONDO_0004975', 'HP_0012115', 'HP_0002014', 'EFO_0005952', 'MONDO_0021094', 'EFO_0000763', 'MONDO_0004976', 'EFO_0000765', 'EFO_0000182', 'EFO_0000180', 'EFO_0000764', 'EFO_0001422', 'EFO_0000544', 'EFO_0004197', 'EFO_0000574', 'MP_0001845', 'EFO_0007313']",False,False,22,Human immunodeficiency virus type 1 reverse transcriptase inhibitor DNA polymerase/reverse transcriptase inhibitor ,INHIBITOR ,single protein 
2084,BEDORADRINE,CHEMBL2111083,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000169252'],"['MONDO_0004979', 'EFO_0000341', 'EFO_0008590']",False,False,3,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
2085,LENIOLISIB PHOSPHATE,CHEMBL3989909,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0015517', 'EFO_0000699']",False,False,2,,,
2086,CAVOSONSTAT,CHEMBL3989910,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000197894'],"['MONDO_0009061', 'MONDO_0004979', 'EFO_0000341']",False,False,3,Alcohol dehydrogenase class III inhibitor ,INHIBITOR ,single protein 
2087,ZOTATIFIN,CHEMBL4303782,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000616']",False,False,2,,,
2088,PHENELZINE,CHEMBL1089,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and has 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1961,"['ENSG00000189221', 'ENSG00000069535']","['EFO_0003761', 'EFO_0000673', 'MONDO_0007254']",True,False,3,Monoamine oxidase inhibitor ,INHIBITOR ,protein family 
2089,BICARBONATE,CHEMBL1161632,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['HP_0000083', 'EFO_0003843', 'EFO_0003884', 'MONDO_0009061']",False,False,4,,,
2090,METHOXYAMINE,CHEMBL1213633,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000519', 'EFO_0000616', 'EFO_0000571', 'EFO_0003050']",False,False,4,,,
2091,HOKT3,CHEMBL2109253,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000198851'],"['EFO_0003778', 'MONDO_0005147']",False,False,2,T-cell surface glycoprotein CD3 epsilon chain inhibitor ,INHIBITOR ,single protein 
2092,TAREXTUMAB,CHEMBL3301588,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,"['ENSG00000074181', 'ENSG00000134250']","['EFO_0000702', 'EFO_0002618', 'EFO_0000616']",False,False,3,Neurogenic locus notch homolog protein 2 inhibitor Neurogenic locus notch homolog protein 3 inhibitor ,INHIBITOR ,single protein 
2093,PBF-680,CHEMBL3545162,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000163485'],"['MONDO_0004979', 'EFO_0000341']",False,True,2,Adenosine A1 receptor antagonist ,ANTAGONIST ,single protein 
2094,IXAZOMIB CITRATE,CHEMBL3545432,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 12 investigational indications.,,4.0,,False,2015,"['ENSG00000173692', 'ENSG00000126067', 'ENSG00000008018', 'ENSG00000100804', 'ENSG00000204264', 'ENSG00000240065', 'ENSG00000142507', 'ENSG00000115233', 'ENSG00000129084', 'ENSG00000106588', 'ENSG00000100567', 'ENSG00000041357', 'ENSG00000143106', 'ENSG00000100902', 'ENSG00000101182', 'ENSG00000154611', 'ENSG00000205220', 'ENSG00000222028', 'ENSG00000277791', 'ENSG00000159377', 'ENSG00000136930', 'ENSG00000130706', 'ENSG00000161057', 'ENSG00000100764', 'ENSG00000013275', 'ENSG00000100519', 'ENSG00000165916', 'ENSG00000087191', 'ENSG00000175166', 'ENSG00000108344', 'ENSG00000197170', 'ENSG00000108671', 'ENSG00000163636', 'ENSG00000103035', 'ENSG00000185627', 'ENSG00000159352', 'ENSG00000099341', 'ENSG00000127922']","['EFO_0000220', 'MONDO_0019438', 'EFO_0009441', 'EFO_0001378', 'EFO_0000222', 'EFO_0000558', 'EFO_0000574', 'MONDO_0004992', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000519', 'MONDO_0000873', 'EFO_1001469', 'EFO_0006475', 'EFO_0000616']",True,False,15,26S proteosome inhibitor ,INHIBITOR ,protein complex 
2095,DIFELIKEFALIN,CHEMBL3989915,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pruritus and chronic kidney disease and has 2 investigational indications.,,4.0,,False,2021,['ENSG00000082556'],"['HP_0000989', 'EFO_0003884', 'EFO_0003843', 'MONDO_0005178']",False,False,4,Kappa opioid receptor agonist ,AGONIST ,single protein 
2096,ROVALPITUZUMAB TESIRINE,CHEMBL3990011,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000090932'],"['MONDO_0004992', 'EFO_0000616', 'EFO_0000702']",True,False,3,Delta-like protein 3 binding agent ,BINDING AGENT ,single protein 
2097,BOMEDEMSTAT,CHEMBL4297289,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000004487'],"['EFO_0000222', 'EFO_0000479', 'EFO_0000198', 'EFO_0000702']",False,False,4,Lysine-specific histone demethylase 1 inhibitor ,INHIBITOR ,single protein 
2098,DARIDOREXANT,CHEMBL4297590,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for insomnia and has 5 investigational indications.,,4.0,,False,2022,"['ENSG00000137252', 'ENSG00000121764']","['EFO_0001421', 'EFO_0004698', 'HP_0000083', 'EFO_0000341', 'EFO_0004698', 'EFO_0003918']",False,False,6,Orexin receptor 2 antagonist Orexin receptor 1 antagonist Orexin receptor antagonist ,ANTAGONIST ,single protein protein family 
2099,NYSTATIN,CHEMBL450895,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for infection and candidiasis and has 18 investigational indications.,,4.0,,False,1964,[],"['EFO_0003768', 'EFO_0009516', 'EFO_0000565', 'EFO_0000544', 'EFO_1001904', 'EFO_0001378', 'EFO_0003819', 'EFO_0003033', 'EFO_0003106', 'EFO_0000198', 'EFO_0003086', 'EFO_0002428', 'EFO_0009688', 'EFO_1000893', 'EFO_0007406', 'MONDO_0013730', 'EFO_0000764', 'EFO_0003932', 'EFO_0000180', 'MONDO_0002026']",False,False,20,,,
2100,GOLCADOMIDE,CHEMBL5095226,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0018906', 'EFO_0005952', 'EFO_0000574', 'EFO_0000403']",False,False,4,,,
2101,CILOMILAST,CHEMBL511115,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,"['ENSG00000065989', 'ENSG00000113448', 'ENSG00000184588', 'ENSG00000105650']",['EFO_0000341'],True,False,1,Phosphodiesterase 4 inhibitor ,INHIBITOR ,protein family 
2102,PEGFILGRASTIM,CHEMBL1201568,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 56 investigational indications.,,4.0,,False,2002,['ENSG00000119535'],"['EFO_0000183', 'EFO_0000544', 'MONDO_0001657', 'EFO_0003859', 'MONDO_0004192', 'EFO_0000756', 'EFO_0000621', 'EFO_0006861', 'MONDO_0004643', 'EFO_0000305', 'EFO_0000096', 'MONDO_0018906', 'EFO_0000222', 'EFO_0001378', 'EFO_0005537', 'EFO_0006859', 'EFO_0000198', 'MONDO_0002087', 'MONDO_0001056', 'MONDO_0008380', 'EFO_0004252', 'EFO_1001469', 'EFO_0000691', 'EFO_0003060', 'MONDO_0001187', 'EFO_0002939', 'EFO_1001951', 'EFO_1000657', 'EFO_0003869', 'EFO_0002913', 'EFO_0000574', 'EFO_0000211', 'EFO_0000702', 'EFO_0008528', 'MONDO_0008315', 'EFO_0000403', 'MONDO_0002158', 'EFO_0000514', 'MONDO_0005147', 'MONDO_0009348', 'MONDO_0002974', 'MONDO_0008170', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000616', 'EFO_0000220', 'MONDO_0008903', 'EFO_0001642', 'MONDO_0021063', 'MONDO_0006058', 'EFO_0005952', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0000637', 'EFO_0000571', 'EFO_0000181', 'MONDO_0007254', 'MONDO_0001475', 'EFO_0000681', 'HP_0001915']",False,False,60,Granulocyte colony stimulating factor receptor agonist ,AGONIST ,single protein 
2103,RITUXIMAB,CHEMBL1201576,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 11 approved and 126 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1997,['ENSG00000156738'],"['MONDO_0002334', 'EFO_0009441', 'EFO_0000309', 'EFO_0003032', 'MONDO_0018906', 'EFO_1000784', 'Orphanet_365', 'EFO_0007187', 'EFO_0004991', 'MONDO_0007915', 'EFO_0003840', 'EFO_0000191', 'EFO_0000403', 'EFO_0009538', 'EFO_0000707', 'EFO_0004244', 'EFO_0002617', 'EFO_0004540', 'MONDO_0010602', 'EFO_0000209', 'EFO_0000685', 'EFO_1000783', 'MONDO_0011382', 'MONDO_0002462', 'EFO_1001264', 'MONDO_0019391', 'MONDO_0001437', 'EFO_0000096', 'EFO_0003884', 'EFO_0000198', 'EFO_0004236', 'EFO_0003898', 'HP_0000093', 'EFO_1001469', 'EFO_0000339', 'EFO_0004288', 'MONDO_0044881', 'EFO_0007316', 'MONDO_0005090', 'EFO_0003144', 'MONDO_0000873', 'EFO_0000095', 'EFO_0003929', 'EFO_0004254', 'MONDO_0019338', 'EFO_0000621', 'EFO_0008522', 'MONDO_0017719', 'HP_0001871', 'EFO_0000772', 'EFO_1000956', 'EFO_0000729', 'EFO_0004256', 'EFO_0007332', 'EFO_0000540', 'EFO_0003086', 'EFO_1000749', 'EFO_0009562', 'EFO_0003778', 'EFO_0005297', 'EFO_0000389', 'MONDO_0021117', 'EFO_0002689', 'MONDO_0013730', 'EFO_0008610', 'EFO_0005761', 'EFO_0003780', 'EFO_0005140', 'EFO_0004255', 'EFO_0004719', 'MONDO_0000432', 'EFO_0004826', 'EFO_0000255', 'EFO_0000183', 'EFO_0006803', 'MONDO_0001718', 'MONDO_0004095', 'EFO_0004145', 'MONDO_0015760', 'EFO_0004289', 'EFO_0000616', 'EFO_1000131', 'MONDO_0000870', 'EFO_0006803', 'MONDO_0004992', 'MONDO_0015564', 'HP_0001915', 'EFO_1001051', 'MONDO_0016537', 'EFO_0003100', 'MONDO_0005147', 'EFO_0004599', 'EFO_0005531', 'MONDO_0005180', 'MONDO_0008315', 'MONDO_0018904', 'EFO_1001486', 'MONDO_0009348', 'EFO_0007160', 'MONDO_0018896', 'HP_0002196', 'EFO_0007498', 'MONDO_0017276', 'EFO_0003860', 'EFO_1000318', 'EFO_0005952', 'EFO_0001378', 'EFO_1000630', 'EFO_0000574', 'EFO_0000717', 'MONDO_0044917', 'EFO_0003897', 'EFO_0000220', 'EFO_0000557', 'EFO_0000699', 'MONDO_0001023', 'EFO_0000094', 'EFO_0000384', 'EFO_0009606', 'EFO_0003869', 'EFO_0001423', 'EFO_1002048', 'EFO_0000565', 'EFO_0007359', 'EFO_1001779', 'EFO_0007208', 'EFO_1001383', 'EFO_1000868', 'EFO_0001642', 'MONDO_0005301', 'EFO_0008520', 'MONDO_0001549', 'EFO_0000222', 'EFO_0000765', 'EFO_0000768', 'EFO_1001365', 'EFO_1001466']",True,False,137,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
2104,AZTREONAM,CHEMBL158,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 6 investigational indications.,,4.0,,False,1986,[],"['HP_0100806', 'HP_0000083', 'EFO_0003106', 'DOID_7551', 'EFO_0000701', 'EFO_0000771', 'EFO_0003103', 'EFO_0000544', 'EFO_1001141', 'EFO_0003102', 'EFO_1001313', 'MONDO_0009061', 'HP_0002110']",False,False,13,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
2105,INCLACUMAB,CHEMBL2109488,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000174175'],"['EFO_0000612', 'EFO_0004265', 'EFO_0001645']",False,False,3,P-selectin antagonist ,ANTAGONIST ,single protein 
2106,CILGAVIMAB,CHEMBL4650258,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
2107,AMANTADINE,CHEMBL660,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 19 investigational indications.,,4.0,,False,1968,"['ENSG00000176884', 'ENSG00000183454', 'ENSG00000273079', 'ENSG00000105464', 'ENSG00000116032', 'ENSG00000161509', 'ENSG00000198785']","['EFO_0003843', 'MONDO_0005090', 'EFO_0000712', 'EFO_0002610', 'MONDO_0002679', 'EFO_0003047', 'MONDO_0005301', 'EFO_0007328', 'MONDO_0005090', 'EFO_0000544', 'EFO_1001402', 'EFO_0003888', 'MONDO_0005180', 'MONDO_0043510', 'EFO_0005411', 'MONDO_0005301', 'MONDO_0005148', 'EFO_0004220', 'EFO_0000544', 'EFO_1001175', 'EFO_0004247', 'HP_0001300', 'MONDO_0100096', 'EFO_0007328', 'EFO_1000860', 'MONDO_0043510', 'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411']",False,False,29,Glutamate [NMDA] receptor antagonist Matrix protein 2 inhibitor ,ANTAGONIST INHIBITOR ,protein complex group single protein 
2108,ICATIBANT,CHEMBL2028850,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hereditary angioedema and angioedema and has 7 investigational indications.,,4.0,,False,2011,['ENSG00000168398'],"['EFO_0000694', 'MONDO_0044970', 'EFO_1000999', 'MONDO_0019623', 'MONDO_0100096', 'MONDO_0100096', 'MONDO_0019623', 'EFO_0005532', 'MP_0001845', 'EFO_0003144', 'EFO_0005532']",False,False,11,Bradykinin B2 receptor antagonist ,ANTAGONIST ,single protein 
2109,FLUOROMISONIDAZOLE,CHEMBL2068841,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0003060', 'MONDO_0007576']",False,False,2,,,
2110,TELAPRISTONE ACETATE,CHEMBL2105694,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000082175'],"['EFO_0001421', 'MONDO_0007254', 'EFO_0001065', 'EFO_0003086', 'EFO_0000731', 'EFO_0010269']",False,False,6,Progesterone receptor modulator ,MODULATOR ,single protein 
2111,LENVATINIB MESYLATE,CHEMBL2105704,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 7 investigational indications.,,4.0,,False,2015,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['EFO_1001961', 'MONDO_0004992', 'EFO_0000313', 'EFO_0003060', 'EFO_0002892', 'EFO_0000681', 'MONDO_0002108', 'EFO_0002517', 'EFO_0002617', 'EFO_0000616']",False,False,10,Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,protein family 
2112,LEVOFLOXACIN,CHEMBL33,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 11 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,[],"['EFO_0003830', 'EFO_0000341', 'EFO_0003894', 'MONDO_0000565', 'EFO_0000544', 'HP_0001945', 'EFO_0007381', 'EFO_0007486', 'MONDO_0019338', 'EFO_0006505', 'MONDO_0018076', 'EFO_1001888', 'EFO_0009449', 'EFO_1001141', 'EFO_0007328', 'EFO_0000701', 'EFO_0000284', 'EFO_0000764', 'EFO_0003102', 'EFO_0007361', 'EFO_0008533', 'EFO_0003035', 'EFO_1001318', 'MONDO_0004992', 'EFO_1000961', 'MONDO_0016047', 'EFO_0009560', 'HP_0031217', 'EFO_0005681', 'MONDO_0001475', 'EFO_0003086', 'EFO_1001459', 'EFO_1001272', 'EFO_1001388', 'MONDO_0005129', 'EFO_0003106', 'EFO_0004992', 'EFO_0000771', 'EFO_0003103', 'EFO_1000781', 'EFO_1000829', 'MONDO_0009061', 'MONDO_0100096', 'EFO_0005952', 'EFO_0007149']",False,False,45,DNA gyrase inhibitor Topoisomerase IV inhibitor ,INHIBITOR ,protein complex 
2113,CONTELTINIB ,CHEMBL3899477,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,"['ENSG00000169398', 'ENSG00000140443', 'ENSG00000171094', 'ENSG00000120899']",['EFO_0003060'],False,False,1,ALK tyrosine kinase receptor inhibitor Focal adhesion kinase 1 inhibitor Insulin-like growth factor I receptor inhibitor Protein tyrosine kinase 2 beta inhibitor ,INHIBITOR ,single protein 
2114,VATALANIB,CHEMBL101253,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.,,3.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000113721', 'ENSG00000134853', 'ENSG00000182578', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052']","['MONDO_0008667', 'EFO_0002618', 'MONDO_0002087', 'EFO_0001378', 'EFO_1000158', 'EFO_0000588', 'EFO_1000657', 'MONDO_0011962', 'MONDO_0002367', 'EFO_0002430', 'EFO_0004288', 'EFO_0000691', 'EFO_0000519', 'EFO_0000339', 'EFO_0000222', 'MONDO_0002974', 'EFO_0000403', 'EFO_0000389', 'EFO_0000756', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0003869', 'EFO_0009708', 'EFO_0000616', 'MONDO_0008315', 'EFO_0003060', 'MONDO_0002158', 'EFO_1001901', 'EFO_0001365', 'MONDO_0004992']",True,False,30,Platelet-derived growth factor receptor inhibitor Stem cell growth factor receptor inhibitor Vascular endothelial growth factor receptor inhibitor Macrophage colony stimulating factor receptor inhibitor ,INHIBITOR ,protein complex single protein protein family 
2115,GIMATECAN,CHEMBL113051,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000198900'],"['EFO_0000702', 'EFO_1000158', 'EFO_0000198', 'EFO_0002618', 'EFO_0000616']",False,False,5,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
2116,ACYCLOVIR SODIUM,CHEMBL1200380,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for genital herpes and has 14 investigational indications.,,4.0,,False,1982,[],"['EFO_1001347', 'MONDO_0005301', 'EFO_0001062', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0000764', 'EFO_0000403', 'EFO_0003060', 'EFO_0003086', 'EFO_1002022', 'EFO_0006862', 'EFO_0000094', 'EFO_0007308', 'EFO_0007282', 'EFO_0000544']",False,False,15,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
2117,TROMETHAMINE,CHEMBL1200391,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for acidosis and has 7 investigational indications.,,4.0,,False,1965,[],"['EFO_0001068', 'MONDO_0004992', 'MONDO_0005129', 'MONDO_0009061', 'EFO_1000014', 'EFO_0000616', 'EFO_0003103', 'EFO_0003843']",False,False,8,,,
2118,DAUNORUBICIN CITRATE,CHEMBL1200475,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000131747'],"['MONDO_0007254', 'EFO_0000691', 'EFO_0000565']",False,False,3,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
2119,INOSITOL,CHEMBL1222251,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000660', 'MONDO_0018075', 'EFO_0000195', 'MONDO_0004975', 'EFO_1001158', 'MP_0001914', 'HP_0012167', 'MONDO_0005147', 'EFO_0003060', 'MONDO_0008903']",False,False,10,,,
2120,LISINOPRIL,CHEMBL1237,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,['ENSG00000159640'],"['EFO_0003144', 'EFO_0003896', 'EFO_0000279', 'EFO_0000319', 'HP_0003124', 'EFO_0004264', 'EFO_0000537', 'EFO_0000400', 'EFO_0000574', 'EFO_1000948', 'EFO_0000373', 'MONDO_0007915', 'EFO_0000612', 'MONDO_0002474', 'EFO_0004236', 'EFO_0000712', 'MONDO_0001134', 'EFO_0000537', 'EFO_0000612', 'MONDO_0002462', 'Orphanet_79292', 'EFO_0000712', 'EFO_0000401', 'EFO_0008620', 'EFO_0000400', 'MONDO_0007254', 'EFO_0000319', 'EFO_0000182', 'EFO_0001645', 'EFO_0003914', 'EFO_1001249', 'EFO_1001375', 'MONDO_0005148', 'EFO_0000373', 'EFO_0003144']",True,False,35,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
2121,PAPAVERINE,CHEMBL19224,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and erectile dysfunction and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0008315', 'EFO_0003060', 'EFO_0010282', 'EFO_0004234', 'EFO_0003060', 'EFO_1001463', 'EFO_0000284']",False,False,7,,,
2122,YTTRIUM Y 90 IBRITUMOMAB TIUXETAN,CHEMBL2108667,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 17 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2002,['ENSG00000156738'],"['MONDO_0013730', 'EFO_0000183', 'EFO_0001378', 'EFO_0003032', 'EFO_0000191', 'EFO_1001365', 'EFO_0009441', 'EFO_0000403', 'EFO_0000565', 'EFO_0000309', 'EFO_1001469', 'MONDO_0000873', 'EFO_0000574', 'EFO_0000095', 'EFO_0005952', 'EFO_0000096', 'MONDO_0018906']",False,False,17,B-lymphocyte antigen CD20 binding agent ,BINDING AGENT ,single protein 
2123,TG100-115,CHEMBL230011,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000105851', 'ENSG00000171608']",['EFO_0000612'],True,False,1,PI3-kinase p110-gamma subunit inhibitor PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
2124,SACUBITRIL,CHEMBL3137301,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for congestive heart failure and heart failure and has 11 investigational indications.,,4.0,,False,2015,['ENSG00000196549'],"['EFO_0000537', 'EFO_0007148', 'EFO_0008583', 'EFO_0000612', 'MONDO_0001134', 'EFO_0004265', 'MONDO_0005149', 'EFO_0000538', 'MONDO_0100096', 'EFO_0000373', 'EFO_0003144', 'EFO_0008585', 'EFO_0005529']",False,False,13,Neprilysin inhibitor ,INHIBITOR ,single protein 
2125,DEGARELIX,CHEMBL415606,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 12 investigational indications.,,4.0,,False,2008,['ENSG00000109163'],"['EFO_0006861', 'MONDO_0021259', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000673', 'EFO_0000228', 'EFO_0000284', 'EFO_0001065', 'MONDO_0100096', 'EFO_0001663', 'EFO_0000196', 'EFO_0000673', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000545']",False,False,16,Gonadotropin-releasing hormone receptor antagonist ,ANTAGONIST ,single protein 
2126,ALFLUTINIB,CHEMBL4297258,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,['ENSG00000146648'],"['MONDO_0008903', 'EFO_0000571', 'EFO_0003060']",False,True,3,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
2127,DAZCAPISTAT,CHEMBL5095225,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0006890', 'EFO_0000768']",False,False,3,,,
2128,BOSEROLIMAB,CHEMBL5095364,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000702', 'EFO_0003060', 'EFO_0003869']",False,False,3,,,
2129,WARFARIN SODIUM,CHEMBL1200879,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 7 approved and 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1954,['ENSG00000167397'],"['EFO_0000712', 'HP_0004936', 'EFO_0003907', 'EFO_0000275', 'EFO_0000612', 'EFO_0000685', 'EFO_0003827', 'HP_0001907', 'EFO_0004239']",True,False,9,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor ,INHIBITOR ,single protein 
2130,PRALATREXATE,CHEMBL1201746,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 14 investigational indications.,,4.0,,False,2009,['ENSG00000228716'],"['EFO_0001378', 'MONDO_0000430', 'EFO_0002913', 'EFO_1000785', 'MONDO_0015760', 'MONDO_0002158', 'MONDO_0008903', 'MONDO_0002087', 'EFO_0000574', 'EFO_0000305', 'EFO_0003060', 'EFO_0000616', 'MONDO_0008170', 'EFO_0003032', 'EFO_0006859', 'MONDO_0019471', 'EFO_0000211', 'MONDO_0004992', 'EFO_1001051']",False,False,19,Dihydrofolate reductase inhibitor ,INHIBITOR ,single protein 
2131,PERAMIVIR,CHEMBL139367,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for influenza and viral disease and has 1 investigational indication.,,4.0,,False,2014,[],"['EFO_0007328', 'EFO_0007328', 'EFO_0000763']",False,False,3,Neuraminidase inhibitor ,INHIBITOR ,single protein 
2132,EMRICASAN,CHEMBL197672,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.,,2.0,,False,no approval year,"['ENSG00000196954', 'ENSG00000132906', 'ENSG00000164305', 'ENSG00000137757', 'ENSG00000138794', 'ENSG00000165806', 'ENSG00000064012', 'ENSG00000137752', 'ENSG00000106144', 'ENSG00000003400', 'ENSG00000105141', 'ENSG00000204403']","['EFO_0010282', 'EFO_0000400', 'MONDO_0100096', 'EFO_1001249', 'EFO_0001422', 'EFO_0004220', 'EFO_0001421', 'EFO_1001345']",True,False,8,Caspase inhibitor ,INHIBITOR ,protein family 
2133,DACLATASVIR,CHEMBL2023898,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for viral disease and chronic hepatitis c virus infection and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2015,[],"['MONDO_0100096', 'EFO_0004197', 'EFO_0000763', 'EFO_0004220', 'EFO_0003047', 'EFO_0000544', 'EFO_0000694', 'EFO_0004220', 'EFO_0003884']",False,False,9,Nonstructural protein 5A inhibitor ,INHIBITOR ,single protein 
2134,DINACICLIB,CHEMBL2103840,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,"['ENSG00000170312', 'ENSG00000164885', 'ENSG00000136807', 'ENSG00000123374']","['EFO_0006861', 'EFO_0000756', 'EFO_0000222', 'EFO_0000616', 'EFO_0000095', 'MONDO_0001023', 'MONDO_0007254', 'EFO_0001378', 'EFO_0000220']",False,False,9,Cyclin-dependent kinase 2 inhibitor Cyclin-dependent kinase 1 inhibitor Cyclin-dependent kinase 5 inhibitor Cyclin-dependent kinase 9 inhibitor ,INHIBITOR ,single protein 
2135,STARCH,CHEMBL2108866,Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) and has 15 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000537', 'EFO_0000676', 'EFO_0001074', 'EFO_0003931', 'EFO_0008572', 'EFO_0000545', 'MONDO_0100096', 'HP_0002014', 'EFO_0005279', 'MP_0001914', 'EFO_0000616', 'EFO_0001073', 'EFO_0000555', 'EFO_0000713', 'EFO_0009314']",False,False,15,,,
2136,VINTAFOLIDE,CHEMBL3039521,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000110195'],"['EFO_0000571', 'EFO_0000616', 'EFO_0003869', 'MONDO_0004992', 'EFO_0003060', 'MONDO_0008170']",True,False,6,Folate receptor alpha binding agent ,BINDING AGENT ,single protein 
2137,SELINEXOR,CHEMBL3545185,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 38 investigational indications.,,4.0,,False,2019,['ENSG00000082898'],"['EFO_0000702', 'EFO_0000574', 'MONDO_0008315', 'EFO_1000581', 'EFO_0000182', 'MONDO_0011962', 'EFO_0000681', 'EFO_0000708', 'EFO_0000616', 'EFO_0003085', 'EFO_0007143', 'EFO_0001642', 'EFO_1000251', 'EFO_0000519', 'EFO_0000211', 'EFO_0000305', 'EFO_0003060', 'EFO_0001378', 'EFO_0000339', 'EFO_0000096', 'EFO_0001075', 'EFO_0000389', 'MONDO_0019460', 'MONDO_0007254', 'MONDO_0100096', 'EFO_1001968', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000220', 'MONDO_0044903', 'EFO_0002617', 'EFO_0004142', 'EFO_0000403', 'EFO_1000657', 'EFO_0000691', 'EFO_0000756', 'MONDO_0019438', 'EFO_0000222', 'EFO_0008528', 'EFO_1001459', 'EFO_1001465', 'EFO_0000707']",True,False,42,Exportin-1 inhibitor ,INHIBITOR ,single protein 
2138,AMIVANTAMAB,CHEMBL4297774,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for neoplasm and non-small cell lung carcinoma and has 2 investigational indications.,,4.0,,False,2021,"['ENSG00000105976', 'ENSG00000146648']","['EFO_0000616', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0004669']",False,True,4,Hepatocyte growth factor receptor inhibitor Epidermal growth factor receptor inhibitor ,INHIBITOR ,single protein 
2139,THALIDOMIDE,CHEMBL468,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for multiple myeloma and immune system disease and has 85 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,"['ENSG00000113851', 'ENSG00000167986', 'ENSG00000139842', 'ENSG00000100387']","['EFO_0000519', 'EFO_0005543', 'EFO_0000403', 'EFO_1000613', 'EFO_0004142', 'EFO_1000158', 'EFO_0000191', 'EFO_0003060', 'MONDO_0044903', 'MONDO_0002158', 'EFO_0003843', 'MONDO_0008170', 'EFO_0001065', 'EFO_0006888', 'EFO_0000676', 'MONDO_0002087', 'MONDO_0018364', 'EFO_0000389', 'MONDO_0004975', 'EFO_0000182', 'MONDO_0019472', 'EFO_0000096', 'MONDO_0015564', 'MONDO_0017816', 'EFO_0004268', 'EFO_0000474', 'EFO_0000681', 'EFO_0002430', 'MONDO_0003196', 'EFO_0002939', 'EFO_1001767', 'MONDO_0019438', 'HP_0003073', 'EFO_0000717', 'EFO_0006859', 'MONDO_0002367', 'EFO_0000095', 'EFO_0000765', 'EFO_0005628', 'EFO_0000756', 'EFO_0009441', 'EFO_1001875', 'MONDO_0004992', 'HP_0012735', 'EFO_0000621', 'EFO_0000673', 'MONDO_0018906', 'EFO_1001951', 'EFO_1001996', 'EFO_1001968', 'EFO_0000384', 'EFO_0000729', 'EFO_0001378', 'EFO_0000574', 'MONDO_0008903', 'EFO_0000691', 'EFO_0000764', 'MONDO_0019338', 'MONDO_0021063', 'EFO_0005952', 'EFO_0000540', 'MONDO_0100096', 'MONDO_0001056', 'EFO_0000198', 'MONDO_0007254', 'EFO_0005570', 'EFO_0003898', 'EFO_0000565', 'Orphanet_848', 'EFO_0000183', 'EFO_0000616', 'EFO_0007160', 'EFO_1001901', 'EFO_0007312', 'EFO_0000365', 'MONDO_0004976', 'EFO_0000342', 'EFO_1000045', 'EFO_1000318', 'EFO_0003865', 'EFO_0000768', 'MONDO_0019558', 'MONDO_0002691', 'EFO_1001469', 'MONDO_0007576', 'EFO_0003047', 'MONDO_0008315']",True,False,87,CRL4(CRBN) E3 ubiquitin ligase inhibitor ,INHIBITOR ,protein complex 
2140,BEMNIFOSBUVIR,CHEMBL5095404,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0004220', 'MONDO_0100096']",False,False,2,,,
2141,FLUTEMETAMOL,CHEMBL579205,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for alzheimer disease and cognitive impairment and has 2 investigational indications.,,4.0,,False,2013,[],"['MONDO_0004975', 'MONDO_0004975', 'HP_0100543', 'EFO_0000318']",False,False,4,,,
2142,GEMCITABINE,CHEMBL888,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 129 investigational indications.,,4.0,,False,1996,"['ENSG00000101868', 'ENSG00000175482', 'ENSG00000077514', 'ENSG00000062822', 'ENSG00000106628', 'ENSG00000177084', 'ENSG00000014138', 'ENSG00000198056', 'ENSG00000146143', 'ENSG00000100479', 'ENSG00000148229', 'ENSG00000167325', 'ENSG00000048392', 'ENSG00000171848']","['MONDO_0001657', 'MONDO_0019472', 'EFO_0000255', 'EFO_0000707', 'EFO_0000681', 'EFO_0006859', 'MONDO_0002367', 'EFO_0000183', 'MONDO_0015760', 'EFO_0001075', 'MONDO_0005575', 'MONDO_0004192', 'EFO_0006861', 'EFO_0000305', 'EFO_0006738', 'MONDO_0001187', 'EFO_0001061', 'MONDO_0005411', 'MONDO_0018906', 'MONDO_0002158', 'MONDO_0004986', 'EFO_0009708', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0002367', 'EFO_0000565', 'MONDO_0000430', 'EFO_0002517', 'MONDO_0001187', 'EFO_0002618', 'EFO_0002913', 'EFO_1001469', 'MONDO_0008627', 'EFO_0001075', 'MONDO_0001056', 'EFO_0000222', 'EFO_1000613', 'MONDO_0004992', 'MONDO_0002087', 'EFO_0009534', 'EFO_0000681', 'MONDO_0011719', 'EFO_1000043', 'EFO_0000096', 'EFO_0003869', 'EFO_0003893', 'MONDO_0008315', 'EFO_0001376', 'MONDO_0011962', 'MONDO_0002087', 'EFO_1001956', 'EFO_0005230', 'MONDO_0016537', 'MONDO_0021054', 'EFO_0000403', 'EFO_0003891', 'MONDO_0001056', 'EFO_0000756', 'EFO_0000637', 'EFO_0000564', 'EFO_0008528', 'EFO_0000181', 'EFO_0000691', 'EFO_0000770', 'EFO_0002517', 'MONDO_0007254', 'EFO_0000182', 'EFO_1001959', 'EFO_0005537', 'EFO_0005088', 'EFO_0010282', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000294', 'EFO_0006859', 'EFO_0000313', 'EFO_0000571', 'EFO_1000026', 'MONDO_0003060', 'EFO_0006475', 'EFO_0000220', 'EFO_0000702', 'EFO_0003060', 'EFO_0003859', 'EFO_0003050', 'MONDO_0021117', 'EFO_0000228', 'EFO_0000174', 'MONDO_0011962', 'EFO_1000251', 'EFO_1001951', 'EFO_1000292', 'MONDO_0002108', 'MONDO_0003059', 'EFO_0003863', 'EFO_1001961', 'EFO_0000588', 'EFO_0005952', 'MONDO_0021063', 'MONDO_0002691', 'MONDO_0015760', 'MONDO_0018364', 'EFO_0000305', 'MONDO_0008903', 'EFO_0005537', 'EFO_0002939', 'HP_0001907', 'EFO_0000466', 'EFO_1001051', 'EFO_1000657', 'EFO_0008528', 'EFO_0000365', 'EFO_0004606', 'EFO_1000251', 'MONDO_0008315', 'EFO_0003060', 'EFO_1001100', 'EFO_1001968', 'MONDO_0005411', 'EFO_0000183', 'Orphanet_145', 'EFO_0000574', 'EFO_0003032', 'MONDO_0004192', 'EFO_0000616', 'EFO_0004252', 'EFO_0000313', 'EFO_0005221', 'EFO_0000565', 'EFO_0003860', 'EFO_0000211', 'EFO_0000691', 'EFO_0000096', 'MONDO_0019471', 'MONDO_0004986', 'EFO_0004252', 'MONDO_0002158', 'MONDO_0008170', 'MONDO_0007576', 'EFO_0000514', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000574', 'EFO_0001416', 'EFO_1001469', 'MONDO_0009348', 'EFO_0000708', 'EFO_1001961', 'EFO_0000588', 'MONDO_0002974', 'EFO_0001378', 'MONDO_0008903', 'MONDO_0002691']",True,True,155,DNA polymerase (alpha/delta/epsilon) inhibitor Ribonucleoside-diphosphate reductase RR1 inhibitor ,INHIBITOR ,protein family protein complex group 
2143,CYCLOPHOSPHAMIDE,CHEMBL1200796,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 10 approved and 237 investigational indications.,,4.0,,False,1959,[],"['MONDO_0019391', 'EFO_0003884', 'EFO_0008498', 'EFO_0002087', 'EFO_0001642', 'EFO_1001779', 'MONDO_0009348', 'HP_0002721', 'EFO_0003032', 'EFO_0003811', 'EFO_0004255', 'MONDO_0015760', 'EFO_1000026', 'EFO_1000292', 'EFO_0006475', 'EFO_0006861', 'EFO_0007147', 'MONDO_0008903', 'EFO_1000749', 'MONDO_0018076', 'EFO_1000309', 'EFO_0002939', 'EFO_0005761', 'MONDO_0000873', 'MONDO_0003060', 'MONDO_0005301', 'Orphanet_145', 'EFO_0009441', 'EFO_0002618', 'MONDO_0007576', 'EFO_0000637', 'MONDO_0011382', 'EFO_0000095', 'EFO_0000220', 'MONDO_0010006', 'EFO_0005561', 'EFO_0003025', 'MONDO_0009254', 'MONDO_0001718', 'EFO_0009259', 'EFO_0009448', 'MONDO_0000870', 'EFO_0004252', 'EFO_0000588', 'EFO_0003840', 'EFO_0006803', 'EFO_0009708', 'EFO_0000222', 'MONDO_0017198', 'EFO_0000309', 'EFO_0000181', 'MONDO_0010100', 'EFO_0002617', 'MONDO_0017816', 'HP_0001871', 'EFO_1001380', 'MONDO_0002380', 'EFO_0003802', 'EFO_0000691', 'EFO_0001376', 'MONDO_0044881', 'MONDO_0008380', 'EFO_0000764', 'MONDO_0019019', 'MONDO_0002691', 'EFO_0000223', 'MONDO_0037745', 'EFO_1000895', 'MONDO_0000432', 'EFO_0003869', 'MONDO_0002898', 'EFO_0000621', 'MONDO_0006058', 'EFO_0004826', 'EFO_0000305', 'EFO_1000158', 'MONDO_0004095', 'EFO_0004145', 'MONDO_0018906', 'MONDO_0020077', 'EFO_0005543', 'EFO_1001042', 'EFO_0000174', 'EFO_1000131', 'MONDO_0013730', 'MONDO_0019472', 'EFO_1000251', 'EFO_0000702', 'EFO_0000182', 'EFO_0000209', 'EFO_0000349', 'EFO_0000502', 'EFO_1000690', 'MONDO_0018149', 'EFO_0003833', 'MONDO_0018944', 'MONDO_0019148', 'MONDO_0019338', 'MONDO_0008315', 'EFO_0005803', 'MONDO_0001657', 'EFO_0002918', 'MONDO_0019438', 'MONDO_0044903', 'EFO_0006859', 'EFO_0003929', 'EFO_0000218', 'EFO_0005952', 'EFO_1002048', 'MONDO_0008978', 'EFO_0001378', 'EFO_0000765', 'EFO_0002430', 'EFO_1001469', 'EFO_0000384', 'EFO_0000221', 'EFO_1001471', 'MONDO_0001187', 'MONDO_0008170', 'EFO_0009709', 'EFO_0000389', 'EFO_0000613', 'EFO_0005537', 'EFO_0003027', 'EFO_0003922', 'EFO_1000965', 'MONDO_0016717', 'EFO_0000768', 'MONDO_0021063', 'MONDO_0002334', 'EFO_0003865', 'MONDO_0002108', 'EFO_0002517', 'EFO_0004719', 'EFO_1001968', 'EFO_0001075', 'EFO_0004272', 'EFO_1001996', 'EFO_0000574', 'MONDO_0024475', 'EFO_1001993', 'EFO_0000545', 'MONDO_0019262', 'MONDO_0004992', 'MONDO_0000159', 'EFO_0000183', 'EFO_0005235', 'MONDO_0018868', 'EFO_1001951', 'MONDO_0015277', 'MONDO_0016537', 'EFO_0005784', 'EFO_0000756', 'EFO_0003060', 'EFO_1000785', 'MONDO_0018544', 'EFO_0004991', 'EFO_0003780', 'EFO_0000339', 'MONDO_0015540', 'HP_0001873', 'EFO_1001465', 'HP_0001915', 'EFO_0000519', 'EFO_0000255', 'EFO_0007160', 'EFO_1000657', 'MONDO_0100342', 'MONDO_0003751', 'MONDO_0003478', 'MONDO_0001705', 'EFO_0000708', 'EFO_0005570', 'EFO_0005297', 'EFO_0000685', 'EFO_0000514', 'MONDO_0018271', 'MONDO_0002367', 'EFO_1000984', 'MONDO_0002087', 'EFO_0000540', 'EFO_0004194', 'EFO_0004254', 'EFO_0009538', 'EFO_0004256', 'EFO_0000191', 'EFO_0006738', 'EFO_0002428', 'EFO_0000616', 'MONDO_0015564', 'EFO_1001365', 'EFO_0000094', 'EFO_0000248', 'EFO_0000437', 'HP_0002017', 'MONDO_0001023', 'EFO_0000403', 'EFO_1000576', 'EFO_1000784', 'EFO_0000228', 'EFO_0007498', 'MONDO_0011962', 'MONDO_0018305', 'EFO_0000717', 'EFO_0000096', 'MONDO_0016700', 'MONDO_0019471', 'EFO_1001857', 'EFO_0000707', 'EFO_0008528', 'MONDO_0009499', 'EFO_1001051', 'EFO_0004281', 'MONDO_0000430', 'EFO_0004236', 'EFO_0000211', 'MONDO_0007254', 'EFO_1000318', 'EFO_0000326', 'EFO_1001901', 'MONDO_0019004', 'MONDO_0001475', 'EFO_1000028', 'EFO_1001875', 'EFO_0003893', 'EFO_0004251', 'MONDO_0007915', 'EFO_0003086', 'MONDO_0002974', 'EFO_0000198', 'MONDO_0018150', 'EFO_0000681', 'MONDO_0002158', 'EFO_1000581', 'EFO_0000569', 'EFO_0000565', 'EFO_0000196', 'EFO_0006911', 'EFO_0001061', 'EFO_0000673', 'EFO_0000199', 'EFO_0006927', 'EFO_0000770', 'EFO_0004289', 'MONDO_0004658', 'EFO_0000313', 'MONDO_0044917']",False,False,247,,,
2144,INFLIXIMAB,CHEMBL1201581,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 45 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1998,['ENSG00000232810'],"['HP_0012378', 'EFO_0003778', 'EFO_0007527', 'EFO_0003767', 'HP_0002039', 'EFO_1001209', 'MONDO_0005041', 'EFO_0003047', 'EFO_0007168', 'EFO_0000706', 'EFO_1000784', 'EFO_0000676', 'EFO_0000685', 'EFO_0000384', 'EFO_0007460', 'MONDO_0005178', 'EFO_0000198', 'EFO_0003780', 'EFO_0000729', 'EFO_0002617', 'MONDO_0008903', 'HP_0003419', 'EFO_0005297', 'EFO_0003872', 'MONDO_0001718', 'EFO_0008518', 'EFO_0001065', 'EFO_0000398', 'EFO_0000341', 'EFO_0004232', 'EFO_1000710', 'MONDO_0019338', 'MONDO_0005147', 'EFO_0003898', 'HP_0004326', 'EFO_0004683', 'EFO_0000540', 'EFO_0000783', 'EFO_0002687', 'EFO_0004599', 'EFO_0004246', 'EFO_0002609', 'MONDO_0004985', 'MONDO_0100096', 'MONDO_0013730', 'EFO_1000747', 'MONDO_0018305', 'EFO_1001857', 'EFO_0004276', 'EFO_0004775', 'EFO_0004220', 'EFO_1000749']",True,True,52,TNF-alpha inhibitor ,INHIBITOR ,single protein 
2145,ESTRADIOL,CHEMBL135,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 3 approved and 47 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1975,['ENSG00000091831'],"['EFO_0003103', 'EFO_0009314', 'MONDO_0005147', 'MONDO_0002146', 'MONDO_0005148', 'EFO_0001358', 'MONDO_0005301', 'HP_0031217', 'EFO_0005204', 'EFO_0000731', 'EFO_1000906', 'EFO_0000545', 'EFO_1000096', 'EFO_0003843', 'EFO_0000305', 'HP_0008209', 'EFO_0004714', 'EFO_0010269', 'HP_0030016', 'EFO_0005411', 'EFO_0004243', 'MONDO_0005351', 'EFO_1001249', 'EFO_1000859', 'EFO_1001375', 'MONDO_0007254', 'HP_0100607', 'EFO_0000764', 'MONDO_0002050', 'Orphanet_145', 'EFO_0001663', 'MONDO_0008315', 'MONDO_0005090', 'MONDO_0005277', 'MONDO_0001410', 'EFO_1001271', 'MONDO_0100096', 'EFO_0003882', 'EFO_0003922', 'EFO_0001065', 'EFO_0000180', 'EFO_0001073', 'EFO_0003914', 'EFO_0003869', 'EFO_0000660', 'HP_0000938', 'GO_0007568', 'MONDO_0004975', 'EFO_0007453', 'MONDO_0019499']",True,True,50,Estrogen receptor alpha agonist ,AGONIST ,single protein 
2146,CB-103,CHEMBL1420319,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000220', 'MONDO_0007254']",False,False,2,,,
2147,ALBUTEROL SULFATE,CHEMBL1441059,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1982,['ENSG00000169252'],"['EFO_0003818', 'MONDO_0100130', 'EFO_0000319', 'EFO_0000341', 'EFO_0008590', 'HP_0025428', 'MONDO_0004979']",False,False,7,Beta-2 adrenergic receptor agonist ,AGONIST ,single protein 
2148,ROSUVASTATIN,CHEMBL1496,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 81 investigational indications.,,4.0,,False,2003,['ENSG00000113161'],"['EFO_0003060', 'EFO_1001512', 'MONDO_0005147', 'EFO_1002048', 'EFO_0009516', 'EFO_0009426', 'MONDO_0008170', 'MONDO_0001583', 'EFO_0000400', 'EFO_0000384', 'EFO_0000668', 'EFO_0000319', 'EFO_0001645', 'EFO_0001645', 'EFO_0000195', 'HP_0003124', 'EFO_1001249', 'EFO_1001454', 'EFO_1001413', 'MONDO_0008315', 'EFO_0000537', 'EFO_0003914', 'EFO_0000373', 'EFO_0000556', 'EFO_0002617', 'MONDO_0005148', 'EFO_1000657', 'EFO_0000764', 'EFO_0003144', 'EFO_1001150', 'MONDO_0100339', 'EFO_0000712', 'EFO_0003047', 'EFO_0005672', 'EFO_0000540', 'EFO_0000729', 'EFO_0000589', 'EFO_0000400', 'EFO_0004211', 'MONDO_0018473', 'MONDO_0004979', 'MONDO_0004992', 'MONDO_0005180', 'MONDO_0019623', 'EFO_1001951', 'MONDO_0021187', 'EFO_0004272', 'MONDO_0007915', 'EFO_0004239', 'MONDO_0002050', 'MONDO_0021187', 'MONDO_0018328', 'EFO_0600064', 'EFO_0003144', 'EFO_0000180', 'EFO_0008583', 'EFO_0000649', 'EFO_0001068', 'EFO_0000266', 'MONDO_0018473', 'HP_0000083', 'EFO_0000685', 'EFO_1000049', 'Orphanet_309005', 'HP_0002140', 'EFO_0000537', 'EFO_0001073', 'EFO_0000701', 'EFO_0003964', 'EFO_0004211', 'EFO_0005226', 'EFO_0000673', 'EFO_0005669', 'Orphanet_309005', 'EFO_0005672', 'HP_0003124', 'EFO_0004286', 'MONDO_0100096', 'Orphanet_79211', 'EFO_0003914', 'EFO_0004911', 'HP_0100806', 'MONDO_0021661', 'EFO_0000717', 'EFO_0009505', 'EFO_0004911', 'EFO_0004826', 'EFO_0000407', 'MONDO_0005148', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000341']",True,False,92,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
2149,DANIRIXIN,CHEMBL3039531,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,['ENSG00000180871'],"['MONDO_0024355', 'EFO_0000341', 'EFO_1001413', 'EFO_0000763']",False,True,4,Interleukin-8 receptor B antagonist ,ANTAGONIST ,single protein 
2150,LY-2584702,CHEMBL3545076,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,['ENSG00000108443'],"['EFO_0000681', 'MONDO_0004992', 'EFO_0003060', 'EFO_1001901', 'EFO_0009708']",False,False,5,Ribosomal protein S6 kinase 1 inhibitor ,INHIBITOR ,single protein 
2151,METHYLDOPA,CHEMBL459,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for hypertension and has 2 investigational indications.,,4.0,,False,1962,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']","['EFO_0000668', 'EFO_0000537', 'MONDO_0005147']",False,False,3,Adrenergic receptor alpha-2 agonist ,AGONIST ,protein family 
2152,GT-0918,CHEMBL4594417,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000169083'],"['MONDO_0007254', 'MONDO_0100096', 'EFO_0000694', 'MONDO_0008315']",True,False,4,Androgen Receptor antagonist ,ANTAGONIST ,single protein 
2153,LINVOSELTAMAB,CHEMBL5095373,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003884', 'EFO_0001378']",False,False,2,,,
2154,FENTANYL,CHEMBL596,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 5 approved and 38 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1968,['ENSG00000112038'],"['EFO_0000546', 'EFO_0009870', 'HP_0003419', 'MONDO_0007254', 'MONDO_0004992', 'HP_0012532', 'EFO_0005762', 'EFO_0005611', 'EFO_0000713', 'EFO_0009267', 'EFO_0003931', 'EFO_0002618', 'EFO_0004209', 'HP_0003419', 'EFO_0003843', 'EFO_0000232', 'EFO_0003884', 'EFO_0003843', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0001056', 'EFO_0003030', 'EFO_1000637', 'EFO_0004273', 'EFO_0001421', 'EFO_0001074', 'EFO_0003918', 'MONDO_0100096', 'HP_0012532', 'EFO_1001139', 'MONDO_0043510', 'MONDO_0005178', 'EFO_1000783', 'HP_0025428', 'EFO_0009842', 'HP_0002093', 'EFO_0004244', 'EFO_0002950', 'EFO_0003843', 'EFO_0001073', 'EFO_0000555', 'MONDO_0005277', 'HP_0002094', 'EFO_1001267', 'EFO_0009727', 'EFO_0005251']",True,False,46,Mu opioid receptor agonist ,AGONIST ,single protein 
2155,RETASPIMYCIN,CHEMBL1184904,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000080824', 'ENSG00000096384']","['EFO_0002617', 'EFO_0003060', 'MONDO_0008903', 'EFO_0000305', 'EFO_0001378', 'MONDO_0011719', 'MONDO_0004992', 'EFO_0003085', 'MONDO_0007254', 'EFO_0000673']",False,False,10,Heat shock protein HSP90 inhibitor ,INHIBITOR ,protein family 
2156,AMRUBICIN,CHEMBL1186894,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.,,3.0,,False,no approval year,['ENSG00000131747'],"['EFO_0001378', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0000702', 'EFO_1000576', 'EFO_0000616', 'EFO_1000581', 'EFO_1001968', 'EFO_0000702', 'MONDO_0001187', 'MONDO_0008903']",True,False,11,DNA topoisomerase II alpha inhibitor ,INHIBITOR ,single protein 
2157,CEPHALOSPORIN,CHEMBL1235646,Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['EFO_0003106'],False,False,1,,,
2158,CAMPTOTHECIN-20-O-PROPIONATE,CHEMBL124162,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000198900'],"['EFO_0000574', 'EFO_0000702', 'EFO_0000616']",False,False,3,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
2159,TEGAFUR,CHEMBL20883,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 39 investigational indications.,,4.0,,False,no approval year,['ENSG00000176890'],"['EFO_0000616', 'MONDO_0007576', 'EFO_0000503', 'EFO_0003897', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000199', 'EFO_0000313', 'MONDO_0001187', 'MONDO_0021355', 'MONDO_0002974', 'EFO_0000228', 'EFO_0003860', 'EFO_1001951', 'EFO_0003086', 'EFO_1001901', 'MONDO_0002120', 'MONDO_0044937', 'EFO_0000178', 'EFO_0001421', 'EFO_0000702', 'EFO_0003891', 'EFO_0000365', 'EFO_0004142', 'EFO_0003060', 'EFO_0002618', 'EFO_0005922', 'EFO_0003869', 'EFO_0002517', 'EFO_0000181', 'EFO_1000657', 'MONDO_0001056', 'MONDO_0005575', 'EFO_0005221', 'EFO_1000045', 'EFO_0004252', 'MONDO_0003060', 'EFO_0002916', 'EFO_0006859', 'EFO_1001956']",True,False,41,Thymidylate synthase inhibitor ,INHIBITOR ,single protein 
2160,RIOCIGUAT,CHEMBL2107834,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 8 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2013,"['ENSG00000061918', 'ENSG00000123201', 'ENSG00000152402', 'ENSG00000164116']","['EFO_0000764', 'EFO_1001993', 'MONDO_0005149', 'EFO_1001145', 'EFO_0000537', 'EFO_0000717', 'MONDO_0011382', 'MONDO_0008347', 'MONDO_0043839', 'EFO_0001361', 'MONDO_0009061', 'EFO_0001645']",False,False,12,Soluble guanylate cyclase positive allosteric modulator ,POSITIVE ALLOSTERIC MODULATOR ,protein complex group 
2161,STREPTOMYCIN SULFATE,CHEMBL3184791,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 7 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,1946,[],"['EFO_0003103', 'EFO_0007291', 'EFO_1001444', 'EFO_0000544', 'EFO_0003106', 'EFO_0007481', 'MONDO_0018076']",False,False,7,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2162,PIMODIVIR,CHEMBL3318007,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0003884', 'EFO_0007328', 'EFO_0001421']",False,False,3,Polymerase basic protein 2 inhibitor ,INHIBITOR ,single protein 
2163,FEXAPOTIDE,CHEMBL3545061,Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000284', 'MONDO_0008315', 'EFO_0000284']",False,False,3,,,
2164,BIRABRESIB,CHEMBL3581647,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000204256', 'ENSG00000141867', 'ENSG00000137948', 'ENSG00000169925']","['EFO_0000519', 'EFO_0003060', 'MONDO_0008315', 'EFO_0000403', 'EFO_0002517', 'MONDO_0007254', 'EFO_0000222']",False,False,7,Bromodomain and extra-terminal motif (BET) inhibitor ,INHIBITOR ,protein family 
2165,ALLICIN,CHEMBL359965,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0018906'],False,False,1,,,
2166,OLECLUMAB,CHEMBL3990016,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000135318'],"['MONDO_0008315', 'EFO_0003060', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0001187']",True,False,7,5'-nucleotidase inhibitor ,INHIBITOR ,single protein 
2167,NANGIBOTIDE,CHEMBL4297793,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000124731'],"['EFO_0006834', 'MONDO_0100096']",True,False,2,Triggering receptor expressed on myeloid cells 1 inhibitor ,INHIBITOR ,single protein 
2168,IBCASERTIB,CHEMBL5095033,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000178999']","['EFO_0005537', 'EFO_0000182', 'EFO_0000702', 'EFO_0005952', 'EFO_1001968', 'MONDO_0008170', 'EFO_0000616']",False,False,7,Serine/threonine-protein kinase Aurora-B inhibitor Vascular endothelial growth factor receptor inhibitor ,INHIBITOR ,single protein protein family 
2169,VOLRUSTOMIG,CHEMBL5095362,Protein drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'EFO_0000681', 'EFO_0000616']",False,False,3,,,
2170,TAMOXIFEN,CHEMBL83,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1977,['ENSG00000091831'],"['MONDO_0001187', 'MONDO_0010679', 'EFO_0009907', 'MONDO_0002158', 'EFO_0003843', 'EFO_0000305', 'EFO_0000616', 'EFO_0000536', 'EFO_0000294', 'MONDO_0011962', 'EFO_0000545', 'MONDO_0007254', 'EFO_0004248', 'EFO_0000519', 'MONDO_0018364', 'HP_0000771', 'EFO_0000305', 'MONDO_0008170', 'EFO_0003833', 'EFO_0009708', 'EFO_1000158', 'EFO_1001512', 'MONDO_0002087', 'EFO_0003922', 'EFO_0000389', 'MONDO_0002691', 'EFO_0004220', 'MONDO_0004985', 'EFO_1001901', 'EFO_0000232', 'EFO_0001075', 'MONDO_0008315', 'MONDO_0019180', 'EFO_1000251', 'EFO_0000616', 'EFO_0006861', 'EFO_0000637', 'EFO_0000764', 'EFO_0005543', 'MONDO_0018848', 'EFO_1001375', 'MONDO_0007254', 'MONDO_0004992', 'MONDO_0100096', 'EFO_0000432', 'Orphanet_145', 'MONDO_0004976', 'EFO_1000984', 'EFO_0000537', 'EFO_0001416', 'EFO_0003869']",True,True,51,Estrogen receptor alpha modulator ,MODULATOR ,single protein 
2171,MESNA,CHEMBL975,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for thrombocytopenia and has 53 investigational indications.,,4.0,,False,1988,[],"['MONDO_0011382', 'EFO_0000183', 'EFO_0000574', 'MONDO_0005301', 'EFO_0000209', 'EFO_0000095', 'EFO_0004991', 'EFO_0000309', 'EFO_0000384', 'EFO_0000565', 'EFO_0003884', 'EFO_0000094', 'EFO_0003865', 'EFO_0000182', 'EFO_0002939', 'EFO_0001073', 'EFO_0001378', 'EFO_0000096', 'MONDO_0008903', 'MONDO_0044903', 'MONDO_0004992', 'EFO_0003833', 'EFO_0005952', 'EFO_0000756', 'EFO_0000621', 'EFO_0000691', 'EFO_0006803', 'MONDO_0000870', 'EFO_0003929', 'MONDO_0008380', 'EFO_0000403', 'EFO_0009708', 'EFO_0004145', 'HP_0001915', 'EFO_0004256', 'EFO_0000174', 'EFO_0007498', 'EFO_1001968', 'EFO_0000222', 'HP_0001873', 'MONDO_0044881', 'EFO_0000637', 'EFO_1001469', 'HP_0001919', 'EFO_0000220', 'EFO_0002617', 'EFO_0000717', 'EFO_0003869', 'MONDO_0007915', 'EFO_0005088', 'EFO_0000514', 'MONDO_0007254', 'EFO_0000198', 'EFO_0001642']",False,False,54,,,
2172,PORACTANT ALFA,CHEMBL1201622,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 3 investigational indications.,,4.0,,False,1999,[],"['EFO_1000637', 'MONDO_0004933', 'EFO_1000644', 'EFO_0000694', 'MONDO_0100096', 'EFO_0003818']",False,False,6,,,
2173,LETROZOLE,CHEMBL1444,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 44 investigational indications.,,4.0,,False,1997,['ENSG00000137869'],"['HP_0001510', 'EFO_0009708', 'EFO_0000279', 'MONDO_0011972', 'MONDO_0018555', 'EFO_0000305', 'EFO_1001346', 'MONDO_0008315', 'EFO_0008509', 'EFO_1001512', 'MONDO_0007254', 'MONDO_0002715', 'MONDO_0002775', 'MONDO_0008170', 'EFO_0001065', 'EFO_0000313', 'EFO_0005537', 'EFO_0001075', 'EFO_0003833', 'EFO_0003922', 'EFO_0003060', 'EFO_0000616', 'EFO_0003869', 'EFO_0000660', 'EFO_0003859', 'MONDO_0018479', 'EFO_0000432', 'EFO_0000588', 'EFO_1000251', 'EFO_0005952', 'EFO_0000545', 'EFO_1000984', 'EFO_0000731', 'EFO_0002950', 'MONDO_0011962', 'EFO_1001757', 'EFO_0000673', 'EFO_0000564', 'EFO_0004230', 'MONDO_0011705', 'HP_0005268', 'Orphanet_145', 'MONDO_0002158', 'EFO_0003968', 'EFO_0000553', 'EFO_0001416', 'MONDO_0002087', 'EFO_0003882']",False,False,48,Cytochrome P450 19A1 inhibitor ,INHIBITOR ,single protein 
2174,ACETYLCARNITINE,CHEMBL1697733,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder and has 10 investigational indications.,,4.0,,False,no approval year,[],"['HP_0012378', 'MONDO_0007079', 'MONDO_0004985', 'MONDO_0005148', 'EFO_0000660', 'EFO_0003888', 'EFO_0003060', 'EFO_0004149', 'EFO_0004143', 'EFO_0008568', 'EFO_0006834']",False,False,11,,,
2175,BENRALIZUMAB,CHEMBL1742991,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for airway obstruction and asthma and has 10 investigational indications.,,4.0,,False,2017,['ENSG00000091181'],"['HP_0006536', 'HP_0002110', 'MONDO_0004979', 'EFO_0004232', 'EFO_0007486', 'EFO_0000274', 'HP_0001871', 'EFO_1000391', 'EFO_0005531', 'EFO_0000341', 'EFO_0007187', 'EFO_1001467']",True,False,12,Interleukin-5 receptor subunit alpha inhibitor ,INHIBITOR ,single protein 
2176,IODOCARB,CHEMBL1893913,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0004540', 'EFO_0000341']",False,False,2,,,
2177,ASCORBIC ACID,CHEMBL196,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 approved and 92 investigational indications.,,4.0,,False,1985,[],"['EFO_0009492', 'EFO_0003777', 'EFO_0003781', 'MONDO_0021063', 'EFO_0003060', 'EFO_0000763', 'EFO_0000275', 'EFO_0000731', 'MONDO_0004992', 'EFO_1000783', 'EFO_0002499', 'EFO_0000479', 'EFO_0000222', 'MONDO_0007254', 'EFO_0005543', 'EFO_0002517', 'MONDO_0015626', 'EFO_0002429', 'EFO_0002501', 'EFO_1001375', 'EFO_0006834', 'EFO_0005952', 'MONDO_0004979', 'HP_0001891', 'HP_0002039', 'EFO_0007328', 'MONDO_0002050', 'EFO_0002970', 'EFO_0000537', 'MONDO_0001187', 'EFO_1001968', 'EFO_0004193', 'EFO_0003843', 'EFO_0003106', 'EFO_0000668', 'EFO_0009444', 'EFO_1001951', 'EFO_0000365', 'EFO_0003884', 'MONDO_0007309', 'EFO_0009606', 'MONDO_0002974', 'MONDO_0001056', 'EFO_0000694', 'EFO_1001998', 'EFO_1000657', 'EFO_0003911', 'EFO_0000519', 'EFO_0005279', 'EFO_1000822', 'HP_0100806', 'EFO_0000183', 'EFO_1000637', 'EFO_0000198', 'EFO_0003894', 'EFO_1000860', 'EFO_0000349', 'EFO_1001465', 'EFO_0003758', 'EFO_0004272', 'HP_0031273', 'EFO_0000673', 'MONDO_0005148', 'EFO_0004142', 'EFO_0000546', 'EFO_0004610', 'EFO_0009516', 'MONDO_0001437', 'EFO_0003922', 'EFO_0000400', 'EFO_0002618', 'EFO_0000612', 'EFO_0000474', 'MONDO_0100342', 'EFO_0003860', 'MP_0001845', 'MONDO_0016486', 'EFO_0001378', 'EFO_0003884', 'EFO_0009579', 'EFO_1001169', 'MONDO_0005147', 'EFO_0000196', 'EFO_0003768', 'EFO_0000224', 'EFO_0003966', 'MONDO_0100096', 'MONDO_0008315', 'MONDO_0008170', 'EFO_0002430', 'EFO_0003103', 'MONDO_0005178', 'MONDO_0024355', 'HP_0012378', 'MONDO_0005090', 'MONDO_0005129', 'EFO_0003144', 'EFO_1001904']",False,False,98,,,
2178,METFORMIN GLYCINATE,CHEMBL2108299,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000400', 'MONDO_0005148', 'MONDO_0100096']",False,False,3,,,
2179,BATEFENTEROL,CHEMBL3039518,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,"['ENSG00000169252', 'ENSG00000181072', 'ENSG00000133019']",['EFO_0000341'],True,True,1,Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M2 antagonist Beta-2 adrenergic receptor agonist ,ANTAGONIST AGONIST ,single protein 
2180,LIRAGLUTIDE,CHEMBL4084119,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2010,['ENSG00000112164'],"['MONDO_0015183', 'EFO_0002546', 'HP_0003074', 'MONDO_0004975', 'MONDO_0002009', 'EFO_0003921', 'EFO_0003144', 'EFO_0004319', 'EFO_0001073', 'EFO_0000400', 'EFO_0003877', 'HP_0001824', 'EFO_1001121', 'MONDO_0005180', 'MONDO_0004985', 'EFO_0000401', 'EFO_0000195', 'EFO_1001249', 'MONDO_0005147', 'Orphanet_552', 'MONDO_0005148', 'EFO_0005203', 'EFO_0005611']",False,False,23,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
2181,CD24FC,CHEMBL4297717,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000142512', 'ENSG00000189403', 'ENSG00000204389', 'ENSG00000204388', 'ENSG00000080824', 'ENSG00000096384']","['EFO_0000616', 'MONDO_0100096', 'EFO_0002617']",True,False,3,Sialic acid-binding Ig-like lectin 10 modulator High mobility group protein B1 inhibitor Heat shock protein HSP90 inhibitor Heat shock 70 kDa protein 1A/1B inhibitor ,MODULATOR INHIBITOR ,single protein protein family 
2182,NAVOCAFTOR,CHEMBL4802150,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000001626'],['MONDO_0009061'],False,True,1,Cystic fibrosis transmembrane conductance regulator positive modulator ,POSITIVE MODULATOR ,single protein 
2183,INDIBULIN,CHEMBL49642,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254']",True,False,3,Tubulin inhibitor ,INHIBITOR ,protein complex group 
2184,BENAZEPRIL,CHEMBL838,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1991,['ENSG00000159640'],"['EFO_1002048', 'EFO_0000712', 'EFO_0000537', 'EFO_0000319', 'EFO_0001645', 'HP_0003124', 'EFO_0003086', 'EFO_0000400', 'EFO_0003914', 'MONDO_0010520', 'Orphanet_79292', 'MONDO_0007915', 'EFO_1000965', 'MONDO_0005148', 'EFO_0000400', 'MONDO_0018965', 'EFO_0000537']",False,False,17,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
2185,DULOXETINE,CHEMBL1175,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 35 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,"['ENSG00000103546', 'ENSG00000108576']","['MONDO_0005301', 'HP_0012532', 'HP_0000020', 'EFO_0005762', 'EFO_0001358', 'MONDO_0002050', 'EFO_1000783', 'MONDO_0002009', 'EFO_0000400', 'EFO_0005762', 'MONDO_0005180', 'MONDO_0005178', 'EFO_0003888', 'EFO_0003100', 'MONDO_0002009', 'HP_0003418', 'EFO_0006788', 'EFO_1000783', 'EFO_0003761', 'EFO_0004701', 'EFO_0005687', 'EFO_0005230', 'EFO_0007169', 'EFO_0005230', 'EFO_0000712', 'HP_0030834', 'EFO_1001951', 'MONDO_0001583', 'MONDO_0005090', 'EFO_0004244', 'EFO_0004540', 'HP_0003326', 'EFO_1001951', 'HP_0000020', 'HP_0003419', 'MONDO_0005301', 'EFO_0005687', 'EFO_0003843', 'EFO_0003843', 'EFO_0004616', 'MONDO_0007079', 'EFO_0003761', 'EFO_1001892', 'EFO_0001358', 'MONDO_0002050', 'MONDO_0005178', 'EFO_0000401', 'EFO_0002970']",False,False,48,Serotonin transporter inhibitor Norepinephrine transporter inhibitor ,INHIBITOR ,single protein 
2186,SELENIUM SULFIDE,CHEMBL1200680,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 4 approved and 18 investigational indications.,,4.0,,False,1951,[],"['EFO_1000764', 'EFO_0000764', 'MONDO_0008315', 'MONDO_0001187', 'EFO_1001898', 'HP_0000989', 'EFO_0000341', 'MONDO_0008903', 'EFO_0001663', 'EFO_0000616', 'MONDO_0002406', 'EFO_1001904', 'MONDO_0005301', 'EFO_1001951', 'EFO_1001466', 'EFO_0007510', 'MONDO_0018076', 'EFO_0009190', 'MONDO_0004975', 'MONDO_0001444', 'HP_0100806', 'HP_0003326']",False,False,22,,,
2187,CYCLOSPORINE,CHEMBL160,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 6 approved and 121 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1983,['ENSG00000196262'],"['EFO_0000389', 'MP_0001845', 'EFO_1001478', 'EFO_0000565', 'EFO_0000685', 'EFO_0000274', 'EFO_0000783', 'EFO_0000681', 'EFO_0000183', 'HP_0009926', 'EFO_0003777', 'MONDO_0019469', 'EFO_0004599', 'EFO_0000400', 'EFO_0000365', 'EFO_1000785', 'EFO_0003884', 'EFO_0004254', 'EFO_1001365', 'MONDO_0001475', 'EFO_0000574', 'MONDO_0013730', 'EFO_1001231', 'MONDO_0018906', 'MONDO_0021193', 'EFO_1001264', 'MONDO_0007254', 'EFO_0008507', 'EFO_0009492', 'EFO_1000560', 'EFO_0000220', 'EFO_0002687', 'EFO_0007141', 'HP_0001915', 'EFO_1001051', 'EFO_0004236', 'EFO_0005676', 'EFO_0009609', 'EFO_0003966', 'EFO_0003086', 'EFO_0001054', 'EFO_0000694', 'MONDO_0005041', 'MONDO_0019249', 'MONDO_0001705', 'EFO_0007160', 'MONDO_0018305', 'EFO_0003780', 'MONDO_0008315', 'EFO_0004220', 'EFO_0000649', 'EFO_0000222', 'MONDO_0004992', 'EFO_0005761', 'MONDO_0008380', 'EFO_0000616', 'MONDO_0018896', 'EFO_0007527', 'EFO_0000341', 'EFO_0003047', 'Orphanet_848', 'EFO_0000198', 'EFO_0000621', 'EFO_0000540', 'EFO_0003818', 'MONDO_0019019', 'EFO_1000906', 'EFO_0004214', 'EFO_1001413', 'EFO_1000690', 'EFO_0008583', 'EFO_0000557', 'MONDO_0015540', 'EFO_0000544', 'EFO_0002428', 'EFO_0001642', 'EFO_0000691', 'EFO_0009708', 'MONDO_0011382', 'MONDO_0002898', 'EFO_0003833', 'EFO_0000612', 'MONDO_0009387', 'EFO_0007157', 'MONDO_0002158', 'MONDO_0005148', 'EFO_0000403', 'EFO_0000764', 'EFO_0000339', 'MONDO_0019623', 'EFO_0004276', 'MONDO_0044881', 'EFO_1001951', 'EFO_0005952', 'MONDO_0100096', 'EFO_0000678', 'EFO_1002048', 'MONDO_0018904', 'MONDO_0008170', 'EFO_0000182', 'EFO_0001378', 'EFO_0000095', 'MONDO_0043510', 'EFO_1001469', 'MONDO_0004768', 'MONDO_0002367', 'MONDO_0020077', 'MONDO_0018923', 'EFO_0000309', 'MONDO_0000870', 'EFO_1001156', 'EFO_0006927', 'MONDO_0005147', 'MONDO_0010788', 'HP_0000964', 'EFO_0000676', 'MONDO_0020290', 'EFO_0007359', 'MONDO_0000873', 'EFO_0001421', 'EFO_0007183', 'EFO_0004286', 'EFO_1000102', 'EFO_0005531', 'MONDO_0019391', 'EFO_0009441', 'HP_0001919']",True,False,127,Cyclophilin A modulator ,MODULATOR ,single protein 
2188,SPERGUALIN,CHEMBL1765508,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
2189,NERATINIB,CHEMBL180022,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 15 investigational indications.,,4.0,,False,2017,"['ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']","['EFO_0000339', 'EFO_0000305', 'EFO_0000616', 'MONDO_0007254', 'EFO_0000313', 'EFO_0003869', 'EFO_1001951', 'EFO_0000673', 'EFO_0003060', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0007254', 'EFO_0000182', 'EFO_0000519', 'EFO_0003968', 'MONDO_0008170', 'EFO_0005537', 'EFO_0000305']",False,True,18,Receptor protein-tyrosine kinase erbB-2 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
2190,MAGNESIUM STEARATE,CHEMBL2106633,Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0000341', 'MONDO_0004979']",False,False,2,,,
2191,MEDI-8968,CHEMBL2109607,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000115594'],"['EFO_1000710', 'EFO_0000341']",True,False,2,Interleukin-1 receptor inhibitor ,INHIBITOR ,single protein 
2192,GSK-2269557,CHEMBL3545250,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000171608'],"['EFO_0000341', 'MONDO_0004979']",False,False,2,PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
2193,BMS-690514,CHEMBL3545396,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000146648', 'ENSG00000141736', 'ENSG00000178568']","['MONDO_0004992', 'EFO_0003060', 'MONDO_0007254']",True,True,3,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-4 inhibitor Vascular endothelial growth factor receptor inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein protein family 
2194,MONGERSEN SODIUM,CHEMBL3707383,Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000101665'],"['EFO_0000729', 'EFO_0000384']",True,False,2,SMAD-7 mRNA antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
2195,OLORINAB,CHEMBL4175981,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000188822'],"['HP_0002027', 'EFO_0000384', 'EFO_0000555']",False,False,3,Cannabinoid CB2 receptor agonist ,AGONIST ,single protein 
2196,PACLITAXEL,CHEMBL428647,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 8 approved and 148 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1992,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0002517', 'MONDO_0005147', 'EFO_0008528', 'EFO_0003869', 'EFO_1000984', 'EFO_0000503', 'EFO_0003859', 'MONDO_0021043', 'EFO_1000043', 'MONDO_0008315', 'MONDO_0007576', 'EFO_0004243', 'EFO_1001931', 'MONDO_0002158', 'EFO_0006818', 'EFO_0002892', 'MONDO_0008170', 'EFO_0001075', 'EFO_1000576', 'MONDO_0100342', 'EFO_0006352', 'MONDO_0011962', 'EFO_0007535', 'EFO_0000685', 'EFO_0006859', 'MONDO_0018364', 'EFO_0000574', 'MONDO_0004658', 'EFO_0001061', 'EFO_0000308', 'MONDO_0001056', 'EFO_0005952', 'EFO_0009708', 'MONDO_0004669', 'MONDO_0021657', 'MONDO_0044704', 'MONDO_0021148', 'MONDO_0008903', 'EFO_0000519', 'EFO_0000514', 'EFO_0000180', 'EFO_0004272', 'EFO_0000294', 'EFO_1000796', 'EFO_0000466', 'MONDO_0005271', 'EFO_0000537', 'MONDO_0003751', 'MONDO_0021251', 'EFO_1001100', 'EFO_1000158', 'EFO_0000702', 'MONDO_0005411', 'MONDO_0004192', 'MONDO_0004992', 'EFO_0000558', 'EFO_0005537', 'EFO_0005567', 'EFO_1001951', 'EFO_0006772', 'EFO_0004224', 'EFO_1000613', 'EFO_0001378', 'EFO_0000199', 'EFO_0003826', 'EFO_0002618', 'EFO_0000182', 'EFO_0001416', 'EFO_0000588', 'MONDO_0001879', 'MONDO_0002715', 'EFO_0004149', 'EFO_1001968', 'MONDO_0002108', 'EFO_0000691', 'EFO_0000616', 'EFO_0003863', 'EFO_0000556', 'MONDO_0001402', 'MONDO_0002974', 'MONDO_0002367', 'EFO_0000305', 'EFO_0000707', 'MONDO_0002120', 'EFO_0000183', 'EFO_1001331', 'MONDO_0011719', 'EFO_0005088', 'EFO_0003060', 'EFO_0003050', 'MONDO_0021355', 'MONDO_0022394', 'MONDO_0002691', 'EFO_0006861', 'EFO_1000350', 'EFO_0003875', 'EFO_0004265', 'EFO_1001471', 'EFO_1000581', 'EFO_0004284', 'EFO_0005922', 'EFO_0002617', 'MONDO_0001528', 'EFO_0003968', 'EFO_0005221', 'EFO_0010282', 'EFO_0000756', 'EFO_0000565', 'EFO_0004281', 'EFO_0004142', 'EFO_0000389', 'EFO_0008524', 'EFO_1000052', 'EFO_1001512', 'EFO_0000228', 'EFO_0003833', 'MONDO_0001187', 'EFO_1000657', 'EFO_0000764', 'MONDO_0002601', 'EFO_0000681', 'MONDO_0004986', 'EFO_0000178', 'MONDO_0044926', 'EFO_0000313', 'Orphanet_145', 'EFO_1000251', 'EFO_0000432', 'MONDO_0018944', 'EFO_0003860', 'EFO_0000284', 'EFO_1001465', 'MONDO_0001325', 'MONDO_0003060', 'EFO_0000676', 'EFO_0002496', 'EFO_0002938', 'EFO_0000708', 'EFO_0000181', 'EFO_0004230', 'MONDO_0021117', 'EFO_1001961', 'EFO_0000673', 'EFO_0003843', 'EFO_0000095', 'EFO_0003893', 'MONDO_0007254', 'MONDO_0002087', 'EFO_0006318', 'EFO_0004252', 'EFO_0003100', 'EFO_0002916', 'EFO_0003897', 'EFO_0000571', 'EFO_0003868', 'EFO_0000365']",True,False,156,Tubulin inhibitor ,INHIBITOR ,protein complex group 
2197,BUCILLAMINE,CHEMBL80830,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004274', 'MONDO_0009067', 'EFO_0000685', 'EFO_0005755', 'MONDO_0100096']",False,False,5,,,
2198,CEFDINIR,CHEMBL927,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 7 approved and 3 investigational indications.,,4.0,,False,1997,[],"['EFO_1001034', 'EFO_0006505', 'HP_0011110', 'EFO_0007149', 'EFO_0000544', 'EFO_0000771', 'MONDO_0002258', 'EFO_0004992', 'EFO_0003102', 'EFO_0003106']",False,False,10,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
2199,SOLIFENACIN SUCCINATE,CHEMBL1200803,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for overactive bladder and urgency urinary incontinence and has 1 investigational indication.,,4.0,,False,2004,"['ENSG00000181072', 'ENSG00000133019']","['EFO_1000781', 'EFO_0000284', 'EFO_0006865']",False,False,3,Muscarinic acetylcholine receptor M2 antagonist Muscarinic acetylcholine receptor M3 antagonist ,ANTAGONIST ,single protein 
2200,COLISTIMETHATE SODIUM,CHEMBL1201441,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for infection and has 4 investigational indications.,,4.0,,False,1970,[],"['EFO_0003106', 'EFO_0001076', 'HP_0002110', 'EFO_0000771', 'EFO_0000544']",False,False,5,,,
2201,DEXTROSE,CHEMBL1222250,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for varicose veins and hemorrhage and has 51 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0005147', 'EFO_0000474', 'EFO_1001896', 'MONDO_0004976', 'EFO_1000948', 'EFO_0001421', 'EFO_0003932', 'EFO_0000612', 'MONDO_0100096', 'EFO_0003869', 'EFO_0001073', 'EFO_0004209', 'HP_0100806', 'MONDO_0043510', 'EFO_0009579', 'EFO_0000182', 'EFO_0000589', 'MONDO_0037939', 'EFO_0003106', 'HP_0001943', 'HP_0002619', 'EFO_0009686', 'EFO_0004888', 'EFO_0000373', 'EFO_0003884', 'MONDO_0005301', 'MONDO_0005178', 'EFO_0003843', 'MONDO_0021187', 'EFO_0000537', 'HP_0003419', 'EFO_0008572', 'EFO_0000544', 'EFO_0006834', 'EFO_0005279', 'MONDO_0004567', 'HP_0002140', 'MONDO_0005090', 'MP_0001914', 'MONDO_0002041', 'EFO_1001434', 'EFO_0003144', 'EFO_0004238', 'EFO_1000985', 'EFO_1000949', 'EFO_1001919', 'EFO_0007214', 'MONDO_0003060', 'MONDO_0001475', 'MONDO_0005148', 'HP_0002902', 'HP_0002153', 'EFO_0000400']",False,False,53,,,
2202,ENOBOSARM,CHEMBL1738889,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000169083'],"['EFO_0009851', 'HP_0004326', 'EFO_0000305', 'MONDO_0007254', 'EFO_0003060', 'HP_0000020']",True,False,6,Androgen Receptor modulator ,MODULATOR ,single protein 
2203,ACYCLOVIR,CHEMBL184,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 7 approved and 15 investigational indications.,,4.0,,False,1982,[],"['EFO_1001347', 'MONDO_0005301', 'EFO_0000763', 'EFO_0001062', 'EFO_0001062', 'EFO_1001347', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0000764', 'EFO_0003086', 'EFO_0003060', 'EFO_0000403', 'EFO_0000764', 'EFO_1002022', 'EFO_0007204', 'EFO_0006862', 'EFO_0007308', 'EFO_1001888', 'EFO_0000094', 'EFO_0006510', 'EFO_1002022', 'EFO_0007282', 'EFO_0007282', 'EFO_0000544']",False,False,24,Human herpesvirus 1 DNA polymerase inhibitor ,INHIBITOR ,single protein 
2204,PERTUZUMAB,CHEMBL2007641,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2012,['ENSG00000141736'],"['EFO_1000657', 'MONDO_0002120', 'MONDO_0021063', 'EFO_0002916', 'MONDO_0008170', 'EFO_0006861', 'EFO_0002618', 'MONDO_0007254', 'EFO_0009708', 'MONDO_0001056', 'EFO_0000365', 'EFO_0003869', 'MONDO_0008315', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0000305', 'MONDO_0002087', 'EFO_0003968', 'EFO_1001951', 'EFO_0003060', 'EFO_1000984', 'EFO_0005537', 'EFO_0000616']",False,True,23,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
2205,TEDUGLUTIDE,CHEMBL2104987,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for short bowel syndrome and primary short bowel syndrome and has 7 investigational indications.,,4.0,,False,2012,['ENSG00000065325'],"['EFO_0000764', 'MONDO_0021187', 'EFO_0001421', 'MONDO_0013730', 'EFO_0000384', 'EFO_0003086', 'MONDO_0015183', 'EFO_0008572', 'MONDO_0018241']",True,False,9,Glucagon-like peptide 2 receptor agonist ,AGONIST ,single protein 
2206,ALBIGLUTIDE,CHEMBL2107841,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2014,['ENSG00000112164'],"['MONDO_0005147', 'MONDO_0005148', 'EFO_0000373', 'EFO_0000400']",False,False,4,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
2207,SIPLIZUMAB,CHEMBL2108742,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000116824'],"['MONDO_0016537', 'EFO_0000676', 'EFO_0003086', 'EFO_0000565', 'EFO_1002048', 'MONDO_0004992', 'EFO_0000574', 'EFO_0003884', 'MONDO_0013730']",False,False,9,T-cell surface antigen CD2 inhibitor ,INHIBITOR ,single protein 
2208,NICORANDIL,CHEMBL284906,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 5 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000612', 'EFO_0003917', 'EFO_0000319', 'EFO_1001411', 'EFO_0001645']",False,False,6,,,
2209,MIVAVOTINIB,CHEMBL3979920,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,['ENSG00000165025'],"['EFO_0000403', 'EFO_0005952', 'EFO_0000222', 'EFO_0000574', 'EFO_0000403', 'MONDO_0018906', 'EFO_0001075']",False,False,7,Tyrosine-protein kinase SYK inhibitor ,INHIBITOR ,single protein 
2210,MEPARTRICIN,CHEMBL3989893,Unknown drug and has 2 investigational indications.,,-1.0,,False,no approval year,[],"['EFO_0000544', 'EFO_0000284']",False,False,2,,,
2211,ENVAFOLIMAB,CHEMBL4298006,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 20 investigational indications.,,2.0,,False,no approval year,['ENSG00000120217'],"['MONDO_0011962', 'EFO_0004252', 'EFO_1001968', 'EFO_0000616', 'EFO_0000182', 'MONDO_0021063', 'MONDO_0008170', 'EFO_0003891', 'MONDO_0007254', 'EFO_1001012', 'MONDO_0021117', 'EFO_1000657', 'EFO_0003060', 'EFO_0002618', 'EFO_0000503', 'EFO_0000180', 'EFO_0004239', 'MONDO_0003060', 'EFO_1001951', 'EFO_0000764']",False,False,20,Programmed cell death 1 ligand 1 binding agent ,BINDING AGENT ,single protein 
2212,LUVIXASERTIB,CHEMBL4469414,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
2213,AMITRIPTYLINE,CHEMBL629,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for unipolar depression and depressive disorder and has 20 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1961,"['ENSG00000103546', 'ENSG00000108576']","['EFO_0007169', 'EFO_1000941', 'EFO_0003843', 'EFO_0005230', 'EFO_1001800', 'EFO_0004698', 'EFO_0003761', 'EFO_0008507', 'EFO_0000400', 'EFO_0003761', 'EFO_0004244', 'MONDO_0005090', 'HP_0002315', 'MONDO_0005277', 'EFO_0000512', 'EFO_0004149', 'EFO_0009387', 'MONDO_0002050', 'EFO_0005762', 'EFO_0005687', 'EFO_0010282', 'HP_0000989', 'MONDO_0002009']",False,False,23,Norepinephrine transporter inhibitor Serotonin transporter inhibitor ,INHIBITOR ,single protein 
2214,BUPROPION,CHEMBL894,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 34 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1985,"['ENSG00000103546', 'ENSG00000142319']","['EFO_0005203', 'EFO_0000616', 'MONDO_0002009', 'EFO_0003768', 'EFO_0004319', 'EFO_0004714', 'EFO_0006859', 'EFO_0001073', 'MONDO_0004975', 'MONDO_0002491', 'MONDO_0008315', 'EFO_0009963', 'EFO_0001073', 'MONDO_0004985', 'EFO_0003761', 'MONDO_0004985', 'EFO_0002610', 'MONDO_0007739', 'EFO_0003890', 'MONDO_0005148', 'EFO_0000384', 'EFO_0007191', 'EFO_0002617', 'EFO_0003060', 'EFO_0005230', 'MONDO_0002009', 'MONDO_0044970', 'EFO_0004701', 'MONDO_0008903', 'EFO_0003888', 'EFO_0004319', 'MONDO_0002050', 'EFO_0003761', 'MONDO_0005090', 'MONDO_0002046', 'MONDO_0007079', 'EFO_0000095', 'MONDO_0010200', 'MONDO_0002050', 'EFO_0003761', 'EFO_0003768', 'EFO_0004247', 'EFO_0004270']",False,False,43,Norepinephrine transporter inhibitor Dopamine transporter inhibitor ,INHIBITOR ,single protein 
2215,CLAVULANATE POTASSIUM,CHEMBL1003,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 6 approved and 6 investigational indications.,,4.0,,False,1984,[],"['EFO_0004992', 'EFO_0007486', 'EFO_0003103', 'MONDO_0018076', 'EFO_0000544', 'HP_0100806', 'EFO_1001141', 'MONDO_0024355', 'EFO_1001034', 'EFO_1001313', 'EFO_0003106', 'EFO_1001391']",False,False,12,Bacterial beta-lactamase TEM inhibitor ,INHIBITOR ,single protein 
2216,METHYLPREDNISOLONE HEMISUCCINATE,CHEMBL1201265,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 16 approved and 27 investigational indications.,,4.0,,False,1959,['ENSG00000113580'],"['EFO_0003929', 'EFO_0000694', 'MP_0001845', 'MONDO_0004979', 'MONDO_0007915', 'MONDO_0002280', 'EFO_0008522', 'EFO_0000095', 'EFO_1001222', 'EFO_0000540', 'MONDO_0002406', 'EFO_0003894', 'MONDO_0100096', 'EFO_1001119', 'MONDO_0005301', 'MONDO_0005301', 'EFO_0000220', 'EFO_0003106', 'EFO_0002609', 'EFO_0003843', 'MONDO_0002471', 'MONDO_0002462', 'MONDO_0013730', 'EFO_0003840', 'MONDO_0005178', 'EFO_0000198', 'EFO_0000685', 'EFO_0004194', 'EFO_1001272', 'EFO_0000574', 'EFO_0004599', 'EFO_0000565', 'EFO_0005952', 'EFO_0001379', 'EFO_0007359', 'EFO_0007332', 'EFO_0003778', 'EFO_0007537', 'EFO_0004228', 'EFO_0001378', 'EFO_0000222', 'EFO_0000474', 'EFO_0001063']",True,False,43,Glucocorticoid receptor agonist ,AGONIST ,single protein 
2217,TREMELIMUMAB,CHEMBL2108658,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hepatocellular carcinoma and has 58 investigational indications.,,4.0,,False,2022,['ENSG00000163599'],"['EFO_0002617', 'EFO_0000514', 'MONDO_0004992', 'EFO_0000501', 'MONDO_0008315', 'EFO_0002517', 'EFO_0000691', 'EFO_0000616', 'EFO_0000181', 'EFO_0000349', 'EFO_0003863', 'MONDO_0008903', 'EFO_0000503', 'EFO_0001075', 'EFO_0000313', 'EFO_0000305', 'MONDO_0001187', 'EFO_0000681', 'EFO_0001378', 'MONDO_0002158', 'EFO_0000702', 'EFO_0000764', 'EFO_0005221', 'EFO_0001642', 'MONDO_0007576', 'EFO_1001100', 'EFO_0000403', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0003001', 'EFO_0003891', 'MONDO_0002108', 'EFO_0000198', 'EFO_0000756', 'EFO_0008528', 'MONDO_0044704', 'EFO_0004142', 'EFO_0000199', 'EFO_0000673', 'EFO_0000574', 'EFO_1000251', 'EFO_0000389', 'EFO_0000182', 'MONDO_0021148', 'EFO_0000641', 'MONDO_0007254', 'EFO_0000708', 'EFO_0003060', 'EFO_1001961', 'EFO_0004284', 'EFO_0000519', 'EFO_0002618', 'EFO_0000588', 'MONDO_0001056', 'EFO_1001951', 'EFO_1001968', 'EFO_0005220', 'MONDO_0003002', 'MONDO_0003060']",True,False,59,Cytotoxic T-lymphocyte protein 4 inhibitor ,INHIBITOR ,single protein 
2218,AMG-820,CHEMBL2109322,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.,,1.0,,False,no approval year,['ENSG00000182578'],"['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004992']",False,False,4,Macrophage colony stimulating factor receptor inhibitor ,INHIBITOR ,single protein 
2219,LUCITANIB,CHEMBL2220486,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000066468', 'ENSG00000102755', 'ENSG00000037280', 'ENSG00000128052', 'ENSG00000077782']","['EFO_0000702', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254', 'MONDO_0021148', 'EFO_0003060']",True,True,6,Fibroblast growth factor receptor 1 inhibitor Vascular endothelial growth factor receptor inhibitor Fibroblast growth factor receptor 2 inhibitor ,INHIBITOR ,single protein protein family 
2220,CAPSAICIN,CHEMBL294199,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 12 approved and 24 investigational indications.,,4.0,,False,2009,['ENSG00000196689'],"['HP_0000989', 'EFO_0001361', 'EFO_0000764', 'EFO_0009364', 'MONDO_0043510', 'EFO_0006859', 'EFO_1000941', 'EFO_0009387', 'EFO_0005762', 'HP_0002829', 'MONDO_0041052', 'EFO_0003843', 'MONDO_0001583', 'EFO_1001434', 'HP_0003394', 'EFO_0009430', 'HP_0002013', 'EFO_0006911', 'EFO_1001896', 'EFO_1000783', 'EFO_0009619', 'EFO_0009625', 'EFO_0004616', 'EFO_1001054', 'EFO_0003913', 'EFO_0000712', 'EFO_0006510', 'HP_0003418', 'MONDO_0005277', 'MONDO_0007254', 'HP_0012735', 'MONDO_0005178', 'EFO_0005856', 'EFO_0009582', 'HP_0003326', 'MONDO_0004976']",False,False,36,Vanilloid receptor opener ,OPENER ,single protein 
2221,NICOTINE,CHEMBL3,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for nicotine dependence and has 28 investigational indications.,,4.0,,False,1984,"['ENSG00000160716', 'ENSG00000101204']","['EFO_0003768', 'HP_0100543', 'MONDO_0005180', 'GO_0007568', 'EFO_0004329', 'EFO_0002610', 'MONDO_0004647', 'MONDO_0019338', 'MONDO_0004938', 'EFO_0003888', 'EFO_0000691', 'EFO_0003144', 'MONDO_0002050', 'EFO_0003768', 'MONDO_0005090', 'EFO_0000341', 'MONDO_0008903', 'MONDO_0100096', 'EFO_0001072', 'MONDO_0002050', 'EFO_0000694', 'MONDO_0018076', 'DOID_13406', 'EFO_0004888', 'EFO_0000546', 'EFO_0000313', 'EFO_0004319', 'MONDO_0002974', 'EFO_0007191', 'EFO_0003768']",False,True,30,Neuronal acetylcholine receptor; alpha4/beta2 agonist ,AGONIST ,protein complex 
2222,SARS-COV,CHEMBL4594493,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000694', 'MONDO_0100096']",False,False,2,,,
2223,CAMOSTAT,CHEMBL590799,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000694', 'EFO_0000694', 'HP_0002243', 'MONDO_0100096', 'MP_0001914', 'MONDO_0100096']",False,False,6,,,
2224,ALITRETINOIN,CHEMBL705,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for eczema and neoplasm and has 5 investigational indications.,,4.0,,False,1999,"['ENSG00000204231', 'ENSG00000172819', 'ENSG00000143171', 'ENSG00000077092', 'ENSG00000131759', 'ENSG00000186350']","['EFO_1000706', 'EFO_0003834', 'EFO_0000676', 'EFO_1000726', 'MONDO_0007254', 'HP_0000964', 'EFO_0000616']",True,False,7,Retinoid receptor agonist ,AGONIST ,protein family 
2225,DEXAMETHASONE PHOSPHORIC ACID,CHEMBL1201302,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 69 approved and 18 investigational indications.,,4.0,,False,1959,['ENSG00000113580'],"['EFO_1000941', 'EFO_1000684', 'MONDO_0007915', 'EFO_0000556', 'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719', 'EFO_1000039', 'EFO_1000764', 'MONDO_0005129', 'MONDO_0002406', 'EFO_1002022', 'EFO_1000997', 'EFO_1001896', 'EFO_0000574', 'HP_0001915', 'EFO_0000676', 'EFO_0001642', 'EFO_1001051', 'MONDO_0005178', 'HP_0012424', 'EFO_0005558', 'HP_0001873', 'EFO_0005854', 'EFO_0007257', 'MONDO_0100096', 'EFO_0004276', 'EFO_1001250', 'EFO_0006738', 'EFO_0005319', 'EFO_0000729', 'EFO_1000049', 'EFO_0007141', 'EFO_0009491', 'EFO_0001378', 'EFO_0009552', 'MONDO_0003005', 'EFO_0003929', 'MONDO_0001718', 'EFO_0005752', 'EFO_0004265', 'EFO_1000906', 'HP_0000559', 'EFO_0007490', 'EFO_0008997', 'EFO_1000845', 'EFO_1000811', 'EFO_1001194', 'EFO_0007403', 'EFO_0004255', 'EFO_0004274', 'MONDO_0015128', 'EFO_1001119', 'EFO_0003778', 'EFO_0003898', 'EFO_0000694', 'EFO_0002609', 'EFO_0000565', 'MONDO_0003005', 'MONDO_0019338', 'EFO_1001222', 'EFO_0003956', 'MONDO_0004992', 'EFO_0003106', 'EFO_0000685', 'EFO_0009560', 'EFO_0000384', 'MP_0001845', 'EFO_0009456', 'HP_0004398', 'HP_0003072', 'EFO_0003894', 'EFO_0007405', 'MONDO_0004979', 'EFO_0005539', 'EFO_0009449', 'EFO_0007520', 'HP_0001094', 'EFO_1001205', 'HP_0001742', 'MONDO_0001280', 'HP_0003040', 'EFO_1000694', 'EFO_0007160', 'EFO_1001435', 'EFO_0000274']",True,False,87,Glucocorticoid receptor agonist ,AGONIST ,single protein 
2226,VILDAGLIPTIN,CHEMBL142703,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 6 investigational indications.,,4.0,,False,no approval year,['ENSG00000197635'],"['EFO_0004593', 'MONDO_0005147', 'MONDO_0005148', 'EFO_1001121', 'EFO_0000400', 'MONDO_0002009', 'EFO_0002546']",False,False,7,Dipeptidyl peptidase IV inhibitor ,INHIBITOR ,single protein 
2227,PYRUVATE SODIUM,CHEMBL181886,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0004979', 'MONDO_0009061']",False,False,2,,,
2228,PACRITINIB,CHEMBL2035187,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 14 investigational indications.,,4.0,,False,2022,"['ENSG00000122025', 'ENSG00000096968']","['EFO_0000616', 'MONDO_0100096', 'EFO_0004251', 'EFO_0002429', 'MONDO_0013730', 'EFO_1001469', 'MONDO_0007254', 'EFO_0002430', 'EFO_0002430', 'EFO_1001951', 'EFO_0000222', 'EFO_0003060', 'EFO_0000095', 'MONDO_0044903', 'EFO_0000183', 'EFO_0000565', 'MONDO_0008315']",True,False,17,Tyrosine-protein kinase JAK2 inhibitor Tyrosine-protein kinase receptor FLT3 inhibitor ,INHIBITOR ,single protein 
2229,THYMALFASIN,CHEMBL2103979,Protein drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000180', 'EFO_0000182', 'HP_0100806', 'EFO_0004220', 'EFO_0001642', 'MONDO_0100096', 'EFO_0000756', 'EFO_0000764', 'EFO_0004239', 'EFO_0000571', 'EFO_1001951', 'EFO_0000702', 'EFO_0003060', 'MONDO_0007576', 'EFO_0003884']",False,False,15,,,
2230,PEGDINETANIB,CHEMBL2108356,Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,['ENSG00000128052'],"['EFO_0003060', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000519', 'EFO_0000365']",False,False,5,Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
2231,ANIFROLUMAB,CHEMBL2364653,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for immune system disease and systemic lupus erythematosus and has 4 investigational indications.,,4.0,,False,2021,['ENSG00000142166'],"['EFO_1001993', 'EFO_0000699', 'EFO_0000540', 'EFO_0000685', 'EFO_0005761', 'MONDO_0007915']",False,False,6,Interferon-alpha/beta receptor alpha chain antagonist ,ANTAGONIST ,single protein 
2232,ULIPRISTAL ACETATE,CHEMBL260538,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 investigational indications. It was withdrawn in at least one region.,,4.0,,False,2010,['ENSG00000082175'],"['EFO_0000731', 'EFO_0003922', 'MONDO_0001572', 'MONDO_0007309', 'EFO_1001757', 'MONDO_0004169', 'MP_0001914', 'MONDO_0007254', 'MONDO_0002050']",False,False,9,Progesterone receptor modulator ,MODULATOR ,single protein 
2233,ARX-788,CHEMBL4297892,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['MONDO_0004992', 'MONDO_0007254', 'EFO_0003869']",True,False,3,Receptor protein-tyrosine kinase erbB-2 binding agent Tubulin inhibitor ,BINDING AGENT INHIBITOR ,single protein protein complex group 
2234,REGN-3051,CHEMBL4594593,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
2235,IRINOTECAN,CHEMBL481,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 147 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000198900'],"['EFO_1001013', 'MONDO_0002120', 'EFO_0001075', 'EFO_0003860', 'MONDO_0004669', 'EFO_0002617', 'EFO_0000681', 'EFO_0000707', 'EFO_0005543', 'EFO_0000178', 'EFO_1000292', 'MONDO_0008315', 'MONDO_0002120', 'EFO_0003893', 'EFO_0003833', 'EFO_0002501', 'EFO_0000309', 'EFO_0000565', 'EFO_1000475', 'EFO_1001951', 'MONDO_0018364', 'EFO_1001051', 'EFO_1001951', 'EFO_0005537', 'MONDO_0008170', 'EFO_0000702', 'MONDO_0007576', 'EFO_0000326', 'HP_0002014', 'MONDO_0008903', 'EFO_0000621', 'MONDO_0021063', 'MONDO_0008903', 'MONDO_0003060', 'EFO_0006352', 'EFO_0002918', 'EFO_1000158', 'MONDO_0002974', 'EFO_0000174', 'EFO_0004243', 'EFO_0009708', 'EFO_1001961', 'MONDO_0001475', 'EFO_1000251', 'EFO_0000621', 'MONDO_0021063', 'MONDO_0005575', 'MONDO_0044937', 'EFO_0003968', 'EFO_0000365', 'EFO_0002939', 'MONDO_0005411', 'EFO_1000895', 'MONDO_0002087', 'MONDO_0024503', 'EFO_0000632', 'EFO_0005952', 'EFO_0003869', 'MONDO_0001325', 'EFO_0001416', 'EFO_0003891', 'EFO_0002499', 'EFO_1000785', 'EFO_1001469', 'EFO_0000502', 'MONDO_0001187', 'EFO_0005922', 'MONDO_0001879', 'EFO_0000389', 'EFO_1001365', 'EFO_0000502', 'EFO_0000637', 'EFO_1001471', 'EFO_0000691', 'EFO_0006859', 'EFO_0002939', 'EFO_1001042', 'EFO_1001949', 'EFO_0000691', 'EFO_0000616', 'EFO_0000503', 'EFO_0000174', 'EFO_0003032', 'EFO_0002499', 'EFO_0005221', 'MONDO_0002367', 'EFO_0000588', 'EFO_0004142', 'MONDO_0021633', 'MONDO_0018271', 'EFO_0002517', 'EFO_0007416', 'EFO_0000255', 'EFO_0001075', 'EFO_1000657', 'MONDO_0002367', 'MONDO_0002158', 'EFO_0000616', 'EFO_1001512', 'EFO_0000313', 'EFO_1000292', 'EFO_0002918', 'EFO_0000707', 'EFO_0000403', 'EFO_0000228', 'MONDO_0100342', 'EFO_0000574', 'MONDO_0016717', 'EFO_0000365', 'EFO_1000350', 'EFO_1000407', 'MONDO_0044926', 'EFO_0003060', 'EFO_0000305', 'MONDO_0000873', 'EFO_0002938', 'MONDO_0001056', 'MONDO_0002165', 'MONDO_0002537', 'EFO_0002618', 'EFO_0002501', 'EFO_0005537', 'MONDO_0002974', 'MONDO_0001056', 'EFO_0004193', 'EFO_0002517', 'EFO_0008549', 'MONDO_0002087', 'EFO_0000519', 'EFO_0000437', 'EFO_1000475', 'EFO_0004288', 'MONDO_0003060', 'MONDO_0008170', 'EFO_0000191', 'EFO_0001061', 'EFO_1001465', 'MONDO_0007254', 'MONDO_0020634', 'EFO_0000702', 'EFO_0000182', 'EFO_0002916', 'EFO_0000313', 'EFO_0000519', 'EFO_0002618', 'MONDO_0007576', 'MONDO_0019004', 'EFO_1000026', 'MONDO_0100342', 'MONDO_0001657', 'EFO_0000095', 'MONDO_0002158', 'MONDO_0019471', 'EFO_0000503', 'MONDO_0016717', 'EFO_0007535', 'MONDO_0011719', 'MONDO_0004992', 'EFO_0000574', 'MONDO_0003196', 'EFO_0000183', 'EFO_0003897', 'EFO_0000197', 'EFO_0006859', 'MONDO_0002691', 'EFO_1000657', 'EFO_1000158', 'EFO_0004142', 'MONDO_0006058', 'EFO_1001465', 'MONDO_0021117', 'EFO_0001071', 'EFO_0000248', 'MONDO_0044937', 'EFO_0000178', 'MONDO_0018906', 'MONDO_0004192', 'MONDO_0004992', 'EFO_1001512', 'MONDO_0007254', 'EFO_0000565', 'MONDO_0002691', 'EFO_0003060']",False,False,183,DNA topoisomerase I inhibitor ,INHIBITOR ,single protein 
2236,ENTRECTINIB,CHEMBL1983268,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications.,,4.0,,False,2019,"['ENSG00000047936', 'ENSG00000198400', 'ENSG00000148053', 'ENSG00000140538', 'ENSG00000171094']","['MONDO_0004992', 'EFO_0003060', 'EFO_0000326', 'EFO_0000389', 'EFO_0000222', 'EFO_0000616', 'EFO_0000553']",False,False,7,Proto-oncogene tyrosine-protein kinase ROS inhibitor Neurotrophic tyrosine kinase receptor inhibitor ALK tyrosine kinase receptor inhibitor ,INHIBITOR ,single protein protein family 
2237,NITROPRUSSIDE,CHEMBL2097081,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,"['ENSG00000061918', 'ENSG00000123201', 'ENSG00000152402', 'ENSG00000164116']","['EFO_0000537', 'EFO_0000537', 'MP_0001914', 'EFO_0005251', 'EFO_0001073', 'MONDO_0005090', 'EFO_1000653', 'MONDO_0002050', 'EFO_0008585', 'EFO_0000373', 'EFO_0000612', 'EFO_1000645', 'EFO_0004272', 'GO_0007568', 'EFO_0005252', 'EFO_0000319', 'MP_0001845', 'EFO_0001358']",True,True,18,Soluble guanylate cyclase activator ,ACTIVATOR ,protein complex group 
2238,ULINASTATIN,CHEMBL2108163,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000546', 'HP_0100806', 'MONDO_0100096', 'EFO_1000637', 'MP_0001914', 'EFO_1001904']",False,False,6,,,
2239,MOLGRAMOSTIM,CHEMBL2109134,Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 7 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0001437', 'EFO_0000389', 'EFO_0000694', 'EFO_0000616', 'MONDO_0100096', 'HP_0001541', 'EFO_0009429', 'EFO_0000222']",False,False,8,,,
2240,TRANSCROCETINATE SODIUM,CHEMBL3137335,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0004244', 'EFO_0000519', 'MONDO_0100096', 'EFO_0009444']",False,False,4,,,
2241,TAZEMETOSTAT,CHEMBL3414621,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 14 investigational indications.,,4.0,,False,2020,['ENSG00000106462'],"['EFO_0000574', 'EFO_0005952', 'MONDO_0001187', 'EFO_0000403', 'EFO_0000702', 'EFO_0000181', 'MONDO_0018906', 'EFO_0000196', 'MONDO_0018906', 'EFO_0000096', 'EFO_0000691', 'EFO_0008528', 'EFO_0001378', 'MONDO_0017387', 'EFO_0000588', 'EFO_0000616', 'EFO_0003060']",False,False,17,Histone-lysine N-methyltransferase EZH2 inhibitor ,INHIBITOR ,single protein 
2242,COPANLISIB HYDROCHLORIDE,CHEMBL3545068,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 7 investigational indications.,,4.0,,False,2017,"['ENSG00000171608', 'ENSG00000121879']","['EFO_0000305', 'MONDO_0018906', 'EFO_1001051', 'EFO_0000616', 'EFO_1001469', 'EFO_0000096', 'EFO_0000403', 'EFO_0001378', 'EFO_0000183']",True,False,9,PI3-kinase p110-alpha subunit inhibitor PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
2243,TENALISIB,CHEMBL4297584,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.,,2.0,,False,no approval year,"['ENSG00000105851', 'ENSG00000171608']","['EFO_0000211', 'EFO_0000574', 'MONDO_0007254', 'EFO_0001642', 'EFO_0000095', 'MONDO_0009348', 'EFO_0005952']",False,False,7,PI3-kinase p110-delta subunit inhibitor PI3-kinase p110-gamma subunit inhibitor ,INHIBITOR ,single protein 
2244,ASUNERCEPT,CHEMBL4297886,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000117560'],"['MONDO_0100096', 'EFO_0000519', 'EFO_0000198']",True,False,3,Tumor necrosis factor ligand superfamily member 6 binding agent ,BINDING AGENT ,single protein 
2245,TUSAMITAMAB RAVTANSINE,CHEMBL4298098,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105388', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000616', 'EFO_0003060']",True,False,2,Tubulin inhibitor Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
2246,REVDOFILIMAB,CHEMBL4594516,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['MONDO_0007254', 'MONDO_0004992', 'EFO_0006859']",False,False,3,,,
2247,ROZIBAFUSP ALFA,CHEMBL4650245,Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007915', 'EFO_0000685']",False,False,2,,,
2248,BUSULFAN,CHEMBL820,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 4 approved and 85 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1954,[],"['EFO_0000222', 'HP_0002721', 'EFO_0000403', 'MONDO_0018906', 'EFO_0005555', 'EFO_0000223', 'MONDO_0019019', 'EFO_0000339', 'EFO_0003811', 'EFO_0002428', 'EFO_0000765', 'MONDO_0044903', 'MONDO_0008380', 'EFO_0000691', 'EFO_0001642', 'EFO_0005952', 'EFO_1000690', 'EFO_0006738', 'EFO_0003025', 'EFO_0000096', 'EFO_0000389', 'EFO_1001365', 'EFO_1001996', 'EFO_0004272', 'EFO_0000095', 'MONDO_0044348', 'EFO_1001451', 'MONDO_0018305', 'EFO_0006475', 'EFO_0006861', 'EFO_0000220', 'EFO_0000540', 'MONDO_0019391', 'MONDO_0019262', 'EFO_1001469', 'MONDO_0020077', 'EFO_0003833', 'EFO_0000183', 'MONDO_0018868', 'EFO_0005803', 'MONDO_0010006', 'MONDO_0009499', 'MONDO_0011382', 'EFO_0000574', 'Orphanet_848', 'MONDO_0002691', 'MONDO_0018544', 'MONDO_0015974', 'EFO_0000621', 'EFO_1000984', 'MONDO_0007254', 'EFO_0000174', 'MONDO_0009254', 'MONDO_0018149', 'EFO_1000318', 'MONDO_0019148', 'MONDO_0008170', 'EFO_0000305', 'EFO_0000565', 'EFO_0000764', 'EFO_1000131', 'MONDO_0010518', 'MONDO_0018150', 'MONDO_0008978', 'EFO_0002430', 'MONDO_0002367', 'MONDO_0044881', 'MONDO_0004992', 'EFO_0000616', 'EFO_0003029', 'EFO_0000326', 'MONDO_0015760', 'MONDO_0017198', 'MONDO_0013730', 'EFO_0003765', 'EFO_0001378', 'MONDO_0010100', 'EFO_1001779', 'EFO_0003027', 'EFO_1000158', 'MONDO_0003751', 'EFO_0000198', 'EFO_0000218', 'EFO_0004251', 'EFO_0000508', 'EFO_1001380', 'EFO_0003802', 'EFO_1000309', 'EFO_0000221']",False,False,89,,,
2249,MYCOPHENOLIC ACID,CHEMBL866,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for immune system disease and has 18 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2004,"['ENSG00000106348', 'ENSG00000178035']","['EFO_0004255', 'EFO_0005761', 'EFO_0005140', 'HP_0001871', 'MONDO_0007915', 'EFO_0000717', 'EFO_0000384', 'EFO_1002048', 'EFO_0003884', 'MONDO_0005147', 'EFO_0004599', 'EFO_0000699', 'EFO_1000906', 'EFO_0003086', 'EFO_0000540', 'EFO_1000986', 'EFO_0000222', 'EFO_0003884', 'EFO_0004599', 'MONDO_0013730', 'EFO_0005761']",False,False,21,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor ,INHIBITOR ,protein family 
2250,LINSITINIB,CHEMBL1091644,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,"['ENSG00000140443', 'ENSG00000171105']","['MONDO_0008170', 'EFO_1001951', 'EFO_0000702', 'EFO_0000174', 'EFO_0006859', 'MONDO_0002898', 'EFO_0000181', 'EFO_0003060', 'EFO_0000673', 'MONDO_0007254', 'EFO_0000182', 'EFO_1000796', 'EFO_0000616']",True,False,13,Insulin-like growth factor I receptor inhibitor Insulin receptor inhibitor ,INHIBITOR ,single protein 
2251,INSULIN ASPART,CHEMBL1201496,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for diabetes mellitus and has 11 investigational indications.,,4.0,,False,2000,['ENSG00000171105'],"['EFO_0000574', 'EFO_0003914', 'EFO_0000565', 'EFO_0000400', 'MONDO_0005148', 'EFO_0004593', 'MONDO_0004975', 'EFO_0000537', 'EFO_0001645', 'MONDO_0005147', 'MONDO_0009061', 'HP_0003124']",False,False,12,Insulin receptor agonist ,AGONIST ,single protein 
2252,TETRAPHENYLPORPHINE TETRASULFONIC ACID,CHEMBL1207607,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
2253,MEROPENEM,CHEMBL127,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 18 investigational indications.,,4.0,,False,1996,[],"['EFO_0000584', 'EFO_0003103', 'EFO_0009686', 'EFO_1000652', 'EFO_0003033', 'EFO_0007149', 'EFO_0006834', 'EFO_0000771', 'EFO_1001865', 'HP_0040187', 'EFO_1001272', 'EFO_0003106', 'EFO_1001141', 'EFO_1000049', 'EFO_0000544', 'MONDO_0018076', 'MONDO_0044881', 'MONDO_0021678', 'MONDO_0021108', 'EFO_1000831', 'EFO_0003102', 'EFO_1001313', 'MONDO_0001187', 'EFO_0005741', 'HP_0100806']",False,False,25,Bacterial penicillin-binding protein inhibitor ,INHIBITOR ,protein family 
2254,ATORVASTATIN,CHEMBL1487,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 14 approved and 101 investigational indications.,,4.0,,False,1996,['ENSG00000113161'],"['EFO_0000400', 'EFO_0009426', 'EFO_0004211', 'MONDO_0021187', 'EFO_0008568', 'MONDO_0019338', 'EFO_0003086', 'MONDO_0005301', 'EFO_0008586', 'EFO_1001771', 'Orphanet_309005', 'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'EFO_0000764', 'EFO_0003914', 'MONDO_0018076', 'EFO_0004911', 'EFO_0003869', 'EFO_0006818', 'EFO_0004616', 'EFO_0000616', 'EFO_0000685', 'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444', 'EFO_0000319', 'EFO_0000180', 'MONDO_0008315', 'EFO_0000519', 'MONDO_0004782', 'EFO_0000319', 'EFO_0003913', 'EFO_0000660', 'Orphanet_79211', 'EFO_0000538', 'EFO_0004211', 'MONDO_0011962', 'HP_0003124', 'EFO_0000195', 'EFO_0000673', 'EFO_1001249', 'EFO_0000384', 'EFO_0003047', 'HP_0002140', 'MONDO_0004992', 'EFO_0003870', 'EFO_1001466', 'EFO_0000649', 'EFO_0000574', 'EFO_0004252', 'EFO_0000681', 'EFO_0001378', 'Orphanet_309005', 'EFO_0003914', 'EFO_0001365', 'EFO_0000668', 'HP_0003124', 'EFO_0004194', 'EFO_0003918', 'EFO_0000195', 'EFO_0007160', 'EFO_0000649', 'EFO_0000565', 'MONDO_0007915', 'EFO_0001645', 'EFO_0000537', 'MONDO_0018473', 'EFO_0001422', 'EFO_0000198', 'EFO_0007328', 'EFO_0007129', 'EFO_0005672', 'MONDO_0002679', 'MONDO_0021661', 'EFO_0003095', 'EFO_0000676', 'MONDO_0013730', 'MONDO_0018373', 'EFO_0004911', 'EFO_0001645', 'EFO_0003144', 'MONDO_0021187', 'HP_0003119', 'EFO_0000373', 'MONDO_0005147', 'EFO_0008583', 'EFO_0000222', 'EFO_0003884', 'MONDO_0007254', 'EFO_0004208', 'EFO_0004264', 'EFO_1000984', 'EFO_1001993', 'Orphanet_413', 'EFO_0005952', 'MONDO_0001134', 'MONDO_0007254', 'MONDO_0005148', 'EFO_0008585', 'HP_0001258', 'MONDO_0005835', 'EFO_0004246', 'EFO_0000400', 'EFO_0003929', 'EFO_0000365', 'MONDO_0005148', 'EFO_0007243', 'EFO_0004236', 'EFO_0004286', 'EFO_0003047', 'EFO_0000612', 'HP_0100806', 'Orphanet_79211', 'EFO_1001801', 'EFO_0000474', 'HP_0000083', 'EFO_0000712', 'MONDO_0004979', 'MONDO_0004975', 'MONDO_0100096', 'HP_0001647', 'MONDO_0011382']",True,True,124,HMG-CoA reductase inhibitor ,INHIBITOR ,single protein 
2255,N6022,CHEMBL1738699,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000197894'],"['MONDO_0004979', 'MONDO_0009061']",False,False,2,Alcohol dehydrogenase class III inhibitor ,INHIBITOR ,single protein 
2256,APITOLISIB,CHEMBL1922094,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198793', 'ENSG00000145675', 'ENSG00000051382', 'ENSG00000105851', 'ENSG00000121879', 'ENSG00000105647', 'ENSG00000171608', 'ENSG00000141506', 'ENSG00000117461']","['MONDO_0004992', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0007254', 'EFO_0000681', 'EFO_1001512']",True,False,6,PI3-kinase class I inhibitor Serine/threonine-protein kinase mTOR inhibitor ,INHIBITOR ,protein complex group single protein 
2257,RIDAFOROLIMUS,CHEMBL2103839,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.,,3.0,,False,no approval year,['ENSG00000198793'],"['EFO_0000569', 'MONDO_0008315', 'EFO_0003869', 'MONDO_0021054', 'EFO_0001378', 'EFO_0002430', 'EFO_0000637', 'EFO_1001968', 'EFO_1001465', 'EFO_0000574', 'MONDO_0011962', 'EFO_0003060', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000565', 'MONDO_0007254', 'EFO_0000691', 'EFO_0000564']",False,False,19,Serine/threonine-protein kinase mTOR inhibitor ,INHIBITOR ,single protein 
2258,TRX-518,CHEMBL2109428,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.,,1.0,,False,no approval year,['ENSG00000186891'],"['MONDO_0008170', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000616', 'EFO_0000756']",False,False,5,Tumor necrosis factor receptor superfamily member 18 agonist ,AGONIST ,single protein 
2259,ARTESUNATE,CHEMBL361497,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for malaria and has 14 investigational indications.,,4.0,,False,2020,[],"['MONDO_0007254', 'EFO_0001062', 'EFO_0007445', 'EFO_0007444', 'EFO_0000616', 'MONDO_0100339', 'HP_0001945', 'EFO_0000182', 'EFO_1001475', 'MONDO_0100096', 'EFO_0007530', 'EFO_0007141', 'EFO_1001951', 'EFO_0000384', 'EFO_0001068']",False,False,15,,,
2260,DARVADSTROCEL,CHEMBL4298180,Cell drug with a maximum clinical trial phase of IV (across all indications) and is indicated for immune system disease and has 1 investigational indication.,,4.0,,False,no approval year,[],"['EFO_0000540', 'EFO_0000384']",False,False,2,,,
2261,SC-005,CHEMBL4594494,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
2262,TEMOZOLOMIDE,CHEMBL810,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 72 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1999,[],"['MONDO_0004992', 'EFO_0000519', 'EFO_0009708', 'MONDO_0008315', 'EFO_0005220', 'EFO_0002501', 'EFO_0000630', 'EFO_1001968', 'EFO_0003828', 'EFO_0000326', 'MONDO_0016717', 'EFO_1000045', 'MONDO_0008903', 'MONDO_0018975', 'EFO_0004142', 'EFO_0000673', 'EFO_0000272', 'EFO_0000437', 'EFO_1000028', 'EFO_0000691', 'EFO_0000702', 'MONDO_0008380', 'EFO_0002918', 'EFO_1000475', 'EFO_0002617', 'EFO_0000182', 'EFO_0009254', 'MONDO_0021632', 'MONDO_0002898', 'EFO_0002499', 'EFO_1000657', 'EFO_0000365', 'EFO_0000616', 'EFO_1000158', 'EFO_1001901', 'EFO_0000565', 'EFO_0000198', 'EFO_0000621', 'EFO_0005543', 'EFO_0005774', 'MONDO_0001657', 'EFO_0001062', 'EFO_1001951', 'EFO_1000478', 'EFO_1001465', 'MONDO_0044881', 'EFO_0002618', 'MONDO_0003268', 'EFO_1000026', 'EFO_1000895', 'EFO_0000574', 'MONDO_0002158', 'MONDO_0008170', 'MONDO_0002120', 'EFO_0000222', 'MONDO_0100342', 'EFO_0007416', 'EFO_0000174', 'EFO_0000248', 'EFO_1000823', 'MONDO_0007254', 'EFO_0000389', 'EFO_0002939', 'EFO_0000756', 'MONDO_0024503', 'MONDO_0011719', 'EFO_0000632', 'EFO_0000502', 'MONDO_0018271', 'Orphanet_145', 'MONDO_0002914', 'EFO_0003060', 'EFO_0003833', 'MONDO_0003060', 'MONDO_0006058']",False,False,75,,,
2263,PREGABALIN,CHEMBL1059,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 44 investigational indications.,,4.0,,False,2004,"['ENSG00000196557', 'ENSG00000153956', 'ENSG00000151067', 'ENSG00000157445', 'ENSG00000081248', 'ENSG00000007402', 'ENSG00000157388', 'ENSG00000141837', 'ENSG00000148408', 'ENSG00000006283', 'ENSG00000151062', 'ENSG00000100346', 'ENSG00000102001', 'ENSG00000198216', 'ENSG00000182389', 'ENSG00000165995', 'ENSG00000067191', 'ENSG00000167535', 'ENSG00000105605', 'ENSG00000075429', 'ENSG00000166862', 'ENSG00000075461', 'ENSG00000142408', 'ENSG00000006116', 'ENSG00000130433', 'ENSG00000108878']","['HP_0002018', 'EFO_0000474', 'EFO_0005611', 'MONDO_0005277', 'HP_0002069', 'EFO_1000877', 'EFO_0000400', 'MONDO_0007079', 'EFO_0009558', 'EFO_0002950', 'EFO_1000906', 'HP_0012532', 'EFO_1001892', 'EFO_0000342', 'HP_0012735', 'EFO_0003108', 'HP_0008419', 'EFO_0003931', 'EFO_1001998', 'HP_0001250', 'EFO_0009846', 'EFO_0009430', 'EFO_0004270', 'HP_0000989', 'EFO_0005230', 'EFO_0005762', 'EFO_1000783', 'EFO_0005687', 'HP_0007359', 'EFO_0003100', 'MONDO_0004892', 'MONDO_0002050', 'MONDO_0002959', 'MONDO_0005090', 'EFO_0004149', 'EFO_1000781', 'EFO_0000707', 'EFO_0003830', 'EFO_0006510', 'MONDO_0007254', 'MONDO_0005178', 'EFO_0007191', 'EFO_0004257', 'EFO_1001919', 'EFO_0004698', 'EFO_1001931', 'EFO_0003768', 'EFO_0003843', 'MONDO_0041052', 'EFO_0000555', 'EFO_0004263']",False,False,51,Voltage-gated calcium channel modulator ,MODULATOR ,protein complex group 
2264,GLYCOPYRRONIUM,CHEMBL1201335,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 8 approved and 10 investigational indications.,,4.0,,False,1961,"['ENSG00000133019', 'ENSG00000168539']","['MONDO_0004979', 'EFO_0010282', 'EFO_0000341', 'EFO_0004269', 'MONDO_0004247', 'EFO_0000341', 'HP_0006536', 'EFO_0006505', 'EFO_1000632', 'HP_0000975', 'MONDO_0002050', 'HP_0002307', 'HP_0000975', 'HP_0000975', 'MONDO_0004979', 'EFO_0009516', 'MONDO_0100096', 'EFO_0000341', 'EFO_0003086']",True,True,19,Muscarinic acetylcholine receptor M3 antagonist Muscarinic acetylcholine receptor M1 antagonist ,ANTAGONIST ,single protein 
2265,CORTICOTROPIN,CHEMBL1201610,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for multiple sclerosis and west syndrome and has 21 investigational indications.,,4.0,,False,1950,['ENSG00000185231'],"['EFO_0003929', 'EFO_0008520', 'EFO_0000685', 'EFO_1001129', 'EFO_0000474', 'EFO_0008522', 'MONDO_0004976', 'MONDO_0005301', 'MONDO_0018097', 'EFO_0000401', 'MONDO_0001718', 'EFO_1001231', 'EFO_0000398', 'EFO_0007405', 'EFO_0000621', 'MONDO_0005301', 'MONDO_0002462', 'MONDO_0019338', 'EFO_0000660', 'EFO_0004254', 'EFO_0003884', 'EFO_0004255', 'MONDO_0005277']",False,False,23,Melanocortin receptor 2 agonist ,AGONIST ,single protein 
2266,LONAPRISAN,CHEMBL146032,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000082175'],['MONDO_0007254'],False,False,1,Progesterone receptor antagonist ,ANTAGONIST ,single protein 
2267,THIAMINE,CHEMBL1588,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved indications.,,4.0,,False,1985,[],"['HP_0001298', 'EFO_0004272', 'EFO_0003884', 'EFO_0008569']",False,False,4,,,
2268,SECUKINUMAB,CHEMBL1743068,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 25 investigational indications.,,4.0,,False,2015,['ENSG00000112115'],"['MONDO_0100017', 'EFO_0005761', 'EFO_1000906', 'EFO_0004192', 'EFO_1000738', 'EFO_1001209', 'EFO_0008518', 'EFO_0000685', 'EFO_1001231', 'MONDO_0005301', 'MONDO_0005178', 'EFO_0000676', 'MONDO_0019558', 'EFO_0009856', 'EFO_0000540', 'EFO_1001434', 'EFO_1001494', 'MONDO_0005147', 'EFO_1000710', 'EFO_1001466', 'EFO_0000384', 'HP_0000999', 'EFO_0003929', 'EFO_0003780', 'EFO_0003898', 'EFO_0003778', 'MONDO_0004979', 'EFO_1000760', 'EFO_0000274', 'EFO_0000706']",True,False,30,Interleukin 17A inhibitor ,INHIBITOR ,single protein 
2269,SARILUMAB,CHEMBL2108730,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for immune system disease and rheumatoid arthritis and has 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2017,['ENSG00000160712'],"['EFO_0000694', 'EFO_0000540', 'EFO_1001231', 'EFO_0000685', 'EFO_0008518', 'MONDO_0100096', 'MONDO_0016586', 'EFO_0002609', 'EFO_0003106', 'EFO_0007328', 'EFO_1001361', 'EFO_1001209', 'EFO_0003898', 'EFO_0000756']",True,False,14,Interleukin-6 receptor alpha subunit antagonist ,ANTAGONIST ,single protein 
2270,POLIOVIRUS VACCINE LIVE ORAL,CHEMBL2108778,Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0007450', 'EFO_0001068', 'EFO_0000694']",False,False,4,,,
2271,UMBRALISIB TOSYLATE,CHEMBL3989869,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 13 investigational indications.,,4.0,,False,2021,"['ENSG00000213923', 'ENSG00000171608', 'ENSG00000097007']","['MONDO_0044903', 'MONDO_0001056', 'EFO_1000630', 'MONDO_0018906', 'MONDO_0007576', 'EFO_0000095', 'EFO_1001469', 'EFO_1001951', 'EFO_0002618', 'MONDO_0011719', 'EFO_0000183', 'EFO_0000403', 'EFO_1000657', 'EFO_0002429', 'EFO_0000211']",True,False,15,Casein kinase I epsilon inhibitor Tyrosine-protein kinase ABL inhibitor PI3-kinase p110-delta subunit inhibitor ,INHIBITOR ,single protein 
2272,MIRIKIZUMAB,CHEMBL3990014,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000113302', 'ENSG00000110944']","['EFO_0000384', 'EFO_0000729', 'EFO_0000676']",False,True,3,Interleukin-23 inhibitor ,INHIBITOR ,protein complex 
2273,DANICOPAN,CHEMBL4250860,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.,,3.0,,False,no approval year,['ENSG00000197766'],"['MONDO_0100096', 'EFO_0001421', 'EFO_0001365', 'MONDO_0019736', 'EFO_0003086']",True,False,5,Complement factor D inhibitor ,INHIBITOR ,single protein 
2274,LSZ-102,CHEMBL4298014,Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
2275,AVIZAKIMAB,CHEMBL4594532,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['MONDO_0007915'],False,False,1,,,
2276,CALCIUM CARBONATE,CHEMBL1200539,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for anemia (phenotype) and osteoporosis and has 25 investigational indications.,,4.0,,False,2000,[],"['EFO_0004288', 'EFO_0003869', 'EFO_1001152', 'EFO_0001422', 'EFO_0000275', 'EFO_0000401', 'HP_0002905', 'EFO_0003854', 'EFO_0004272', 'EFO_0003957', 'HP_0002014', 'Orphanet_733', 'EFO_0005952', 'EFO_0009451', 'GO_0007568', 'EFO_0001073', 'EFO_0003762', 'EFO_0000764', 'EFO_0003819', 'EFO_0003882', 'MONDO_0004992', 'MONDO_0007079', 'HP_0000938', 'EFO_0002609', 'EFO_0003103', 'EFO_0003884', 'EFO_0000180']",False,False,27,,,
2277,PLAZOMICIN,CHEMBL1650559,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2018,[],"['EFO_0003103', 'HP_0000083', 'EFO_0003884', 'EFO_0000771', 'EFO_1001141', 'EFO_1001141']",False,False,6,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2278,NALTREXONE,CHEMBL19019,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 48 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1984,"['ENSG00000082556', 'ENSG00000116329', 'ENSG00000112038']","['EFO_0005203', 'HP_0012076', 'MONDO_0005277', 'EFO_0007224', 'EFO_0003768', 'EFO_1000906', 'MONDO_0002009', 'EFO_0004242', 'MONDO_0005301', 'MONDO_0100096', 'MONDO_0002050', 'EFO_0001358', 'EFO_0000274', 'MONDO_0007254', 'MONDO_0000594', 'EFO_0003843', 'MONDO_0021698', 'HP_0012532', 'HP_0012532', 'HP_0012167', 'EFO_0003761', 'EFO_0000764', 'EFO_0003890', 'EFO_0010702', 'EFO_0004699', 'EFO_0004329', 'HP_0012378', 'EFO_0005687', 'EFO_0004240', 'MONDO_0015626', 'EFO_0001065', 'EFO_0008507', 'EFO_0007191', 'EFO_0005611', 'EFO_0005611', 'EFO_0002610', 'EFO_0000729', 'EFO_0005924', 'EFO_0010702', 'EFO_0001073', 'EFO_0004701', 'MONDO_0005090', 'MONDO_0100096', 'MONDO_0002046', 'EFO_1000783', 'HP_0003419', 'EFO_1000637', 'EFO_0003843', 'MONDO_0007079', 'EFO_0004701', 'EFO_0000676', 'EFO_0000384', 'EFO_0000694']",True,False,53,Opioid receptors; mu/kappa/delta antagonist ,ANTAGONIST ,protein family 
2279,AZD1981,CHEMBL1914489,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000183134'],"['MONDO_0004979', 'EFO_0000341', 'EFO_0000545']",False,False,3,G protein-coupled receptor 44 antagonist ,ANTAGONIST ,single protein 
2280,ACOLBIFENE HYDROCHLORIDE,CHEMBL2105965,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0007254'],False,False,1,,,
2281,REGRAMOSTIM,CHEMBL2107881,Protein drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.,,3.0,,False,no approval year,['ENSG00000119535'],"['MONDO_0008170', 'EFO_0000403', 'MONDO_0100342', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0000519', 'EFO_0000180', 'EFO_0003060', 'EFO_0001378', 'EFO_0000764', 'EFO_0000574', 'EFO_1001951', 'EFO_0000770', 'EFO_0000365', 'EFO_0007149', 'EFO_0004265', 'EFO_0000389', 'EFO_0000681', 'EFO_0000756', 'MONDO_0021063', 'MONDO_0008315', 'MONDO_0007254', 'EFO_1001923', 'EFO_0004252', 'MONDO_0001437', 'EFO_0000309', 'MONDO_0008903', 'EFO_0000621']",False,False,28,Granulocyte colony stimulating factor receptor agonist ,AGONIST ,single protein 
2282,MRA 003 US,CHEMBL2109615,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000136244'],['MONDO_0007915'],True,False,1,Interleukin-6 inhibitor ,INHIBITOR ,single protein 
2283,ENCORAFENIB,CHEMBL3301612,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 9 investigational indications.,,4.0,,False,2018,['ENSG00000157764'],"['MONDO_0004992', 'EFO_0002617', 'EFO_1001951', 'EFO_0002618', 'EFO_1000657', 'EFO_0000756', 'EFO_1000956', 'EFO_0001378', 'EFO_0000389', 'EFO_0003060', 'EFO_0002892', 'EFO_1001949', 'EFO_0000365', 'EFO_0000616']",False,True,14,Serine/threonine-protein kinase B-raf inhibitor ,INHIBITOR ,single protein 
2284,VITAMIN E,CHEMBL3989727,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 69 investigational indications.,,4.0,,False,1985,[],"['EFO_0003777', 'EFO_0003781', 'EFO_0004248', 'MONDO_0002050', 'EFO_0004284', 'MONDO_0001187', 'HP_0001919', 'EFO_0003763', 'EFO_0003860', 'EFO_1001518', 'MONDO_0005277', 'MONDO_0008170', 'MONDO_0019200', 'EFO_0000544', 'MONDO_0007254', 'EFO_0004272', 'EFO_0009267', 'EFO_0009516', 'MONDO_0018373', 'EFO_1001249', 'MONDO_0004975', 'EFO_0001421', 'EFO_0006859', 'EFO_1001375', 'EFO_1001902', 'MONDO_0100339', 'EFO_0009606', 'HP_0003549', 'MONDO_0008903', 'EFO_0000341', 'EFO_0003843', 'EFO_0002687', 'MONDO_0017774', 'MONDO_0004992', 'EFO_0002618', 'MONDO_0015339', 'EFO_0000612', 'EFO_1000860', 'EFO_0001065', 'MONDO_0004979', 'EFO_1000657', 'MONDO_0005148', 'EFO_0003100', 'EFO_0000660', 'EFO_0000545', 'EFO_0003086', 'EFO_0000319', 'HP_0001397', 'EFO_0003869', 'EFO_0003914', 'MONDO_0005180', 'EFO_0006890', 'EFO_0001422', 'EFO_0003922', 'EFO_0005774', 'MONDO_0005041', 'EFO_1001904', 'MONDO_0008315', 'EFO_1001366', 'EFO_1001951', 'EFO_0000685', 'EFO_0003095', 'MONDO_0004976', 'EFO_0003768', 'EFO_0000546', 'EFO_0003884', 'MONDO_0005090', 'MONDO_0005129', 'EFO_0003144']",False,False,69,,,
2285,LISOCABTAGENE MARALEUCEL,CHEMBL4297236,Gene drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000177455'],"['MONDO_0018906', 'EFO_0000095', 'EFO_1001469', 'EFO_0000220', 'EFO_0005952', 'EFO_0000403']",False,False,6,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
2286,ZANIDATAMAB,CHEMBL4650256,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.,,3.0,,False,no approval year,['ENSG00000141736'],"['MONDO_0004992', 'MONDO_0001056', 'MONDO_0003060', 'MONDO_0007254']",False,False,4,Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
2287,LARSUCOSTEROL,CHEMBL4802158,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,[],"['EFO_1001345', 'EFO_0000676', 'EFO_0004268', 'MONDO_0100096']",False,False,4,,,
2288,INSULIN LISPRO,CHEMBL1201538,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for diabetes mellitus and has 3 investigational indications.,,4.0,,False,1996,['ENSG00000171105'],"['HP_0003074', 'MONDO_0005147', 'MONDO_0005148', 'EFO_0000400']",False,False,4,Insulin receptor agonist ,AGONIST ,single protein 
2289,TRANSPLATIN,CHEMBL1386,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0001378', 'MONDO_0021364', 'EFO_0002618', 'EFO_0000770', 'EFO_0000403', 'EFO_0003060', 'MONDO_0003478']",False,False,7,,,
2290,TOSEDOSTAT,CHEMBL2103847,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000166825', 'ENSG00000141279', 'ENSG00000176393', 'ENSG00000164024', 'ENSG00000113441', 'ENSG00000123992', 'ENSG00000138792', 'ENSG00000108039', 'ENSG00000002549', 'ENSG00000111142', 'ENSG00000122121', 'ENSG00000164308', 'ENSG00000164307', 'ENSG00000172901', 'ENSG00000148120', 'ENSG00000172878', 'ENSG00000215440', 'ENSG00000142327', 'ENSG00000196236']","['EFO_0000616', 'EFO_0000198', 'EFO_0000222', 'EFO_0003060', 'EFO_0002618']",False,False,5,Aminopeptidase inhibitor ,INHIBITOR ,protein family 
2291,APRINOCARSEN,CHEMBL2108287,Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,['ENSG00000154229'],['EFO_0003060'],False,False,1,Protein kinase C alpha mRNA 3'UTR  antisense inhibitor ,ANTISENSE INHIBITOR ,nucleic-acid 
2292,INSULIN TREGOPIL,CHEMBL2108305,Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,['ENSG00000171105'],"['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400']",False,False,3,Insulin receptor agonist ,AGONIST ,single protein 
2293,VINDESINE,CHEMBL238071,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 15 investigational indications.,,4.0,,False,no approval year,[],"['EFO_0000220', 'EFO_0000096', 'EFO_0000702', 'EFO_0005952', 'EFO_0000211', 'EFO_0000096', 'EFO_0000621', 'MONDO_0021117', 'MONDO_0002974', 'MONDO_0008903', 'EFO_0000565', 'MONDO_0000873', 'MONDO_0019471', 'EFO_0000616', 'EFO_0000403', 'EFO_0000574']",False,False,16,,,
2294,ATENOLOL,CHEMBL24,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 12 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1981,['ENSG00000043591'],"['MONDO_0007947', 'EFO_0007372', 'EFO_0003882', 'EFO_0003896', 'EFO_0000400', 'EFO_0003777', 'EFO_0003763', 'EFO_0000537', 'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'EFO_0000712', 'EFO_1000635', 'EFO_0003144', 'MONDO_0021661', 'EFO_0000275', 'MONDO_0001134', 'EFO_0003913', 'EFO_0001358']",False,False,19,Beta-1 adrenergic receptor antagonist ,ANTAGONIST ,single protein 
2295,PYROTINIB,CHEMBL3544956,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.,,3.0,,False,no approval year,"['ENSG00000141736', 'ENSG00000146648']","['EFO_0008549', 'MONDO_0001056', 'EFO_0000339', 'EFO_0003869', 'MONDO_0007254', 'EFO_1001951', 'EFO_0000616', 'EFO_0000182', 'EFO_0003060', 'EFO_0005537']",False,True,10,Epidermal growth factor receptor erbB1 inhibitor Receptor protein-tyrosine kinase erbB-2 inhibitor ,INHIBITOR ,single protein 
2296,ACALABRUTINIB,CHEMBL3707348,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 19 investigational indications.,,4.0,,False,2017,['ENSG00000010671'],"['MONDO_0001023', 'EFO_0000403', 'MONDO_0018906', 'EFO_0000095', 'EFO_0000565', 'EFO_0001378', 'EFO_1001469', 'EFO_0000519', 'EFO_0000181', 'EFO_0009441', 'EFO_0003060', 'EFO_0000095', 'MONDO_0100096', 'MONDO_0044881', 'EFO_1001890', 'EFO_1001469', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0000096', 'EFO_0000574', 'EFO_0000685', 'EFO_0002618', 'EFO_0005741', 'EFO_0005952']",True,False,25,Tyrosine-protein kinase BTK inhibitor ,INHIBITOR ,single protein 
2297,LONCASTUXIMAB TESIRINE,CHEMBL4297778,Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for b-cell non-hodgkins lymphoma and diffuse large b-cell lymphoma and has 7 investigational indications.,,4.0,,False,2021,['ENSG00000177455'],"['EFO_1001938', 'EFO_0000309', 'EFO_1001469', 'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000220', 'MONDO_0018906', 'EFO_0000403']",False,False,9,B-lymphocyte antigen CD19 binding agent ,BINDING AGENT ,single protein 
2298,BRYOSTATIN,CHEMBL449158,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 25 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000403', 'EFO_0004289', 'EFO_0000198', 'EFO_0000565', 'MONDO_0018906', 'EFO_0000309', 'EFO_0000574', 'MONDO_0002367', 'MONDO_0002974', 'EFO_0001378', 'EFO_1001469', 'MONDO_0001056', 'MONDO_0008315', 'EFO_0006859', 'EFO_0000681', 'MONDO_0000873', 'MONDO_0008170', 'MONDO_0004975', 'EFO_1001951', 'EFO_0000616', 'EFO_0000764', 'EFO_1001365', 'MONDO_0007254', 'EFO_0000222', 'MONDO_0008903']",False,False,25,,,
2299,CASIRIVIMAB,CHEMBL4650248,Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,Spike glycoprotein inhibitor ,INHIBITOR ,single protein 
2300,ERITORAN,CHEMBL501259,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,"['ENSG00000136869', 'ENSG00000154589']","['HP_0100806', 'EFO_0007328', 'EFO_0000565', 'EFO_0002614', 'MONDO_0100096', 'EFO_0003106']",True,False,6,Toll-like receptor 4/MD-2 antagonist ,ANTAGONIST ,protein complex 
2301,IFINATAMAB DERUXTECAN,CHEMBL5095331,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,[],"['EFO_0000616', 'EFO_0000702']",False,False,2,,,
2302,SAR-407899,CHEMBL1667969,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000134318', 'ENSG00000067900']","['EFO_0003884', 'EFO_0004234', 'EFO_0001645']",False,False,3,Rho-associated protein kinase inhibitor ,INHIBITOR ,protein family 
2303,AFLIBERCEPT,CHEMBL1742982,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 12 approved and 36 investigational indications.,,4.0,,False,2011,"['ENSG00000119630', 'ENSG00000112715']","['EFO_0007310', 'EFO_0004683', 'EFO_0005753', 'EFO_1001951', 'EFO_1000657', 'MONDO_0005041', 'MONDO_0004992', 'MONDO_0005575', 'EFO_1001060', 'EFO_0004207', 'EFO_0004142', 'EFO_0000565', 'EFO_0000616', 'EFO_1001158', 'EFO_0004243', 'MONDO_0004986', 'EFO_0000365', 'EFO_0000681', 'EFO_0000702', 'EFO_0002499', 'EFO_0002617', 'EFO_0003770', 'EFO_0000641', 'MONDO_0003268', 'EFO_0000574', 'EFO_0003839', 'EFO_0001365', 'EFO_0008626', 'MONDO_0004192', 'EFO_0000756', 'EFO_0000501', 'MONDO_0003005', 'EFO_0002501', 'EFO_1001465', 'EFO_0003060', 'EFO_0009606', 'EFO_0009784', 'EFO_1000880', 'EFO_0005952', 'EFO_1001512', 'EFO_1001466', 'Orphanet_758', 'MONDO_0001576', 'EFO_0000389', 'MONDO_0021063', 'EFO_1001157', 'EFO_0001378', 'MONDO_0007254']",True,False,48,Vascular endothelial growth factor A inhibitor Placenta growth factor inhibitor ,INHIBITOR ,single protein 
2304,DALOTUZUMAB,CHEMBL1743006,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.,,2.0,,False,no approval year,['ENSG00000140443'],"['MONDO_0007254', 'EFO_1000657', 'EFO_0003060', 'EFO_1001901', 'MONDO_0008903', 'EFO_0003869', 'EFO_0001378', 'EFO_0000616', 'EFO_1001951']",False,False,9,Insulin-like growth factor I receptor antagonist ,ANTAGONIST ,single protein 
2305,HYDRALAZINE,CHEMBL276832,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for hypertension and has 18 investigational indications.,,4.0,,False,1953,[],"['EFO_0000373', 'EFO_0005669', 'EFO_0001365', 'EFO_0008620', 'EFO_1000657', 'EFO_0000537', 'MONDO_0008170', 'EFO_0001645', 'EFO_0000616', 'HP_0003124', 'MONDO_0002974', 'EFO_0003914', 'MONDO_0008903', 'EFO_0000712', 'MONDO_0007254', 'MONDO_0005148', 'EFO_0000668', 'EFO_0000373', 'EFO_0000537', 'MONDO_0004975', 'EFO_0003777']",False,False,21,,,
2306,GLECAPREVIR,CHEMBL3545363,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for chronic hepatitis c virus infection and has 4 investigational indications.,,4.0,,False,2017,[],"['EFO_0004220', 'EFO_0001421', 'EFO_0003047', 'EFO_0003086', 'EFO_0003884']",False,False,5,"Hepatitis C virus serine protease, NS3/NS4A inhibitor ",INHIBITOR ,protein complex 
2307,DIAPEP-277,CHEMBL4297934,Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.,,3.0,,False,no approval year,[],['MONDO_0005147'],False,False,1,,,
2308,CEPHARANTHINE,CHEMBL449782,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,[],['MONDO_0100096'],False,False,1,,,
2309,HEPARIN,CHEMBL4650299,Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.,,3.0,,False,no approval year,['ENSG00000117601'],"['MONDO_0005148', 'MONDO_0100096']",False,False,2,Antithrombin-III activator ,ACTIVATOR ,single protein 
2310,NELFINAVIR,CHEMBL584,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 25 investigational indications.,,4.0,,False,1997,[],"['EFO_0003060', 'EFO_0000763', 'MONDO_0007915', 'MONDO_0001528', 'EFO_0000691', 'EFO_0000681', 'EFO_0000616', 'EFO_0000574', 'MONDO_0002974', 'EFO_0000569', 'EFO_1000910', 'EFO_0003860', 'EFO_0000519', 'EFO_0000313', 'EFO_0007313', 'EFO_0001378', 'EFO_0000765', 'EFO_0005543', 'HP_0002014', 'EFO_0000180', 'EFO_0000764', 'HP_0100806', 'EFO_0000764', 'EFO_0000365', 'EFO_0000558', 'EFO_1000158', 'MONDO_0008903', 'EFO_0001378', 'MONDO_0008903']",False,False,29,Human immunodeficiency virus type 1 protease inhibitor ,INHIBITOR ,single protein 
2311,TALABOSTAT,CHEMBL67279,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000756', 'EFO_0003060', 'MONDO_0002367', 'EFO_0000095', 'EFO_0002618', 'MONDO_0002898', 'EFO_0000616', 'MONDO_0008903']",False,False,8,,,
2312,TAMSULOSIN,CHEMBL836,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 12 investigational indications.,,4.0,,False,1997,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['HP_0000016', 'EFO_0005323', 'EFO_0005323', 'EFO_0000284', 'EFO_0004253', 'EFO_1001228', 'EFO_0004234', 'EFO_0000284', 'MONDO_0024647', 'HP_0000016', 'EFO_0000537', 'HP_0000011', 'EFO_0000536', 'EFO_0003830', 'EFO_0001663', 'MONDO_0008315']",False,False,16,Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
2313,HYALURONIDASE,CHEMBL1201636,Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 20 investigational indications.,,4.0,,False,2004,[],"['EFO_0000612', 'EFO_0003843', 'MONDO_0005271', 'EFO_1001375', 'EFO_0001378', 'MONDO_0005147', 'MONDO_0007254', 'MONDO_0018906', 'EFO_1001469', 'EFO_1001466', 'EFO_0000095', 'EFO_0000096', 'HP_0001257', 'EFO_0000389', 'EFO_1000941', 'EFO_0005762', 'MONDO_0004992', 'EFO_0000403', 'EFO_0000209', 'EFO_0005558']",False,False,20,,,
2314,PEVONEDISTAT,CHEMBL1231160,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.,,3.0,,False,no approval year,"['ENSG00000144744', 'ENSG00000159593']","['EFO_0000403', 'EFO_0001378', 'EFO_0000182', 'EFO_0003060', 'EFO_0000220', 'MONDO_0004992', 'EFO_0002617', 'EFO_0000588', 'EFO_0000616', 'EFO_0000222', 'EFO_0000198', 'EFO_1001961', 'EFO_1001779']",False,False,13,NEDD8 activating enzyme inhibitor ,INHIBITOR ,protein complex 
2315,HELIUM,CHEMBL1796997,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications.,,4.0,,False,2015,[],"['EFO_0008590', 'EFO_0000341']",False,False,2,,,
2316,TAFAMIDIS,CHEMBL2103837,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 3 investigational indications.,,4.0,,False,2019,['ENSG00000118271'],"['EFO_1001875', 'EFO_0000318', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438', 'EFO_0004129', 'EFO_0004129', 'EFO_1001875']",False,True,8,Transthyretin stabiliser ,STABILISER ,single protein 
2317,ATALUREN,CHEMBL256997,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications.,,4.0,,False,no approval year,"['ENSG00000168028', 'ENSG00000177954', 'ENSG00000137154', 'ENSG00000140988', 'ENSG00000149273', 'ENSG00000145425', 'ENSG00000198034', 'ENSG00000129824', 'ENSG00000083845', 'ENSG00000171863', 'ENSG00000142937', 'ENSG00000170889', 'ENSG00000124614', 'ENSG00000142534', 'ENSG00000112306', 'ENSG00000110700', 'ENSG00000164587', 'ENSG00000115268', 'ENSG00000134419', 'ENSG00000105193', 'ENSG00000182774', 'ENSG00000231500', 'ENSG00000105372', 'ENSG00000008988', 'ENSG00000171858', 'ENSG00000186468', 'ENSG00000138326', 'ENSG00000118181', 'ENSG00000197728', 'ENSG00000143947', 'ENSG00000233927', 'ENSG00000213741', 'ENSG00000149806', 'ENSG00000100316', 'ENSG00000174444', 'ENSG00000122406', 'ENSG00000089009', 'ENSG00000147604', 'ENSG00000148303', 'ENSG00000161016', 'ENSG00000163682', 'ENSG00000147403', 'ENSG00000198755', 'ENSG00000142676', 'ENSG00000197958', 'ENSG00000167526', 'ENSG00000142541', 'ENSG00000188846', 'ENSG00000174748', 'ENSG00000265681', 'ENSG00000063177', 'ENSG00000105640', 'ENSG00000108298', 'ENSG00000122026', 'ENSG00000116251', 'ENSG00000125691', 'ENSG00000198242', 'ENSG00000114391', 'ENSG00000161970', 'ENSG00000131469', 'ENSG00000166441', 'ENSG00000108107', 'ENSG00000162244', 'ENSG00000156482', 'ENSG00000071082', 'ENSG00000144713', 'ENSG00000109475', 'ENSG00000136942', 'ENSG00000182899', 'ENSG00000130255', 'ENSG00000241343', 'ENSG00000145592', 'ENSG00000197756', 'ENSG00000172809', 'ENSG00000198918', 'ENSG00000229117', 'ENSG00000089157', 'ENSG00000137818']","['MONDO_0010602', 'MONDO_0009061', 'MONDO_0010311', 'MONDO_0019172', 'MONDO_0010604', 'EFO_0000474', 'MONDO_0010679']",True,False,7,80S Ribosome modulator ,MODULATOR ,protein nucleic-acid complex 
2318,ABRILUMAB,CHEMBL3137351,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000115232', 'ENSG00000139626']","['EFO_0000384', 'EFO_0000729']",False,True,2,Integrin alpha-4/beta-7 inhibitor ,INHIBITOR ,protein complex 
2319,FILGOTINIB,CHEMBL3301607,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for immune system disease and has 11 investigational indications.,,4.0,,False,no approval year,['ENSG00000162434'],"['EFO_0003086', 'EFO_0003767', 'EFO_0003834', 'EFO_0000699', 'MONDO_0007915', 'EFO_0003898', 'EFO_0003778', 'EFO_0000384', 'EFO_0000729', 'EFO_1001231', 'EFO_0000685', 'EFO_0000540']",False,False,12,Tyrosine-protein kinase JAK1 inhibitor ,INHIBITOR ,single protein 
2320,DALBAVANCIN,CHEMBL3301669,Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for bacterial disease and infection and has 7 investigational indications.,,4.0,,False,2014,[],"['EFO_0003030', 'EFO_0000544', 'EFO_0000771', 'EFO_0003106', 'EFO_0000544', 'EFO_0005681', 'EFO_0003033', 'EFO_0003102', 'EFO_0003035']",False,False,9,,,
2321,AMISELIMOD,CHEMBL3707375,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.,,2.0,,False,no approval year,"['ENSG00000180739', 'ENSG00000267534', 'ENSG00000125910', 'ENSG00000213694', 'ENSG00000170989']","['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729', 'MONDO_0007915', 'EFO_0000384']",True,False,6,Sphingosine 1-phosphate receptor modulator ,MODULATOR ,protein family 
2322,TELISOTUZUMAB VEDOTIN,CHEMBL3990032,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,"['ENSG00000105976', 'ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0000708', 'MONDO_0004992', 'EFO_0003060']",True,False,3,Tubulin inhibitor Hepatocyte growth factor receptor binding agent ,INHIBITOR BINDING AGENT ,protein complex group single protein 
2323,EXENATIDE,CHEMBL414357,Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 21 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,2005,['ENSG00000112164'],"['EFO_0003095', 'EFO_0001645', 'HP_0000083', 'EFO_0001073', 'MONDO_0005147', 'HP_0002140', 'EFO_1001050', 'EFO_0007318', 'EFO_0004319', 'EFO_0001074', 'EFO_0008493', 'HP_0001824', 'EFO_0000712', 'EFO_0008583', 'EFO_1001121', 'EFO_0000400', 'MONDO_0007079', 'EFO_0002610', 'MONDO_0005148', 'EFO_0000612', 'EFO_0000660', 'MONDO_0005180', 'HP_0003074']",False,True,23,Glucagon-like peptide 1 receptor agonist ,AGONIST ,single protein 
2324,BALSTILIMAB,CHEMBL4297877,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.,,3.0,,False,no approval year,['ENSG00000188389'],"['EFO_0000756', 'EFO_0000294', 'EFO_1001931', 'EFO_0003968', 'MONDO_0002974', 'EFO_1000026', 'EFO_0000616', 'EFO_0001668', 'MONDO_0008170', 'MONDO_0011962', 'EFO_1001968', 'EFO_0003060']",False,False,12,Programmed cell death protein 1 antagonist ,ANTAGONIST ,single protein 
2325,NAVITOCLAX,CHEMBL443684,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.,,3.0,,False,no approval year,"['ENSG00000258643', 'ENSG00000129473', 'ENSG00000171791', 'ENSG00000171552']","['MONDO_0008315', 'MONDO_0000873', 'MONDO_0008170', 'EFO_0000220', 'EFO_0004251', 'EFO_0000616', 'EFO_0000095', 'EFO_0000702', 'EFO_0000403', 'EFO_0000222', 'EFO_0001642', 'EFO_0003060', 'EFO_0002430', 'MONDO_0004992']",False,False,14,Apoptosis regulator Bcl-2 inhibitor Apoptosis regulator Bcl-X inhibitor Apoptosis regulator Bcl-W inhibitor ,INHIBITOR ,single protein 
2326,CARVEDILOL,CHEMBL723,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 27 investigational indications.,,4.0,,False,1995,"['ENSG00000043591', 'ENSG00000169252', 'ENSG00000188778', 'ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['MONDO_0001134', 'EFO_0002610', 'EFO_0003896', 'EFO_0000612', 'EFO_0004264', 'EFO_0001378', 'EFO_0000537', 'EFO_0000373', 'EFO_0000275', 'EFO_0000666', 'HP_0003124', 'EFO_0000574', 'EFO_0000612', 'MONDO_0008315', 'EFO_0003913', 'EFO_0009545', 'EFO_0000537', 'EFO_0000373', 'EFO_0001358', 'MONDO_0005149', 'EFO_0003086', 'EFO_0000222', 'EFO_0004289', 'EFO_0000319', 'EFO_0001645', 'EFO_0003914', 'EFO_0000474', 'MONDO_0007254', 'MONDO_0004992', 'MONDO_0005148', 'EFO_0000519', 'HP_0001943', 'EFO_0001361', 'EFO_0003144']",True,False,34,Adrenergic receptor beta antagonist Adrenergic receptor alpha-1 antagonist ,ANTAGONIST ,protein family 
2327,CIPROFLOXACIN,CHEMBL8,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 12 approved and 44 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1987,[],"['EFO_1001888', 'EFO_1000025', 'EFO_0003033', 'HP_0100806', 'EFO_0000778', 'EFO_0000771', 'HP_0002014', 'EFO_0003830', 'EFO_0003030', 'EFO_1000802', 'EFO_0003047', 'EFO_0003106', 'EFO_0000384', 'MONDO_0024647', 'EFO_0000222', 'EFO_0003818', 'EFO_0003102', 'EFO_0002618', 'EFO_0009425', 'EFO_1001459', 'EFO_0003103', 'EFO_0000616', 'EFO_0009560', 'EFO_1001141', 'EFO_0000544', 'EFO_0006505', 'EFO_0002517', 'EFO_0004992', 'EFO_0000095', 'EFO_1001141', 'MONDO_0001475', 'HP_0002110', 'EFO_1001463', 'EFO_0000341', 'MONDO_0007254', 'EFO_0010282', 'EFO_1000657', 'MONDO_0008315', 'EFO_1001345', 'EFO_0004238', 'EFO_0000574', 'EFO_0009560', 'HP_0100523', 'EFO_0000544', 'EFO_0001076', 'EFO_1001391', 'EFO_0007486', 'DOID_7551', 'EFO_0005741', 'MONDO_0001187', 'EFO_0007470', 'HP_0001945', 'MONDO_0016047', 'MONDO_0009061', 'MONDO_0004976', 'MONDO_0005129', 'EFO_0006789', 'EFO_0003103', 'EFO_0007160', 'EFO_0008588']",False,False,60,Bacterial DNA gyrase inhibitor Topoisomerase IV ,INHIBITOR ,protein complex 
2328,DOXYCYCLINE,CHEMBL1200699,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 59 investigational indications.,,4.0,,False,1967,"['ENSG00000137745', 'ENSG00000118113', 'ENSG00000137673', 'ENSG00000196611']","['EFO_0008510', 'EFO_1001466', 'EFO_0002618', 'EFO_1000906', 'EFO_0009536', 'EFO_0000341', 'EFO_0004214', 'EFO_0009659', 'EFO_0003102', 'MONDO_0018076', 'EFO_0007470', 'EFO_0009425', 'EFO_0000662', 'EFO_0001068', 'MONDO_0007947', 'EFO_0000778', 'EFO_0000574', 'EFO_1002047', 'EFO_0007460', 'HP_0001250', 'MONDO_0004992', 'EFO_0000729', 'EFO_0007205', 'EFO_1001788', 'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438', 'MP_0001914', 'EFO_1001051', 'EFO_0000612', 'EFO_0007430', 'MONDO_0004975', 'MONDO_0005178', 'EFO_0002913', 'EFO_0003770', 'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_0000464', 'EFO_0000199', 'EFO_0000756', 'EFO_0003894', 'EFO_1001951', 'EFO_1001388', 'EFO_0000649', 'EFO_0000274', 'EFO_1000760', 'HP_0000964', 'EFO_0000365', 'EFO_0000771', 'MONDO_0005180', 'MONDO_0017816', 'EFO_0003878', 'EFO_0005952', 'EFO_0008517', 'EFO_0009117', 'EFO_0007272', 'EFO_0007480', 'EFO_0000096', 'EFO_0000544', 'EFO_0003106', 'EFO_1001459', 'EFO_1001875', 'EFO_0007410', 'EFO_0003843', 'DOID_7551', 'EFO_0003060', 'EFO_0007504', 'EFO_1000785', 'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444', 'EFO_0002687']",True,True,74,Matrix metalloproteinase 7 inhibitor Bacterial 70S ribosome inhibitor Matrix metalloproteinase 13 inhibitor Matrix metalloproteinase-1 inhibitor Matrix metalloproteinase 8 inhibitor ,INHIBITOR ,single protein protein nucleic-acid complex 
2329,NALTREXONE HYDROCHLORIDE,CHEMBL1201149,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 7 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1984,"['ENSG00000082556', 'ENSG00000116329', 'ENSG00000112038']","['MONDO_0015626', 'EFO_0005203', 'MONDO_0100096', 'EFO_0005611', 'HP_0012532', 'EFO_0010702', 'EFO_0003843', 'EFO_0004701']",True,False,8,Opioid receptors; mu/kappa/delta antagonist ,ANTAGONIST ,protein family 
2330,DOXYCYCLINE HYDROCHLORIDE,CHEMBL1256723,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.,,3.0,,False,no approval year,[],"['EFO_0000544', 'MONDO_0100096', 'EFO_0000694']",False,False,3,,,
2331,TRANDOLAPRIL,CHEMBL1519,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved indications. This drug has a black box warning from the FDA.,,4.0,,True,1996,['ENSG00000159640'],"['EFO_0000319', 'EFO_0000537', 'EFO_0003144', 'EFO_0000612']",True,False,4,Angiotensin-converting enzyme inhibitor ,INHIBITOR ,single protein 
2332,OMADACYCLINE,CHEMBL1689772,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications.,,4.0,,False,2018,[],"['EFO_0000701', 'EFO_0003103', 'EFO_0000544', 'EFO_1001272', 'EFO_0000771', 'EFO_1001141', 'EFO_1001272', 'EFO_0003106', 'EFO_0000701']",False,False,9,Bacterial 70S ribosome inhibitor ,INHIBITOR ,protein nucleic-acid complex 
2333,PIMASERTIB,CHEMBL2107832,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.,,2.0,,False,no approval year,"['ENSG00000169032', 'ENSG00000126934']","['EFO_0000756', 'EFO_0000389', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000182', 'EFO_0000616', 'MONDO_0004992', 'EFO_1001951', 'EFO_0000756', 'EFO_0000222', 'MONDO_0008170', 'EFO_0003060']",True,False,12,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor Dual specificity mitogen-activated protein kinase kinase 1 inhibitor ,INHIBITOR ,single protein 
2334,RIVOCERANIB,CHEMBL3186534,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 62 investigational indications.,,3.0,,False,no approval year,['ENSG00000128052'],"['EFO_0000182', 'EFO_0000231', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000231', 'EFO_0001061', 'EFO_0000702', 'EFO_0004252', 'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221', 'MONDO_0002120', 'EFO_0004142', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'MONDO_0001056', 'MONDO_0003060', 'EFO_0001071', 'EFO_0000756', 'EFO_0005537', 'EFO_0000503', 'MONDO_0100342', 'EFO_0000199', 'MONDO_0002108', 'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869', 'HP_0001541', 'EFO_0000182', 'EFO_0003891', 'EFO_0000637', 'EFO_0002916', 'EFO_0000313', 'MONDO_0002974', 'EFO_0005543', 'EFO_0003897', 'EFO_0002618', 'EFO_0000181', 'EFO_0000571', 'EFO_0005922', 'EFO_0000621', 'EFO_0003893', 'EFO_0000691', 'MONDO_0018944', 'EFO_0000707', 'MONDO_0007576', 'EFO_1002017', 'EFO_0009708', 'EFO_0000365', 'MONDO_0002691', 'EFO_0000574', 'EFO_0000503', 'EFO_0003860', 'EFO_0000681', 'MONDO_0008315']",False,False,65,Vascular endothelial growth factor receptor 2 inhibitor ,INHIBITOR ,single protein 
2335,KW-2450,CHEMBL3545156,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,"['ENSG00000171105', 'ENSG00000140443']","['MONDO_0007254', 'EFO_0000616']",True,False,2,Insulin-like growth factor I receptor inhibitor Insulin receptor inhibitor ,INHIBITOR ,single protein 
2336,PF-06459988,CHEMBL3786098,Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.,,2.0,,False,no approval year,['ENSG00000146648'],['EFO_0003060'],False,True,1,Epidermal growth factor receptor erbB1 inhibitor ,INHIBITOR ,single protein 
2337,VOBARILIZUMAB,CHEMBL3833343,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.,,2.0,,False,no approval year,['ENSG00000160712'],"['EFO_0000685', 'MONDO_0007915']",True,False,2,Interleukin-6 receptor alpha subunit inhibitor ,INHIBITOR ,single protein 
2338,CERDULATINIB,CHEMBL4116008,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000162434', 'ENSG00000165025', 'ENSG00000105397', 'ENSG00000105639']","['EFO_0004208', 'EFO_0000095', 'MONDO_0019473', 'MONDO_0018906']",False,False,4,Tyrosine-protein kinase JAK1 inhibitor Tyrosine-protein kinase SYK inhibitor Tyrosine-protein kinase JAK3 inhibitor Tyrosine-protein kinase TYK2 inhibitor ,INHIBITOR ,single protein 
2339,OBEFAZIMOD,CHEMBL4297344,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,"['ENSG00000114503', 'ENSG00000136937']","['EFO_0000764', 'EFO_0000729', 'EFO_0000384', 'MONDO_0100096', 'EFO_0000685']",True,False,5,Cap binding complex modulator ,MODULATOR ,protein complex 
2340,ALFUZOSIN,CHEMBL709,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 7 investigational indications.,,4.0,,False,2003,"['ENSG00000120907', 'ENSG00000171873', 'ENSG00000170214']","['EFO_0000284', 'EFO_0003830', 'HP_0002019', 'EFO_0000284', 'MONDO_0005301', 'EFO_1001228', 'EFO_0004253', 'HP_0000016', 'HP_0000011', 'EFO_0004253']",False,False,10,Adrenergic receptor alpha-1 agonist ,AGONIST ,protein family 
2341,ESTRADIOL CYPIONATE,CHEMBL1200973,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 9 approved and 1 investigational indication. This drug has a black box warning from the FDA.,,4.0,,True,1979,['ENSG00000091831'],"['MONDO_0001410', 'EFO_0004266', 'EFO_1000096', 'EFO_0003854', 'MONDO_0100096', 'EFO_0003922', 'MONDO_0002146', 'HP_0030016', 'EFO_0003882', 'MONDO_0007254']",True,True,10,Estrogen receptor alpha agonist ,AGONIST ,single protein 
2342,CLONIDINE,CHEMBL134,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 29 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1974,"['ENSG00000150594', 'ENSG00000184160', 'ENSG00000274286']","['EFO_0005762', 'MONDO_0005041', 'EFO_0002950', 'MONDO_0005299', 'EFO_0005230', 'MONDO_0005277', 'EFO_0007355', 'EFO_0000274', 'EFO_0002610', 'EFO_0005252', 'EFO_0003756', 'EFO_0003888', 'MONDO_0043510', 'EFO_0003888', 'EFO_0001358', 'EFO_0004240', 'EFO_0009676', 'MONDO_0004992', 'EFO_0005611', 'EFO_0003843', 'EFO_0004273', 'EFO_1000783', 'MP_0001914', 'EFO_0007191', 'EFO_0000537', 'EFO_0009267', 'EFO_0000537', 'EFO_0003890', 'EFO_1000971', 'EFO_1000645', 'EFO_0005323', 'EFO_0005799', 'HP_0003419', 'EFO_0009523', 'MONDO_0007254', 'EFO_0003843', 'EFO_0000319', 'EFO_1001904']",True,False,38,Adrenergic receptor alpha-2 agonist ,AGONIST ,protein family 
2343,PAMREVLUMAB,CHEMBL2109377,Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.,,3.0,,False,no approval year,['ENSG00000118523'],"['EFO_0000400', 'EFO_0004239', 'EFO_0002618', 'EFO_0004236', 'EFO_0000768', 'MONDO_0010679', 'MONDO_0100096']",False,False,7,Connective tissue growth factor inhibitor ,INHIBITOR ,single protein 
2344,MAGNESIUM CITRATE,CHEMBL3989480,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for constipation and constipation disorder and has 4 investigational indications.,,4.0,,False,no approval year,[],"['MONDO_0100096', 'EFO_0000401', 'EFO_0000537', 'MONDO_0001134', 'HP_0002019', 'MONDO_0002203']",False,False,6,,,
2345,IRX-2,CHEMBL4594479,Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.,,2.0,,False,no approval year,[],"['MONDO_0007254', 'EFO_0000199', 'EFO_0000181', 'EFO_0000182', 'MONDO_0024475']",False,False,5,,,
2346,VOBRAMITAMAB DUOCARMAZINE,CHEMBL4594576,Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.,,1.0,,False,no approval year,[],"['EFO_0003060', 'MONDO_0007254', 'MONDO_0008315']",False,False,3,,,
2347,BROMOCRIPTINE,CHEMBL493,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 7 investigational indications.,,4.0,,False,1978,"['ENSG00000149295', 'ENSG00000151577', 'ENSG00000069696']","['MONDO_0005351', 'EFO_0000232', 'MONDO_0002146', 'EFO_0000545', 'EFO_1001757', 'MONDO_0005180', 'HP_0001249', 'MONDO_0005180', 'MONDO_0005148', 'MONDO_0004975', 'MONDO_0011972', 'MONDO_0005147', 'EFO_0001073', 'EFO_1001485', 'EFO_0007319']",False,False,15,D2-like dopamine receptor agonist ,AGONIST ,protein family 
2348,IRX-4204,CHEMBL75133,Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.,,2.0,,False,no approval year,"['ENSG00000204231', 'ENSG00000143171', 'ENSG00000186350']","['MONDO_0004992', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0005180']",False,False,4,Retinoid X receptor agonist ,AGONIST ,protein family 
2349,RUBOXISTAURIN,CHEMBL91829,Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.,,3.0,,False,no approval year,['ENSG00000166501'],"['EFO_0003770', 'MONDO_0005147', 'EFO_1000783', 'EFO_0003144', 'EFO_0000400', 'MONDO_0005148']",False,False,6,Protein kinase C beta inhibitor ,INHIBITOR ,single protein 
2350,COLCHICINE,CHEMBL107,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for gout and familial mediterranean fever and has 36 investigational indications.,,4.0,,False,1961,"['ENSG00000188229', 'ENSG00000101162', 'ENSG00000198033', 'ENSG00000127824', 'ENSG00000258947', 'ENSG00000167552', 'ENSG00000104833', 'ENSG00000261456', 'ENSG00000196230', 'ENSG00000123416', 'ENSG00000167553', 'ENSG00000152086', 'ENSG00000137267', 'ENSG00000137285', 'ENSG00000176014']","['EFO_0004274', 'EFO_0007541', 'EFO_0003144', 'EFO_0004220', 'EFO_0000401', 'EFO_0003818', 'EFO_0000537', 'EFO_0000551', 'EFO_0008586', 'EFO_0005672', 'MONDO_0004976', 'EFO_0001645', 'EFO_0003780', 'EFO_0000694', 'EFO_0001422', 'EFO_0003777', 'EFO_1001486', 'EFO_0005221', 'EFO_0006803', 'MONDO_0100096', 'EFO_0007224', 'MONDO_0004979', 'EFO_0003884', 'MONDO_0018088', 'EFO_0008585', 'EFO_0007427', 'EFO_0003863', 'EFO_0003938', 'EFO_0004264', 'EFO_0003914', 'EFO_0000612', 'EFO_1001404', 'EFO_0000616', 'EFO_1001129', 'EFO_0004269', 'EFO_0000275', 'MONDO_0008315', 'MONDO_0005178']",True,False,38,Tubulin inhibitor ,INHIBITOR ,protein complex group 
2351,CAFFEINE,CHEMBL113,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 4 approved and 55 investigational indications.,,4.0,,False,1948,"['ENSG00000163485', 'ENSG00000170425', 'ENSG00000282608', 'ENSG00000128271']","['HP_0012228', 'EFO_0005741', 'MONDO_0007079', 'EFO_0002610', 'HP_0002104', 'EFO_0003843', 'EFO_0005252', 'EFO_1001249', 'EFO_0003929', 'EFO_0003888', 'EFO_0001421', 'EFO_1001158', 'MONDO_0005299', 'MONDO_0005180', 'EFO_0004272', 'EFO_0002617', 'EFO_0000685', 'MONDO_0100431', 'EFO_0000764', 'MONDO_0004938', 'EFO_0004220', 'HP_0002094', 'EFO_0009692', 'MONDO_0004976', 'MONDO_0021107', 'MONDO_0001020', 'HP_0002315', 'EFO_0009444', 'EFO_0000384', 'MONDO_0008315', 'EFO_0007214', 'MONDO_0004567', 'EFO_0000305', 'HP_0002104', 'EFO_0000274', 'EFO_0001645', 'EFO_0000676', 'HP_0030833', 'MONDO_0005475', 'EFO_0001072', 'EFO_0003917', 'MONDO_0005277', 'EFO_0001073', 'MONDO_0044970', 'EFO_0000275', 'EFO_1001919', 'EFO_0010072', 'EFO_0600064', 'MONDO_0005148', 'HP_0001298', 'EFO_0000729', 'EFO_0003843', 'HP_0100607', 'EFO_0000616', 'HP_0012532', 'HP_0003418', 'EFO_0003876', 'HP_0003419', 'MONDO_0004975']",True,False,59,Adenosine receptor antagonist ,ANTAGONIST ,protein family 
2352,MAVRILIMUMAB,CHEMBL1743039,Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.,,2.0,,False,no approval year,"['ENSG00000198223', 'ENSG00000100368']","['EFO_0000685', 'MONDO_0100096', 'EFO_1001209']",True,False,3,Granulocyte-macrophage colony-stimulating factor receptor antagonist ,ANTAGONIST ,protein complex 
2353,MASITINIB,CHEMBL1908391,Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 16 investigational indications.,,4.0,,False,no approval year,"['ENSG00000157404', 'ENSG00000068078', 'ENSG00000113721', 'ENSG00000134853']","['EFO_0002618', 'EFO_0002617', 'EFO_0000616', 'MONDO_0004979', 'MONDO_0100096', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004975', 'EFO_0003840', 'EFO_0000685', 'EFO_0009001', 'MONDO_0011719', 'EFO_0001378', 'MONDO_0004976', 'EFO_0000676', 'MONDO_0016586', 'MONDO_0005301']",True,False,17,Fibroblast growth factor receptor 3 inhibitor Stem cell growth factor receptor inhibitor Platelet-derived growth factor receptor inhibitor ,INHIBITOR ,single protein protein complex 
2354,GSK-610677,CHEMBL3544968,Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,['ENSG00000112062'],['EFO_0000341'],False,False,1,MAP kinase p38 alpha inhibitor ,INHIBITOR ,single protein 
2355,FERRIC CITRATE,CHEMBL3991241,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications.,,4.0,,False,2014,[],"['MONDO_0002280', 'HP_0002905', 'EFO_0003884']",False,False,3,,,
2356,ETOPOSIDE,CHEMBL44657,Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for cancer and neoplasm and has 134 investigational indications. This drug has a black box warning from the FDA.,,4.0,,True,1983,"['ENSG00000131747', 'ENSG00000077097']","['EFO_0005235', 'EFO_0000191', 'EFO_0009441', 'EFO_0003811', 'MONDO_0002158', 'MONDO_0004992', 'MONDO_0015760', 'MONDO_0001475', 'MONDO_0008903', 'MONDO_0016717', 'EFO_1000437', 'EFO_0003025', 'EFO_0000221', 'EFO_1000564', 'MONDO_0002601', 'EFO_0008524', 'EFO_1000796', 'EFO_0005952', 'EFO_0004281', 'MONDO_0013730', 'EFO_0000209', 'EFO_0000223', 'EFO_0003802', 'EFO_0000211', 'MONDO_0021657', 'MONDO_0019472', 'EFO_0006475', 'EFO_0000180', 'MONDO_0002367', 'MONDO_0001056', 'EFO_0004289', 'EFO_0000616', 'MONDO_0021193', 'MONDO_0005575', 'EFO_1001052', 'EFO_0000558', 'EFO_0000174', 'MONDO_0018906', 'MONDO_0008380', 'EFO_1001471', 'EFO_0004256', 'EFO_1000574', 'EFO_0000403', 'EFO_0000702', 'EFO_0000574', 'MONDO_0008170', 'EFO_0000095', 'EFO_0000632', 'MONDO_0020077', 'EFO_0000248', 'EFO_0000630', 'EFO_1001469', 'EFO_0000621', 'EFO_0000198', 'EFO_0000220', 'EFO_1001365', 'HP_0001871', 'MONDO_0003478', 'MONDO_0003001', 'EFO_1001465', 'EFO_0007362', 'EFO_0003032', 'MONDO_0002087', 'EFO_1001383', 'EFO_1001968', 'EFO_1000581', 'EFO_0003027', 'MONDO_0016691', 'EFO_0004251', 'MONDO_0003751', 'EFO_0003028', 'EFO_0007416', 'EFO_0000222', 'EFO_0000096', 'EFO_0000437', 'MONDO_0009348', 'MONDO_0024503', 'EFO_0000309', 'EFO_0007498', 'EFO_1000292', 'EFO_0000339', 'EFO_0003833', 'MONDO_0002730', 'MONDO_0015540', 'MONDO_0000870', 'MONDO_0004095', 'EFO_0000514', 'EFO_0000691', 'EFO_1000415', 'MONDO_0000873', 'EFO_0002626', 'EFO_0004991', 'MONDO_0006058', 'MONDO_0015564', 'EFO_0002618', 'EFO_0000182', 'EFO_0003060', 'MONDO_0016700', 'EFO_0009538', 'EFO_0003029', 'EFO_0004599', 'EFO_1001779', 'EFO_0000326', 'MONDO_0001657', 'MONDO_0100096', 'EFO_0002939', 'MONDO_0044881', 'EFO_0009254', 'MONDO_0007254', 'EFO_0003929', 'EFO_0000565', 'EFO_0000313', 'EFO_0000502', 'EFO_0000218', 'MONDO_0019004', 'EFO_0000183', 'MONDO_0018944', 'EFO_1000028', 'MONDO_0021364', 'EFO_0005088', 'EFO_0000519', 'MONDO_0044917', 'EFO_0001378', 'EFO_0005543', 'EFO_0002499', 'EFO_0002918', 'MONDO_0002120', 'EFO_0000571', 'MONDO_0019471', 'EFO_1000158', 'EFO_0002428', 'EFO_0002501', 'EFO_0000637', 'EFO_0000765', 'EFO_0000708', 'MONDO_0008315']",True,False,136,DNA topoisomerase II inhibitor ,INHIBITOR ,protein family 
2357,NIVATROTAMAB,CHEMBL4650409,Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.,,1.0,,False,no approval year,[],['EFO_0000702'],False,False,1,,,
